(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 December 2022 (15.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/261257 A1

(51) International Patent Classification:
A61K 38/12 (2006.01) *C07K 7/50* (2006.01)
A61K 38/04 (2006.01) *C07K 7/54* (2006.01)
A61P 35/00 (2006.01) *C07K 14/00* (2006.01)

(21) International Application Number:
PCT/US2022/032738

(22) International Filing Date:
08 June 2022 (08.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/208,487	08 June 2021 (08.06.2021)	US
63/224,834	22 July 2021 (22.07.2021)	US
63/303,952	27 January 2022 (27.01.2022)	US

(71) Applicant: **FOG PHARMACEUTICALS, INC.** [US/US]; 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US).

(72) Inventors: **WHITE, Brian Halbert**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **LA, Daniel Seungduk**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **ALFARO-LOPEZ, Lorenzo Josue**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **ORTET, Paula Cristina**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **CAPPUCCI, Sarah Isabelle**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **LI, Zhi**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **MCGEE, John Hanney**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **TREMBLAY, Martin Robert**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **VERDINE, Gregory L.**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **SI, Yaguang**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **LING, Kevin**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **DU, Peicheng**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US). **HUROV, Jonathan Barry**; c/o FOG PHARMACEUTICALS, INC., 30 Acorn Park Drive, Cambridge, Massachusetts 02140 (US).

(54) Title: STAPLED PEPTIDES AND METHODS THEREOF

(57) Abstract: Among other things, the present disclosure provides various useful agents. In some embodiments, provided agents can bind to beta-catenin. In some embodiments, the present disclosure provides technologies for modulating beta-catenin functions. In some embodiments, the present disclosure provides technologies for preventing and/or treating conditions, disorders or diseases associated with beta-catenin. In some embodiments, the present disclosure provides designed amino acids and agents which can provide improved properties and/or activities.




FIG. 1

[Continued on next page]

WO 2022/261257 A1

(74) **Agent: LI, Xiaodong** et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

STAPLED PEPTIDES AND METHODS THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to United States Provisional Application Nos. 63/208,487, filed June 08, 2021, 63/224,834, filed July 22, 2021, and 63/303,952, filed January 27, 2022, the entirety of each of which is incorporated herein by reference.

BACKGROUND

[0002] Stapled peptides are useful for various applications. For example, as biologically active agents, they can be utilized to modulate various biological functions.

SUMMARY

[0003] Among other things, the present disclosure provides powerful technologies (e.g., agents (e.g., those that are or comprise peptides, in many embodiments, stapled peptides), compositions, methods, etc.) for modulating various biological functions.

[0004] In some embodiments, the present disclosure provides agents, e.g., stapled peptides that comprise multiple staples. In some embodiments, the present disclosure provides agents, e.g., stapled peptides that comprise three or more staples. In some embodiments, the present disclosure provides agents, e.g., stapled peptides that comprise three or more staples within 10-20 amino acid residues, e.g., 10-15, 11-15, 11-14, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 consecutive amino acid residues. In some embodiments, the present disclosure provides agents, e.g., stapled peptides that comprise three or more staples within 11 consecutive amino acid residues. In some embodiments, the present disclosure provides agents, e.g., stapled peptides that comprise three or more staples within 14 consecutive amino acid residues. In some embodiments, within such numbers of amino acid residues there are three staples. In some embodiments, within such numbers of consecutive amino acid residues there are four staples. Without the intention to be limited by theory, in some embodiments, provided agents, e.g., stapled peptides have increased rigidity than reference peptides (e.g., unstapled peptides, or stapled peptides having fewer staples (in some embodiments, fewer staples within certain numbers of amino acid residues as described herein), etc.). In some embodiments, provided agents, e.g., stapled peptides demonstrate various desired properties and/or activities. In some embodiments, provided agents, e.g., stapled peptides provide improved desired properties and/or activities than reference peptides (e.g., unstapled peptides, or stapled peptides having fewer staples (in some embodiments, fewer staples within certain numbers of amino acid residues as described herein), etc.).

[0005] In some embodiments, provided technologies comprise designed structural features, e.g., novel amino acid residues, that can provide significantly improved properties and/or activities compared to comparable reference technologies that do not contain such designed structural features. In some

embodiments, the present disclosure provides designed amino acids as described herein, whose incorporation into peptide agents, including stapled peptides, can provide significantly improved properties and/or activities such as improved lipophilicity and/or delivery into cells compared to reference amino acids (e.g., Asp). In some embodiments, the present disclosure provides technologies including peptides comprising such designed amino acid residues. In some embodiments, the present disclosure provides stapled peptides comprise such designed amino acid residues.

[0006] In some embodiments, the present disclosure provides technologies for modulating one or more functions of beta-catenin. Particularly, in some embodiments, the present disclosure provides various agents, e.g., peptides, in many instances stapled peptides, that can bind to beta-catenin and modulate its functions. As demonstrated herein, in some embodiments, the present disclosure binds agents that can interact with beta-catenin at a unique set of residues. In some embodiments, a binding site comprises one or more or all of the set of residues. In some embodiments, provided agents interact with one or more of a set of residues that are or correspond to the following residues of SEQ ID NO: 1: A305, Y306, G307, N308, Q309, K312, R342, K345, V346, V349, Q375, R376, Q379, N380, L382, W383, R386, N387, D413, N415, V416, T418, and C419. In some embodiments, provided agents interact with one or more of amino acid residue that are or correspond to A305, Y306, G307, N308, Q309, K312, R342, K345, V346, V349, Q375, Q379, N380, L382, W383, R386, N387, D413, N415, V416, T418, and C419 of SEQ ID NO: 1. In some embodiments, provided agents interact with one or more of amino acid residues that are or correspond to A305, Y306, G307, N308, Q309, K312, K345, V346, V349, Q379, N380, L382, W383, R386, N387, D413, N415, V416, T418, and C419 of SEQ ID NO: 1. In some embodiments, provided agents interact with one or more of amino acid residues that are or correspond to G307, K312, K345, W383, N387, D413, and N415 of SEQ ID NO: 1. In some embodiments, provided agents interact with one or more of amino acid residues that are or correspond to K312, K345, R386 and W383 of SEQ ID NO: 1. In some embodiments, provided agents interact with one or more of a set of residues that are or correspond to the following residues of SEQ ID NO: 1: G307, K312, K345, Q379, L382, W383, N387, N415, and V416. In some embodiments, provided agents interact with all of a set of residues that are or correspond to the following residues of SEQ ID NO: 1: Y306, G307, K312, K345, Q379, L382, W383, N387, N415, and V416. In some embodiments, provided agents interact with all of a set of residues that are or correspond to the following residues of SEQ ID NO: 1: G307, K312, K345, Q379, L382, W383, N387, N415, and V416. In some embodiments, provided agents interact with all of a set of residues that are or correspond to the following residues of SEQ ID NO: 1: Y306, G307, K312, K345, Q379, L382, W383, N387, N415, and V416. In some embodiments, provided agents interact with one or more of amino acid residues that are or correspond to K312, K345 and W383 of SEQ ID NO: 1. In some embodiments, provided agents interact with the amino acid residues that are or correspond to K312, K345 and W383 of SEQ ID NO: 1.

[0007] As demonstrated herein, provided technologies can modulate one or more biological processes associated with beta-catenin. In some embodiments, provided agents, e.g., stapled peptides, compete with a

ligand (e.g., with a member of the T cell factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors) for binding to beta-catenin. In some embodiments, provided agents compete with a ligand for binding to beta-catenin at a particular binding site (e.g., with a member of the T cell factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors at the TCF site on beta-catenin). In some embodiments, provided technologies compete with TCF for interactions with beta-catenin. In some embodiments, binding of provided agents to a beta-catenin site decreases, suppresses and/or blocks binding to beta-catenin by another binding partner (e.g., a kinase). In some embodiments, binding of provided agents blocks binding of beta-catenin by a TCF/LEF family member. In some embodiments, the present disclosure provides agents that can bind to a site of beta-catenin selectively over one of more other binding sites by other ligands (e.g., peptides, proteins, etc.; in some embodiments, a ligand is Axin; in some embodiments, a ligand is Bcl9). In some embodiments, provided technologies modulate one or more beta-catenin functions associated with its interactions with TCF. In some embodiments, provided technologies selectively modulate beta-catenin functions, e.g., functions associated with TCF interactions. In some embodiments, provided technologies selectively modulate beta-catenin functions and do not significantly impact functions that are not associated with beta-catenin (e.g., various functions and/or processes in the Wnt pathway that are not associated with beta-catenin). In some embodiments, provided technologies are useful for inhibiting beta-catenin functions. In some embodiments, provided technologies are usefully for promoting and/or enhancing immune activities, e.g., anti-tumor adaptive immunity.

[0008] In some embodiments, provided technologies are useful for preventing or treating various conditions, disorders or diseases including cancer. In some embodiments, the present disclosure provides methods for treating or preventing a condition, disorder or disease associated with beta-catenin, comprising administering to a subject suffered therefrom or susceptible thereto an effective amount of a provided agent or a pharmaceutically acceptable salt thereof. In some embodiments, a condition, disorder or disease is associated with beta-catenin's interactions with TCF. In some embodiments, an agent, e.g., a staple peptide, is administered as a pharmaceutical composition. In some embodiments, the present disclosure provides pharmaceutical compositions which comprise or deliver a provided agent or a pharmaceutically acceptable salt thereof. In some embodiments, a pharmaceutical composition further comprises a lipid. As demonstrated herein, in some embodiments, a suitable lipid can promote delivery/activities. In some embodiments, an agent is or comprises a peptide. In some embodiments, an agent is or comprises a stapled peptides. In some embodiments, provided agents that can bind beta-catenin comprise one or more designed amino acid residues.

[0009] In some embodiments, the present disclosure provides agents that bind to a polypeptide comprising or consisting of SEQ ID NO: 1 (Uniprot ID P35222), or residues 250-450 of SEQ ID NO: 1, or residues 305-419 of SEQ ID NO: 1:

Uniprot No. P35222

MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYE

WEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQ MLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMV SAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNL LLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIM RTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATK QEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDRED ITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAP LREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGL NTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFR MSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQD ALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL (SEQ ID NO: 1).

[0010] In some embodiments, provided agents specifically interact with one or more residues which are or correspond to residues 305-419 of SEQ ID NO: 1. In some embodiments, provided agents bind to a motif (e.g., a portion of a polypeptide, a domain of a polypeptide, etc.) that comprise one or more residues corresponding to Ala305, Tyr306, Gly307, Asn 308, Gln309, Lys312, Arg342, Lys345, Val346, Val349, Gln375, Arg376, Gln379, Asn380, Leu382, Trp383, Arg386, Asn387, Asp413, Asn415, Val416, Thr418, and Cys419 of SEQ ID NO: 1. In some embodiments, provided agents bind to a motif (e.g., a portion of a polypeptide, a domain of a polypeptide, etc.) that comprise one or more residues corresponding to Ala305, Tyr306, Gly307, Asn 308, Gln309, Lys312, Lys345, Val346, Val349, Gln375, Arg376, Gln379, Asn380, Leu382, Trp383, Arg386, Asn387, Asp413, Asn415, Val416, Thr418, and Cys419 of SEQ ID NO: 1. In some embodiments, an agent binds to a motif comprising one or more of the following residues within SEQ ID NO: 1: Ala305, Tyr306, Gly307, Asn 308, Gln309, Lys312, Arg342, Lys345, Val346, Val349, Gln375, Arg376, Gln379, Asn380, Leu382, Trp383, Arg386, Asn387, Asp413, Asn415, Val416, Thr418, and Cys419. In some embodiments, an agent binds to a motif comprising one or more of the following residues within SEQ ID NO: 1: Ala305, Tyr306, Gly307, Asn 308, Gln309, Lys312, Lys345, Val346, Val349, Gln375, Arg376, Gln379, Asn380, Leu382, Trp383, Arg386, Asn387, Asp413, Asn415, Val416, Thr418, and Cys419. In some embodiments, an agent binds to a motif comprising one or more of the following residues within SEQ ID NO: 1: Ala305, Tyr306, Gly307, Asn 308, Gln309, Lys312, Arg342, Lys345, Val346, Val349, Gln 375, Gln379, Asn380, Leu382, Trp383, Arg386, Asn387, Asp413, Asn415, Val416, Thr418, and Cys419. In some embodiments, an agent binds to a motif comprising one or more of the following residues within SEQ ID NO: 1: Ala305, Tyr306, Gly307, Asn 308, Gln309, Lys312, Lys345, Val346, Val349, Gln379, Asn380, Leu382, Trp383, Arg386, Asn387, Asp413, Asn415, Val416, Thr418, and Cys419. In some embodiments, provided technologies bind to a motif comprising at least 2, 3, 4, 5, or 6 of G307, K312, K345, W383, N387, and N415. In some embodiments, provided technologies bind to a motif comprising at least 2, 3, 4, 5, 6, or 7 of G307, K312, K345, W383, N387, D413, and N415. In some embodiments, provided agents specifically

bind to such motifs. In some embodiments, a motif may be referred to as a binding site. In some embodiments, provided technologies selectively bind to such a binding site over an Axin binding site. In some embodiments, provided technologies selectively bind to such a binding site over a Bcl9 binding site. In some embodiments, provided technologies selectively bind to such a binding site over a TCF binding site. In some embodiments, provided technology binds to such a binding site in a reverse N to C direction compared to TCF. In some embodiments, provided technologies do not bind to Axin binding site of beta-catenin. In some embodiments, provided technologies do not bind to Bcl9 binding site of beta-catenin. In some embodiments, provided technologies do not bind to ICAT binding site of beta-catenin. Various technologies, e.g., crystallography, NMR, biochemical assays, etc., may be utilized to assess interactions with beta-catenin in accordance with the present disclosure.

[0011] In some embodiments, the provided technology provides an agent, e.g., a stapled peptide, that comprises three staples within 10-20, 10-15, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 consecutive amino acids residues. In some embodiments, there are three or more staples within 10 consecutive amino acid residues. In some embodiments, there are three or more staples within 11 consecutive amino acid residues. In some embodiments, there are three or more staples within 12 consecutive amino acid residues. In some embodiments, there are three or more staples within 13 consecutive amino acid residues. In some embodiments, there are three or more staples within 14 consecutive amino acid residues. In some embodiments, there are three or more staples within 15 consecutive amino acid residues. In some embodiments, there are three or more staples within 16 consecutive amino acid residues. In some embodiments, there are three or more staples within 17 consecutive amino acid residues. In some embodiments, there are three or more staples within 18 consecutive amino acid residues. In some embodiments, there are three or more staples within 19 consecutive amino acid residues. In some embodiments, there are three or more staples within 20 consecutive amino acid residues. In some embodiments, two staples are bonded to the same amino acid residue. In some embodiments, two staples are bonded to the same backbone atom. In some embodiments, two staples are bonded to the same backbone carbon atom. In some embodiments, two staples are bonded to an alpha-carbon atom of an amino acid residue, and each independently bonds to another amino acid residue.

[0012] In some embodiments, a first staple in an agent, e.g., a staple peptide, are bonded to amino acid residues at positions i and i+3. In some embodiments, there is a second staple bonded to amino acid residues at positions i+3 and i+10. In some embodiments, there a third staple bonded to amino acid residues at positions i+9 and i+13. Those skilled in the art appreciate that as used in the art, i, i+3, i+9, i+10, i+13, etc. are routinely utilized to indicate relevant positions of amino acid residues. In some embodiments, they may also indicate absolute positions in an agent, e.g., a peptide. In some embodiments, i is an integer of 1-50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20). In some embodiments, i is 1. In some embodiments, there is a fourth staple in an agent, e.g., a stapled peptide.

[0013] In some embodiments, there are two amino acid residues between two amino acid residues

bonded to the same staple. Such a staple may be referred to as a (i, i+3) staple. Similarly, in some embodiments, there are 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues between two amino acid residues bonded to the same staple, and such a staple may be referred to as a (i, i+4), (i, i+5), (i, i+6), (i, i+7), (i, i+8), (i, i+9), (i, i+10), or (i, i+11) staple, respectively.

[0014] In some embodiments, an agent, e.g., a stapled peptide, comprises a (i, i+2) staple and a (i, i+7) staple. In some embodiments, an agent, e.g., a stapled peptide, comprises a (i, i+3) staple and a (i, i+7) staple. In some embodiments, a (i, i+3) staple and (i, i+7) staple are bonded to the same amino acid residue. In some embodiments, a (i, i+3) staple and (i, i+7) staple bond to the same atom. In some embodiments, a (i, i+3) staple and (i, i+7) staple bond to the same alpha carbon atom. For example, in compound I-1, a (i, i+3) staple is bonded to amino acid residues at positions 1 and 4, and a (i, i+7) staple is bonded to amino acid residues at positions 4 and 11, and the two staples are both bonded to the alpha carbon of the amino acid residue at position 4. In some embodiments, an agent further comprises a third staple. In some embodiments, a third staple is (i, i+4). In some embodiments, a third staple is (i, i+7). In some embodiments, a third staple is not bonded to any of the amino acid residues that are bonded to the first two staples. In some embodiments, an agent further comprises a fourth staple. In some embodiments, a fourth staple is (i, i+4). In some embodiments, a fourth staple is (i, i+7). In some embodiments, a fourth staple is not bonded to any of the amino acid residues that are bonded to the first two staples. In some embodiments, a fourth staple is not bonded to any of the amino acid residues that are bonded to the first third staples.

[0015] In some embodiments, a provided agent, e.g., a peptide agent such as a stapled peptide agent, comprises one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) of the following groups (in some embodiments, from the N to C direction):

a first acidic group (e.g., of a first acidic amino acid residue);
a second acidic group (e.g., of a second acidic amino acid residue);
optionally a third acidic group (e.g., of a third acidic amino acid residue);
optionally a hydrophobic group (e.g., of a hydrophobic amino acid residue)
a first aromatic group (e.g., of a first aromatic amino acid residue);
a second aromatic group (e.g., of a first aromatic amino acid residue); and
a third aromatic group (e.g., of a third aromatic amino acid residue).

In some embodiments, an agent comprises a first and second acidic group and a first, second and third aromatic group. In some embodiments, such an agent additionally comprises a third acidic group (e.g., of a third acid amino acid residue) and/or a hydrophobic group (e.g., of a hydrophobic amino acid residue). In some embodiments, such an agent additionally comprises a third acidic group (e.g., of a third acid amino acid residue) and a hydrophobic group (e.g., of a hydrophobic amino acid residue). In some embodiments, the distance between a first acidic group and a second acidic group is about the distance between the acidic groups of two acidic amino acid residues of a peptide motif, wherein there are two amino acid residues between the two acidic amino acid residues (e.g., if the first acidic amino acid residue is at position N, the

second is at position N+3), the distance between a first acidic group and a third acidic group (if present) is about the distance between the acidic groups of two acidic amino acid residues of a peptide motif, wherein there are three amino acid residues between the two acidic amino acid residues (e.g., if the first acidic amino acid residue is at position N, the third is at position N+4), the distance between a first acidic group and a hydrophobic group (if present) is about the distance between the acidic group of an acidic amino acid residue and the hydrophobic group of a hydrophobic amino acid residue of a peptide motif, wherein there are five amino acid residues between the first acidic amino acid residue and the hydrophobic amino acid residue (e.g., if the first acidic amino acid residue is at position N, the hydrophobic amino acid residue is at position N+6), the distance between a first acidic group and a first aromatic group is about the distance between the acidic group of a first acidic amino acid residue and the aromatic group of an aromatic amino acid residue of a peptide motif, wherein there are six amino acid residues between the first acidic amino acid residue and the first aromatic amino acid residue (e.g., if the first acidic amino acid residue is at position N, the first aromatic amino acid residue is at position N+7), the distance between the first aromatic group and the second aromatic group is about the distance between the aromatic groups of two aromatic amino acid residues of a peptide motif, wherein there are two amino acid residues between the two aromatic amino acid residues (e.g., if the first aromatic amino acid residue is at position M, the second is at position M+3), and/or the distance between the first aromatic group and the third aromatic group is about the distance between the aromatic groups of two aromatic amino acid residues of a peptide motif, wherein there are three amino acid residues between the two aromatic amino acid residues (e.g., if the first aromatic amino acid residue is at position M, the third is at position M+4). In some embodiments, a first acidic amino acid residue is at position N, a second acidic amino acid residue is at position N+3, and a first, second and third aromatic amino acid residue are at positions N+7, N+10 and N+11, respectively. In some embodiments, a first acidic amino acid residue is at position N, a second acidic amino acid residue is at position N+3, a third acidic amino acid residue is at position N+4, and a first, second and third aromatic amino acid residue are at positions N+7, N+10 and N+11, respectively. In some embodiments, a first acidic amino acid residue is at position N, a second acidic amino acid residue is at position N+3, a hydrophobic amino acid residue is at position N+6, and a first, second and third aromatic amino acid residue are at positions N+7, N+10 and N+11, respectively. In some embodiments, a first acidic amino acid residue is at position N, a second acidic amino acid residue is at position N+3, a third acidic amino acid residue is at position N+4, a hydrophobic amino acid residue is at position N+6, and a first, second and third aromatic amino acid residue are at positions N+7, N+10 and N+11, respectively. In some embodiments, M is N+7. In some embodiments, N is 1-7. In some embodiments, N is 1, 2, 3, 4, or 5. In some embodiments, N is 1. In some embodiments, N is 2. In some embodiments, N is 3. In some embodiments, N is 4. In some embodiments, N is 5. In some embodiments, M is 8-16. In some embodiments, M is 8. In some embodiments, M is 9. In some embodiments, M is 10. In some embodiments, M is 11. In some embodiments, M is 12. In some embodiments, M is 13. In some embodiments, a peptide motif is an alpha-helical motif wherein each amino acid residue is independently an

alpha amino acid residue. In some embodiments, a peptide motif is stapled. In some embodiments, there are two or more staples in a peptide motif; in some embodiments, there are three; in some embodiments, there are four; in some embodiments, there are four or more. In some embodiments, a peptide motif is or comprises an agent described in a Table herein (e.g., I-xxxx wherein xxxx is a number (e.g., I-1, I-10, I-100, I-1000, etc.)). In some embodiments, a first acidic group is of X^2 as described herein, a second acidic group is of X^5 as described herein, a third acidic group (if present) is of X^6 as described herein, a hydrophobic group (if present) is of X^8 as described herein, a first aromatic group is of X^9 as described herein, a second aromatic group is of X^{12} as described herein, and/or a third aromatic group is of X^{13} as described herein. In some embodiments, as described herein, a provided agent is a stapled peptide comprising one or more staples. In some embodiments, as described herein, a provided agent is a stapled peptide comprising two or more staples. In some embodiments, as described herein, a provided agent is a stapled peptide comprising three or more staples. In some embodiments, when contacted with a beta-catenin polypeptide, a first acidic group interacts with Lys312 and/or Gly307 or amino acid residues corresponding thereto, a second acidic group interacts with Asn387, Trp383 and/or Arg386 or amino acid residues corresponding thereto, a first aromatic group interacts with Lys345 and/or Trp383 or amino acid residues corresponding thereto, a second aromatic group interacts with Trp383 and/or Asn415 or amino acid residues corresponding thereto, and a third aromatic group interacts with Gln379, Leu383, Val416, Asn415 and/or Trp383 or amino acid residues corresponding thereto. In some embodiments, a third acidic group interacts with Asn387, Trp383 and/or Arg386 or amino acid residues corresponding thereto. In some embodiments, a hydrophobic group interacts with Trp383 or an amino acid residue corresponding thereto.

[0016] In some embodiments, the present disclosure provides an agent having the structure of formula I:

$$R^N\text{–}L^{P1}\text{–}L^{AA1}\text{–}L^{P2}\text{–}L^{AA2}\text{–}L^{P3}\text{–}L^{AA3}\text{–}L^{P4}\text{–}L^{AA4}\text{–}L^{P5}\text{–}L^{AA5}\text{–}L^{P6}\text{–}L^{AA6}\text{–}L^{P7}\text{–}R^C,$$

I

or a salt thereof, wherein each variable is independently as described herein.

[0017] In some embodiments, the present disclosure provides an agent which is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue.

[0018] In some embodiments, the present disclosure provides an agent which is or comprises a peptide comprising:

$$[X]_pX^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}[X]_{p'},$$

wherein:

each of p15, p16 and p17 is independently 0 or 1;

each of p and p' is independently 0-10;

each of X, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue.

[0019] In some embodiments, an agent is R^N–[X]p$X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}[X^{14}]_{p14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}$[X]p'–$R^C$, wherein each variable is independently as described herein.

[0020] In some embodiments, an agent is or comprises $X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}[X^{14}]_{p14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}[X^{18}]_{p18}[X^{19}]_{p19}[X^{20}]_{p20}[X^{21}]_{p21}[X^{22}]_{p22}[X^{23}]_{p23}$, wherein each of p14, p15, p16, p17, p18, p19, p20, p21, p22, and p23 is independently 0 or 1, and each of X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, X^{17}, X^{18}, X^{19}, X^{20}, X^{21}, X^{22}, and X^{23} is independently an amino acid residue as described herein.

[0021] In some embodiments, such a peptide comprises three or more staples. In some embodiments, such a peptide comprises five or more residues suitable for stapling.

[0022] In some embodiments, the present disclosure provides an agent, wherein the agent is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group;

X^{13} comprises a side chain comprising an optionally substituted aromatic group; and

two or more of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

[0023] In some embodiments, the present disclosure provides an agent, wherein the agent is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group;

X^6 comprises a side chain comprising an acidic or a polar group;

X^{13} comprises a side chain comprising an optionally substituted aromatic group; and

two or more of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

[0024] In some embodiments, an agent is or comprises a peptide. In some embodiments, an agent is or comprises a stapled peptide. In some embodiments, an agent is a peptide. In some embodiments, an agent is a stapled peptide. In some embodiments, an agent, a peptide, or a stapled peptide has the structure of $[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}$. In some embodiments, X^1 and X^4, and/or X^4 and X^{11} are independently amino acid residues suitable for stapling, or are stapled, or X^3 and X^{10} independently amino acid residues suitable for stapling, or are stapled. In some embodiments, X^1 and X^4 are independently amino acid residues suitable for stapling. In some embodiments, X^1 and X^4 are stapled. In some embodiments, X^4 and X^{11} are independently amino acid residues suitable for stapling. In some embodiments, X^4 and X^{11} are stapled. In some embodiments, X^1 and X^4, and X^4 and X^{11} are independently amino acid residues suitable for stapling. In some embodiments, a stapled peptide is a stitched peptide comprising two or more staples, some of which may bond to the same backbone atom. In some embodiments, X^1 and X^4 are stapled, and X^4 and X^{11} are stapled. In some embodiments, a staple connecting X^1 and X^4 and a staple connecting X^4 and X^{11} are bonded to a common backbone atom of X^4. In some embodiments, a common backbone atom is the alpha-carbon of X^4. In some embodiments, X^3 and X^{10} are independently amino acid residues suitable for stapling. In some embodiments, X^3 and X^{10} are stapled. In some embodiments, X^1 and X^3 are independently amino acid residues suitable for stapling. In some embodiments, X^1 and X^3 are stapled. In some embodiments, X^{10} and X^{14} are independently amino acid residues suitable for stapling. In some embodiments, X^{10} and X^{14} are stapled. In some embodiments, X^7 and X^{10} are independently amino acid residues suitable for stapling. In some embodiments, X^7 and X^{10} are stapled. In some embodiments, X^7 and X^{14} are independently amino acid residues suitable for stapling. In some embodiments, X^7 and X^{14} are stapled. In some embodiments, X^3 and X^7 are independently amino acid residues suitable for stapling. In some embodiments, X^3 and X^7 are stapled.

[0025] In some embodiments, the present disclosure provides agents that bind to a polypeptide comprising or consisting of residues 305-419 of SEQ ID NO: 1 as described herein. In some embodiments, an agent, e.g., a peptide, has a molecular mass of no more than about 5000 Daltons. In some embodiments, it is no more than about 2500, 3000, 3500, 4000, 4500 or 5000 Daltons. In some embodiments, it is no more than about 2500 Daltons. In some embodiments, it is no more than about 3000 Daltons. In some embodiments, it is no more than about 3500 Daltons. In some embodiments, it is no more than about 4000 Daltons. In some embodiments, it is no more than about 500 Daltons.

[0026] In some embodiments, the present disclosure provides various technologies, e.g., reagents methods, etc., for preparing, characterizing, assessing and using provided agents and compositions thereof. In some embodiments, the present disclosure provides, e.g., methods, reagents and/or systems for identifying, characterizing and/or assessing provided agents and use thereof (e.g., as therapeutic or diagnostic agents).

[0027] In some embodiments, the present disclosure provides pharmaceutical compositions comprising

or delivering a provided agent and a pharmaceutical acceptable carrier. In some embodiments, a provided agent is a pharmaceutically acceptable salt form. In some embodiments, a provided composition comprises a pharmaceutically acceptable salt form an agent. In some embodiments, in various compositions and methods, agents are provided as pharmaceutically acceptable salt forms.

[0028] In some embodiments, the present disclosure provides methods for modulating a property, activity and/or function of beta-catenin, comprising contacting beta-catenin with a provided agent. In some embodiments, the present disclosure provides methods for modulating a property, activity and/or function of beta-catenin in a system comprising beta-catenin, comprising administering to a system an effective amount of a provided agent. In some embodiments, the present disclosure provides methods for modulating a property, activity and/or function of beta-catenin in a system expressing beta-catenin, comprising administering or delivering to a system an effective amount of a provided agent. In some embodiments, an activity of beta-catenin is inhibited or reduced. In some embodiments, a function of beta-catenin is inhibited or reduced. In some embodiments, a property, activity and/or function is associated with beta-catenin/TCF interaction.

[0029] In some embodiments, the present disclosure provides methods for modulating beta-catenin/TCF interaction. In some embodiments, the present disclosure provides methods for modulating beta-catenin/TCF interaction, comprising contacting beta-catenin with a provided agent. In some embodiments, the present disclosure provides methods for modulating beta-catenin/TCF interaction in a system comprising beta-catenin and TCF, comprising administering or delivering to the system an effective amount a provided agent. In some embodiments, the present disclosure provides methods for modulating beta-catenin/TCF interaction in a system expressing beta-catenin and TCF, comprising administering or delivering to the system an effective amount a provided agent. In some embodiments, interactions between beta-catenin and TCF is reduced. In some embodiments, interactions between beta-catenin and TCF is inhibited.

[0030] In some embodiments, the present disclosure provides methods for inhibiting cell proliferation, comprising administering or delivering to a population of cells an effective amount of a provided agent. In some embodiments, the present disclosure provides methods for inhibiting cell proliferation in a system, comprising administering or delivering to the system an effective amount of a provided agent. In some embodiments, the present disclosure provides methods for inhibiting cell growth, comprising administering or delivering to a population of cells an effective amount of a provided agent. In some embodiments, the present disclosure provides methods for inhibiting cell growth in a system, comprising administering or delivering to the system an effective amount of a provided agent. In some embodiments, such cell proliferation is beta-catenin dependent. In some embodiments, such cell growth is beta-catenin dependent. In some embodiments, such proliferation or growth is dependent on beta-catenin interactions with TCF.

[0031] In some embodiments, the present disclosure provides methods for reducing or preventing activation of a WNT pathway. In some embodiments, the present disclosure provides methods for reducing or preventing activation of a WNT pathway in a system, comprising administering or delivering to the system

an effective amount of a provided agent.

[0032] In some embodiments, a system is *in vitro*. In some embodiments, a system is *ex vivo*. In some embodiments, a system is *in vivo*. In some embodiments, a system is or comprise a cell. In some embodiments, a system is or comprises a tissue. In some embodiments, a system is or comprises an organ. In some embodiments, a system is or comprises an organism. In some embodiments, a system is an animal. In some embodiments, a system is human. In some embodiments, a system is or comprises cells, tissues or organs associated with a condition, disorder or disease. In some embodiments, a system is or comprises cancer cells.

[0033] In some embodiments, the present disclosure provides methods for preventing conditions, disorders or diseases. In some embodiments, the present disclosure provides methods for reducing risks of conditions, disorders or diseases. In some embodiments, the present disclosure provides methods for preventing a condition, disorder or disease, comprising administering or delivering to a subject susceptible thereto an effective amount of an agent of the present disclosure. In some embodiments, the present disclosure provides methods for reducing risk of a condition, disorder or disease, comprising administering or delivering to a subject susceptible thereto an effective amount of an agent of the present disclosure. In some embodiments, the present disclosure provides methods for reducing risks of a condition, disorder or disease in a population, comprising administering or delivering to a population of subjects susceptible thereto an effective amount of an agent of the present disclosure. In some embodiments, the present disclosure provides methods for treating conditions, disorders or diseases. In some embodiments, the present disclosure provides methods for treating a condition, disorder or disease, comprising administering or delivering to a subject suffering therefrom an effective amount of an agent of the present disclosure. In some embodiments, a symptom is reduced, removed or prevented. In some embodiments, one or more parameters for assessing a condition, disorder or disease are improved. In some embodiments, survival of subjects are extended. As appreciated by those skilled in the art, in some embodiments, prevention, reduced risks, and/or effects of treatment may be assessed through clinical trials and may be observed in subject populations. In some embodiments, a condition, disorder or disease is cancer. In some embodiments, a condition, disorder or disease is associated with beta-catenin. In some embodiments, a condition, disorder or disease is associated with beta-catenin interaction with TCF. In some embodiments, a condition, disorder or disease is bladder cancer. In some embodiments, a condition, disorder or disease is endometrial cancer. In some embodiments, a condition, disorder or disease is adrenocortical carcinoma. In some embodiments, a condition, disorder or disease is gastric cancer. In some embodiments, a condition, disorder or disease is lung cancer. In some embodiments, a condition, disorder or disease is melanoma. In some embodiments, a condition, disorder or disease is esophageal cancer. In some embodiments, a condition, disorder or disease is colorectal cancer. In some embodiments, a cancer is liver cancer. In some embodiments, a cancer is prostate cancer. In some embodiments, a cancer is breast cancer. In some embodiments, a cancer is endometrial cancer. Mutations that lead to constitutive activation of Wnt/beta-catenin-mediated signaling are reported to be present in

approximately 20% of all human cancers. In some embodiments, a condition, disorder or disease is associated with WNT signaling. In some embodiments, a condition, disorder or disease is associated with beta-catenin dependent WNT signaling. In some embodiments, a condition, disorder or disease is associated with beta-catenin/TCF interaction. In some embodiments, it has been reported that beta-catenin/TCFs interactions may promote cell proliferation, epithelial-mesenchymal transition (EMT), a cancer stem cell phenotype, etc.

[0034] In some embodiments, agents are administered as pharmaceutically compositions that comprise or deliver such agents. In some embodiments, agents are provided and/or delivered in pharmaceutically acceptable salt forms. In some embodiments, in a composition (e.g., a liquid composition of certain pH) an agent may exist in various forms including various pharmaceutically acceptable salt forms.

[0035] In some embodiments, a provided agent is utilized in combination with a second therapy. In some embodiments, a provided agent is utilized in combination with a second therapeutic agent. In some embodiments, a second therapy or therapeutic agent is administered prior to an administration or delivery of a provided agent. In some embodiments, a second therapy or therapeutic agent is administered at about the same time as an administration or delivery of a provided agent. In some embodiments, a second therapy or therapeutic agent is administered subsequently to an administration or delivery of a provided agent. In some embodiments, a subject is exposed to both a provided agent and a second therapeutic agent. In some embodiments, a subject is exposed to a therapeutic effect of a provided agent and a therapeutic effect of a second therapeutic agent. In some embodiments, a second therapy is or comprises surgery. In some embodiments, a second therapy is or comprises radiation therapy. In some embodiments, a second therapy is or comprises immunotherapy. In some embodiments, a second therapeutic agent is or comprises a drug. In some embodiments, a second therapeutic agent is or comprises a cancer drug. In some embodiments, a second therapeutic agent is or comprises a chemotherapeutic agent. In some embodiments, a second therapeutic agent is or comprises a hormone therapy agent. In some embodiments, a second therapeutic agent is or comprises a kinase inhibitor. In some embodiments, a second therapeutic agent is or comprises a checkpoint inhibitor (e.g., antibodies against PD-1, PD-L1, CTLA-4, etc.). In some embodiments, a provide agent can be administered with lower unit dose and/or total dose compared to being used alone. In some embodiments, a second agent can be administered with lower unit dose and/or total dose compared to being used alone. In some embodiments, one or more side effects associated with administration of a provided agent and/or a second therapy or therapeutic agent are reduced. In some embodiments, a combination therapy provides improved results, e.g., when compared to each agent utilized individually. In some embodiments, a combination therapy achieves one or more better results, e.g., when compared to each agent utilized individually.

[0036] Further description of certain embodiments of provided technologies is presented below.

BRIEF DESCRIPTION OF THE DRAWING

[0037] Figure 1. Provided technologies can inhibit beta-catenin driven gene transcription selectively in cells expressing beta-catenin. Stapled peptides inhibited endogenous gene expression in wild HAP1 isogenic cell but not in CTNNB1 knockout (KO) cells. (A): beta-catenin levels. CHIR: CHIR99021, which can activate beta-catenin pathway and increase AXIN2 and SP5 expression. (B): SP5 expression (24h). (C): AXIN2 expression (24h). For each group, from left to right, DMSO ("0" and "0"), Peptide A (1 and 5 uM), I-66 (1 and 5 uM) and I-470 (1 and 5 uM). Expression assessed after 24 hour treatment.

[0038] Figure 2. Provided technologies can reduce nuclear beta-catenin levels. Results for total beta-catenin in nuclear fraction (24 h) are shown as examples.

[0039] Figure 3. Provided technologies can inhibit cell proliferation, modulate transcription and/or induce cell cycle arrest. (A): Provided technologies can reduce cell proliferation. (B) and (C): Provided technologies can modulate gene expression. (B): AXIN 24 hr. (C): CXCL12 24 hr. (D): Provided technologies can induce cell cycle arrest. For left to right: Peptide A (1, 5 and 10 uM), I-66 (1, 5 and 10 uM), I-470 (1, 5 and 10 uM) and DMSO.

[0040] Figure 4. Provided technologies can provide robust, dose-dependent anti-tumor effects *in vivo*. Both dose levels assessed provided robust reduction of tumor sizes, and the higher dose levels provided greater reductions. COLO320DM cells (colon cancer, mutations: APC, TP53) were utilized for the presented data. Top line is for vehicle treatment, the middle line is for I-66, 30 mg/kg, Q4D, and the bottom line is for I-66, 75 mg/kg, Q4D.

[0041] Figure 5. Provided technologies can provide sustained tumor exposure, suitable pharmacokinetic profiles and broad tissue distribution. (A): Sustained COLO320DM xenograft tumor exposure after a single i.p. injection of I-66 at 50 mg/kg was shown as an example. Dotted line indicates *in vitro* proliferation IC_{50} (0.7 uM). (B): Mouse plasma pharmacokinetics. Data presented are I-66 plasma concentration (ng/mL) over time as examples. (C): Tissue distribution observed for I-66 in one assessment. Mouse single dose IP, 50 mg/kg. For each sample, the left column is 24 h data and the right is 96 h data.

[0042] Figure 6. ^{1}H NMR of a preparation of I-66 prepared as described in Example 9 (DMSO-d6, 373K).

[0043] Figure 7. Integration of peaks in a ^{1}H NMR spectrum of a preparation of I-66 prepared as described in Example 9 (DMSO-d6, 373K). Those skilled in the art appreciate that integration may be further adjusted and/or optimized.

[0044] Figure 8. Provided technologies can provide robust anti-tumor effects *in vivo* in multiple tumor models. (A): Certain data from a PDX colon cancer model. (B): Certain data from a PDX CRC model.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

Definitions

[0045] As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this disclosure, the chemical elements are identified in accordance with the Periodic Table of the Elements,

CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001.

[0046] *Administration:* As used herein, the term "administration" typically refers to the administration of a composition to a subject or system. Those of ordinary skill in the art will be aware of a variety of routes that may, in appropriate circumstances, be utilized for administration to a subject, for example a human. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, *etc.* In some particular embodiments, administration may be bronchial (*e.g.*, by bronchial instillation), buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, *etc*), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e. g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (*e.g.*, by intratracheal instillation), vaginal, vitreal, *etc.* In some embodiments, administration may involve dosing that is intermittent (*e.g.*, a plurality of doses separated in time) and/or periodic (*e.g.*, individual doses separated by a common period of time) dosing. In some embodiments, administration may involve continuous dosing (*e.g.*, perfusion) for at least a selected period of time.

[0047] *Affinity*: As is known in the art, "affinity" is a measure of the tightness with a particular ligand (e.g., an agent) binds to its partner (e.g., beta-catenin or a portion thereof). Affinities can be measured in different ways. In some embodiments, affinity is measured by a quantitative assay. In some such embodiments, binding partner concentration may be fixed to be in excess of ligand concentration so as to mimic physiological conditions. Alternatively or additionally, in some embodiments, binding partner concentration and/or ligand concentration may be varied. In some such embodiments, affinity may be compared to a reference under comparable conditions (e.g., concentrations).

[0048] *Agent:* In general, the term "agent", as used herein, may be used to refer to a compound or entity of any chemical class including, for example, a polypeptide, nucleic acid, saccharide, lipid, small molecule, metal, or combination or complex thereof. In appropriate circumstances, as will be clear from context to those skilled in the art, the term may be utilized to refer to an entity that is or comprises a cell or organism, or a fraction, extract, or component thereof. Alternatively or additionally, as context will make clear, the term may be used to refer to a natural product in that it is found in and/or is obtained from nature. In some instances, again as will be clear from context, the term may be used to refer to one or more entities that is man-made in that it is designed, engineered, and/or produced through action of the hand of man and/or is not found in nature. In some embodiments, an agent may be utilized in isolated or pure form; in some embodiments, an agent may be utilized in crude form. In some embodiments, potential agents may be provided as collections or libraries, for example that may be screened to identify or characterize active agents within them. In some cases, the term "agent" may refer to a compound or entity that is or comprises a

polymer; in some cases, the term may refer to a compound or entity that comprises one or more polymeric moieties. In some embodiments, the term "agent" may refer to a compound or entity that is not a polymer and/or is substantially free of any polymer and/or of one or more particular polymeric moieties. In some embodiments, the term may refer to a compound or entity that lacks or is substantially free of any polymeric moiety. In some embodiments, an agent is a compound. In some embodiments, an agent is a stapled peptide.

[0049] *Aliphatic*: As used herein, "aliphatic" means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a substituted or unsubstituted monocyclic, bicyclic, or polycyclic hydrocarbon ring that is completely saturated or that contains one or more units of unsaturation (but not aromatic), or combinations thereof. In some embodiments, aliphatic groups contain 1-50 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-20 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-9 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-7 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1, 2, 3, or 4 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0050] *Alkenyl*: As used herein, the term "alkenyl" refers to an aliphatic group, as defined herein, having one or more double bonds.

[0051] *Alkyl*: As used herein, the term "alkyl" is given its ordinary meaning in the art and may include saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In some embodiments, alkyl has 1-100 carbon atoms. In certain embodiments, a straight chain or branched chain alkyl has about 1-20 carbon atoms in its backbone (*e.g.*, C_1-C_{20} for straight chain, C_2-C_{20} for branched chain), and alternatively, about 1-10. In some embodiments, cycloalkyl rings have from about 3-10 carbon atoms in their ring structure where such rings are monocyclic, bicyclic, or polycyclic, and alternatively about 5, 6 or 7 carbons in the ring structure. In some embodiments, an alkyl group may be a lower alkyl group, wherein a lower alkyl group comprises 1-4 carbon atoms (*e.g.*, C_1-C_4 for straight chain lower alkyls).

[0052] *Amino acid:* In its broadest sense, as used herein, refers to any compound and/or substance that can be incorporated into a polypeptide chain, *e.g.*, through formation of one or more peptide bonds. In some embodiments, an amino acid comprising an amino group and an a carboxylic acid group. In some embodiments, an amino acid has the structure of $NH(R^{a1})–L^{a1}–C(R^{a2})(R^{a3})–L^{a2}–COOH$, wherein each variable is independently as described in the present disclosure. In some embodiments, an amino acid has the general structure $NH(R')–C(R')_2–COOH$, wherein each R' is independently as described in the present disclosure. In some embodiments, an amino acid has the general structure $H_2N–C(R')_2–COOH$, wherein R'

is as described in the present disclosure. In some embodiments, an amino acid has the general structure H_2N–C(H)(R')–COOH, wherein R' is as described in the present disclosure. In some embodiments, an amino acid is a naturally-occurring amino acid. In some embodiments, an amino acid is a non-natural amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid. "Standard amino acid" refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. "Nonstandard amino acid" refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source. In some embodiments, an amino acid, including a carboxy- and/or amino-terminal amino acid in a polypeptide, can contain a structural modification as compared with the general structure above. For example, in some embodiments, an amino acid may be modified by methylation, amidation, acetylation, pegylation, glycosylation, phosphorylation, and/or substitution (*e.g.*, of the amino group, the carboxylic acid group, one or more protons, one or more hydrogens, and/or the hydroxyl group) as compared with the general structure. In some embodiments, such modification may, for example, alter the circulating half-life of a polypeptide containing the modified amino acid as compared with one containing an otherwise identical unmodified amino acid. In some embodiments, such modification does not significantly alter a relevant activity of a polypeptide containing the modified amino acid, as compared with one containing an otherwise identical unmodified amino acid. As will be clear from context, in some embodiments, the term "amino acid" may be used to refer to a free amino acid; in some embodiments it may be used to refer to an amino acid residue of a polypeptide.

[0053] *Analog:* As used herein, the term "analog" refers to a substance that shares one or more particular structural features, elements, components, or moieties with a reference substance. Typically, an "analog" shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways. In some embodiments, an analog is a substance that can be generated from the reference substance, *e.g.*, by chemical manipulation of the reference substance. In some embodiments, an analog is a substance that can be generated through performance of a synthetic process substantially similar to (*e.g.*, sharing a plurality of steps with) one that generates the reference substance. In some embodiments, an analog is or can be generated through performance of a synthetic process different from that used to generate the reference substance.

[0054] *Animal*: As used herein refers to any member of the animal kingdom. In some embodiments, "*animal*" refers to humans, of either sex and at any stage of development. In some embodiments, "*animal*" refers to non-human animals, at any stage of development. In certain embodiments, the non-human animal is a mammal (*e.g.*, a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and/or worms. In some embodiments, an animal may be a transgenic animal, genetically engineered animal, and/or a clone.

[0055] *Approximately:* As used herein, the term "approximately" or "about," as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the

term "approximately" or "about" refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

[0056] *Aryl*: The term "aryl" used alone or as part of a larger moiety as in "aralkyl," "aralkoxy," "aryloxyalkyl," *etc.* refers to monocyclic, bicyclic or polycyclic ring systems having a total of five to thirty ring members, wherein at least one ring in the system is aromatic. In some embodiments, an aryl group is a monocyclic, bicyclic or polycyclic ring system having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 3 to 7 ring members. In some embodiments, an aryl group is a biaryl group. The term "aryl" may be used interchangeably with the term "aryl ring." In certain embodiments of the present disclosure, "aryl" refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, binaphthyl, anthracyl and the like, which may bear one or more substituents. In some embodiments, also included within the scope of the term "aryl," as it is used herein, is a group in which an aromatic ring is fused to one or more non–aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like, where a radical or point of attachment is on an aryl ring.

[0057] *Associated with:* Two events or entities are "associated" with one another, as that term is used herein, if the presence, level and/or form of one is correlated with that of the other. For example, a particular entity (*e.g.*, nucleic acid (*e.g.*, genomic DNA, transcripts, mRNA, *etc.*), polypeptide, genetic signature, metabolite, microbe, *etc.*) is considered to be associated with a particular disease, disorder, or condition, if its presence, level and/or form correlates with incidence of and/or susceptibility to the disease, disorder, or condition (*e.g.*, across a relevant population).

[0058] *Binding*: It will be understood that the term "binding", as used herein, typically refers to a non-covalent association between or among agents. In many embodiments herein, binding is addressed with respect to particular agents and beta-catenin. It will be appreciated by those of ordinary skill in the art that such binding may be assessed in any of a variety of contexts. In some embodiments, binding is assessed with respect to beta-catenin. In some embodiments, binding is assessed with respect to one or more amino acid residues of beta-catenin. In some embodiments, binding is assessed with respect to one or more amino acid residues corresponding to (e.g., similarly positioned in three dimensional space and/or having certain similar properties and/or functions) those of beta-catenin.

[0059] *Binding site*: The term "binding site", as used herein, refers to a region of a target polypeptide, formed in three-dimensional space, that includes one or more or all interaction residues of the target polypeptide. In some embodiments, "binding site" may refer to one or more amino acid residues which comprise or are one or more or all interaction amino acid residues of a target polypeptide. As will be understood by those of ordinary skill in the art, a binding site may include residues that are adjacent to one another on a linear chain, and/or that are distal to one another on a linear chain but near to one another in

three-dimensional space when a target polypeptide is folded. A binding site may comprise amino acid residues and/or saccharide residues.

[0060] *Carrier:* as used herein, refers to a diluent, adjuvant, excipient, or vehicle with which a composition is administered. In some exemplary embodiments, carriers can include sterile liquids, such as, for example, water and oils, including oils of petroleum, animal, vegetable or synthetic origin, such as, for example, peanut oil, soybean oil, mineral oil, sesame oil and the like. In some embodiments, carriers are or include one or more solid components.

[0061] *Comparable:* As used herein, the term "comparable" refers to two or more agents, entities, situations, sets of conditions, *etc.*, that may not be identical to one another but that are sufficiently similar to permit comparison there between so that one skilled in the art will appreciate that conclusions may reasonably be drawn based on differences or similarities observed. In some embodiments, comparable sets of conditions, circumstances, individuals, or populations are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, *etc.* to be considered comparable. For example, those of ordinary skill in the art will appreciate that sets of circumstances, individuals, or populations are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are caused by or indicative of the variation in those features that are varied.

[0062] *Composition:* Those skilled in the art will appreciate that the term "composition" may be used to refer to a discrete physical entity that comprises one or more specified components. In general, unless otherwise specified, a composition may be of any form – *e.g.*, gas, gel, liquid, solid, *etc.*

[0063] *Cycloaliphatic*: The term "cycloaliphatic," as used herein, refers to saturated or partially unsaturated aliphatic monocyclic, bicyclic, or polycyclic ring systems having, *e.g.*, from 3 to 30, members, wherein the aliphatic ring system is optionally substituted. Cycloaliphatic groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, norbornyl, adamantyl, and cyclooctadienyl. In some embodiments, the cycloalkyl has 3–6 carbons. The terms "cycloaliphatic" may also include aliphatic rings that are fused to one or more aromatic or nonaromatic rings, such as decahydronaphthyl or tetrahydronaphthyl, where a radical or point of attachment is on an aliphatic ring. In some embodiments, a carbocyclic group is bicyclic. In some embodiments, a carbocyclic group is tricyclic. In some embodiments, a carbocyclic group is polycyclic. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C_3-C_{10}, or C_3-C_6 hydrocarbon, or a C_4-C_{10}, or C_8-C_{10} bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, or a C_9-C_{16} tricyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic.

[0064] *Derivative:* As used herein, the term "derivative" refers to a structural analogue of a reference substance. That is, a "derivative" is a substance that shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways. In some embodiments, a derivative is a substance that can be generated from the reference substance by chemical manipulation. In some embodiments, a derivative is a substance that can be generated through performance of a synthetic process substantially similar to (*e.g.*, sharing a plurality of steps with) one that generates the reference substance.

[0065] *Dosage form* or *unit dosage form:* Those skilled in the art will appreciate that the term "dosage form" may be used to refer to a physically discrete unit of an active agent (*e.g.*, a therapeutic or diagnostic agent) for administration to a subject. Typically, each such unit contains a predetermined quantity of active agent. In some embodiments, such quantity is a unit dosage amount (or a whole fraction thereof) appropriate for administration in accordance with a dosing regimen that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population (i.e., with a therapeutic dosing regimen). Those of ordinary skill in the art appreciate that the total amount of a therapeutic composition or agent administered to a particular subject is determined by one or more attending physicians and may involve administration of multiple dosage forms.

[0066] *Dosing regimen:* Those skilled in the art will appreciate that the term "dosing regimen" may be used to refer to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses. In some embodiments, a dosing regimen comprises a plurality of doses each of which is separated in time from other doses. In some embodiments, individual doses are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses. In some embodiments, all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount different from the first dose amount. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount same as the first dose amount. In some embodiments, a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population (*i.e.*, is a therapeutic dosing regimen).

[0067] *Engineered:* In general, the term "engineered" refers to the aspect of having been manipulated by the hand of man. For example, in some embodiments, a peptide may be considered to be engineered if its amino acid sequence has been selected by man. For example, an engineered agent has an amino acid sequence that was selected based on preferences for corresponding amino acids at particular sites of protein-protein interactions. In some embodiments, an engineered sequence has an amino acid sequence that differs from the amino acid sequence of polypeptides included in the NCBI database that binds to a TCF site of beta-

catenin. In many embodiments, provided agents are engineered agents. In some embodiments, engineered agents are peptide agents comprising non-natural amino acid residues, non-natural amino acid sequences, and/or peptide staples. In some embodiments, provided agents comprise or are engineered peptide agents which comprise engineered sequences.

[0068] *Halogen*: The term "halogen" means F, Cl, Br, or I.

[0069] *Heteroaliphatic*: The term "heteroaliphatic" is given its ordinary meaning in the art and refers to aliphatic groups as described herein in which one or more carbon atoms are replaced with one or more heteroatoms (*e.g.*, oxygen, nitrogen, sulfur, silicon, phosphorus, and the like).

[0070] *Heteroalkyl*: The term "heteroalkyl" is given its ordinary meaning in the art and refers to alkyl groups as described herein in which one or more carbon atoms is replaced with a heteroatom (*e.g.*, oxygen, nitrogen, sulfur, silicon, phosphorus, and the like). Examples of heteroalkyl groups include, but are not limited to, alkoxy, poly(ethylene glycol)-, alkyl-substituted amino, tetrahydrofuranyl, piperidinyl, morpholinyl, *etc.*

[0071] *Heteroaryl*: The terms "heteroaryl" and "heteroar–," used alone or as part of a larger moiety, *e.g.*, "heteroaralkyl," or "heteroaralkoxy," refer to monocyclic, bicyclic or polycyclic ring systems having, for example, a total of five to thirty, *e.g.*, 5, 6, 9, 10, 14, *etc.*, ring members, wherein at least one ring in the system is aromatic and at least one aromatic ring atom is a heteroatom. In some embodiments, a heteroatom is nitrogen, oxygen or sulfur. In some embodiments, a heteroaryl group is a group having 5 to 10 ring atoms (*i.e.*, monocyclic, bicyclic or polycyclic), in some embodiments 5, 6, 9, or 10 ring atoms. In some embodiments, a heteroaryl group has 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. In some embodiments, a heteroaryl is a heterobiaryl group, such as bipyridyl and the like. The terms "heteroaryl" and "heteroar–", as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where a radical or point of attachment is on a heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4*H*–quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3–b]–1,4–oxazin–3(4H)–one. A heteroaryl group may be monocyclic, bicyclic or polycyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which terms include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl group, wherein the alkyl and heteroaryl portions independently are optionally substituted.

[0072] *Heteroatom*: The term "heteroatom" means an atom that is not carbon and is not hydrogen. In some embodiments, a heteroatom is oxygen, sulfur, nitrogen, phosphorus, boron or silicon (including any

oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or a substitutable nitrogen of a heterocyclic ring (for example, N as in 3,4-dihydro-2*H*-pyrrolyl), NH (as in pyrrolidinyl) or NR^+ (as in N-substituted pyrrolidinyl); *etc.*). In some embodiments, a heteroatom is boron, nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen or sulfur.

[0073] *Heterocyclyl*: As used herein, the terms "heterocycle," "heterocyclyl," "heterocyclic radical," and "heterocyclic ring" are used interchangeably and refer to a monocyclic, bicyclic or polycyclic ring moiety (*e.g.*, 3-30 membered) that is saturated or partially unsaturated and has one or more heteroatom ring atoms. In some embodiments, a heteroatom is boron, nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen or sulfur. In some embodiments, a heterocyclyl group is a stable 5– to 7–membered monocyclic or 7– to 10–membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0–3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4–dihydro–2*H*–pyrrolyl), NH (as in pyrrolidinyl), or $^+$NR (as in *N*–substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms "heterocycle," "heterocyclyl," "heterocyclyl ring," "heterocyclic group," "heterocyclic moiety," and "heterocyclic radical," are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3*H*–indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where a radical or point of attachment is on a heteroaliphatic ring. A heterocyclyl group may be monocyclic, bicyclic or polycyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.

[0074] *Homology:* As used herein, the term "homology" refers to the overall relatedness between polymeric molecules, *e.g.*, between nucleic acid molecules (*e.g.*, DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be "homologous" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. In some embodiments, polymeric molecules are considered to be "homologous" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%,

50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% similar (*e.g.*, containing residues with related chemical properties at corresponding positions). For example, as is well known by those of ordinary skill in the art, certain amino acids are typically classified as similar to one another as "hydrophobic" or "hydrophilic" amino acids, and/or as having "polar" or "non-polar" side chains. Substitution of one amino acid for another of the same type may often be considered a "homologous" substitution. Typical amino acid categorizations are summarized below (hydrophobicity scale of Kyte and Doolittle, 1982: A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105-132):

Amino Acid	3 Letter Code	1 Letter Code	Side Chain Polarity	Side Chain Acidity / Basicity	Hydropathy Index of Kyte and Doolittle
Alanine	Ala	A	nonpolar	neutral	1.8
Arginine	Arg	R	polar	basic	-4.5
Asparagine	Asn	N	polar	neutral	-3.5
Aspartic acid	Asp	D	polar	acidic	-3.5
Cysteine	Cys	C	nonpolar	neutral	2.5
Glutamic acid	Glu	E	polar	acidic	-3.5
Glutamine	Gln	Q	polar	neutral	-3.5
Glycine	Gly	G	nonpolar	neutral	-0.4
Histidine	His	H	polar	basic	-3.2
Isoleucine	Ile	I	nonpolar	neutral	4.5
Leucine	Leu	L	nonpolar	neutral	3.8
Lysine	Lys	K	polar	basic	-3.9
Methionine	Met	M	nonpolar	neutral	1.9
Phenylalanine	Phe	F	nonpolar	neutral	2.8
Proline	Pro	P	nonpolar	neutral	-1.6
Serine	Ser	S	polar	neutral	-0.8
Threonine	Thr	T	polar	neutral	-0.7
Tryptophan	Trp	W	nonpolar	neutral	-0.9
Tyrosine	Tyr	Y	polar	neutral	-1.3
Valine	Val	V	nonpolar	neutral	4.2

Ambiguous Amino Acids	3-Letter	1-Letter
Asparagine or aspartic acid	Asx	B
Glutamine or glutamic acid	Glx	Z
Leucine or Isoleucine	Xle	J
Unspecified or unknown amino acid	Xaa	X

[0075] As will be understood by those skilled in the art, a variety of algorithms are available that permit comparison of sequences in order to determine their degree of homology, including by permitting gaps of designated length in one sequence relative to another when considering which residues "correspond" to one another in different sequences. Calculation of the percent homology between two nucleic acid sequences, for

example, can be performed by aligning the two sequences for optimal comparison purposes (*e.g.*, gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-corresponding sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position; when a position in the first sequence is occupied by a similar nucleotide as the corresponding position in the second sequence, then the molecules are similar at that position. The percent homology between the two sequences is a function of the number of identical and similar positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. Representative algorithms and computer programs useful in determining the percent homology between two nucleotide sequences include, for example, the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent homology between two nucleotide sequences can, alternatively, be determined for example using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.

[0076] *Interaction residues*: The term "interaction residues", "interaction motifs", as used herein, refers to, with respect to an agent, residues or motifs in an agent that are designed to interact with particular target residues in a target polypeptide, or with respect to a target polypeptide, residues in a target polypeptide that interact with particular motifs (e.g., aromatic groups, amino acid residues, etc.) of an agent. Specifically, interaction residues and motifs of various agents are selected and arranged within the agents so that they will be displayed in three dimensional space within a predetermined distance (or volume) of identified target residues (e.g., upon binding, docking or other interaction assays). In many embodiments, interaction residues are direct-binding residues.

[0077] *"Improved," "increased"* or *"reduced":* As used herein, these terms, or grammatically comparable comparative terms, indicate values that are relative to a comparable reference measurement. For example, in some embodiments, an assessed value achieved with an agent of interest may be "improved" relative to that obtained with a comparable reference agent. Alternatively or additionally, in some embodiments, an assessed value achieved in a subject or system of interest may be "improved" relative to that obtained in the same subject or system under different conditions (*e.g.*, prior to or after an event such as administration of an agent of interest), or in a different, comparable subject (*e.g.*, in a comparable subject or system that differs from the subject or system of interest in presence of one or more indicators of a particular disease, disorder or condition of interest, or in prior exposure to a condition or agent, *etc*). In some embodiments, comparative terms refer to statistically relevant differences (*e.g.*, that are of a prevalence and/or magnitude sufficient to achieve statistical relevance). Those skilled in the art will be aware, or will

readily be able to determine, in a given context, a degree and/or prevalence of difference that is required or sufficient to achieve such statistical significance.

[0078] *Partially unsaturated*: As used herein, the term "partially unsaturated" refers to a moiety that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass groups having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties.

[0079] *Peptide:* The term "peptide" as used herein refers to a polypeptide. In some embodiments, a peptide is a polypeptide that is relatively short, for example having a length of less than about 100 amino acids, less than about 50 amino acids, less than about 40 amino acids less than about 30 amino acids, less than about 25 amino acids, less than about 20 amino acids, less than about 15 amino acids, or less than 10 amino acids. In some embodiments, a length is about 5-20, 5-19, 5-18, 5-17, 5-16, 5-15, 10-20, 10-19, 10-18, 10-17, 10-16, 10-15, 11-20, 11-19, 11-18, 11-17, 11-16, 11-15, 12-20, 12-19, 12-18, 12-17, 12-16, 12-15, 13-20, 13-19, 13-18, 13-17, 13-16, 13-15, 14-20, 14-19, 14-18, 14-17, 14-16, 14-15, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids.

[0080] *Pharmaceutical composition:* As used herein, the term "pharmaceutical composition" refers to an active agent, formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, active agent is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, *e.g.*, those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin, lungs, or oral cavity; intravaginally or intrarectally, for example, as a pessary, cream, or foam; sublingually; ocularly; transdermally; or nasally, pulmonary, and to other mucosal surfaces.

[0081] *Pharmaceutically acceptable:* As used herein, the phrase "pharmaceutically acceptable" refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0082] *Pharmaceutically acceptable carrier:* As used herein, the term "pharmaceutically acceptable carrier" means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not

injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; RingeR's solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and/or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.

[0083] *Pharmaceutically acceptable salt:* The term "pharmaceutically acceptable salt", as used herein, refers to salts of such compounds that are appropriate for use in pharmaceutical contexts, i.e., salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). In some embodiments, pharmaceutically acceptable salts include, but are not limited to, nontoxic acid addition salts, which are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other known methods such as ion exchange. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, *p*-toluenesulfonate, undecanoate, valerate salts, and the like. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, nontoxic base addition salts, such as those formed by acidic groups of provided compounds with bases. Representative alkali or alkaline earth metal salts include salts of sodium, lithium, potassium, calcium, magnesium, and the like. In some embodiments, pharmaceutically acceptable salts are ammonium salts (*e.g.*, $-N(R)_3^+$). In some embodiments, pharmaceutically acceptable salts are sodium salts. In some embodiments, pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.

[0084] *Polypeptide:* As used herein refers to any polymeric chain of amino acids. In some embodiments, a polypeptide has an amino acid sequence that occurs in nature. In some embodiments, a polypeptide has an amino acid sequence that does not occur in nature. In some embodiments, a polypeptide has an amino acid sequence that is engineered in that it is designed and/or produced through action of the hand of man. In some embodiments, a polypeptide may comprise or consist of natural amino acids, non-natural amino acids, or both. In some embodiments, a polypeptide may comprise or consist of only natural amino acids or only non-natural amino acids. In some embodiments, a polypeptide may comprise D-amino acids, L-amino acids, or both. In some embodiments, a polypeptide may comprise only D-amino acids. In some embodiments, a polypeptide may comprise only L-amino acids. In some embodiments, a polypeptide may include one or more pendant groups or other modifications, *e.g.*, modifying or attached to one or more amino acid side chains, at the polypeptide's N-terminus, at the polypeptide's C-terminus, or any combination thereof. In some embodiments, such pendant groups or modifications may be selected from the group consisting of acetylation, amidation, lipidation, methylation, pegylation, *etc.*, including combinations thereof. In some embodiments, a polypeptide may be cyclic, and/or may comprise a cyclic portion. In some embodiments, a polypeptide is not cyclic and/or does not comprise any cyclic portion. In some embodiments, a polypeptide is linear. In some embodiments, a polypeptide may be or comprise a stapled polypeptide. In some embodiments, the term "polypeptide" may be appended to a name of a reference polypeptide, activity, or structure; in such instances it is used herein to refer to polypeptides that share the relevant activity or structure and thus can be considered to be members of the same class or family of polypeptides. For each such class, the present specification provides and/or those skilled in the art will be aware of exemplary polypeptides within the class whose amino acid sequences and/or functions are known; in some embodiments, such exemplary polypeptides are reference polypeptides for the polypeptide class or family. In some embodiments, a member of a polypeptide class or family shows significant sequence homology or identity with, shares a common sequence motif (*e.g.*, a characteristic sequence element) with, and/or shares a common activity (in some embodiments at a comparable level or within a designated range) with a reference polypeptide of the class; in some embodiments with all polypeptides within the class). For example, in some embodiments, a member polypeptide shows an overall degree of sequence homology or identity with a reference polypeptide that is at least about 30-40%, and is often greater than about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more and/or includes at least one region (*e.g.*, a conserved region that may in some embodiments be or comprise a characteristic sequence element) that shows very high sequence identity, often greater than 90% or even 95%, 96%, 97%, 98%, or 99%. Such a conserved region usually encompasses at least 3-4 and often up to 20 or more amino acids; in some embodiments, a conserved region encompasses at least one stretch of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids. In some embodiments, a relevant polypeptide may comprise or consist of a fragment of a parent polypeptide. In some embodiments, a useful polypeptide as may comprise or consist of a plurality of fragments, each of which is found in the same parent polypeptide in a different

spatial arrangement relative to one another than is found in the polypeptide of interest (*e.g.*, fragments that are directly linked in the parent may be spatially separated in the polypeptide of interest or vice versa, and/or fragments may be present in a different order in the polypeptide of interest than in the parent), so that the polypeptide of interest is a derivative of its parent polypeptide.

[0085] *Prevent* or *prevention:* as used herein when used in connection with the occurrence of a disease, disorder, and/or condition, refers to reducing the risk of developing the disease, disorder and/or condition and/or to delaying onset of one or more characteristics or symptoms of the disease, disorder or condition. Prevention may be considered complete when onset of a disease, disorder or condition has been delayed for a predefined period of time.

[0086] *Protecting group*: The term "protecting group," as used herein, is well known in the art and includes those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. Also included are those protecting groups specially adapted for nucleoside and nucleotide chemistry described in Current Protocols in Nucleic Acid Chemistry, edited by Serge L. Beaucage et al. 06/2012, the entirety of Chapter 2 is incorporated herein by reference. Suitable amino–protecting groups include methyl carbamate, ethyl carbamante, 9–fluorenylmethyl carbamate (Fmoc), 9–(2–sulfo)fluorenylmethyl carbamate, 9–(2,7–dibromo)fluoroenylmethyl carbamate, 2,7–di–t–butyl–[9–(10,10–dioxo–10,10,10,10–tetrahydrothioxanthyl)]methyl carbamate (DBD–Tmoc), 4–methoxyphenacyl carbamate (Phenoc), 2,2,2–trichloroethyl carbamate (Troc), 2–trimethylsilylethyl carbamate (Teoc), 2–phenylethyl carbamate (hZ), 1–(1–adamantyl)–1–methylethyl carbamate (Adpoc), 1,1–dimethyl–2–haloethyl carbamate, 1,1–dimethyl–2,2–dibromoethyl carbamate (DB–t–BOC), 1,1–dimethyl–2,2,2–trichloroethyl carbamate (TCBOC), 1–methyl–1–(4–biphenylyl)ethyl carbamate (Bpoc), 1–(3,5–di–t–butylphenyl)–1–methylethyl carbamate (t–Bumeoc), 2–(2'– and 4'–pyridyl)ethyl carbamate (Pyoc), 2–(N,N–dicyclohexylcarboxamido)ethyl carbamate, t–butyl carbamate (BOC), 1–adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1–isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4–nitrocinnamyl carbamate (Noc), 8–quinolyl carbamate, N–hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p–methoxybenzyl carbamate (Moz), p–nitobenzyl carbamate, p–bromobenzyl carbamate, p–chlorobenzyl carbamate, 2,4–dichlorobenzyl carbamate, 4–methylsulfinylbenzyl carbamate (Msz), 9–anthrylmethyl carbamate, diphenylmethyl carbamate, 2–methylthioethyl carbamate, 2–methylsulfonylethyl carbamate, 2–(p–toluenesulfonyl)ethyl carbamate, [2–(1,3–dithianyl)]methyl carbamate (Dmoc), 4–methylthiophenyl carbamate (Mtpc), 2,4–dimethylthiophenyl carbamate (Bmpc), 2–phosphonioethyl carbamate (Peoc), 2–triphenylphosphonioisopropyl carbamate (Ppoc), 1,1–dimethyl–2–cyanoethyl carbamate, m–chloro–p–acyloxybenzyl carbamate, p–(dihydroxyboryl)benzyl carbamate, 5–benzisoxazolylmethyl carbamate, 2–(trifluoromethyl)–6–chromonylmethyl carbamate (Tcroc), m–nitrophenyl carbamate, 3,5–dimethoxybenzyl carbamate, o–nitrobenzyl carbamate, 3,4–dimethoxy–6–nitrobenzyl carbamate, phenyl(o–nitrophenyl)methyl carbamate, phenothiazinyl–(10)–carbonyl derivative, N'–p–toluenesulfonylaminocarbonyl derivative, N'–

phenylaminothiocarbonyl derivative, t–amyl carbamate, S–benzyl thiocarbamate, p–cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p–decyloxybenzyl carbamate, 2,2–dimethoxycarbonylvinyl carbamate, o–(N,N–dimethylcarboxamido)benzyl carbamate, 1,1–dimethyl–3–(N,N–dimethylcarboxamido)propyl carbamate, 1,1–dimethylpropynyl carbamate, di(2–pyridyl)methyl carbamate, 2–furanylmethyl carbamate, 2–iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p–(p'–methoxyphenylazo)benzyl carbamate, 1–methylcyclobutyl carbamate, 1–methylcyclohexyl carbamate, 1–methyl–1–cyclopropylmethyl carbamate, 1–methyl–1–(3,5–dimethoxyphenyl)ethyl carbamate, 1–methyl–1–(p–phenylazophenyl)ethyl carbamate, 1–methyl–1–phenylethyl carbamate, 1–methyl–1–(4–pyridyl)ethyl carbamate, phenyl carbamate, p–(phenylazo)benzyl carbamate, 2,4,6–tri–t–butylphenyl carbamate, 4–(trimethylammonium)benzyl carbamate, 2,4,6–trimethylbenzyl carbamate, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3–phenylpropanamide, picolinamide, 3–pyridylcarboxamide, N–benzoylphenylalanyl derivative, benzamide, p–phenylbenzamide, o–nitophenylacetamide, o–nitrophenoxyacetamide, acetoacetamide, (N'–dithiobenzyloxycarbonylamino)acetamide, 3–(p–hydroxyphenyl)propanamide, 3–(o–nitrophenyl)propanamide, 2–methyl–2–(o–nitrophenoxy)propanamide, 2–methyl–2–(o–phenylazophenoxy)propanamide, 4–chlorobutanamide, 3–methyl–3–nitrobutanamide, o–nitrocinnamide, N–acetylmethionine derivative, o–nitrobenzamide, o–(benzoyloxymethyl)benzamide, 4,5–diphenyl–3–oxazolin–2–one, N–phthalimide, N–dithiasuccinimide (Dts), N–2,3–diphenylmaleimide, N–2,5–dimethylpyrrole, N–1,1,4,4–tetramethyldisilylazacyclopentane adduct (STABASE), 5–substituted 1,3–dimethyl–1,3,5–triazacyclohexan–2–one, 5–substituted 1,3–dibenzyl–1,3,5–triazacyclohexan–2–one, 1–substituted 3,5–dinitro–4–pyridone, N–methylamine, N–allylamine, N–[2–(trimethylsilyl)ethoxy]methylamine (SEM), N–3–acetoxypropylamine, N–(1–isopropyl–4–nitro–2–oxo–3–pyroolin–3–yl)amine, quaternary ammonium salts, N–benzylamine, N–di(4–methoxyphenyl)methylamine, N–5–dibenzosuberylamine, N–triphenylmethylamine (Tr), N–[(4–methoxyphenyl)diphenylmethyl]amine (MMTr), N–9–phenylfluorenylamine (PhF), N–2,7–dichloro–9–fluorenylmethyleneamine, N–ferrocenylmethylamino (Fcm), N–2–picolylamino N'–oxide, N–1,1–dimethylthiomethyleneamine, N–benzylideneamine, N–p–methoxybenzylideneamine, N–diphenylmethyleneamine, N–[(2–pyridyl)mesityl]methyleneamine, N–(N',N'–dimethylaminomethylene)amine, N,N'–isopropylidenediamine, N–p–nitrobenzylideneamine, N–salicylideneamine, N–5–chlorosalicylideneamine, N–(5–chloro–2–hydroxyphenyl)phenylmethyleneamine, N–cyclohexylideneamine, N–(5,5–dimethyl–3–oxo–1–cyclohexenyl)amine, N–borane derivative, N–diphenylborinic acid derivative, N–[phenyl(pentacarbonylchromium– or tungsten)carbonyl]amine, N–copper chelate, N–zinc chelate, N–nitroamine, N–nitrosoamine, amine N–oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o–nitrobenzenesulfenamide (Nps), 2,4–dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2–nitro–4–methoxybenzenesulfenamide, triphenylmethylsulfenamide, 3–

nitropyridinesulfenamide (Npys), p–toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,–trimethyl–4–methoxybenzenesulfonamide (Mtr), 2,4,6–trimethoxybenzenesulfonamide (Mtb), 2,6–dimethyl–4–methoxybenzenesulfonamide (Pme), 2,3,5,6–tetramethyl–4–methoxybenzenesulfonamide (Mte), 4–methoxybenzenesulfonamide (Mbs), 2,4,6–trimethylbenzenesulfonamide (Mts), 2,6–dimethoxy–4–methylbenzenesulfonamide (iMds), 2,2,5,7,8–pentamethylchroman–6–sulfonamide (Pmc), methanesulfonamide (Ms), β–trimethylsilylethanesulfonamide (SES), 9–anthracenesulfonamide, 4–(4',8'–dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.

[0087] In some embodiments, suitable mono-protected amines include, but are not limited to, aralkylamines, carbamates, allyl amines, amides, and the like. Examples of suitable mono-protected amino moieties include t-butyloxycarbonylamino (–NHBOC), ethyloxycarbonylamino, methyloxycarbonylamino, trichloroethyloxycarbonylamino, allyloxycarbonylamino (–NHAlloc), benzyloxocarbonylamino (–NHCBZ), allylamino, benzylamino (–NHBn), fluorenylmethylcarbonyl (–NHFmoc), formamido, acetamido, chloroacetamido, dichloroacetamido, trichloroacetamido, phenylacetamido, trifluoroacetamido, benzamido, t-butyldiphenylsilyl, and the like. In some embodiments, suitable di-protected amines include amines that are substituted with two substituents independently selected from those described above as mono-protected amines, and further include cyclic imides, such as phthalimide, maleimide, succinimide, and the like. In some embodiments, suitable di-protected amines include pyrroles and the like, 2,2,5,5-tetramethyl-[1,2,5]azadisilolidine and the like, and azide.

[0088] Suitably protected carboxylic acids further include, but are not limited to, silyl–, alkyl–, alkenyl–, aryl–, and arylalkyl–protected carboxylic acids. Examples of suitable silyl groups include trimethylsilyl, triethylsilyl, t–butyldimethylsilyl, t–butyldiphenylsilyl, triisopropylsilyl, and the like. Examples of suitable alkyl groups include methyl, benzyl, p–methoxybenzyl, 3,4–dimethoxybenzyl, trityl, t–butyl, tetrahydropyran–2–yl. Examples of suitable alkenyl groups include allyl. Examples of suitable aryl groups include optionally substituted phenyl, biphenyl, or naphthyl. Examples of suitable arylalkyl groups include optionally substituted benzyl (e.g., p–methoxybenzyl (MPM), 3,4–dimethoxybenzyl, O–nitrobenzyl, p–nitrobenzyl, p–halobenzyl, 2,6–dichlorobenzyl, p–cyanobenzyl), and 2– and 4–picolyl. In some embodiments, suitable protected carboxylic acids include, but are not limited to, optionally substituted C_{1-6} aliphatic esters, optionally substituted aryl esters, silyl esters, activated esters, amides, hydrazides, and the like. Examples of such ester groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, and phenyl ester, wherein each group is optionally substituted. Additional suitable protected carboxylic acids include oxazolines and ortho esters.

[0089] Suitable hydroxyl protecting groups include methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t–butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p–methoxybenzyloxymethyl (PMBM), (4–methoxyphenoxy)methyl (p–AOM), guaiacolmethyl (GUM), t–butoxymethyl, 4–pentenyloxymethyl (POM), siloxymethyl, 2–methoxyethoxymethyl (MEM), 2,2,2–

trichloroethoxymethyl, bis(2–chloroethoxy)methyl, 2–(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3–bromotetrahydropyranyl, tetrahydrothiopyranyl, 1–methoxycyclohexyl, 4–methoxytetrahydropyranyl (MTHP), 4–methoxytetrahydrothiopyranyl, 4–methoxytetrahydrothiopyranyl S,S–dioxide, 1–[(2–chloro–4–methyl)phenyl]–4–methoxypiperidin–4–yl (CTMP), 1,4–dioxan–2–yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a–octahydro–7,8,8–trimethyl–4,7–methanobenzofuran–2–yl, 1–ethoxyethyl, 1–(2–chloroethoxy)ethyl, 1–methyl–1–methoxyethyl, 1–methyl–1–benzyloxyethyl, 1–methyl–1–benzyloxy–2–fluoroethyl, 2,2,2–trichloroethyl, 2–trimethylsilylethyl, 2–(phenylselenyl)ethyl, t–butyl, allyl, p–chlorophenyl, p–methoxyphenyl, 2,4–dinitrophenyl, benzyl, p–methoxybenzyl, 3,4–dimethoxybenzyl, o–nitrobenzyl, p–nitrobenzyl, p–halobenzyl, 2,6–dichlorobenzyl, p–cyanobenzyl, p–phenylbenzyl, 2–picolyl, 4–picolyl, 3–methyl–2–picolyl N–oxido, diphenylmethyl, p,p'–dinitrobenzhydryl, 5–dibenzosuberyl, triphenylmethyl, α–naphthyldiphenylmethyl, p–methoxyphenyldiphenylmethyl, di(p–methoxyphenyl)phenylmethyl, tri(p–methoxyphenyl)methyl, 4–(4'–bromophenacyloxyphenyl)diphenylmethyl, 4,4',4''–tris(4,5–dichlorophthalimidophenyl)methyl, 4,4',4''–tris(levulinoyloxyphenyl)methyl, 4,4',4''–tris(benzoyloxyphenyl)methyl, 3–(imidazol–1–yl)bis(4',4''–dimethoxyphenyl)methyl, 1,1–bis(4–methoxyphenyl)–1'–pyrenylmethyl, 9–anthryl, 9–(9–phenyl)xanthenyl, 9–(9–phenyl–10–oxo)anthryl, 1,3–benzodithiolan–2–yl, benzisothiazolyl S,S–dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t–butyldimethylsilyl (TBDMS), t–butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri–p–xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t–butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p–chlorophenoxyacetate, 3–phenylpropionate, 4–oxopentanoate (levulinate), 4,4–(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4–methoxycrotonate, benzoate, p–phenylbenzoate, 2,4,6–trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9–fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2–trichloroethyl carbonate (Troc), 2–(trimethylsilyl)ethyl carbonate (TMSEC), 2–(phenylsulfonyl) ethyl carbonate (Psec), 2–(triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate alkyl allyl carbonate, alkyl p–nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p–methoxybenzyl carbonate, alkyl 3,4–dimethoxybenzyl carbonate, alkyl o–nitrobenzyl carbonate, alkyl p–nitrobenzyl carbonate, alkyl S–benzyl thiocarbonate, 4–ethoxy–1–napththyl carbonate, methyl dithiocarbonate, 2–iodobenzoate, 4–azidobutyrate, 4–nitro–4–methylpentanoate, o–(dibromomethyl)benzoate, 2–formylbenzenesulfonate, 2–(methylthiomethoxy)ethyl, 4–(methylthiomethoxy)butyrate, 2–(methylthiomethoxymethyl)benzoate, 2,6–dichloro–4–methylphenoxyacetate, 2,6–dichloro–4–(1,1,3,3–tetramethylbutyl)phenoxyacetate, 2,4–bis(1,1–dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)–2–methyl–2–butenoate, o–(methoxycarbonyl)benzoate, α–naphthoate, nitrate, alkyl N,N,N',N'–tetramethylphosphorodiamidate, alkyl N–phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4–dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). For

protecting 1,2– or 1,3–diols, the protecting groups include methylene acetal, ethylidene acetal, 1–t–butylethylidene ketal, 1–phenylethylidene ketal, (4–methoxyphenyl)ethylidene acetal, 2,2,2–trichloroethylidene acetal, acetonide, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal, benzylidene acetal, p–methoxybenzylidene acetal, 2,4–dimethoxybenzylidene ketal, 3,4–dimethoxybenzylidene acetal, 2–nitrobenzylidene acetal, methoxymethylene acetal, ethoxymethylene acetal, dimethoxymethylene ortho ester, 1–methoxyethylidene ortho ester, 1–ethoxyethylidine ortho ester, 1,2–dimethoxyethylidene ortho ester, α–methoxybenzylidene ortho ester, 1–(N,N–dimethylamino)ethylidene derivative, α–(N,N'–dimethylamino)benzylidene derivative, 2–oxacyclopentylidene ortho ester, di–t–butylsilylene group (DTBS), 1,3–(1,1,3,3–tetraisopropyldisiloxanylidene) derivative (TIPDS), tetra–t–butoxydisiloxane–1,3–diylidene derivative (TBDS), cyclic carbonates, cyclic boronates, ethyl boronate, and phenyl boronate.

[0090] In some embodiments, a hydroxyl protecting group is acetyl, t-butyl, tbutoxymethyl, methoxymethyl, tetrahydropyranyl, 1 -ethoxyethyl, 1 -(2-chloroethoxy)ethyl, 2- trimethylsilylethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, benzoyl, p-phenylbenzoyl, 2,6- dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, triphenylmethyl (trityl), 4,4'-dimethoxytrityl, trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triphenylsilyl, triisopropylsilyl, benzoylformate, chloroacetyl, trichloroacetyl, trifiuoroacetyl, pivaloyl, 9- fluorenylmethyl carbonate, mesylate, tosylate, triflate, trityl, monomethoxytrityl (MMTr), 4,4'-dimethoxytrityl, (DMTr) and 4,4',4"-trimethoxytrityl (TMTr), 2-cyanoethyl (CE or Cne), 2-(trimethylsilyl)ethyl (TSE), 2-(2-nitrophenyl)ethyl, 2-(4-cyanophenyl)ethyl 2-(4-nitrophenyl)ethyl (NPE), 2-(4-nitrophenylsulfonyl)ethyl, 3,5-dichlorophenyl, 2,4-dimethylphenyl, 2-nitrophenyl, 4-nitrophenyl, 2,4,6-trimethylphenyl, 2-(2-nitrophenyl)ethyl, butylthiocarbonyl, 4,4',4"-tris(benzoyloxy)trityl, diphenylcarbamoyl, levulinyl, 2-(dibromomethyl)benzoyl (Dbmb), 2-(isopropylthiomethoxymethyl)benzoyl (Ptmt), 9-phenylxanthen-9-yl (pixyl) or 9-(p-methoxyphenyl)xanthine-9-y1 (MOX). In some embodiments, each of the hydroxyl protecting groups is, independently selected from acetyl, benzyl, t- butyldimethylsilyl, t-butyldiphenylsilyl and 4,4'-dimethoxytrityl. In some embodiments, the hydroxyl protecting group is selected from the group consisting of trityl, monomethoxytrityl and 4,4'-dimethoxytrityl group. In some embodiments, a phosphorous linkage protecting group is a group attached to the phosphorous linkage (e.g., an internucleotidic linkage) throughout oligonucleotide synthesis. In some embodiments, a protecting group is attached to a sulfur atom of an phosphorothioate group. In some embodiments, a protecting group is attached to an oxygen atom of an internucleotide phosphorothioate linkage. In some embodiments, a protecting group is attached to an oxygen atom of the internucleotide phosphate linkage. In some embodiments a protecting group is 2-cyanoethyl (CE or Cne), 2-trimethylsilylethyl, 2-nitroethyl, 2-sulfonylethyl, methyl, benzyl, o-nitrobenzyl, 2-(p-nitrophenyl)ethyl (NPE or Npe), 2-phenylethyl, 3-(N-tert-butylcarboxamido)-1-propyl, 4-oxopentyl, 4-methylthio-l-butyl, 2-cyano-1,1-dimethylethyl, 4-N-methylaminobutyl, 3-(2-pyridyl)-1-propyl, 2-[N-methyl-N-(2-pyridyl)]aminoethyl, 2-(N-formyl,N-methyl)aminoethyl, or 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl.

[0091] Protected thiols are well known in the art and include those described in detail in Greene (1999). Suitable protected thiols further include, but are not limited to, disulfides, thioethers, silyl thioethers, thioesters, thiocarbonates, and thiocarbamates, and the like. Examples of such groups include, but are not limited to, alkyl thioethers, benzyl and substituted benzyl thioethers, triphenylmethyl thioethers, and trichloroethoxycarbonyl thioester, to name but a few.

[0092] *Reference:* As used herein describes a standard or control relative to which a comparison is performed. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and/or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment. Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and/or comparison to a particular possible reference or control.

[0093] *Specificity*: As is known in the art, "specificity" is a measure of the ability of a particular ligand (e.g., an agent) to distinguish its binding partner (e.g., beta-catenin) from other potential binding partners (e.g., another protein, another portion (e.g., domain) of beta-catenin.

[0094] *Substitution*: As described herein, compounds of the disclosure may contain optionally substituted and/or substituted moieties. In general, the term "substituted," whether preceded by the term "optionally" or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable," as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, example substituents are described below.

[0095] Suitable monovalent substituents are halogen; $-(CH_2)_{0-4}R°$; $-(CH_2)_{0-4}OR°$; $-O(CH_2)_{0-4}R^o$, $-O-(CH_2)_{0-4}C(O)OR°$; $-(CH_2)_{0-4}CH(OR°)_2$; $-(CH_2)_{0-4}Ph$, which may be substituted with R°; $-(CH_2)_{0-4}O(CH_2)_{0-1}Ph$ which may be substituted with R°; –CH=CHPh, which may be substituted with R°; $-(CH_2)_{0-4}O(CH_2)_{0-1}$-pyridyl which may be substituted with R°; $-NO_2$; –CN; $-N_3$; $-(CH_2)_{0-4}N(R°)_2$; $-(CH_2)_{0-4}N(R°)C(O)R°$; $-N(R°)C(S)R°$; $-(CH_2)_{0-4}N(R°)C(O)N(R°)_2$; $-N(R°)C(S)N(R°)_2$; $-(CH_2)_{0-4}N(R°)C(O)OR°$; $-N(R°)N(R°)C(O)R°$; $-N(R°)N(R°)C(O)N(R°)_2$; $-N(R°)N(R°)C(O)OR°$; $-(CH_2)_{0-4}C(O)R°$; $-C(S)R°$; $-(CH_2)_{0-4}C(O)OR°$; $-(CH_2)_{0-4}C(O)SR°$; $-(CH_2)_{0-4}C(O)OSi(R°)_3$; $-(CH_2)_{0-4}OC(O)R°$; $-OC(O)(CH_2)_{0-4}SR°$,

$-SC(S)SR°$; $-(CH_2)_{0-4}SC(O)R°$; $-(CH_2)_{0-4}C(O)N(R°)_2$; $-C(S)N(R°)_2$; $-C(S)SR°$; $-SC(S)SR°$, $-(CH_2)_{0-4}OC(O)N(R°)_2$; $-C(O)N(OR°)R°$; $-C(O)C(O)R°$; $-C(O)CH_2C(O)R°$; $-C(NOR°)R°$; $-(CH_2)_{0-4}SSR°$; $-(CH_2)_{0-4}S(O)_2R°$; $-(CH_2)_{0-4}S(O)_2OR°$; $-(CH_2)_{0-4}OS(O)_2R°$; $-S(O)_2N(R°)_2$; $-(CH_2)_{0-4}S(O)R°$; $-N(R°)S(O)_2N(R°)_2$; $-N(R°)S(O)_2R°$; $-N(OR°)R°$; $-C(NH)N(R°)_2$; $-Si(R°)_3$; $-OSi(R°)_3$; $-P(R°)_2$; $-P(OR°)_2$; $-OP(R°)_2$; $-OP(OR°)_2$; $-N(R°)P(R°)_2$; $-B(R°)_2$; $-OB(R°)_2$; $-P(O)(R°)_2$; $-OP(O)(R°)_2$; $-N(R°)P(O)(R°)_2$; $-(C_{1-4}$ straight or branched alkylene)$O-N(R°)_2$; or $-(C_{1-4}$ straight or branched alkylene)$C(O)O-N(R°)_2$; wherein each R° may be substituted as defined below and is independently hydrogen, C_{1-20} aliphatic, C_{1-20} heteroaliphatic having 1–5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, $-CH_2-(C_{6-14}$ aryl), $-O(CH_2)_{0-1}(C_{6-14}$ aryl), $-CH_2$-(5-14 membered heteroaryl ring), a 5–20 membered, monocyclic, bicyclic, or polycyclic, saturated, partially unsaturated or aryl ring having 0–5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 5–20 membered, monocyclic, bicyclic, or polycyclic, saturated, partially unsaturated or aryl ring having 0–5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, which may be substituted as defined below.

[0096] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, $-(CH_2)_{0-2}R^•$, $-(haloR^•)$, $-(CH_2)_{0-2}OH$, $-(CH_2)_{0-2}OR^•$, $-(CH_2)_{0-2}CH(OR^•)_2$; $-O(haloR^•)$, $-CN$, $-N_3$, $-(CH_2)_{0-2}C(O)R^•$, $-(CH_2)_{0-2}C(O)OH$, $-(CH_2)_{0-2}C(O)OR^•$, $-(CH_2)_{0-2}SR^•$, $-(CH_2)_{0-2}SH$, $-(CH_2)_{0-2}NH_2$, $-(CH_2)_{0-2}NHR^•$, $-(CH_2)_{0-2}NR^•_2$, $-NO_2$, $-SiR^•_3$, $-OSiR^•_3$, $-C(O)SR^•$, $-(C_{1-4}$ straight or branched alkylene)$C(O)OR^•$, or $-SSR^•$ wherein each $R^•$ is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently selected from C_{1-4} aliphatic, $-CH_2Ph$, $-O(CH_2)_{0-1}Ph$, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =O and =S.

[0097] Suitable divalent substituents are the following: =O, =S, $=NNR^*_2$, $=NNHC(O)R^*$, $=NNHC(O)OR^*$, $=NNHS(O)_2R^*$, $=NR^*$, $=NOR^*$, $-O(C(R^*_2))_{2-3}O-$, or $-S(C(R^*_2))_{2-3}S-$, wherein each independent occurrence of R^* is selected from hydrogen, C_{1-6} aliphatic which may be substituted as defined below, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted" group include: $-O(CR^*_2)_{2-3}O-$, wherein each independent occurrence of R^* is selected from hydrogen, C_{1-6} aliphatic which may be substituted as defined below, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0098] Suitable substituents on the aliphatic group of R^* are halogen, $-R^•$, $-(haloR^•)$, $-OH$, $-OR^•$, $-O(haloR^•)$, $-CN$, $-C(O)OH$, $-C(O)OR^•$, $-NH_2$, $-NHR^•$, $-NR^•_2$, or $-NO_2$, wherein each $R^•$ is unsubstituted

or where preceded by "halo" is substituted only with one or more halogens, and is independently C_{1-4} aliphatic, $-CH_2Ph$, $-O(CH_2)_{0-1}Ph$, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0099] In some embodiments, suitable substituents on a substitutable nitrogen are $-R^{\dagger}$, $-NR^{\dagger}_2$, $-C(O)R^{\dagger}$, $-C(O)OR^{\dagger}$, $-C(O)C(O)R^{\dagger}$, $-C(O)CH_2C(O)R^{\dagger}$, $-S(O)_2R^{\dagger}$, $-S(O)_2NR^{\dagger}_2$, $-C(S)NR^{\dagger}_2$, $-C(NH)NR^{\dagger}_2$, or $-N(R^{\dagger})S(O)_2R^{\dagger}$; wherein each $R^{\dagger}$ is independently hydrogen, C_{1-6} aliphatic which may be substituted as defined below, unsubstituted –OPh, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or, notwithstanding the definition above, two independent occurrences of $R^{\dagger}$, taken together with their intervening atom(s) form an unsubstituted 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0100] Suitable substituents on the aliphatic group of $R^{\dagger}$ are independently halogen, $-R^{\bullet}$, -(halo$R^{\bullet}$), –OH, $-OR^{\bullet}$, –O(halo$R^{\bullet}$), –CN, –C(O)OH, $-C(O)OR^{\bullet}$, $-NH_2$, $-NHR^{\bullet}$, $-NR^{\bullet}_2$, or $-NO_2$, wherein each $R^{\bullet}$ is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C_{1-4} aliphatic, $-CH_2Ph$, $-O(CH_2)_{0-1}Ph$, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0101] *Subject:* As used herein, the term "subject" or "test subject" refers to any organism to which a provided compound or composition is administered in accordance with the present disclosure *e.g.,* for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include animals (*e.g.,* mammals such as mice, rats, rabbits, non-human primates, and humans; insects; worms; *etc.*) and plants. In some embodiments, a subject may be suffering from, and/or susceptible to a disease, disorder, and/or condition. In some embodiments, a subject is a human.

[0102] *Susceptible to*: An individual who is "susceptible to" a disease, disorder, and/or condition is one who has a higher risk of developing the disease, disorder, and/or condition than does a member of the general public. In some embodiments, an individual who is susceptible to a disease, disorder and/or condition may not have been diagnosed with the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition may exhibit symptoms of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition may not exhibit symptoms of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will develop the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will not develop the disease, disorder, and/or condition.

[0103] *Target polypeptide*: A "target polypeptide", as that term is used herein, is a polypeptide with which an agent interacts. In some embodiments, a target polypeptide is a beta-catenin polypeptide. In some embodiments, a target polypeptide comprises, consists essentially of, or is a binding site of beta-catenin polypeptide.

[0104] *Target residue*: A "target residue", as that term is used herein, is a residue within a target polypeptide with which an agent is designed to interact. For example, an agent may be characterized by particular interaction motifs (e.g., aromatic groups as described herein) and/or residues (e.g., amino acid residues comprising aromatic groups as described herein) selected and arranged (by virtue of being presented on the selected scaffold) to be within a certain predetermined distance (or volume) of a target residue. In some embodiments, a target residue is or comprises an amino acid residue.

[0105] *Therapeutic agent:* As used herein, the phrase "therapeutic agent" refers to an agent that, when administered to a subject, has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect. In some embodiments, a therapeutic agent is any substance that can be used to alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and/or reduce incidence of one or more symptoms or features of a disease, disorder, and/or condition.

[0106] *Therapeutic regimen*: A "therapeutic regimen", as that term is used herein, refers to a dosing regimen whose administration across a relevant population may be correlated with a desired or beneficial therapeutic outcome.

[0107] *Therapeutically effective amount:* As used herein, the term "therapeutically effective amount" means an amount of a substance (*e.g.,* a therapeutic agent, composition, and/or formulation) that elicits a desired biological response when administered as part of a therapeutic regimen. In some embodiments, a therapeutically effective amount of a substance is an amount that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, diagnose, prevent, and/or delay the onset of the disease, disorder, and/or condition. As will be appreciated by those of ordinary skill in this art, the effective amount of a substance may vary depending on such factors as the desired biological endpoint, the substance to be delivered, the target cell or tissue, *etc.* For example, the effective amount of compound in a formulation to treat a disease, disorder, and/or condition is the amount that alleviates, ameliorates, relieves, inhibits, prevents, delays onset of, reduces severity of and/or reduces incidence of one or more symptoms or features of the disease, disorder, and/or condition. In some embodiments, a therapeutically effective amount is administered in a single dose; in some embodiments, multiple unit doses are required to deliver a therapeutically effective amount.

[0108] *Treat:* As used herein, the term "treat," "treatment," or "treating" refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and/or reduce incidence of one or more symptoms or features of a disease, disorder, and/or condition. Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition. In some embodiments, treatment may be administered to a subject who exhibits only early signs of the disease, disorder, and/or condition, for example for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and/or condition.

[0109] *Unit dose*: The expression "unit dose" as used herein refers to an amount administered as a single dose and/or in a physically discrete unit of a pharmaceutical composition. In many embodiments, a

unit dose contains a predetermined quantity of an active agent. In some embodiments, a unit dose contains an entire single dose of the agent. In some embodiments, more than one unit dose is administered to achieve a total single dose. In some embodiments, administration of multiple unit doses is required, or expected to be required, in order to achieve an intended effect. A unit dose may be, for example, a volume of liquid (*e.g.*, an acceptable carrier) containing a predetermined quantity of one or more therapeutic agents, a predetermined amount of one or more therapeutic agents in solid form, a sustained release formulation or drug delivery device containing a predetermined amount of one or more therapeutic agents, *etc.* It will be appreciated that a unit dose may be present in a formulation that includes any of a variety of components in addition to the therapeutic agent(s). For example, acceptable carriers (*e.g.*, pharmaceutically acceptable carriers), diluents, stabilizers, buffers, preservatives, *etc.*, may be included as described infra. It will be appreciated by those skilled in the art, in many embodiments, a total appropriate daily dosage of a particular therapeutic agent may comprise a portion, or a plurality, of unit doses, and may be decided, for example, by the attending physician within the scope of sound medical judgment. In some embodiments, the specific effective dose level for any particular subject or organism may depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of specific active compound employed; specific composition employed; age, body weight, general health, sex and diet of the subject; time of administration, and rate of excretion of the specific active compound employed; duration of the treatment; drugs and/or additional therapies used in combination or coincidental with specific compound(s) employed, and like factors well known in the medical arts.

[0110] *Unsaturated*: The term "unsaturated" as used herein, means that a moiety has one or more units of unsaturation.

[0111] Unless otherwise specified, salts, such as pharmaceutically acceptable acid or base addition salts, stereoisomeric forms, and tautomeric forms, of provided compound are included.

[0112] As used herein in the present disclosure, unless otherwise clear from context, (i) the term "a" or "an" may be understood to mean "at least one"; (ii) the term "or" may be understood to mean "and/or"; (iii) the terms "comprising", "comprise", "including" (whether used with "not limited to" or not), and "include" (whether used with "not limited to" or not) may be understood to encompass itemized components or steps whether presented by themselves or together with one or more additional components or steps; (iv) the term "another" may be understood to mean at least an additional/second one or more; (v) the terms "about" and "approximately" may be understood to permit standard variation as would be understood by those of ordinary skill in the art; and (vi) where ranges are provided, endpoints are included.

Stapled Peptides

[0113] In some embodiments, a provided agent is or comprises a peptide. In some embodiments, a provided agent is a peptide. In some embodiments, a peptide is a stapled peptide. In some embodiments, a provided agent is a stapled peptide. In some embodiments, a peptide is a stitched peptide. In some

embodiments, a provided agent is a stitched peptide. In some embodiments, a stitched peptide comprises two or more staples, wherein two staples are bonded to the same peptide backbone atom. Stapled peptides as described herein are typically peptides in which two or more amino acids of a peptide chain are linked through connection of two peptide backbone atoms of the amino acid residues and, as is understood by those skilled in the art, the connection is not through the peptide backbone between the linked amino acid residues. In some embodiments, a staple as described herein is a linker that link one amino acid residue to another amino acid residue, e.g., through bonding to a peptide backbone atom of each of the amino acid residues and, as is understood by those skilled in the art, the connection through a staple is not through the peptide backbone between the linked amino acid residues. In some embodiments, a staple bonds to the peptide backbone by replacing one or more hydrogen and/or substituents (e.g., side chains, O, S, etc.) on peptide backbone atoms (e.g., C, N, etc.). In some embodiments, side chains form portions of staples. In some embodiments, a staple is bonded to two carbon backbone atoms, e.g., two alpha carbon atoms. In some embodiments, a staple comprises $C(R')_2$ or $N(R')$, either individually or as part of a large moiety, wherein R' is R and is taken together with another group attached to a backbone atom which can be R (e.g., R^{a3}) and their intervening atoms to form a ring as described herein (e.g., when PyrS2 is stapled in various peptides).

[0114] In some embodiments, a stapled peptide comprises one or more staples. In some embodiments, a stapled peptide comprises two or more staples. In some embodiments, a stapled peptide comprises three or more staples. In some embodiments, a stapled peptide comprises four or more staples. In some embodiments, there are three staples in a stapled peptide. In some embodiments, there are four staples in a stapled peptide.

[0115] As will be appreciated by those of ordinary skill in the art, a variety of peptide stapling technologies are available, including both hydrocarbon-stapling and non-hydrocarbon-stapling technologies, and can be utilized in accordance with the present disclosure. Various technologies for stapled and stitched peptides, including various staples and/or methods for manufacturing are available and may be utilized in accordance with the present disclosure, e.g., those described in WO 2019/051327 and WO 2020/041270, the staples of each of which are incorporated herein by reference.

[0116] In some embodiments, a peptide, e.g., a stapled peptide, is or comprise a helical structure. In some embodiments, a peptide is a stapled peptide.

[0117] In some embodiments, a staple is a hydrocarbon staple. In some embodiments, a staple as described herein is a non-hydrocarbon staple. In some embodiments, a non-hydrocarbon staple comprises one or more chain heteroatoms wherein a chain of a staple is the shortest covalent connection within the staple from one end of the staple to the other end of the staple. In some embodiments, a non-hydrocarbon staple is or comprises at least one sulfur atom derived from an amino acid residue of a polypeptide. In some embodiments, a non-hydrocarbon staple comprises two sulfur atom derived from two different amino acid residues of a polypeptide. In some embodiments, a non-hydrocarbon staple comprises two sulfur atoms derived from two different cysteine residues of a polypeptide. In some embodiments, a staple is a cysteine

staple. In some embodiments, a staple is a non-cysteine staple. In some embodiments, a non-hydrocarbon staple is a carbamate staple and comprises a carbamate moiety (e.g., −N(R')−C(O)−O−) in its chain. In some embodiments, a non-hydrocarbon staple is an amino staple and comprises an amino group (e.g., −N(R')−) in its chain. In some embodiments, an amino group in an amino staple, e.g., (−N(R')−) is not bonded to a carbon atom that additionally forms a double bond with a heteroatom (*e.g.*, −C(=O), −C(=S), −C(=N−R'), *etc.*) so that it is not part of another nitrogen-containing group such as amide, carbamate, etc. In some embodiments, a non-hydrocarbon staple is an ester staple and comprises an ester moiety (−C(O)−O−) in its chain. In some embodiments, a non-hydrocarbon staple is an amide staple and comprises an amide moiety (−C(O)−N(R')−) in its chain. In some embodiments, a non-hydrocarbon staple is a sulfonamide staple and comprises a sulfonamide moiety (−$S(O)_2$−N(R')−) in its chain. In some embodiments, a non-hydrocarbon staple is an ether staple and comprises an ether moiety (−O−) in its chain. In some embodiments, R' of a carbamate moiety, amino group, amide moiety, sulfonamide moiety, or ether moiety is R, and is taken together with an R group attached to a backbone (e.g., R^{a3} when it is R) and their intervening atoms to form a ring as described herein. In some embodiments, R' of a carbamate moiety or amino group is R, and is taken together with an R group attached to a backbone (e.g., R^{a3} when it is R) and their intervening atoms to form a ring as described herein.

[0118] In some embodiments, a staple comprises one or more amino groups, e.g., −N(R')−, wherein each R' is independently as described herein. In some embodiments, −N(R')− bonds to two carbon atoms. In some embodiments, −N(R')− bonds to two carbon atoms, wherein neither of the two carbon atoms are bond to any heteroatoms through a double bond. In some embodiments, −N(R')− bonds to two sp3 carbon atoms. In some embodiments, a staple comprises one or more −C(O)−N(R')− groups, wherein each R' is independently as described herein. In some embodiments, a staple comprises one or more carbamate groups, e.g., one or more −(O)−C(O)−N(R')−, wherein each R' is independently as described herein. In some embodiments, R' is −H. In some embodiments, R' is optionally substituted C_{1-6} aliphatic. In some embodiments, R' is optionally substituted C_{1-6} alkyl. In some embodiments, R' is C_{1-6} aliphatic. In some embodiments, R' is C_{1-6} alkyl. In some embodiments, R' is methyl.

[0119] In some embodiments, a stapled peptide comprise one or more staples. In some embodiments, a stapled peptide comprises one and no more than one staple. In some embodiments, a stapled peptide comprises two and no more than two staples. In some embodiments, two staples of a stapled peptide bond to a common backbone atom. In some embodiments, two staples of a stapled peptide bond to a common backbone atom which is an alpha carbon atom of an amino acid residue. In some embodiments, a stapled peptide comprises three or more staples. In some embodiments, a stapled peptides comprise four or more staples. In some embodiments, a stapled peptide comprises three and no more than three staples. In some embodiments, a stapled peptide comprises four and no more than four staples. In some embodiments, each staple independently has the structure of $-L^{s1}-L^{s2}-L^{s3}-$ as described herein. In some embodiments, each staple is independently bonded to two amino acid residues. In some embodiments, each staple is

independently bonded to two alpha carbon atoms.

[0120] In some embodiments, two, three, four, or all staples of a stapled peptide are within a region that has a length of several amino acid residues. In some embodiments, two staples are within such a region. In some embodiments, three staples are within such a region. In some embodiments, four staples are within such a region. In some embodiments, all staples are within such a region. In some embodiments, a region has a length of 5-20, 5-15, 5-14, 5-113, 5-12, 5-11, 5-10, 6-20, 6-15, 6-14, 6-113, 6-12, 6-11, 6-10, 7-20, 7-15, 7-14, 7-113, 7-12, 7-11, 7-10, 10-16, 10-15, 10-14, 11-16, 11-15, 11-14, 12-16, 12-15, 12-14, 13-15 or 13-14 amino acid residues. In some embodiments, a region has a length of 5 amino acid residues. In some embodiments, a region has a length of 6 amino acid residues. In some embodiments, a region has a length of 7 amino acid residues. In some embodiments, a region has a length of 8 amino acid residues. In some embodiments, a region has a length of 9 amino acid residues. In some embodiments, a region has a length of 10 amino acid residues. In some embodiments, a region has a length of 11 amino acid residues. In some embodiments, a region has a length of 12 amino acid residues. In some embodiments, a region has a length of 13 amino acid residues. In some embodiments, a region has a length of 14 amino acid residues. In some embodiments, a region has a length of 15 amino acid residues. In some embodiments, a region has a length of 16 amino acid residues. In some embodiments, a region has a length of 17 amino acid residues. In some embodiments, a region has a length of 18 amino acid residues. In some embodiments, a region has a length of 19 amino acid residues. In some embodiments, a region has a length of 20 amino acid residues. For example, in various embodiments, stapled peptides comprise three staples within in a region of 14 amino acids (e.g., a staple bonded to aa1 and aa4, a staple bonded to aa4 and aa11, and a staple bonded to aa10 and aa14).

[0121] In some embodiments, peptides, e.g., staple peptides, of the present disclosure is or comprises a helix structure. As those skilled in the art will appreciate, helixes can have various lengths. In some embodiments, lengths of helixes range from 5 to 30 amino acid residues. In some embodiments, a length of a helix is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or more, amino acid residues. In some embodiments, a length of a helix is 6 amino acid residues. In some embodiments, a length of a helix is 8 amino acid residues. In some embodiments, a length of a helix is 10 amino acid residues. In some embodiments, a length of a helix is 12 amino acid residues. In some embodiments, a length of a helix is 14 amino acid residues. In some embodiments, a length of a helix is 16 amino acid residues. In some embodiments, a length of a helix is 17 amino acid residues. In some embodiments, a length of a helix is 18 amino acid residues. In some embodiments, a length of a helix is 19 amino acid residues. In some embodiments, a length of a helix is 20 amino acid residues.

[0122] Amino acids stapled together can have various number of amino acid residues in between, e.g., 1-20, 1-15, 1-10, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, etc. In some embodiments, a staple is (i, i+4) which means there are three amino acid residues between the two amino acids (at positions i and i+4, respectively) that bond to the staple (at positions i+1, i+2, i+3, respectively). In some embodiments, a staple is (i, i+2). In some

embodiments, a staple is (i, i+3). In some embodiments, a staple is (i, i+5). In some embodiments, a staple is (i, i+6). In some embodiments, a staple is (i, i+7). In some embodiments, a staple is (i, i+8). In some embodiments, a stapled peptide comprises two staples, one is (i, i+2) and the other is (i, i+7). In some embodiments, a stapled peptide comprises two staples, one is (i, i+3) and the other is (i, i+7). In some embodiments, a stapled peptide comprises two staples, one is (i, i+3) and the other is (i, i+4). In some embodiments, a stapled peptide comprises two staples, one is (i, i+4) and the other is (i, i+7). In some embodiments, a stapled peptide comprises two staples, one is (i, i+3) and the other is (i, i+3). In some embodiments, a stapled peptide comprises two staples, one is (i, i+4) and the other is (i, i+4). In some embodiments, a stapled peptide comprises two staples, one is (i, i+7) and the other is (i, i+7). In some embodiments, the two staples are bonded to a common backbone atom, e.g., an alpha carbon atom of an amino acid residue. In some embodiments, a stapled peptide further comprises a third staple. In some embodiments, a third staple is (i, i+3). In some embodiments, a third staple is (i, i+4). In some embodiments, a third staple is (i, i+7). In some embodiments, a stapled peptide further comprises a fourth staple. In some embodiments, a fourth staple is (i, i+3). In some embodiments, a fourth staple is (i, i+4). In some embodiments, a fourth staple is (i, i+7).

[0123] In some embodiments, a stapled peptide comprises a staple which staple is L^s, wherein L^s is $-L^{s1}-L^{s2}-L^{s3}-$, each of L^{s1}, L^{s2}, and L^{s3} is independently L, wherein each L is independently as described in the present disclosure. In some embodiments, a provided staple is L^s.

[0124] In some embodiments, L^{s1} comprises at least one $-N(R')-$, wherein R' is as described in the present disclosure. In some embodiments, the $-N(R')-$ is bonded to two carbon atoms, wherein neither of the two carbon atoms forms a double bond with a heteroatom. In some embodiments, the $-N(R')-$ is not bonded to $-C(O)-$. In some embodiments, the $-N(R')-$ is not bonded to $-C(S)-$. In some embodiments, the $-N(R')-$ is not bonded to $-C(=NR')-$. In some embodiments, L^{s1} is $-L'-N(R')-$, wherein L' is optionally substituted bivalent C_1-C_{19} aliphatic. In some embodiments, L^{s1} is $-L'-N(CH_3)-$, wherein L' is optionally substituted bivalent C_1-C_{19} aliphatic.

[0125] In some embodiments, R' is optionally substituted C_{1-6} alkyl. In some embodiments, R' is C_{1-6} alkyl. In some embodiments, R' is methyl. In some embodiments, the peptide backbone atom to which L^{s1} is bonded is also bonded to R^1, and R' and R^1 are both R and are taken together with their intervene atoms to form an optionally substituted ring as described in the present disclosure. In some embodiments, a formed ring has no additional ring heteroatoms in addition to the nitrogen atom to which R' is bonded. In some embodiments, a formed ring is 3-membered. In some embodiments, a formed ring is 4-membered. In some embodiments, a formed ring is 5-membered. In some embodiments, a formed ring is 6-membered.

[0126] In some embodiments, L' is optionally substituted bivalent C_1-C_{20} aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_{19} aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_{15} aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_{10} aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_9 aliphatic. In some embodiments,

L' is optionally substituted bivalent C_1-C_8 aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_7 aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_6 aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_5 aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_4 aliphatic. In some embodiments, L' is optionally substituted alkylene. In some embodiments, L' is optionally substituted alkenylene. In some embodiments, L' is unsubstituted alkylene. In some embodiments, L' is $-CH_2-$. In some embodiments, L' is $-(CH_2)_2-$. In some embodiments, L' is $-(CH_2)_3-$. In some embodiments, L' is $-(CH_2)_4-$. In some embodiments, L' is $-(CH_2)_5-$. In some embodiments, L' is $-(CH_2)_6-$. In some embodiments, L' is $-(CH_2)_7-$. In some embodiments, L' is $-(CH_2)_8-$. In some embodiments, L' is bonded to a peptide backbone atom. In some embodiments, L' is optionally substituted alkenylene. In some embodiments, L' is unsubstituted alkenylene. In some embodiments, L' is $-CH_2-CH=CH-CH_2-$.

[0127] In some embodiments, L' is optionally substituted phenylene.

[0128] In some embodiments, L^{s1} comprises at least one $-N(R')C(O)-$, wherein R' is as described in the present disclosure. In some embodiments, L^{s1} is $-L'-N(R')C(O)-$, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L^{s1} is $-L'-N(CH_3)C(O)-$, wherein L' is independently as described in the present disclosure.

[0129] In some embodiments, L^{s1} comprises at least one $-C(O)O-$. In some embodiments, L^{s1} comprises at least one $-C(O)O-$. In some embodiments, L^{s1} is $-L'-C(O)O-$ or $-L'-OC(O)-$, wherein each L' is independently as described in the present disclosure. In some embodiments, L^{s1} is $-L'-C(O)O-$, wherein each L' is independently as described in the present disclosure. In some embodiments, L^{s1} is $-L'-OC(O)-$, wherein each L' is independently as described in the present disclosure.

[0130] In some embodiments, L^{s1} comprises at least one $-S(O)_2-N(R')-$, wherein R' is as described in the present disclosure. In some embodiments, L^{s1} comprises at least one $-S(O)_2-N(R')-$, wherein R' is as described in the present disclosure. In some embodiments, L^{s1} is $-L'-N(R')-S(O)_2-$ or $-L'-S(O)_2-N(R')-$, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L^{s1} is $-L'-N(R')-S(O)_2-$, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L^{s1} is $-L'-S(O)_2-N(R')-$, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L^{s1} is $-L'-N(CH_3)-S(O)_2-$ or $-L'-S(O)_2-N(CH_3)-$, wherein each L' is independently as described in the present disclosure. In some embodiments, L^{s1} is $-L'-N(CH_3)-S(O)_2-$, wherein L' is as described in the present disclosure. In some embodiments, L^{s1} is $-L'-S(O)_2-N(CH_3)-$, wherein L' is as described in the present disclosure.

[0131] In some embodiments, L^{s1} comprises at least one $-O-$. In some embodiments, L^{s1} is $-L'-O-$, wherein L' is independently as described in the present disclosure.

[0132] In some embodiments, L^{s1} is a covalent bond.

[0133] In some embodiments, L^{s1} is L', wherein L' is as described in the present disclosure.

[0134] In some embodiments, L^{s2} is L, wherein L is as described in the present disclosure. In some

embodiments, L^{s2} is L', wherein L' is as described in the present disclosure. In some embodiments, L^{s2} comprises $-CH_2-CH=CH-CH_2-$. In some embodiments, L^{s2} is $-CH_2-CH=CH-CH_2-$. In some embodiments, L^{s2} comprises $-(CH_2)_4-$. In some embodiments, L^{s2} is $-(CH_2)_4-$.

[0135] In some embodiments, L^{s3} comprises at least one $-N(R')-$, wherein R' is as described in the present disclosure. In some embodiments, the $-N(R')-$ is bonded to two carbon atoms, wherein neither of the two carbon atoms forms a double bond with a heteroatom. In some embodiments, the $-N(R')-$ is not bonded to $-C(O)-$. In some embodiments, the $-N(R')-$ is not bonded to $-C(S)-$. In some embodiments, the $-N(R')-$ is not bonded to $-C(=NR')-$. In some embodiments, L^{s3} is $-L'-N(R')-$, wherein L' is optionally substituted bivalent C_1-C_{19} aliphatic. In some embodiments, L^{s3} is $-L'-N(CH_3)-$, wherein L' is optionally substituted bivalent C_1-C_{19} aliphatic.

[0136] In some embodiments, L^{s3} comprises at least one $-N(R')C(O)-$, wherein R' is as described in the present disclosure. In some embodiments, L^{s3} is $-L'-N(R')C(O)-$, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L^{s3} is $-L'-N(CH_3)C(O)-$, wherein L' is independently as described in the present disclosure.

[0137] In some embodiments, L^{s3} comprises at least one $-C(O)O-$. In some embodiments, L^{s3} comprises at least one $-C(O)O-$. In some embodiments, L^{s3} is $-L'-C(O)O-$ or $-L'-OC(O)-$, wherein each L' is independently as described in the present disclosure. In some embodiments, L^{s3} is $-L'-C(O)O-$, wherein each L' is independently as described in the present disclosure. In some embodiments, L^{s3} is $-L'-OC(O)-$, wherein each L' is independently as described in the present disclosure.

[0138] In some embodiments, L^{s3} comprises at least one $-S(O)_2-N(R')-$, wherein R' is as described in the present disclosure. In some embodiments, L^{s3} comprises at least one $-S(O)_2-N(R')-$, wherein R' is as described in the present disclosure. In some embodiments, L^{s3} is $-L'-N(R')-S(O)_2-$ or $-L'-S(O)_2-N(R')-$, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L^{s3} is $-L'-N(R')-S(O)_2-$, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L^{s3} is $-L'-S(O)_2-N(R')-$, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L^{s3} is $-L'-N(CH_3)-S(O)_2-$ or $-L'-S(O)_2-N(CH_3)-$, wherein each L' is independently as described in the present disclosure. In some embodiments, L^{s3} is $-L'-N(CH_3)-S(O)_2-$, wherein L' is as described in the present disclosure. In some embodiments, L^{s3} is $-L'-S(O)_2-N(CH_3)-$, wherein L' is as described in the present disclosure.

[0139] In some embodiments, L^{s3} comprises at least one $-O-$. In some embodiments, L^{s3} is $-L'-O-$, wherein L' is independently as described in the present disclosure.

[0140] In some embodiments, L^{s3} is L', wherein L' is as described in the present disclosure. In some embodiments, L^{s3} is optionally substituted alkylene. In some embodiments, L^{s3} is unsubstituted alkylene.

[0141] In some embodiments, L^{s} comprises at least one $-N(R')-$, wherein R' is as described in the present disclosure. In some embodiments, the $-N(R')-$ is bonded to two carbon atoms, wherein neither of the two carbon atoms forms a double bond with a heteroatom. In some embodiments, the $-N(R')-$ is not

bonded to −C(O)−. In some embodiments, the −N(R')− is not bonded to −C(S)−. In some embodiments, the −N(R')− is not bonded to −C(=NR')−. In some embodiments, L^s comprises at least one −N(R')C(O)−, wherein R' is as described in the present disclosure.

[0142] In some embodiments, L^s, L^{s1}, L^{s2}, and L^{s3} each independently and optionally comprise a R' group, e.g., a R' group in $-C(R')_2-$, −N(R')−, etc., and the R' group is taken with a group (e.g., a group that can be R) attached to a backbone atom (e.g., R^{a1}, R^{a2}, R^{a3}, a R' group of L^{a1} or L^{a2} (e.g., a R' group in $-C(R')_2-$, −N(R')−, etc.), etc.) to form a double bond or an optionally substituted ring as two R groups can. In some embodiments, a formed ring is an optionally substituted 3-10 membered ring. In some embodiments, a formed ring is an optionally substituted 3-membered ring. In some embodiments, a formed ring is an optionally substituted 4-membered ring. In some embodiments, a formed ring is an optionally substituted 5-membered ring. In some embodiments, a formed ring is an optionally substituted 6-membered ring. In some embodiments, a formed ring is monocyclic. In some embodiments, a formed ring is saturated. In some embodiments, a formed ring is partially unsaturated. In some embodiments, a formed ring is aromatic. In some embodiments, a formed ring comprises one or more ring heteroatom (e.g., nitrogen). In some embodiments, a staple, or L^s, L^{s1}, L^{s2}, and/or L^{s3} comprises −N(R')−, and the R' is taken together with a group attached to a backbone atom to form an optionally substituted ring as described herein. In some embodiments, a staple, or L^s, L^{s1}, L^{s2}, and/or L^{s3} comprises $-C(R')_2-$, and the R' is taken together with a group attached to a backbone atom to form an optionally substituted ring as described herein.

[0143] In some embodiments, a staple, or L^s, L^{s1}, L^{s2}, and/or L^{s3} comprises portions of one or more amino acid side chains (e.g., a side chain other than its terminal $=CH_2$).

[0144] As will be clear to those skilled in the art reading the present disclosure, the letter "L" is used to refer to a linker moiety as described herein; each $L^{\text{superscript}}$ (e.g., L^a, L^{s1}, L^{s2}, L^{s3}, L^s, etc.) therefore is understood, in some embodiments, to be L, unless otherwise specified.

[0145] In some embodiments, L comprises at least one −N(R')−, wherein R' is as described in the present disclosure. In some embodiments, the −N(R')− is bonded to two carbon atoms, wherein neither of the two carbon atoms forms a double bond with a heteroatom. In some embodiments, the −N(R')− is not bonded to −C(O)−. In some embodiments, the −N(R')− is not bonded to −C(S)−. In some embodiments, the −N(R')− is not bonded to −C(=NR')−. In some embodiments, L is −L'−N(R')−, wherein L' is optionally substituted bivalent C_1-C_{19} aliphatic. In some embodiments, L is $-L'-N(CH_3)-$, wherein L' is optionally substituted bivalent C_1-C_{19} aliphatic.

[0146] In some embodiments, L comprises at least one −N(R')C(O)−, wherein R' is as described in the present disclosure. In some embodiments, L is −L'−N(R')C(O)−, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L is $-L'-N(CH_3)C(O)-$, wherein L' is independently as described in the present disclosure.

[0147] In some embodiments, L comprises at least one −C(O)O−. In some embodiments, L comprises at least one −C(O)O−. In some embodiments, L is −L'−C(O)O− or −L'−OC(O)−, wherein each L' is

independently as described in the present disclosure. In some embodiments, L is −L'−C(O)O−, wherein each L' is independently as described in the present disclosure. In some embodiments, L is −L'−OC(O)−, wherein each L' is independently as described in the present disclosure.

[0148] In some embodiments, L comprises at least one $-S(O)_2-N(R')-$, wherein R' is as described in the present disclosure. In some embodiments, L comprises at least one $-S(O)_2-N(R')-$, wherein R' is as described in the present disclosure. In some embodiments, L is $-L'-N(R')-S(O)_2-$ or $-L'-S(O)_2-N(R')-$, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L is $-L'-N(R')-S(O)_2-$, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L is $-L'-S(O)_2-N(R')-$, wherein each of L' and R' is independently as described in the present disclosure. In some embodiments, L is $-L'-N(CH_3)-S(O)_2-$ or $-L'-S(O)_2-N(CH_3)-$, wherein each L' is independently as described in the present disclosure. In some embodiments, L is $-L'-N(CH_3)-S(O)_2-$, wherein L' is as described in the present disclosure. In some embodiments, L is $-L'-S(O)_2-N(CH_3)-$, wherein L' is as described in the present disclosure.

[0149] In some embodiments, L comprises at least one −O−. In some embodiments, L is −L'− O−, wherein L' is independently as described in the present disclosure.

[0150] In some embodiments, L is L', wherein L' is as described in the present disclosure. In some embodiments, L is optionally substituted alkylene. In some embodiments, L is unsubstituted alkylene.

[0151] In some embodiments, L is optionally substituted bivalent C_1-C_{25} aliphatic. In some embodiments, L is optionally substituted bivalent C_1-C_{20} aliphatic. In some embodiments, L is optionally substituted bivalent C_1-C_{15} aliphatic. In some embodiments, L is optionally substituted bivalent C_1-C_{10} aliphatic. In some embodiments, L is optionally substituted bivalent C_1-C_9 aliphatic. In some embodiments, L is optionally substituted bivalent C_1-C_8 aliphatic. In some embodiments, L is optionally substituted bivalent C_1-C_7 aliphatic. In some embodiments, L is optionally substituted bivalent C_1-C_6 aliphatic. In some embodiments, L is optionally substituted bivalent C_1-C_5 aliphatic. In some embodiments, L is optionally substituted bivalent C_1-C_4 aliphatic. In some embodiments, L is optionally substituted alkylene. In some embodiments, L is optionally substituted alkenylene. In some embodiments, L is unsubstituted alkylene. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is $-(CH_2)_5-$. In some embodiments, L is $-(CH_2)_6-$. In some embodiments, L is $-(CH_2)_7-$. In some embodiments, L is $-(CH_2)_8-$. In some embodiments, L is bonded to a peptide backbone atom. In some embodiments, L is optionally substituted alkenylene. In some embodiments, L is unsubstituted alkenylene. In some embodiments, L is $-CH_2-CH=CH-CH_2-$.

[0152] In some embodiments, one end of a staple is connected to an atom A^{n1} of the peptide backbone, wherein A^{n1} is optionally substituted with R^1 and is an atom of an amino acid residue at amino acid position n^1 of the peptide from the N-terminus, and the other end is connected to an atom A^{n2} of the peptide backbone, wherein A^{n2} is optionally substituted with R^2 (in some embodiments, R^1 and/or R^2 is R which can be

hydrogen) and is an atom of an amino acid residue at amino acid position n^2 of the peptide from the N-terminus, wherein each of n^1 and n^2 is independently an integer, and $n^2 = n^1 + m$, wherein m is 3-12.

[0153] In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8. In some embodiments, m is 9. In some embodiments, m is 10. In some embodiments, m is 11. In some embodiments, a staple is referred to a (i, i+m) staple.

[0154] In some embodiments, A^{n1} is a carbon atom. In some embodiments, A^{n1} is achiral. In some embodiments, A^{n1} is chiral. In some embodiments, A^{n1} is *R*. In some embodiments, A^{n1} is *S*.

[0155] In some embodiments, A^{n2} is a carbon atom. In some embodiments, A^{n2} is achiral. In some embodiments, A^{n2} is chiral. In some embodiments, A^{n2} is *R*. In some embodiments, A^{n2} is *S*.

[0156] In some embodiments, A^{n1} is achiral and A^{n2} is achiral. In some embodiments, A^{n1} is achiral and A^{n2} is R. In some embodiments, A^{n1} is achiral and A^{n2} is S. In some embodiments, A^{n1} is R and A^{n2} is achiral. In some embodiments, A^{n1} is R and A^{n2} is R. In some embodiments, A^{n1} is R and A^{n2} is S. In some embodiments, A^{n1} is S and A^{n2} is achiral. In some embodiments, A^{n1} is S and A^{n2} is R. In some embodiments, A^{n1} is S and A^{n2} is S.

[0157] In some embodiments, provided stereochemistry at staple-backbone connection points and/or combinations thereof, optionally together with one or more structural elements of provided peptide, *e.g.*, staple chemistry (hydrocarbon, non-hydrocarbon), staple length, *etc.* can provide various benefits, such as improved preparation yield, purity, and/or selectivity, improved properties (*e.g.*, improved solubility, improved stability, lowered toxicity, improved selectivity, *etc.*), improved activities, *etc.* In some embodiments, provided stereochemistry and/or stereochemistry combinations are different from those typically used, *e.g.*, those of US 9617309, US 2015-0225471, US 2016-0024153, US 2016-0215036, US 2016-0244494, WO 2017/062518, and provided one or more of benefits described in the present disclosure.

[0158] In some embodiments, a staple can be of various lengths, in some embodiments, as represent by the number of chain atoms of a staple. In some embodiments, a chain of a staple is the shortest covalent connection in the staple from a first end (connection point with a peptide backbone) of a staple to a second end of the staple, wherein the first end and the second end are connected to two different peptide backbone atoms. In some embodiments, a staple comprises 5-30 chain atoms, *e.g.*, 5-20, 5-15, 5, 6, 7, 8, 9, or 10 to 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 chain atoms. In some embodiments, a staple comprises 5 chain atoms. In some embodiments, a staple comprises 6 chain atoms. In some embodiments, a staple comprises 7 chain atoms. In some embodiments, a staple comprises 8 chain atoms. In some embodiments, a staple comprises 9 chain atoms. In some embodiments, a staple comprises 10 chain atoms. In some embodiments, a staple comprises 11 chain atoms. In some embodiments, a staple comprises 12 chain atoms. In some embodiments, a staple comprises 13 chain atoms. In some embodiments, a staple comprises 14 chain atoms. In some embodiments, a staple comprises 15 chain atoms. In some embodiments, a staple comprises 16 chain atoms. In some embodiments, a staple comprises 17 chain atoms. In some

embodiments, a staple comprises 18 chain atoms. In some embodiments, a staple comprises 19 chain atoms. In some embodiments, a staple comprises 20 chain atoms. In some embodiments, a staple has a length of 5 chain atoms. In some embodiments, a staple has a length of 6 chain atoms. In some embodiments, a staple has a length of 7 chain atoms. In some embodiments, a staple has a length of 8 chain atoms. In some embodiments, a staple has a length of 9 chain atoms. In some embodiments, a staple has a length of 10 chain atoms. In some embodiments, a staple has a length of 11 chain atoms. In some embodiments, a staple has a length of 12 chain atoms. In some embodiments, a staple has a length of 13 chain atoms. In some embodiments, a staple has a length of 14 chain atoms. In some embodiments, a staple has a length of 15 chain atoms. In some embodiments, a staple has a length of 16 chain atoms. In some embodiments, a staple has a length of 17 chain atoms. In some embodiments, a staple has a length of 18 chain atoms. In some embodiments, a staple has a length of 19 chain atoms. In some embodiments, a staple has a length of 20 chain atoms. In some embodiments, a staple has a length of 8-15 chain atoms. In some embodiments, a staple has 8-12 chain atoms. In some embodiments, a staple has 9-12 chain atoms. In some embodiments, a staple has 9-10 chain atoms. In some embodiments, a staple has 8-10 chain atoms. In some embodiments, length of a staple can be adjusted according to the distance of the amino acid residues it connects, for example, a longer staple may be utilized for a (i, i+7) staple than a (i, i+4) or (i, i+3) staple. In some embodiments, a (i, i+2) staple has about 5-10, 5-8, e.g., about 5, 6, 7, 8, 9 or 10 chain atoms. In some embodiments, a (i, i+2) staple has 5 chain atoms. In some embodiments, a (i, i+2) staple has 6 chain atoms. In some embodiments, a (i, i+2) staple has 7 chain atoms. In some embodiments, a (i, i+2) staple has 8 chain atoms. In some embodiments, a (i, i+2) staple has 9 chain atoms. In some embodiments, a (i, i+2) staple has 10 chain atoms. In some embodiments, a (i, i+3) staple has about 5-10, 5-8, e.g., about 5, 6, 7, 8, 9 or 10 chain atoms. In some embodiments, a (i, i+3) staple has 5 chain atoms. In some embodiments, a (i, i+3) staple has 6 chain atoms. In some embodiments, a (i, i+3) staple has 7 chain atoms. In some embodiments, a (i, i+3) staple has 8 chain atoms. In some embodiments, a (i, i+3) staple has 9 chain atoms. In some embodiments, a (i, i+3) staple has 10 chain atoms. In some embodiments, a (i, i+4) staple has about 5-12, 5-10, 7-12, 5-8, e.g., about 5, 6, 7, 8, 9, 10, 11 or 12 chain atoms. In some embodiments, a (i, i+4) staple has 5 chain atoms. In some embodiments, a (i, i+4) staple has 6 chain atoms. In some embodiments, a (i, i+4) staple has 7 chain atoms. In some embodiments, a (i, i+4) staple has 8 chain atoms. In some embodiments, a (i, i+4) staple has 9 chain atoms. In some embodiments, a (i, i+4) staple has 10 chain atoms. In some embodiments, a (i, i+4) staple has 11 chain atoms. In some embodiments, a (i, i+4) staple has 12 chain atoms. In some embodiments, a (i, i+7) staple has about 8-25, 10-25, 10-16, 12-15, e.g., about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 chain atoms. In some embodiments, a (i, i+7) staple has 8 chain atoms. In some embodiments, a (i, i+7) staple has 9 chain atoms. In some embodiments, a (i, i+7) staple has 10 chain atoms. In some embodiments, a (i, i+7) staple has 11 chain atoms. In some embodiments, a (i, i+7) staple has 12 chain atoms. In some embodiments, a (i, i+7) staple has 13 chain atoms. In some embodiments, a (i, i+7) staple has 14 chain atoms. In some embodiments, a (i, i+7) staple

has 15 chain atoms. In some embodiments, a (i, i+7) staple has 16 chain atoms. In some embodiments, a (i, i+7) staple has 17 chain atoms. In some embodiments, a (i, i+7) staple has 18 chain atoms. In some embodiments, a (i, i+7) staple has 19 chain atoms. In some embodiments, a (i, i+7) staple has 20 chain atoms. In some embodiments, a (i, i+7) staple has 21 chain atoms. In some embodiments, a (i, i+7) staple has 22 chain atoms. In some embodiments, a stapled peptide comprises three or more staples, each of which is independently such a (I, i+2), (i, i+3), (i, i+4) or (i, i+7) staple. In some embodiments, a stapled peptide comprises such a (i, i+2) staple, such a (i, i+4) staple and such a (i, i+7) staple. In some embodiments, a stapled peptide comprises such a (i, i+3) staple, such a (i, i+4) staple and such a (i, i+7) staple. In some embodiments, a stapled peptide comprises such a (i, i+3) staple, such a (i, i+7) staple and such a (i, i+7) staple.

[0159] Staple lengths may be otherwise described. For example, in some embodiments, staple lengths may be described as the total number of chain atoms and non-chain ring atoms, where a non-chain ring atom is an atom of the staple which forms a ring with one or more chain atoms but is not a chain atom in that it is not within the shortest covalent connection from a first end of the staple to a second end of the staple. In some embodiments, staples formed using Monomer A (which comprises an azetidine moiety), Monomer B (which comprises a pyrrolidine moiety), and/or Monomer C (which comprises a pyrrolidine moiety), etc., may comprise one or two non-chain ring atoms.

[0160] In some embodiments, a staple has no heteroatoms in its chain. In some embodiments, a staple comprises at least one heteroatom in its chain. In some embodiments, a staple comprises at least one nitrogen atom in its chain.

[0161] In some embodiments, a staple is L^s, wherein L^s is an optionally substituted, bivalent C_{8-14} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, a staple is L^s, wherein L^s is an optionally substituted, bivalent C_{9-13} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, a staple is L^s, wherein L^s is an optionally substituted, bivalent C_{10-15} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, a staple is L^s, wherein L^s is an optionally substituted, bivalent C_{11-14} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, a staple is a (i, i+2) staple in that not including the two amino

acid residues that are directly connected to the staple, there are one amino acid residue between the two amino acid residues that are directly connected to the staple. In some embodiments, a staple is a (i, i+3) staple in that not including the two amino acid residues that are directly connected to the staple, there are two amino acid residues between the two amino acid residues that are directly connected to the staple. In some embodiments, a staple is a (i, i+4) staple in that not including the two amino acid residues that are directly connected to the staple, there are three amino acid residues between the two amino acid residues that are directly connected to the staple. In some embodiments, a staple is a (i, i+7) staple in that not including the two amino acid residues that are directly connected to the staple, there are six amino acid residues between the two amino acid residues that are directly connected to the staple.

[0162] In some embodiments, for each of L^s, L^{s1}, L^{s2}, and L^{s3}, any replacement of methylene units, if any, is replaced with −N(R')−, −C(O)−N(R')−, −N(R')C(O)O−, −C(O)O−, $-S(O)_2N(R')-$, or −O−. In some embodiments, for each of L^s, L^{s1}, L^{s2}, and L^{s3}, any replacement of methylene units, if any, is replaced with −N(R')−, −N(R')−C(O)−, or −N(R')C(O)O−. In some embodiments, for each of L^s, L^{s1}, L^{s2}, and L^{s3}, any replacement of methylene units, if any, is replaced with −N(R')− or −N(R')C(O)O−. In some embodiments, for each of L^s, L^{s1}, L^{s2}, and L^{s3}, any replacement of methylene units, if any, is replaced with −N(R')−. In some embodiments, for each of L^s, L^{s1}, L^{s2}, and L^{s3}, any replacement of methylene units, if any, is replaced with −N(R')C(O)O−.

[0163] In some embodiments, a staple comprises a double bond. In some embodiments, a staple comprises a double bond may be formed by olefin metathesis of two olefins. In some embodiments, staples are formed by metathesis reactions, e.g., involving one or more double bonds in amino acid residues as described herein. In some embodiments, a first amino acid residue comprising an olefin (e.g., AA1−CH=CH_2) and a second amino acid residue comprising an olefin (e.g., AA2−CH=CH_2) are stapled (e.g., forming AA1−CH=CH−AA2, wherein AA1 and AA2 are typically linked through one or more amino acid residues). In some embodiments, an olefin, e.g., in a staple, is converted into −CHR'−CHR'−, wherein each R' is independently as described herein. In some embodiments, R' is R as described herein. In some embodiments, R' is −H. In some embodiments, each R' is −H. In some embodiments, R' is −OR, wherein R is as described herein. In some embodiments, R' is −OH. In some embodiments, R' is $-N(R)_2$ wherein each R is independently as described herein. In some embodiments, R' is −SR wherein R is as described herein. In some embodiments, R' is R wherein R is optionally substituted aliphatic, e.g., C_{1-10} aliphatic. In some embodiments, R' is R wherein R is optionally substituted aliphatic, e.g., C_{1-10} alkenyl. In some embodiments, R' is R wherein R is optionally substituted aliphatic, e.g., C_{1-10} alkynyl. In some embodiments, −CHR'−CHR'− is $-CH_2-CH_2-$. In some embodiments, each of the two olefins is independently of a side chain of an amino acid residue. In some embodiments, each olefin is independently a terminal olefin. In some embodiments, each olefin is independently a mono-substituted olefin.

[0164] In some embodiments, an amino acid of formula A-I or a salt thereof is a compound having the structure of formula A-II:

$$NH(R^{a1})–L^{a1}–C(–L^{a}–CH=CH_2)(R^{a3})–L^{a2}–COOH,$$

A-II

or a salt thereof, wherein each variable is independently as described in the present disclosure. In some embodiments, an amino acid suitable for stapling has the structure of formula A-II or a salt thereof, wherein each variable is independently as described in the present disclosure.

[0165] In some embodiments, an amino acid of formula A-II or a salt thereof is a compound having the structure of formula A-II-b:

$$NH(R^{a1})–C(–L^{a}–CH=CH_2)(R^{a3})–COOH,$$

A-II-b

or a salt thereof, wherein each variable is independently as described in the present disclosure. In some embodiments, an amino acid suitable for stapling has the structure of formula A-II-b or a salt thereof, wherein each variable is independently as described in the present disclosure.

[0166] In some embodiments, an amino acid of formula A-I or a salt thereof is a compound having the structure of formula A-III:

$$N(–L^{a}–CH=CH_2)(R^{a1})–L^{a1}–C(–L^{a}–CH=CH_2)(R^{a3})–L^{a2}–COOH,$$

A-III

or a salt thereof, wherein each variable is independently as described in the present disclosure. In some embodiments, an amino acid suitable for stapling has the structure of formula A-II or a salt thereof, wherein each variable is independently as described in the present disclosure.

[0167] In some embodiments, an amino acid of formula A-I or a salt thereof has structure of formula A-IV:

$$NH(R^{a1})–L^{a1}–C(–L^{a}–COOH)(R^{a3})–L^{a2}–COOH,$$

A-IV

or a salt thereof, wherein each variable is independently as described in the present disclosure. In some embodiments, an amino acid suitable for stapling has the structure of formula A-IV or a salt thereof, wherein each variable is independently as described in the present disclosure.

[0168] In some embodiments, an amino acid has structure of formula A-V:

$$NH(R^{a1})–L^{a1}–C(–L^{a}–R^{SP1})(R^{a3})–L^{a2}–COOH,$$

A-V

or a salt thereof, wherein each variable is independently as described in the present disclosure. In some embodiments, an amino acid suitable for stapling has the structure of formula A-V or a salt thereof, wherein each variable is independently as described in the present disclosure.

[0169] In some embodiments, an amino acid for stapling has structure of formula A-VI:

$$NH(R^{a1})–L^{a1}–C(–L^{a}–R^{SP1})(–L^{a}–R^{SP2})–L^{a2}–COOH,$$

A-VI

or a salt thereof, wherein each variable is independently as described in the present disclosure. In some embodiments, an amino acid suitable for stapling has the structure of formula A-VI or a salt thereof, wherein each variable is independently as described in the present disclosure.

[0170] As used herein, each of R^{SP1} and R^{SP2} independently comprises a reactive group. In some embodiments, each of R^{SP1} and R^{SP2} is independently a reactive group. In some embodiments, a reactive group is optionally substituted $-CH=CH_2$. In some embodiments, a reactive group is $-CH=CH_2$. In some embodiments, a reactive group is an amino group, e.g., $-NHR$, wherein R is as described herein. In some embodiments, a reactive group is an acid group. In some embodiments, a reactive group is $-COOH$ or an activated form thereof. In some embodiments, a reactive group is for a cycloaddition reaction (e.g., [3+2], [4+2], etc.), e.g., an alkene, an alkyne, a diene, a 1,3-dipole (e.g., $-N_3$), etc. In some embodiments, a reactive group is optionally substituted $-C\equiv CH$. In some embodiments, a reactive group is $-C\equiv CH$. In some embodiments, a reactive group is $-N_3$.

[0171] In some embodiments, R^{SP1} or R^{SP2} of a first amino acid residue and R^{SP1} or R^{SP2} of a second amino acid residue can react with each other so that the two amino acid residues are connected with a staple. In some embodiments, a reactive is olefin metathesis between two olefin, e.g., two $-CH=CH_2$. In some embodiments, a reaction is amidation and one reactive group is an amino group, e.g., $-NHR$ wherein R is as described herein (e.g., in some embodiments, R is $-H$; in some embodiments, R is optionally substituted C_{1-6} aliphatic), and the other is an acid group (e.g., $-COOH$) or an activated form thereof. In some embodiments, a reaction is a cycloaddition reaction, e.g., [4+2], [3+2], etc. In some embodiments, a first and a second reactive groups are two reactive groups suitable for a cycloaddition reaction. In some embodiments, a reaction is a click reaction. In some embodiments, one reaction group is or comprises $-N_3$, and the other is or comprises an alkyne, e.g., a terminal alkyne or a activated/strained alkyne. In some embodiments, the other is or comprises $-C\equiv CH$.

[0172] In some embodiments, R^{SP1} or R^{SP2} of a first amino acid residue and R^{SP1} or R^{SP2} of a second amino acid residue can react with a reagent so that the two are connected to form a staple. In some embodiments, a reagent comprises two reactive groups, one of which reacts with R^{SP1} or R^{SP2} of a first amino acid residue, and the other reacts with R^{SP1} or R^{SP2} of a first amino acid residue. In some embodiments, R^{SP1} or R^{SP2} of both amino acid residues are the same or the same type, e.g., both are amino groups, and the two reactive groups of a linking reagent are also the same, e.g., both are acid groups such as $-COOH$ or activated form thereof. In some embodiments, R^{SP1} or R^{SP2} of both amino acid residues are both acid groups, e.g., $-COOH$ or activated form thereof, and both reactive groups of a linking agent are amino groups. In some embodiments, R^{SP1} or R^{SP2} of both amino acid residues are both nucleophilic groups, e.g., $-SH$, and both reactive groups of a linking reagent are electrophilic (e.g., carbon attached to leaving groups such as $-Br$, $-I$, etc.).

[0173] In some embodiments, R^{SP1} and R^{SP2} are the same. In some embodiments, R^{SP1} and R^{SP2} are different. In some embodiments, R^{SP1} is or comprises $-CH=CH_2$. In some embodiments, R^{SP1} is or

comprises −COOH. In some embodiments, R^{SP1} is or comprises an amino group. In some embodiments, R^{SP1} is or comprises −NHR. In some embodiments, R is hydrogen or optionally substituted C_{1-6} aliphatic. In some embodiments, R^{SP1} is or comprises $-NH_2$. In some embodiments, R^{SP1} is or comprises $-N_3$. In some embodiments, R^{SP2} is or comprises $-CH=CH_2$. In some embodiments, R^{SP2} is or comprises −COOH. In some embodiments, R^{SP2} is or comprises an amino group. In some embodiments, R^{SP2} is or comprises −NHR. In some embodiments, R is hydrogen or optionally substituted C_{1-6} aliphatic. In some embodiments, R^{SP2} is or comprises $-NH_2$. In some embodiments, R^{SP2} is or comprises $-N_3$.

[0174] In some embodiments, each amino acid residue of a pair of amino acid residues is independently a residue of an amino acid of formula A-II or A-III or a salt thereof. In some embodiments, such a pair of amino acid residues is stapled, e.g., through olefin metathesis. In some embodiments, a staple has the structure of $-L^a-CH=CH-L^a-$, wherein each variable is independently as described herein. In some embodiments, olefin in a staple is reduced. In some embodiments, In some embodiments, a staple has the structure of $-L^a-CH_2-CH_2-L^a-$, wherein each variable is independently as described herein. In some embodiments, one L^a is L^{s1} as described herein, and one L^a is L^{s3} as described herein.

[0175] In some embodiments, two amino acid residues, e.g., of amino acids independently of formula A-I or a salt of, connected by a staple have the structure of $-N(R^{a1})-L^{a1}-C(-L^s-R^{AA})(R^{a3})-L^{a2}-CO-$, wherein each variable is independently as described herein, and R^{AA} is an amino acid residue. In some embodiments, two amino acid residues, e.g., of amino acids independently of formula A-I or a salt of, connected by a staple have the structure of $-N(-L^s-R^{AA})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-CO-$, wherein each variable is independently as described herein, and R^{AA} is an amino acid residue. In some embodiments, two amino acid residues, e.g., of amino acids independently of formula A-I or a salt of, connected by a staple have the structure of $R^{a1}-N(-L^s-R^{AA})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-CO-$, wherein each variable is independently as described herein, and R^{AA} is an amino acid residue. In some embodiments, three amino acid residues, e.g., of amino acids independently of formula A-I or a salt of, connected by two staples have the structure of $R^{a1}-N(-L^s-R^{AA})-L^{a1}-C(-L^s-R^{AA})(R^{a3})-L^{a2}-CO-$, wherein each variable is independently as described herein, and R^{AA} is an amino acid residue. In some embodiments, three amino acid residues, e.g., of amino acids independently of formula A-I or a salt of, connected by two staples have the structure of $-N(-L^s-R^{AA})-L^{a1}-C(-L^s-R^{AA})(R^{a3})-L^{a2}-CO-$, wherein each variable is independently as described herein, and R^{AA} is an amino acid residue. In some embodiments, three amino acid residues, e.g., of amino acids independently of formula A-I or a salt of, connected by two staples (e.g., X^4 stapled with both X^1 and X^{14}) have the structure of $-N(R^{a1})-L^{a1}-C(-L^s-R^{AA})(-L^s-R^{AA})-L^{a2}-CO-$, wherein each variable is independently as described herein, and R^{AA} is an amino acid residue. In some embodiments, each R^{AA} is independently a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof. In some embodiments, R^{AA} is $-C(R^{a3})[-L^{a1}-N(R^{a1})-](-L^{a2}-CO-)$, wherein each variable is independently as described herein. In some embodiments, R^{AA} is $-C(R^{a3})[-N(R^{a1})-](-CO-)$, wherein each variable is independently as described herein. In some embodiments, each R^{AA} is independently

$-N(-)[-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-CO-]$, wherein each variable is independently as described herein, wherein $-C(-)(R^{a3})-$ is bonded to a staple. In some embodiments, each R^{AA} is independently $-N(-)[-C(R^{a2})(R^{a3})-CO-]$, wherein each variable is independently as described herein, wherein $-C(-)(R^{a3})-$ is bonded to a staple. In some embodiments, each R^{AA} is independently $R^{a1}-N(-)[-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-CO-]$, wherein each variable is independently as described herein, wherein $-C(-)(R^{a3})-$ is bonded to a staple. In some embodiments, each R^{AA} is independently $R^{a1}-N(-)[-C(R^{a2})(R^{a3})-CO-]$, wherein each variable is independently as described herein, wherein $-C(-)(R^{a3})-$ is bonded to a staple.

[0176] Various staples, e.g., L^s, are as described herein. In some embodiments, L^s is $-L^{s1}-L^{s2}-L^{s3}-$ as described herein. In some embodiments, L^{s1} is L^a as described herein. In some embodiments, L^{s3} is L^a as described herein. In some embodiments, L^{s1} is L^a of a first of two stapled amino acid residues. In some embodiments, L^{s2} is L^a of a second of two stapled amino acid residues. In some embodiments, L^{s2} is or comprises a double bond. In some embodiments, L^{s2} is or comprises $-CH=CH-$. In some embodiments, L^{s2} is or comprises optionally substituted $-CH_2-CH_2-$. In some embodiments, L^{s2} is or comprises $-CH_2-CH_2-$. In some embodiments, L^{s2} is or comprises $-C(O)N(R')-$ (e.g., a staple formed by two amino acid residues one of which has a R^{SP1} group that is or comprises an amino group and the other of which has a R^{SP2} group that is or comprises $-COOH$). In some embodiments, L^{s2} is or comprises $-C(O)NH-$. In some embodiments, each of L^{s1} and L^{s3} is independently optionally substituted linear or branched C_{1-10} hydrocarbon chain. In some embodiments, each of L^{s1} and L^{s3} is independently $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L^{s1} is $-CH_2-$. In some embodiments, L^{s3} is $-(CH_2)_3-$.

[0177] In some embodiments, L^s is $-CH_2-CH=CH-(CH_2)_3-$. In some embodiments, L^s is $-(CH_2)_6-$.

[0178] In some embodiments, L^s is $-(CH_2)_2-C(O)NH-(CH_2)_4-$.

[0179] In some embodiments, L^s is bonded to two backbone carbon atoms. In some embodiments, L^s is bonded to two alpha carbon atoms of two stapled amino acid residues. In some embodiments, L^s is bonded to a backbone nitrogen atom and a backbone carbon atom (e.g., an alpha carbon).

[0180] In some embodiments, L^a comprises at least one $-N(R')-$ wherein R' is independently as described in the present disclosure. In some embodiments, L^a comprises $-L^{am1}-N(R')-$ wherein R' is independently as described in the present disclosure, and L^{am1} is as described herein. In some embodiments, L^a is or comprises $-L^{am1}-N(R')-L^{am2}-$, wherein each of L^{am1}, R', and L^{am2} is independently as described herein. In some embodiments, R' is optionally substituted C_{1-6} aliphatic. In some embodiments, R' is methyl. In some embodiments, R' is taken together with R^{a3} to form an optionally substituted ring as described herein. In some embodiments, a formed ring is a 3-10 membered monocyclic saturated ring as described herein. In some embodiments, a formed ring has no additional heteroatom ring atom in addition to the nitrogen of $-N(R')-$. In some embodiments, a formed ring is 3-membered. In some embodiments, a formed ring is 4-membered. In some embodiments, a formed ring is 5-membered. In some embodiments, a formed ring is 6-membered.

[0181] In some embodiments, L^a comprises at least one $-C(R')_2-$ wherein each R' is independently as described in the present disclosure. In some embodiments, L^a comprises $-L^{am1}-C(R')_2-$ wherein R' is independently as described in the present disclosure, and L^{am1} is as described herein. In some embodiments, L^a is or comprises $-L^{am1}-C(R')_2-L^{am2}-$, wherein each of L^{am1}, R', and L^{am2} is independently as described herein. In some embodiments, R' is −H. In some embodiments, $-C(R')_2-$ is optionally substituted $-CH_2-$. In some embodiments, $-C(R')_2-$ is $-CH_2-$. In some embodiments, one R' is taken together with R^{a3} to form an optionally substituted ring as described herein. In some embodiments, a formed ring is a 3-10 membered monocyclic saturated ring as described herein. In some embodiments, a formed ring has no additional heteroatom ring atom in addition to the nitrogen of $-N(R')-$. In some embodiments, a formed ring is 3-membered. In some embodiments, a formed ring is 4-membered. In some embodiments, a formed ring is 5-membered. In some embodiments, a formed ring is 6-membered.

[0182] As described herein, each of L^{am1} and L^{am2} is independently L^{am} as described herein. As described herein, L^{am} is a covalent bond, or an optionally substituted, bivalent C_1-C_{10} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, −Cy−, −O−, −S−, −S−S−, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, L^{am} is a covalent bond. In some embodiments, L^{am} is an optionally substituted bivalent C_1-C_{10} aliphatic group. In some embodiments, L^{am} is an optionally substituted bivalent linear C_1-C_{10} aliphatic group. In some embodiments, L^{am} is optionally substituted C_{1-10} alkylene. In some embodiments, L^{am} is C_{1-10} alkylene. In some embodiments, L^{am} is optionally substituted linear C_{1-10} alkylene. In some embodiments, L^{am} is optionally substituted $-CH_2-$. In some embodiments, L^{am} is $-CH_2-$.

[0183] In some embodiments, L^{am1} is a covalent bond. In some embodiments, L^{am1} is an optionally substituted bivalent C_1-C_{10} aliphatic group. In some embodiments, L^{am1} is an optionally substituted bivalent linear C_1-C_{10} aliphatic group. In some embodiments, L^{am1} is optionally substituted C_{1-10} alkylene. In some embodiments, L^{am1} is C_{1-10} alkylene. In some embodiments, L^{am1} is optionally substituted linear C_{1-10} alkylene. In some embodiments, L^{am1} is optionally substituted $-CH_2-$. In some embodiments, L^{am1} is $-CH_2-$. In some embodiments, L^{am1} is bonded to a backbone atom. In some embodiments, L^{am1} is bonded to an alpha-carbon of an amino acid.

[0184] In some embodiments, L^{am2} is a covalent bond. In some embodiments, L^{am2} is an optionally substituted bivalent C_1-C_{10} aliphatic group. In some embodiments, L^{am2} is an optionally substituted bivalent linear C_1-C_{10} aliphatic group. In some embodiments, L^{am2} is optionally substituted C_{1-10} alkylene. In some embodiments, L^{am2} is C_{1-10} alkylene. In some embodiments, L^{am2} is optionally substituted linear C_{1-10} alkylene. In some embodiments, L^{am2} is optionally substituted $-CH_2-$. In some embodiments, L^{am2} is $-CH_2-$. In some embodiments, L^{am2} is or comprises $-C(O)-$. In some embodiments, $-C(O)-$ is bonded to a nitrogen atom. In some embodiments, L^{am2} is or comprises $-S(O)_2-$. In some embodiments, $-S(O)_2-$ is bonded to a nitrogen atom. In some embodiments, L^{am2} is or comprises $-O-$. In some embodiments, L^{am2} is




or comprises −C(O)−O−. In some embodiments, −C(O)−O− is bonded to a nitrogen atom. In some embodiments, L^{am2} is bonded to a nitrogen atom, and it comprises a −C(O)− group which is bonded to the nitrogen atom. In some embodiments, L^{am2} is bonded to a nitrogen atom, and it comprises a −C(O)−O− group which is bonded to the nitrogen atom. In some embodiments, L^{am2} is or comprises −C(O)−O−CH_2−, wherein the −CH_2− is optionally substituted. In some embodiments, L^{am2} is −C(O)−O−CH_2−.

[0185] In some embodiments, L^a is L^{s1} as described herein. In some embodiments, L^a is L^{s2} as described herein.







[0186] In some embodiments, R^{a3} is −L^a−CH=CH_2, wherein L^a is independently as described herein. In some embodiments, each of R^{a2} and R^{a3} independently comprises a double bond, e.g., a terminal olefin which can be optionally and independently stapled with another residue comprising an olefin. In some embodiments, each of R^{a2} and R^{a3} are independently −L^a−CH=CH_2. In some embodiments, an amino acid are stapled with two amino acid residues independently through R^{a2} and R^{a3}. In some embodiments, such an amino acid is B5. In some embodiments, it is B3. In some embodiments, it is B4. In some embodiments, it is B6.

[0187] In some embodiments, an amino acid is selected from Tables A-I, A-II, A-III and A-IV (may be presented as Fmoc-protected). As appreciated by those skilled in the art, among other things, when incorporated into peptides, Fmoc-protected amino groups and carboxyl groups may independently form amide connections with other amino acid residues (or N- or C-terminus capping groups, or exist as N- or C-terminus amino or carboxyl groups). Olefins, including those in Alloc groups, may be utilized to form staples through olefin metathesis. Staples comprising olefins may be further modified, e.g., through hydrogenation to convert olefin double bonds into single bonds, and/or through CO_2 extrusion to convert carbamate moieties (e.g., −O−(CO)−N(R')−) into amine moieties (e.g., −N(R')−). In some embodiments, an agent is or comprises a stapled peptide (e.g., a stapled peptide described according to Table E2 or Table E3) or a salt thereof, in which stapled peptide each double bond is converted into a single bond. In some embodiments, a conversion is achieved through hydrogenation which adds a −H to each olefin carbon atom. In some embodiments, an olefin double bond is replaced with −CHR'−CHR'−, wherein each R' is independently as described herein. In some embodiments, R' is R as described herein. In some embodiments, R' is −H. In some embodiments, each R' is −H. In some embodiments, R' is −OR, wherein R is as described herein. In some embodiments, R' is −OH. In some embodiments, R' is −$N(R)_2$ wherein each R is independently as described herein. In some embodiments, R' is −SR wherein R is as described herein. In some embodiments, R' is R wherein R is optionally substituted aliphatic, e.g., C_{1-10} aliphatic. In some embodiments, R' is R wherein R is optionally substituted aliphatic, e.g., C_{1-10} alkenyl. In some embodiments, R' is R wherein R is optionally substituted aliphatic, e.g., C_{1-10} alkynyl. In some embodiments, −CHR'−CHR'− is −CH_2−CH_2−.







[0188] Table A-I. Exemplary amino acids (Fmoc-Protected).






















Monomer A (M_A)	Monomer B (M_B)	Monomer C (M_C)
		

[0189] Table A-II. Exemplary amino acids (Fmoc-Protected).

Monomer D (M_D)	Monomer E (M_E)	Monomer F (M_F)
		
Monomer G (M_G)	**Monomer H (M_H)**	**Monomer I (M_I)**
		

[0190] Table A-III. Exemplary amino acids (Fmoc-Protected).

S3	R3	S4
		
R4	**S5**	**R5**
		
B5	**S6**	**R6**

		
S7	R7	S8
		
R8		
	 n is 1-5, e.g., 1, 2 or 3	 n is 1-5, e.g., 1, 2 or 3
PL3	PyrS	PyrS1
		
PyrS2	PyrS3	RdN
		
ReN	RgN	S_{10}
		
SdN	SeN	SgN
		

[0191] In some embodiments, an amino acid is an alpha-amino acid. In some embodiments, an amino acid is an L-amino acid. In some embodiments, an amino acid is a D-amino acid. In some embodiments, the alpha-carbon of an amino acid is achiral. In some embodiments, an amino acid is a beta-amino acid. In some embodiments, an amino acid is a gamma-amino acid.

[0192] In some embodiments, a provided amino acid sequence contains two or more amino acid residues whose side chains are linked together to form one or more staples. In some embodiments, a provided amino acid sequence contains two or more amino acid residues, each of which independently has a side chain comprising an olefin. In some embodiments, a provided amino acid sequence contains two or more amino acid residues, each of which independently has a side chain comprising a terminal olefin. In some embodiments, a provided amino acid sequence contains two and no more than two amino acid residues, each of which independently has a side chain comprising an olefin. In some embodiments, a provided amino acid sequence contains two and no more than two amino acid residues, each of which independently has a side chain comprising a terminal olefin. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid that comprises an olefin and a nitrogen atom other than the nitrogen atom of its amino group. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid that comprises a terminal olefin and a nitrogen atom other than the nitrogen atom of its amino group. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid that has a side chain than comprises a terminal olefin and a nitrogen atom. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid of formula A-I, wherein R^{a2} comprising an olefin and a −N(R')− moiety, wherein R' is as described in the present disclosure (including, in some embodiments, optionally taken together with R^{a3} and their intervening atoms to form an optionally substituted ring as described in the present disclosure). In some embodiments, R^{a2} comprising a terminal olefin and a −N(R')− moiety wherein R' is as described in the present disclosure. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid selected from Table A-I. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid selected from Table A-II. In some embodiments, a provided amino acid sequence comprises at least one residue of an amino acid selected from Table A-III. In some embodiments, two olefins from two side chains are linked together through olefin metathesis to form a staple. In some embodiments, a staple is preferably formed by side chains of amino acid residues that are not at the corresponding positions of a target of interest. In some embodiments, a formed staple does not disrupt interaction between the peptide and a target of interest.

[0193] In some embodiments, a provided staple is a hydrocarbon staple. In some embodiments, a hydrocarbon staple comprises no chain heteroatoms wherein a chain of a staple is the shortest covalent connection within the staple from one end of the staple to the other end of the staple.

[0194] In some embodiments, an olefin in a staple is a *Z*-olefin. In some embodiments, an olefin in a staple in an *E*-olefin. In some embodiments, a provided composition comprises stapled peptides comprising a staple that contains a *Z*-olefin and stapled peptides comprising a staple that contains an *E*-olefin. In some

embodiments, a provided composition comprises stapled peptides comprising a staple that contains a *Z*-olefin. In some embodiments, a provided composition comprises stapled peptides comprising a staple that contains an *E*-olefin. In some embodiments, otherwise identical stapled peptides that differ only in the *E/Z* configuration of staple olefin demonstrate different properties and/or activities as demonstrated herein. In some embodiments, stapled peptides with *E*-olefin in a staple may provide certain desirable properties and/or activities given the context. In some embodiments, stapled peptides with *Z*-olefin in a staple may provide certain desirable properties and/or activities given the context.


[0195] In some embodiments, the present disclosure provides compositions comprising stapled peptides. In some embodiments, a composition comprises one and only one stereoisomer of a stapled peptide (e.g., *E* or *Z* isomer, and/or a single diastereomer/enantiomer with respect to a chiral center, etc.). In some embodiments, a composition comprises two or more stereoisomers (*e.g.*, both *E* and *Z* isomers of one or more double bonds, and/or one or more diastereomers/enantiomers with respect to a chiral center, etc.). In some embodiments, a composition corresponds to a single peak in a chromatographic separation, e.g., HPLC. In some embodiments, a peak comprises one and only one stereoisomers. In some embodiments, a peak comprises two or more stereoisomers.


[0196] In some embodiments, two staples may be bonded to the same atom of the peptide backbone, forming a stitched peptide.


[0197] In some embodiments, a staple is pro-lock wherein one end of the staple is bonded to the alpha-carbon of a proline residue.


[0198] In some embodiments, a staple is a staple illustrated below in Tables S-1, S-2, S-3, S-4 and S-5 (with exemplary peptide backbone illustrated for clarity (can be applied to other peptide backbone), each X independently being an amino acid residue). In some embodiments, a staple is a staple in Table S-6 (with amino acid residues bonded to staples illustrated). In some embodiments, the olefin is *Z*. In some embodiments, the olefin is *E*. In some embodiments, an (i, i+3) staple is selected from Table S-1. In some embodiments, an (i, i+3) staple is selected from Table S-2. Those skilled in the art reading the present disclosure will appreciate that when staples in Table S-1 and Table S-2 are utilized for (i, i+3), "X_3" in those tables would be "X_2" (i.e., two amino acid residues instead of three amino acid residues). In some embodiments, an (i, i+4) staple is selected from Table S-1. In some embodiments, an (i, i+4) staple is selected from Table S-2. In some embodiments, an (i, i+7) staple is selected from Table S-3. In some embodiments, an (i, i+7) staple is selected from Table S-4.

[0199] Table S-1. Exemplary staples.




























[0200] Table S-2. Exemplary staples.






,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,





[0201] Table S-3. Exemplary staples.



















[0202] Table S-4. Exemplary staples.
























[0203] Certain useful staples are described in, e.g., WO 2019/051327, WO 2022/020652, etc. and are incorporated herein by reference.








[0204] In some embodiments, a staple may be one of the following, connecting the amino acids at the indicated position:







Table S-5. Certain amino acids and staples.








Amino Acid 1	Amino Acid 2 (*i* +7	staple
Monomer A	S_8	
Monomer A	S_7	
Monomer A	S_5	
R_8	Monomer A	
R_7	Monomer A	
R_6	Monomer A	
Monomer E	S_8	








Amino Acid 1	Amino Acid 2 (i +7	Staple
Monomer E	S_7	
Monomer E	S_6	
Monomer E	S_5	
R_8	Monomer D	
R_7	Monomer D	
R_6	Monomer D	
R_5	Monomer D	








Amino Acid 1	Amino Acid 2 (i +7	Staple
Monomer G	S_7	
Monomer G	S_8	
Monomer G	S_5	
Monomer G	S_4	
R_7	Monomer F	
R_8	Monomer F	
R_5	Monomer F	








Amino Acid 1	Amino Acid 2 (i +7	Staple
R_5	Monomer F	
R_4	Monomer F	
Monomer I	S_5	
Monomer I	S_5	
Monomer I	S_8	
Monomer I	S_3	
Monomer C	S_8	








Amino Acid 1	Amino Acid 2 (i+7	staple
Monomer C	S_7	
Monomer C	S_8	
Monomer C	S_5	
R_8	Monomer B	
R_7	Monomer B	
R_5	Monomer B	
R_5	Monomer B	








Amino Acid 1	Amino Acid 2 (*i* +7	Staple
R_3	Monomer H	
R_4	Monomer H	
R_5	Monomer H	
R_6	Monomer H	
Monomer G	S_7	
R_7	Monomer F	
Monomer I	S_8	








Amino Acid 1	Amino Acid 2 (*i* +7	staple
R_6	Monomer H	
Monomer A	Monomer B	
Monomer A	Monomer C	
Monomer A	Monomer A	
Monomer A	Monomer F	
Monomer A	Monomer E	
Monomer A	Monomer G	






Amino Acid 1	Amino Acid 2 (i+7	Staple
Monomer A	Monomer I	
Monomer I	Monomer A	
Monomer G	Monomer A	
Monomer E	Monomer A	
Monomer F	Monomer A	
Monomer C	Monomer A	
Monomer B	Monomer A	







Amino Acid 1	Amino Acid 2 (i+7	Staple
Monomer B	Monomer B	
Monomer B	Monomer F	
Monomer C	Monomer F	
Monomer C	Monomer C	
Monomer C	Monomer B	
Monomer C	Monomer E	
Monomer C	Monomer G	

Amino Acid 1	Amino Acid 2 (i +7	staple
Monomer C	Monomer I	
Monomer I	Monomer F	
Monomer I	Monomer G	
Monomer I	Monomer E	
Monomer I	Monomer B	
Monomer I	Monomer C	
Monomer I	Monomer I	

Amino Acid 1	Amino Acid 2 (i +7	staple
Monomer G	Monomer F	
Monomer G	Monomer G	
Monomer G	Monomer E	
Monomer G	Monomer B	
Monomer G	Monomer C	
Monomer G	Monomer I	
Monomer E	Monomer F	

Amino Acid 1	Amino Acid 2 (i+7	staple
Monomer E	Monomer G	
Monomer E	Monomer E	
Monomer E	Monomer B	
Monomer E	Monomer C	
Monomer E	Monomer I	
Monomer F	Monomer F	
Monomer F	Monomer B	


Amino Acid 1 (*i* position)	Amino Acid 2 (*i*+7 position)	staple
R_7	Monomer A	
Monomer E	S_8	
R_8	Monomer D	
R_7	Monomer D	
R_7	Monomer F	
R_8	Monomer F	


Amino Acid 1 (*i* position)	Amino Acid 2 (*i*+7 position)	staple
Monomer I	S_5	
Monomer I	S_5	
R_5	Monomer B	
R_5	Monomer H	
R_5	Monomer H	
R_5	Monomer H	


[0205] In some embodiments, a peptide comprises a staple or stitch (two staples) from Table S-6. In Table 6, the amino acid residues can either be from N to C or C to N. In some embodiments, it is N to C. In some embodiments, it is C to N. In some embodiments, a double bond is *E*. In some embodiments, a double bond is *Z*. In some embodiments, a staple is a (i, i+2) staple. In some embodiments, a staple is a (i, i+3) staple. In some embodiments, a staple is a (i, i+4) staple. In some embodiments, a staple is a (i, i+7) staple. In some embodiments, each double is independently *E* or *Z* when a structure comprises more than one double bond. In some embodiments, each staple is independently a (i, i+2) or a (i, i+3) or a (i, i+4) staple or a (i, i+7) staple. In some embodiments, each staple is independently a (i, i+2) or a (i, i+4) staple or a (i, i+7)


staple. In some embodiments, each staple is independently a (i, i+3) or a (i, i+4) staple or a (i, i+7) staple. In some embodiments, each staple is independently a (i, i+4) staple or a (i, i+7) staple in a structure comprising two staples. In some embodiments, one staple is a (i, i+4) staple and the other is a (i, i+7) staple. In some embodiments, one staple is a (i, i+3) staple, one staple is a (i, i+4) staple and one staple is a (i, i+7) staple. In some embodiments, one staple is a (i, i+2) staple, one staple is a (i, i+4) staple and one staple is a (i, i+7) staple. In some embodiments, a PL3 residue is bonded to a (i, i+3) staple. In some embodiments, a PL3 residue is bonded to a (i, i+4) staple. In some embodiments, staples (e.g., those in Table 6) are formed by metathesis of double bonds in side chains of amino acid residues, e.g., RdN and S7, R8 and PyrS, R5 and SeN, R6 and SeN, ReN and S5, ReN and S6, R7 and PyrS, Az and S7, R8 and SgN, Az and S8, R4 and SeN, R5 and SdN, R7 and Az, R8 and Az, RdN and S4, RgN and S8, RgN and S7, R8 and S5, PL3 and B5 and the same B5 and S8, PL3 and B5 and the same B5 and SeN, PL3 and B5 and the same B5 and SdN, PL3 and B5 and the same B5 and S7, PL3 and B5 and the same B5 and PyrS2, PL3 and B5 and the same B5 and PyrS3, R5 and PyrS2, PL3 and B5 and the same B5 and PyrS1, PL3 and B5 and the same B5 and S10, PL3 and B5 and the same B5 and PyrR2, PL3 and B5 and the same B5 and PyrS, PL3 and B5 and the same B5 and Az, PL3 and B5 and the same B5 and SeNc5, HypEs5 and B5 and the same B5 and PyrS2, HypEs4 and B5 and the same B5 and PyrS2, ProSAm3 and B5 and the same B5 and PyrS2, ProAm5 and B5 and the same B5 and PyrS2, ProAm6 and B5 and the same B5 and PyrS2, BzAm3Oallyl and B5 and the same B5 and PyrS2, HypBzEs3OAllyl and B5 and the same B5 and PyrS2, ProBzAm3OAllyl and B5 and the same B5 and PyrS2, PAc3OAllyl and B5 and the same B5 and PyrS2, ProPAc3OAllyl and B5 and the same B5 and PyrS2, HypPAc3OAllyl and B5 and the same B5 and PyrS2, Bn3OAllyl and B5 and the same B5 and PyrS2, R3 and B5 and the same B5 and PyrS2, R5 and B5 and the same B5 and PyrS2, [BzAm2Allyl]MePro and B5 and the same B5 and PyrS2, PL3 and B5 and the same B5 and SPip1, PL3 and B5 and the same B5 and SPip2, PL3 and B5 and the same B5 and SPip3, PL3 and B5 and the same B5 and Az2, PL3 and B5 and the same B5 and Az3, PL3 and S5, R5 and S5, PL3 and B4 and the same B4 and PyrS1, PL3 and B4 and the same B4 and PyrS2, PL3 and B4 and the same B4 and PyrS3, PL3 and S6, PL3 and S4, PL3 and S3, R6 and PyrS2, R4 and PyrS2, R3 and PyrS2, PL3 and B3 and the same B3 and PyrS2, PL3 and B3 and the same B3 and PyrS3, PL3 and B3 and the same B3 and PyrS4, PL3 and B6 and the same B6 and PyrS, PL3 and B6 and the same B6 and PyrS1, PL3 and B6 and the same B6 and PyrS2.


Table S-6. Certain staples (including amino acid residues bonded to staples).


























































































































,




,




,




,




,




,




,




,




,





,





,






















































































[0206] In some embodiments, the double bond in a (i, i+3) staple is *Z*. In some embodiments, the double bond in a (i, i+4) staple is *Z*. In some embodiments, the double bond in a (i, i+7) staple is *Z*. In some embodiments, the double bond in a (i, i+3) staple is *E*. In some embodiments, the double bond in a (i, i+4)

staple is *E*. In some embodiments, the double bond in a (i, i+7) staple is *E*.

[0207] In some embodiments, a staple comprises −S−. In some embodiments, stapling technologies comprise utilization of one or more, e.g., two or more, sulfur-containing moieties. In some embodiments, a stapled peptide comprises cysteine stapling. In some embodiments, two cysteine residues are stapled wherein the −S− moieties of the two cysteine residues are connected optionally through a linker. In some embodiments, a stapled peptide comprises one and no more than one staples from cysteine stapling. In some embodiments, a stapled peptide comprises one and no more than one staples having the structure of  ,  , or  . In some embodiments, a stapled peptide comprises one and no more than one staples having the structure of  . In some embodiments, a stapled peptide comprises one and no more than one staples having the structure of  . In some embodiments, a stapled peptide comprises one and no more than one staples having the structure of  . In some embodiments, a stapled peptide comprises no staples having the structure of  ,  , or  . In some embodiments, a stapled peptide comprises no staples having the structure of  . In some embodiments, a stapled peptide comprises no staples having the structure of  . In some embodiments, a stapled peptide comprises no staples having the structure of  .

[0208] In some embodiments, the present disclosure provides useful technologies relating to cysteine stapling. Among other things, the present disclosure appreciates that peptides amenable to cysteine stapling and/or comprising one or more cysteine staples, can be produced and/or assessed in a biological system. The present disclosure further appreciates that certain such systems permit development, production, and/or

assessment of cysteine stapled peptides having a range of different structures (e.g., different amino acid sequences), and in fact can provide a user with complete control over selection and implementation of amino acid sequences to be incorporated into stapled peptides.

[0209] Cysteine stapling, as described herein, involves linking one cysteine residue to another cysteine residue, where the resulting bond is not through the peptide backbone between the linked cysteine residues.

[0210] In some embodiments, a stapled peptide as described herein comprises a staple which staple is L^s, wherein:

L^s is $-L^{s1}-S-L^{s2}-S-L^{s3}-$;

L^{s1} and L^{s3} are each independently L;

L^{s2} is L and comprises at least one $-C(O)-$; and

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each $-Cy-$ is independently an optionally substituted bivalent group selected from a C_{3-20} cycloaliphatic ring, a C_{6-20} aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon;

each R' is independently $-R$, $-C(O)R$, $-CO_2R$, or $-SO_2R$;

each R is independently $-H$, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or

two R groups are optionally and independently taken together to form a covalent bond; or

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

[0211] In some embodiments, L is independently a bivalent C_1-C_{25} aliphatic group. In some

embodiments, L is independently a bivalent C_1-C_{20} aliphatic group. In some embodiments, L is independently a bivalent C_1-C_{10} aliphatic group. In some embodiments, L is independently a bivalent C_1-C_5 aliphatic group. In some embodiments, L is independently a bivalent C_1 aliphatic group. In some embodiments, L is $-CH_2$.

[0212] In some embodiments, L^{s1} is $-CH_2-$. In some embodiments, L^{s3} is $-CH_2-$. In some embodiments, L^{s1} and L^{s3} are both $-CH_2-$. In some embodiments, L^s is $-CH_2-S-L^{s2}-S-CH_2-$.

[0213] In some embodiments, L^{s2} comprises $-C(R')_2-L'-C(R')_2-$, wherein L' is described in the present disclosure. In some embodiments, L^{s2} is $-L^{x1}-C(O)Q-L'-QC(O)-L^{x1}-$, wherein each variable is independently as described in the present disclosure. In some embodiments, L^{s2} is $-CH_2C(O)Q-L'-QC(O)CH_2-$, wherein each $-CH_2-$ is independently and optionally substituted. In some embodiments, L^{s2} is $-CH_2C(O)Q-L'-QC(O)CH_2-$.

[0214] In some embodiments, L^{s2} In some embodiments, L^{s2} is L and comprises at least one $-C(O)-$. In some embodiments, L^{s2} is L and comprises at least two $-C(O)-$. In some embodiments, L^{s2} is L and comprises at least one $-C(O)Q-$, wherein Q is selected from the group consisting of: a covalent bond, $-N(R')-$, $-O-$, and $-S-$. In some embodiments, L^{s2} is L and comprises at least one $-C(O)Q-$, wherein Q is selected between $-N(R')-$ and $-O-$. In some embodiments, L^{s2} is L and comprises at least two $-C(O)Q-$, wherein Q is selected from the group consisting of: $-N(R')-$, $-O-$, and $-S-$. In some embodiments, L^{s2} is L and comprises at least two $-C(O)Q-$, wherein Q is selected between $-N(R')-$ and $-O-$. In some embodiments, L^{s2} is L and comprises at least one $-C(O)N(R')-$. In some embodiments, L^{s2} is L and comprises at least two $-C(O)N(R')-$. In some embodiments, L^{s2} is L and comprises at least one $-C(O)O-$. In some embodiments, L^{s2} is L and comprises at least two $-C(O)O-$.

[0215] In some embodiments, L^{s2} comprises $-Q-L'-Q-$, wherein Q is independently selected from the group consisting of: $-N(R')-$, $-O-$, and $-S$, wherein L' is described in the present disclosure.

[0216] In some embodiments, L^{s2} comprises $-Q-L'-Q-$, wherein Q is independently selected between $-N(R')-$ and $-O-$, wherein L' is described in the present disclosure. In some embodiments, L^{s2} comprises $-C(O)Q-L'-QC(O)-$, wherein Q is independently selected from the group consisting of: $-N(R')-$, $-O-$, and $-S$, wherein L' is described in the present disclosure. In some embodiments, L^{s2} comprises $-C(O)Q-L'-QC(O)-$, wherein Q is independently selected between $-N(R')-$ and $-O$, wherein L' is described in the present disclosure. In some embodiments, L^{s2} comprises $-C(R')_2C(O)Q-L'-QC(O)C(R')_2-$, wherein Q is independently selected from the group consisting of: $-N(R')-$, $-O-$, and $-S$, wherein L' is described in the present disclosure. In some embodiments, L^{s2} comprises $-C(R')_2C(O)Q-L'-QC(O)C(R')_2-$, wherein Q is independently selected between $-N(R')-$ and $-O$, wherein L' is described in the present disclosure.

[0217] In some embodiments, L^{s2} comprises $-N(R')-L'-N(R')-$, wherein L' is described in the present disclosure. In some embodiments, L^{s2} comprises $-C(O)N(R')-L'-N(R')C(O)-$, wherein L' is described in the present disclosure. In some embodiments, L^{s2} is $-C(R')_2C(O)N(R')-L'-N(R')C(O)C(R')_2-$, wherein L' is described in the present disclosure.

[0218] In some embodiments, L^{s2} comprises $-O(R')-L'-O(R')-$, wherein L' is described in the present disclosure. In some embodiments, L^{s2} comprises $-C(O)O-L'-OC(O)-$, wherein L' is described in the present disclosure. In some embodiments, L^{s2} is $-C(R')_2C(O)O-L'-OC(O)C(R')_2-$, wherein L' is described in the present disclosure.

[0219] In some embodiments, R' is an optionally substituted C_{1-30} aliphatic. In some embodiments, R' is an optionally substituted C_{1-15} aliphatic. In some embodiments, R' is an optionally substituted C_{1-10} aliphatic. In some embodiments, R' is an optionally substituted C_{1-5} aliphatic. In some embodiments, R' is hydrogen.

[0220] In some embodiments, L' is optionally substituted bivalent C_1-C_{19} aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_{15} aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_{10} aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_9 aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_8 aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_7 aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_6 aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_5 aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_3 aliphatic. In some embodiments, L' is optionally substituted bivalent C_1-C_2 aliphatic. In some embodiments, L' is optionally substituted bivalent C_1 aliphatic. In some embodiments, L' is $-CH_2-$. In some embodiments, L' is $-(CH_2)_2-$. In some embodiments, L' is $-(CH_2)_3-$. In some embodiments, L' is $-(CH_2)_4-$. In some embodiments, L' is $-(CH_2)_5-$. In some embodiments, L' is $-(CH_2)_6-$. In some embodiments, L' is $-(CH_2)_7-$. In some embodiments, L' is $-(CH_2)_8-$.

[0221] In some embodiments, L' is optionally substituted bivalent C_{6-20} aryl ring. In some embodiments, L' is optionally substituted bivalent C_{6-14} aryl ring. In some embodiments, L' is optionally substituted bivalent C_{6-10} aryl ring. In some embodiments, L' is optionally substituted bivalent C_6 aryl ring. In some embodiments, L' is bivalent C_6 aryl substituted with at least one halogen. In some embodiments, L' is bivalent C_6 aryl substituted with at least two halogen. In some embodiments, L' is bivalent C_6 aryl substituted with at least three halogen. In some embodiments, L' is bivalent C_6 aryl substituted with four halogen. In some embodiments, L' is bivalent C_6 aryl substituted with at least one fluorine. In some embodiments, L' is bivalent C_6 aryl substituted with at least two fluorine. In some embodiments, L' is bivalent C_6 aryl substituted with at least three fluorine. In some embodiments, L' is bivalent C_6 aryl substituted with four fluorine. In some embodiments, L' is bivalent C_6 aryl substituted with at least one chlorine. In some embodiments, L' is bivalent C_6 aryl substituted with at least two chlorine. In some embodiments, L' is bivalent C_6 aryl substituted with at least three chlorine. In some embodiments, L' is bivalent C_6 aryl substituted with four chlorine. In some embodiments, L' is bivalent C_6 aryl substituted at with least one $-O(CH2)_{0-4}CH_3$. In some embodiments, L' is bivalent C_6 aryl substituted with at least two $-O(CH2)_{0-4}CH_3$. In some embodiments, L' is bivalent C_6 aryl substituted with at least three $-O(CH2)_{0-4}CH_3$. In some embodiments, L' is bivalent C_6 aryl substituted with four $-O(CH2)_{0-4}CH_3$.

[0222] In some embodiments, L' is bivalent 5-20 membered heteroaryl ring having 1-10 heteroatoms

independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, L' is bivalent 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, L' is bivalent 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, L' is bivalent 6 membered heteroaryl ring having 1-2 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, L' is bivalent 6 membered heteroaryl ring having 2 nitrogen.

[0223] In some embodiments, L' is optionally substituted bivalent C_{3-20} cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_{3-15} cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_{3-10} cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_{3-9} cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_{3-8} cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_{3-7} cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_{3-6} cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_{3-5} cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_{3-4} cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_3 cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_4 cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_5 cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_5 cycloalkyl ring. In some embodiments, L' is optionally substituted bivalent C_5 cycloalkenyl ring. In some embodiments, L' is optionally substituted bivalent C_6 cycloaliphatic ring. In some embodiments, L' is optionally substituted bivalent C_6 cycloalkyl ring.

[0224] In some embodiments, L^{s2} comprises $-N(R')-L'-N(R')-$ and L' is a covalent bond. In some embodiments L^{s2} comprises $-N(R)-N(R)-$, wherein:

each R is independently $-H$, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, or


two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

[0225] In some embodiments L^{s2} comprises $-N(R)-N(R)-$, wherein:

each R is independently optionally substituted C_{1-30} aliphatic; or









two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered monocyclic ring.



[0226] In some embodiments, L^{s2} is a staple selected from the group consisting of:



























[0227] In some embodiments, L^{s1} is optionally substituted bivalent C_{1-6} aliphatic. In some embodiments, L^{s1} is bivalent C_{1-6} aliphatic. In some embodiments, L^{s1} is bivalent C_{1-4} aliphatic. In some embodiments, L^{s1} is saturated. In some embodiments, L^{s1} is linear. In some embodiments, L^{s1} is branched. In some embodiments, L^{s1} is optionally substituted $-CH_2-$. In some embodiments, L^{s1} is $-CH_2-$. In some embodiments, L^{s1} is optionally substituted $-CH_2-CH_2-$. In some embodiments, L^{s1} is $-CH_2-CH_2-$. In some embodiments, L^{s1} is optionally substituted $-C(CH_3)_2-$. In some embodiments, L^{s1} is $-C(CH_3)_2-$.

[0228] In some embodiments, L^{s2} is optionally substituted bivalent C_{1-6}, (e.g., C_{3-6}, C_3, C_4, C_5, C_6, etc.) aliphatic wherein one or more methylene units are optionally and independently replaced with $-Cy-$ or $-C(R')_2-$. In some embodiments, L^{s2} is optionally substituted bivalent C_{1-6} aliphatic. In some embodiments, L^{s2} is optionally substituted bivalent C_{3-6} aliphatic. In some embodiments, L^{s2} is bivalent C_{1-6} aliphatic. In some embodiments, L^{s2} is bivalent C_{1-4} aliphatic. In some embodiments, L^{s2} is optionally substituted bivalent

C_2 aliphatic. In some embodiments, L^{s2} is optionally substituted bivalent C_3 aliphatic. In some embodiments, L^{s2} is optionally substituted bivalent C_4 aliphatic. In some embodiments, L^{s2} is optionally substituted bivalent C_5 aliphatic. In some embodiments, L^{s2} is optionally substituted bivalent C_6 aliphatic. In some embodiments, L^{s2} is substituted. In some embodiments, L^{s2} is unsubstituted. In some embodiments, L^{s2} is saturated. In some embodiments, L^{s2} is linear. In some embodiments, L^{s2} is branched. In some embodiments, L^{s2} is optionally substituted bivalent C_{3-6}, (e.g., C_{3-5}, C_3, C_4, C_5, C_6, etc.) aliphatic wherein one or two methylene units are independently replaced with −Cy−. In some embodiments, L^{s2} is $-CH_2-Cy-CH_2-$. In some embodiments, L^{s2} is $-CH_2-CH_2-Cy-CH_2-CH_2-$. In some embodiments, L^{s2} is $-CH_2-Cy-Cy-CH_2-$. Various useful embodiments of −Cy− are as described herein. For example, in some embodiments, −Cy− is an optionally substituted monocyclic 5-membered aromatic ring having 0-4 heteroatoms. In some embodiments, −Cy− is an optionally substituted monocyclic 6-membered aromatic ring having 0-4 heteroatoms. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is optionally substituted 1,2-phenylene. In some embodiments, −Cy− is 1,2-phenylene. In some embodiments, −Cy− is optionally substituted 1,3-phenylene. In some embodiments, −Cy− is 1,3-phenylene. In some embodiments, −Cy− is optionally substituted 1,5-phenylene. In some embodiments, −Cy− is 1,5-phenylene. In some embodiments, −Cy− is 3-methyl-1,5-phenylene. In some embodiments, −Cy− is 3-methoxy-1,5-phenylene. In some embodiments, −Cy− is an optionally substituted bivalent pyridyl ring. In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is  . In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is  . In some embodiments, −Cy− is an optionally substituted bicyclic 9-membered aromatic ring having 0-4 heteroatoms. In some embodiments, −Cy− is an optionally substituted bicyclic 10-membered aromatic ring having 0-4 heteroatoms. In some embodiments, −Cy− is an optionally substituted bivalent naphthyl ring. In some embodiments, −Cy− is a bivalent naphthyl ring. In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is  . In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is  . In some embodiments, −Cy− is an optionally substituted 3-10 (e.g., 5-10, 5-6, 3, 4, 5, 6, 7, 8, 9, 10, etc.) membered bivalent cycloaliphatic ring. In some embodiments, it is saturated. In some embodiments, −Cy− is an optionally substituted 6-membered cycloalkyl ring. In some embodiments, −Cy− is optionally


substituted  . In some embodiments, −Cy− is  . In some embodiments, L^{s2} is optionally substituted bivalent C_{3-6}, (e.g., C_{3-5}, C_3, C_4, C_5, C_6, etc.) aliphatic wherein one or two methylene units are independently replaced with $-C(R')_2-$. In some embodiments, L^{s2} is $-CH_2-C(R')_2-CH_2-$. In some embodiments, the two R' are taken together with the carbon atom to form an optionally substituted ring as described herein, e.g., an optionally substituted 3-10 (e.g., 5-10, 5-6, 3, 4, 5, 6, 7, 8, 9, 10, etc.) membered ring having 0-4 (e.g., 1-4, 0, 1, 2, 3, 4, etc.) heteroatoms. In some embodiments, a ring is saturated. In some embodiments, a ring has one or more heteroatoms. In some embodiments, $-C(R')_2-$ is  .

[0229] In some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted $-(CH_2)_4-$. In some embodiments, L^{s2} is optionally substituted $-(CH_2)_3-$. In some embodiments, L^{s2} is optionally substituted $-CH_2-CH=CH-CH_2-$. In some embodiments, L^{s2} is optionally substituted (*E*)$-CH_2-CH=CH-CH_2-$. In some embodiments, L^{s2} is optionally substituted $-CH_2-C(O)-CH_2-$. In some embodiments, L^{s2} is optionally substituted  . In


some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted  . In some embodiments, L^{s2} is optionally substituted  . In some embodiments, it is substituted. In some embodiments, it is unsubstituted. In some embodiments,  ,  ,  , $-(CH_2)_4-$, (*E*)$-CH_2-CH=CH-CH_2-$, $-(CH_2)_3-$, and/or $-CH_2-C(O)-CH_2-$ provide higher binding and/or potency than  ,  ,  ,  ,  ,  , and/or  under comparable conditions.





[0230] In some embodiments, L^{s3} is optionally substituted bivalent C_{1-6} aliphatic. In some embodiments, L^{s3} is bivalent C_{1-6} aliphatic. In some embodiments, L^{s3} is bivalent C_{1-4} aliphatic. In some embodiments, L^{s3} is saturated. In some embodiments, L^{s3} is linear. In some embodiments, L^{s3} is branched. In some embodiments, L^{s3} is optionally substituted $-CH_2-$. In some embodiments, L^{s3} is $-CH_2-$. In some embodiments, L^{s3} is optionally substituted $-CH_2-CH_2-$. In some embodiments, L^{s3} is $-CH_2-CH_2-$. In some embodiments, L^{s3} is optionally substituted $-C(CH_3)_2-$. In some embodiments, L^{s3} is $-C(CH_3)_2-$.

[0231] In some embodiments, an amino acid residue for forming a staple is selected from:




In some embodiments, both amino acid residue for forming a staple are independently residues of these amino acids. In some embodiments, each of L^{s1} and L^{s3} is independently $-CH_2-$, $-CH_2-CH_2-$, or $-C(CH_3)_2-$. In some embodiments, a staple is formed by reacting the thiol groups with a thiol reactive linker compound. In some embodiments, such a linker compound has the structure of $LG-L^{s2}-LG$ or a salt thereof, wherein each LG is independently a leaving group, e.g., −Br, −I, etc. In some embodiments, each LG is independently −Br or −I. In some embodiments, each LG is −Br. In some embodiments, each LG is −I. In some embodiments, L^{s2} are of such structures that $LG-L^{s2}-LG$ (each LG is independently −Br or −I) is a compound selected from:



[0232] Various technologies are available for constructing of thioether staples. For example, in some embodiments, a peptide and excess equivalents (e.g., about 2-10, 5-10, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.; in some embodiments, 5) of a linker compound were added to a 1:1 DMF : 100 mM Na_2CO_3 pH 8.0 solution and stirred at a suitable temperature, e.g., room temperature for a suitable period of time, in some embodiments, 1-2 hours. In some embodiments, e.g., for relatively weaker electrophiles, excess equivalents (e.g., about 10-30, 10-20, 10, 20, etc.; in some embodiments, 20) of a metal salt, e.g., $Zn(acac)_2$ and an excess equivalents (e.g., about 5-20, 10-15, 10, 15, 20, etc.; in some embodiments, 10-15) of a linker compound were added to a peptide in DMA, and the mixture was stirred for a suitable period of time, e.g., overnight, at a suitable temperature, e.g., 37 °C. In some embodiments, equivalents of $Zn(acac)_2$ and linker compounds were doubled, and/or the temperature was increased to 50 °C. In some embodiments, certain linker compounds react better than others. For example, in some embodiments,  ,  ,  , or  provides poor reaction yields or failed reactions. Those skilled in the art appreciate that other technologies may be utilized to introduce the corresponding linker moieties (L^{s2}), e.g., through utilizing other leaving groups or through other reaction mechansms/routes.

[0233] In some embodiments, a staple having the structure of $-L^{s1}-S-L^{s2}-S-L^{s3}-$ is a (i, i+4) staple. In some embodiments, such a staple is in closer to a C-terminus. In some embodiments, such a staple is in closer to a N-terminus. For example, in some embodiments, such a staple is between X^{10} and X^{14}.

[0234] In some embodiments, certain staples provide better properties and/or activities. For example, in some embodiments, based on target binding affinity certain staples/scaffolds is ranked in the following order:



[0235] As those skilled in the art will appreciate, provided technologies can be utilized to prepare collection of peptides using non-cysteine residues and suitable chemistry therefor. For example, in some embodiments, cysteine stapling is replaced with lysine stapling, wherein the cysteine residues for cysteine stapling are replaced with lysine residues for lysine stapling (e.g., using agents that can crosslink two lysine residues, for example, through reactions with side chain amino groups). In some embodiments, for lysine stapling, R^E in various formulae is or comprises an activated carboxylic acid group (e.g., NHS ester group), an imidoester group, etc. Suitable reagents are widely known in the art including many commercially available ones. In some embodiments, cysteine stapling is replaced with methionine stapling. In some embodiments, cysteine residues for cysteine stapling are replaced with methionine residues for methionine stapling. In some embodiments, cysteine stapling is replaced with tryptophan stapling. In some embodiments, cysteine residues for cysteine stapling are replaced with tryptophan residues for tryptophan stapling. As those skilled in the art will appreciate, various technologies (e.g., reagents, reactions, etc.) are described in the art and can be utilized in accordance with the present disclosure for, e.g., methionine stapling, tryptophan stapling, etc. In some embodiments, such stapling can be performed using reagents having various formulae described herein, wherein R^E is or comprises a group that are suitable for methionine and/or tryptophan stapling. In some embodiments, stapling may be performed using one residue at a first position, and a different residue at a second position. Useful reagents for such stapling may comprise a first reactive group for stapling at a first position (e.g., through a first R^E), and a second reactive group for stapling at a second position (e.g., through a second R^E).

[0236] In some embodiments, for various types of stapling (e.g., cysteine stapling, or non-cysteine stapling), stapling is between residues (e.g., cysteine residues for cysteine stapling) separated by two residues (i+3 stapling). In some embodiments, stapling is between residues separated by three residues (i+4 stapling). In some embodiments, stapling is between residues separated by six residues (i+7 stapling).


[0237] As appreciated by those skilled in the art, in some embodiments, more than two residues can be stapled at the same time. For example, in some embodiments, three or more cysteines are stapled using crosslinking reagents containing three or more reactive groups (e.g., R^E groups).

[0238] In some embodiments, as described herein, the present disclosure provides useful technologies relating to non-cysteine stapling. Among other things, the present disclosure appreciates that peptides amenable to cysteine stapling and/or comprising one or more non-cysteine staples, can have its cysteine residues and cysteine staple replaced with other amino acids and staples described herein (e.g. hydrocarbon and other non-hydrocarbon amino acid and staples). In some embodiments, the resulting non-cysteine stapled peptide maintains the same or similar interaction with a target of interest when compared to a


reference cysteine stapled peptide.

[0239] Certain useful agents (peptides prior to stapling and stapled peptides post stapling) and compositions thereof are presented in Table E2 or Table E3 as examples, which includes various amino acid residues and N- and C-terminus capping groups for various positions as examples; also illustrated are various stapling patterns, e.g., X^1–X^4–X^{11}, X^1–X^3, X^3–X^7, X^3–X^{10}, X^4–X^{11}, X^7–X^{10}, X^7–X^{14}, X^{10}–X^{14}, etc. As demonstrated herein, provided technologies can deliver improved useful properties and/or activities.

[0240] In some embodiments, a provided agent, a peptide, or a stapled peptide is a compound as described herein. In some embodiments, a provided agent has a structure selected from Table E2 or Table E3, or a salt thereof. In some embodiments, a provided agent is a stereoisomer of a structure selected from Table E2 or Table E3, or a salt thereof. In some embodiments, a provided agent is a stereoisomer, with respect to a chiral center bonded to two staples (e.g., in B4, B5, etc.), of a structure selected from Table E2 or Table E3, or a salt thereof. In some embodiments, a provided agent is a stereoisomer, with respect to olefin double bond(s) in staple(s), of a structure selected from Table E2 or Table E3, or a salt thereof. In some embodiments, a provided agent is a stereoisomer, with respect to olefin double bond(s) in staple(s) and/or a chiral center bonded to two staples (e.g., in B4, B5, etc.), of a structure selected from Table E2 or Table E3, or a salt thereof. In some embodiments, a provided composition is a composition described in Table E2 or Table E3. In some embodiments, a compound has the structure of




(SP-1) or a salt thereof. In some embodiments, a




compound has the structure of (SP-2) or a salt thereof.


In some embodiments, a compound has the structure of




(SP-3) or a salt thereof. In some embodiments, a compound has the structure of




(SP-4) or a salt thereof. In some embodiments, a compound has the structure of




(SP-5) or a salt thereof. In some embodiments, a




compound has the structure of (SP-6) or a salt thereof. In some embodiments, a compound has the structure of




(SP-7) or a salt thereof. In some




embodiments, a compound has the structure of (SP-8) or a salt thereof. In some embodiments, a compound has the structure of




(SP-9) or a salt thereof. In some embodiments, a




compound has the structure of (SP-10) or a salt thereof. In some embodiments, a compound has the structure of




(SP-11) or a salt thereof. In some embodiments, a




compound has the structure of (SP-12) or a salt thereof. In some embodiments, a compound has the structure of



(SP-13) or a salt thereof. In some embodiments, a compound has the structure of




(SP-14) or a salt thereof. In some embodiments,





a compound has the structure of (SP-15) or a salt thereof. In some embodiments, a double bond of a (i, i+2) staple is *E*. In some embodiments, a double bond

of a (i, i+2) staple is *Z*. In some embodiments, a double bond of a (i, i+3) staple is *E*. In some embodiments, a double bond of a (i, i+3) staple is *Z*. In some embodiments, a double bond of a (i, i+7) staple is *E*. In some embodiments, a double bond of a (i, i+7) staple is *Z*. In some embodiments, both double bonds are *E*. In some embodiments, both double bonds are *Z*. In some embodiments, a (i, i+3) staple is *E*, and the other is *Z*. In some embodiments, a (i, i+3) staple is *Z*, and the other is *E*. In some embodiments, a (i, i+4) staple is *E*, and the other is *Z*. In some embodiments, a (i, i+4) staple is *Z*, and the other is *E*. In some embodiments, a double bond of a (i, i+7) staple is *Z*, and a double bond of a second staple (e.g., (i, i+2), (i, i+3), (i, i+4), etc.) is *E*. In some embodiments, a double bond of a (i, i+7) staple is *Z*, and a double bond of a second staple (e.g., (i, i+2), (i, i+3), (i, i+4), etc.) is *Z*. In some embodiments, a double bond of a (i, i+7) staple is *E*, and a double bond of a second staple (e.g., (i, i+2), (i, i+3), (i, i+4), etc.) is *E*. In some embodiments, a double bond of a (i, i+7) staple is *E*, and a double bond of a second staple (e.g., (i, i+2), (i, i+3), (i, i+4), etc.) is *Z*. In some embodiments, two staples are bonded to a chiral center (e.g., a carbon atom in B5), and the chiral center is *R*. In some embodiments, two staples are bonded to a chiral center (e.g., a carbon atom in B5), and the chiral center is *S*.


[0241] In some embodiments, a compound has the structure selected from below or a salt thereof:









SP-1-3




SP-1-4




SP-1-5




SP-1-6




SP-1-7




SP-1-8




SP-2-1




SP-2-2




SP-2-3




SP-2-4




SP-2-5




SP-2-6




SP-2-7




SP-2-8




SP-3-1




SP-3-2




SP-4-1




SP-4-2




SP-4-3




SP-4-4




SP-4-5




SP-4-6




SP-4-7




SP-4-8




SP-5-1




SP-5-2




SP-5-3




SP-5-4




SP-5-5




SP-5-6




SP-5-7




SP-5-8




SP-7-1




SP-7-2




SP-7-3




SP-7-4




SP-7-5




SP-7-6




SP-7-7




SP-7-8




SP-8-1




SP-8-2




SP-8-3




SP-8-4




SP-8-5




SP-8-6




SP-8-7




SP-8-8




SP-9-1




SP-9-2




SP-9-3




SP-9-4




SP-9-5




SP-9-6




SP-9-7




SP-9-8




SP-10-1




SP-10-2




SP-10-3




SP-10-4




SP-10-5




SP-10-6




SP-10-7




SP-10-8




SP-11-1




SP-11-2




SP-11-3




SP-11-4




SP-11-5




SP-11-6




SP-11-7




SP-11-8




SP-12-1




SP-12-2




SP-12-3




SP-12-4




SP-12-5




SP-12-6




SP-12-7




SP-12-8




SP-13-1




SP-13-2




SP-13-3




SP-13-4




SP-13-5




SP-13-6




SP-13-7




SP-13-8




SP-14-1




SP-14-2




SP-14-3




SP-14-4




SP-14-5




SP-14-6




SP-14-7




SP-14-8




SP-15-1




SP-15-2




SP-15-3




SP-15-4




SP-15-5



SP-15-6



SP-15-7



SP-15-8

In some embodiments, an agent is SP-1-1 or a salt thereof. In some embodiments, an agent is SP-1-2 or a salt thereof. In some embodiments, an agent is SP-1-3 or a salt thereof. In some embodiments, an agent is SP-1-4 or a salt thereof. In some embodiments, an agent is SP-1-5 or a salt thereof. In some embodiments, an agent is SP-1-6 or a salt thereof. In some embodiments, an agent is SP-1-7 or a salt thereof. In some embodiments, an agent is SP-1-8 or a salt thereof. In some embodiments, an agent is SP-2-1 or a salt thereof.

In some embodiments, an agent is SP-2-2 or a salt thereof. In some embodiments, an agent is SP-2-3 or a salt thereof. In some embodiments, an agent is SP-2-4 or a salt thereof. In some embodiments, an agent is SP-2-5 or a salt thereof. In some embodiments, an agent is SP-2-6 or a salt thereof. In some embodiments, an agent is SP-2-7 or a salt thereof. In some embodiments, an agent is SP-2-8 or a salt thereof. In some embodiments, an agent is SP-3-1 or a salt thereof. In some embodiments, an agent is SP-3-2 or a salt thereof. In some embodiments, an agent is SP-4-1 or a salt thereof. In some embodiments, an agent is SP-4-2 or a salt thereof. In some embodiments, an agent is SP-4-3 or a salt thereof. In some embodiments, an agent is SP-4-4 or a salt thereof. In some embodiments, an agent is SP-4-5 or a salt thereof. In some embodiments, an agent is SP-4-6 or a salt thereof. In some embodiments, an agent is SP-4-7 or a salt thereof. In some embodiments, an agent is SP-4-8 or a salt thereof. In some embodiments, an agent is SP-5-1 or a salt thereof. In some embodiments, an agent is SP-5-2 or a salt thereof. In some embodiments, an agent is SP-5-3 or a salt thereof. In some embodiments, an agent is SP-5-4 or a salt thereof. In some embodiments, an agent is SP-5-5 or a salt thereof. In some embodiments, an agent is SP-5-6 or a salt thereof. In some embodiments, an agent is SP-5-7 or a salt thereof. In some embodiments, an agent is SP-5-8 or a salt thereof. In some embodiments, an agent is SP-6 or a salt thereof. In some embodiments, an agent is SP-7-1 or a salt thereof. In some embodiments, an agent is SP-7-2 or a salt thereof. In some embodiments, an agent is SP-7-3 or a salt thereof. In some embodiments, an agent is SP-7-4 or a salt thereof. In some embodiments, an agent is SP-7-5 or a salt thereof. In some embodiments, an agent is SP-7-6 or a salt thereof. In some embodiments, an agent is SP-7-7 or a salt thereof. In some embodiments, an agent is SP-7-8 or a salt thereof. In some embodiments, an agent is SP-8-1 or a salt thereof. In some embodiments, an agent is SP-8-2 or a salt thereof. In some embodiments, an agent is SP-8-3 or a salt thereof. In some embodiments, an agent is SP-8-4 or a salt thereof. In some embodiments, an agent is SP-8-5 or a salt thereof. In some embodiments, an agent is SP-8-6 or a salt thereof. In some embodiments, an agent is SP-8-7 or a salt thereof. In some embodiments, an agent is SP-8-8 or a salt thereof. In some embodiments, an agent is SP-9-1 or a salt thereof. In some embodiments, an agent is SP-9-2 or a salt thereof. In some embodiments, an agent is SP-9-3 or a salt thereof. In some embodiments, an agent is SP-9-4 or a salt thereof. In some embodiments, an agent is SP-9-5 or a salt thereof. In some embodiments, an agent is SP-9-6 or a salt thereof. In some embodiments, an agent is SP-9-7 or a salt thereof. In some embodiments, an agent is SP-9-8 or a salt thereof. In some embodiments, an agent is SP-10-1 or a salt thereof. In some embodiments, an agent is SP-10-2 or a salt thereof. In some embodiments, an agent is SP-10-3 or a salt thereof. In some embodiments, an agent is SP-10-4 or a salt thereof. In some embodiments, an agent is SP-10-5 or a salt thereof. In some embodiments, an agent is SP-10-6 or a salt thereof. In some embodiments, an agent is SP-10-7 or a salt thereof. In some embodiments, an agent is SP-10-8 or a salt thereof. In some embodiments, an agent is SP-11-1 or a salt thereof. In some embodiments, an agent is SP-11-2 or a salt thereof. In some embodiments, an agent is SP-11-3 or a salt thereof. In some embodiments, an agent is SP-11-4 or a salt thereof. In some embodiments, an agent is SP-11-5 or a salt thereof. In some embodiments, an agent is SP-11-6 or a salt thereof. In some embodiments, an

agent is SP-11-7 or a salt thereof. In some embodiments, an agent is SP-11-8 or a salt thereof. In some embodiments, an agent is SP-12-1 or a salt thereof. In some embodiments, an agent is SP-12-2 or a salt thereof. In some embodiments, an agent is SP-12-3 or a salt thereof. In some embodiments, an agent is SP-12-4 or a salt thereof. In some embodiments, an agent is SP-12-5 or a salt thereof. In some embodiments, an agent is SP-12-6 or a salt thereof. In some embodiments, an agent is SP-12-7 or a salt thereof. In some embodiments, an agent is SP-12-8 or a salt thereof. In some embodiments, an agent is SP-13-1 or a salt thereof. In some embodiments, an agent is SP-13-2 or a salt thereof. In some embodiments, an agent is SP-13-3 or a salt thereof. In some embodiments, an agent is SP-13-4 or a salt thereof. In some embodiments, an agent is SP-13-5 or a salt thereof. In some embodiments, an agent is SP-13-6 or a salt thereof. In some embodiments, an agent is SP-13-7 or a salt thereof. In some embodiments, an agent is SP-13-8 or a salt thereof. In some embodiments, an agent is SP-14-1 or a salt thereof. In some embodiments, an agent is SP-14-2 or a salt thereof. In some embodiments, an agent is SP-14-3 or a salt thereof. In some embodiments, an agent is SP-14-4 or a salt thereof. In some embodiments, an agent is SP-14-5 or a salt thereof. In some embodiments, an agent is SP-14-6 or a salt thereof. In some embodiments, an agent is SP-14-7 or a salt thereof. In some embodiments, an agent is SP-14-8 or a salt thereof. In some embodiments, an agent is SP-15-1 or a salt thereof. In some embodiments, an agent is SP-15-2 or a salt thereof. In some embodiments, an agent is SP-15-3 or a salt thereof. In some embodiments, an agent is SP-15-4 or a salt thereof. In some embodiments, an agent is SP-15-5 or a salt thereof. In some embodiments, an agent is SP-15-6 or a salt thereof. In some embodiments, an agent is SP-15-7 or a salt thereof. In some embodiments, an agent is SP-15-8 or a salt thereof.

[0242] Agents, e.g., peptides including stapled peptides, can contain various numbers of amino acid residues. In some embodiments, a length of a peptide agent is about 5-20, 5-19, 5-18, 5-17, 5-16, 5-15, 10-20, 10-19, 10-18, 10-17, 10-16, 10-15, 11-20, 11-19, 11-18, 11-17, 11-16, 11-15, 12-20, 12-19, 12-18, 12-17, 12-16, 12-15, 13-20, 13-19, 13-18, 13-17, 13-16, 13-15, 14-20, 14-19, 14-18, 14-17, 14-16, 14-15, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues. In some embodiments, a length is about 10 amino acid residues. In some embodiments, a length is about 11 amino acid residues. In some embodiments, a length is about 12 amino acid residues. In some embodiments, a length is about 13 amino acid residues. In some embodiments, a length is about 14 amino acid residues. In some embodiments, a length is about 15 amino acid residues. In some embodiments, a length is about 16 amino acid residues. In some embodiments, a length is about 17 amino acid residues. In some embodiments, a length is about 18 amino acid residues. In some embodiments, a length is about 19 amino acid residues. In some embodiments, a length is about 20 amino acid residues.

[0243] In some embodiments, as described herein, one or more staples independently comprise an olefin double bond (e.g., formed through olefin metathesis). In some embodiments, one or more staples independently comprise an amide group (e.g., formed through amidation). In some embodiments, at least one staple does not contain an olefin double bond. In some embodiments, there is at least one staple whose

formation does not comprise reactions of olefins such as olefin metathesis and/or modification of olefin double bonds (e.g., hydrogenation, epoxidation, etc.).

[0244] In some embodiments, a residue of a staple (e.g., B5) is so positioned that if its position is P (e.g., X^4), a first acidic amino acid residue is at position P-2 (e.g., X^2), a second acidic amino acid residue is positioned at P+1 (e.g., X^5), a third acidic amino acid residue is positioned at P+2 (e.g., X^6), a hydrophobic amino acid residue is positioned at P+4 (e.g., X^8), a first aromatic amino acid residue is positioned at P+5 (e.g., X^9), a second aromatic amino acid residue is positioned at P+8 (e.g., X^{12}), and/or a third aromatic amino acid residue is positioned at P+9 (e.g., X^{13}). In some embodiments, a staple is a (i, i+7) staple, and the other residue of the staple is positioned at P+7 (e.g., X^{11}). In some embodiments, a first acidic amino acid residue is at position P-2 (e.g., X^2). In some embodiments, a second acidic amino acid residue is positioned at P+1 (e.g., X^5). In some embodiments, a third acidic amino acid residue is positioned at P+2 (e.g., X^6). In some embodiments, a hydrophobic amino acid residue is positioned at P+4 (e.g., X^8). In some embodiments, a first aromatic amino acid residue is positioned at P+5 (e.g., X^9). In some embodiments, a second aromatic amino acid residue is positioned at P+8 (e.g., X^{12}). In some embodiments, a third aromatic amino acid residue is positioned at P+9 (e.g., X^{13}). In some embodiments, a first acidic amino acid residue is at position P-2 (e.g., X^2), a second acidic amino acid residue is positioned at P+1 (e.g., X^5), a first aromatic amino acid residue is positioned at P+5 (e.g., X^9), a second aromatic amino acid residue is positioned at P+8 (e.g., X^{12}), and a third aromatic amino acid residue is positioned at P+9 (e.g., X^{13}). In some embodiments, a first acidic amino acid residue is at position P-2 (e.g., X^2), a second acidic amino acid residue is positioned at P+1 (e.g., X^5), a third acidic amino acid residue is positioned at P+2 (e.g., X^6), a hydrophobic amino acid residue is positioned at P+4 (e.g., X^8), a first aromatic amino acid residue is positioned at P+5 (e.g., X^9), a second aromatic amino acid residue is positioned at P+8 (e.g., X^{12}), and a third aromatic amino acid residue is positioned at P+9 (e.g., X^{13}). In some embodiments, a stapled peptide agent comprises acidic amino acid residues at positions P-2 and P+1, and aromatic amino acid residues at positions P+5, P+8 and P+9. In some embodiments, a stapled peptide agent comprises acidic amino acid residues at positions P-2, P+1 and P+2, and aromatic amino acid residues at positions P+5, P+8 and P+9. In some embodiments, a stapled peptide agent comprises acidic amino acid residues at positions P-2 and P+1, a hydrophobic amino acid residue at position P+4, and aromatic amino acid residues at positions P+5, P+8 and P+9. In some embodiments, a stapled peptide agent comprises acidic amino acid residues at positions P-2, P+1 and P+2, a hydrophobic amino acid residue at position P+4, and aromatic amino acid residues at positions P+5, P+8 and P+9. In some embodiments, P is 3. In some embodiments, P is 4. In some embodiments, P is 5. In some embodiments, P is 6. In some embodiments, P is 7. In some embodiments, an amino acid residue at position P comprises two groups for stapling, e.g., B4, B5, B6, etc. In some embodiments, it is B4. In some embodiments, it is B5. In some embodiments, it is B6. In some embodiments, an agent comprises a staple and a first additional staple, e.g., a (i, i+3) or (i, i+4) staple. In some embodiments, a staple and a first additional staple are bonded to the same residue (e.g., B5, B6, etc.). In some embodiments, the other residue of a first additional residue is at position P-2 (e.g., when a

moiety for stapling like a terminal olefin is in a P-terminal group which is considered a portion of X^1), P-3 or P-4. In some embodiments, an agent comprises a second additional staple, e.g., a (i, i+4) staple (e.g., stapling residues at positions P+6 (e.g., X^{10}) and P+10 (e.g., X^{14}), a (i, i+3) staple (e.g., stapling residues at positions P+3 (e.g., X^7) and P+6 (e.g., X^{10}), a (i, i+7) staple (e.g., stapling residues at positions P+3 (e.g., X^7) and P+10 (e.g., X^{14}), etc.). In some embodiments, an agent comprises a second additional staple which is a (i, i+4) staple stapling residues at positions P+6 (e.g., X^{10}) and P+10 (e.g., X^{14}). In some embodiments, an agent comprises a third additional staple, e.g., a (i, i+4) staple stapling residues at positions P-1 (e.g., X^3) and P+3 (e.g., X^7). In some embodiments, there are three staples in a stapled peptide agent. In some embodiments, there are four staples in a stapled peptide agent. As demonstrated herein, stapled agents comprising so positioned staples and residues can provide various desired properties and activities. In some embodiments, positioning of one or more staples may be shifted relevant to various acidic, hydrophobic and/or aromatic amino acid residues described herein, e.g., in some embodiments, stapled peptide agents comprise stapled residues at position P and P+7 (and optionally P-3 or P-4), acidic amino acid residues are at positions P-1, and P+2, and aromatic amino acid residues at positions P+6, P+9 and P+10, and optionally an acid amino acid residue at P+3 and/or a hydrophobic amino acid residue at positon P+5. It was observed that various stapled peptide agents with shifted staples can bind to beta-catenin when assessed by fluorescence polarization.

[0245] Certain useful staples are described in the "Agents" section, below.

Beta-catenin

[0246] Among other things, the present disclosure provides technologies for modulating one or more beta-catenin functions. In some embodiments, the present disclosure provides useful technologies for inhibiting one or more beta-catenin functions that are associated with cancer or hyperplasia. In some embodiments, provided technologies are useful for preventing and treating conditions, disorders or diseases whose prevention and/or treatment will benefits from inhibition of beta-catenin. In some embodiments, a condition, disorder or disease is cancer.

[0247] Beta-catenin is reported to have various functions. For example, it can regulate and coordinate transcription of various genes. It is reported that high beta-catenin activity and/or expression levels may contribute to the development various conditions, disorders or diseases including cancer. Mutations and overexpression of beta-catenin are reported to be associated with conditions, disorders or diseases including many cancers including colorectal cancer, lung cancer, and breast cancer. Dysregulation of the Wnt/β-catenin signaling pathway has reportedly been linked to a number of conditions, disorders or diseases, including neurodegenerative diseases, psychiatric diseases, cancers, asthma, and even wound healing. An abundance of published research, both clinical and preclinical, has indicated that hyperactivated Wnt/beta-catenin activity drives tumorigenesis and is required for tumor maintenance in various cancers. Many Wnt inhibitors largely modulate this pathway at the extracellular ligand/receptor level, e.g., by preventing Wnt

ligand secretion or by blocking Wnt ligand interaction with its receptors at the plasma membrane. It has been reported that many activating Wnt pathway mutations are found in APC and/or CTNNB1, which are downstream of membrane-proximal events. Among other things, the present disclosure encompasses the recognition that many agents at the extracellular ligand/receptor level are insufficient to treat many relevant patients, e.g., those with downstream mutations/abnormalities. In some embodiments, Wnt pathway-activating mutations converge on beta-catenin/TCF node. In some embodiments, the present disclosure targets beta-catenin/TCF interaction, e.g., as a therapeutic approach. Agents that can modulate beta-catenin functions are useful for various purposes including preventing and/or treating various conditions, disorders or diseases associated with beta-catenin.

Binding Sites

[0248] Beta-catenin may interact with various agents at various binding sites each independently comprising a set of amino acid residues that interact with binding agents. For example, certain binding sites are utilized for beta-catenin interactions with Axin, APC, C-cadherin, E-cadherin, TCF3, and Bcl9. For interactions with TCF3, it has been reported that two or more binding sites may be utilized simultaneously to interact with different portions of TCF3. See, e.g., Graham et al. Cell, Vol. 103, 885–896, 2000.

[0249] In some embodiments, provided agents bind to beta-catenin at a unique binding site. In some embodiments, provided agents interact with beta-catenin at a set of amino acid residues that are different from previously reported binding sites, e.g., those for Axin, APC, C-cadherin, E-cadherin, TCF3 or Bcl9.

[0250] For example, in some embodiments, provided agents interact with one or more or all (e.g., about 1-23, 1-20, 1-15, 1-10, 1-5, 5-23, 5-20, 5-15, 5-10, 6-23, 6-20, 6-15, 6-10, 7-23, 7-20, 7-15, 7-10, 8-23, 8-20, 8-15, 8-10, 9-23, 9-20, 9-15, 9-10, 10-23, 10-20, 10-15, 11-23, 11-20, 11-15, 12-23, 12-20, 12-15, 13-23, 13-20, 13-15, 13-23, 14-20, 15-23, 15-20, 16-23, 16-20, 17-23, 17-20, 18-23, or 18-20, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23, etc.) of a set of amino acid residues that are or correspond to amino acid residues in SEQ ID NO: 1, e.g., in some embodiments, the following amino acid residues of SEQ ID NO: 1: A305, Y306, G307, N308, Q309, K312, R342, K345, V346, V349, Q375, R376, Q379, N380, L382, W383, R386, N387, D413, N415, V416, T418, and C419. In some embodiments, a set of amino acid residues are or correspond to amino acid residues A305, Y306, G307, N308, Q309, K312, R342, K345, V346, V349, Q375, Q379, N380, L382, W383, R386, N387, D413, N415, V416, T418, and C419 of SEQ ID NO: 1. In some embodiments, a set of amino acid residues are or correspond to amino acid residues A305, Y306, G307, N308, Q309, K312, K345, V346, V349, Q379, N380, L382, W383, R386, N387, D413, N415, V416, T418, and C419 of SEQ ID NO: 1. In some embodiments, a set of amino acid residues are or correspond to amino acid residues G307, K312, K345, W383, N387, D413, and N415 of SEQ ID NO: 1. In some embodiments, a set of amino acid residues are or correspond to amino acid residues G307, K312, K345, Q379, L382, W383, N387, N415 and V416 of SEQ ID NO: 1. In some embodiments, a set of amino acid residues are or correspond to amino acid residues Y306, G307, K312, K345, Q379, L382, W383, N387,

N415 and V416 of SEQ ID NO: 1. In some embodiments, a set of amino acid residues are or correspond to amino acid residues G307, K312, K345, Q379, L382, W383, R386, N387, N415 and V416 of SEQ ID NO: 1. In some embodiments, a set of amino acid residues are or correspond to amino acid residues Y306, G307, K312, K345, Q379, L382, W383, R386, N387, N415 and V416 of SEQ ID NO: 1. In some embodiments, a set of amino acid residues are or correspond to amino acid residues Y306, G307, K312, K345, V349, Q379, L382, W383, N387, N415 and V416 of SEQ ID NO: 1. In some embodiments, a set of amino acid residues are or correspond to amino acid residues Y306, G307, K312, K345, V349, Q379, L382, W383, R386, N387, N415 and V416 of SEQ ID NO: 1. In some embodiments, a set of amino acid residues are or correspond to amino acid residues G307, K312, K345, W383, and N387 of SEQ ID NO: 1. In some embodiments, a set of amino acid residues are or correspond to amino acid residues Y306, G307, K312, R386 and N387 of SEQ ID NO: 1. In some embodiments, provided agents interact with Y306 or an amino acid residue corresponding thereto. In some embodiments, provided agents interact with G307 or an amino acid residue corresponding thereto. In some embodiments, provided agents interact with K312 or an amino acid residue corresponding thereto. In some embodiments, provided agents interact with K345 or an amino acid residue corresponding thereto. In some embodiments, provided agents interact with V349 or an amino acid residue corresponding thereto. In some embodiments, provided agents interact with Q379 or an amino acid residue corresponding thereto. In some embodiments, provided agents interact with L382 or an amino acid residue corresponding thereto. In some embodiments, provided agents interact with W383 or an amino acid residue corresponding thereto. In some embodiments, provided agents interact with R386 or an amino acid residue corresponding thereto. In some embodiments, provided agents interact with N387 or an amino acid residue corresponding thereto. In some embodiments, provided agents interact with N415 or an amino acid residue corresponding thereto. In some embodiments, provided agents interact with V416 or an amino acid residue corresponding thereto.

[0251] In some embodiments, a present agent interacts with a polypeptide whose sequence corresponds to aa 146-aa665 of human beta-catenin. In some embodiments, a present agent interacts with a polypeptide whose sequence comprises or is SEQ ID NO: 2:
SVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIIL ASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCL WTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEAL VRT (SEQ ID NO: 2).

[0252] In some embodiments, all amino acid residues that interact with a provided agent is with SEQ ID NO: 2. In some embodiments, amino acid residues that interact with a provided agent (e.g., one or more amino acid residues in an agent) interacts with an agent through hydrogen bonding, hydrophobic interactions or salt bridge. As appreciated by those skilled in the art, when two amino acid residues interacting with each other, they are typically within a certain range of distances when, e.g., assessed using crystallography, NMR, etc.

[0253] In some embodiments, certain amino acid residues reported to interact with one or more polypeptides are not significantly involved in interactions between provided and beta-catenin. In some embodiments, provided agents do not interact with an Axin binding site. In some embodiments, provided agents do not interact with a Bcl9 binding site. In some embodiments, provided agents do not interact with one or more or all of amino acid residues that are or correspond to N426, C429, K435, R469, H470, S473, R474, K508 and N516 of SEQ ID NO: 1. In some embodiments, provided agents do not interact with N426 or an amino acid residue corresponding thereto. In some embodiments, provided agents do not interact with C429 or an amino acid residue corresponding thereto. In some embodiments, provided agents do not interact with K435 or an amino acid residue corresponding thereto. In some embodiments, provided agents do not interact with R469 or an amino acid residue corresponding thereto. In some embodiments, provided agents do not interact with H470 or an amino acid residue corresponding thereto. In some embodiments, provided agents do not interact with S473 or an amino acid residue corresponding thereto. In some embodiments, provided agents do not interact with R474 or an amino acid residue corresponding thereto. In some embodiments, provided agents do not interact with K508 or an amino acid residue corresponding thereto. In some embodiments, provided agents do not interact with N516 or an amino acid residue corresponding thereto.

[0254] In some embodiments, mutation of one or more amino acid residues outside of SEQ ID NO: 2 in beta-catenin does not significant/y (e.g., not exceeding 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90% or more) reduce interactions of beta-catenin with a provided agent. In some embodiments, mutation of one or more or all of amino acid residues that are or correspond to N426, C429, K435, R469, H470, S473, R474, K508 and N516 of SEQ ID NO: 1 does not significantly reduce interactions of beta-catenin with a provided agent. In some embodiments, mutation of N426 or an amino acid residue corresponding thereto does not significantly reduce interaction of beta-catenin with an agent. In some embodiments, mutation of Q379 or an amino acid residue corresponding thereto (e.g., to Ala, Glu, Phe, Trp, etc.) does not significantly reduce interaction of beta-catenin with an agent.

[0255] In some embodiments, an agent binds to a TCF site of beta-catenin. In some embodiments, an agent interacts with one or more but not all amino acid residues that interact with TCF. In some embodiments, an agent interacts with one or more but not all amino acid residues that interact with an extended region of XTcf3-CBD. In some embodiments, an agent does not interact with beta-catenin amino acid residues that interact with a beta-hairpin module of XTcf3-CBD. In some embodiments, an agent does not interact with beta-catenin amino acid residues that interact with a helix module of XTcf3-CBD. For certain amino acid residues that interact various modules of XTcF3-CBD, see, e.g., Graham et al. Cell, Vol. 103, 885–896, 2000.

[0256] In some embodiments, an agent competes with TCF for beta-catenin binding. In some embodiments, an agent competes with an extended region of TCF (e.g., Ala14-Glu24, or Asp16-Glu24, as described in Graham et al. Cell, Vol. 103, 885–896, 2000) for beta-catenin binding. In some embodiments,

compared to an extended region of TCF, an agent does not compete, or competes at a less degree, with Axin for beta-catenin binding. In some embodiments, compared to an extended region of TCF, an agent does not compete, or competes at a less degree, with Bcl9 for beta-catenin binding. In some embodiments, compared to an extended region of TCF, an agent does not compete, or competes at a less degree, with a beta-hairpin module of XTcf3-CBD for beta-catenin binding. In some embodiments, compared to an extended region of TCF, an agent does not compete, or competes at a less degree, with a helix module of XTcf3-CBD for beta-catenin binding. In some embodiments, an agent competes with E-cadherin for beta-catenin binding.

[0257] In some embodiments, the present disclosure provides complexes of peptides (e.g., polypeptides whose sequences are or comprises SEQ ID NO: 1 or 2) and provided agents. In some embodiments, in such complexes polypeptides and provided agents interact with one or more or all amino acid residues as described herein, and optionally do not interact with one or more or all amino acid residues as described herein.

[0258] In some embodiments, the present disclosure provides complexes comprising a provided agent and a beta-catenin polypeptide or a portion thereof. In some embodiments, a portion thereof comprises one or more or all of the interacting residues as described herein. In some embodiments, an agent and a beta-catenin polypeptide or a portion thereof interact with other at one or more or all of the interacting residues.

Certain Agents

[0259] In some embodiments, the present disclosure provides an agent having the structure of formula I:

$$R^N–L^{P1}–L^{AA1}–L^{P2}–L^{AA2}–L^{P3}–L^{AA3}–L^{P4}–L^{AA4}–L^{P5}–L^{AA5}–L^{P6}–L^{AA6}–L^{P7}–R^C,$$

I

or a salt thereof, wherein:

R^N is a peptide, an amino protecting group or R'–L^{RN}–;

each of L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} is independently L, wherein L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} comprise:

a first R' group and a second R' group which are taken together to form −L^s− which is bonded to the atom to which a first R' group is attached and the atom to which a second R' group is attached; and

a third R' group and a fourth R' group which are taken together to form −L^s− which is bonded to the atom to which a third R' group is attached and the atom to which a fourth R' group is attached;

each L^s is independently −L^{s1}–L^{s2}–L^{s3}–, wherein each L^{s1}, L^{s2} and L^{s3} is independently L;

L^{AA1} is an amino acid residue that comprises a side chain comprising an acidic or polar group;

L^{AA2} is an amino acid residue that comprises a side chain comprising an acidic or polar group;

L^{AA3} is an amino acid residue;

L^{AA4} is an amino acid residue that comprises a side chain comprising an optionally substituted aromatic group;

L^{AA5} is an amino acid residue that comprises a side chain comprising an optionally substituted aromatic group;

L^{AA6} is an amino acid residue that comprises a side chain comprising an optionally substituted aromatic group;

R^C is a peptide, a carboxyl protecting group, $-L^{RC}-R'$, $-O-L^{RC}-R'$ or $-N(R')-L^{RC}-R'$;

each of L^{RN} and L^{RC} is independently L;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each $-Cy-$ is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;

each R' is independently $-L-R$, $-C(O)R$, $-CO_2R$, or $-SO_2R$;

each R is independently $-H$, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atom(s), 0-10 heteroatoms.

[0260] In some embodiments, the present disclosure provides an agent having the structure of formula I:

$$R^N-L^{P1}-L^{AA1}-L^{P2}-L^{AA2}-L^{P3}-L^{AA3}-L^{P4}-L^{AA4}-L^{P5}-L^{AA5}-L^{P6}-L^{AA6}-L^{P7}-R^C,$$

I

or a salt thereof, wherein:

R^N is a peptide, an amino protecting group or $R'-L^{RN}-$;

each of L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} is independently L, wherein L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} comprise:

a first R' group and a second R' group which are taken together to form $-L^s-$ which is bonded to the atom to which a first R' group is attached and the atom to which a second R' group is attached; and

a third R' group and a fourth R' group which are taken together to form $-L^s-$ which is

bonded to the atom to which a third R' group is attached and the atom to which a fourth R' group is attached;

each L^s is independently $-L^{s1}-L^{s2}-L^{s3}-$, wherein each L^{s1}, L^{s2} and L^{s3} is independently L;

L^{AA1} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS1}-R^{AA1}$, wherein R^{AA1} is $-CO_2R$ or $-SO_2R$;

L^{AA2} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS2}-R^{AA2}$, wherein R^{AA2} is $-CO_2R$ or $-SO_2R$;

L^{AA3} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS3}-R^{AA3}$, wherein R^{AA3} is R';

L^{AA4} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS4}-R^{AA4}$, wherein R^{AA4} is an optionally substituted group selected from 6-14 membered aryl or 5-14 membered heteroaryl having 1-6 heteroatoms;

L^{AA5} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS5}-R^{AA5}$, wherein R^{AA5} is an optionally substituted group selected from 6-14 membered aryl or 5-14 membered heteroaryl having 1-6 heteroatoms;

L^{AA6} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS6}-R^{AA6}$, wherein R^{AA6} is an optionally substituted group selected from 6-14 membered aryl or 5-14 membered heteroaryl having 1-6 heteroatoms;

R^C is a peptide, a carboxyl protecting group, $-L^{RC}-R'$, $-O-L^{RC}-R'$ or $-N(R')-L^{RC}-R'$;

each of L^{RN} and L^{RC} is independently L;

each L^{AR} is independently an optionally substituted, bivalent C_1-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each of L^{AS1}, L^{AS2}, L^{AS3}, L^{AS4}, L^{AS5}, and L^{AS6} is independently L^{AS};

each R^{AS} is independently $-L^{AS}-R'$;

each L^{AS} is independently an optionally substituted, bivalent C_1-C_{10} aliphatic or heteroaliphatic group having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each $-Cy-$ is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic

or polycyclic ring having 0-10 heteroatoms;

each R' is independently −L−R, −C(O)R, $-CO_2R$, or $-SO_2R$;

each R is independently −H, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atom(s), 0-10 heteroatoms.

[0261] In some embodiments, a second R' group and a third R' group are attached to the same atom. In some embodiments, none of the first, second and fourth R' groups are attached to the same atom. In some embodiments, none of the first, second, fourth, fifth and sixth R' groups are attached to the same atom. In some embodiments, none of the first, second, fourth, fifth, sixth, seventh and eighth R' groups are attached to the same atom. In some embodiments, each of the first, second, third and fourth R' groups is independently attached to a different atom. In some embodiments, each of the first, second, third, fourth, fifth and sixth R' groups is independently attached to a different atom. In some embodiments, each of the first, second, third, fourth, fifth, sixth, seventh and eighth R' groups is independently attached to a different atom.

[0262] In some embodiments, a compound of formula I is a stapled peptide as described herein.

[0263] In some embodiments, each L^s is independently a staple as described herein. In some embodiments, L^s, e.g., L^s formed by taking a first and a second R' groups, has a length of 5-20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms. Unless specified otherwise, a length between two connection sites, e.g., of L^s, L, etc., is the shortest covalent connection from one site to the other. For example, the length of $-CH_2-CH_2-$ is 2 atoms (−C−C−), the length of 1, 3-phenylene is 3 atoms. In some embodiments, L^s, e.g., L^s formed by taking a third and a fourth R' groups, has a length of 5-20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms. In some embodiments, L^s, e.g., L^s formed by taking a fifth and a sixth R' groups, has a length of 5-20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms. In some embodiments, L^s, e.g., L^s formed by taking a seventh and an eighth R' groups, has a length of 5-20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms.

[0264] Those skilled in the art reading the present disclosure will appreciate that staples, e.g., L^s, connecting two atoms having a longer distance typically has a longer length than staples connecting two atom having a shorter distance, e.g., (i, i+7) staples typically have longer lengths than (i, i+3) or (i, i+4) staples. In some embodiments, a length is 5 atoms. In some embodiments, a length is 6 atoms. In some embodiments, a

length is 7 atoms. In some embodiments, a length is 8 atoms. In some embodiments, a length is 9 atoms. In some embodiments, a length is 10 atoms. In some embodiments, a length is 11 atoms. In some embodiments, a length is 12 atoms. In some embodiments, a length is 13 atoms. In some embodiments, a length is 14 atoms. In some embodiments, a length is 15 atoms. In some embodiments, a length is 16 atoms. In some embodiments, a length is 17 atoms. In some embodiments, a length is 18 atoms. In some embodiments, a length is 19 atoms. In some embodiments, a length is 20 atoms.

L^{P1}

[0265] In some embodiments, L^{P1} is a covalent bond, or an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, the length of L^{P1} is 2-10 atoms. In some embodiments, it is 2 atoms. In some embodiments, it is 3 atoms. In some embodiments, it is 4 atoms. In some embodiments, it is 5 atoms. In some embodiments, it is 6 atoms. In some embodiments, it is 7 atoms. In some embodiments, it is 8 atoms. In some embodiments, it is 9 atoms. In some embodiments, it is 10 atoms. In some embodiments, one or more methylene units are independently replaced with $-N(R')-$, $-C(R')_2-$, $-C(O)-$ or $-C(O)N(R')-$. In some embodiments, a methylene unit is replace with $-N(R')-$. In some embodiments, a methylene unit is replace with $-C(R')_2-$. In some embodiments, a methylene unit is replace with $-C(O)-$. In some embodiments, a methylene unit is replace with $-C(O)N(R')-$. In some embodiments, each methylene unit is independently replaced with $-N(R')-$, $-C(R')_2-$ or $-C(O)-$. In some embodiments, L^{P1} is or comprises an amino acid residue. In some embodiments, L^{P1} is or comprises a peptide.

[0266] In some embodiments, L^{P1} is or comprises $-[X]_p-X^1-$, wherein each of p, X and X^1 is independently as described herein, and X^1 is bonded to L^{AA1}. In some embodiments, L^{P1} is or comprises $-X^1-$.

[0267] In some embodiments, L^{P1} comprises a $-C(R')_2-$ group, wherein one of the R' groups is a first R' group of the four. In some embodiments, such a $-C(R')_2-$ group is of an amino acid residue. In some embodiments, such a $-C(R')_2-$ group is of X^1. In some embodiments, such a carbon atom is an alpha carbon of an amino acid residue.

L^{AA1}

[0268] In some embodiments, L^{AA1} is or comprises amino acid residue. In some embodiments, L^{AA1} is or comprises an amino acid residue that comprises a side chain comprising an acidic or polar group. In some embodiments, L^{AA1} is an amino acid residue that comprises a side chain comprising an acidic group.

[0269] In some embodiments, L^{AA1} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein each variable is independently as described herein. In some embodiments, L^{AA1} is an optionally substituted, bivalent C_1-C_6 (e.g., C_1, C_2, C_3, C_4, C_5, or C_6) aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$,

−S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, $-S(O)_2-$, $-S(O)_2N(R')-$, −C(O)S−, or −C(O)O−, wherein each variable is independently as described herein. In some embodiments, L^{AA1} is an optionally substituted, bivalent C_2-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,−Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, $-S(O)_2-$, $-S(O)_2N(R')-$, −C(O)S−, or −C(O)O−, wherein each variable is independently as described herein. In some embodiments, L^{AA1} is $-N(R')-C(R')(R^{AS})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, L^{AA1} is $-NH-C(R')(R^{AS})-C(O)-$, wherein each variable is independently as described herein.

[0270] In some embodiments, L^{AS1} is L^{AS} as described herein. In some embodiments, R^{AA1} is $-CO_2R$, wherein R is as described herein. In some embodiments, R is H. In some embodiments, L^{AA1} is a residue of an acidic amino acid residue, e.g., Asp, Glu, etc. In some embodiments, L^{AA1} is X^2 as described herein.

L^{P2}

[0271] In some embodiments, L^{P2} is a covalent bond, or an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, −Cy−, −O−, −S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, $-S(O)_2-$, $-S(O)_2N(R')-$, −C(O)S−, or −C(O)O−. In some embodiments, the length of L^{P2} is 2-10 atoms. In some embodiments, it is 2 atoms. In some embodiments, it is 3 atoms. In some embodiments, it is 4 atoms. In some embodiments, it is 5 atoms. In some embodiments, it is 6 atoms. In some embodiments, it is 7 atoms. In some embodiments, it is 8 atoms. In some embodiments, it is 9 atoms. In some embodiments, it is 10 atoms. In some embodiments, one or more methylene units are independently replaced with −N(R')−, $-C(R')_2-$, −C(O)− or −C(O)N(R')−. In some embodiments, a methylene unit is replace with −N(R')−. In some embodiments, a methylene unit is replace with $-C(R')_2-$. In some embodiments, a methylene unit is replace with −C(O)−. In some embodiments, a methylene unit is replace with −C(O)N(R')−. In some embodiments, each methylene unit is independently replaced with −N(R')−, $-C(R')_2-$ or −C(O)−. In some embodiments, L^{P2} is or comprises an amino acid residue. In some embodiments, L^{P2} is or comprises a peptide.

[0272] In some embodiments, L^{P2} is or comprises $-[X]pX^4[X]p'-$, wherein each of p, p', X and X^4 is independently as described herein. In some embodiments, L^{P2} is or comprises $-[X]pX^3X^4[X]p'-$, wherein each X, X^3 and X^4 is independently an amino acid residue, and each of p and p' is independently 0-10. In some embodiments, L^{P2} is or comprises $-X^3X^4-$, wherein each X^3 and X^4 is independently as described herein, and X^4 is bonded to L^{AA2}.

[0273] In some embodiments, L^{P2} comprises a $-C(R')_2-$ group, wherein one of the R' groups is a second R' group and the other is a third of the four. In some embodiments, such a $-C(R')_2-$ group is of an amino acid residue. In some embodiments, such a $-C(R')_2-$ group is of X^4. In some embodiments, such a carbon atom is an alpha carbon of an amino acid residue. In some embodiments, such a carbon atom is an alpha

carbon of X^4.

[0274] In some embodiments, a methylene unit of L^{P2} is replaced with $-C(R')_2-$, wherein one of the R' groups is a second or fifth or seventh R' group. In some embodiments, such a $-C(R')_2-$ group is of an amino acid residue. In some embodiments, such a $-C(R')_2-$ group is of X^3. In some embodiments, such a carbon atom is an alpha carbon of an amino acid residue. In some embodiments, such a carbon atom is an alpha carbon of X^3. In some embodiments, it is a second R' group. In some embodiments, it is a fifth R' group. In some embodiments, it is a seventh R' group.

[0275] In some embodiments, a methylene unit of L^{P2} is replaced with $-C(R')_2-$, wherein one of the R' groups is a first or third R' group. In some embodiments, such a $-C(R')_2-$ group is of an amino acid residue. In some embodiments, such a $-C(R')_2-$ group is of X^4. In some embodiments, such a carbon atom is an alpha carbon of an amino acid residue. In some embodiments, such a carbon atom is an alpha carbon of X^4. In some embodiments, it is a first R' group. In some embodiments, it is a third R' group.

L^{AA2}

[0276] In some embodiments, L^{AA2} is or comprises amino acid residue. In some embodiments, L^{AA2} is or comprises an amino acid residue that comprises a side chain comprising an acidic or polar group. In some embodiments, L^{AA2} is an amino acid residue that comprises a side chain comprising an acidic group.

[0277] In some embodiments, L^{AA2} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein each variable is independently as described herein. In some embodiments, L^{AA2} is an optionally substituted, bivalent C_1-C_6 (e.g., C_1, C_2, C_3, C_4, C_5, or C_6) aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$, wherein each variable is independently as described herein. In some embodiments, L^{AA2} is an optionally substituted, bivalent C_2-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$, wherein each variable is independently as described herein. In some embodiments, L^{AA2} is $-N(R')-C(R')(R^{AS})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, L^{AA2} is $-NH-C(R')(R^{AS})-C(O)-$, wherein each variable is independently as described herein.

[0278] In some embodiments, L^{AS2} is L^{AS} as described herein. In some embodiments, R^{AA2} is $-CO_2R$, wherein R is as described herein. In some embodiments, R is H. In some embodiments, L^{AA2} is a residue of an acidic amino acid residue, e.g., Asp, Glu, etc. In some embodiments, L^{AA2} is X^5 as described herein.

L^{P3}

[0279] In some embodiments, L^{P3} is a covalent bond. In some embodiments, L^{P3} is an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$,

−C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −$S(O)_2$−, −$S(O)_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, the length of L^{P3} is 0-10 atoms. In some embodiments, the length of L^{P3} is 2-10 atoms. In some embodiments, it is 2 atoms. In some embodiments, it is 3 atoms. In some embodiments, it is 4 atoms. In some embodiments, it is 5 atoms. In some embodiments, it is 6 atoms. In some embodiments, it is 7 atoms. In some embodiments, it is 8 atoms. In some embodiments, it is 9 atoms. In some embodiments, it is 10 atoms. In some embodiments, one or more methylene units are independently replaced with −N(R')−, −$C(R')_2$−, −C(O)− or −C(O)N(R')−. In some embodiments, a methylene unit is replace with −N(R')−. In some embodiments, a methylene unit is replace with −$C(R')_2$−. In some embodiments, a methylene unit is replace with −C(O)−. In some embodiments, a methylene unit is replace with −C(O)N(R')−. In some embodiments, each methylene unit is independently replaced with −N(R')−, −$C(R')_2$− or −C(O)−. In some embodiments, L^{P3} is or comprises an amino acid residue. In some embodiments, L^{P3} is or comprises a peptide. In some embodiments, L^{P3} is or comprises −[X]pX^6X^7[X]p'−, wherein each X, X^6 and X^7 is independently an amino acid residue, and each of p and p' is independently 0-10. In some embodiments, L^{P3} is or comprises −X^6X^7−, wherein each X^6 and X^7 is independently an amino acid residue. In some embodiments, X^7 is bonded to L^{AA3}. In some embodiments, a methylene unit of L^{P3} is replaced with −$C(R')_2$−, wherein one of the R' groups is the fifth, sixth, seventh or eighth R' group. In some embodiments, X^7 comprises −$C(R')_2$−, wherein one of the R' groups is the fifth, sixth, seventh or eighth R' group.

L^{AA3}

[0280] In some embodiments, L^{AA3} is or comprises amino acid residue. In some embodiments, L^{AA3} is or comprises an amino acid residue that comprises a side chain comprising an acidic or polar group. In some embodiments, L^{AA3} is an amino acid residue that comprises a side chain comprising an acidic group.

[0281] In some embodiments, L^{AA3} is L^{AR}, wherein a methylene unit is replaced with −C(R')(R^{AS})−, wherein each variable is independently as described herein. In some embodiments, L^{AA3} is an optionally substituted, bivalent C_1-C_6 (e.g., C_1, C_2, C_3, C_4, C_5, or C_6) aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with −$C(R')_2$−, −C(R')(R^{AS})−,−Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −$S(O)_2$−, −$S(O)_2$N(R')−, −C(O)S−, or −C(O)O−, wherein each variable is independently as described herein. In some embodiments, L^{AA3} is an optionally substituted, bivalent C_2-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with −$C(R')_2$−, −C(R')(R^{AS})−,−Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −$S(O)_2$−, −$S(O)_2$N(R')−, −C(O)S−, or −C(O)O−, wherein each variable is independently as described herein. In some embodiments, L^{AA3} is −N(R')−C(R')(R^{AS})−C(O)−, wherein each variable is independently as described herein. In some embodiments, L^{AA3} is −NH−C(R')(R^{AS})−C(O)−, wherein each variable is independently as described herein.

[0282] In some embodiments, L^{AS3} is L^{AS} as described herein. In some embodiments, R^{AA3} is −CO_2R,

wherein R is as described herein. In some embodiments, R is H. In some embodiments, L^{AA3} is a residue of an acidic amino acid residue, e.g., Asp, Glu, etc. In some embodiments, L^{AA3} is X^6 as described herein.

[0283] In some embodiments, L^{AA3} comprises a hydrophobic group. In some embodiments, L^{AA3} is or comprises a hydrophobic amino acid residue. In some embodiments, L^{AA3} is X^8 as described herein.

L^{P4}

[0284] In some embodiments, L^{P4} is a covalent bond, or an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, the length of L^{P4} is 0-10 atoms. In some embodiments, the length of L^{P4} is 2-10 atoms. In some embodiments, it is 2 atoms. In some embodiments, it is 3 atoms. In some embodiments, it is 4 atoms. In some embodiments, it is 5 atoms. In some embodiments, it is 6 atoms. In some embodiments, it is 7 atoms. In some embodiments, it is 8 atoms. In some embodiments, it is 9 atoms. In some embodiments, it is 10 atoms. In some embodiments, one or more methylene units are independently replaced with $-N(R')-$, $-C(R')_2-$, $-C(O)-$ or $-C(O)N(R')-$. In some embodiments, a methylene unit is replace with $-N(R')-$. In some embodiments, a methylene unit is replace with $-C(R')_2-$. In some embodiments, a methylene unit is replace with $-C(O)-$. In some embodiments, a methylene unit is replace with $-C(O)N(R')-$. In some embodiments, each methylene unit is independently replaced with $-N(R')-$, $-C(R')_2-$ or $-C(O)-$. In some embodiments, L^{P4} is or comprises an amino acid residue. In some embodiments, L^{P4} is or comprises a peptide.

[0285] In some embodiments, L^{P4} is or comprises $-[X]pX^7X^8[X]p'-$, wherein each X, X^7 and X^8 is independently an amino acid residue, and each of p and p' is independently 0-10. In some embodiments, L^{P4} is or comprises $-X^7X^8-$, wherein each X^7 and X^8 is independently as described herein, and X^8 is bonded to L^{AA4}.




[0286] In some embodiments, a methylene unit of L^{P4} is replaced with $-C(R')_2-$, wherein one of the R' groups is a fifth, sixth, seventh or eighth R' group. In some embodiments, such a $-C(R')_2-$ group is of an amino acid residue. In some embodiments, such a $-C(R')_2-$ group is of X^7. In some embodiments, such a carbon atom is an alpha carbon of an amino acid residue. In some embodiments, such a carbon atom is an alpha carbon of X^7. In some embodiments, it is a fifth R' group. In some embodiments, it is a sixth R' group. In some embodiments, it is a seventh R' group. In some embodiments, it is an eighth R' group.

L^{AA4}

[0287] In some embodiments, L^{AA4} is or comprises amino acid residue. In some embodiments, L^{AA4} is or comprises an amino acid residue that comprises a side chain comprising an aromatic group.

[0288] In some embodiments, L^{AA4} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein each variable is independently as described herein. In some embodiments, L^{AA4} is an optionally substituted, bivalent C_1-C_6 (e.g., C_1, C_2, C_3, C_4, C_5, or C_6) aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$,

−S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, $-S(O)_2-$, $-S(O)_2N(R')-$, −C(O)S−, or −C(O)O−, wherein each variable is independently as described herein. In some embodiments, L^{AA4} is an optionally substituted, bivalent C_2-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,−Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, $-S(O)_2-$, $-S(O)_2N(R')-$, −C(O)S−, or −C(O)O−, wherein each variable is independently as described herein. In some embodiments, L^{AA4} is $-N(R')-C(R')(R^{AS})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, L^{AA4} is $-NH-C(R')(R^{AS})-C(O)-$, wherein each variable is independently as described herein.

[0289] In some embodiments, L^{AS4} is L^{AS} as described herein. In some embodiments, R^{AA4} is optionally substituted C_{6-14} aryl. In some embodiments, R^{AA4} is optionally substituted phenyl. In some embodiments, R^{AA4} is phenyl. In some embodiments, R^{AA4} is optionally substituted 10-membered C_{10} bicyclic aryl. In some embodiments, R^{AA4} is optionally substituted 5-membered monocyclic heteroaryl having 1-4 heteroatoms. In some embodiments, R^{AA4} is optionally substituted 6-membered monocyclic heteroaryl having 1-4 heteroatoms. In some embodiments, R^{AA4} is optionally substituted 9-membered bicyclic heteroaryl having 1-4 heteroatoms. In some embodiments, R^{AA4} is optionally substituted 10-membered bicyclic heteroaryl having 1-4 heteroatoms. In some embodiments, a heteroaryl has no more than one heteroatom. In some embodiments, a heteroaryl has two or more heteroatoms. In some embodiments, a heteroatom is oxygen. In some embodiments, a heteroatom is nitrogen. In some embodiments, a heteroatom is sulfur. In some embodiments, R^{AA4} is optionally substituted  . In some embodiments, R^{AA4} is optionally substituted  . In some embodiments, R^{AA4} is optionally substituted  . In some embodiments, L^{AA4} is an aromatic amino acid residue as described herein. In some embodiments, L^{AA4} is X^9 as described herein.

L^{P5}

[0290] In some embodiments, L^{P5} is a covalent bond, or an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, −Cy−, −O−, −S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, $-S(O)_2-$, $-S(O)_2N(R')-$, −C(O)S−, or −C(O)O−. In some embodiments, the length of L^{P5} is 2-10 atoms. In some embodiments, it is 2 atoms. In some embodiments, it is 3 atoms. In some embodiments, it is 4 atoms. In some embodiments, it is 5 atoms. In some embodiments, it is 6 atoms. In some embodiments, it is 7 atoms. In some embodiments, it is 8 atoms. In some embodiments, it is 9 atoms. In some embodiments, it is 10 atoms. In some embodiments, one or more methylene units are independently

replaced with −N(R')−, −C(R')$_2$−, −C(O)− or −C(O)N(R')−. In some embodiments, a methylene unit is replace with −N(R')−. In some embodiments, a methylene unit is replace with −C(R')$_2$−. In some embodiments, a methylene unit is replace with −C(O)−. In some embodiments, a methylene unit is replace with −C(O)N(R')−. In some embodiments, each methylene unit is independently replaced with −N(R')−, −C(R')$_2$− or −C(O)−. In some embodiments, L^{P5} is or comprises an amino acid residue. In some embodiments, L^{P5} is or comprises a peptide.

[0291] In some embodiments, L^{P5} is or comprises −[X]pX^{11}[X]p'−, wherein each variable is independently as described herein. In some embodiments, L^{P5} is or comprises −X^{10}X^{11}−, wherein each X^{10} and X^{11} is independently as described herein, and X^{11} is bonded to L^{AA5}.




[0292] In some embodiments, L^{P5} comprises a −C(R')$_2$− group, wherein one of the R' groups is a fourth R' group. In some embodiments, L^{P5} comprises a −C(R')$_2$− group, wherein one of the R' groups is a second R' group. In some embodiments, such a −C(R')$_2$− group is of an amino acid residue. In some embodiments, such a −C(R')$_2$− group is of X^{11}. In some embodiments, such a carbon atom is an alpha carbon of an amino acid residue. In some embodiments, such a carbon atom is an alpha carbon of X^{11}.

[0293] In some embodiments, L^{P5} comprises a −C(R')$_2$− group, wherein one of the R' groups is a fifth, sixth, seventh or eighth R' group. In some embodiments, such a −C(R')$_2$− group is of an amino acid residue. In some embodiments, such a −C(R')$_2$− group is of X^{10}. In some embodiments, such a carbon atom is an alpha carbon of an amino acid residue. In some embodiments, such a carbon atom is an alpha carbon of X^{10}. In some embodiments, it is a fifth R' group. In some embodiments, it is a sixth R' group. In some embodiments, it is a seventh R' group. In some embodiments, it is an eighth R' group.

L^{AA5}

[0294] In some embodiments, L^{AA5} is or comprises amino acid residue. In some embodiments, L^{AA5} is or comprises an amino acid residue that comprises a side chain comprising an aromatic group.

[0295] In some embodiments, L^{AA5} is L^{AR}, wherein a methylene unit is replaced with −C(R')(R^{AS})−, wherein each variable is independently as described herein. In some embodiments, L^{AA5} is an optionally substituted, bivalent C$_1$-C$_6$ (e.g., C$_1$, C$_2$, C$_3$, C$_4$, C$_5$, or C$_6$) aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −C(R')(R^{AS})−,−Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−, wherein each variable is independently as described herein. In some embodiments, L^{AA5} is an optionally substituted, bivalent C$_2$-C$_4$ aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −C(R')(R^{AS})−,−Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−, wherein each variable is independently as described herein. In some embodiments, L^{AA5} is −N(R')−C(R')(R^{AS})−C(O)−, wherein each variable is independently as described herein. In some embodiments, L^{AA5} is −NH−C(R')(R^{AS})−C(O)−, wherein each variable is independently as described herein.

[0296] In some embodiments, L^{AS5} is L^{AS} as described herein. In some embodiments, R^{AA5} is optionally substituted C_{6-14} aryl. In some embodiments, R^{AA5} is optionally substituted phenyl. In some embodiments, R^{AA5} is phenyl. In some embodiments, R^{AA5} is optionally substituted 10-membered C_{10} bicyclic aryl. In some embodiments, R^{AA5} is optionally substituted 5-membered monocyclic heteroaryl having 1-4 heteroatoms. In some embodiments, R^{AA5} is optionally substituted 6-membered monocyclic heteroaryl having 1-4 heteroatoms. In some embodiments, R^{AA5} is optionally substituted 9-membered bicyclic heteroaryl having 1-4 heteroatoms. In some embodiments, R^{AA5} is optionally substituted 10-membered bicyclic heteroaryl having 1-4 heteroatoms. In some embodiments, a heteroaryl has no more than one heteroatom. In some embodiments, a heteroaryl has two or more heteroatoms. In some embodiments, a heteroatom is oxygen. In some embodiments, a heteroatom is nitrogen. In some embodiments, a heteroatom is sulfur. In some embodiments, R^{AA5} is optionally substituted  . In some embodiments, R^{AA5} is optionally substituted  . In some embodiments, R^{AA5} is optionally substituted  . In some embodiments, L^{AA5} is an aromatic amino acid residue as described herein. In some embodiments, L^{AA5} is X^{12} as described herein.

L^{P6}




[0297] In some embodiments, L^{P6} is a covalent bond. In some embodiments, L^{P6} is an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, the length of L^{P6} is 0-10 atoms (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, etc.). In some embodiments, the length of L^{P6} is 2-10 atoms. In some embodiments, it is 2 atoms. In some embodiments, it is 3 atoms. In some embodiments, it is 4 atoms. In some embodiments, it is 5 atoms. In some embodiments, it is 6 atoms. In some embodiments, it is 7 atoms. In some embodiments, it is 8 atoms. In some embodiments, it is 9 atoms. In some embodiments, it is 10 atoms. In some embodiments, one or more methylene units are independently replaced with $-N(R')-$, $-C(R')_2-$, $-C(O)-$ or $-C(O)N(R')-$. In some embodiments, a methylene unit is replace with $-N(R')-$. In some embodiments, a methylene unit is replace with $-C(R')_2-$. In some embodiments, a methylene unit is replace with $-C(O)-$. In some embodiments, a methylene unit is replace with $-C(O)N(R')-$. In some embodiments, each methylene unit is independently replaced with $-N(R')-$, $-C(R')_2-$ or $-C(O)-$. In some embodiments, L^{P6} is or comprises an amino acid residue. In some embodiments, L^{P6} is or comprises a peptide.

L^{AA6}

[0298] In some embodiments, L^{AA6} is or comprises amino acid residue. In some embodiments, L^{AA6} is

or comprises an amino acid residue that comprises a side chain comprising an aromatic group.

[0299] In some embodiments, L^{AA6} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein each variable is independently as described herein. In some embodiments, L^{AA6} is an optionally substituted, bivalent C_1-C_6 (e.g., C_1, C_2, C_3, C_4, C_5, or C_6) aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$, wherein each variable is independently as described herein. In some embodiments, L^{AA6} is an optionally substituted, bivalent C_2-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$, wherein each variable is independently as described herein. In some embodiments, L^{AA6} is $-N(R')-C(R')(R^{AS})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, L^{AA6} is $-NH-C(R')(R^{AS})-C(O)-$, wherein each variable is independently as described herein.

[0300] In some embodiments, L^{AS6} is L^{AS} as described herein. In some embodiments, R^{AA6} is optionally substituted C_{6-14} aryl. In some embodiments, R^{AA6} is optionally substituted phenyl. In some embodiments, R^{AA6} is phenyl. In some embodiments, R^{AA6} is optionally substituted 10-membered C_{10} bicyclic aryl. In some embodiments, R^{AA6} is optionally substituted 5-membered monocyclic heteroaryl having 1-4 heteroatoms. In some embodiments, R^{AA6} is optionally substituted 6-membered monocyclic heteroaryl having 1-4 heteroatoms. In some embodiments, R^{AA6} is optionally substituted 9-membered bicyclic heteroaryl having 1-4 heteroatoms. In some embodiments, R^{AA6} is optionally substituted 10-membered bicyclic heteroaryl having 1-4 heteroatoms. In some embodiments, a heteroaryl has no more than one heteroatom. In some embodiments, a heteroaryl has two or more heteroatoms. In some embodiments, a heteroatom is oxygen. In some embodiments, a heteroatom is nitrogen. In some embodiments, a heteroatom is sulfur. In some embodiments, R^{AA6} is optionally substituted  . In some embodiments, R^{AA6} is optionally substituted  . In some embodiments, R^{AA6} is optionally substituted  . In some embodiments, L^{AA6} is an aromatic amino acid residue as described herein. In some embodiments, L^{AA6} is X^{13} as described herein.

L^{P7}

[0301] In some embodiments, L^{P7} is a covalent bond. In some embodiments, L^{P7} is an optionally substituted, bivalent C_1-C_{25} (e.g., C_{1-20}, C_{1-15}, C_{1-10}, C_{1-5}, C_1, C_2, C_3, C_4, C_5, C_6, C_7, C_8, C_9, C_{10}, C_{11}, C_{12}, C_{13}, C_{14}, C_{15}, C_{16}, C_{17}, C_{18}, C_{19}, or C_{20}) aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or

more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, L^{P7} is an optionally substituted, bivalent C_1-C_{25} (e.g., C_{1-20}, C_{1-15}, C_{1-10}, C_{1-5}, C_1, C_2, C_3, C_4, C_5, C_6, C_7, C_8, C_9, C_{10}, C_{11}, C_{12}, C_{13}, C_{14}, C_{15}, C_{16}, C_{17}, C_{18}, C_{19}, or C_{20}) aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, L^{P7} is an optionally substituted, bivalent C_1-C_{20} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, L^{P7} is an optionally substituted, bivalent C_1-C_{15} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, L^{P7} is an optionally substituted, bivalent C_1-C_{10} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

[0302] In some embodiments, is or comprises $-X^{14}-[X]p'-$, wherein p' is 0-10. In some embodiments, X^{14} is bonded to L^{AA6}. In some embodiments, L^{P7} comprises a $-C(R')_2-$ group, wherein one of the R' groups is a sixth or eighth R' group. In some embodiments, such a $-C(R')_2-$ group is of an amino acid residue. In some embodiments, such a $-C(R')_2-$ group is of X^{14}. In some embodiments, such a carbon atom is an alpha carbon of an amino acid residue. In some embodiments, such a carbon atom is an alpha carbon of X^{14}. In some embodiments, it is a sixth R' group. In some embodiments, it is an eighth R' group.

L^{AS}

[0303] In some embodiments, L^{AS} is a covalent bond. In some embodiments, L^{AS} is an optionally substituted, bivalent C_1-C_{10} (e.g., C_{1-5}, C_1, C_2, C_3, C_4, C_5, C_6, C_7, C_8, C_9, or C_{10}) aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, L^{AS} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-S(O)-$, or $-S(O)_2-$. In some embodiments, L^{AS} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-O-$, $-S-$, or $-N(R')-$. In some

embodiments, L^{AS} is an optionally substituted, bivalent C_1-C_{10} alkylene group. In some embodiments, L^{AS} is optionally substituted $-CH_2-$. In some embodiments, L^{AS} is $-CH_2-$. In some embodiments, the length of L^{AS} is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 atoms. In some embodiments, it is 1 atom. In some embodiments, it is 2 atoms. In some embodiments, it is 3 atoms. In some embodiments, it is 4 atoms. In some embodiments, it is 5 atoms. In some embodiments, it is 6 atoms. In some embodiments, it is 7 atoms. In some embodiments, it is 8 atoms. In some embodiments, it is 9 atoms. In some embodiments, it is 10 atoms.

[0304] In some embodiments, an agent of formula I is a stapled peptide as described herein. In some embodiments, an agent of formula I is an agent selected from Table E2 or a pharmaceutically acceptable salt thereof. In some embodiments, an agent of formula I is an agent selected from Table E3 or a pharmaceutically acceptable salt thereof.

[0305] Among other things, the present disclosure provides agents, e.g. peptides, that can bind to beta-catenin. In some embodiments, an agent is or comprises $X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}$ wherein each of X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13} and X^{14} is independently an amino acid residue. In some embodiments, an agent is or comprises $[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}$, wherein each of p0, p15, p16 and p17 is independently 0 or 1, and each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue.

[0306] Various amino acid residues, e.g., those of formula A-I, A-II, A-III, A-IV, A-V, A-VI, PA, etc., can be utilized in accordance with the present disclosure. Certain useful amino acid residues are described in the present disclosure.

[0307] In some embodiments, each of X^2 and X^5 is independently an acidic residue as described herein. In some embodiments, each of X^2, X^5 and X^6 is independently an acidic residue as described herein. In some embodiments, each of X^9, X^{12} and X^{13} are independently an amino acid residue comprising a side chain that comprises an aromatic group.

[0308] In some embodiments, X^2 is an acidic residue. In some embodiments, X^2 comprises a side chain that comprises $-COOH$ or a derivative thereof. In some embodiments, X^2 comprises a side chain that comprises $-COOH$. In some embodiments, X^2 is Asp. Various other amino acid residues for X^2 are described else in the present disclosure.

[0309] In some embodiments, X^5 is an acidic residue. In some embodiments, X^5 comprises a side chain that comprises $-COOH$ or a derivative thereof. In some embodiments, X^5 comprises a side chain that comprises $-COOH$. In some embodiments, X^5 is Asp. Various other amino acid residues for X^5 are described else in the present disclosure.

[0310] In some embodiments, X^6 is an acidic residue. In some embodiments, X^6 comprises a side chain that comprises $-COOH$ or a derivative thereof. In some embodiments, X^6 comprises a side chain that comprises $-COOH$. In some embodiments, X^6 is Asp. Various other amino acid residues for X^6 are described else in the present disclosure.

[0311] In some embodiments, X^9 comprises a side chain that comprises an aromatic group. In some embodiments, X^9 comprises a side chain that comprises −R, wherein R is an optionally substituted group selected from phenyl, 10-membered bicyclic aryl, 5-membered heteroaryl having 1-3 hetereoatoms, and 9-10 membered bicyclic heteroaryl having 1-5 heteroatoms. In some embodiments, each heteroatom is independently sleeved from nitrogen, oxygen and sulfur. In some embodiments, X^9 is Phe. Various other amino acid residues for X^9 are described else in the present disclosure.

[0312] In some embodiments, X^{12} comprises a side chain that comprises an aromatic group. In some embodiments, X^{12} comprises a side chain that comprises −R, wherein R is an optionally substituted group selected from phenyl, 10-membered bicyclic aryl, 5-membered heteroaryl having 1-3 hetereoatoms, and 9-10 membered bicyclic heteroaryl having 1-5 heteroatoms. In some embodiments, each heteroatom is independently sleeved from nitrogen, oxygen and sulfur. In some embodiments, X^{12} is 3Thi. In some embodiments, X^{12} is 2F3MeF. In some embodiments, X^{12} is Phe. Various other amino acid residues for X^{12} are described else in the present disclosure.

[0313] In some embodiments, X^{13} comprises a side chain that comprises an aromatic group. In some embodiments, X^{13} comprises a side chain that comprises −R, wherein R is an optionally substituted group selected from phenyl, 10-membered bicyclic aryl, 5-membered heteroaryl having 1-3 hetereoatoms, and 9-10 membered bicyclic heteroaryl having 1-5 heteroatoms. In some embodiments, each heteroatom is independently sleeved from nitrogen, oxygen and sulfur. In some embodiments, X^{13} is BtzA. In some embodiments, X^{13} is 34ClF. In some embodiments, X^{13} is 2NapA. Various other amino acid residues for X^{13} are described else in the present disclosure.

[0314] As described herein, in some embodiments, a peptide is a stapled peptide. In some embodiments, an agent is or comprises a peptide, wherein a peptide is a stapled peptide. In some embodiments, a peptide is a stitched peptide. In some embodiments, a peptide comprises three or more staples as described herein. In some embodiments, a peptide comprises three or more staples within a region having a length of, e.g., 11-15, such as 11, 14, etc., amino acid residues as described herein. In some embodiments, such a peptide provides improved rigidity, activity, delivery, solubility, and/or other desired properties comprising a reference peptide that is not stapled or that comprises fewer staples.

[0315] In some embodiments, the present disclosure provides an agent, e.g., a peptide, comprising $X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}$, wherein X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, and X^{14} are each independently an amino acid residue and comprises two or more pairs of amino acid residues, wherein each pair of amino acid residues are independently two amino acid residues suitable for stapling or stapled. In some embodiments, the present disclosure provides an agent, e.g., a peptide, comprising $X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}$, wherein X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, and X^{14} are each independently an amino acid residue and comprises two or more pairs of amino acid residues, wherein each pair of amino acid residues are independently three amino acid residues suitable for stapling or stapled.

[0316] In some embodiments, the present disclosure provides an agent, e.g., a peptide, comprising $[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}$, wherein each of p0, p15, p16 and p17 is independently 0 or 1, and X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} are each independently an amino acid residue and comprises two or more pairs of amino acid residues, wherein each pair of amino acid residues are independently two amino acid residues suitable for stapling or stapled. In some embodiments, the present disclosure provides an agent, e.g., a peptide, comprising $[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}$, wherein each of p0, p15, p16 and p17 is independently 0 or 1, and X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} are each independently an amino acid residue and comprises three or more pairs of amino acid residues, wherein each pair of amino acid residues are independently two amino acid residues suitable for stapling or stapled. In some embodiments, each amino acid residue in such pairs of amino acid residues are independently selected from X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, and X^{14}.

[0317] In some embodiments, there are three such pairs of amino acid residues. In some embodiments, there are four such pairs of amino acid residues. In some embodiments, there are four or more such pairs of amino acid residues. In some embodiments, each pair is independently not stapled. In some embodiments, one or more pairs are independently stapled. In some embodiments, two or more pairs are independently stapled. In some embodiments, three or more pairs are independently stapled. In some embodiments, four or more pairs are independently stapled. In some embodiments, two pairs are independently stapled. In some embodiments, three pairs are independently stapled. In some embodiments, four pairs are independently stapled.

[0318] In some embodiments, a pair is X^1 and X^4. In some embodiments, a pair is X^4 and X^{11}. In some embodiments, a pair is X^1 and X^3. In some embodiments, a pair is X^4 and X^{11}. In some embodiments, a pair is X^{10} and X^{14}. In some embodiments, a pair is X^7 and X^{10}. In some embodiments, a pair is X^7 and X^{14}. In some embodiments, a pair is X^3 and X^7.

[0319] In some embodiments, a pair is X^1 and X^{14} and a pair is X^4 and X^{11}. In some embodiments, a pair is X^1 and X^{14}, a pair is X^4 and X^{11} and a pair is X^{10} and X^{14}. In some embodiments, a pair is X^1 and X^{14}, a pair is X^4 and X^{11} and a pair is X^7 and X^{10}. In some embodiments, a pair is X^1 and X^{14}, a pair is X^4 and X^{11} and a pair is X^7 and X^{14}. In some embodiments, a pair is X^1 and X^{14}, a pair is X^4 and X^{11}, a pair is X^3 and X^7, and a pair is X^7 and X^{14}. In some embodiments, each pair is independently a pair of amino acid residues suitable for stapling. In some embodiments, each pair is independently stapled.

[0320] In some embodiments, a pair is X^1 and X^3, a pair is X^4 and X^{11}, and a pair is X^{10} and X^{14}. In some embodiments, each pair is independently a pair of amino acid residues suitable for stapling. In some embodiments, each pair is independently stapled.

[0321] In some embodiments, the present disclosure provides an agent, which is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein the agent binds to beta-catenin.

[0322] In some embodiments, X^2 comprises a side chain comprising an acidic or a polar group. In some embodiments, X^2 comprises a side chain comprising an acidic group. In some embodiments, X^2 comprises a side chain comprising a polar group. In some embodiments, X^5 comprises a side chain comprising an acidic or a polar group. In some embodiments, X^5 comprises a side chain comprising an acidic group. In some embodiments, X^5 comprises a side chain comprising a polar group. In some embodiments, X^{13} comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, two or more of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

[0323] In some embodiments, the present disclosure provides an agent, which is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group;

X^{13} comprises a side chain comprising an optionally substituted aromatic group; and

two or more of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled. In some embodiments, three or more of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled. In some embodiments, four or more of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled. In some embodiments, five of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled. In some embodiments, X^1 and X^4 are each independently an amino acid residue suitable for stapling. In some embodiments, X^1 and X^3 are each independently an amino acid residue suitable for stapling. In some embodiments, X^4 and X^{11} are each independently an amino acid suitable for stapling. In some embodiments, X^1, X^4, and X^{11} are each independently an amino acid residue suitable for stapling. In some embodiments, X^{10} and X^{14} are each independently an amino acid residue suitable for stapling. In some embodiments, X^7 and X^{10} are each independently an amino acid residue suitable for stapling. In some embodiments, X^7 and X^{14} are each independently an amino acid residue suitable for stapling. In some embodiments, X^3 and X^7 are each independently an amino acid residue suitable for stapling. In some

embodiments, X^1 and X^4 are connected by a staple. In some embodiments, X^1 and X^3 are connected by a staple. In some embodiments, X^4 and X^{11} are connected by a staple. In some embodiments, X^1 and X^4 connected by a staple, and X^4 and X^{11} are connected by a staple. In some embodiments, X^{10} and X^{14} are connected by a staple. In some embodiments, X^7 and X^{10} are connected by a staple. In some embodiments, X^7 and X^{14} are connected by a staple. In some embodiments, X^3 and X^7 are connected by a staple.

[0324] In some embodiments, the present disclosure provides an agent, which is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group;

X^{13} comprises a side chain comprising an optionally substituted aromatic group; and wherein:

X^1 and X^4 are connected by a staple and/or X^4 and X^{11} are connected by a staple, and X^{10} and X^{14} are connected by a staple.

[0325] In some embodiments, the present disclosure provides an agent, which is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group;

X^{13} comprises a side chain comprising an optionally substituted aromatic group; and wherein:

X^1 and X^4 are connected by a staple and/or X^4 and X^{11} are connected by a staple, and X^7 and X^{10} are connected by a staple.

[0326] In some embodiments, the present disclosure provides an agent, which is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group;

X^{13} comprises a side chain comprising an optionally substituted aromatic group; and wherein:

X^1 and X^4 are connected by a staple and/or X^4 and X^{11} are connected by a staple, and X^7 and X^{14} are connected by a staple.

[0327] In some embodiments, the present disclosure provides an agent, which is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group;

X^{13} comprises a side chain comprising an optionally substituted aromatic group; and wherein:

X^1 and X^4 are connected by a staple and/or X^4 and X^{11} are connected by a staple; and X^{10} and X^{14} are connected by a staple and/or X^3 and X^7 are connected by a staple.

[0328] In some embodiments, the present disclosure provides an agent, which is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group;

X^{13} comprises a side chain comprising an optionally substituted aromatic group; and wherein:

X^1 and X^3 are connected by a staple, X^4 and X^{11} are connected by a staple; and X^{10} and X^{14} are connected by a staple.

[0329] In some embodiments, X^2 comprises a side chain comprising an acidic (e.g., −COOH) or a polar group. In some embodiments, X^2 comprises a side chain comprising an acid group. In some embodiments, X^5 comprises a side chain comprising an acidic or a polar group. In some embodiments, X^5 comprises a side chain comprising an acid group. In some embodiments, X^6 comprises a side chain comprising an acidic or a polar group. In some embodiments, X^6 comprises a side chain comprising an acid group. In some embodiments, X^9 comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, X^{12} comprises a side chain comprising an optionally substituted aromatic group. In some

embodiments, X^{13} comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, X^2 and X^5 each independently comprise a side chain comprising an acidic or a polar group. In some embodiments, X^2 and X^6 each independently comprise a side chain comprising an acidic or a polar group. In some embodiments, X^5 and X^6 each independently comprise a side chain comprising an acidic or a polar group. In some embodiments, X^2 and X^5 each independently comprise a side chain comprising an acidic group. In some embodiments, X^2 and X^6 each independently comprise a side chain comprising an acidic group. In some embodiments, X^5 and X^6 each independently comprise a side chain comprising an acidic group. In some embodiments, X^2, X^5 and X^6 each independently comprise a side chain comprising an acidic or a polar group. In some embodiments, X^2, X^5 and X^6 each independently comprise a side chain comprising an acidic group. In some embodiments, each of X^9 and X^{12} independently comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, each of X^9 and X^{13} independently comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, each of X^9, X^{12} and X^{13} independently comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, each of X^2 and X^5 independently comprises a side chain comprising an acidic group (e.g., −COOH), and each of X^9, X^{12} and X^{13} independently comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, each of X^2, X^5 and X^6 independently comprises a side chain comprising an acidic group (e.g., −COOH), and each of X^9, X^{12} and X^{13} independently comprises a side chain comprising an optionally substituted aromatic group.

[0330] As described herein, various types of amino acid residues (e.g., those of amino acids having the structure of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc.) can be utilized in accordance with the present disclosure. Certain examples are described herein for X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, X^{17}, etc.

[0331] In some embodiments, p0 is 0. In some embodiments, p0 is 1. Various types of amino acid residues can be used for X^0. In some embodiments, X^0 is selected from Gly, Sar, and NMebAla. In some embodiments, X^0 is Gly. In some embodiments, X^0 is Sar. In some embodiments, X^0 is NMebAla. In some embodiments, X^0 is present in various peptides (e.g., in some embodiments, p0 is 1). In some embodiments, X^0 is absent from various peptides (e.g., in some embodiments, p0 is 0).

[0332] In some embodiments, X^0 is a N-terminus residue. In some embodiments, it is bonded to a N-terminal group.

[0333] In some embodiments, X^0 is an amino acid reside suitable for stapling.

[0334] In some embodiments, an amino acid residue suitable for stapling comprises a double bond, e.g., a terminal double bond in its side chain. In some embodiments, it has a side chain having the structure of $-L^a-CH=CH_2$. In some embodiments, it is a residue of an amino acid having the structure of formula A-II or A-III or a salt thereof. In some embodiments, X^0 is $-N(R^{a1})-L^{a1}-C(-L^a-CH=CH_2)(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^0 is $-N(R^{a1})-C(-L^a-CH=CH_2)(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some

embodiments, X^0 is a residue of PL3 and stapled.

[0335] In some embodiments, X^0 is $N(-L^a-CH=CH_2)(R^{a1})-L^{a1}-C(-L^a-CH=CH_2)(R^{a3})-L^{a2}-C(O)-$, or $-N(-L^a-CH=CH_2)-L^{a1}-C(-L^a-CH=CH_2)(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^0 is $-N(-L^a-CH=CH_2)-C(-L^a-CH=CH_2)(R^{a3})-C(O)-$, wherein each variable is independently as described herein.

[0336] In some embodiments, X^0 is S5. In some embodiments, X^0 is S6.

[0337] In some embodiments, X^0 is stapled. Various types of staples may be utilized as described herein. In some embodiments, X^0 is stapled with X^4. In some embodiments, X^4 is stapled with X^{11}. In some embodiments, a stapled peptide comprises X^0-X^4-X^{11} stapling. In some embodiments, a stapled peptide comprises another staple, e.g., X^{10}-X^{14}.

[0338] In some embodiments, X^0 is X^1 as described herein.

[0339] Various types of amino acid residues can be used for X^1, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^1 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^1 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^1 is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0340] As shown herein (e.g., for various amino acids and residues thereof), in various embodiments, L^a is L as described herein. For example, in some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, one or more methylene units of L are independently replaced with $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, a methylene unit is replaced with $-C(O)-$. In some embodiments, a methylene unit is replaced with $-N(R')-$. In some embodiments, a methylene unit is replaced with $-Cy-$. In some embodiments, $-Cy-$ is optionally substituted phenylene. In some embodiments, $-Cy-$ is 1,2-phenylene. In some embodiments, a methylene unit is replaced with $-O-$. In some embodiments, L is $-C(O)-(CH_2)n-$. In some embodiments, L is $-C(O)-(CH_2)_2-$. In some embodiments, L is $-C(O)-(CH_2)_3-$. In some embodiments, L is $-C(O)-$1,2-phenylene$-O-CH_2-$. As appreciated by those skilled in the art, embodiments described for each group or moiety, e.g., L, is applicable to all groups that can be such a group or moiety (e.g., L^a, L^{s1}, L^{s2}, L^{s3}, etc.), no matter where such embodiments are described.

[0341] In some embodiments, X^1 is a residue of amino acid that comprises an optionally substituted ring. In some embodiments, the amino group of X^1 is part of an optionally substituted ring. In some embodiments, X^1 is an amino acid as described herein, e.g., of formula A-I, A-II, A-III, etc. In some embodiments, R^{a1} and


R^{a3} are taken together to form an optionally substituted ring, e.g., an optionally substituted 3-10 membered ring. In some embodiments, R^{a1} and R^{a3} are taken together with their intervening atoms to form an optionally substituted 3-10 membered saturated or partially saturated ring having, in addition to the intervening atoms, 0-5 heteroatoms. In some embodiments, a formed ring is saturated. In some embodiments, a formed ring is monocyclic. In some embodiments, a formed ring has no heteroatoms in addition to the intervening atoms. In some embodiments, L^{a1} and L^{a2} are covalent bonds. In some embodiments, a formed ring is unsubstituted. In some embodiments, a formed ring is substituted. In some embodiments, a substituent comprises a double bond which is suitable for metathesis with another double bond to form a staple. In some embodiments, X^1 is MePro.

[0342] In some embodiments, X^1 is an amino acid reside suitable for stapling.


[0343] In some embodiments, an amino acid residue suitable for stapling comprises a double bond, e.g., a terminal double bond in its side chain. In some embodiments, it has a side chain having the structure of $--L^a-CH=CH_2$. In some embodiments, it is a residue of an amino acid having the structure of formula A-II or A-III or a salt thereof. In some embodiments, X^1 is $-N(R^{a1})-L^{a1}-C(-L^a-CH=CH_2)(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^1 is $-N(R^{a1})-C(-L^a-CH=CH_2)(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^1 is a residue of PL3 and stapled.

[0344] In some embodiments, X^1 is $N(-L^a-CH=CH_2)(R^{a1})-L^{a1}-C(-L^a-CH=CH_2)(R^{a3})-L^{a2}-C(O)-$, or $-N(-L^a-CH=CH_2)-L^{a1}-C(-L^a-CH=CH_2)(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^1 is $-N(-L^a-CH=CH_2)-C(-L^a-CH=CH_2)(R^{a3})-C(O)-$, wherein each variable is independently as described herein.


[0345] In some embodiments, it is PL3. In some embodiments, it is an residue of [4pentenyl]MePro (



). In some embodiments, it is a residue of [5hexenyl]MePro (



). In some embodiments, it is an residue of [BzAm2OAllyl]MePro (



).

[0346] In some embodiments, X^1 is PL3. In some embodiments, X^1 is S5. In some embodiments, X^1 is MePro. In some embodiments, X^1 is Asp. In some embodiments, X^1 is S6. In some embodiments, X^1 is Pro. In some embodiments, X^1 is Ala. In some embodiments, X^1 is Ser. In some embodiments, X^1 is ThioPro. In some embodiments, X^1 is Gly. In some embodiments, X^1 is NMebAla. In some embodiments, X^1 is Asn. In

some embodiments, X^1 is TfeGA. In some embodiments, X^1 is Glu. In some embodiments, X^1 is an acidic amino acid residue. In some embodiments, X^1 is a polar amino acid residue. In some embodiments, X^1 comprises a hydrophobic side chain.

[0347] In some embodiments, an agent comprises a N-terminal group. In some embodiments, X^1 is bonded to a N-terminal group. In some embodiments, X^1 comprises a N-terminal group. In some embodiments, a N-terminal group is Ac, 4pentenyl, 5hexenyl, BzAm2OAllyl, Hex, Bua, 2PyzCO, 3Phc3, MeOPr, lithocholate, 2FPhc, PhC, MeSO2, Ts, Isobutyryl, Isovaleryl, EtHNCO, TzPyr, 15PyraPy, 8IAP, 3PydCO, 2PyBu, 2PymCO, 5PymCO, or 4PymCO. In some embodiments, a N-terminal group is Ac, 2PyBu, 1Imidac, 2F2PyAc, 2IAPAc, 124TriPr, 6QuiAc, 3PyAc, 123TriAc, 1PyrazoleAc, 4PyPrpc, 3PyPrpc, 5PymAc, 1PydoneAc, 124TriAc, 3IAPAc, Me2NAc, 4MePipzPrpC, MePipAc, MeImid4SO2, 8QuiSO2, mPEG4, mPEG8, mPEG16, mPEG24, NPyroR3, C3a, Bua, isobutyryl, Cpc, Bnc, CF3CO, 2PyCypCO, Cbc, CypCO, 4THPCO, 2PyzCO, 3Phc3, MeOPr, lithocholate, 2FPhc, PhC, MeSO2, Ts, Isovaleryl, EtHNCO, 5hexenyl, TzPyr, 15PyraPy, 8IAP, 3PydCO, 2PymCO, 5PymCO, 4PymCO, or 4pentenyl. In some embodiments, a N-terminal group contains a moiety, e.g., a terminal olefin, for stapling. In some embodiments, a N-terminal group is Ac. In some embodiments, a N-terminal group is NPyroR3. In some embodiments, a N-terminal group is 5hexenyl. In some embodiments, a N-terminal group is 4pentenyl.

[0348] In some embodiments, X^1 is Ac-PL3, Ac-S5, NPyroR3-Asp, Ac-MePro, 5hexenyl-MePro, Ac-S6, 4pentenyl-MePro, Ac-Pro, Ac-Ala, Bua-PL3, C3a-PL3, Cpc-PL3, Cbc-PL3, CypCO-PL3, 4THPCO-PL3, Isobutyryl-PL3, Ac-Asp, Ac-Ser, Ts-PL3, 15PyraPy-PL3, 2PyBu-PL3, 4PymCO-PL3, 4pentenyl-ThioPro, 4PyPrpc-PL3, 3IAPAc-PL3, 4MePipzPrpC-PL3, MePipAc-PL3, MeImid4SO2-PL3, BzAm2OAllyl-MePro, Ac-Gly, Ac-Sar, Ac-NMebAla, Hex-PL3, 2PyzCO-PL3, 3Phc3-PL3, MeOPr-PL3, lithocholate-PL3, 2FPhc-PL3, PhC-PL3, MeSO2-PL3, Isovaleryl-PL3, EtHNCO-PL3, TzPyr-PL3, 8IAP-PL3, 3PydCO-PL3, 2PymCO-PL3, 5PymCO-PL3, 1Imidac-PL3, 2F2PyAc-PL3, 2IAPAc-PL3, 124TriPr-PL3, 6QuiAc-PL3, 3PyAc-PL3, 123TriAc-PL3, 1PyrazoleAc-PL3, 3PyPrpc-PL3, 5PymAc-PL3, 1PydoneAc-PL3, 124TriAc-PL3, Me2NAc-PL3, 8QuiSO2-PL3, mPEG4-PL3, mPEG8-PL3, mPEG16-PL3, mPEG24-PL3, NPyroR3-Asn, or NPyroR3-Ser. In some embodiments, X^1 is Ac-PL3. In some embodiments, X^1 is Ac-S5. In some embodiments, X^1 is NPyroR3-Asp. In some embodiments, X^1 is Ac-MePro. In some embodiments, X^1 is Ac-S6. In some embodiments, X^1 is 4pentenyl-MePro. In some embodiments, X^1 is Ac-Pro. In some embodiments, X^1 is Ac-Ala. In some embodiments, X^1 is Bua-PL3. In some embodiments, X^1 is C3a-PL3. In some embodiments, X^1 is Cpc-PL3. In some embodiments, X^1 is Cbc-PL3. In some embodiments, X^1 is CypCO-PL3. In some embodiments, X^1 is 4THPCO-PL3. In some embodiments, X^1 is Isobutyryl-PL3. In some embodiments, X^1 is Bnc-PL3. In some embodiments, X^1 is CF3CO-PL3.

[0349] In some embodiments, X^1 is or comprises a residue of an amino acid or a moiety selected from Table A-I, Table A-II, Table A-III and Table A-IV.

[0350] In some embodiments, X^1 is stapled (a staple bonds to X^1). In some embodiments, X^1 is a residue of PL3 and stapled. In some embodiments, X^1 is stapled with X^4. In some embodiments, a staple

connecting a pair of amino acid residues, e.g., X^1 and X^4, has the structure of L^s, $-L^{s1}-L^{s2}-L^{s3}-$, wherein L^{s1} is L^a of one amino acid residue, e.g., X^1, and L^{s3} is L^a of the other amino acid residue, e.g., X^4.

[0351] As described herein, in some embodiments, a staple is L^s. In some embodiments, L^{s1} is L^a of one amino acid residue of a pair of stapled amino acid residues, and L^{s3} is L^a of the other amino acid residue of a pair of stapled amino acid residues. In some embodiments, L^s is $-L^a-L^{s2}-L^a-$, wherein each variable is independently as described herein. Various embodiments of L^a are described herein. In some embodiments, L^{s1} is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L^{s3} is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, each of L^{s1} and L^{s3} is independently an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, each of L^{s1} and L^{s3} is independently $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L^{s1} is $-CH_2-$. In some embodiments, L^{s3} is $-(CH_2)_3-$.

[0352] In some embodiments, L^{s2} is L as described herein. In some embodiments, L is optionally substituted $-CH=CH-$. In some embodiments, L is optionally substituted $-CH_2-CH_2-$. In some embodiments, L is $-CH_2-CH_2-$.

[0353] In some embodiments, L^s is $-CH_2-CH=CH-(CH_2)_3-$. In some embodiments, L^s is $-(CH_2)_6-$. In some embodiments, such a staple connects X^1 and X^4. In some embodiments, such a staple may connect other pairs of stapled amino acid residues.

[0354] In some embodiments, a staple, e.g., L^s, is bonded to two backbone atoms. In some embodiments, it is bonded to two carbon backbone atoms. In some embodiments, it is independently bonded to an alpha carbon atom of an amino acid residue at each end. In some embodiments, it is bonded to a nitrogen backbone atom (e.g., of an alpha-amino group) and a carbon backbone atom (e.g., an alpha-carbon atom). In some embodiments, it is bonded to two nitrogen backbone atoms (e.g., in some embodiments, each independently of an alpha-amino group).

[0355] In some embodiments, X^1 is [4pentyenyl]MePro, [5pentenyl]MePro or [BzAm2OAllyl]MePro. In some embodiments, X^1 is stapled with X^3. In some embodiments, a staple connecting X^1 and X^3 has the structure of L^s as described herein.

[0356] As described herein, in some embodiments, a staple is L^s. In some embodiments, L^{s1} is L^a of an amino acid residue as described herein. In some embodiments, L^{s1} is L as described herein. For example, in some embodiments, one or more methylene units of L are independently replaced with $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is $-N(R')-C(O)-(CH_2)_n-O-CH_2-$, wherein n is 1-10. In some embodiments, L is $-C(O)-(CH_2)_n-O-CH_2-$, wherein n is 1-10. In some embodiments, L is $-N(R')-C(O)-(CH_2)_2-O-CH_2-$. In some embodiments, L is $-C(O)-(CH_2)_2-O-CH_2-$. In some embodiments, L is $-N(R')-C(O)-(CH_2)_3-O-CH_2-$. In some embodiments, L is $-C(O)-(CH_2)_3-O-CH_2-$. In some embodiments, L is $-N(R')-C(O)-$(1,2-phenylene)$-O-CH_2-$. In some embodiments, L is $-C(O)-$(1,2-phenylene)$-O-CH_2-$. In some embodiments, one or more methylene units of L are replaced with $-C(R')_2-$. In some embodiments, one or more methylene units of L are replaced with $-CHR'-$. In

some embodiments, R' (e.g., of −N(R')−, −C(R')$_2$−, etc.) and another group that can be R, e.g., R^{a1}, R^{a2}, R^{a3}, etc. of an amino acid residue (e.g., X^1) are taken together with their intervening atoms to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms as described herein. In some embodiments, R' (e.g., of −N(R')−, −C(R')$_2$−, etc.) of a staple and another group that can be R, e.g., R^{a1}, R^{a2}, R^{a3}, etc. of an amino acid residue to which the staple is bonded to (e.g., X^1) are taken together with their intervening atoms to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms as described herein. In some embodiments, R' (e.g., of −N(R')−, −C(R')$_2$−, etc.) of a staple and another group that R^{a1} of an amino acid residue to which the staple is bonded to (e.g., X^1) are taken together with their intervening atoms to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms as described herein. In some embodiments, R' (e.g., of −N(R')−, −C(R')$_2$−, etc.) of a staple and another group that R^{a2} of an amino acid residue to which the staple is bonded to (e.g., X^1) are taken together with their intervening atoms to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms as described herein. In some embodiments, R' (e.g., of −N(R')−, −C(R')$_2$−, etc.) of a staple and another group that R^{a3} of an amino acid residue to which the staple is bonded to (e.g., X^1) are taken together with their intervening atoms to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms as described herein. In some embodiments, a formed ring is a ring existed in an amino acid residue, e.g., X^1.

[0357] In some embodiments, L^{s3} is L as described herein. In some embodiments, L^{s3} is L^a of an amino acid residue as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-CH_2-N(R')-CH_2-$. In some embodiments, R' is Bn. In some embodiments, R' is −C(O)R. In some embodiments, R is phenyl. In some embodiments, R is t-butyl. In some embodiments, R is cyclohexyl.

[0358] In some embodiments, L^{s2} is optionally substituted −CH=CH−. In some embodiments, L^{s2} is optionally substituted $-CH_2-CH_2-$. In some embodiments, L^{s2} is $-CH_2-CH_2-$.

[0359] As demonstrated herein, in some embodiments, a staple is bonded to two carbon backbone atoms. In some embodiments, it is independently bonded to an alpha carbon atom of an amino acid residue at each end. In some embodiments, it is bonded to a nitrogen backbone atom (e.g., of an alpha-amino group) and a carbon backbone atom (e.g., an alpha-carbon atom). In some embodiments, it is bonded to two nitrogen backbone atoms (e.g., in some embodiments, each independently of an alpha-amino group).

[0360] In some embodiments, X^1 is the 1st amino acid from the N-terminus. In some embodiments, an amino group of X^1 is a tertiary amine. In some embodiments, an amino group of X^1 is a primary or

secondary amine. In some embodiments, an amino group of X^1 is capped. In some embodiments, a capping group is R' as described herein. In some embodiments, a capping group is −C(O)R wherein R is as described herein. In some embodiments, R is optionally substituted C_{1-6} aliphatic. In some embodiments, R is optionally substituted C_{1-6} alkyl. In some embodiments, R is methyl.

[0361] In some embodiments, X^1 interacts with Val349 of beta-catenin or an amino acid residue corresponding thereto.

[0362] In some embodiments, X^1 is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0363] Various types of amino acid residues can be used for X^2, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^2 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^2 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^2 is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is −H. In some embodiments, R^{a3} is −H.

[0364] In some embodiments, X^2 is a residue of amino acid (e.g., of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof) that comprises an acidic or polar group. In some embodiments, X^2 is a residue of amino acid whose side chain comprises an acidic group (in some embodiments, may be referred to as an "acidic amino acid residue").

[0365] In some embodiments, an amino acid residue whose side chain comprises an acidic group comprises −COOH in its side chain. In some embodiments, it is a residue of an amino acid having the structure of formula A-IV or a salt thereof. In some embodiments, it is a residue of amino acid having the structure of formula PA, PA-a, PA-b, PA-c, etc. In some embodiments, R^{PA} is −H and R^{PS} and R^{PC} are −OH. In some embodiments, it is $-N(R^{a1})-L^{a1}-C(-L^{a}-COOH)(R^{a3})-L^{a2}-C(O)-$. In some embodiments, it is $-NH-L^{a1}-C(-L^{a}-COOH)(R^{a3})-L^{a2}-C(O)-$. In some embodiments, it is $-NH-CH(-L^{a}-COOH)-C(O)-$.

[0366] As described herein, L^a is L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$.

[0367] In some embodiments, an acidic amino acid residue is Asp. In some embodiments, it is Glu. Other acidic amino acid residues are described herein and can be utilized at various amino acid residue positions.

[0368] In some embodiments, X^2 is a residue of Asp, Glu, Aad, SbMeAsp, RbMeAsp, aMeDAsp, or OAsp. In some embodiments, X^2 is a residue of Asp, Glu, or Aad. In some embodiments, X^2 is a residue of Asp. In some embodiments, X^2 is a residue of Glu. In some embodiments, X^2 is a residue of Aad. In some embodiments, X^2 is a residue of SbMeAsp. In some embodiments, X^2 is a residue of RbMeAsp. In some embodiments, X^2 is a residue of aMeDAsp. In some embodiments, X^2 is a residue of OAsp.

[0369] In some embodiments, X^2 is a residue of amino acid (e.g., of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof) whose side chain comprises a polar group (in some embodiments, may be referred to as a "polar amino acid residue"; in some embodiments, it does not include amino acid residue whose side chains are electrically charged at, e.g., about pH 7.4).

[0370] In some embodiments, an amino acid residue whose side chain comprises a polar group is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$. In some embodiments, an amino acid residue whose side chain comprises a polar group is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$. In some embodiments, an amino acid residue whose side chain comprises an amide group, e.g., $-C(O)N(R')_2$ such as $-CONH_2$. In some embodiments, R^{a2} is $-L^a-C(O)N(R')_2$ wherein each variable is independently as described herein. In some embodiments, R^{a2} is $-L^a-C(O)NH_2$ wherein L is independently as described herein. In some embodiments, L^a is L' as described herein. In some embodiments, R^{a3} is H. In some embodiments, such a polar amino acid residue is Asn. In some embodiments, it is MeAsn. In some embodiments, an amino acid residue whose side chain comprises a polar group is an amino acid residue whose side chain comprises $-OH$. In some embodiments, R^{a2} is $-L^a-OH$ wherein each variable is independently as described herein. In some embodiments, R^{a2} is $-L^a-OH$ wherein L is independently as described herein. In some embodiments, L^a is L' as described herein. For example, in some embodiments, such an amino acid residue is a residue of Hse, Ser, aThr, or Thr. In some embodiments, it is a residue of Hse, Ser, or aThr. In some embodiments, it is a residue of Hse. In some embodiments, it is a residue of Ser. In some embodiments, it is a residue of aThr. In some embodiments, it is a residue of Thr. Other polar amino acid residues are described herein and can be utilized at various amino acid residue positions.

[0371] For example, in some embodiments, X^2 is a residue of Asn. In some embodiments, X^2 is a residue of MeAsn. In some embodiments, X^2 is a residue of Hse, Ser, aThr, or Thr. In some embodiments, X^2 is a residue of Hse, Ser, or aThr. In some embodiments, X^2 is a residue of Hse. In some embodiments, X^2 is a residue of Ser. In some embodiments, X^2 is a residue of aThr. In some embodiments, X^2 is a residue of Thr.

[0372] In some embodiments, X^2 is Asp, Ala, Asn, Glu, Npg, Ser, Hse, Val, S5, S6, AcLys, TfeGA, aThr, Aad, Pro, Thr, Phe, Leu, PL3, Gln, isoGlu, MeAsn, isoDAsp, RbGlu, SbGlu, AspSH, Ile, SbMeAsp, RbMeAsp, aMeDAsp, OAsp, 3COOHF, NAsp, 3Thi, NGlu, isoDGlu, BztA, Tle, Aib, MePro, Chg, Cha, or

DipA.

[0373] In some embodiments, X^2 is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0374] In some embodiments, X^2 interacts with Gly307 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^2 interacts with Lys312 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^2 interacts with each of Gly307 and Lys312 of beta-catenin or an amino acid residue corresponding thereto.

[0375] Various types of amino acid residues can be used for X^3, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^3 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^3 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^3 is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0376] In some embodiments, L^a is L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-CH_2-N(R')-CH_2-$. In some embodiments, R' is Bn. In some embodiments, R' is $-C(O)R$. In some embodiments, R is phenyl. In some embodiments, R is t-butyl. In some embodiments, R is cyclohexyl.

[0377] In some embodiments, X^3 is a hydrophobic amino acid residue.

[0378] In some embodiments, a hydrophobic amino acid residue is an amino acid residue whose side chain is an optionally substituted aliphatic group. In some embodiments, it is a residue of an amino acid whose side chain is optionally substituted C_{1-10} alkyl. In some embodiments, it is a residue of an amino acid whose side chain is C_{1-10} alkyl. In some embodiments, it is a residue of an amino acid whose side chain is C_{1-10} aliphatic optionally substituted with one or more non-polar and non-charged groups. In some embodiments, it is a residue of an amino acid whose side chain is C_{1-10} alkyl optionally substituted with one or more non-polar and non-charged groups. In some embodiments, it is a residue of an amino acid whose side chain is C_{1-}

$_{10}$ aliphatic optionally substituted with one or more hydrophobic substituents. In some embodiments, it is a residue of an amino acid whose side chain is C_{1-10} aliphatic. In some embodiments, it is a residue of an amino acid whose side chain is C_{1-10} alkyl. Various hydrophobic amino acid residues can be utilized in accordance with the present disclosure.

[0379] In some embodiments, a hydrophobic amino acid residue, e.g., X^3, has the structure of $-NH_2-C(R^{a2})(R^{a3})-C(O)-$ or $-NH-C(R^{a2})H-C(O)-$ wherein each variable is independently as described herein. As described herein, R^{a2} is $-L^a-R'$. In some embodiments, R' is R as described herein. In some embodiments, R is optionally substituted group selected from C_{1-10} aliphatic, phenyl, 10-membered aryl, and 5-10 membered heteroaryl having 1-5 heteroatoms. In some embodiments, each substituent, if any, is independently a non-polar group. In some embodiments, R is optionally substituted C_{1-10} aliphatic. In some embodiments, R is optionally substituted C_{1-10} alkyl. In some embodiments, R is C_{1-10} aliphatic. In some embodiments, R is C_{1-10} alkyl. For example, in some embodiments, R is methyl. In some embodiments, R is isopropyl. In some embodiments, R is 1-methylpropyl. In some embodiments, R is 2-methylpropyl. In some embodiments, R is optionally substituted aryl. In some embodiments, R is aryl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is phenyl. In some embodiments, R is optionally substituted 5-6 membered heteroaryl having 1-4 heteroatoms. In some embodiments, R is optionally substituted 5-6 membered heteroaryl having 1 heteroatom. In some embodiments, R is 5-6 membered heteroaryl having 1-4 heteroatoms. In some embodiments, R is 5-6 membered heteroaryl having 1 heteroatom. In some embodiments, R is optionally substituted 9-10 membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is optionally substituted 9-10 membered heteroaryl having 1 heteroatom. In some embodiments, R is 9-10 membered heteroaryl having 1-4 heteroatoms. In some embodiments, R is 9-10 membered heteroaryl having 1 heteroatom. In some embodiments, a heteroatom is nitrogen. In some embodiments, a heteroatom is oxygen. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, a hydrophobic amino acid residue is a residue of Ala, Val, Ile, Leu, Met, Phe, Tyr, Trp, etc. Other hydrophobic amino acid residues are described herein and can be utilized at various amino acid residue positions.

[0380] In some embodiments, X^3 comprises a side chain comprising a cycloaliphatic group (e.g., a 4-, 5-

, or 6-membered cycloalkyl group). In some embodiments, X^3 is a residue of Npg, Leu, Cha, Val, nLeu, Ile, CypA, CyLeu, Chg, DiethA, Ala, Aib, OctG, or Cba. In some embodiments, X^3 is a residue of Npg, Leu, or Cha. In some embodiments, X^3 is a residue of Npg. In some embodiments, X^3 is a residue of Leu. In some embodiments, X^3 is a residue of Cha. In some embodiments, X^3 is a residue of Val. In some embodiments, X^3 is a residue of nLeu. In some embodiments, X^3 is a residue of Ile. In some embodiments, X^3 is a residue of CypA. In some embodiments, X^3 is a residue of CyLeu. In some embodiments, X^3 is a residue of Chg. In some embodiments, X^3 is a residue of DiethA. In some embodiments, X^3 is a residue of Ala. In some embodiments, X^3 is a residue of Aib. In some embodiments, X^3 is a residue of OctG. In some embodiments, X^3 is a residue of Cba.

[0381] In some embodiments, X^3 comprises a side chain which is or comprises an optionally substituted aromatic group (in some embodiments, may be referred to as an "aromatic amino acid residue").







[0382] In some embodiments, an aromatic amino acid residue has a side chain which is or comprises an optionally substituted aromatic group. In some embodiments, an aromatic amino acid residue, e.g., X^3, has the structure of $-NH_2-C(R^{a2})(R^{a3})-C(O)-$ or $-NH-C(R^{a2})H-C(O)-$ wherein each variable is independently as described herein, and R^{a2} comprises an optionally substituted aromatic group.

[0383] In some embodiments, an aromatic amino acid residue has a side chain which is or comprises an optionally substituted aromatic group, wherein each substituent of the aromatic group is independently halogen. In some embodiments, it comprises a side chain which is or comprises two optionally substituted aromatic groups. In some embodiments, it comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each substituent of the aromatic group is independently selected from halogen or −OH. In some embodiments, an aromatic group is phenyl. In some embodiments, an aromatic group is optionally substituted 8-10 membered bicyclic aryl or heteroaryl having 0-5 heteroatoms. In some embodiments, an aromatic group is optionally substituted 9-10 membered bicyclic aryl or heteroaryl having one heteroatom. In some embodiments, it is a residue of an amino acid of formula A-I or a salt thereof. In some embodiments, an amino acid residue has the structure of $-NH-C(R^{a2})(R^{a3})-C(O)-$ or $-NH-CH(R^{a3})-C)O)-$. As described herein, R^{a3} is $-L^a-R'$ wherein each variable is independently as described herein. In some embodiments, R' is an optionally substituted group selected from phenyl, 10-membered bicyclic aryl, 5-6 membered heteroaryl having 1-4 heteroatoms, and 9-10 membered bicyclic heteroaryl having 1-5 heteroatoms. In some embodiments, each substituent is independently halogen or −OH. In some embodiments, R' is optionally substituted phenyl. In some embodiments, R' is phenyl. In some embodiments, R' is optionally substituted aryl. In some embodiments, R' is aryl. In some embodiments, R' is optionally substituted 5-membered heteroaryl having 1-4 heteroatoms. In some embodiments, R' is optionally substituted 5-membered heteroaryl having 1 heteroatom. In some embodiments, R' is 5-6 membered heteroaryl having 1-4 heteroatoms. In some embodiments, R' is 5-6 membered heteroaryl having 1 heteroatom. In some embodiments, R' is optionally substituted 9-10 membered heteroaryl having 1-5 heteroatoms. In some embodiments, R' is optionally substituted 9-10

membered heteroaryl having 1 heteroatom. In some embodiments, R' is 9-10 membered heteroaryl having 1-4 heteroatoms. In some embodiments, R' is 9-10 membered heteroaryl having 1 heteroatom. In some embodiments, a heteroatom is nitrogen. In some embodiments, a heteroatom is oxygen. In some embodiments, a heteroatom is sulfur. In some embodiments, L^a is a covalent bond. In some embodiments, L^a is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, L^a is $-(CH_2)n-$. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, L^a is $-CH(Ph)-$. In some embodiments, an aromatic amino acid residue is Phe. In some embodiments, an aromatic amino acid residue is Tyr. In some embodiments, an aromatic amino acid residue is Trp. Other aromatic amino acid residues are described herein and can be utilized at various amino acid residue positions.

[0384] In some embodiments, X^3 is a residue of Phe. In some embodiments, X^3 is a residue of Pff. In some embodiments, X^3 is a residue of Tyr. In some embodiments, X^3 is a residue of Trp. In some embodiments, X^3 is a residue of Phg. In some embodiments, X^3 is a residue of DipA.

[0385] In some embodiments, X^3 is or comprises a residue of an amino acid or a moiety selected from Table A-I, Table A-II, Table A-III and Table A-IV.

[0386] In some embodiments, X^3 is a residue of an amino acid suitable for stapling. In some embodiments, X^3 is a residue of an amino acid comprising a double bond, e.g., a terminal olefin, suitable for stapling. In some embodiments, X^3 is a residue of an amino acid having the structure of A-II, A-III, etc. or a salt thereof. In some embodiments, X^3 is $-N(R^{a1})-L^{a1}-C(-L^a-CH=CH_2)(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^3 is $-N(R^{a1})-C(-L^a-CH=CH_2)(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^3 is residue of AllylGly ( , residue being ). In some embodiments, X^3 is [Bn][Allyl]Dap (). In some embodiments, X^3 is [Phc][Allyl]Dap (). In some embodiments, X^3 is [Piv][Allyl]Dap (). In some embodiments, X^3 is [CyCO][Allyl]Dap ().

[0387] In some embodiments, X^3 is stapled. In some embodiments, X^3 is stapled with X^1 (e.g., through olefin metathesis wherein both X^1 and X^3 comprises $-CH=CH_2$). In some embodiments, a staple has the

structure of $-L^{s1}-L^{s2}-L^{s3}-$, wherein each variable is as described herein. In some embodiments, L^{s1} is L^a of one stapled amino acid residue (e.g., X^1) and L^{s3} is L^a of the other stapled amino acid residue (e.g., X^3). For example, in some embodiments, L^s is $-C(O)-(CH_2)n-L^{s2}-(CH_2)n-$, wherein each variable is independently as described herein. In some embodiments, L^s is $-C(O)-(CH_2)n-L^{s2}-CH_2-N(R')-CH_2-$, wherein each variable is independently as described herein. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, L^s is $-C(O)-Cy-O-CH_2-L^{s2}-CH_2-$, each variable is independently as described herein. In some embodiments, L^s is $-C(O)-Cy-O-CH_2-L^{s2}-CH_2-N(R')-CH_2-$, each variable is independently as described herein. In some embodiments, $-Cy-$ is optionally substituted phenylene. In some embodiments, $-Cy-$ is 1,2-phenylene. In some embodiments, R' is Bn. In some embodiments, R' is $-C(O)R$. In some embodiments, R is phenyl. In some embodiments, R is t-butyl. In some embodiments, R is cyclohexyl. In some embodiments, L^{s2} is optionally substituted $-CH=CH-$. In some embodiments, L^{s2} is $-CH=CH-$. In some embodiments, L^{s2} is optionally substituted $-CH_2-CH_2-$. In some embodiments, L^{s2} is $-CH_2-CH_2-$. In some embodiments, one end of a staple, e.g., L^s, is bonded to a backbone nitrogen atom (e.g., of an alpha amino group, at $-C(O)-$ of a staple) and the other end is bonded to a backbone carbon atom (e.g., an alpha carbon atom, at $-CH_2-$ of a staple).

[0388] In some embodiments, an amino acid residue suitable for stapling, e.g., X^3, is of an amino acid of formula V or VI or a salt thereof. In some embodiments, such an amino acid residue is $-N(R^{a1})-L^{a1}-C(-L^a-R^{SP1})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, such an amino acid residue is $-N(R^{a1})-C(-L^a-R^{SP1})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, a reactive group R^{SP1} is $-COOH$. In some embodiments, an amino acid suitable for stapling is an amino acid of formula IV or a salt thereof. In some embodiments, such an amino acid is GlnR. In some embodiments, such an amino acid residue can be stapled with another amino acid residue suitable for stapling, e.g., that comprises a R^{SP1} group that is $-NH_2$ (e.g., in Lys).

[0389] In some embodiments, X^3 is GlnR.

[0390] In some embodiments, X^3 is stapled with X^7. In some embodiments, a side chain of X^3 comprises $-COOH$ that forms a staple with, e.g., a side chain of another amino acid comprising an amino group (e.g., Lys).

[0391] As described herein, in some embodiments, a staple, e.g., L^s, comprises $-C(O)N(R')-$ wherein R' is as described herein. In some embodiments, R' is $-H$. In some embodiments, a staple, e.g., L^s has the structure of $-L^{s1}-C(O)N(R')-L^{s3}-$, wherein each variable is independently as described herein. In some embodiments, L^{s1} is L as described herein. In some embodiments, L^{s3} is L as described herein. In some embodiments, L^{s1} is L^a as described herein of one amino acid residue of a stapled pair. In some embodiments, L^{s1} is L^a as described herein of the other amino acid residue of a stapled pair. In some embodiments, L^{s1} is independently an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L^{s3} is independently an optionally substituted bivalent linear or branched C_{1-10}

hydrocarbon chain. In some embodiments, each of L^{s1} and L^{s3} is independently an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, each of L^{s1} and L^{s3} is independently $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L^{s1} is $-CH_2-$. In some embodiments, L^{s3} is $-(CH_2)_3-$.

[0392] In some embodiments, L^{s2} is L as described herein. In some embodiments, L is or comprises $-C(O)N(R')-$ wherein R' is as described herein. In some embodiments, L is or comprises $-C(O)NH-$.

[0393] In some embodiments, L^s is $-(CH_2)_{n1}-C(O)NH-(CH_2)_{n2}-$, wherein each of n1 and n2 is independently n as described herein. In some embodiments, L^s is $-(CH_2)_2-C(O)NH-(CH_2)_4-$. In some embodiments, such a staple connects X^3 and X^7. In some embodiments, such a staple may connect other pairs of stapled amino acid residues.

[0394] In some embodiments, X^3 is a residue of amino acid that comprises an acidic or polar group. In some embodiments, X^3 is a residue of amino acid whose side chain comprises an acidic group, e.g., a $-COOH$ group or a salt form thereof (e.g., a compound of formula A-IV, PA, PA-a, PA-b, PA-c, etc.). In some embodiments, X^3 is $-N(R^{a1})-L^{a1}-C(-L^a-COOH)(R^{a3})-L^{a2}-C(O)-$ wherein each variable is independently as described herein. In some embodiments, X^3 is $-N(R^{a1})-C(-L^a-COOH)(R^{a3})-C(O)-$ wherein each variable is independently as described herein. In some embodiments, X^3 is a residue of Asp. In some embodiments, X^3 is a residue of amino acid whose side chain comprises $-OH$. For example, in some embodiments, X^3 is a residue of Tyr. In some embodiments, X^3 is a residue of Ser.

[0395] In some embodiments, X^3 is a residue selected from Npg, Leu, Cha, AllylGly, GlnR, Val, nLeu, Asp, [Bn][Allyl]Dap, [Phc][Allyl]Dap, Ile, Phe, CypA, CyLeu, Chg, Pff, DiethA, Ala, Tyr, Trp, Ser, Aib, Phg, OctG, Cba, MorphNva, F2PipNva, [Piv][Allyl]Dap, and [CyCO][Allyl]Dap.

[0396] In some embodiments, X^3 is a residue of Npg, Ile, Asp, Cha, DipA, Chg, Leu, B5, Cba, S5, Ala, Glu, AllylGly, nLeu, Ser, B6, Asn, B4, GlnR, Val, [Phc][Allyl]Dap, Hse, [Bn][Allyl]Dap, 1MeK, R5, Phe, CypA, CyLeu, Pff, DiethA, Tyr, Trp, Aib, Phg, OctG, MorphNva, F2PipNva, [Piv][Allyl]Dap, [CyCO][Allyl]Dap, Lys, or S3. In some embodiments, X^3 is Npg. In some embodiments, X^3 is Leu. In some embodiments, Npg provides better properties and/or activities than, e.g., Ala.

[0397] In some embodiments, X^3 interacts with Tyr306 of beta-catenin or an amino acid residue corresponding thereto.

[0398] In some embodiments, X^3 is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0399] Various types of amino acid residues can be used for X^4, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^4 is a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof. In some embodiments, X^4 is a residue of an amino acid of formula A-II or salt thereof. In some embodiments, X^4 is a residue of an amino acid of formula A-III or salt thereof. In some embodiments, X^4 is a residue of an amino acid of formula A-IV or salt thereof. In some embodiments, X^4 is a residue of an amino

acid of formula A-V or salt thereof. In some embodiments, X^4 is a residue of an amino acid of formula A-VI or salt thereof. In some embodiments, X^4 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^4 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$ wherein each variable is independently as described herein. In some embodiments, X^4 is $-N(R^{a1})-C(R^{a2})H-C(O)-$ wherein each variable is independently as described herein. In some embodiments, R^{a2} is $-L^a-CH=CH_2$, wherein L^a is as described herein. In some embodiments, R^{a3} is $-L^a-CH=CH_2$, wherein L^a is as described herein. In some embodiments, X^4 is $-N(R^{a1})-L^{a1}-C(-L^a-R^{SP1})(-L^a-R^{SP2})-L^{a2}-C(O)-$ wherein each variable is independently as described herein. In some embodiments, X^4 is $-N(R^{a1})-C(-L^a-R^{SP1})(-L^a-R^{SP2})-C(O)-$ wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0400] In some embodiments, each of R^{SP1} and R^{SP2} is or comprises independently optionally substituted $-CH=CH_2$. In some embodiments, each of R^{SP1} and R^{SP2} is independently $-CH=CH_2$. In some embodiments, each of $-L^a-$ connected R^{SP1} or R^{SP2} is independent L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$.

[0401] In some embodiments, X^4 is or comprises a residue of an amino acid or a moiety selected from Table A-I, Table A-II, Table A-III and Table A-IV.

[0402] In some embodiments, X^4 is residue of an amino acid suitable for stapling. In some embodiments, X^4 is a residue of an amino acid which comprises two functional groups suitable for stapling. In some embodiments, X^4 is a residue of an amino acid which comprises one and only one functional group suitable for stapling. In some embodiments, X^4 is a residue of an amino acid which comprises two olefins, e.g., two terminal olefins. In some embodiments, X^4 is a residue of an amino acid which comprises one and only one double bond for stapling, e.g., a terminal olefin. In some embodiments, X^4 is a residue of an amino acid which has the structure of formula A-I, A-II, A-III, etc., wherein both R^{a2} and R^{a3} are independently $-L^a-CH=CH_2$, wherein each L^a is independently as described herein. In some embodiments, X^4 is a residue of an amino acid which has the structure of formula A-I, A-II, A-III, etc., wherein only one of R^{a2} and R^{a3} is $-L^a-CH=CH_2$, wherein each L^a is independently as described herein. In some embodiments, each L^a is independently optionally substituted bivalent C_{1-10} alkylene or heteroalkylene. In some embodiments, each L^a

is independently optionally substituted −(CH_2)n− wherein n is 1-10. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8. In some embodiments, n is 9. In some embodiments, n is 10. In some embodiments, X^4 is a residue of B5, R5, R4, or R6. In some embodiments, X^4 is a residue of B5 or R5. In some embodiments, X^4 is a residue of B5. In some embodiments, X^4 is residue of R5. In some embodiments, X^4 is a residue of R4. In some embodiments, X^4 is a residue of R6.

[0403] In some embodiments, X^4 is stapled. In some embodiments, X^4 is connected to two residues independently through two staples (e.g., when X^4 is B5). In some embodiments, X^4 is staple with X^1, and X^4 is stapled with X^{11}.

[0404] As described herein, various staples may be utilized for connecting stapled amino acid residues. In some embodiments, a staple is L^s as described herein. In some embodiments, each staple connected to X^4 is independently L^s as described herein.

[0405] In some embodiments, L^s is $-L^{s1}-L^{s2}-L^{s3}-$, wherein each variable is independently as described herein. In some embodiments, one of L^{s1} and L^{s3} is L^a of one of two stapled amino acid residues, and the other is L^a of the other of two stapled amino acid residues. In some embodiments, L^{s3} is L^a of X^4, e.g., when X^4 is stapled with an amino acid residue to its N-terminus side (e.g., X^1). In some embodiments, L^{s1} is L^a of X^4, e.g., when X^4 is stapled with an amino acid residue to its C-terminus side (e.g., X^{11}). In some embodiments, L^{s1} is L^a of X^1, and L^{s3} is L^a of X^4. In some embodiments, L^{s1} is L^a of X^4, and L^{s3} is L^a of X^{11}. In some embodiments, two staples are bonded to X^4, wherein a first staple staples X^4 with an amino acid residue to the N-terminus side of X^4 (an amino acid residue to a N-terminus side of a reference amino acid residue may be referred to as "N-direction amino acid residue" of the reference amino acid residue, e.g., X^1 is a N-direction amino acid residue of X^4), wherein the first staple is L^s having the structure of $-L^{s1}-L^{s2}-L^{s3}-$, wherein L^{s1} is L^a of the N-direction amino acid residue, and L^{s3} is L^a of X^4, and wherein a second staple staples X^4 with an amino acid residue to the C-terminus side of X^4 (an amino acid residue to a C-terminus side of a reference amino acid residue may be referred to as "C-direction amino acid residue" of the reference amino acid residue, e.g., X^{11} is a C-direction amino acid residue of X^4), wherein the second staple is L^s having the structure of $-L^{s1}-L^{s2}-L^{s3}-$, wherein L^{s3} is L^a of the C-direction amino acid residue, and L^{s1} is L^a of X^4. Various embodiments of L^a are described herein and can be utilized for various amino acid residues including X^4 and N-direction (e.g., X^1) and C-direction (e.g., X^{11}) amino acid residues. For example, in some embodiments, for X^4 each L^a is $-(CH_2)_3-$.

[0406] As described herein, in some embodiments, L^{s2} is optionally substituted −CH=CH−. In some embodiments, L^{s2} is −CH=CH−. In some embodiments, L^{s2} is optionally substituted $-CH_2-CH_2-$. In some embodiments, L^{s2} is $-CH_2-CH_2-$.

[0407] In some embodiments, as described herein, each staple is independently bonded to two alpha carbon atoms of two stapled amino acid residues.

[0408] In some embodiments, X^4 is stapled with two amino acid residues, e.g., X^1 and X^{11}. In some embodiments, X^4 is stapled with only one residue, e.g., X^{11} (e.g., when X^4 is a residue of R5, R4, or R6). In some embodiments, X^4 is $-N(R^{a1})-L^{a1}-C(-L^a-CH=CH_2)(R^{a3})-L^{a2}-C(O)-$ wherein each variable is independently as described herein. In some embodiments, X^4 is $-N(R^{a1})-C(-L^a-CH=CH_2)(R^{a3})-C(O)-$ wherein each variable is independently as described herein. In some embodiments, X^4 is a residue of R4. In some embodiments, X^4 is a residue of R5. In some embodiments, X^4 is a residue of R6.

[0409] In some embodiments, a staple is L^s as described herein. For example, in some embodiments, L^{s1} is L^a of a first amino acid residue of two stapled amino acid residues, e.g., X^4,, and L^{s3} is L^a of a second amino acid residue of two stapled amino acid residues, e.g., X^{11}, wherein a second amino acid residue (e.g., X^{11}) is a C-direction amino acid residue of a first amino acid residue (e.g., X^4).

[0410] In some embodiments, X^4 is not stapled (e.g., when other residues are optionally stapled, in pre-stapling agents, etc.).

[0411] In some embodiments, X^4 is B5, Npg, Asp, R5, Ile, Ala, Cha, Chg, Ser, Leu, R4, R6, Phe, or S5.

[0412] Various types of amino acid residues can be used for X^5, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^5 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^5 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^5 is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0413] In some embodiments, X^5 is a residue of amino acid that comprises an acidic or polar group. In some embodiments, X^5 is a residue of amino acid whose side chain comprises an acidic group, e.g., a $-COOH$ group or a salt form thereof. In some embodiments, X^5 is a residue of an amino acid of formula A-IV or a salt thereof. In some embodiments, X^5 is a residue of an amino acid of formula PA, PA-a, PA-b, PA-c, or a salt thereof. In some embodiments, R^{PA} is $-H$ and R^{PS} and R^{PC} are $-OH$. In some embodiments, X^5 is $-N(R^{a1})-L^{a1}-C(-L^a-COOH)(R^{a3})-L^{a2}-C(O)-$ wherein each variable is independently as described herein. In some embodiments, X^5 is $-N(R^{a1})-C(-L^a-COOH)(R^{a3})-C(O)-$ wherein each variable is independently as described herein. In some embodiments, L^a is L as described herein. For example, in some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is $-CH(CH_3)-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(O)-$,

−N(R')−, −Cy− or −O−.

[0414] In some embodiments, X^5 is a residue of Asp, Glu, Aad, SbMeAsp, or RbMeAsp. In some embodiments, X^5 is a residue of Asp or Glu. In some embodiments, X^5 is a residue of Asp. In some embodiments, X^5 is a residue of Glu. In some embodiments, X^5 is a residue of Aad. In some embodiments, X^5 is a residue of SbMeAsp. In some embodiments, X^5 is a residue of RbMeAsp.

[0415] In some embodiments, X^5 is a residue of amino acid whose side chain comprises a polar group. In some embodiments, X^5 is a residue of amino acid whose side chain comprises an amide group, e.g., $-C(O)N(R')_2$ such as $-CONH_2$. In some embodiments, R^{a2} is $-L^a-C(O)N(R')_2$ wherein each variable is independently as described herein. In some embodiments, R^{a2} is $-L^a-C(O)NH_2$ wherein L is independently as described herein. In some embodiments, L^a is L' as described herein. For example, in some embodiments, X^5 is a residue of Asn. In some embodiments, X^5 is a residue of MeAsn. In some embodiments, X^5 is a residue of amino acid whose side chain comprises −OH. For example, in some embodiments, X^5 is a residue of Hse, aThr, Ser, or Thr. In some embodiments, X^5 is a residue of Hse or aThr. In some embodiments, X^5 is a residue of Hse. In some embodiments, X^5 is a residue of aThr. In some embodiments, X^5 is a residue of Ser. In some embodiments, X^5 is a residue of Thr.





[0416] In some embodiments, X^5 is Asp, B5, 3COOHF, Glu, Asn, Npg, Hse, aThr, Aad, Ser, Thr, MeAsn, AspSH, SbMeAsp, RbMeAsp. In some embodiments, X^5 is Asp. In some embodiments, X^5 is 3COOHF. In some embodiments, X^5 is Glu. In some embodiments, X^5 is B5. In some embodiments, X^5 is DipA. In some embodiments, X^5 is Chg.

[0417] In some embodiments, X^5 is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0418] In some embodiments, X^5 interacts with Trp383 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^5 interacts with Arg386 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^5 interacts with Asn387 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^5 interacts with Asn387 and Trp383 of beta-catenin or amino acid residues corresponding thereto.

[0419] Various types of amino acid residues can be used for X^6, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^6 is a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof. In some embodiments, X^6 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^6 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^6 is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^6 is a residue of an amino acid of formula A-IV or a salt thereof. In some embodiments, X^6 is a residue of an amino acid of formula PA, PA-a, PA-b, PA-c, or a salt thereof. In some embodiments, R^{PA} is −H and R^{PS} and R^{PC} are −OH. In some embodiments, R^{a1} is −H. In some embodiments, R^{a3} is −H.

[0420] In some embodiments, X^6 is a residue of amino acid that comprises an acidic or polar group. In some embodiments, X^6 is a residue of amino acid whose side chain comprises an acidic group, e.g., a −COOH group or a salt form thereof. In some embodiments, X^6 is a residue of an amino acid having the structure of formula A-IV or a salt thereof. In some embodiments, X^6 is a residue of amino acid having the structure of formula PA, PA-a, PA-b, PA-c, etc. In some embodiments, R^{PA} is −H and R^{PS} and R^{PC} are −OH. In some embodiments, X^6 is $-N(R^{a1})-L^{a1}-C(-L^a-COOH)(R^{a3})-L^{a2}-C(O)-$. In some embodiments, X^6 is $-NH-L^{a1}-C(-L^a-COOH)(R^{a3})-L^{a2}-C(O)-$. In some embodiments, X^6 is $-NH-CH(-L^a-COOH)-C(O)-$.

[0421] As described herein, L^a is L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, a methylene unit is replaced with −Cy−. In some embodiments, L is $-CH_2-Cy-CH_2-$. In some embodiments, L is $-CH_2-Cy-$. In some embodiments, L is $-(CH_2)_4-Cy-CH_2-C(CH_3)_2-$. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is phenylene. In some embodiments, −Cy− is substituted phenylene. In some embodiments, −Cy− is mono-substituted phenylene. In some embodiments, a substituent is −F. In some embodiments, a substituent is optionally substituted C_{1-6} alkyl. In some embodiments, a substituent is $-CF_3$. In some embodiments, a substituent is −OH. In some embodiments, phenylene is 1,2-phenylene. In some embodiments, phenylene is 1,3-phenylene. In some embodiments, phenylene is 1,4-phenylene. In some embodiments, a substituent is ortho to the carbon atom closed to −COOH. In some embodiments, it is meta. In some embodiments, it is para. In some embodiments, −Cy− is 1,3-phenylene (e.g., in 3COOHF). In some embodiments, −Cy− is an optionally substituted bivalent 5-10 membered heteroaryl group having 1-5 heteroatoms. In some embodiments, −Cy− is an optionally substituted bivalent 5-membered heteroaryl group having 1-4 heteroatoms. In some embodiments, −Cy− is an optionally substituted bivalent 6-membered heteroaryl group having 1-4 heteroatoms. In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is  . In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is  . In

some embodiments, L is bonded to a backbone atom, e.g., an alpha carbon atom, at $-CH_2-$. In some embodiments, a methylene unit is replaced with $-N(R')-$ wherein R' is as described herein. In some embodiments, L is $-CH_2-N(R')-CH_2-$ wherein R' is as described herein. In some embodiments, R' is R as described herein. In some embodiments, R is optionally substituted C_{1-6} alkyl. In some embodiments, R is $-CH_2CF_3$.

[0422] In some embodiments, X^6 is a residue of an amino acid of formula PA, PA-a, PA-b, PA-c, or a salt thereof, wherein R^{PA} is –H and R^{PS} and R^{PC} are –OH. In some embodiments, X^6 is a residue of 3COOHF, TfeGA, Asp, [CH2CMe2CO2H]TriAzDap, Glu, 2OH3COOHF, 4OH3COOHF, 4COOHF, 2COOHF, 5F3Me2COOHF, 4F3Me2COOHF, 5F3Me3COOHF, 4F3Me3COOHF, 3F2COOHF, or dGlu. In some embodiments, X^6 is a residue of 3COOHF, TfeGA, Asp, or [CH2CMe2CO2H]TriAzDap. In some embodiments, X^6 is a residue of 3COOHF. In some embodiments, X^6 is a residue of TfeGA. In some embodiments, X^6 is a residue of Asp. In some embodiments, X^6 is a residue of [CH2CMe2CO2H]TriAzDap. In some embodiments, X^6 is a residue of Glu. In some embodiments, X^6 is a residue of 2OH3COOHF. In some embodiments, X^6 is a residue of 4OH3COOHF. In some embodiments, X^6 is a residue of 4COOHF. In some embodiments, X^6 is a residue of 2COOHF. In some embodiments, X^6 is a residue of 5F3Me2COOHF. In some embodiments, X^6 is a residue of 4F3Me2COOHF. In some embodiments, X^6 is a residue of 5F3Me3COOHF. In some embodiments, X^6 is a residue of 4F3Me3COOHF. In some embodiments, X^6 is a residue of 3F2COOHF. In some embodiments, X^6 is a residue of dGlu.

[0423] In some embodiments, X^6 is a residue of amino acid whose side chain comprises a polar group. Certain such amino acid residues useful for X^6 include those described for, e.g., X^2, X^5, etc., whose side chain comprise a polar group. In some embodiments, X^6 is a residue of amino acid whose side chain comprises –OH. For example, in some embodiments, X^6 is a residue of Thr, Tyr, Ser, aThr, or hTyr. In some embodiments, X^6 is a residue of Thr. In some embodiments, X^6 is a residue of Tyr. In some embodiments, X^6 is a residue of Ser. In some embodiments, X^6 is a residue of aThr. In some embodiments, X^6 is a residue of hTyr. In some embodiments, X^6 is a residue of amino acid whose side chain comprises an amide group, e.g., $-C(O)N(R')_2$ such as $-CONH_2$. In some embodiments, X^6 is a residue of Asn. In some embodiments, X^6 is Me2Gln.

[0424] In some embodiments, X^6 is a residue of an amino acid whose side chain is hydrophobic. Certain such amino acid residues include those hydrophobic amino acid residues described for, e.g., X^3. In some embodiments, X^6 is a residue of an amino acid whose side chain is an optionally substituted aliphatic group. In some embodiments, X^6 is a residue of Val. In some embodiments, X^6 is a residue of Ala. In some embodiments, X^6 is a residue of Leu. In some embodiments, X^6 is a residue of Ile.

[0425] As those skilled in the art reading the present disclosure will readily appreciate, amino acid residues of certain properties, structures, etc. described for one position may also be utilized at other positions where amino acid residues of the same properties, structures, etc. can be utilized. For example, when hydrophobic amino acid residues can be utilized at both positions X^3 and X^6, hydrophobic amino acid

residues described for X^3 can be utilized for X^6 and vice versa. Similarly, when acidic amino acid residues can be utilized at positions X^2, X^5 and X^6, acidic amino acid residues described for one of them may be utilized at the other two positions as well.

[0426] In some embodiments, X^6 comprises a side chain comprising an optionally substituted aromatic group. Certain such amino acid residues include those amino acid residues whose side chains comprise aromatic groups described for, e.g., X^3. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having 1-3 nitrogen atoms. In some embodiments, an aromatic group is optionally substituted 8-10 membered bicyclic aryl or heteroaryl having 1-5 heteroatoms. In some embodiments, an aromatic group is phenyl. In some embodiments, an aromatic group is optionally substituted phenyl. In some embodiments, X^6 is a residue of His. In some embodiments, X^6 is a residue of Trp. In some embodiments, X^6 is a reside of Phe. In some embodiments, X^6 is a residue of 3cbmf.

[0427] In some embodiments, X^6 is a residue selected from 3COOHF, TfeGA, Asp, [CH2CMe2CO2H]TriAzDap, Glu, 2OH3COOHF, 4OH3COOHF, 4COOHF, 2COOHF, 5F3Me2COOHF, 4F3Me2COOHF, 5F3Me3COOHF, 4F3Me3COOHF, 3F2COOHF, dGlu, Thr, Tyr, Ser, aThr, hTyr, Glyn, Lys, Arg, Val, Ala, Leu, Phe, Ile, His, Trp, or 3cbmf. In some embodiments, X^6 is a residue of Gln. In some embodiments, X^6 is a residue of Lys. In some embodiments, X^6 is a residue of Arg.

[0428] In some embodiments, X^6 is 3COOHF, Asp, TfeGA, Aib, Glu, Npg, Gln, [CH2CMe2CO2H]TriAzDap, B5, Thr, Ser, Asn, Ala, Hse, 4BOH2F, 2OH3COOHF, 4OH3COOHF, 4COOHF, 2COOHF, His, Tyr, 5F3Me2COOHF, 4F3Me2COOHF, 5F3Me3COOHF, 4F3Me3COOHF, 3F2COOHF, Val, Trp, Arg, dGlu, aThr, hTyr, 3cbmf, Leu, Phe, Lys, Ile, SbMeAsp, bMe2Asp, 3BOH2F, [Ac]Dap, [CH2CO2H]Acp, [Pfbn]GA, [Tfb]GA, [Succinate]Dap, [Malonate]Dap, [Me2Mal]Dap, [SaiPrSuc]Dap, [SaMeSuc]Dap, or [RaiPrSuc]Dap. In some embodiments, X^6 is 3COOHF. In some embodiments, X^6 is Asp. In some embodiments, X^6 is TfeGA. In some embodiments, X^6 is Glu. In some embodiments, 3COOHF provides better properties and/or activities than, e.g., Asp.

[0429] In some embodiments, X^6 is an amino acid residue for stapling as described herein. In some embodiments, X^6 is stapled. In some embodiments, X^6 is a reside of B5

[0430] In some embodiments, X^6 is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0431] In some embodiments, X^6 interacts with Tyr306 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^6 interacts with Lys345 of beta-catenin or an amino acid residue corresponding thereto.

[0432] Various types of amino acid residues can be used for X^7, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^7 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^7 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^7 is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each

variable is independently as described herein. In some embodiments, R^{a1} is −H. In some embodiments, R^{a3} is −H.

[0433] In some embodiments, R^{a2} is R, wherein R is C_{1-10} aliphatic. In some embodiments, R^{a3} is R, wherein R is C_{1-10} aliphatic. In some embodiments, each of R^{a2} and R^{a3} is independently R as described herein. In some embodiments, R^{a2} and R^{a3} are the same. In some embodiments, R is C_{1-10} alkyl. In some embodiments, R is methyl.

[0434] In some embodiments, X^7 is a residue of an amino acid whose side chain is hydrophobic. In some embodiments, X^7 is a hydrophobic amino acid residue described herein, e.g., those described for X^3. In some embodiments, X^7 is a residue of an amino acid whose side chain is optionally substituted C_{1-10} alkyl. In some embodiments, X^7 is a residue of an amino acid whose side chain is C_{1-10} alkyl. In some embodiments, X^7 is a residue of an amino acid whose side chain is C_{1-10} alkyl optionally substituted with one or more non-polar and non-charged groups. In some embodiments, X^7 comprises a side chain comprising a cycloaliphatic group (e.g., a 3-, 4-, 5-, or 6-membered cycloalkyl group). In some embodiments, X^7 is a residue of Aib, Ala, nLeu, Cha, Npg, sAla, Val, CyLeu, Leu, aMeL, DaMeL, or aMeV. In some embodiments, X^7 is a residue of Aib, Ala, nLeu, or Cha. In some embodiments, X^7 is a residue of Aib. In some embodiments, X^7 is a residue of Ala. In some embodiments, X^7 is a residue of nLeu. In some embodiments, X^7 is a residue of Cha. In some embodiments, X^7 is a residue of Npg. In some embodiments, X^7 is a residue of sAla. In some embodiments, X^7 is a residue of Val. In some embodiments, X^7 is a residue of CyLeu. . In some embodiments, X^7 is a residue of Leu. In some embodiments, X^7 is a residue of Cpg. In some embodiments, X^7 is a residue of Cbg. In some embodiments, X^7 is a residue of aMeL. In some embodiments, X^7 is a residue of DaMeL. In some embodiments, X^7 is a residue of aMeV.

[0435] In some embodiments, X^7 is a residue of amino acid whose side chain comprises a polar group. Various polar amino acid residues described herein may be utilized for X^7. In some embodiments, X^7 is a residue of amino acid whose side chain comprises −OH. For example, in some embodiments, X^7 is a residue of Ser. In some embodiments, X^7 is a residue of Hse. In some embodiments, X^7 is a residue of Thr. In some embodiments, X^7 is a residue of DaMeS. In some embodiments, X^7 is a residue of aMeS.

[0436] In some embodiments, X^7 is a residue of amino acid that comprises an acidic or polar group. In some embodiments, X^7 is a residue of amino acid whose side chain comprises an acidic group, e.g., a −COOH group or a salt form thereof (e.g., a compound of formula A-IV, etc.). Various acidic amino acid residues described herein may be utilized for X^7. In some embodiments, X^7 is a residue of 3COOHF. In some embodiments, X^7 is a residue of amino acid whose side chain comprises an amide group, e.g., $-C(O)N(R')_2$ such as $-CONH_2$. In some embodiments, X^7 is a residue of Asn. In some embodiments, X^7 is a residue of Gln. In some embodiments, X^7 is a residue of Me2Gln. In some embodiments, X^7 is a residue of AcLys.

[0437] In some embodiments, X^7 comprises a side chain comprising an optionally substituted aromatic group. Various aromatic amino acid residues described herein may be utilized for X^7. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having 1-3 nitrogen atoms. In some






embodiments, X^7 is a residue of Phe. In some embodiments, X^7 is a residue of aMeDF. In some embodiments, X^7 is a residue of aMeF. In some embodiments, X^7 is a residue of His.





[0438] In some embodiments, X^7 is selected from Aib, Ala, MorphGln, Gln, GlnR, Ser, iPrLys, nLeu, Cha, Hse, Lys, Npg, sAla, TriAzLys, Val, CyLeu, 3COOHF, Thr, Phe, [29N2spiroundecane]GlnR, Acp, Asn, DaMeS, aMeDF, [4aminopiperidine]GlnR, Leu, Cpg, Cbg, Me2Gln, Met2O, AcLys, His, aMeL, DaMeL, aMeV, aMeS, aMeF, [isophthalate]Lys, [succinate]Lys, [Me2Mal]Lys, [diphenate]Lys, or [Biphen33COOH]Lys. In some embodiments, X^7 is selected from GlnR, Lys, [29N2spiroundecane]GlnR, [4aminopiperidine]GlnR, sAla, TriAzLys, [isophthalate]Lys, [succinate]Lys, [Me2Mal]Lys, [diphenate]Lys, or [Biphen33COOH]Lys.



[0439] In some embodiments, X^7 is an amino acid residue suitable for stapling as described herein.

[0440] In some embodiments, an amino acid residue suitable for stapling is $-N(R^{a1})-L^{a1}-C(-L^{a}-R^{SP1})(R^{a3})-L^{a2}-C(O)-$ wherein each variable is independently as described herein. In some embodiments, it is $-N(R^{a1})-C(-L^{a}-R^{SP1})(R^{a3})-C(O)-$ wherein each variable is independently as described herein. In some embodiments, in a pair of amino acid residues suitable for stapling, each amino acid residue is independently $-N(R^{a1})-L^{a1}-C(-L^{a}-R^{SP1})(R^{a3})-L^{a2}-C(O)-$ or $-N(R^{a1})-C(-L^{a}-R^{SP1})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is −H. In some embodiments, R^{a3} is −H. In some embodiments, both R^{a1} and R^{a3} are −H.






[0441] In some embodiments, R^{SP1} of a one amino acid residue in a pair is −NHR wherein R is as described herein. In some embodiments, R is −H. In some embodiments, R is optionally substituted C_{1-6} aliphatic. In some embodiments, R is optionally substituted C_{1-6} alkyl. In some embodiments, R is C_{1-6} aliphatic. In some embodiments, R is C_{1-6} alkyl. In some embodiments, R^{SP1} is $-NH_2$. In some embodiments, such an amino acid residue can be stapled with another amino acid residue comprising −COOH through amidation to form a staple comprising −C(O)N(R')−, e.g., L^s wherein L^{s2} is or comprising −C(O)N(R')−. In some embodiments, in the other amino acid residue of a pair R^{SP1} is −COOH or an active derivative thereof. In some embodiments, in the other amino acid residue of a pair R^{SP1} is −COOH. In some embodiments, R' is R. In some embodiments, R' is −H. In some embodiments, L^{s1} is L^a of a first amino acid residue, e.g., X^7. In some embodiments, L^{s3} is L^a of a second amino acid residue, e.g., a C-direction amino acid residue of a first amino acid residue. In some embodiments, a first amino acid residue is X^7, and a second amino acid residue is a C-direction amino acid residue of X^7, e.g., X^{10}. In some embodiments, each of L^{s1} and L^{s3} is independently L. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or






branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, each of L^{s1} and L^{s3} is independently L, wherein L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, each of L^{s1} and L^{s3} is independently L, wherein L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L^s $-(CH_2)n1-C(O)N(R')-(CH_2)n2-$ wherein each variable is independently as described herein. In some embodiments, each of n1 and n2 is independently 1-10. In some embodiments, a first amino acid residue has R^{SP1} which is an amino group, and a second amino acid residue has R^{SP1} which is $-COOH$ or an activated form thereof. In some embodiments, a second amino acid residue has R^{SP1} which is an amino group, and a first amino acid residue has R^{SP1} which is $-COOH$ or an activated form thereof. In some embodiments, a first amino acid residue is X^7 and a second amino acid residue is one of its C-direction amino acid residue, e.g., X^{10}. In some embodiments, a second amino acid residue is X^7 and a first amino acid residue is one of its N-direction amino acid residue, e.g., X^3. In some embodiments, a first amino acid residue is X^7. In some embodiments, X^7 is Lys. In some embodiments, a second amino acid residue is X^{10}. In some embodiments, X^{10} is GlnR. In some embodiments, n1 is 4 as in Lys. In some embodiments, n2 is 2 as in GlnR. In some embodiments, a first amino acid residue is X^7, e.g., GlnR. In some embodiments, n1 is 2. In some embodiments, a second amino acid residue is X^{10}, e.g., Lys. In some embodiments, n2 is 4. In some embodiments, a second amino acid residue is  (e.g., X^{14}). In some embodiments, L^{s3} is $-(CH_2)_2-C(O)NH-(CH_2)_4-$. In some embodiments, a second amino acid residue is  (e.g., X^{14}). In some embodiments, L^{s3} is $-(CH_2)_2-C(O)-Cy-$. In some embodiments, $-Cy-$ is optionally substituted  wherein the nitrogen is bonded to $-C(O)-$. In some embodiments, L^{s3} is $-(CH_2)_2-C(O)-N(R')-(CH_2)n-CHR'-$, wherein the two R' are taken together with their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is optionally substituted  . In some embodiments, a second amino acid residue is  (e.g., X^{14}). In some embodiments, L^{s3} is

−$(CH_2)_2$−C(O)−N(R')−(CH_2)n−Cy−. In some embodiments, R' is R as described herein. In some embodiments, R is −H. In some embodiments, R optionally substituted C_{1-6} aliphatic. In some embodiments, R optionally substituted C_{1-6} alkyl. In some embodiments, R is methyl. In some embodiments, n is 1. In some embodiments, −Cy− is optionally substituted  wherein the nitrogen is bonded to L^{s2} which is or comprises −C(O)−. In some embodiments, L^{s3} is −$(CH_2)_2$−C(O)−N(R')−CH_2−CHR'−(CH_2)n−. In some embodiments, n is 2. In some embodiments, −(CH_2)n− is bonded to −N(R')− of L^{s2} which is −C(O)−N(R')−. In some embodiments, R' of −CHR'− of L^{s3} is taken together with R' of −N(R')− of L^{s2} and their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is optionally substituted  . In some embodiments, a second amino acid residue is  (e.g., X^{14}). In some embodiments, a second amino acid residue is  (e.g., X^{14}). In some embodiments, L^{s3} −$(CH_2)_2$−C(O)−N(R')−$(CH_2)_{n1}$−C(R')$_2$−$(CH_2)_{n2}$−. In some embodiments, each of n1 and n2 is independently 1-10. In some embodiments, n1 is 1. In some embodiments, n1 is 2. In some embodiments, n2 is 2. In some embodiments, R' of −N(R')− and one R' of −C(R')$_2$− are taken together with their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is an optionally substituted 6-membered monocyclic saturated ring having no heteroatoms in addition to the nitrogen atom of −N(R')−. In some embodiments, L^{s2} is −C(O)N(R')−. In some embodiments, −N(R')− is bonded to −$(CH_2)_{n2}$−. In some embodiments, one R' of −C(R')$_2$− of L^{s3} is taken together with R' of −N(R')− of L^{s2} and their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is an optionally substituted 6-membered monocyclic saturated ring having no heteroatoms in addition to the nitrogen atom of −N(R')−.

[0442] In some embodiments, a first amino acid residue is  (e.g., X^7). In some embodiments, L^{s1} is −$(CH_2)_2$−C(O)−N(R')−(CH_2)n−CHR'−, wherein the two R' are taken together with their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is optionally substituted  . In some embodiments, a second amino acid residue is

GlnR (e.g., X^{14}). In some embodiments, L^{s3} is $-(CH_2)_2-$.

[0443] In some embodiments, a first amino acid residue is  (e.g., X^7). In some embodiments, L^{s1} is $-(CH_2)_2-C(O)-N(R')-(CH_2)n-Cy-$. In some embodiments, R' is R as described herein. In some embodiments, R is −H. In some embodiments, R optionally substituted C_{1-6} aliphatic. In some embodiments, R optionally substituted C_{1-6} alkyl. In some embodiments, R is methyl. In some embodiments, n is 1. In some embodiments, −Cy− is optionally substituted  wherein the nitrogen is bonded to L^{s2} which is or comprises $-C(O)-$. In some embodiments, L^{s1} is $-(CH_2)_2-C(O)-N(R')-CH_2-CHR'-(CH_2)n-$. In some embodiments, n is 2. In some embodiments, $-(CH_2)n-$ is bonded to $-N(R')-$ of L^{s2} which is $-C(O)-N(R')-$. In some embodiments, R' of $-CHR'-$ of L^{s1} is taken together with R' of $-N(R')-$ of L^{s2} and their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is optionally substituted  . In some embodiments, a first amino acid residue is  (e.g., X^7). In some embodiments, a first amino acid residue is  (e.g., X^7). In some embodiments, L^{s1} is $-(CH_2)_2-C(O)-N(R')-(CH_2)_{n1}-C(R')_2-(CH_2)_{n2}-$. In some embodiments, each of n1 and n2 is independently 1-10. In some embodiments, n1 is 1. In some embodiments, n1 is 2. In some embodiments, n2 is 2. In some embodiments, R' of $-N(R')-$ and one R' of $-C(R')_2-$ are taken together with their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is an optionally substituted 6-membered monocyclic saturated ring having no heteroatoms in addition to the nitrogen atom of $-N(R')-$. In some embodiments, L^{s2} is $-C(O)N(R')-$. In some embodiments, $-N(R')-$ is bonded to $-(CH_2)_{n2}-$. In some embodiments, one R' of $-C(R')_2-$ of L^{s1} is taken together with R' of $-N(R')-$ of L^{s2} and their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is an optionally substituted 6-membered monocyclic saturated ring having no heteroatoms in addition to the nitrogen atom of $-N(R')-$. In some embodiments, a second amino acid residue is GlnR (e.g., X^{14}).

[0444] In some embodiments, a first residue is  (e.g., X^7). In some embodiments, a first residue is  (e.g., X^7). In some embodiments, a first residue is  (e.g., X^7). In some embodiments, L^{s1} is $-(CH_2)n-N(R')-C(O)-Cy-Cy-$, wherein each variable is independently as described herein. In some embodiments, L^{s1} is $-(CH_2)n-N(R')-C(O)-Cy-$, wherein each variable is independently as described herein. In some embodiments, a first residue is  (e.g., X^7). In some embodiments, L^{s1} is $-(CH_2)n-N(R')-C(O)-CH_2-$, wherein R is as described herein, and the $-CH_2-$ bonded to C(O)− is optionally substituted. In some embodiments, L^{s1} is $-(CH_2)n-N(R')-C(O)-C(R')_2-$, wherein each R is independently as described herein. In some embodiments, L^{s1} is $-(CH_2)n-N(R')-C(O)-C(CH_3)_2-$, wherein R is as described herein. In some embodiments, a first residue is  (e.g., X^7). In some embodiments, L^{s1} is $-(CH_2)_{n1}-N(R')-C(O)-(CH_2)_{n2}-$, wherein each variable is independently as described herein. In some embodiments, each of n1 and n2 is independently n as described herein. In some embodiments, L^{s1} is $-(CH_2)_4-N(R')-C(O)-(CH_2)_2-$, wherein each R is independently as described herein. In some embodiments, n is 1-10. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, R' is R as described herein. In some embodiments, R is −H. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is optionally substituted 1,2-phenylene. In some embodiments, −Cy− is optionally substituted 1,3-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,2-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,3-phenylene. In some embodiments, L^{s2} is or comprises −C(O)−N(R')− as described herein. In some embodiments, R' is R as described herein. In some embodiments, R is −H. In some embodiments, L^{s2} is −C(O)NH−. In some embodiments, −C(O)− is bonded to −Cy− of L^{s1}. In some embodiments, a second residue is X^{14}, e.g., Lys. In

some embodiments, L^{s3} is as described herein, e.g., optionally substituted $-(CH_2)n-$. In some embodiments, L^{s3} is $-(CH_2)n-$. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4 (e.g., as in Lys).





[0445] In some embodiments, R^{SP1} of a first amino acid residue is or comprises −COOH or a protected or activated form thereof. In some embodiments, a first amino acid residue is X^3, e.g., GlnR. In some embodiments, R^{SP1} of a second amino acid residue is or comprises an amino group, e.g., −NHR as described herein. In some embodiments, R^{SP1} of a second amino acid residue is or comprises $-NH_2$. In some embodiments, a second amino acid residue is X^7, e.g., Lys. In some embodiments, each of L^{s1} and L^{s3} is independently optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L^{s1} is $-(CH_2)_2-$. In some embodiments, L^{s1} is $-(CH_2)_4-$.

[0446] In some embodiments, R^{SP1} of a one amino acid residue in a pair is a first reaction group of a cycloaddition reaction. In some embodiments, such an amino acid residue can be stapled with another amino acid residue comprising a second reactive group of a cycloaddition reaction through a cycloaddition reaction. In some embodiments, in the other amino acid residue of a pair R^{SP1} is a second reactive group of a cycloaddition reaction. In some embodiments, a cycloaddition reaction is [3+2]. In some embodiments, a cycloaddition reaction is a click chemistry reaction. In some embodiments, a cycloaddition reaction is [4+2]. In some embodiments, one of the first and the second reactive groups is or comprises $-N_3$, and the other is or comprises an alkyne (e.g., a terminal alkyne or activated/strained alkyne).

[0447] In some embodiments, R^{SP1} of a first amino acid residue is $-N_3$. In some embodiments, L^a of a first amino acid residue is L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, −C(O)−, −N(R')−, −Cy− or −O−.

[0448] In some embodiments, R^{SP1} of a second amino acid residue is or comprises −C≡C−. In some embodiments, R^{SP1} of a second amino acid residue is −≡−H. In some embodiments, R^{SP1} of a second amino acid residue comprises a strained alkyne, e.g., in a ring. In some embodiments, L^a of a first amino acid residue is L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In

some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$.

[0449] In some embodiments, L^s is $-L^{s1}-L^{s2}-L^{s3}-$, wherein L^{s2} is or comprises $-Cy-$. In some embodiments, L^{s2} is $-Cy-$. In some embodiments, $-Cy-$ is formed by a cycloaddition reaction. In some embodiments, $-Cy-$ is optionally substituted  . In some embodiments, $-Cy-$ is  . In some embodiments, $-Cy-$ is formed by a cycloaddition reaction. In some embodiments, $-Cy-$ is optionally substituted  . In some embodiments, $-Cy-$ is  . In some embodiments, L^{s1} is L^a of a first amino acid residue, and L^{s3} is L^a of a second amino acid residue. In some embodiments, L^{s1} is L^a of a second amino acid residue, and L^{s3} is L^a of a first amino acid residue. In some embodiments, each of L^{s1} and L^{s3} is independently L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L^{s1} is optionally substituted $-(CH_2)_n-$, wherein n is 1-10. In some embodiments, L^{s1} is $-(CH_2)_n-$, wherein n is 1-10. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, L^{s3} is optionally substituted $-(CH_2)_n-$, wherein n is 1-10. In some embodiments, L^{s3} is $-(CH_2)_n-$, wherein n is 1-10. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4.

[0450] In some embodiments, a first amino acid residue is X^7. In some embodiments, R^{SP1} of X^7 is $-N_3$. In some embodiments, L^a of X^7 is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments,

L^a of X^7 is $-(CH_2)_4-$. In some embodiments, L^a of X^7 is $-(CH_2)_3-$. In some embodiments, L^a of X^7 is $-(CH_2)_2-$. In some embodiments, L^a of X^7 is $-CH_2-$. In some embodiments, a second amino acid residue is X^{10}. In some embodiments, R^{SP1} of X^{10} is or comprises an alkyne, e.g., a strained/activated alkyne. In some embodiments, R^{SP1} of X^{10} is $-C\equiv CH$. In some embodiments, L^a of X^{10} is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, L^a of X^{10} is $-(CH_2)_4-$. In some embodiments, L^a of X^{10} is $-(CH_2)_3-$. In some embodiments, L^a of X^{10} is $-(CH_2)_2-$. In some embodiments, L^a of X^{10} is $-CH_2-$. In some embodiments, L^{s3} is L^a of X^{10}. In some embodiments, L^{s3} is bonded to a carbon atom of L^{s2}.

[0451] In some embodiments, a first amino acid residue is X^7. In some embodiments, R^{SP1} of X^7 is or comprises an alkyne, e.g., a strained/activated alkyne. In some embodiments, R^{SP1} of X^7 is $-C\equiv CH$. In some embodiments, L^a of X^7 is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, L^a of X^7 is $-(CH_2)_4-$. In some embodiments, L^a of X^7 is $-(CH_2)_3-$. In some embodiments, L^a of X^7 is $-(CH_2)_2-$. In some embodiments, L^a of X^7 is $-CH_2-$. In some embodiments, L^{s1} is L^a of X^7. In some embodiments, L^{s1} is bonded to a carbon atom of L^{s2}.In some embodiments, a second amino acid residue is X^{10}. In some embodiments, R^{SP1} of X^{10} is $-N_3$. In some embodiments, L^a of X^{10} is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, L^a of X^{10} is $-(CH_2)_4-$. In some embodiments, L^a of X^{10} is $-(CH_2)_3-$. In some embodiments, L^a of X^{10} is $-(CH_2)_2-$. In some embodiments, L^a of X^{10} is $-CH_2-$.





[0452] In some embodiments, R^{SP1} of two amino acid residues of a pair of amino acid residues suitable for stapling can each independently react with a linking reagent to form a staple. In some embodiments, a suitable linking reagent comprises two reactive groups, each can independently react with R^{SP1} of each amino acid residue. In some embodiments, a linking reagent has the structure of H–L"–H or a salt thereof, wherein the reagent comprises two amino groups, and L" is a covalent bond, or an optionally substituted, bivalent C_1-C_{20} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, –Cy–, –O–, –S–, –S–S–, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, such a linking agent can react with two amino acid residues each independently having a R^{SP1} group that is –COOH or an activated form thereof.


[0453] Suitable embodiments for L" including those described for L herein that fall within the scope of L". For example, in some embodiments, L" is L wherein L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, –Cy– or –O–. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted

bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(R')$_2$−, −C(O)−, −N(R')−, −Cy− or −O−.


[0454] In some embodiments, a linking reagent is a diamine or a salt thereof. In some embodiments, a reagent has the structure of NHR−L"−NHR or a salt thereof, wherein each variable is independently as described herein. In some embodiments, each R is independently −H or optionally substituted C_{1-6} aliphatic. In some embodiments, each R is independently −H or C_{1-6} aliphatic. In some embodiments, each R is independently −H or optionally substituted C_{1-6} alkyl. In some embodiments, each R is independently −H or C_{1-6} alkyl. In some embodiments, a reagent has the structure of NH_2−L"−NH_2 or a salt thereof. In some embodiments, L" is optionally substituted −(CH_2)n− wherein n is 1-10. In some embodiments, L" is −(CH_2)$_4$−.


[0455] In some embodiments, a staple, L^s, is −L^{s1}−L^{s2}−L^{s3}−, wherein L^{s1} is L^a of a first amino acid residue of a stapled pair, L^{s3} is L^a of a second amino acid residue of a stapled pair, and L^{s2} is −C(O)−N(R')−L"−N(R')−C(O)−, wherein each variable is independently as described herein. In some embodiments, L" is optionally substituted −(CH_2)n− wherein n is 1-10. In some embodiments, L" is −(CH_2)$_4$−. In some embodiments, each of L^{s1} and L^{s3} is independently optionally substituted −(CH_2)n− wherein n is 1-10. In some embodiments, n is 2. In some embodiments, a first amino acid residue is Gln (e.g., X^7). In some embodiments, a second amino acid residue is GlnR (e.g., X^{14}). In some embodiments, two GlnR can form such a staple through [diaminobutane].

[0456] In some embodiments, a linking reagent has the structure of H−Cy−L"−NHR or a salt thereof, wherein −Cy− comprises a second amino group. In some embodiments, R is −H or optionally substituted C_{1-6} aliphatic. In some embodiments, R is −H or C_{1-6} aliphatic. In some embodiments, R is −H or optionally substituted C_{1-6} alkyl. In some embodiments, R is −H or C_{1-6} alkyl. In some embodiments, R is methyl. In some embodiments, a linking reagent has the structure of H−Cy−L"−NH_2 or a salt thereof, wherein −Cy− comprises a second amino group. In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is  . In some embodiments, L" is a covalent bond. In some embodiments, L" is optionally substituted −(CH_2)n− wherein n is 1-10. In some embodiments, L" is −(CH_2)−. In some embodiments, a linking reagent is  or a salt thereof. In some embodiments, a linking reagent is  or a salt thereof.

[0457] In some embodiments, L^{s2} is −C(O)−Cy−N(R')−C(O)−, wherein each variable is independently as described herein. In some embodiments, R' is −H. In some embodiments, −Cy− is  . In some

embodiments, each of L^{s1} and L^{s3} is independently optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, n is 2. In some embodiments, −Cy− is closer to a N-terminus than −N(R')−. In some embodiments, −Cy− is closer to a C-terminus than −N(R')−. In some embodiments, a first amino acid residue is Gln (e.g., X^7). In some embodiments, a second amino acid residue is GlnR (e.g., X^{14}). In some embodiments, two GlnR can form such a staple through [4aminopiperidine].






[0458] In some embodiments, L^{s2} is $-C(O)-Cy-(CH_2)n-N(R')-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R' is −H. In some embodiments, R' is R as described herein, e.g., optionally substituted C_{1-6} aliphatic, C_{1-6} alkyl, etc. In some embodiments, R is methyl. In some embodiments, n is 1. In some embodiments, −Cy− is  . In some embodiments, −Cy− is closer to a N-terminus than −N(R')−. In some embodiments, −Cy− is closer to a C-terminus than −N(R')−. In some embodiments, each of L^{s1} and L^{s3} is independently optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, n is 2. In some embodiments, a first amino acid residue is Gln (e.g., X^7). In some embodiments, a second amino acid residue is GlnR (e.g., X^{14}). In some embodiments, two GlnR can form such a staple through [4mampiperidine].

[0459] In some embodiments, a methylene unit is replaced with −Cy−. In some embodiments, a linking reagent has the structure of H−Cy−H, wherein Cy comprises two secondary amino groups. In some embodiments, −Cy− is optionally substituted 8-20 membered bicyclic ring. In some embodiments, H−Cy−H comprises two −NH−. In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is optionally substituted  . In some embodiments, the meta connection site (relative to the spiro carbon atom) is closer to a N-terminus than the para connection site (relative to the spiro carbon atom). In some embodiments, the meta connection site (relative to the spiro carbon atom) is closer to a C-terminus than the para connection site (relative to the spiro carbon atom).

[0460] In some embodiments, L^{s2} is $-C(O)-Cy-C(O)-$ wherein −Cy− is as described herein. In some embodiments, each of L^{s1} and L^{s3} is independently optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, n is 2. In some embodiments, a first amino acid residue is Gln (e.g., X^7). In some embodiments, a second amino acid residue is GlnR (e.g., X^{14}). In some embodiments, two GlnR can form such a staple through [29N2spiroundecane]. In some embodiments, two GlnR can form such a staple through [39N2spiroundecane].

[0461] In some embodiments, a pair of amino acid residue suitable for stapling both independently has the structure of $-N(R^{a1})-L^{a1}-C(-L^a-R^{SP1})(R^{a3})-L^{a2}-C(O)-$ or $-N(R^{a1})-C(-L^a-R^{SP1})(R^{a3})-C(O)-$, wherein each variable is independently as described herein, and R^{SP1} is an amino group. In some embodiments, R^{SP1} is −NHR wherein R is as described herein. In some embodiments, R is −H. In some embodiments, R is

optionally substituted C_{1-6} aliphatic. In some embodiments, R is optionally substituted C_{1-6} alkyl. In some embodiments, R is C_{1-6} aliphatic. In some embodiments, R is C_{1-6} alkyl. In some embodiments, R^{SP1} is $-NH_2$. In some embodiments, such two amino acid residue may be linked by a di-acid linking reagent.

[0462] In some embodiments, a linking reagent has the structure of HOOC−L"−COOH, or a salt thereof, or an activated form thereof, wherein L" is as described herein. In some embodiments, L" is −Cy−Cy−. In some embodiments, L" is −Cy−. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is optionally substituted 1,2-phenylene. In some embodiments, −Cy− is optionally substituted 1,3-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,2-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,3-phenylene. In some embodiments, L" is optionally substituted  . In some embodiments, a linking agent is  or a salt or an activated form thereof. In some embodiments, L" is optionally substituted  . In some embodiments, a linking agent is  or a salt or an activated form thereof. In some embodiments, L" is 1,3-phenylene. In some embodiments, a linking agent is  or a salt or an activated form thereof. In some embodiments, L" is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L" is optionally substituted $-CH_2-$. In some embodiments, L" is $-C(R')_2-$. In some embodiments, L" is $-C(CH_3)_2-$. In some embodiments, a linking agent is $(CH_3)_2C(COOH)_2$ or a salt or an activated form thereof. In some embodiments, L" is $-CH_2CH_2-$. In some embodiments, a linking agent is $HOOCCH_2CH_2COOH$ or a salt or an activated form thereof.

[0463] In some embodiments, a staple is L^s, wherein L^{s2} is −N(R')−L"−N(R')−, and each of L^{s1} and L^{s3} is independently as described herein. In some embodiments, L" is −Cy−Cy−, wherein each −Cy− is independently as described herein. In some embodiments, L" is −Cy− as described herein. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is optionally substituted 1,2-phenylene. In some embodiments, −Cy− is optionally substituted 1,3-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,2-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,3-phenylene. In some embodiments, L" is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L" is optionally substituted $-CH_2-$. In some embodiments, L" is $-C(R')_2-$. In some embodiments, L" is $-C(CH_3)_2-$. In some embodiments, L" is $-CH_2CH_2-$. In some embodiments, each of L^{s1} and L^{s3} is independently optionally substituted $-(CH_2)n-$

wherein n is 1-10. In some embodiments, n is 2. In some embodiments, n is 4. In some embodiments, a first amino acid residue is Lys (e.g., X^7). In some embodiments, a second amino acid residue is Lys (e.g., X^{14}). In some embodiments, two Lys can form such a staple through [Biphen33COOH]. In some embodiments, two Lys can form such a staple through [diphenate]. In some embodiments, two Lys can form such a staple through [isophthalate]. In some embodiments, two Lys can form such a staple through [Me2Mal]. In some embodiments, two Lys can form such a staple through [succinate].

[0464] In some embodiments, X^7 is stapled. In some embodiments, X^7 is stapled with X^{14}. In some embodiments, X^7 is stapled with X^{10}. In some embodiments, X^{10} is stapled with X^7. In some embodiments, X^7 is stapled with X^3.

[0465] In some embodiments, X^7 is Aib, Ala, 3COOHF, CyLeu, Phe, Asp, nLeu, B5, Val, Gln, MorphGln, GlnR, Cha, Ser, Leu, Cbg, CyhLeu, iPrLys, Aic, Lys, Lys*, Hse, GlnR, Npg, GlnR*, Dpg, Gly, sAla, TriAzLys, Thr, Asn, dAla, [isophthalate]-Lys, [succinate]-Lys, [29N2spiroundecane]GlnR, Acp, DaMeS, aMeDF, DGlnR, [Ac]Acp, [Phc]Acp, [isovaleryl]Acp, [Me2Mal]-Lys, [diphenate]-Lys, [Biphen33COOH]-Lys, [Me2Mal]Lys, [diphenate]Lys, [Biphen33COOH]Lys, [4aminopiperidine]GlnR, Cpg, Me2Gln, Met2O, AcLys, His, aMeL, DaMeL, aMeV, aMeS, aMeF, dLys, [ethylenediamine]GlnR, [Me2ethylenediamine]GlnR, [diaminopropane]GlnR, [diaminopentane]GlnR, [Me2diaminohexane]GlnR, [Ac]PyrSa, [Phc]PyrSa, [isovaleryl]PyrSa, [Ac]PyrRa, [Phc]PyrRa, [isovaleryl]PyrRa, 2COOHF, 4COOHF, or Glu. In some embodiments, X^7 is Aib. In some embodiments, X^7 is Ala. In some embodiments, X^7 is 3COOHF. In some embodiments, X^7 is CyLeu. In some embodiments, X^7 is Phe. In some embodiments, X^7 is nLeu. In some embodiments, X^7 is Val. In some embodiments, X^7 is Cha. In some embodiments, X^7 is Leu. In some embodiments, X^7 is Cbg. In some embodiments, X^7 is CyhLeu. In some embodiments, Aib provides better properties and/or activities than, e.g., Ala. In some embodiments, X^7 is GlnPDA*3. In some embodiments, X^7 is GlnBDA*3. In some embodiments, X^7 is GlnR*3. In some embodiments, X^7 is GlnMeBDA*3. In some embodiments, X^7 is GlnT4CyMe*3. In some embodiments, X^7 is GlnC4CyMe*3. In some embodiments, X^7 is Gln3ACPip*3. In some embodiments, X^7 is GlnPipAz*3. In some embodiments, X^7 is Gln4Pippip*3. In some embodiments, X^7 is GlnPip4AE*3.

[0466] In some embodiments, X^7 is or comprises a residue of an amino acid or a moiety selected from Table A-I, Table A-II, Table A-III and Table A-IV.

[0467] Various types of amino acid residues can be used for X^8, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^8 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^8 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^8 is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0468] In some embodiments, X^8 is a residue of an amino acid whose side chain is hydrophobic. In

some embodiments, X^8 is a hydrophobic amino acid residue as described herein, e.g., those described for X^3. In some embodiments, X^8 is a residue of Ala. In some embodiments, X^8 is a residue of Aib. In some embodiments, X^8 is a residue of Cpg. In some embodiments, X^8 is a residue of Val. In some embodiments, X^8 is a residue of Leu. In some embodiments, X^8 is a residue of nLeu. In some embodiments, X^8 is a residue of Cba.

[0469] In some embodiments, X^8 is a residue of amino acid that comprises an acidic or polar group. In some embodiments, X^8 is a residue of amino acid whose side chain comprises a polar group. In some embodiments, X^8 is a polar amino acid residue as described herein. In some embodiments, X^8 is a residue of amino acid whose side chain comprises −OH. In some embodiments, X^8 comprises a side chain comprising an optionally substituted aromatic group. For example, in some embodiments, X^8 is a residue of Ser. In some embodiments, X^8 is a residue of Thr. In some embodiments, X^8 is a residue of aThr. In some embodiments, X^8 is a residue of hTyr. In some embodiments, X^8 is a residue of amino acid whose side chain comprises an amide group, e.g., $-C(O)N(R')_2$ such as $-CONH_2$. In some embodiments, X^8 is a residue of Gln. In some embodiments, X^8 is a residue of AcLys.

[0470] In some embodiments, X^8 is a residue of amino acid whose side chain comprises an acidic group, e.g., a −COOH group or a salt form thereof (e.g., a compound of formula A-IV, etc.). In some embodiments, X^8 is an acidic amino acid residue as described herein, e.g., those descried for X^2, X^5, X^6, etc. In some embodiments, X^8 is a residue of Asp. In some embodiments, X^8 is a residue of Glu. In some embodiments, X^8 is a residue of Aad.

[0471] In some embodiments, X^8 comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, X^8 is an aromatic amino acid residue as described herein. In some embodiments, an aromatic group is phenyl. In some embodiments, X^8 is a residue of Phe. In some embodiments, X^8 is a residue of hPhe. In some embodiments, X^8 is a residue of hTyr.

[0472] In some embodiments, X^8 is selected from Ala, Aib, Cpg, Val, Leu, Gln, Lys, Asp, Glu, Aad, nLeu, Cba, Ser, Thr, aThr, MorphGln, Phe, hPhe, hTyr, and AcLys.

[0473] In some embodiments, X^8 is Ala, Aib, Phe, Asp, 3COOHF, aThr, Gly, Ser, nLeu, Thr, Cpg, Val, Leu, Gln, Lys, Glu, Aad, Cba, MorphGln, hPhe, hTyr, or AcLys. In some embodiments, X^8 is Ala. In some embodiments, X^8 is Aib. In some embodiments, X^8 is Phe. In some embodiments, X^8 is Asp. In some embodiments, X^8 is 3COOHF.

[0474] In some embodiments, X^8 is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0475] In some embodiments, X^8 interacts with Trp383 of beta-catenin or an amino acid residue corresponding thereto.

[0476] Various types of amino acid residues can be used for X^9, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^9 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as

described herein. In some embodiments, X^9 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^9 is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0477] In some embodiments, X^9 comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, X^9 is an aromatic amino acid residue as described herein. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having 1-3 heteroatoms. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having 1-3 nitrogen atoms. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having one sulfur atom. In some embodiments, an aromatic group is optionally substituted phenyl. In some embodiments, X^9 comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each substituent of the aromatic group is independently selected from halogen, $-OR$, $-R$, -C(O)OH, or $-CN$, wherein each R is independently hydrogen or C_{1-4} alkyl or haloalkyl. In some embodiments, an aromatic group is phenyl. In some embodiments, an aromatic group is optionally substituted 8-10 membered bicyclic aryl or heteroaryl having 1-5 heteroatoms. In some embodiments, X^9 comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each substituent of the aromatic group is independently halogen. In some embodiments, X^9 comprises a side chain which is or comprises two optionally substituted aromatic groups. In some embodiments, X^9 comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each substituent of the aromatic group is independently selected from halogen or $-OH$. In some embodiments, an aromatic group is phenyl. In some embodiments, an aromatic group is optionally substituted 8-10 membered bicyclic aryl or heteroaryl having 0-5 heteroatoms. In some embodiments, an aromatic group is optionally substituted 9-10 membered bicyclic aryl or heteroaryl having one heteroatom. In some embodiments, X^9 is a residue of an amino acid of formula A-I or a salt thereof. In some embodiments, an amino acid residue has the structure of $-NH-C(R^{a2})(R^{a3})-C(O)-$ or a salt thereof. In some embodiments, an amino acid residue has the structure of $-NH-CH(R^{a3})-C)O)-$ or a salt thereof. As described herein, R^{a3} is $-L^a-R'$ wherein each variable is independently as described herein. In some embodiments, R' is R as described herein. In some embodiments, R is an optionally substituted group selected from phenyl, 10-membered bicyclic aryl, 5-6 membered heteroaryl having 1-4 heteroatoms, and 9-10 membered bicyclic heteroaryl having 1-5 heteroatoms. In some embodiments, each substituent is independently halogen or $-OH$ or C_{1-6} haloaliphatic. In some embodiments, each substituent is independently halogen or $-OH$. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is phenyl. In some embodiments, R is optionally substituted aryl. In some embodiments, R is aryl. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1-4 heteroatoms. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1 heteroatom. In some embodiments, optionally substituted R is 6-membered heteroaryl having 1-4 heteroatoms. In some embodiments, optionally substituted R is 6-membered heteroaryl

having 1 heteroatom. In some embodiments, R is optionally substituted 9-membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is optionally substituted 9-membered heteroaryl having 1 heteroatom. In some embodiments, R is optionally substituted 10-membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is optionally substituted 10-membered heteroaryl having 1 heteroatom. In some embodiments, a heteroatom is nitrogen. In some embodiments, a heteroatom is oxygen. In some embodiments, a heteroatom is sulfur. As described herein, L^a is L. In some embodiments, L is a covalent bond. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$.

[0478] In some embodiments, X^9 is a residue of an amino acid selected from Phe, 3COOHF, 2NapA, Tyr, 3Thi, 4FF, 4ClF, 4BrF, 3FF, 3ClF, 3BrF, 2FF, 3OMeF, 4CNF, 3CNF, 4MeF, 3MeF, Aic, RbiPrF, SbiPrF, RbiPrDF, RbMeXylA, RbMeXylDA, BztA, 1NapA, Trp, 2Thi, 4TriA, 3F3MeF, His, SbMeXylA, and SbMeXylDA. In some embodiments, X^9 is Phe. In some embodiments, X^9 is 3COOHF. In some embodiments, X^9 is 2NapA. In some embodiments, X^9 is Tyr. In some embodiments, X^9 is 3Thi. In some embodiments, X^9 is 4FF. In some embodiments, X^9 is 4ClF. In some embodiments, X^9 is 4BrF. In some embodiments, X^9 is 3FF. In some embodiments, X^9 is 3ClF. In some embodiments, X^9 is 3BrF. In some embodiments, X^9 is 2FF. In some embodiments, X^9 is 3OMeF. In some embodiments, X^9 is 4CNF. In some embodiments, X^9 is 3CNF. In some embodiments, X^9 is 4MeF. In some embodiments, X^9 is 3MeF. In some embodiments, X^9 is Aic. In some embodiments, X^9 is RbiPrF. In some embodiments, X^9 is SbiPrF. In some embodiments, X^9 is RbiPrDF. In some embodiments, X^9 is RbMeXylA. In some embodiments, X^9 is RbMeXylDA. In some embodiments, X^9 is BztA. In some embodiments, X^9 is 1NapA. In some embodiments, X^9 is Trp. In some embodiments, X^9 is 2Thi. In some embodiments, X^9 is 4TriA. In some embodiments, X^9 is 3F3MeF. In some embodiments, X^9 is His. In some embodiments, X^9 is SbMeXylA. In some embodiments, X^9 is SbMeXylDA.

[0479] In some embodiments, X^9 is a residue of an amino acid whose side chain is hydrophobic. In some embodiments, X^9 is a hydrophobic amino acid residue as described herein. In some embodiments, X^9 is selected from nLeu, Ala, Cba, CypA, Leu, Ile, Chg, Val, and 2Cpg.

[0480] In some embodiments, X^9 is a residue of amino acid that comprises an acidic or polar group. .In

some embodiments, X^9 is a residue of amino acid whose side chain comprises a polar group. In some embodiments, X^9 is a polar amino acid residue as described herein. In some embodiments, X^9 is a residue of amino acid whose side chain comprises −OH. For example, in some embodiments, X^9 is a residue of Ser. In some embodiments, X^9 is a residue of Hse. In some embodiments, X^9 is a residue of amino acid whose side chain comprises an amide group, e.g., $-C(O)N(R')_2$ such as $-CONH_2$. For example, in some embodiments, X^9 is a residue of Asn. In some embodiments, X^9 is Gln.

[0481] In some embodiments, X^9 is Phe, Ala, Lys, 3COOHF, Aib, 2NapA, nLeu, 2Thi, Tyr, 3Thi, 4FF, 4ClF, 4BrF, 3FF, 3ClF, 3BrF, 2FF, 3OMeF, 4CNF, 3CNF, 4MeF, 3MeF, Aic, RbiPrF, SbiPrF, RbiPrDF, RbMeXylA, RbMeXylDA, Cba, CypA, BztA, 1NapA, Trp, Leu, Ile, Ser, Chg, Hse, 4TriA, 3F3MeF, Thr, His, Val, Asn, Gln, 2Cpg, SbMeXylA, or SbMeXylDA. In some embodiments, X^9 is Phe. In some embodiments, X^9 is Ala.

[0482] In some embodiments, X^9 is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0483] In some embodiments, X^9 interacts with Lys345 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^9 interacts with Trp383 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^9 interacts with Lys345 and Trp383 of beta-catenin or amino acid residues corresponding thereto.

[0484] Various types of amino acid residues can be used for X^{10}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{10} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{10} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{10} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is −H. In some embodiments, R^{a3} is −H.

[0485] In some embodiments, X^{10} is Lys, GlnR, TriAzLys, sAla, dLys, AsnR, hGlnR, iPrLys, TriAzOrn, DGlnR, Orn, 4PipA, sCH2S, [8FBB]Cys, [mXyl]Cys, [oXyl]Cys, [pXyl]Cys, dOrn, dDab, NMeOrn, [2_6-naph]Cys, or [3_3-biph]Cys. In some embodiments, X^{10} is Lys, GlnR, or TriAzLys. In some embodiments, X^{10} is Lys. In some embodiments, X^{10} is Gln. In some embodiments, X^{10} is TriAzLys. In some embodiments, X^{10} is sAla. In some embodiments, X^{10} is dLys. In some embodiments, X^{10} isAsnR. In some embodiments, X^{10} is hGlnR. In some embodiments, X^{10} is iPrLys. In some embodiments, X^{10} is TriAzOrn. In some embodiments, X^{10} is DGlnR. In some embodiments, X^{10} is Orn. In some embodiments, X^{10} is 4PipA. In some embodiments, X^{10} is sCH2S. In some embodiments, X^{10} is [8FBB]Cys. In some embodiments, X^{10} is [4FB]Cys. In some embodiments, X^{10} is [mXyl]Cys. In some embodiments, X^{10} is [oXyl]Cys. In some embodiments, X^{10} is [pXyl]Cys. In some embodiments, X^{10} is dOrn. In some embodiments, X^{10} is dDab. In some embodiments, X^{10} is NMeOrn. In some embodiments, X^{10} is [2_6-naph]Cys. In some embodiments, X^{10} is [3_3-biph]Cys.

[0486] In some embodiments, X^{10} is not stapled (e.g., when other residues are optionally stapled). In some embodiments, X^{10} is a residue of Leu or Phe. In some embodiments, X^{10} is a residue of Leu. In some embodiments, X^{10} is a residue of Phe.

[0487] In some embodiments, X^{10} is an amino acid residue suitable for stapling as described herein.

[0488] In some embodiments, an amino acid residue suitable for stapling is $-N(R^{a1})-L^{a1}-C(-L^{a}-R^{SP1})(R^{a3})-L^{a2}-C(O)-$ wherein each variable is independently as described herein. In some embodiments, it is $-N(R^{a1})-C(-L^{a}-R^{SP1})(R^{a3})-C(O)-$ wherein each variable is independently as described herein. In some embodiments, in a pair of amino acid residues suitable for stapling, each amino acid residue is independently $-N(R^{a1})-L^{a1}-C(-L^{a}-R^{SP1})(R^{a3})-L^{a2}-C(O)-$ or $-N(R^{a1})-C(-L^{a}-R^{SP1})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is −H. In some embodiments, R^{a3} is −H. In some embodiments, both R^{a1} and R^{a3} are −H.



[0489] In some embodiments, R^{SP1} of a one amino acid residue in a pair is −NHR wherein R is as described herein. In some embodiments, R is −H. In some embodiments, R is optionally substituted C_{1-6} aliphatic. In some embodiments, R is optionally substituted C_{1-6} alkyl. In some embodiments, R is C_{1-6} aliphatic. In some embodiments, R is C_{1-6} alkyl. In some embodiments, R^{SP1} is $-NH_2$. In some embodiments, such an amino acid residue can be stapled with another amino acid residue comprising −COOH through amidation to form a staple comprising −C(O)N(R')−, e.g., L^{s} wherein L^{s2} is or comprising −C(O)N(R')−. In some embodiments, L^{s2} is −C(O)N(R')− wherein R' is as described herein. In some embodiments, R' is R as described herein. In some embodiments, R is −H. In some embodiments, R is optionally substituted C_{1-6} aliphatic. In some embodiments, R is optionally substituted C_{1-6} alkyl. In some embodiments, R is methyl. In some embodiments, R is ethyl. In some embodiments, R is isopropyl. In some embodiments, −N(R')− is from an amino acid residue which before stapling comprises an amino group. In some embodiments, −C(O)− is from an amino acid residue which before stapling comprises −COOH or an activated form thereof. In some embodiments, in the other amino acid residue of a pair R^{SP1} is −COOH or an active derivative thereof. In some embodiments, in the other amino acid residue of a pair R^{SP1} is −COOH. In some embodiments, R' is R. In some embodiments, R' is −H. In some embodiments, L^{s1} is L^{a} of a first amino acid residue, e.g., X^{10}. In some embodiments, L^{s3} is L^{a} of a second amino acid residue, e.g., a C-direction amino acid residue of a first amino acid residue. In some embodiments, a first amino acid residue is X^{10}, and a second amino acid residue is a C-direction amino acid residue of X^{10}, e.g., X^{14}. In some embodiments, each of L^{s1} and L^{s3} is independently L. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or

branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, each of L^{s1} and L^{s3} is independently L, wherein L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, each of L^{s1} and L^{s3} is independently L, wherein L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L^s $-(CH_2)n1-C(O)N(R')-L^{s3}-$ wherein each variable is independently as described herein. In some embodiments, L^s $-L^{s1}-C(O)N(R')-(CH_2)n2-$ wherein each variable is independently as described herein. In some embodiments, L^s $-(CH_2)n1-C(O)N(R')-(CH_2)n2-$ wherein each variable is independently as described herein. In some embodiments, each of n1 and n2 is independently 1-10. In some embodiments, a first amino acid residue has R^{SP1} which is an amino group, and a second amino acid residue has R^{SP1} which is $-COOH$ or an activated form thereof. In some embodiments, a second amino acid residue has R^{SP1} which is an amino group, and a first amino acid residue has R^{SP1} which is $-COOH$ or an activated form thereof.

[0490] In some embodiments, a first amino acid residue is X^{10} and a second amino acid residue is one of its C-direction amino acid residue, e.g., X^{14}. In some embodiments, a second amino acid residue is X^{10} and a first amino acid residue is one of its N-direction amino acid residue, e.g., X^7.

[0491] In some embodiments, a first amino acid residue is X^{10}. In some embodiments, X^{10} is Lys. In some embodiments, X^{10} is dLys. In some embodiments, X^{10} is iPrLys. In some embodiments, X^{10} is NMeOrn. In some embodiments, R' of $-N(R')-$ of L^{s2} is optionally substituted C_{1-6} alkyl. In some embodiments, it is methyl. In some embodiments, it is isopropyl. In some embodiments, n1 is 4. In some embodiments, n1 is 3. In some embodiments, X^{10} is Orn. In some embodiments, X^{10} is dOrn. In some embodiments, n1 is 3. In some embodiments, X^{10} is dDab. In some embodiments, n1 is 2. In some embodiments, $-N(R')-$ of L^{s2} is bonded L^{s1}. In some embodiments, a second amino acid residue is X^{14}. In some embodiments, X^{14} is GlnR. In some embodiments, X^{14} is hGlnR. In some embodiments, n1 is 4 as in Lys. In some embodiments, n2 is 2 as in GlnR. In some embodiments, n2 is 3.



[0492] In some embodiments, a first amino acid residue is X^{10} which is 4PipA. In some embodiments, L^{s1} is $-(CH_2)_{n1}-C(R')_2-(CH_2)_{n3}-$, wherein each of n1 and n3 is independently n as described herein (e.g., 1-10, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), and each R' is independently as described herein. In some embodiments, one R' is $-H$. In some embodiments, n1 is 1. In some embodiments, n3 is 2. In some embodiments, $-(CH_2)n3-$ is connected to $-N(R')-$ of L^{s2}. In some embodiments, one R' of $-C(R')_2-$ of L^{s1} and R' of $-N(R')-$ of L^{s2} are taken together with their intervening atoms to form an optionally substituted as described herein. In some embodiments, a formed ring is an optionally substituted 3-10 membered saturated ring. In some embodiments, a formed ring is 3-membered. In some embodiments, it is 4-membered. In some embodiments, it is 5-membered. In some embodiments, it is 6-membered. In some embodiments, it is 7-membered. In some embodiments, it is 8-membered. In some embodiments, a formed ring has no additional




ring heteroatoms in addition to the nitrogen to which R' is attached. In some embodiments, L^s is $-L^{s1}-Cy-C(O)-L^{s3}-$ wherein each variable is independently as described herein. In some embodiments, −Cy− is optionally substituted  , wherein the nitrogen atom is bonded to −C(O)−. In some embodiments, each L^{s1} and L^{s3} is independently L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L^s $-(CH_2)n1-Cy-C(O)-(CH_2)n2-$ wherein each variable is independently as described herein. In some embodiments, −Cy− is optionally substituted  , wherein the nitrogen atom is bonded to −C(O)−. In some embodiments, n1 is 1. In some embodiments, a second amino acid residue is X^{14}. In some embodiments, X^{14} is GlnR. In some embodiments, n2 is 2.







[0493] In some embodiments, a first amino acid residue is X^7, e.g., GlnR. In some embodiments, n1 is 2. In some embodiments, a second amino acid residue is X^{10}, e.g., Lys. In some embodiments, n2 is 4. In some embodiments, a first amino acid residue is X^7, e.g., Lys. In some embodiments, n1 is 4. In some embodiments, a second amino acid residue is X^{10}, e.g., GlnR. In some embodiments, n2 is 2.



[0494] In some embodiments, a first amino acid residue is X^{10}. In some embodiments, X^{10} is GlnR. In some embodiments, X^{10} is DGlnR. In some embodiments, n1 is 2. In some embodiments, X^{10} is AsnR. In some embodiments, n1 is 1. In some embodiments, −C(O)− of L^{s2} is bonded to L^{s1}. In some embodiments, a first amino acid residue is X^{10}, e.g., hGlnR. In some embodiments, n1 is 3. In some embodiments, a second amino acid residue is X^{14}, e.g., iPrLys. In some embodiments, R' of −N(R')− of L^{s2} is optionally substituted C_{1-6} alkyl. In some embodiments, it is isopropyl. In some embodiments, n2 is 4. In some embodiments, a second amino acid residue is X^{14}, e.g., Lys. In some embodiments, a second amino acid residue is X^{14}, e.g., Orn. In some embodiments, n2 is 3.






[0495] In some embodiments, a second amino acid residue is X^{14} which is 4PipA. In some embodiments, L^{s3} is $-(CH_2)_{n2}-C(R')_2-(CH_2)_{n3}-$, wherein each of n2 and n3 is independently n as described herein (e.g., 1-10, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), and each R' is independently as described herein. In some embodiments, one R' is −H. In some embodiments, n2 is 1. In some embodiments, n3 is 2. In some

embodiments, −(CH2)n3− is connected to −N(R')− of L^{s2}. In some embodiments, one R' of −C(R')2− of L^{s3} and R' of −N(R')− of L^{s2} are taken together with their intervening atoms to form an optionally substituted as described herein. In some embodiments, a formed ring is an optionally substituted 3-10 membered saturated ring. In some embodiments, a formed ring is 3-membered. In some embodiments, it is 4-membered. In some embodiments, it is 5-membered. In some embodiments, it is 6-membered. In some embodiments, it is 7-membered. In some embodiments, it is 8-membered. In some embodiments, a formed ring has no additional ring heteroatoms in addition to the nitrogen to which R' is attached. In some embodiments, L^s is $-L^{s1}-C(O)-Cy-L^{s3}-$ wherein each variable is independently as described herein. In some embodiments, −Cy− is optionally substituted  , wherein the nitrogen atom is bonded to −C(O)−. In some embodiments, each L^{s1} and L^{s3} is independently L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted −(CH2)n−, wherein n is 1-10. In some embodiments, L is −(CH2)n−, wherein n is 1-10. In some embodiments, L is −CH2−. In some embodiments, L is −(CH2)2−. In some embodiments, L is −(CH2)3−. In some embodiments, L is −(CH2)4−. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(R')2−, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(R')2−, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L^s −(CH2)n1−C(O)−Cy−(CH2)n2− wherein each variable is independently as described herein. In some embodiments, −Cy− is optionally substituted  , wherein the nitrogen atom is bonded to −C(O)−. In some embodiments, n1 is 2. In some embodiments, n2 is 1.




[0496] In some embodiments, a second amino acid residue is  (e.g., X^{14}). In some embodiments, L^{s3} is $-(CH_2)_2-C(O)NH-(CH_2)_4-$. In some embodiments, a second amino acid residue is  (e.g., X^{14}). In some embodiments, L^{s3} is $-(CH_2)_2-C(O)-Cy-$. In some embodiments, −Cy− is optionally substituted  wherein the nitrogen is bonded to −C(O)−. In some embodiments, L^{s3} is $-(CH_2)_2-C(O)-N(R')-(CH_2)n-CHR'-$, wherein the two R' are taken together



with their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is optionally substituted  . In some embodiments, a second amino acid residue is  (e.g., X^{14}). In some embodiments, L^{s3} is $-(CH_2)_2-C(O)-N(R')-(CH_2)n-Cy-$. In some embodiments, R' is R as described herein. In some embodiments, R is −H. In some embodiments, R optionally substituted C_{1-6} aliphatic. In some embodiments, R optionally substituted C_{1-6} alkyl. In some embodiments, R is methyl. In some embodiments, n is 1. In some embodiments, −Cy− is optionally substituted  wherein the nitrogen is bonded to L^{s2} which is or comprises −C(O)−. In some embodiments, L^{s3} is $-(CH_2)_2-C(O)-N(R')-CH_2-CHR'-(CH_2)n-$. In some embodiments, n is 2. In some embodiments, $-(CH_2)n-$ is bonded to −N(R')− of L^{s2} which is −C(O)−N(R')−. In some embodiments, R' of −CHR'− of L^{s3} is taken together with R' of −N(R')− of L^{s2} and their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is optionally substituted  . In some embodiments, a second amino acid residue is  (e.g., X^{14}). In some embodiments, a second amino acid residue is  (e.g., X^{14}). In some embodiments, L^{s3} is $-(CH_2)_2-C(O)-N(R')-(CH_2)_{n1}-C(R')_2-(CH_2)_{n2}-$. In some embodiments, each of n1 and n2 is independently 1-10. In some embodiments, n1 is 1. In some embodiments, n1 is 2. In some embodiments, n2 is 2. In some embodiments, R' of −N(R')− and one R' of $-C(R')_2-$ are taken together with their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is an optionally substituted 6-membered monocyclic saturated ring having no heteroatoms in addition to the nitrogen atom of −N(R')−. In some embodiments, L^{s2} is −C(O)N(R')−. In some embodiments, −N(R')− is bonded to $-(CH_2)_{n2}-$. In some embodiments, one R' of $-C(R')_2-$ of L^{s3} is taken together with R' of −N(R')− of L^{s2} and their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is an optionally substituted 6-membered monocyclic saturated ring having no heteroatoms in addition to the nitrogen atom of −N(R')−.

[0497] In some embodiments, a first amino acid residue is  (e.g., X^{10}). In some embodiments, L^{s1} is $-(CH_2)_2-C(O)-N(R')-(CH_2)n-CHR'-$, wherein the two R' are taken together with their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is optionally substituted  . In some embodiments, a second amino acid residue is GlnR (e.g., X^{14}). In some embodiments, L^{s3} is $-(CH_2)_2-$.

[0498] In some embodiments, a first amino acid residue is  (e.g., X^{10}). In some embodiments, L^{s1} is $-(CH_2)_2-C(O)-N(R')-(CH_2)n-Cy-$. In some embodiments, R' is R as described herein. In some embodiments, R is −H. In some embodiments, R optionally substituted C_{1-6} aliphatic. In some embodiments, R optionally substituted C_{1-6} alkyl. In some embodiments, R is methyl. In some embodiments, n is 1. In some embodiments, −Cy− is optionally substituted  wherein the nitrogen is bonded to L^{s2} which is or comprises −C(O)−. In some embodiments, L^{s1} is $-(CH_2)_2-C(O)-N(R')-CH_2-CHR'-(CH_2)n-$. In some embodiments, n is 2. In some embodiments, $-(CH_2)n-$ is bonded to $-N(R')-$ of L^{s2} which is $-C(O)-N(R')-$. In some embodiments, R' of $-CHR'-$ of L^{s1} is taken together with R' of $-N(R')-$ of L^{s2} and their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is optionally substituted  . In some embodiments, a first amino acid residue is  (e.g., X^{10}). In some embodiments, a first amino acid residue is  (e.g., X^{10}). In some embodiments, L^{s1} is $-(CH_2)_2-C(O)-N(R')-(CH_2)_{n1}-C(R')_2-(CH_2)_{n2}-$. In some embodiments, each of n1 and n2 is independently 1-10. In some embodiments, n1 is 1. In some embodiments, n1 is 2. In some embodiments, n2 is 2. In some embodiments, R' of $-N(R')-$ and one R' of $-C(R')_2-$ are taken together with their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is an optionally substituted 6-membered monocyclic saturated ring having no heteroatoms in addition to the nitrogen atom of

−N(R')−. In some embodiments, L^{s2} is −C(O)N(R')−. In some embodiments, −N(R')− is bonded to $-(CH_2)_{n2}-$. In some embodiments, one R' of $-C(R')_2-$ of L^{s1} is taken together with R' of −N(R')− of L^{s2} and their intervening atoms to form an optionally substituted ring as described herein. In some embodiments, a formed ring is an optionally substituted 6-membered monocyclic saturated ring having no heteroatoms in addition to the nitrogen atom of −N(R')−. In some embodiments, a second amino acid residue is GlnR (e.g., X^{14}).

[0499] In some embodiments, a first residue is  (e.g., X^{10}). In some embodiments, a first residue is  (e.g., X^{10}). In some embodiments, a first residue is  (e.g., X^{10}). In some embodiments, L^{s1} is $-(CH_2)n-N(R')-C(O)-Cy-Cy-$, wherein each variable is independently as described herein. In some embodiments, L^{s1} is $-(CH_2)n-N(R')-C(O)-Cy-$, wherein each variable is independently as described herein.

In some embodiments, a first residue is  (e.g., X^{10}). In some embodiments, L^{s1} is $-(CH_2)n-N(R')-C(O)-CH_2-$, wherein R is as described herein, and the $-CH_2-$ bonded to C(O)− is optionally substituted. In some embodiments, L^{s1} is $-(CH_2)n-N(R')-C(O)-C(R')_2-$, wherein each R is independently as described herein. In some embodiments, L^{s1} is $-(CH_2)n-N(R')-C(O)-C(CH_3)_2-$, wherein R is as described herein. In some embodiments, a first residue is  (e.g., X^{10}). In some embodiments, L^{s1} is $-(CH_2)_{n1}-N(R')-C(O)-(CH_2)_{n2}-$, wherein each variable is independently as described herein. In some embodiments, each of n1 and n2 is independently n as described herein. In some embodiments, L^{s1} is $-(CH_2)_4-N(R')-C(O)-(CH_2)_2-$, wherein each R is independently as described herein. In some embodiments, n is 1-10. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, R' is R as described herein. In some embodiments, R is −H. In some embodiments, −Cy− is optionally substituted phenylene. In some





embodiments, −Cy− is optionally substituted 1,2-phenylene. In some embodiments, −Cy− is optionally substituted 1,3-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,2-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,3-phenylene. In some embodiments, L^{s2} is or comprises −C(O)−N(R')− as described herein. In some embodiments, R' is R as described herein. In some embodiments, R is −H. In some embodiments, L^{s2} is −C(O)NH−. In some embodiments, −C(O)− is bonded to −Cy− of L^{s1}. In some embodiments, a second residue is X^{14}, e.g., Lys. In some embodiments, L^{s3} is as described herein, e.g., optionally substituted $-(CH_2)n-$. In some embodiments, L^{s3} is $-(CH_2)n-$. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4 (e.g., as in Lys).

[0500] In some embodiments, R^{SP1} of a one amino acid residue in a pair is a first reaction group of a cycloaddition reaction. In some embodiments, such an amino acid residue can be stapled with another amino acid residue comprising a second reactive group of a cycloaddition reaction through a cycloaddition reaction. In some embodiments, in the other amino acid residue of a pair R^{SP1} is a second reactive group of a cycloaddition reaction. In some embodiments, a cycloaddition reaction is [3+2]. In some embodiments, a cycloaddition reaction is a click chemistry reaction. In some embodiments, a cycloaddition reaction is [4+2]. In some embodiments, one of the first and the second reactive groups is or comprises $-N_3$, and the other is or comprises an alkyne (e.g., a terminal alkyne or activated/strained alkyne).

[0501] In some embodiments, R^{SP1} of a first amino acid residue is $-N_3$. In some embodiments, L^a of a first amino acid residue is L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, −C(O)−, −N(R')−, −Cy− or −O−.

[0502] In some embodiments, R^{SP1} of a second amino acid residue is or comprises −C≡C−. In some embodiments, R^{SP1} of a second amino acid residue is −≡−H. In some embodiments, R^{SP1} of a second amino acid residue comprises a strained alkyne, e.g., in a ring. In some embodiments, L^a of a first amino acid residue is L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally

substituted −(CH2)n−, wherein n is 1-10. In some embodiments, L is −(CH2)n−, wherein n is 1-10. In some embodiments, L is −CH2−. In some embodiments, L is −(CH2)2−. In some embodiments, L is −(CH2)3−. In some embodiments, L is −(CH2)4−. In some embodiments, L is an optionally substituted bivalent linear or branched C1-10 hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(R')2−, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear C1-10 hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(R')2−, −C(O)−, −N(R')−, −Cy− or −O−.

[0503] In some embodiments, L^s is $-L^{s1}-L^{s2}-L^{s3}-$, wherein L^{s2} is or comprises −Cy−. In some embodiments, L^{s2} is −Cy−. In some embodiments, −Cy− is formed by a cycloaddition reaction. In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is  . In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is  . In some embodiments, L^{s1} is L^a of a first amino acid residue, and L^{s3} is L^a of a second amino acid residue. In some embodiments, L^{s1} is L^a of a second amino acid residue, and L^{s3} is L^a of a first amino acid residue. In some embodiments, each of L^{s1} and L^{s3} is independently L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C1-10 hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C1-10 hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C1-10 hydrocarbon chain. In some embodiments, L is a bivalent linear C1-10 hydrocarbon chain. In some embodiments, L is optionally substituted −(CH2)n−, wherein n is 1-10. In some embodiments, L is −(CH2)n−, wherein n is 1-10. In some embodiments, L is −CH2−. In some embodiments, L is −(CH2)2−. In some embodiments, L is −(CH2)3−. In some embodiments, L is −(CH2)4−. In some embodiments, L is an optionally substituted bivalent linear or branched C1-10 hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(R')2−, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear C1-10 hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(R')2−, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L^{s1} is optionally substituted $-(CH_2)_n-$, wherein n is 1-10. In some embodiments, L^{s1} is $-(CH_2)_n-$, wherein n is 1-10. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, L^{s3} is optionally substituted $-(CH_2)_n-$, wherein n is 1-10. In some embodiments, L^{s3} is $-(CH_2)_n-$, wherein n is 1-10. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4.


[0504] In some embodiments, a first amino acid residue is X^{10}. In some embodiments, R^{SP1} of X^{10} is −N3. In some embodiments, L^a of X^{10} is optionally substituted −(CH2)n− wherein n is 1-10. In some embodiments, L^a of X^{10} is $-(CH_2)_4-$. In some embodiments, L^a of X^{10} is $-(CH_2)_3-$. In some embodiments,

L^a of X^{10} is $-(CH_2)_2-$. In some embodiments, L^a of X^{10} is $-CH_2-$. In some embodiments, a second amino acid residue is X^{14}. In some embodiments, R^{SP1} of X^{14} is or comprises an alkyne, e.g., a strained/activated alkyne. In some embodiments, R^{SP1} of X^{14} is $-C\equiv CH$. In some embodiments, L^a of X^{14} is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, L^a of X^{14} is $-(CH_2)_4-$. In some embodiments, L^a of X^{14} is $-(CH_2)_3-$. In some embodiments, L^a of X^{14} is $-(CH_2)_2-$. In some embodiments, L^a of X^{14} is $-CH_2-$. In some embodiments, a methylene unit is replaced with $-O-$. In some embodiments, L^a of X^{14} is $-CH_2-O-CH_2-$. In some embodiments, L^{s3} is L^a of X^{14}. In some embodiments, L^{s3} is bonded to a carbon atom of L^{s2}.

[0505] In some embodiments, a first amino acid residue is X^{10}. In some embodiments, R^{SP1} of X^{10} is or comprises an alkyne, e.g., a strained/activated alkyne. In some embodiments, R^{SP1} of X^{10} is $-C\equiv CH$. In some embodiments, L^a of X^{10} is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, L^a of X^{10} is $-(CH_2)_4-$. In some embodiments, L^a of X^{10} is $-(CH_2)_3-$. In some embodiments, L^a of X^{10} is $-(CH_2)_2-$. In some embodiments, L^a of X^{10} is $-CH_2-$. In some embodiments, a methylene unit is replaced with $-O-$. In some embodiments, L^a of X^{10} is $-CH_2-O-CH_2-$. In some embodiments, L^{s1} is L^a of X^{10}. In some embodiments, L^{s1} is bonded to a carbon atom of L^{s2}.In some embodiments, a second amino acid residue is X^{14}. In some embodiments, R^{SP1} of X^{14} is $-N_3$. In some embodiments, L^a of X^{14} is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, L^a of X^{14} is $-(CH_2)_4-$. In some embodiments, L^a of X^{14} is $-(CH_2)_3-$. In some embodiments, L^a of X^{14} is $-(CH_2)_2-$. In some embodiments, L^a of X^{14} is $-CH_2-$.

[0506] In some embodiments, R^{SP1} is a nucleophile. In some embodiments, R^{SP1} is $-SH$, e.g., as in Cys. In some embodiments, L^{s2} is L" as described herein. In some embodiments, L^{s2} is $-S-CH_2-L"-CH_2-S-$ wherein L" is as described herein. In some embodiments, a staple has the structure of $-L^{s1}-S-CH_2-L"-CH_2-S-L^{s3}-$, wherein each variable is independently as described herein, and each $-CH_2-$ is optionally substituted. In some embodiments, L^{s2} is $-S-C(R')_2-L"-C(R')_2-S-$, wherein each variable is independently as described herein. In some embodiments, a staple has the structure of $-L^{s1}-S-C(R')_2-L"-C(R')_2-S-L^{s3}-$, wherein each variable is independently as described herein. In some embodiments, each R' is independently R as described herein. In some embodiments, each R' is $-H$. In some embodiments, L^{s2} is $-S-Cy-S-$ wherein $-Cy-$ is as described herein. In some embodiments, a staple has the structure of $-L^{s1}-S-Cy-S-L^{s3}-$, wherein each variable is independently as described herein. In some embodiments, L^{s2} is $-S-Cy-Cy-S-$ wherein $-Cy-$ is as described herein. In some embodiments, a staple has the structure of $-L^{s1}-S-Cy-Cy-S-L^{s3}-$, wherein each variable is independently as described herein. In some embodiments, L^{s1} is L^a of a first amino acid residue. In some embodiments, L^{s3} is L^a of a second amino acid residue. In some embodiments, each of L^{s1} and L^{s3} is L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is

−(CH_2)n−, wherein n is 1-10. In some embodiments, L is −CH_2−. In some embodiments, L is −$(CH_2)_2$−. In some embodiments, L is −$(CH_2)_3$−. In some embodiments, L is −$(CH_2)_4$−. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(R')$_2$−, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with −C(R')$_2$−, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, each of a pair of amino acid residues is Cys. In some embodiments, L^{s1} is −CH_2−. In some embodiments, L^{s3} is −CH_2−. In some embodiments, L" is −Cy− as described herein. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is phenylene. In some embodiments, −Cy− is optionally substituted 1,2-phenylene. In some embodiments, −Cy− is 1,2-phenylene. In some embodiments, −Cy− is optionally substituted 1,3-phenylene. In some embodiments, −Cy− is 1,3-phenylene. In some embodiments, −Cy− is optionally substituted 1,4-phenylene. In some embodiments, −Cy− is tetrafluoro-1,4-phenylene. In some embodiments, −Cy− is 1,4-phenylene. In some embodiments, −Cy− is optionally substituted naphthylene. In some embodiments, −Cy− is optionally substituted



. In some embodiments, L" is −Cy−Cy−, wherein each −Cy− is independently as described herein. In some embodiments, each −Cy− is independently optionally substituted phenylene. In some embodiments, each −Cy− is independently phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,2-phenylene. In some embodiments, each −Cy− is independently 1,2-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,3-phenylene. In some embodiments, each −Cy− is independently 1,3-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,4-phenylene. In some embodiments, each −Cy− is independently 1,4-phenylene. In some embodiments, each −Cy− is independently tetrafluoro-1,4-phenylene.

[0507] As appreciated by those skilled in the art, such staples may be formed by linking Cys residues with a linking reagent having the structure of R^x–L^{s2}–R^x, wherein each variable is independently as described herein. In some embodiments, each R^x is −Br.


[0508] In some embodiments, R^{SP1} of two amino acid residues of a pair of amino acid residues suitable for stapling can each independently react with a linking reagent to form a staple. In some embodiments, a suitable linking reagent comprises two reactive groups, each can independently react with R^{SP1} of each amino acid residue. In some embodiments, a linking reagent has the structure of H−L"−H or a salt thereof, wherein the reagent comprises two amino groups, and L" is a covalent bond, or an optionally substituted, bivalent C_1-C_{20} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −$S(O)_2$−, −$S(O)_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, such a linking agent can react with two amino acid residues each




independently having a R^{SP1} group that is −COOH or an activated form thereof.


[0509] Suitable embodiments for L" including those described for L herein that fall within the scope of L". For example, in some embodiments, L" is L wherein L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, −C(O)−, −N(R')−, −Cy− or −O−. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, −C(O)−, −N(R')−, −Cy− or −O−.


[0510] In some embodiments, a linking reagent is a diamine or a salt thereof. In some embodiments, a reagent has the structure of NHR−L"−NHR or a salt thereof, wherein each variable is independently as described herein. In some embodiments, each R is independently −H or optionally substituted C_{1-6} aliphatic. In some embodiments, each R is independently −H or C_{1-6} aliphatic. In some embodiments, each R is independently −H or optionally substituted C_{1-6} alkyl. In some embodiments, each R is independently −H or C_{1-6} alkyl. In some embodiments, a reagent has the structure of $NH_2-L"-NH_2$ or a salt thereof. In some embodiments, L" is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, L" is $-(CH_2)_4-$.


[0511] In some embodiments, a staple, L^s, is $-L^{s1}-L^{s2}-L^{s3}-$, wherein L^{s1} is L^a of a first amino acid residue of a stapled pair, L^{s3} is L^a of a second amino acid residue of a stapled pair, and L^{s2} is −C(O)−N(R')−L"−N(R')−C(O)−, wherein each variable is independently as described herein. In some embodiments, L" is optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, L" is $-(CH_2)_4-$. In some embodiments, each of L^{s1} and L^{s3} is independently optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, n is 2. In some embodiments, a first amino acid residue is Gln (e.g., X^{10}). In some embodiments, a second amino acid residue is GlnR (e.g., X^{14}). In some embodiments, two GlnR can form such a staple through [diaminobutane].

[0512] In some embodiments, a linking reagent has the structure of H−Cy−L"−NHR or a salt thereof, wherein −Cy− comprises a second amino group. In some embodiments, R is −H or optionally substituted C_{1-6} aliphatic. In some embodiments, R is −H or C_{1-6} aliphatic. In some embodiments, R is −H or optionally substituted C_{1-6} alkyl. In some embodiments, R is −H or C_{1-6} alkyl. In some embodiments, R is methyl. In some embodiments, a linking reagent has the structure of $H-Cy-L"-NH_2$ or a salt thereof, wherein −Cy− comprises a second amino group. In some embodiments, −Cy− is optionally substituted  . In

some embodiments, −Cy− is  . In some embodiments, L" is a covalent bond. In some embodiments, L" is optionally substituted −(CH_2)n− wherein n is 1-10. In some embodiments, L" is −(CH_2)−. In some embodiments, a linking reagent is  or a salt thereof. In some embodiments, a linking reagent is  or a salt thereof.

[0513] In some embodiments, L^{s2} is −C(O)−Cy−N(R')−C(O)−, wherein each variable is independently as described herein. In some embodiments, R' is −H. In some embodiments, −Cy− is  . In some embodiments, each of L^{s1} and L^{s3} is independently optionally substituted −(CH_2)n− wherein n is 1-10. In some embodiments, n is 2. In some embodiments, −Cy− is closer to a N-terminus than −N(R')−. In some embodiments, −Cy− is closer to a C-terminus than −N(R')−. In some embodiments, a first amino acid residue is Gln (e.g., X^{10}). In some embodiments, a second amino acid residue is GlnR (e.g., X^{14}). In some embodiments, two GlnR can form such a staple through [4aminopiperidine].






[0514] In some embodiments, L^{s2} is −C(O)−Cy−(CH_2)n−N(R')−C(O)−, wherein each variable is independently as described herein. In some embodiments, R' is −H. In some embodiments, R' is R as described herein, e.g., optionally substituted C_{1-6} aliphatic, C_{1-6} alkyl, etc. In some embodiments, R is methyl. In some embodiments, n is 1. In some embodiments, −Cy− is  . In some embodiments, −Cy− is closer to a N-terminus than −N(R')−. In some embodiments, −Cy− is closer to a C-terminus than −N(R')−. In some embodiments, each of L^{s1} and L^{s3} is independently optionally substituted −(CH_2)n− wherein n is 1-10. In some embodiments, n is 2. In some embodiments, a first amino acid residue is Gln (e.g., X^{10}). In some embodiments, a second amino acid residue is GlnR (e.g., X^{14}). In some embodiments, two GlnR can form such a staple through [4mampiperidine].

[0515] In some embodiments, a methylene unit is replaced with −Cy−. In some embodiments, a linking reagent has the structure of H−Cy−H, wherein Cy comprises two secondary amino groups. In some embodiments, −Cy− is optionally substituted 8-20 membered bicyclic ring. In some embodiments, H−Cy−H comprises two −NH−. In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is optionally substituted  . In some embodiments, the meta connection site (relative to the spiro carbon atom) is closer to a N-terminus than the para connection site (relative to the spiro carbon atom). In some embodiments, the meta connection site (relative to the spiro carbon atom) is

closer to a C-terminus than the para connection site (relative to the spiro carbon atom).

[0516] In some embodiments, L^{s2} is −C(O)−Cy−C(O)− wherein −Cy− is as described herein. In some embodiments, each of L^{s1} and L^{s3} is independently optionally substituted −(CH_2)n− wherein n is 1-10. In some embodiments, n is 2. In some embodiments, a first amino acid residue is Gln (e.g., X^{10}). In some embodiments, a second amino acid residue is GlnR (e.g., X^{14}). In some embodiments, two GlnR can form such a staple through [29N2spiroundecane]. In some embodiments, two GlnR can form such a staple through [39N2spiroundecane].

[0517] In some embodiments, a pair of amino acid residue suitable for stapling both independently has the structure of $-N(R^{a1})-L^{a1}-C(-L^{a}-R^{SP1})(R^{a3})-L^{a2}-C(O)-$ or $-N(R^{a1})-C(-L^{a}-R^{SP1})(R^{a3})-C(O)-$, wherein each variable is independently as described herein, and R^{SP1} is an amino group. In some embodiments, R^{SP1} is −NHR wherein R is as described herein. In some embodiments, R is −H. In some embodiments, R is optionally substituted C_{1-6} aliphatic. In some embodiments, R is optionally substituted C_{1-6} alkyl. In some embodiments, R is C_{1-6} aliphatic. In some embodiments, R is C_{1-6} alkyl. In some embodiments, R^{SP1} is $-NH_2$. In some embodiments, such two amino acid residue may be linked by a di-acid linking reagent.

[0518] In some embodiments, a linking reagent has the structure of HOOC−L"−COOH, or a salt thereof, or an activated form thereof, wherein L" is as described herein. In some embodiments, L" is −Cy−Cy−. In some embodiments, L" is −Cy−. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is optionally substituted 1,2-phenylene. In some embodiments, −Cy− is optionally substituted 1,3-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,2-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,3-phenylene. In some embodiments, L" is optionally substituted  . In some embodiments, a linking agent is  or a salt or an activated form thereof. In some embodiments, L" is optionally substituted  . In some embodiments, a linking agent is  or a salt or an activated form thereof. In some embodiments, L" is 1,3-phenylene. In some embodiments, a linking agent is  or a salt or an activated form thereof. In some embodiments, L" is optionally substituted −(CH_2)n−, wherein n is 1-10. In some embodiments, L" is optionally substituted $-CH_2-$. In some embodiments, L" is $-C(R')_2-$. In some embodiments, L" is $-C(CH_3)_2-$. In some embodiments, a linking agent is $(CH_3)_2C(COOH)_2$ or a salt or an activated form thereof. In some embodiments, L" is $-CH_2CH_2-$. In

some embodiments, a linking agent is $HOOCCH_2CH_2COOH$ or a salt or an activated form thereof.

[0519] In some embodiments, a staple is L^s, wherein L^{s2} is $-N(R')-L''-N(R')-$, and each of L^{s1} and L^{s3} is independently as described herein. In some embodiments, L" is −Cy−Cy−, wherein each −Cy− is independently as described herein. In some embodiments, L" is −Cy− as described herein. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is optionally substituted 1,2-phenylene. In some embodiments, −Cy− is optionally substituted 1,3-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,2-phenylene. In some embodiments, each −Cy− is independently optionally substituted 1,3-phenylene. In some embodiments, L" is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L" is optionally substituted $-CH_2-$. In some embodiments, L" is $-C(R')_2-$. In some embodiments, L" is $-C(CH_3)_2-$. In some embodiments, L" is $-CH_2CH_2-$. In some embodiments, each of L^{s1} and L^{s3} is independently optionally substituted $-(CH_2)n-$ wherein n is 1-10. In some embodiments, n is 2. In some embodiments, n is 4. In some embodiments, a first amino acid residue is Lys (e.g., X^{10}). In some embodiments, a second amino acid residue is Lys (e.g., X^{14}). In some embodiments, two Lys can form such a staple through [Biphen33COOH]. In some embodiments, two Lys can form such a staple through [diphenate]. In some embodiments, two Lys can form such a staple through [isophthalate]. In some embodiments, two Lys can form such a staple through [Me2Mal]. In some embodiments, two Lys can form such a staple through [succinate].

[0520] In some embodiments, X^{10} is stapled. In some embodiments, X^{10} is stapled with X^{14}. In some embodiments, X^{10} is stapled with X^7.

[0521] In some embodiments, X^{10} is Lys, Phe, TriAzLys, GlnR, Leu, PyrS2, Aib, Ala, sAla, AsnR, hGlnR, dOrn, PyrS1, dLys, dDab, [mPyr]Cys, PyrS3, iPrLys, [mXyl]Cys, TriAzOrn, 1MeK, [C3]Cys, [IsoE]Cys, DGlnR, Orn, [mPyr]hCys, [Red]Cys, [C3]hCys, 4PipA, sCH2S, [8FBB]Cys, [pXyl]Cys, [pXyl]hCys, [33Oxe]Cys, [Red]hCys, [IsoE]hCys, [13Ac]hCys, [m5Meb]Cys, [m5Meb]hCys, GlnS3APyr, AsnMeEDA, AsnR3APyr, [m5Pyr]Cys, [m5OMeb]Cys, [4FB]Cys, [oXyl]Cys, NMeOrn, [2_6-naph]Cys, [3_3-biph]Cys, [mXyl]hCys, [3_3-biPh]hCys, [2_6-naph]hCys, [33Oxe]hCys, [13Ac]Cys, GlnR3APyr, AsnS3APyr, [IsoE]hCysOx, or [m5Pyr]hCys. In some embodiments, X^{10} is Lys. In some embodiments, X^{10} is Phe. In some embodiments, X^{10} is TriAxLys. In some embodiments, X^{10} is GlnR. In some embodiments, X^{10} is Leu. In some embodiments, X^{10} is PryS2. In some embodiments, X^{10} is Aib. In some embodiments, X^{10} is Ala. In some embodiments, X^{10} is Val.

[0522] In some embodiments, X^{10} is or comprises a residue of an amino acid or a moiety selected from Table A-I, Table A-II, Table A-III and Table A-IV.

[0523] Various types of amino acid residues can be used for X^{11}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{11} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{11} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{11} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each

variable is independently as described herein. In some embodiments, R^{a1} is −H. In some embodiments, R^{a3} is −H.

[0524] In some embodiments, X^{11} is a residue of an amino acid suitable for stapling as described herein. In some embodiments, an amino acid residue suitable for stapling is $-N(R^{a1})-L^{a1}-C(-L^{a}-R^{SP1})(R^{a3})-L^{a2}-C(O)-$ wherein each variable is independently as described herein. In some embodiments, it is $-N(R^{a1})-C(-L^{a}-R^{SP1})(R^{a3})-C(O)-$ wherein each variable is independently as described herein. In some embodiments, in a pair of amino acid residues suitable for stapling, each amino acid residue is independently $-N(R^{a1})-L^{a1}-C(-L^{a}-R^{SP1})(R^{a3})-L^{a2}-C(O)-$ or $-N(R^{a1})-C(-L^{a}-R^{SP1})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is −H. In some embodiments, R^{a3} is −H. In some embodiments, both R^{a1} and R^{a3} are −H. In some embodiments, R^{SP1} comprises optionally substituted −CH=CH−. In some embodiments, R^{SP1} is or comprises optionally substituted $-CH=CH_2$. In some embodiments, R^{SP1} is $-CH=CH_2$.

[0525] In some embodiments, X^{11} is a residue of an amino acid, e.g., having the structure of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc., whose side chain comprise a functional group suitable for stapling, e.g., a double bond. In some embodiments, X^{11} is a residue of an amino acid that comprises one and no more than one functional groups for stapling. In some embodiments, X^{11} is a residue of an amino acid that comprises one and no more than one double bond for stapling. As in certain embodiments of X^{1}, in some embodiments, X^{11} comprises a ring structure, and its amino group is part of a ring. In some embodiments, X^{11} is an amino acid as described herein (e.g., of formula A-I, A-II, A-III, etc.), wherein R^{a1} and R^{a3} are taken together to form an optionally substituted ring, e.g., an optionally substituted 3-10 membered ring. In some embodiments, R^{a1} and R^{a3} are taken together with their intervening atoms to form an optionally substituted 3-10 membered saturated or partially saturated ring having, in addition to the intervening atoms, 0-5 heteroatoms.

[0526] In some embodiments, R^{a2} and R^{a3} are taken together to form an optionally substituted ring, e.g., an optionally substituted 3-10 membered ring. In some embodiments, R^{a2} and R^{a3} are taken together with their intervening atoms to form an optionally substituted 3-10 membered saturated or partially saturated ring having, in addition to the intervening atoms, 0-5 heteroatoms.

[0527] As described herein, in some embodiments, a formed ring, e.g., by R^{a1} and R^{a3} taken together with their intervening atoms, by R^{a2} and R^{a3} taken together with their intervening atoms, or by any other two suitable R taken together with their intervening atoms, either in X^{11} or another moiety, is saturated. In some embodiments, a formed ring is monocyclic. In some embodiments, a formed ring has no heteroatoms in addition to the intervening atoms. In some embodiments, a formed ring has at least one heteroatom in addition to the intervening atoms. In some embodiments, a formed ring has at least one nitrogen in addition to the intervening atoms. In some embodiments, L^{a1} and L^{a2} are covalent bond. In some embodiments, a formed ring is unsubstituted. In some embodiments, a formed ring is substituted. In some embodiments, a substituent comprises a double bond which is suitable for metathesis with another double bond to form a

staple. In some embodiments, a substituent has the structure of −C(O)−O−(CH2)n−CH=CH2, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, a substituent bonds to a nitrogen ring atom (e.g., see PyrS2). In some embodiments, X^{11} is a residue of PyrS2.

[0528] In some embodiments, L^a is $-(CH_2)_{n1}-N(R')-C(O)-(CH_2)_{n2}-$, wherein each variable is independently as described herein, and each $-CH_2-$ is optionally substituted. In some embodiments, L^a is $-(CH_2)_{n1}-N(R')-C(O)-(CH_2)_{n2}-$, wherein each variable is independently as described herein. In some embodiments, $-(CH_2)_{n1}-$ is bonded to X^{11}. In some embodiments, n1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, n1 is 1. In some embodiments, n1 is 2. In some embodiments, n1 is 3. In some embodiments, n2 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, n2 is 1. In some embodiments, n2 is 2. In some embodiments, n2 is 3. In some embodiments, n2 is 4. In some embodiments, n2 is 5. In some embodiments, R' of $-N(R')-$ of L^a and R^{a3} are taken together with their intervening atoms to form an optionally substituted ring. In some embodiments, a formed ring is optionally substituted 3-10 membered monocyclic, saturated or partially unsaturated ring having, in addition to the nitrogen atom to which R' is attached, 0-3 heteroatoms. In some embodiments, a formed ring is saturated. In some embodiments, a formed ring is 3-membered. In some embodiments, a formed ring is 4-membered. In some embodiments, a formed ring is 5-membered. In some embodiments, a formed ring is 6-membered. In some embodiments, a formed ring is 7-membered. In some embodiments, a formed ring is 8-membered. In some embodiments, a formed ring has no ring heteroatoms other than the nitrogen atom to which R' is attached. In some embodiments, X^{11} is a residue of PyrS2.

[0529] In some embodiments, X^{11} is stapled. In some embodiments, X^{11} is stapled with X^4. In some embodiments, X^{11} is PyrS2 and stapled. In some embodiments, X^{11} is Lys and stapled.

[0530] In some embodiments, X^{11} is a residue of PyrS2 or Lys.

[0531] In some embodiments, X^{11} is a residue of PyrS2 and stapled.

[0532] In some embodiments, a staple, e.g., L^s, has the structure of $-L^{s1}-L^{s2}-L^{s3}$, wherein each variable is independently as described herein. In some embodiments, L^{s1} or L^{s3} is L^a of X^{11} as described herein. In some embodiments, L^{s3} is L^a of X^{11} as described herein. In some embodiments, L^{s1} is L^a of another amino acid residue, e.g., X^4. In some embodiments, L^{s1} is L as described herein. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more

methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L^{s3} is L as described herein. In some embodiments, L^{s3} is $-(CH_2)_{n1}-N(R')-C(O)-(CH_2)_{n2}-$, wherein each variable is independently as described herein, and each $-CH_2-$ is optionally substituted. In some embodiments, L^{s3} is $-(CH_2)_{n1}-N(R')-C(O)-(CH_2)_{n2}-$, wherein each variable is independently as described herein. In some embodiments, $-(CH_2)_{n1}-$ is bonded to X^{11}. In some embodiments, n1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, n1 is 1. In some embodiments, n1 is 2. In some embodiments, n1 is 3. In some embodiments, n2 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, n2 is 1. In some embodiments, n2 is 2. In some embodiments, n2 is 3. In some embodiments, n2 is 4. In some embodiments, n2 is 5. In some embodiments, R' of $-N(R')-$ of L^a and R^{a3} are taken together with their intervening atoms to form an optionally substituted ring. In some embodiments, a formed ring is optionally substituted 3-10 membered monocyclic, saturated or partially unsaturated ring having, in addition to the nitrogen atom to which R' is attached, 0-3 heteroatoms. In some embodiments, a formed ring is saturated. In some embodiments, a formed ring is 3-membered. In some embodiments, a formed ring is 4-membered. In some embodiments, a formed ring is 5-membered. In some embodiments, a formed ring is 6-membered. In some embodiments, a formed ring is 7-membered. In some embodiments, a formed ring is 8-membered. In some embodiments, a formed ring has no ring heteroatoms other than the nitrogen atom to which R' is attached.

[0533] In some embodiments, L^{s2} is optionally substituted $-CH=CH-$. In some embodiments, L^{s2} is $-CH=CH-$. In some embodiments, L^{s2} is optionally substituted $-CH_2-CH_2-$. In some embodiments, L^{s2} is $-CH_2-CH_2-$.

[0534] In some embodiments, X^{11} is PyrS2, Lys, 3Thi, Ala, Phe, SPip3, PyrSadNip3Butene, SPip2, Az3, DapAc7EDA, Leu, 3allyloxyPyrSa, PyrSaV3Butene, Az2, PyrS1, PyrSc72SMe3ROMe, PyrSc72RMe3SOMe, PyrSc7O45RMe, PyrSc7O45SMe, PyrSc73Me2, PyrSc7, PyrSaA3Butene, PyrSadA3Butene, Dap7Gly, Dap7Pent, DapAc7PDA, Dap7Abu, 4VinylPyrSa, PyrSadV3Butene, PyrSaSar3Butene, PyrSaNip3Butene, PyrSaPro3Butene, PyrSa4VinMe2PhAc, or 3allylPyrSa. In some embodiments, X^{11} is PyrS2. In some embodiments, X^{11} is Lys. In some embodiments, X^{11} is 3Thi. In some embodiments, X^{11} is Ala. In some embodiments, X^{11} is Phe. In some embodiments, X^{11} is S3MePyrSc7. In some embodiments, X^{11} is R3MePyrSc7. In some embodiments, X^{11} is S3iPrPyrSc7. In some embodiments, X^{11} is R3iPrPyrSc7.

[0535] In some embodiments, X^{11} is or comprises a residue of an amino acid or a moiety selected from Table A-I, Table A-II, Table A-III and Table A-IV.

[0536] Various types of amino acid residues can be used for X^{12}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{12} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{12} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{12} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is

−H.

[0537] In some embodiments, X^{12} comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, X^{12} is an aromatic amino acid residue as described herein. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having 1-3 heteroatoms. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having 1-3 nitrogen atoms. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having one oxygen atom. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having one sulfur atom. In some embodiments, an aromatic group is optionally substituted 6-membered heteroaryl having 1-3 heteroatoms. In some embodiments, an aromatic group is optionally substituted 6-membered heteroaryl having 1 nitrogen atom. In some embodiments, an aromatic group is optionally substituted phenyl. In some embodiments, X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each substituent of the aromatic group is independently selected from halogen, −OR, −R, −C(O)OH, −C(O)NH_2, −CN, or –NO_2, wherein each R is independently C_{1-4} alkyl or haloalkyl. In some embodiments, an aromatic group is phenyl. In some embodiments, an aromatic group is optionally substituted 8-10 membered bicyclic aryl or heteroaryl having 1-5 heteroatoms. In some embodiments, X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each substituent of the aromatic group is independently halogen. In some embodiments, X^{12} comprises a side chain which is or comprises two optionally substituted aromatic groups. In some embodiments, X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each substituent of the aromatic group is independently selected from halogen or −OH. In some embodiments, an aromatic group is phenyl. In some embodiments, an aromatic group is optionally substituted 8-10 membered bicyclic aryl or heteroaryl having 0-5 heteroatoms. In some embodiments, an aromatic group is optionally substituted 9-10 membered bicyclic aryl or heteroaryl having one heteroatom. In some embodiments, X^{12} is a residue of an amino acid of formula A-I or a salt thereof. In some embodiments, an amino acid residue has the structure of −NH−C(R^{a2})(R^{a3})−C(O)− or a salt thereof. In some embodiments, an amino acid residue has the structure of −NH−CH(R^{a3})−C)O)− or a salt thereof. As described herein, R^{a3} is $-L^a-R'$ wherein each variable is independently as described herein. In some embodiments, R' is R as described herein. In some embodiments, R is an optionally substituted group selected from phenyl, 10-membered bicyclic aryl, 5-6 membered heteroaryl having 1-4 heteroatoms, and 9-10 membered bicyclic heteroaryl having 1-5 heteroatoms. In some embodiments, each substituent is independently halogen or −OH or C_{1-6} haloaliphatic. In some embodiments, each substituent is independently halogen or −OH. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is phenyl. In some embodiments, R is optionally substituted aryl. In some embodiments, R is aryl. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1-4 heteroatoms. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1 heteroatom. In some embodiments, optionally substituted R is 6-membered heteroaryl having 1-4 heteroatoms. In some embodiments, optionally substituted R is 6-

membered heteroaryl having 1 heteroatom. In some embodiments, R is optionally substituted 9-membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is optionally substituted 9-membered heteroaryl having 1 heteroatom. In some embodiments, R is optionally substituted 10-membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is optionally substituted 10-membered heteroaryl having 1 heteroatom. In some embodiments, a heteroatom is nitrogen. In some embodiments, a heteroatom is oxygen. In some embodiments, a heteroatom is sulfur. As described herein, L^a is L. In some embodiments, L is a covalent bond. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$.

[0538] In some embodiments, X^{12} is a residue of an amino acid selected from 3Thi, 2F3MeF, Phe, 2COOHF, 2ClF, 2FurA, 2OMeF, 2MeF, 2BrF, 2CNF, 2NO2F, 2PyrA, 3PyrA, 4PyrA, His, 1NapA, 2Thi, and 2cmbF. In some embodiments, X^{12} is a residue of 3Thi, 2F3MeF, or Phe. In some embodiments, X^{12} is a residue of 3Thi. In some embodiments, X^{12} is a residue of 2F3MeF. In some embodiments, X^{12} is a residue of Phe. In some embodiments, X^{12} is a residue of 2COOHF. In some embodiments, X^{12} is a residue of 2ClF. In some embodiments, X^{12} is a residue of 2FurA. In some embodiments, X^{12} is a residue of 2OMeF. In some embodiments, X^{12} is a residue of 2MeF. In some embodiments, X^{12} is a residue of 2BrF. In some embodiments, X^{12} is a residue of 2CNF. In some embodiments, X^{12} is a residue of 2NO2F. In some embodiments, X^{12} is a residue of 2PyraA. In some embodiments, X^{12} is a residue of 3PyrA. In some embodiments, X^{12} is a residue of 4PyrA. In some embodiments, X^{12} is a residue of His. In some embodiments, X^{12} is a residue of 1NapA. In some embodiments, X^{12} is a residue of 2Thi. In some embodiments, X^{12} is a residue of 2cmbF. In some embodiments, 3Thi provides better properties and/or activities than, e.g., Phe.

[0539] In some embodiments, X^{12} is a residue of an amino acid whose side chain is hydrophobic. Various hydrophobic amino acid residues described herein may be utilized for X^{12}, e.g., those described for X^3, X^7, etc. In some embodiments, X^{12} is a residue of nLeu, CypA, Ala, Leu, hLeu, Npg, Cpa, Nva, Cba, ChA, Val, Ile, Chg, hnLeu, or OctG. In some embodiments, X^{12} is a residue of nLeu or CypA. In some embodiments, X^{12} is a residue of nLeu. In some embodiments, X^{12} is a residue of CypA. In some embodiments, X^{12} is a residue of Ala. In some embodiments, X^{12} is a residue of Leu. In some embodiments,

X^{12} is a residue of hLeu. In some embodiments, X^{12} is a residue of Npg. In some embodiments, X^{12} is a residue of Cpa. In some embodiments, X^{12} is a residue of Nva. In some embodiments, X^{12} is a residue of Cba. In some embodiments, X^{12} is a residue of ChA. In some embodiments, X^{12} is a residue of Val. In some embodiments, X^{12} is a residue of Ile. In some embodiments, X^{12} is a residue of Chg. In some embodiments, X^{12} is a residue of hnLeu. In some embodiments, X^{12} is a residue of OctG.

[0540] In some embodiments, X^{12} is a residue of amino acid that comprises an acidic or polar group. In some embodiments, X^{12} is a residue of amino acid whose side chain comprises an acidic group, e.g., a −COOH group or a salt form thereof (e.g., a compound of formula A-IV, etc.). Various acidic amino acid residues described herein may be utilized for X^{12}, e.g., those described for X^2, X^5, X^6, etc. In some embodiments, X^{12} is 2COOHF. In some embodiments, X^{12} is a residue of amino acid whose side chain comprises a polar group. In some embodiments, X^{12} is a residue of amino acid whose side chain comprises an amide group, e.g., $-C(O)N(R')_2$ such as $-CONH_2$. For example, in some embodiments, X^{12} is a residue of 2cbmF. Various other polar amino acid residues described herein may also be utilized for X^{12}.

[0541] In some embodiments, X^{12} is a residue of an amino acid selected from 3Thi, 2F3MeF, Phe, nLeu, 2COOHF, CypA, 2ClF, Ala, Abu, Leu, hLeu, Npg, Cpa, Nva, Cba, ChA, 2FurA, 2OMeF, 2MeF, 2BrF, 2CNF, 2NO2F, 2PyrA, 3PyrA, 4PyrA, His, 1NapA, Val, Ile, Chg, DiethA, hnLeu, OctG, 2Thi, and 2cmbF.

[0542] In some embodiments, X^{12} is 3Thi, Phe, 2F3MeF, PyrS2, 2ClF, hnLeu, BztA, 2Thi, 2MeF, 2FF, 34ClF, Lys, nLeu, 2COOHF, 2PhF, hCbA, hCypA, hCha, CypA, hPhe, DipA, HepG, Dap7Abu, hhLeu, hhSer, HexG, [2IAPAc]2NH2F, Ala, Abu, Leu, hLeu, Npg, Cpa, PyrS1, [Bnc]2NH2F, [Phc]2NH2F, [BiPh]2NH2F, [3PyAc]2NH2F, Nva, Cba, ChA, 2FurA, 2OMeF, 2BrF, 2CNF, 2NO2F, 2PyrA, 3PyrA, 4PyrA, His, 1NapA, Val, Ile, Chg, DiethA, OctG, 2cbmF, c6Phe, [MePipAc]2NH2F, or [2PyCypCO]2NH2F. In some embodiments, X^{12} is 3Thi. In some embodiments, X^{12} is Phe. In some embodiments, X^{12} is 3F3MeF. In some embodiments, X^{12} is PyrS2. In some embodiments, X^{12} is 2ClF. In some embodiments, X^{12} is hnLeu. In some embodiments, X^{12} is BztA. In some embodiments, X^{12} is 2Thi. In some embodiments, X^{12} is 2MeF. In some embodiments, X^{12} is 2FF. In some embodiments, X^{12} is 34ClF. In some embodiments, X^{12} is 2NH2F. In some embodiments, X^{12} is Trp. In some embodiments, X^{12} is 5ClW. In some embodiments, X^{12} is 6ClW. In some embodiments, X^{12} is 2NH2F. In some embodiments, X^{12} is [124TriAc]2NH2F. In some embodiments, X^{12} is [124TriPr]2NH2F. In some embodiments, X^{12} is [6QuiAc]2NH2F. In some embodiments, X^{12} is [2PyAc]2NH2F. In some embodiments, X^{12} is [2PyPrpc]2NH2F. In some embodiments, X^{12} is [3PyPrpc]2NH2F. In some embodiments, X^{12} is [4PyPrpc]2NH2F. In some embodiments, X^{12} is [MeOPr]2NH2F. In some embodiments, X^{12} is [PhOPr]2NH2F. In some embodiments, X^{12} is [Me2MeOPr]2NH2F. In some embodiments, X^{12} is [Me2NAc]2NH2F. In some embodiments, X^{12} is [Me2NPr]2NH2F. In some embodiments, X^{12} is [NdiMeButC]2NH2F. In some embodiments, X^{12} is [3IAPAc]2NH2F. In some embodiments, X^{12} is [15PyraPy]2NH2F. In some embodiments, X^{12} is [MorphAc]2NH2F. In some embodiments, X^{12} is [Nic]2NH2F. In some embodiments, X^{12} is [2PyzCO]2NH2F. In some embodiments, X^{12} is

[5pymCO]2NH2F. In some embodiments, X^{12} is [3FPyr2c]2NH2F. In some embodiments, X^{12} is [4FPyr3c]2NH2F.

[0543] In some embodiments, X^{12} is an amino acid residue for stapling as described herein. In some embodiments, X^{12} is stapled, e.g., with X^5. In some embodiments, X^{12} is PyrS1. In some embodiments, X^{12} is PyrS2.

[0544] In some embodiments, X^{12} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0545] In some embodiments, X^{12} interacts with Trp383 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^{12} interacts with Asn415 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^{12} interacts with Trp383 and Asn415 of beta-catenin or amino acid residues corresponding thereto.

[0546] Various types of amino acid residues can be used for X^{13}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{13} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{13} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{13} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0547] In some embodiments, X^{13} comprises a side chain which is or comprises an optionally substituted aromatic group. In some embodiments, X^{13} is an aromatic amino acid residue as described herein.

[0548] In some embodiments, X^{13} comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, X^{13} is an aromatic amino acid residue as described herein. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having 1-3 heteroatoms. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having 1-3 nitrogen atoms. In some embodiments, an aromatic group is optionally substituted 5-membered heteroaryl having one sulfur atom. In some embodiments, an aromatic group is optionally substituted phenyl. In some embodiments, X^{13} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each substituent of the aromatic group is independently selected from halogen, $-OR$, $-R$, $-C(O)OH$, or $-CN$, wherein each R is independently hydrogen or C_{1-4} alkyl or haloalkyl. In some embodiments, an aromatic group is phenyl. In some embodiments, an aromatic group is optionally substituted 8-10 membered bicyclic aryl or heteroaryl having 1-5 heteroatoms. In some embodiments, X^{13} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each substituent of the aromatic group is independently halogen. In some embodiments, X^{13} comprises a side chain which is or comprises two optionally substituted aromatic groups. In some embodiments, X^{13} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each substituent of the aromatic group is independently selected from halogen or $-OH$. In some embodiments, an aromatic group is phenyl. In some

embodiments, an aromatic group is optionally substituted 8-10 membered bicyclic aryl or heteroaryl having 0-5 heteroatoms. In some embodiments, an aromatic group is optionally substituted 9-10 membered bicyclic aryl or heteroaryl having one heteroatom. In some embodiments, X^{13} is a residue of an amino acid of formula A-I or a salt thereof. In some embodiments, an amino acid residue has the structure of $-NH-C(R^{a2})(R^{a3})-C(O)-$ or a salt thereof. In some embodiments, an amino acid residue has the structure of $-NH-CH(R^{a3})-C)O)-$ or a salt thereof. As described herein, R^{a3} is $-L^a-R'$ wherein each variable is independently as described herein. In some embodiments, R' is R as described herein. In some embodiments, R is an optionally substituted group selected from phenyl, 10-membered bicyclic aryl, 5-6 membered heteroaryl having 1-4 heteroatoms, and 9-10 membered bicyclic heteroaryl having 1-5 heteroatoms. In some embodiments, each substituent is independently halogen or −OH or C_{1-6} haloaliphatic. In some embodiments, each substituent is independently halogen or −OH. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is phenyl. In some embodiments, R is optionally substituted aryl. In some embodiments, R is aryl. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1-4 heteroatoms. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1 heteroatom. In some embodiments, optionally substituted R is 6-membered heteroaryl having 1-4 heteroatoms. In some embodiments, optionally substituted R is 6-membered heteroaryl having 1 heteroatom. In some embodiments, R is optionally substituted 9-membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is optionally substituted 9-membered heteroaryl having 1 heteroatom. In some embodiments, R is optionally substituted 10-membered heteroaryl having 1-5 heteroatoms. In some embodiments, R is optionally substituted 10-membered heteroaryl having 1 heteroatom. In some embodiments, a heteroatom is nitrogen. In some embodiments, a heteroatom is oxygen. In some embodiments, a heteroatom is sulfur. As described herein, L^a is L. In some embodiments, L is a covalent bond. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear or branched C_{1-10} hydrocarbon chain. In some embodiments, L is a bivalent linear C_{1-10} hydrocarbon chain. In some embodiments, L is optionally substituted $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-(CH_2)n-$, wherein n is 1-10. In some embodiments, L is $-CH_2-$. In some embodiments, L is $-(CH_2)_2-$. In some embodiments, L is $-(CH_2)_3-$. In some embodiments, L is $-(CH_2)_4-$. In some embodiments, L is an optionally substituted bivalent linear or branched C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$. In some embodiments, L is an optionally substituted bivalent linear C_{1-10} hydrocarbon chain wherein one or more methylene units of L are independently replaced with $-C(R')_2-$, $-C(O)-$, $-N(R')-$, $-Cy-$ or $-O-$.

[0549] In some embodiments, X^{13} is a residue of BztA, 34ClF, or 2NapA. In some embodiments, X^{13} is a residue of BztA. In some embodiments, X^{13} is a residue of 34ClF. In some embodiments, X^{13} is a residue of 2NapA. In some embodiments, X^{13} is a residue of 3BrF. In some embodiments, X^{13} is a residue of 3Thi. In

some embodiments, X^{13} is a residue of 34MeF.

[0550] In some embodiments, X^{13} is BztA, 34ClF, 3Thi, Phe, GlnR, 34MeF, 2NapA, Lys, PyrS2, 3BrF, 7FBztA, 2BrF, 3F3MeF, 4F3MeF, RbMe2NapA, RbMeBzta, SbMeBzta, 5IndA, 7ClBztA, 7MeBztA, Leu, 2ClF, 3ClF, 4BrF, 4ClF, or 3MeF. In some embodiments, X^{13} is BztA. In some embodiments, X^{13} is 34ClF. In some embodiments, X^{13} is 3Thi. In some embodiments, X^{13} is Phe. In some embodiments, X^{13} is GlnR. In some embodiments, X^{13} is 34MeF. In some embodiments, X^{13} is 2NapA. In some embodiments, X^{13} is Lys. In some embodiments, BztA provides better properties and/or activities than, e.g., Trp.

[0551] In some embodiments, X^{13} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0552] In some embodiments, X^{13} interacts with Gln379 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^{13} interacts with Leu382 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^{13} interacts with Val416 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^{13} interacts with Asn415 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^{13} interacts with Trp383 of beta-catenin or an amino acid residue corresponding thereto. In some embodiments, X^{13} interacts with Gln379, Leu382, Val416, Asn415, and Trp383 of beta-catenin or amino acid residues corresponding thereto.

[0553] Various types of amino acid residues can be used for X^{14}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{14} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{14} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{14} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0554] In some embodiments, X^{14} is an amino acid residue suitable for stapling. In some embodiments, X^{14} is stapled. In some embodiments, X^{14} is stapled with X^{10} as described herein. In some embodiments, X^{14} is stapled with X^{7} as described herein.


[0555] In some embodiments, X^{14} is an amino acid residue suitable for stapling, e.g., those described for X^{7}, X^{10}, etc.


[0556] Various types of amino acid residues can be used for X^{14}. In some embodiments, X^{14} is GlnR, Lys, sAla, Gln, Cys, TriAzLys, AsnR, hGlnR, 4PipA, sAbu, Orn, dGlnR, [4mampiperidine]GlnR, [39N2spiroundecane]GlnR, [29N2spiroundecane]GlnR, iPrLys, sCH2S, [diaminobutane]GlnR, or [4aminopiperidine]GlnR. In some embodiments, X^{14} is GlnR. In some embodiments, X^{14} is Lys. In some embodiments, X^{14} is sAla. In some embodiments, X^{14} is Gln. In some embodiments, X^{14} is Cys. In some embodiments, X^{14} is TriAzLys. In some embodiments, X^{14} is AsnR. In some embodiments, X^{14} is hGlnR. In some embodiments, X^{14} is 4PipA. In some embodiments, X^{14} is sAbu. In some embodiments, X^{14} is Orn. In some embodiments, X^{14} is dGlnR. In some embodiments, X^{14} is [4mampiperidine]GlnR. In some

embodiments, X^{14} is [39N2spiroundecane]GlnR. In some embodiments, X^{14} is [29N2spiroundecane]GlnR. In some embodiments, X^{14} is iPrLys. In some embodiments, X^{14} is sCH2S. In some embodiments, X^{14} is [diaminobutane]GlnR. In some embodiments, X^{14} is [4aminopiperidine]GlnR.

[0557] In some embodiments, X^{14} is an aromatic amino acid residue as described herein. In some embodiments, X^{14} is BtzA.

[0558] In some embodiments, v14 is a polar amino acid residue as described herein. In some embodiments, X^{14} is Gln.

[0559] In some embodiments, X^{14} is a C-terminus amino acid residue. In some embodiments, X^{14} has a free −COOH or a salt form thereof. In some embodiments, −C(O)OH of X^{14} is capped. In some embodiments, −C(O)OH of X^{14} is converted into $-C(O)N(R')_2$, wherein each R is independently as described herein. In some embodiments, $-C(O)N(R')_2$ is −C(O)NHR'. In some embodiments, each R' is independently R. In some embodiments, each R' is −H. In some embodiments, R is H. In some embodiments, R is optionally substituted C_{1-6} aliphatic. In some embodiments, R is optionally substituted C_{1-6} alkyl. In some embodiments, R is ethyl. In some embodiments, R is  . In some embodiments, R is $-CH(CH_3)CH_2OH$. In some embodiments, R is $-(S)-CH(CH_3)CH_2OH$. In some embodiments, R is $-(R)-CH(CH_3)CH_2OH$. In some embodiments, R is $-CH(CH_2OH)_2$.

[0560] In some embodiments, two R' groups are taken together with the nitrogen atom to which they are attached to form a ring as described herein. In some embodiments, $-N(R')_2$ is  .

[0561] In some embodiments, X^{14} is GlnR, BztA, sAla, 34ClF, Cys, Ala, Lys, AsnR, aMeC, PyrS2, Gln, hGlnR, 3Thi, Lys, Pen, GlnR, TriAzLys, hCys, 4PipA, sAbu, Orn, 1MeK, [4mampiperidine]GlnR, [39N2spiroundecane]GlnR, [29N2spiroundecane]GlnR, iPrLys, sCH2S, AsnEDA, AsnS3APyr, [diaminobutane]GlnR, [4aminopiperidine]GlnR, dGlnR, GlnEDA, AsnPpz, GlnPpz, GlnR3APyr, GlnS3APyr, GlnMe2EDA, AsnMe2EDA, AsnMeEDA, AsnR3APyr. In some embodiments, X^{14} is GlnR. In some embodiments, X^{14} is BztA. In some embodiments, X^{14} is sAla. In some embodiments, X^{14} is 34ClF. In some embodiments, X^{14} is Cys. In some embodiments, X^{14} is Ala. In some embodiments, X^{14} is Lys. In some embodiments, X^{14} is AsnR. In some embodiments, X^{14} is aMeC. In some embodiments, X^{14} is PyrS2. In some embodiments, X^{14} comprises a C-terminal group, e.g., −NH2. In some embodiments, X^{14} is Gln. In some embodiments, X^{14} is hGlnR. In some embodiments, X^{14} is 3Thi. In some embodiments, X^{14} is Lys. In some embodiments, X^{14} is GlnR*3. In some embodiments, X^{14} is dLys. In some embodiments, X^{14} is GlnMePDA. In some embodiments, X^{14} is GlnT4CyMe. In some embodiments, X^{14} is GlnMeBDA. In some embodiments, X^{14} is Gln5DA. In some embodiments, X^{14} is Gln6DA. In some embodiments, X^{14} is TriAzOrn. In some embodiments, X^{14} is Phe. In some embodiments, X^{14} is GlnC4CyMe. In some embodiments, X^{14} is Gln3ACPip. In some embodiments, X^{14} is GlnPipAz. In some embodiments, X^{14} is

GlnPip4AE. In some embodiments, X^{14} forms intramolecular hydrogen bonding.

[0562] In some embodiments, X^{14} is or comprises a residue of an amino acid or a moiety selected from Table A-I, Table A-II, Table A-III and Table A-IV.

[0563] In some embodiments, p15 is 1. In some embodiments, p15 is 0.

[0564] Various types of amino acid residues can be used for X^{15}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{15} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{15} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{15} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0565] Various types of amino acid residues can be used for X^{15}. In some embodiments, X^{15} is a residue of Ala, Leu, Val, Aib, MorphNva, Thr, dAla, dLeu, [BiotinPEG8]Lys, Glu, or AzLys.

[0566] In some embodiments, X^{15} is or comprises a label, e.g., a label for detection, binding, etc. In some embodiments, a label is or comprises biotin. In some embodiments, X^{15} is [BiotinPEG8]Lys.

[0567] In some embodiments, X^{15} is a hydrophobic amino acid residue as described herein, e.g., those described for X^3, X^8, etc. In some embodiments, X^{15} is Ala. In some embodiments, X^{15} is Leu. In some embodiments, X^{15} is Val. In some embodiments, X^{15} is Aib. In some embodiments, X^{15} is dAla. In some embodiments, X^{15} is dLeu.


[0568] In some embodiments, X^{15} is an amino acid residue whose side chain comprises an amino group. In some embodiments, X^{15} is MorphNva.

[0569] In some embodiments, X^{15} is an amino acid residue suitable for stapling as described herein. In some embodiments, X^{15} is GlnR. In some embodiments, it is stapled with X^{11}. In some embodiments, X^{11} is Lys.

[0570] In some embodiments, X^{15} is a polar amino acid residue as described herein, e.g., those described for X^2, X^5, X^6, etc. In some embodiments, X^{15} is Thr. In some embodiments, X^{15} is $-$Ser.

[0571] In some embodiments, X^{15} is an acidic amino acid residue as described herein, e.g., those described for X^2, X^5, X^6, etc. In some embodiments, X^{15} is Glu.

[0572] In some embodiments, X^{15} is a C-terminus amino acid residue. In some embodiments, X^{15} has a free $-COOH$ or a salt form thereof. In some embodiments, $-C(O)OH$ of X^{15} is capped. In some embodiments, $-C(O)OH$ of X^{15} is converted into $-C(O)N(R')_2$, wherein each R is independently as described herein. In some embodiments, $-C(O)N(R')_2$ is $-C(O)NHR'$. In some embodiments, each R' is independently R. In some embodiments, each R' is $-H$. In some embodiments, R is H. In some embodiments, R is optionally substituted C_{1-6} aliphatic. In some embodiments, R is optionally substituted C_{1-}

$_6$ alkyl. In some embodiments, R is  . In some embodiments, R is $-CH(CH_3)CH_2OH$. In some embodiments, R is $-(S)-CH(CH_3)CH_2OH$. In some embodiments, R is $-(R)-CH(CH_3)CH_2OH$. In some embodiments, R is $-CH(CH_2OH)_2$.

[0573] In some embodiments, an agent comprises a C-terminal group. In some embodiments, a C-terminal group is $-OH$. In some embodiments, a C-terminal group is $-NH_2$.

[0574] In some embodiments, X^{15} is Ala, GlnR, Leu, Val, Ser, Thr, 3Thi, BztA, Aib, MorphNva, dAla, dLeu, Pro, Phe, [BiotinPEG8]Lys, Throl, Glu, AzLys, Npg, Trp, Tyr, Lys, Prool, Alaol, Gly, dPro, Asn, Gln, Ala_D3, [mPEG4]Lys, [mPEG8]Lys, [mPEG16]Lys. In some embodiments, X^{15} is Ala. In some embodiments, X^{15} comprises a C-terminal group, e.g., $-NH_2$. In some embodiments, X^{15} is GlnR. In some embodiments, X^{15} is Leu. In some embodiments, X^{15} is Val. In some embodiments, X^{15} is Ser. In some embodiments, X^{15} is Thr. In some embodiments, X^{15} is 3Thi. In some embodiments, X^{15} is BztA. In some embodiments, X^{15} is [mPEG37]-Lys. In some embodiments, X^{15} is dVal. In some embodiments, X^{15} is 34ClF.

[0575] In some embodiments, X^{15} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0576] In some embodiments, p16 is 1. In some embodiments, p16 is 0.

[0577] Various types of amino acid residues can be used for X^{16}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{16} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{16} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{16} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0578] Various types of amino acid residues can be used for X^{16}. In some embodiments, X^{16} is a residue of Ser, Ala, Glu, Aib, Asp, Thr, or aThr.

[0579] In some embodiments, X^{16} is a polar amino acid residue as described herein, e.g., those described for X^2, X^5, X^6, etc. In some embodiments, X^{16} is Thr. In some embodiments, X^{16} is $-$Ser. In some embodiments, X^{16} is aThr.

[0580] In some embodiments, X^{16} is a hydrophobic amino acid residue as described herein, e.g., those described for X^3, X^8, etc. In some embodiments, X^{16} is Ala. In some embodiments, X^{16} is Leu. In some embodiments, X^{16} is Val. In some embodiments, X^{16} is Aib. In some embodiments, X^{16} is dAla. In some embodiments, X^{16} is dLeu.

[0581] In some embodiments, X^{16} is an acidic amino acid residue as described herein, e.g., those described for X^2, X^5, X^6, etc. In some embodiments, X^{16} is Glu. In some embodiments, X^{16} is Asp.

[0582] In some embodiments, X^{16} is Ala, Ser, Glu, GlnR, BztA, Thr, Aib, Asp, Lys, aThr, Val, or Arg. In some embodiments, X^{16} comprises a C-terminal group, e.g., NH_2, OH, Serol, NHEt, NHMe, dAlaol, etc.

[0583] In some embodiments, X^{16} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0584] In some embodiments, p17 is 1. In some embodiments, p17 is 0.

[0585] Various types of amino acid residues can be used for X^{17}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{17} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{17} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{17} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0586] In some embodiments, X^{17} is a hydrophobic amino acid residue as described herein, e.g., those described for X^3, X^8, etc. In some embodiments, X^{17} is a residue of Ala or Leu. In some embodiments, X^{17} is a residue of Ala. In some embodiments, X^{17} is a residue of Leu.

[0587] In some embodiments, X^{17} is Ala, Leu, GlnR, GlnR, Pro, Thr, Val, Lys, Arg, [Ac]Lys, [mPEG4]Lys, [mPEG8]Lys, or [mPEG16]Lys. In some embodiments, X^{17} comprises a C-terminal group, e.g., NH_2, NHEt, OH, etc. In some embodiments, X^{17} is [Ac-dPEG2]-Lys. In some embodiments, X^{17} is [Ac-PEG8]-Lys. In some embodiments, X^{17} is [Oct-dPEG2]-Lys. In some embodiments, X^{17} is [Oct-PEG8]-Lys. In some embodiments, X^{17} is [C18-dPEG2]-Lys. In some embodiments, X^{17} is [C18-PEG8]-Lys. In some embodiments, X^{17} is [AdamantC-dPEG2]-Lys. In some embodiments, X^{17} is [AdamantC-PEG8]-Lys. In some embodiments, X^{17} is [lithocholate-dPEG2]-Lys. In some embodiments, X^{17} is [lithocholate-PEG8]-Lys.

[0588] In some embodiments, X^{17} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0589] In some embodiments, X^{17} comprises a polar side chain. In some embodiments, it is a polar amino acid residue as described herein. In some embodiments, X^{17} comprises a non-polar side chain. In some embodiments, X^{17} comprises a hydrophobic side chain. In some embodiments, it is a hydrophobic amino acid residue as described herein. In some embodiments, X^{17} comprises an aliphatic side chain. In some embodiments, X^{17} comprises an alkyl side chain. In some embodiments, a side chain of X^{17} is C_{1-10} alkyl. In some embodiments, X^{17} comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, it is an aromatic amino acid residue as described herein. In some embodiments, X^{17} comprises a side chain comprising an acidic group, e.g., $-COOH$. In some embodiments, it is an acidic amino acid residue as described herein. In some embodiments, X^{17} comprises a side chain comprising a basic group, e.g., $-N(R)_2$. In some embodiments, it is a basic amino acid residue as described herein. In some embodiments, X^{17} comprises a detectable moiety such as a fluorescent moiety. In some

embodiments, X^{17} is Ala, dAla, or Leu. In some embodiments, X^{17} is Ala. In some embodiments, X^{17} is dAla. In some embodiments, X^{17} is Leu.

[0590] In some embodiments, X^{17} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0591] In some embodiments, p17 is 1. In some embodiments, p17 is 0.

[0592] Various types of amino acid residues can be used for X^{18}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{18} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{18} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{18} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0593] In some embodiments, X^{18} comprises a polar side chain. In some embodiments, it is a polar amino acid residue as described herein. In some embodiments, X^{18} comprises a non-polar side chain. In some embodiments, X^{18} comprises a hydrophobic side chain. In some embodiments, it is a hydrophobic amino acid residue as described herein. In some embodiments, X^{18} comprises an aliphatic side chain. In some embodiments, X^{18} comprises an alkyl side chain. In some embodiments, a side chain of X^{18} is C_{1-10} alkyl. In some embodiments, X^{18} comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, it is an aromatic amino acid residue as described herein. In some embodiments, X^{18} comprises a side chain comprising an acidic group, e.g., $-COOH$. In some embodiments, it is an acidic amino acid residue as described herein. In some embodiments, X^{18} comprises a side chain comprising a basic group, e.g., $-N(R)_2$. In some embodiments, it is a basic amino acid residue as described herein. In some embodiments, X^{18} comprises a detectable moiety such as a fluorescent moiety. In some embodiments, X^{18} is Aib, Ala, or Leu. In some embodiments, X^{18} is Ala or Leu. In some embodiments, X^{18} is Aib. In some embodiments, X^{18} is Ala. In some embodiments, X^{18} is Leu. In some embodiments, X^{18} is Pro. In some embodiments, X^{18} is [Ac]Lys. In some embodiments, X^{18} is [mPEG4]Lys. In some embodiments, X^{18} is [mPEG8]Lys. In some embodiments, X^{18} is [mPEG16]Lys. In some embodiments, X^{18} is Thr. In some embodiments, X^{18} is GlnR. In some embodiments, X^{18} is [mPEG37]Lys. In some embodiments, X^{18} is [PEG4triPEG16]Lys. In some embodiments, X^{18} is [PEG4triPEG36]Lys. In some embodiments, X^{18} comprises a C-terminal group as described herein.

[0594] In some embodiments, X^{18} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0595] In some embodiments, p18 is 1. In some embodiments, p18 is 0.

[0596] Various types of amino acid residues can be used for X^{19}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{19} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as

described herein. In some embodiments, X^{19} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{19} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0597] In some embodiments, X^{19} comprises a polar side chain. In some embodiments, it is a polar amino acid residue as described herein. In some embodiments, X^{19} comprises a non-polar side chain. In some embodiments, X^{19} comprises a hydrophobic side chain. In some embodiments, it is a hydrophobic amino acid residue as described herein. In some embodiments, X^{19} comprises an aliphatic side chain. In some embodiments, X^{19} comprises an alkyl side chain. In some embodiments, a side chain of X^{19} is C_{1-10} alkyl. In some embodiments, X^{19} comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, it is an aromatic amino acid residue as described herein. In some embodiments, X^{19} comprises a side chain comprising an acidic group, e.g., $-COOH$. In some embodiments, it is an acidic amino acid residue as described herein. In some embodiments, X^{19} comprises a side chain comprising a basic group, e.g., $-N(R)_2$. In some embodiments, it is a basic amino acid residue as described herein. In some embodiments, X^{19} comprises a detectable moiety such as a fluorescent moiety. In some embodiments, X^{19} is Aib, Ala, or Leu. In some embodiments, X^{19} is Ala or Leu. In some embodiments, X^{19} is Aib. In some embodiments, X^{19} is Ala. In some embodiments, X^{19} is Leu. In some embodiments, X^{19} is Thr. In some embodiments, X^{19} is Val. In some embodiments, X^{19} is Pro.

[0598] In some embodiments, X^{19} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0599] In some embodiments, p19 is 1. In some embodiments, p19 is 0.

[0600] Various types of amino acid residues can be used for X^{20}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{20} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{20} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{20} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0601] In some embodiments, X^{20} comprises a polar side chain. In some embodiments, it is a polar amino acid residue as described herein. In some embodiments, X^{20} comprises a non-polar side chain. In some embodiments, X^{20} comprises a hydrophobic side chain. In some embodiments, it is a hydrophobic amino acid residue as described herein. In some embodiments, X^{20} comprises an aliphatic side chain. In some embodiments, X^{20} comprises an alkyl side chain. In some embodiments, a side chain of X^{20} is C_{1-10} alkyl. In some embodiments, X^{20} comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, it is an aromatic amino acid residue as described herein. In some embodiments, X^{20} comprises a side chain comprising an acidic group, e.g., $-COOH$. In some embodiments,

it is an acidic amino acid residue as described herein. In some embodiments, X^{20} comprises a side chain comprising a basic group, e.g., $-N(R)_2$. In some embodiments, it is a basic amino acid residue as described herein. In some embodiments, X^{20} comprises a detectable moiety such as a fluorescent moiety. In some embodiments, X^{20} is Aib, Ala, or Leu. In some embodiments, X^{20} is Ala or Leu. In some embodiments, X^{20} is Aib. In some embodiments, X^{20} is Ala. In some embodiments, X^{20} is Leu. In some embodiments, X^{20} is Lys. In some embodiments, X^{20} is nLeu. In some embodiments, X^{20} is Val. In some embodiments, X^{20} is Arg.

[0602] In some embodiments, X^{20} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0603] In some embodiments, p20 is 1. In some embodiments, p20 is 0.

[0604] Various types of amino acid residues can be used for X^{21}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{21} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{21} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{21} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0605] In some embodiments, X^{21} comprises a polar side chain. In some embodiments, it is a polar amino acid residue as described herein. In some embodiments, X^{21} comprises a non-polar side chain. In some embodiments, X^{21} comprises a hydrophobic side chain. In some embodiments, it is a hydrophobic amino acid residue as described herein. In some embodiments, X^{21} comprises an aliphatic side chain. In some embodiments, X^{21} comprises an alkyl side chain. In some embodiments, a side chain of X^{21} is C_{1-10} alkyl. In some embodiments, X^{21} comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, it is an aromatic amino acid residue as described herein. In some embodiments, X^{21} comprises a side chain comprising an acidic group, e.g., $-COOH$. In some embodiments, it is an acidic amino acid residue as described herein. In some embodiments, X^{21} comprises a side chain comprising a basic group, e.g., $-N(R)_2$. In some embodiments, it is a basic amino acid residue as described herein. In some embodiments, X^{21} comprises a detectable moiety such as a fluorescent moiety. In some embodiments, X^{21} is Aib, Ala, or Leu. In some embodiments, X^{21} is Ala or Leu. In some embodiments, X^{21} is Aib. In some embodiments, X^{21} is Ala. In some embodiments, X^{21} is Leu. In some embodiments, X^{21} is Lys. In some embodiments, X^{21} is nLeu. In some embodiments, X^{21} is Arg.

[0606] In some embodiments, X^{21} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0607] In some embodiments, p21 is 1. In some embodiments, p21 is 0.

[0608] Various types of amino acid residues can be used for X^{22}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In

some embodiments, X^{22} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{22} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{22} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0609] In some embodiments, X^{22} comprises a polar side chain. In some embodiments, it is a polar amino acid residue as described herein. In some embodiments, X^{22} comprises a non-polar side chain. In some embodiments, X^{22} comprises a hydrophobic side chain. In some embodiments, it is a hydrophobic amino acid residue as described herein. In some embodiments, X^{22} comprises an aliphatic side chain. In some embodiments, X^{22} comprises an alkyl side chain. In some embodiments, a side chain of X^{22} is C_{1-10} alkyl. In some embodiments, X^{22} comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, it is an aromatic amino acid residue as described herein. In some embodiments, X^{22} comprises a side chain comprising an acidic group, e.g., $-COOH$. In some embodiments, it is an acidic amino acid residue as described herein. In some embodiments, X^{22} comprises a side chain comprising a basic group, e.g., $-N(R)_2$. In some embodiments, it is a basic amino acid residue as described herein. In some embodiments, X^{22} comprises a detectable moiety such as a fluorescent moiety. In some embodiments, X^{22} is Aib, Ala, or Leu. In some embodiments, X^{22} is Ala or Leu. In some embodiments, X^{22} is Aib. In some embodiments, X^{22} is Ala. In some embodiments, X^{22} is Leu. In some embodiments, X^{22} is Lys.

[0610] In some embodiments, X^{22} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0611] In some embodiments, p22 is 1. In some embodiments, p22 is 0.

[0612] Various types of amino acid residues can be used for X^{23}, e.g., a residue of an amino acid of formula A-I, A-II, A-III, A-IV, A-V, A-VI, etc. or a salt thereof in accordance with the present disclosure. In some embodiments, X^{23} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{23} is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$, wherein each variable is independently as described herein. In some embodiments, X^{23} is $-N(R^{a1})-C(R^{a2})H-C(O)-$, wherein each variable is independently as described herein. In some embodiments, R^{a1} is $-H$. In some embodiments, R^{a3} is $-H$.

[0613] In some embodiments, X^{23} comprises a polar side chain. In some embodiments, it is a polar amino acid residue as described herein. In some embodiments, X^{23} comprises a non-polar side chain. In some embodiments, X^{23} comprises a hydrophobic side chain. In some embodiments, it is a hydrophobic amino acid residue as described herein. In some embodiments, X^{23} comprises an aliphatic side chain. In some embodiments, X^{23} comprises an alkyl side chain. In some embodiments, a side chain of X^{23} is C_{1-10} alkyl. In some embodiments, X^{23} comprises a side chain comprising an optionally substituted aromatic group. In some embodiments, it is an aromatic amino acid residue as described herein. In some

embodiments, X^{23} comprises a side chain comprising an acidic group, e.g., −COOH. In some embodiments, it is an acidic amino acid residue as described herein. In some embodiments, X^{23} comprises a side chain comprising a basic group, e.g., $-N(R)_2$. In some embodiments, it is a basic amino acid residue as described herein. In some embodiments, X^{23} comprises a detectable moiety such as a fluorescent moiety. In some embodiments, X^{23} is Aib, Ala, or Leu. In some embodiments, X^{23} is Ala or Leu. In some embodiments, X^{23} is Aib. In some embodiments, X^{23} is Ala. In some embodiments, X^{23} is Leu.

[0614] In some embodiments, X^{23} is or comprises a residue of an amino acid or a moiety selected from Table A-IV.

[0615] In some embodiments, p23 is 1. In some embodiments, p23 is 0.

[0616] In some embodiments, an agent is or comprises a peptide having the structure of:

$$R^N-[X]_p-[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}-[X]_{p'}-R^C,$$

or a salt thereof, wherein:

each X is independently an amino acid residue;

each p and p' is independently 0-10;

R^N is independently a peptide, an amino protecting group or $R'-L^{RN}-$;

R^C is independently a peptide, a carboxyl protecting group, $-L^{RC}-R'$, $-O-L^{RC}-R'$ or $-N(R')-L^{RC}-R'$;

each of L^{RN} and L^{RC} is independently L;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, −Cy−, −O−, −S−, −S−S−, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each −Cy− is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;

each R' is independently −R, $-C(O)R$, $-CO_2R$, or $-SO_2R$;

each R is independently −H, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring






having, in addition to the intervening atoms, 0-10 heteroatoms.






[0617] In some embodiments, p is 0. In some embodiments, p is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5. In some embodiments, p is 6. In some embodiments, p is 7. In some embodiments, p is 8. In some embodiments, p is 9. In some embodiments, p is 10.

[0618] In some embodiments, p' is 0. In some embodiments, p' is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, p' is 1. In some embodiments, p' is 2. In some embodiments, p' is 3. In some embodiments, p' is 4. In some embodiments, p' is 5. In some embodiments, p' is 6. In some embodiments, p' is 7. In some embodiments, p' is 8. In some embodiments, p' is 9. In some embodiments, p' is 10.

[0619] In some embodiments, R^N is an N-terminus capping group. In some embodiments, R^N is −C(O)R, wherein R is as described herein. In some embodiments, R is −H. In some embodiments, R is optionally substituted C_{1-6} aliphatic. In some embodiments, R is optionally substituted C_{1-6} alkyl. In some embodiments, R is methyl. In some embodiments, R^N is Ac. In some embodiments, R^N is a group suitable for stapling, or is stapled. In some embodiments, R^N is 4pentenyl. In some embodiments, R^N is 5hexenyl. In some embodiments, R^N is BzAm2OAllyl. In some embodiments, R^N is Ac, NPyroR3, 5hexenyl, 4pentenyl, Bua, C3a, Cpc, Cbc, CypCO, Bnc, CF3CO, 2PyCypCO, 4THPCO, Isobutyryl, Ts, 15PyraPy, 2PyBu, 4PymCO, 4PyPrpc, 3IAPAc, 4MePipzPrpC, MePipAc, MeImid4SO2, BzAm2OAllyl, Hex, 2PyzCO, 3Phc3, MeOPr, lithocholate, 2FPhc, PhC, MeSO2, Isovaleryl, EtHNCO, TzPyr, 8IAP, 3PydCO, 2PymCO, 5PymCO, 1Imidac, 2F2PyAc, 2IAPAc, 124TriPr, 6QuiAc, 3PyAc, 123TriAc, 1PyrazoleAc, 3PyPrpc, 5PymAc, 1PydoneAc, 124TriAc, Me2NAc, 8QuiSO2, mPEG4, mPEG8, mPEG16 or mPEG24.

[0620] In some embodiments, R^C is a C-terminus capping group. In some embodiments, R^C is $-N(R')_2$ wherein each R' is independently as described herein. In some embodiments, R^C is −NHR' wherein R' is as described herein. In some embodiments, R^C is $-N(R)_2$ wherein each R is independently as described herein. In some embodiments, R^C is −NHR wherein R is as described herein. In some embodiments, R is −H. In some embodiments, R is optionally substituted C_{1-6} aliphatic. In some embodiments, R is optionally substituted C_{1-6} alkyl. In some embodiments, R is methyl. In some embodiments, R is ethyl. In some embodiments, R^C is $-NH_2$. In some embodiments, R^C is −NHEt.

[0621] In some embodiments, R^C is $-NHC(CH_3)CH_2OH$. In some embodiments, R^C is $-(S)-NHC(CH_3)CH_2OH$. In some embodiments, R^C is $-(R)-NHC(CH_3)CH_2OH$. In some embodiments, R^C is  . In some embodiments, R^C is  . In some embodiments, R^C is  . In some embodiments, R^C is  . In some embodiments, R^C is  .

[0622] In some embodiments, R^C is −Alaol, wherein the amino group of −Alaol is bonded to the last −C(O)− of the peptide backbone (R^C is ). In some embodiments, R^C is −dAlaol, wherein the amino group of −dAlaol is bonded to the last −C(O)− of the peptide backbone (R^C is ). In some embodiments, R^C is −Prool, wherein the amino group of −Prool is bonded to the last −C(O)− of the peptide backbone (R^C is ). In some embodiments, R^C is −Throl, wherein the amino group of −Throl is bonded to the last −C(O)− of the peptide backbone (R^C is ). In some embodiments, R^C is −Serol, wherein the amino group of −Serol is bonded to the last −C(O)− of the peptide backbone (R^C is ).

[0623] In some embodiments, R^C is −OH.

Amino Acids

[0624] As appreciated by those skilled in the art, various amino acids may be utilized in accordance with the present disclosure. For example, both naturally occurring and non-naturally occurring amino acids can be utilized in accordance with the present disclosure. In some embodiments, an amino acid is a compound comprising an amino group that can form an amide group with a carboxyl group and a carboxyl group. In some embodiments, an amino acid is an alpha amino acid. In some embodiments, an amino acid is a beta-amino acid. In some embodiments, an amino acid is a D-amino acid. In some embodiments, an amino acid is a L-amino acid. In some embodiments, an amino acid is an naturally encoded amino acid, e.g., in mammalian cells.

[0625] In some embodiments, an amino acid is a compound having the structure of formula A-I:

$$N(R^{a1})_2–L^{a1}–C(R^{a2})(R^{a3})–L^{a2}–COOH,$$

A-I

or a salt thereof, wherein:

each of R^{a1}, R^{a2}, R^{a3} is independently $–L^a–R'$;

each of L^a, L^{a1} and L^{a2} is independently L;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the

group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each $-Cy-$ is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;

each R' is independently $-R$, $-C(O)R$, $-CO_2R$, or $-SO_2R$;

each R is independently $-H$, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

[0626] In some embodiments, a compound having the structure of formula A-I or a salt thereof has the structure of $NH(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-COOH$ or a salt thereof.

[0627] In some embodiments, a ring moiety of, e.g., $-Cy-$, R (including those formed by R groups taken together), etc. is monocyclic. In some embodiments, a ring moiety is bicyclic or polycyclic. In some embodiments, a monocyclic ring is an optionally substituted 3-10 (3, 4, 5, 6, 7, 8, 9, or 10, 3-8, 3-7, 4-7, 4-6, 5-6, etc.) membered, saturated, partially unsaturated or aromatic ring having 0-5 heteroatoms. In some embodiments, each monocyclic ring unit of a bicyclic or polycyclic ring moiety is independently an optionally substituted 3-10 (3, 4, 5, 6, 7, 8, 9, or 10, 3-8, 3-7, 4-7, 4-6, 5-6, etc.) membered, saturated, partially unsaturated or aromatic ring having 0-5 heteroatoms.

[0628] In some embodiments, each heteroatom is independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, each heteroatom is independently selected from oxygen, nitrogen, and sulfur.

[0629] In some embodiments, L^{a1} is a covalent bond. In some embodiments, a compound of formula A-1 is of the structure $NH(R^{a1})-C(R^{a2})(R^{a3})-L^{a2}-COOH$.

[0630] In some embodiments, L^{a2} is a covalent bond. In some embodiments, a compound of formula A-1 is of the structure $NH(R^{a1})-C(R^{a2})(R^{a3})-L^{a2}-COOH$.

[0631] In some embodiments, L^{a1} is a covalent bond and L^{a2} is a covalent bond. In some embodiments, a compound of formula A-1 is of the structure $NH(R^{a1})-C(R^{a2})(R^{a3})-COOH$.

[0632] In some embodiments, an amino acid is suitable for stapling. In some embodiments, an amino

acid comprises a terminal olefin. Certain such amino acids are exemplified herein (e.g., those described in or utilized in peptides of various Tables).

[0633] In some embodiments, an agent comprises a detectable moiety, which can either be detected directly or indirectly. For example, in some embodiments, a detectable moiety is or comprises a fluorescent group. In some embodiments, a detectable moiety is or comprises a biotin moiety. In some embodiments, a detectable moiety is connected to the rest of an agent at an amino acid residue, e.g., through a side chain, optionally through a linker (e.g., L as described herein). In some embodiments, a detectable moiety is $-N_3$, which may be detected after a click chemistry reaction with a labeled agent comprising an alkyne.

[0634] In some embodiments, the present disclosure provides various compounds, which among other things may be utilized as amino acids for a number of applications, e.g., for preparation of peptides or other useful compounds.

[0635] In some embodiments, a compound (e.g., an amino acid or a protected and/or activated form thereof) or a salt thereof comprises 1) a first group which is an optionally protected amino group, 2) a second group which is an optionally protected and/or activated carboxyl group, and 3) a side chain (typically bonded to an atom between the first and second groups ("a side chain attachment atom")) which comprises an optionally protected and/or activated carboxyl group and a) an optionally substituted ring (which ring is typically between the optionally protected and/or activated carboxyl group of the side chain and a side chain attachment atom) or b) an amino group (which amino group is typically between the optionally protected and/or activated carboxyl group of the side chain and a side chain attachment atom). In some embodiments, a provided compound is an optionally protected and/or activated amino acid or a salt thereof, wherein the side chain of the amino acid comprises an optionally protected and/or activated carboxyl group, and an optionally substituted ring or an amino group, wherein the optionally substituted ring or an amino group is between the optionally protected and/or activated carboxyl group and a backbone atom to which a side chain is attached (e.g., an atom between an amino and carboxyl group, both of which can be optionally and independently protected and/or activated (e.g., an alpha carbon atom in an amino acid)).

[0636] In some embodiments, the present disclosure provides compounds having the structure of formula PA:

$$N(R^{PA})(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)R^{PC},$$

PA

or a salt thereof, wherein:

R^{PA} is $-H$ or an amino protecting group;

each of R^{a1} and R^{a3} is independently $-L^{a}-R'$;

R^{a2} is $-L^{aa}-C(O)R^{PS}$;

each of L^{a}, L^{a1} and L^{a2} is independently L;

$-C(O)R^{PS}$ is optionally protected or activated $-COOH$;

$-C(O)R^{PC}$ is optionally protected or activated $-COOH$;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−;

each −Cy− is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;

each R' is independently −R, −C(O)R, −CO$_2$R, or −SO$_2$R; and

each R is independently −H, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

[0637] In some embodiments, compounds (e.g., amino acids, such as those of formula A-I or protected/activated forms thereof) having the structure of formula PA:

$$N(R^{PA})(R^{a1})–L^{a1}–C(R^{a2})(R^{a3})–L^{a2}–C(O)R^{PC},$$

PA

or a salt thereof, wherein:

R^{PA} is −H or an amino protecting group;

each of R^{a1} and R^{a3} is independently $-L^a-R'$;

R^{a2} is $-L^{aa}-C(O)R^{PS}$, wherein L^{aa} is L and L^{aa} comprises −N(R')− or −Cy−;

each of L^{a1} and L^{a2} is independently L;

$-C(O)R^{PS}$ is optionally protected or activated −COOH;

$-C(O)R^{PC}$ is optionally protected or activated −COOH;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−;

each −Cy− is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic

or polycyclic ring having 0-10 heteroatoms;

each R' is independently −R, −C(O)R, −CO_2R, or −SO_2R; and

each R is independently −H, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.









[0638] In some embodiments, L^{a1} is a covalent bond. In some embodiments, L^{a1} is not a covalent bond.

[0639] In some embodiments, L^{a2} is a covalent bond. In some embodiments, L^{a2} is not a covalent bond.

[0640] In some embodiments, R^{a2} is $-L^{aa}-C(O)R^{PS}$, wherein L^{aa} is an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −$S(O)_2$−, −$S(O)_2$N(R')−, −C(O)S−, or −C(O)O−, wherein at least one methylene unit is replaced with −Cy−.

[0641] As used herein, in some embodiments, −Cy− is an optionally substituted bivalent 3-10 (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) membered monocyclic cycloaliphatic group. In some embodiments, −Cy− is an optionally substituted 3-10 (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) membered monocyclic cycloalkyl ring. In some embodiments, −Cy− is an optionally substituted 3-10 (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) membered monocyclic heteroaliphatic ring having 1-5 heteroatoms. In some embodiments, −Cy− is an optionally substituted 3-10 (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) membered monocyclic heteroalkyl ring having 1-5 heteroatoms. In some embodiments, −Cy− is an optionally substituted bivalent 5-15 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) membered bicyclic or polycyclic cycloaliphatic group. In some embodiments, −Cy− is an optionally substituted bivalent 5-15 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) membered bicyclic or polycyclic cycloalkyl group. In some embodiments, −Cy− is an optionally substituted 5-15 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) membered bicyclic or polycyclic heteroaliphatic ring having 1-5 heteroatoms. In some embodiments, −Cy− is an optionally substituted 5-15 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) membered bicyclic or polycyclic heterocyclyl ring having 1-5 heteroatoms. In some embodiments, a cycloaliphatic, cycloalkyl, heteroaliphatic or heteroalkyl ring is 3-membered. In some embodiments, it is 4-membered. In some embodiments, it is 5-membered. In some embodiments, it is 6-membered. In some embodiments, it is 7-membered. In some embodiments, it is 8-membered. In some embodiments, it is 9-membered. In some embodiments, it is 10-

membered. In some embodiments, it is 11-membered. In some embodiments, it is 12-membered. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is an optionally substituted bivalent 10-membered bicyclic aryl ring. In some embodiments, −Cy− is an optionally substituted 5-membered heteroaryl ring having 1-4 heteroatoms. In some embodiments, −Cy− is an optionally substituted 6-membered heteroaryl ring having 1-4 heteroatoms. In some embodiments, −Cy− is an optionally substituted 9-membered bicyclic heteroaryl ring having 1-5 heteroatoms. In some embodiments, −Cy− is an optionally substituted 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms. In some embodiments, a heteroaliphatic, heterocyclyl or heteroaryl ring contains no more than 1 heteroatom. In some embodiments, each heteroatom is independently selected from nitrogen, oxygen and sulfur.

[0642] In some embodiments, −Cy− is an optionally substituted 4-7 membered ring having 0-3 heteroatoms. In some embodiments, −Cy− is an optionally substituted 6-membered aryl ring. In some embodiments, an aryl ring is substituted. In some embodiments, it is substituted with one or more halogen. In some embodiments, it is substituted with one or more −F. In some embodiments, it is not substituted. In some embodiments, it is optionally substituted  . In some embodiments, it is  . In some embodiments, it is optionally substituted  . In some embodiments, it is  . In some embodiments, it is optionally substituted  . In some embodiments, it is  . In some embodiments, −Cy− is an optionally substituted 5-membered heteroaryl ring having 1-3 heteroatoms. In some embodiments, a heteroatom is nitrogen. In some embodiments, a heteroatom is oxygen. In some embodiments, a heteroatom is sulfur. In some embodiments, −Cy− is optionally substituted  . In some embodiments, −Cy− is  .

[0643] In some embodiments, L^{aa} is $-L^{am1}-Cy-L^{am2}-$, wherein each of L^{am1} and L^{am2} is independently L^{am}, wherein each L^{am} is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{10} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, −Cy−, −O−, −S−, −S−S−, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

[0644] In some embodiments, L^{aa} comprises −Cy−. In some embodiments, L^{aa} is $-L^{am1}-Cy-L^{am2}-$, wherein each of L^{am1} and L^{am2} is independently L^{am}, wherein each L^{am} is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{10} aliphatic group wherein one or more methylene units of the aliphatic

group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, $-L^{am2}-$ is bonded to $-C(O)R^{PS}$. In some embodiments, L^{am2} is a covalent bond. In some embodiments, $-Cy-$ is an optionally substituted 4-7 membered ring having 0-3 heteroatoms. In some embodiments, $-Cy-$ is an optionally substituted 5-7 membered ring having 0-3 heteroatoms. In some embodiments, $-Cy-$ is an optionally substituted 6-7 membered ring having 0-3 heteroatoms. In some embodiments, $-Cy-$ is an optionally substituted 4-membered ring having 0-1 heteroatoms. In some embodiments, $-Cy-$ is an optionally substituted 5-membered ring having 0-2 heteroatoms. In some embodiments, $-Cy-$ is an optionally substituted 6-membered ring having 0-2 heteroatoms. In some embodiments, $-Cy-$ is an optionally substituted 7-membered ring having 0-3 heteroatoms.

[0645] In some embodiments, R^{a2} is $-L^{aa}-C(O)R^{PS}$, wherein L^{aa} is an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$, wherein at least one methylene unit is replaced with $-N(R')-$.

[0646] In some embodiments, L^{aa} comprises $-N(R')-$. In some embodiments, L^{aa} is $-L^{am1}-(NR')-L^{am2}-$, wherein each of L^{am1} and L^{am2} is independently L^{am}, wherein each L^{am} is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{10} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$. In some embodiments, $-L^{am2}-$ is bonded to $-C(O)R^{PS}$. In some embodiments, L^{am1} is optionally substituted C_{1-4} alkylene. In some embodiments, L^{am1} is optionally substituted $-(CH_2)m-$, wherein m is 1, 2, 3, or 4. In some embodiments, L^{am1} is $-CH_2-$. In some embodiments, L^{am2} is optionally substituted linear C_{1-2} alkylene. In some embodiments, L^{am2} is $-[C(R')_2]n$, wherein n is 1 or 2. In some embodiments, L^{am2} is $-[CHR']n$, wherein n is 1 or 2. In some embodiments, each R' is independently $-H$ or optionally substituted C_{1-6} alkyl. In some embodiments, L^{am2} is optionally substituted $-CH_2-$. In some embodiments, L^{am2} is $-CH_2-$. In some embodiments, R' is $-R^{NR}$, wherein R^{NR} is R. In some embodiments, R' is $-CH_2-R^{NR}$, wherein R^{NR} is R. In some embodiments, R' of the $-N(R')-$ is $-C(O)R^{NR}$, wherein R^{NR} is R. In some embodiments, R' of the $-N(R')-$ is $-SO_2R^{NR}$, wherein R^{NR} is R. In some embodiments, R is optionally substituted C_{1-6} aliphatic or heteroaliphatic having 1-4 heteroatoms. In some embodiments, R^{NR} is C_{1-7} alkyl or heteroalkyl having 1-4 heteroatoms optionally substituted with one or more groups independently selected from halogen, a C_{5-6} aromatic ring having 0-4 heteroatoms, and an optionally substituted 3-10 membered cycloalkyl or heteroalkyl ring having 1-4 heteroatoms. In some embodiments, R is $-CF_3$. In some embodiments, L^{am2} is or comprises $-C(R')_2-$ wherein the R' group and R' in $-N(R')-$ are taken together with their intervening atoms to form an optionally substituted, 3-30 membered,

monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

[0647] In some embodiments, L^{aa} is $-L^{am1}-N(R')-L^{am2}-$, wherein each of L^{am1} and L^{am2} is independently L^{am}, wherein each L^{am} is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{10} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

[0648] In some embodiments, $-N(R')-$ is bonded to two carbon atoms which two carbon atoms do not form any double bonds with heteroatoms. In some embodiments, $-N(R')-$ is bonded to two sp3 atoms. In some embodiments, $-N(R')-$ is bonded to two sp3 carbon atoms. In some embodiments, $-N(R')-$ is bonded to two $-CH_2-$, each of which is independently and optionally substituted with one or two monovalent substituent. In some embodiments, $-N(R')-$ is bonded to two $-CH_2-$.

[0649] In some embodiments, L^{aa} comprises $-N(R')-$. In some embodiments, R' of the $-N(R')-$ is $-R^{NR}$, wherein R^{NR} is R. In some embodiments, R' of the $-N(R')-$ is $-CH_2-R^{NR}$, wherein R^{NR} is R, and the $-CH_2-$ is optionally substituted. In some embodiments, R' of the $-N(R')-$ is $-C(O)R^{NR}$, wherein R^{NR} is R. In some embodiments, R' of the $-N(R')-$ is $-SO_2R^{NR}$, wherein R^{NR} is R. In some embodiments, $-N(R')-$ is $-N(Et)-$. In some embodiments, $-N(R')-$ is $-N(CH_2CF_3)-$. In some embodiments, R' is optionally substituted C_{1-6} aliphatic or heteroaliphatic having 1-4 heteroatoms. In some embodiments, R' is C_{1-7} alkyl or heteroalkyl having 1-4 heteroatoms, wherein the alkyl or heteroalkyl is optionally substituted with one or more groups independently selected from halogen, a C_{5-6} aromatic ring having 0-4 heteroatoms, and an optionally substituted 3-10 membered cycloalkyl or heteroalkyl ring having 1-4 heteroatoms. In some embodiments, R^{NR} is $-CF_3$.

[0650] In some embodiments, R' of $-N(R')-$ is R, R^{a3} is R, and the two R groups are taken together with their intervening atoms to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atoms. In some embodiments, a formed ring is 3-membered. In some embodiments, a formed ring is 4-membered. In some embodiments, a formed ring is 5-membered. In some embodiments, a formed ring is 6-membered. In some embodiments, a formed ring is 7-membered. In some embodiments, a formed ring is monocyclic. In some embodiments, a formed ring is bicyclic or polycyclic. In some embodiments, a formed ring is saturated. In some embodiments, a formed ring is partially unsaturated.

[0651] In some embodiments, L^{am1} is a covalent bond. In some embodiments, L^{am1} is not a covalent bond. In some embodiments, L^{am1} is optionally substituted C_{1-4} alkylene. In some embodiments, L^{am1} is optionally substituted $-(CH_2)m-$, wherein m is 1, 2, 3, or 4. In some embodiments, L^{am1} is optionally substituted $-CH_2-$. In some embodiments, L^{am1} is $-CH_2-$.

[0652] In some embodiments, L^{am2} is bonded to $-C(O)R^{PS}$.

[0653] In some embodiments, L^{am2} is a covalent bond. In some embodiments, L^{am2} is a covalent bond when it is between $-Cy-$ and $-C(O)R^{PS}$. In some embodiments, L^{am2} is not a covalent bond. In some

embodiments, L^{am2} is optionally substituted C_{1-4} alkylene. In some embodiments, L^{am2} is optionally substituted $-(CH_2)m-$, wherein m is 1, 2, 3, or 4. In some embodiments, L^{am2} is optionally substituted linear C_{1-2} alkylene. In some embodiments, L^{am2} is $-[C(R')_2]n$, wherein n is 1 or 2. In some embodiments, L^{am2} is $-[CHR']n$, wherein n is 1 or 2. In some embodiments, each R' is independently $-H$ or optionally substituted C_{1-6} alkyl. In some embodiments, L^{am2} is optionally substituted $-CH_2-$. In some embodiments, L^{am2} is $-CH_2-$. In some embodiments, L^{am2} is optionally substituted $-CH_2-CH_2-$. In some embodiments, L^{am2} is $-CH_2-C(CH_3)_2-$.

[0654] In some embodiments, L^{am2} is or comprises $-C(R')_2-$ wherein the R' group and R' in $-N(R')-$ of L^{aa} are taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

[0655] In some embodiments, R^{a2} is $-L^{aa}-C(O)R^{PS}$, wherein L^{aa} is L as described herein. In some embodiments, L^{aa} is L^{am2} as described herein. In some embodiments, L^{aa} is optionally substituted branched or linear C_{1-10} hydrocarbon chain. In some embodiments, L^{aa} is optionally substituted C_{1-10} (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) alkylene. In some embodiments, L^{aa} is optionally substituted $-CH_2-CH_2-$. In some embodiments, L^{aa} is $-CH_2-CH_2-$. In some embodiments, L^{aa} is optionally substituted $-CH_2-$. In some embodiments, L^{aa} is $-CH_2-$.

[0656] In some embodiments, L^{a} is L^{aa} as described herein.

[0657] In some embodiments, L^{aa} is L^{a} as described herein.

[0658] As described above, each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

[0659] In some embodiments, L is a covalent bond.

[0660] In some embodiments, L (or L^{a}, L^{aa}, L^{a1}, L^{a2}, L^{s1}, L^{s2}, L^{s3}, or another variable or moiety that can be L, or a linker moiety) is an optionally substituted, bivalent C_1-C_{25}, C_1-C_{20}, C_1-C_{15}, C_1-C_{10}, C_1-C_9, C_1-C_8, C_1-C_7, C_1-C_6, C_1-C_5, C_1-C_4, C_1-C_3, C_1-C_2, or C_1, C_2, C_3, C_4, C_5, C_6, C_7, C_8, C_9, C_{10}, C_{11}, C_{12}, C_{13}, C_{14}, C_{15}, C_{16}, C_{17}, C_{18}, C_{19}, or C_{20}, aliphatic wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

[0661] In some embodiments, L, L^{a}, L^{aa}, L^{a1}, L^{a2}, L^{s1}, L^{s2}, L^{s3}, L", or another variable or moiety that can be L, or a linker moiety, is an optionally substituted, bivalent C_1-C_{25}, C_1-C_{20}, C_1-C_{15}, C_1-C_{10}, C_1-C_9, C_1-C_8, C_1-C_7, C_1-C_6, C_1-C_5, C_1-C_4, C_1-C_3, C_1-C_2, or C_1, C_2, C_3, C_4, C_5, C_6, C_7, C_8, C_9, C_{10}, C_{11}, C_{12}, C_{13}, C_{14}, C_{15}, C_{16}, C_{17}, C_{18}, C_{19}, or C_{20}, aliphatic wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$,

−C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, it is an optionally substituted, bivalent C$_1$-C$_{10}$, C$_1$-C$_9$, C$_1$-C$_8$, C$_1$-C$_7$, C$_1$-C$_6$, C$_1$-C$_5$, C$_1$-C$_4$, C$_1$-C$_3$, C$_1$-C$_2$, or C$_1$, C$_2$, C$_3$, C$_4$, C$_5$, C$_6$, C$_7$, C$_8$, C$_9$, or C$_{10}$, aliphatic wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, it is an optionally substituted, bivalent C$_2$ aliphatic wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, it is an optionally substituted, bivalent C$_3$ aliphatic wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, it is an optionally substituted, bivalent C$_4$ aliphatic wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, it is an optionally substituted, bivalent C$_5$ aliphatic wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, it is an optionally substituted, bivalent C$_6$ aliphatic wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, the bivalent aliphatic is saturated. In some embodiments, the bivalent aliphatic is linear. In some embodiments, the bivalent aliphatic is branched. In some embodiments, it is an optionally substituted, bivalent linear saturated C$_6$ aliphatic wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, each replacement if any is independently with −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, each replacement if any is independently with −Cy−, −O−, −S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, each replacement if any is independently with −O−, −S−, −N(R')−, −C(O)−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−. In some embodiments, each replacement if any is independently with −O−, −S−, −N(R')−, or −C(O)−. In some embodiments, L, L^a, L^{aa}, L^{a1}, L^{a2}, L^{s1}, L^{s2}, L^{s3}, L", or another variable or moiety that can be L, or a linker

moiety, is an optionally substituted, bivalent C_1-C_6 linear saturated aliphatic wherein one or more methylene units is optionally and independently replaced with −O−, −S−, −N(R')−, or −C(O)−. In some embodiments, it is an optionally substituted, bivalent C_1-C_5 linear saturated aliphatic wherein one or more methylene units is optionally and independently replaced with −O−, −S−, −N(R')−, or −C(O)−. In some embodiments, it is an optionally substituted, bivalent C_1-C_4 linear saturated aliphatic wherein one or more methylene units is optionally and independently replaced with −O−, −S−, −N(R')−, or −C(O)−. In some embodiments, it is an optionally substituted, bivalent C_1-C_3 linear saturated aliphatic wherein one or more methylene units is optionally and independently replaced with −O−, −S−, −N(R')−, or −C(O)−. In some embodiments, it is an optionally substituted, bivalent C_1-C_2 linear saturated aliphatic wherein one or more methylene units is optionally and independently replaced with −O−, −S−, −N(R')−, or −C(O)−. In some embodiments, it is a bivalent C_1-C_6 linear saturated aliphatic wherein one or more methylene units is optionally and independently replaced with −O−, −S−, −N(R')−, or −C(O)−. In some embodiments, it is a bivalent C_1-C_5 linear saturated aliphatic wherein one or more methylene units is optionally and independently replaced with −O−, −S−, −N(R')−, or −C(O)−. In some embodiments, it is a bivalent C_1-C_4 linear saturated aliphatic wherein one or more methylene units is optionally and independently replaced with −O−, −S−, −N(R')−, or −C(O)−. In some embodiments, it is a bivalent C_1-C_3 linear saturated aliphatic wherein one or more methylene units is optionally and independently replaced with −O−, −S−, −N(R')−, or −C(O)−. In some embodiments, it is a bivalent C_1-C_2 linear saturated aliphatic wherein one or more methylene units is optionally and independently replaced with −O−, −S−, −N(R')−, or −C(O)−. In some embodiments, there is no replacement of methylene unit. In some embodiments, there is one replacement. In some embodiments, there is two replacement. In some embodiments, there is three replacement. In some embodiments, there is four or more replacement. In some embodiments, R' in each moiety that is utilized to replace a methylene unit (e.g., −N(R')−) as described herein is hydrogen or optionally substituted C_{1-6} aliphatic or phenyl. In some embodiments, R' is each such moiety is hydrogen or optionally substituted C_{1-6} alkyl. In some embodiments, R' is each such moiety is hydrogen or C_{1-6} alkyl. In some embodiments, each −Cy− is optionally substituted bivalent ring selected from 3-10, 3-9, 3-8, 3-7, 5-10, 5-9, 5-8, 5-7, 5-6, or 3, 4, 5, 6, 7, 8, 9, or 10 membered cycloaliphatic and heterocyclylene having 1-3 heteroatoms, phenylene, and 5-6 membered heteroarylene having 1-3 heteroatoms. In some embodiments, −Cy− is optionally substituted bivalent 3-10, 3-9, 3-8, 3-7, 5-10, 5-9, 5-8, 5-7, 5-6, or 3, 4, 5, 6, 7, 8, 9, or 10 membered cycloaliphatic. In some embodiments, −Cy− is optionally substituted 3-10, 3-9, 3-8, 3-7, 5-10, 5-9, 5-8, 5-7, 5-6, or 3, 4, 5, 6, 7, 8, 9, or 10 membered heterocyclylene having 1-3 heteroatoms. In some embodiments, −Cy− is optionally substituted 3-10, 3-9, 3-8, 3-7, 5-10, 5-9, 5-8, 5-7, 5-6, or 3, 4, 5, 6, 7, 8, 9, or 10 membered heterocyclylene having 1 heteroatom. In some embodiments, −Cy− is optionally substituted phenylene. In some embodiments, −Cy− is phenylene. In some embodiments, −Cy− is optionally substituted 5-6 membered heteroarylene having 1-3 heteroatoms. In some embodiments, −Cy− is optionally substituted 5-6 membered heteroarylene having 1 heteroatom. In some embodiments, a heteroatom is nitrogen. In some embodiments, a heteroatom is oxygen. In some

embodiments, a heteroatom is sulfur. In some embodiments, L, L^a, L^{aa}, L^{a1}, L^{a2}, L^{s1}, L^{s2}, L^{s3}, L", or another variable or moiety that can be L, or a linker moiety, is optionally substituted $-(CH_2)n-$. In some embodiments, it is $-(CH_2)n-$. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8. In some embodiments, n is 9. In some embodiments, n is 10.

[0662] In some embodiments, L, L^a, L^{aa}, L^{a1}, L^{a2}, L^{s1}, L^{s2}, L^{s3}, L", or another variable or moiety that can be L, or a linker moiety, is an optionally substituted, bivalent heteroaliphatic group having 1-10 heteroatoms wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

[0663] Those skilled in the art appreciate that embodiments described for one linker moiety that can be L or L" (e.g., L^{aa}, L^{s1}, L^{s2}, L^{s3}, L^s, L^a, L^{a1}, L^{a2}, L^{RN}, etc.) may also be utilized for another group that can be L or L" to the extent that such embodiments fall within the definition of L or L".

[0664] As described above, each R' is independently $-R$, $-C(O)R$, $-CO_2R$, or $-SO_2R$. In some embodiments, R' is $-L^a-R$. In some embodiments, R' is R. In some embodiments, R' is $-C(O)R$. In some embodiments, R' is $-CO_2R$. In some embodiments, R' is $-SO_2R$. In some embodiments, R' is $-H$.

[0665] As described above, each R is independently $-H$, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

[0666] As described herein, in some embodiments, R is $-H$. In some embodiments, R is not $-H$. In some embodiments, R is optionally substituted C_{1-10} aliphatic. In some embodiments, R is optionally substituted C_{1-10} alkyl. In some embodiments, R is methyl. In some embodiments, R is ethyl. In some embodiments, R is isopropyl. In some embodiments, R is $-CF_3$. In some embodiments, R is $-CH_2CF_3$. In some embodiments, R is butyl. In some embodiments, R is t-butyl. In some embodiments, R is optionally substituted C_{3-10} cycloaliphatic. In some embodiments, R is optionally substituted C_{3-10} cycloalkyl. In some embodiments, R is optionally substituted cyclopropyl. In some embodiments, R is optionally substituted cyclobutyl. In some embodiments, R is optionally substituted cyclopentyl. In some embodiments, R is


optionally substituted cyclohexyl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is phenyl. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1-3 heteroatoms. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1 heteroatom. In some embodiments, R is optionally substituted 6-membered heteroaryl having 1-3 heteroatoms. In some embodiments, R is optionally substituted 6-membered heteroaryl having 1 heteroatom. In some embodiments, R is optionally substituted bicyclic 8-10 membered aromatic ring having 0-5 heteroatoms. In some embodiments, R is optionally substituted bicyclic 9-membered aromatic ring having 1-5 heteroatoms. In some embodiments, R is optionally substituted bicyclic 10-membered aromatic ring having 1-5 heteroatoms. In some embodiments, R is optionally substituted bicyclic 9-membered aromatic ring having 1 heteroatom. In some embodiments, R is optionally substituted bicyclic 10-membered aromatic ring having 1 heteroatom. In some embodiments, R is optionally substituted bicyclic 10-membered aromatic ring having no heteroatom. In some embodiments, R is optionally substituted 3-10 membered heterocyclyl having 1-5 heteroatoms. In some embodiments, R is optionally substituted 5-14 membered bicyclic heterocyclyl having 1-5 heteroatoms.

[0667] In some embodiments, two R groups (or two groups that can be R, e.g., two groups each independently selected from R', R^{a1}, R^{a2}, R^{a3}, R^{a5}, R^{RN}, etc.) are taken together with their intervening atom(s) to form an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms. In some embodiments, a formed ring is substituted. In some embodiments, a formed ring is unsubstituted. In some embodiments, a formed ring is 3-30, 3-20, 3-15, 3-10, 3-9, 3-8, 3-7, 3-6, 4-10, 4-9, 4-8, 4-7, 4-6, 5-10, 5-9, 5-8, 5-7, 5-6, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 membered. In some embodiments, a formed ring is 3-10 membered. In some embodiments, a formed ring is 3-7 membered. In some embodiments, a formed ring is 4-10 membered. In some embodiments, a formed ring is 4-7 membered. In some embodiments, a formed ring is 5-10 membered. In some embodiments, a formed ring is 5-7 membered. In some embodiments, a formed ring is 3-membered. In some embodiments, a formed ring is 4-membered. In some embodiments, a formed ring is 5-membered. In some embodiments, a formed ring is 6-membered. In some embodiments, a formed ring is 7-membered. In some embodiments, a formed ring is 8-membered. In some embodiments, a formed ring is 9-membered. In some embodiments, a formed ring is 10-membered. In some embodiments, a formed ring is monocyclic. In some embodiments, a formed ring is bicyclic. In some embodiments, a formed ring is polycyclic. In some embodiments, a formed ring has no heteroatoms in addition to the intervening atom(s). In some embodiments, a formed ring has 1-10, e.g., 1-5, 1-3, or 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 heteroatoms in addition to the intervening atom(s). In some embodiments, a formed ring is saturated. In some embodiments, a formed ring is partially unsaturated. In some embodiments, a formed ring comprises one or more aromatic ring. In some embodiments, a formed ring is bicyclic or polycyclic, and each monocyclic unit is independently 3-10 membered, saturated, partially unsaturated or aromatic and having 0-5 heteroatoms. In some embodiments, each heteroatom is independently selected from nitrogen, oxygen and

sulfur.

[0668] In some embodiments, a group that can be R, e.g., R', R^{a1}, R^{a2}, R^{a3}, R^{a5}, R^{RN}, etc., is R as described herein. Those skilled in the art appreciate that embodiments described for one group that can be R may also be utilized for another group that can be R to the extent that such embodiments fall within the definition of R.

[0669] In some embodiments, the present disclosure provides compounds having the structure of



PA-a

or a salt thereof, wherein:

each of m and n is independently 1, 2, 3, or 4;

L^{RN} is L;

R^{RN} is R;

R^{a5} is R'; and

each other variable is independently as described herein.


[0670] In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.

[0671] In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4.

[0672] In some embodiments, L^{RN} is $-CH_2-$, $-CO-$, or $-SO_2-$. In some embodiments, L^{RN} is $-CH_2-$. In some embodiments, L^{RN} is $-CO-$. In some embodiments, L^{RN} is $-SO_2-$. In some embodiments, L^{RN} is optionally substituted bivalent C_{1-4} alkylene. In some embodiments, L^{RN} is optionally substituted bivalent linear C_{1-4} alkylene. In some embodiments, L^{RN} is $-CH_2-CH_2-$. In some embodiments, L^{RN} is $-CH_2-CH_2-CH_2-$. In some embodiments, L^{RN} is $-C(CH_3)-$.

[0673] In some embodiments, R^{RN} is R as described herein. In some embodiments, R^{RN} is C_{1-7} alkyl or heteroalkyl having 1-4 heteroatoms, wherein the alkyl or heteroalkyl is optionally substituted with one or more groups independently selected from halogen, a C_{5-6} aromatic ring having 0-4 heteroatoms, and an optionally substituted 3-10 membered cycloalkyl or heteroalkyl ring having 1-4 heteroatoms.

[0674] In some embodiments, R (e.g., R^{RN}, R', etc.) is optionally substituted aliphatic, e.g., C_{1-10} aliphatic. In some embodiments, R is optionally substituted alkyl, e.g., C_{1-10} alkyl. In some embodiments, R is optionally substituted cycloalkyl, e.g., C_{1-10} cycloalkyl. In some embodiments, R is optionally substituted aryl. In some embodiments, R is optionally substituted heterocyclyl. In some embodiments, R is optionally

substituted heteroaryl. In some embodiments, is methyl. In some embodiments, R is $-CF_3$. In some embodiments, R is ethyl. In some embodiments, R is  . In some embodiments, R is phenyl. In some embodiments, R is pentafluorophenyl. In some embodiments, R is pyridinyl.


[0675] In some embodiments, one or more R^{a5} are independently –H. In some embodiments, one or more R^{a5} are independently optionally substituted C_{1-6} alkyl. In some embodiments, each R^{a5} is –H.

[0676] In some embodiments, $-L^{RN}-R^{RN}$ is R, and is taken together with a R^{a5} and their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms.

[0677] As described in the present disclosure, various rings, including those in various moieties (e.g., R or various groups that can be R, various bivalent rings such as those in –Cy–) and those formed by two entities (e.g., two groups that are or can be R) taken together with their intervening forms, can be various sizes, e.g., 3-30. In some embodiments, a ring is 3-30-membered. In some embodiments, a ring is 3-20 membered. In some embodiments, a ring is 3-10 membered. In some embodiments, a ring is e.g., 3, 4, 5, 6, 7, 8, 9, or 10-membered. In some embodiments, a ring is 3-membered. In some embodiments, a ring is 4-membered. In some embodiments, a ring is 5-membered. In some embodiments, a ring is 6-membered. In some embodiments, a ring is 7-membered. In some embodiments, a ring is 8-membered. In some embodiments, a ring is 9-membered. In some embodiments, a ring is 10-membered. In some embodiments, a ring is substituted (in addition to potential groups already drawn out in formulae). In some embodiments, a ring is not substituted. In some embodiments, a ring is saturated. In some embodiments, a ring is partially unsaturated. In some embodiments, a ring is aromatic. In some embodiments, a ring comprise one or more, e.g., 1-5, heteroatoms. In some embodiments, one or more heteroatoms are oxygen. In some embodiments, one or more heteroatoms are nitrogen. In some embodiments, one or more heteroatoms are sulfur. In some embodiments, a ring is a cycloaliphatic, e.g., cycloalkyl ring. In some embodiments, a ring is a heterocycloaliphatic, e.g., heterocycloalkyl ring. In some embodiments, a ring is an aryl ring. In some embodiments, a ring is a heteroaryl ring. In some embodiments, a ring is a heteroaryl ring. In some embodiments, a ring is monocyclic. In some embodiments, a ring is bicyclic or polycyclic. In some embodiments, each monocyclic unit in a ring is independently an optionally substituted, 3-10 membered (e.g., 3, 4, 5, 6, 7, 8, 9, or 10-membered) , saturated, partially unsaturated or aromatic ring having 0-5 heteroatoms.

[0678] As described herein, in some embodiments, a heteroatom is selected from nitrogen, oxygen, sulfur, silicon and phosphorus. As described herein, in some embodiments, a heteroatom is selected from nitrogen, oxygen, and sulfur.


[0679] In some embodiments, R^{a1} is –H. In some embodiments, R^{a1} is optionally substituted C_{1-6} alkyl. In some embodiments, R^{a1} are taken together with another group, e.g., R^{a3} and their intervening atoms to form an optionally substituted ring as described herein.

[0680] In some embodiments, $-C(O)R^{PC}$ is a protected carboxylic acid group. In some embodiments, $-C(O)R^{PC}$ is an activated carboxylic acid group. Those skilled in the art will appreciate that various groups are available for protecting/activating carboxyl groups, including various groups that are useful in peptide synthesis, and can be utilized in accordance with the present disclosure. In some embodiments, $-C(O)R^{PC}$ is an ester. In some embodiments, $-C(O)R^{PC}$ is an activated ester for synthesis. In some embodiments, $-C(O)R^{PC}$ is $-C(O)OR'$. In some embodiments, R' is R. In some embodiments, R' is optionally substituted C_{1-10} aliphatic. In some embodiments, R' optionally substituted phenyl. In some embodiments, R' is pentafluorophenyl. In some embodiments, R' is  .

[0681] In some embodiments, $-C(O)R^{PC}$ is $-COOH$.


[0682] In some embodiments, $-C(O)R^{PS}$ is a protected carboxylic acid group. In some embodiments, $-C(O)R^{PS}$ is an activated carboxylic acid group if it is to be reacted with another moiety. Those skilled in the art will appreciate that various groups are available for protecting/activating carboxyl groups, including various groups that are useful in peptide synthesis, and can be utilized in accordance with the present disclosure. In some embodiments, $-C(O)R^{PS}$ is an ester. In some embodiments, $-C(O)R^{PS}$ is an ester. In some embodiments, $-C(O)R^{PS}$ is $-C(O)OR'$. In some embodiments, R' is R. In some embodiments, R is optionally substituted C_{1-10} aliphatic. In some embodiments, R optionally substituted phenyl. In some embodiments, R is optionally substituted t-Bu. In some embodiments, R is t-Bu. In some embodiments, R is benzyl. In some embodiments, R is allyl. In some embodiments, $-C(O)R^{PS}$ is a protected carboxylic acid group that is compatible with peptide synthesis (e.g., Fmoc-based peptide synthesis). In some embodiments, $-C(O)R^{PS}$ is a protected carboxylic acid group which is orthogonal to $-C(O)R^{PC}$ and R^{PA}, and remains intact when $-C(O)R^{PC}$ and/or $N(R^{PA})(R^{a1})$ are protected, deprotected, and/or reacted (e.g., in peptide synthesis such as Fmoc-based peptide synthesis). In some embodiments, $-C(O)R^{PS}$ is deprotected at a late stage during synthesis, e.g., after a peptide backbone is or is largely constructed such that an unprotected side chain $-COOH$ does not impact synthesis.






[0683] In some embodiments, $-C(O)R^{PS}$ is $-COOH$.

[0684] As described above, R^{PA} is $-H$ or an amino protecting group. In some embodiments, R^{PA} is $-H$. In some embodiments, R^{PA} is an amino protecting group. In some embodiments, R^{PA} is an amino protecting group suitable for peptide synthesis. In some embodiments, R^{PA} is $-C(O)-O-R$, wherein R is optionally substituted  . In some embodiments, R^{PA} is $-Fmoc$. In some embodiments, R^{PA} is $-Cbz$. In some embodiments, R^{PA} is $-Boc$.


[0685] In some embodiments, R^{PS} is a protecting group orthogonal to R^{PA}. In some embodiments, R^{PS} is

a protecting group orthogonal to R^{PC}. In some embodiments, R^{PS} is compatible with peptide synthesis. In some embodiments, R^{PS} is optionally substituted C_{1-6} aliphatic. In some embodiments, R^{PS} is t-butyl.


[0686] In some embodiments, R^{PS} is $-S-L-R'$, wherein each variable is independently as described herein. In some embodiments, L is optionally substituted $-CH_2-$. In some embodiments, L is $-CH_2-$. In some embodiments, R^{PS} is $-S-CH_2-R'$, wherein R' is as described herein. In some embodiments, R' is R as described herein. In some embodiments, R is optionally substituted C_{6-30} aryl. In some embodiments, R is optionally substituted C_{6-10} aryl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is phenyl. In some embodiments, R is substituted phenyl wherein one or more substituents are independently alkoxy. In some embodiments, R is 2, 4, 6-trimethoxyphenyl. In some embodiments, R is optionally substituted 5-30 membered heteroaryl having 1-10 heteroatoms. In some embodiments, R is optionally substituted 5-10 membered heteroaryl having 1-4 heteroatoms. In some embodiments, R is optionally substituted 5-membered heteroaryl having 1-4 heteroatoms. In some embodiments, R^{PS} is $-S-CH_2-Cy-R'$, wherein the $-CH_2-$ is optionally substituted, and $-Cy-$ is as described herein. In some embodiments, R^{PS} is $-S-CH_2-Cy-O-R'$, wherein the $-CH_2-$ is optionally substituted, and $-Cy-$ is as described herein. In some embodiments, $-Cy-$ is an optionally substituted aromatic ring. In some embodiments, $-Cy-$ is optionally substituted phenylene. In some embodiments, $-Cy-$ is 2, 6-dimethoxy-1, 4-phenylene. In some embodiments, $-Cy-$ is 2, 4, 6-trimethoxy-1, 3-phenylene. In some embodiments, R^{PS} is  . In some embodiments, R^{PS} is $-SH$.

[0687] In some embodiments, R^{a2} is  . In some embodiments, R^{a2} is  . In some embodiments, R^{a2} is  . In some embodiments, R^{a2} is  . In some embodiments, $-C(R^{a2})(R^{a3})-$ is  .


[0688] In some embodiments, a provided compound, e.g., an amino acid, is selected from:





(TfeGA)





(EtGA)






























[0689] In some embodiments, R^{a2} is R^{a2} in a compound described above (a non-hydrogen group attached to an alpha carbon).

[0690] In some embodiments, the present disclosure provides compounds having the structure of:



PA-b

or a salt thereof, wherein:

Ring A is an optionally substituted 3-10 membered ring;


n is 0-6;

m is 0-6; and

each other variable is independently as described herein.

[0691] In some embodiments, m is 0. In some embodiments, m is 1-6.

[0692] In some embodiments, the present disclosure provides compounds having the structure of:



PA-c

or a salt thereof, wherein:

Ring A is an optionally substituted 3-10 membered ring;


n is 0-6;

m is 0-6; and

each other variable is as described herein.

[0693] In some embodiments, m is 0. In some embodiments, m is 1-6.

[0694] In some embodiments, the present disclosure provides compounds having the structure of:



PA-d

or a salt thereof, wherein:

Ring A is an optionally substituted 3-10 membered ring;

n is 0-6; and

each other variable is as described herein.

[0695] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 0, 1, or 2.

[0696] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 1, 2, or 3.


[0697] In some embodiments, Ring A is a ring as described herein. In some embodiments, Ring A is 3-



membered. In some embodiments, Ring A is 4-membered. In some embodiments, Ring A is 5-membered. In some embodiments, Ring A is 6-membered. In some embodiments, Ring A is 7-membered. In some embodiments, Ring A is 8-membered. In some embodiments, Ring A is 9-membered. In some embodiments, Ring A is 10-membered. In some embodiments, Ring A is saturated. In some embodiments, Ring A is partially unsaturated. In some embodiments, Ring A is aromatic. In some embodiments, Ring A has no additional heteroatoms in addition to the nitrogen atom. In some embodiments, Ring is unsubstituted. In some embodiments, Ring A is substituted with one or more halogen. In some embodiments, Ring A is substituted with one or more −F. In some embodiments, Ring A has a carbon substituted with two −F. In some embodiments, $-C(O)R^{PS}$ is at 2'-position (N being position 1). In some embodiments, $-C(O)R^{PS}$ is at 3'-position. In some embodiments, $-C(O)R^{PS}$ is at 4'-position. In some embodiments, $-C(O)R^{PS}$ is attached to a chiral center, e.g., a chiral carbon atom. In some embodiments, a chiral center is *R*. In some embodiments, a chiral center is *S*. In some embodiments, Ring A is bonded to $-(CH_2)n-$ at a chiral carbon which is *R*. In some embodiments, Ring A is bonded to $-(CH_2)n-$ at a chiral carbon which is *S*. In some embodiments, $-(CH_2)n-$ is at position 2 (the N is at position 1). In some embodiments, $-(CH_2)n-$ is at position 3 (the N is at position 1). In some embodiments, $-(CH_2)n-$ is at position 4 (the N is at position 1).



[0698] In some embodiments, Ring A is substituted. In some embodiments, substituents on Ring A are of suitable properties, e.g., volumes, for various utilizations. In some embodiments, substituents are independently selected from halogen, −R, $-CF_3$, $-N(R)_2$, −CN, and −OR, wherein each R is independently C_{1-6} aliphatic optionally substituted with one or more −F. In some embodiments, substituents are independently selected from halogen, C_{1-5} linear, branched or cyclic alkyl, −OR wherein R is C_{1-4} linear, branched or cyclic alkyl, fluorinated alkyl, $-N(R)_2$ wherein each R is independently C_{1-6} linear, branched or cyclic alkyl, or −CN. In some embodiments, substituents are selected from halogen, a C_{5-6} aromatic ring having 0-4 heteroatoms, and an optionally substituted 3-10 membered cycloalkyl or heteroalkyl ring having 1-4 heteroatoms. In some embodiments, a substituent is halogen. In some embodiments, it is −F. In some embodiments, it is −Cl. In some embodiments, it is −Br. In some embodiments, it is −I. In some embodiments, a substituent is optionally substituted C_{1-4} alkyl. In some embodiments, a substituent is C_{1-4} alkyl. In some embodiments, it is methyl. In some embodiments, it is ethyl. In some embodiments, it is i-Pr. In some embodiments, a substituent is C_{1-4} haloalkyl. In some embodiments, a substituent is C_{1-4} alkyl optionally substituted with one or more −F. In some embodiments, it is $-CF_3$. In some embodiments, it is −CN. In some embodiments, it is −OR wherein R is optionally substituted C_{1-4} alkyl. In some embodiments, it is −OR wherein R is C_{1-4} alkyl. In some embodiments, it is −OR wherein R is C_{1-4} haloalkyl. In some embodiments, it is −OR wherein R is C_{1-4} alkyl optionally substituted with one or more −F. In some embodiments, it is $-OCF_3$.


[0699] In some embodiments, Ring A is or comprises an optionally substituted saturated monocyclic ring. In some embodiments, Ring A is or comprises an optionally substituted partially unsaturated monocyclic ring. In some embodiments, Ring A is or comprises an optionally substituted aromatic

monocyclic ring. In some embodiments, Ring A is optionally substituted phenyl. In some embodiments, Ring A is optionally substituted 5-6 membered heteroaryl having 1-3 heteroatoms. In some embodiments, Ring A is optionally substituted 5-6 membered heteroaryl having 1-3 heteroatoms, wherein at least one heteroatom is nitrogen. In some embodiments, Ring A is an optionally substituted 8-10 membered bicyclic ring having 1-6 heteroatoms. In some embodiments, Ring A is an optionally substituted 8-10 membered bicyclic aromatic ring having 1-6 heteroatoms, wherein each monocyclic unit is independently an optionally 5-6 membered aromatic ring having 0-3 heteroatoms. In some embodiments, Ring A is bonded to $-(CH_2)n-$ at a carbon atom. In some embodiments, Ring A is bonded to $-(CH_2)n-$ at a nitrogen atom. In some embodiments, Ring A or −Cy− in L^{aa} is optionally substituted, and each substitute is independently selected from halogen, −R, $-CF_3$, $-N(R)_2$, −CN, and −OR, wherein each R is independently C_{1-6} aliphatic optionally substituted with one or more −F. In some embodiments, Ring A or −Cy− in L^{aa} is optionally substituted, and each substitute is independently selected from halogen, C_{1-5} linear, branched or cyclic alkyl, −OR wherein R is C_{1-4} linear, branched or cyclic alkyl, fluorinated alkyl, $-N(R)_2$ wherein each R is independently C_{1-6} linear, branched or cyclic alkyl, or −CN.


[0700] In some embodiments, Ring A is optionally substituted phenyl. In some embodiments, the present disclosure provides a compound of formula  or a salt thereof, wherein Ring A is optionally substituted phenyl, and each variable is as described herein.

[0701] In some embodiments, the present disclosure provides compounds having the structure of  or a salt thereof, wherein each variable is independent as described herein. In some embodiments, the present disclosure provides compounds having the structure of  or a salt thereof, wherein each variable is independent as described herein.





[0702] In some embodiments, a compound is selected from:  (2COOHF)  (3COOHF)










[0703] In some embodiments, the present disclosure provides a compound of formula




or a salt thereof, wherein Ring A is optionally substituted phenyl, and each variable is as described herein. In some embodiments, a compound is selected from:


[0704] In some embodiments, Ring A is an optionally substituted 5- or 6-membered heteroaryl having 1-4 heteroatoms. In some embodiments, a provided compound has the structure of  , wherein Z is carbon or a heteroatom, Ring Het is an optionally substituted 5- or 6-membered heteroaryl having 1-4 heteroatoms, and each other variable is independently as described herein. In some embodiments, a provided compound is selected from:


[0705] In some embodiments, Ring A is a 8-10 membered bicyclic aryl or a heteroaryl ring having 1-5 heteroatoms. In some embodiments, Ring A is a 10-membered bicyclic aryl ring. In some embodiments, Ring A is a 8-membered bicyclic heteroaryl ring having 1-5 heteroatoms. In some embodiments, Ring A is a 9-membered bicyclic heteroaryl ring having 1-5 heteroatoms. In some embodiments, Ring A is a 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms. In some embodiments, Ring A is an optionally substituted 5- or 6-membered heteroaryl having 1-4 heteroatoms. In some embodiments, a provided




compound has the structure of , wherein each of Ring r1 and r2 is independently an optionally substituted 5- or 6-membered aryl or heteroaryl ring having 1-4 heteroatoms, and each other variable is independently as described herein. In some embodiments, a provided compound has the structure




of , wherein Z is carbon or a heteroatom, each of Ring r1 and r2 is independently an optionally substituted 5- or 6-membered aryl or heteroaryl ring having 1-4 heteroatoms, and each other variable is independently as described herein. In some embodiments, a provided compound is selected from:



[0706] In some embodiments, the present disclosure provides a compound of structure




or a salt thereof. In some embodiments, $-C(O)R^{PS}$ is $-C(O)-OtBu$. In some embodiments, the present disclosure provides a compound of structure




or a salt thereof, wherein each variable is independently as described herein.


[0707] In some embodiments, a provided compound is selected from:



[0708] In some embodiments, the present disclosure provides compounds having the structure of




or a salt thereof, wherein each variable is independently as described herein. In some embodiments, the present disclosure provides compounds having the structure of



or a salt thereof, wherein each variable is independently as described herein.

[0709] In some embodiments, a provided compound is selected from:



[0710] In some embodiments, a provided compound is an amino acid. In some embodiments, a

provided compound is a protected amino acid. In some embodiments, a provided compound is a protected and/or activated amino acid. In some embodiments, a provided compound is suitable for

[0711] In some embodiments, a ring moiety of, e.g., −Cy−, R (including those formed by R groups taken together), etc. is monocyclic. In some embodiments, a ring moiety is bicyclic or polycyclic. In some embodiments, a monocyclic ring is an optionally substituted 3-10 (3, 4, 5, 6, 7, 8, 9, or 10, 3-8, 3-7, 4-7, 4-6, 5-6, etc.) membered, saturated, partially unsaturated or aromatic ring having 0-5 heteroatoms. In some embodiments, each monocyclic ring unit of a bicyclic or polycyclic ring moiety is independently an optionally substituted 3-10 (3, 4, 5, 6, 7, 8, 9, or 10, 3-8, 3-7, 4-7, 4-6, 5-6, etc.) membered, saturated, partially unsaturated or aromatic ring having 0-5 heteroatoms.

[0712] In some embodiments, each heteroatom is independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, each heteroatom is independently selected from oxygen, nitrogen, and sulfur.











[0713] In some embodiments, L^{a1} is a covalent bond. In some embodiments, a compound of formula PA is of the structure $NH(R^{a1})-C(R^{a2})(R^{a3})-L^{a2}-COOH$.









[0714] In some embodiments, L^{a2} is a covalent bond. In some embodiments, a compound of formula PA is of the structure $NH(R^{a1})-C(R^{a2})(R^{a3})-L^{a2}-COOH$.


[0715] In some embodiments, L^{a1} is a covalent bond and L^{a2} is a covalent bond. In some embodiments, a compound of formula PA is of the structure $NH(R^{a1})-C(R^{a2})(R^{a3})-COOH$.

[0716] In some embodiments, an amino acid is suitable for stapling. In some embodiments, an amino acid comprises a terminal olefin.

[0717] In some embodiments, an amino acid has the structure of $NH(R^{a1})-L^{a1}-C(-L^{aa}-COOH)(R^{a3})-L^{a2}-COOH$, or a salt thereof, wherein each variable is independently as described in the present disclosure. In some embodiments, L^{aa} is $-L^{am1}-N(R')-L^{am2}-$, wherein each variable is as described herein. In some embodiments, each of L^{am1} and L^{am2} is optionally substituted bivalent C_{1-6} aliphatic. In some embodiments, each of L^{am1} and L^{am2} is bivalent C_{1-6} aliphatic. In some embodiments, each of L^{am1} and L^{am2} is optionally substituted bivalent C_{1-6} alkyl. In some embodiments, each of L^{am1} and L^{am2} is bivalent C_{1-6} alkyl. In some embodiments, each of L^{am1} and L^{am2} is optionally substituted bivalent linear C_{1-6} alkyl. In some embodiments, each of L^{am1} and L^{am2} is bivalent linear C_{1-6} alkyl. In some embodiments, L^{am1} is $-CH_2-$. In some embodiments, L^{am2} is a covalent bond. In some embodiments, L^{am2} is $-CH_2-$. In some embodiments, both L^{am1} and L^{am2} are $-CH_2-$. In some embodiments, L^{am1} is $-CH_2-$ and L^{am2} is a covalent bond. In some embodiments, $-N(R')-$ is $-N(Et)-$. In some embodiments, $-N(R')-$ is $-N(CH_2CF_3)-$. In some embodiments, L^{aa} is $-L^{am1}-Cy-L^{am2}-$, wherein each variable is as described herein. In some embodiments, −Cy− is optionally substituted phenyl. In some embodiments, −Cy− is optionally substituted 5-6 membered heteroaryl having 1-4 heteroatoms.

[0718] In some embodiments, a compound is  (2COOHF) or a salt thereof. In some embodiments, a compound is  (3COOHF) or a salt thereof. In some embodiments, a compound is  (TfeGA) or a salt thereof. In some embodiments, a compound is  (EtGA) or a salt thereof. In some embodiments, a compound is  or a salt thereof. In some embodiments, a compound is  or a salt thereof. In some embodiments, a compound is  or a salt thereof. In some embodiments, a compound is  or a salt thereof. In some embodiments, a compound is  or a salt thereof. In some embodiments, a compound is  or a salt thereof. Among other things, such compounds may be utilized as amino acid residues in peptides including stapled peptides.

[0719] In some embodiments, the present disclosure provides a compound, e.g., a peptide, comprising a residue of a compound of formula PA or a salt form thereof. In some embodiments, a residue has the structure of $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$ or a salt form thereof, wherein each variable is independently as described herein. In some embodiments, a residue has the structure of $-N(R^{a1})-L^{a1}-C(-L^{aa}-COOH)(R^{a3})-L^{a2}-C(O)-$ or a salt form thereof, wherein each variable is independently as described herein. For example, in some embodiments, a residue is  or a salt form thereof. In some embodiments, a residue is  or a salt form thereof. In some embodiments, a residue is  or a salt form thereof. In some embodiments, a residue is  or a salt form thereof. In some embodiments, a residue is  or a salt form thereof. In some embodiments, a residue is  or a salt form thereof. In some embodiments, a residue is  or a salt form thereof. In some embodiments, a residue is  or a salt form thereof. In some embodiments, a residue is



























or a salt form thereof.





















[0720] Certain amino acids and structure moieties are described in WO 2022/020651 and WO 2022/020652, the amino acids and structure moieties of each of which are independently incorporated herein by reference, and can be utilized in accordance with the present disclosure





















[0721] In some embodiments, an amino acid, or a structure moiety, of an amino acid or an agent (e.g., a peptide), is selected from below. A N-terminal cap (N-Term) is connected via R_1 to the amino group (R_1) of the first amino acid (AA1). In some embodiments, a N-Term cap may be properly considered as part of AA1. From there, each carboxylate (R_2) of that amino acid is connected to the amino group (R_1) of the subsequent amino acid, until the carboxylate (R_2) of the final amino acid is connected to R_1 of a C-terminal group. For any amino acid that has a branch point (R_3) and a branching monomer is indicated in brackets, R_1 of the monomer in brackets is attached to R_3 of the amino acid. For the amino acid Dap, with two potential branch points (R_3 and R_4), if two branches are indicated, the R_1 of the first branch is connected to R_3, and R_1 of the second branch connected to R_4. For any pair of amino acids that terminate in a *3 designation, the R_3 groups of each of those amino acids are linked to each other. Likewise, for any pair of amino acids that terminate in a **3 designation, the R_3 groups of those amino acids are linked to each other. For any sequence that contains a pair of branching amino acids with R_3 groups, and one contains a branching monomer that contains both R_1 and R_2 groups, then R_1 is attached to the branching amino acid adjacent to it in the sequence, and the R_2 group of the branching monomer is attached to R_3 of the amino acid with no branching monomer designated. For example, in various peptides that have one of Cys, hCys, Pen, or aMeC at position 10 and also one of Cys, hCys, Pen, or aMeC at position 14, and a branching group off of the amino acid residue 10, the R_1 of that branching group is tied to the R_3 of the amino acid residue at position 10, while the R_2 of that branching group is tied to the R_3 of the amino acid residue at position 14. For any amino acid which has a branching amino acid containing R_3 and nothing attached to it by the above, then R_3 = H. Typically, all residues with terminal olefins are linked (stapled) by ring-closing metathesis. Certain examples are provided in Table E2 and Table E3. In some embodiments, the present disclosure provides agents, e.g., peptides such as stapled peptides, comprising one or more amino acid residues selected from below.





















[0722] Table A-IV. Certain useful compounds or moieties.





















Compound/ Bracket Moiety	Structure	Compound/ Bracket Moiety	Structure
Ala		Gly	























Cys		His	
Asp		Ile	
Glu		Lys	
Phe		Leu	
nLeu		Arg	
Asn		Ser	
Pro		Thr	
Gln		aThr	
GlnR		Val	
Trp		4F3MeF	
Tyr		Npg	





















MePro		Aib	
PL3		Cpg	
B5		Cbg	
PyrS2		CyLeu	
BztA		Orn	
3Thi		Dab	
2Thi		TriAzLys	
2F3MeF		TriAzOrn	
sAla		TfeGA	
sAbu		iPrLys	






















sCH2S		MeAsn	
dLys		hGlnR	
dOrn		2OH3COOHF	
DGlnR		4OH3COOHF	
DAsnR		TriAzDap	
3COOHF		4COOHF	
Hse		2COOHF	
Cha		5F3Me2COOHF	
4F3Me2COOHF		Cba	
5F3Me3COOHF		SbMeAsp	

























4F3Me3COOHF		RbMeAsp	
3F2COOHF		2FurA	
dGlu		2OMeF	
hTyr		2MeF	
3cbmf		2BrF	
MorphNva		2ClF	
R4		2CNF	
R5		2NO2F	
R6		2PyrA	
CypA		3PyrA	





















Chg		4PryA	
Pff		3BrF	
DiethA		34MeF	
4PipA		34ClF	
Abu		Phg	
Nva		DipA	
hLeu		OctG	
Cpa		F2PipNva	
MorphGln		Aad	
1NapA		hPhe	

























2NapA		hnLeu	
Me2Gln		2cbmf	
AcLys		dOrn	
Met2O		dDab	
Acp		MeOrn	
2Cpg		Dap	
aMeL		4FF	
DaMeL		4ClF	
aMeV		4BrF	
aMeS		4CNF	
DaMeS		4MeF	






















aMeF		3FF	
aMeDF		3ClF	
dAla		3BrF	
dLeu		3OMeF	
OAsp		3MeF	
Sar		3CNF	
NMebAla		2FF	
Aic		[BzAm2OAllyl]	
RbiPrF		[oXyl]	
SbiPrF		[mXyl]	





















RbiPrDF		[pXyl]	
RbMeXylA		[4FB]	
RbMeXylDA		[8FBB]	
SbMeXylA		[CH2CMe2CO2H]	
SbMeXylDA		[NHEt]	
AzLys		[29N2spirounddecane]	
AllylGly		[39N2spirounddecane]	
[CyCO]		[4mampiperidine]	
[Piv]		[4aminopiperidine]	
[Phc]		[diaminobutane]	
[Bn]		NH2	
[3butenyl]		OH	





















[Allyl]		dAlaol	
[5hexenyl]		Alaol	
[4pentenyl]		Serol	
[3_3-biph]		Prool	
[2_6-naph]		Throl	
4TriA		[2COOH4NH2Ph]	
3F3MeF		[2COOH4NO2Ph]	
AsnR		[2COOHPh]	
aMeDAsp		[2Nic]	
[isophthalate]		[2OxoPpz]	
[succinate]		[3C]	
[Me2MaI]		[3Py]	























[diphenate]		[4AcMePip]	
[Biphen33COOH]		[4CF3PhAc]	
ThioPro		[4F3CPip]	
[4MePpzPip]		[EtSSEt]	
[4Pippip]		[EtSSHex]	
[4PyPip]		[EtSSPh]	
[Ac]		[EtSSpy]	
[AcPpz]		[H4IAP]	
[bismethoxyethylamine]		[isoindoline]	
[Bn]		[lithocholate]	
[CCpCO2H]		[PEG2]	





















[CF3CO]		[Me]	
[CH2CChCO2H]		[Me2diaminobutane]	
[CH2CCpCO2H]		[Me2NCBz]	
[CH2CH2CO2H]		[Me2Npr]	
[CH2CMe2CO2H]		[Me2NPrPip]	
[CH2CO2H]		[Me3AdamantC]	
[CH2NMe2]		[MeMorphBz]	
[CH2Ppz]		[MePipAc]	
[CMe2CO2H]		[MeSO2]	
[CyPr]		[Morph]	
[Et]		[MorphAc]	
[EtSO2Ppz]		[MorphCH2]	
[MorphEt]		2F3MeW	





















[NdiMeButC]		2NH2F	
[NHBn]		34ClF	
[NHEt]		34MeF	
[NMe2]		3Br4FF	
[PfbGA]		3BrF	
[Pfbn]		3CBMF	
[PfBz]		3CH2NMe2F	
[PfPhAc]		3CO2PhF	
[Ph]		3SF	
[Phc]		3SO2F	
[Pic]		3TzF	

[Ppz]		4BrF	
[RDMAPyr]		4ClBztA	
[Red]		4ClW	
[sBu]		4F3COOHF	
[SO2MorphCH2]		4FW	
[Tfb]		4SEF	
[TfePpz]		4TzF	
[Tfp]		5F3Me3COOHF	
5IndA		BzAm3Oallyl	
5iPr3COOHF		Cba	

7AzaW		Cbg	
7ClBztA		ClAc	
7FBztA		CO	
AcAsp		CO2Bu	
AcLys		CO2Hex	
AspE		CO2iBu	
AspSH		CO2Me	
Az2		CO2Ph	
Az3		Cpg	
B3		CyLeu	

B4		dAla	
B6		dIle	
bMe2Asp		dLeu	
Bn3OAllyl		F2PipAbu	
BnBoroleK		F2PipNva	
Bnc		GA	
BrAc		GAbu	
BzAm2Allyl		GlnR	
GluE		NMebAla	
GluSH		Npa	
hhLeu		PAc3OAllyl	

HypBzEs3O Allyl		ProAm5	
HypEs4		ProAm6	
HypEs5		ProBzAm3O Allyl	
HypPAc3OA llyl		ProPAc3OAll yl	
Me2Asn		PropynOH	
Me2Gln		ProSAm3	
MeAsn		PyrR	
MeGln		PyrR2	
MePpzAbu		PyrS4	
MePpzAsn		R2COOPipA	

MePpzNva		R3COOPipA	
MePro		RbMe2NapA	
Met2O		RbMeBztA	
MorphAbu		RbOHAsp	
MorphAsn		S2COOPipA	
MorphGln		S3COOPipA	
MorphNva		sAc	
sAla		SPip2	
Sar		SPip3	
SbMe2NapA		sPr	












SbMeBztA		TriAzDap	
sBut		TriAzDab	
SeNc5		TriAzLys	
SPip1		TriAzdLys	
BiotinPEG8			


Table A-IV (Continued; certain moieties may be presented in [])

Certain moieties useful as, e.g., Lys analogs, branch point amino acid residues, or non-RCM stapling amino acid residues







iPrLys




TriAzDap




4PipA




GlnR




AsnR




NMeOrn




Dap




hGlnR




Orn




Dab




TriAzLys




TriAzOrn




Acp




3AmPhe




4AmPhe




Pen




1MeK




hGlnR





AsnEDA





GlnEDA



AsnPpz



GlnPpz



GlnR3APyr



GlnS3APyr



GlnMe2EDA



AsnMe2EDA



AsnMeEDA


AsnR3APyr



AsnS3APyr



PyrRa



PyrSa



hCysOx


Certain moieties useful as, e.g., stapling amino acid residues (e.g., RCM for other stapling technologies)



PL3



B5



PyrS2



PyrS3



PyrS



PyrS1



R4



R5



R6



R7



R8



B4



B3



B6



RgN



SgN



RdN



SdN



ReN



SeN



S4



S5



S6



S7



S8



Az



SeNc5



AllylGly



PyrS4



PyrR2



PyrR



PyrS5



PyrSc72RMe3SOMe



Az2 Az3



SPip2 SPip3



PyrSc72SMe3ROMe



PyrSc7



PyrSc73Me2



DapAc7



PyrSc7O45RMe



PyrSc7O45SMe



PyrSaA3Butene



PyrSadA3Butene



Dap7Gly



Dap7Pent



DapAc7EDA



DapAc7PDA



Dap7Abu



4VinylPyrSa



3allyloxyPyrSa



PyrSaV3Butene



PyrSadV3Butene



PyrSaSar3Butene


PyrSaNip3Butene



PyrSadNip3Butene



PyrSaPro3Butene



PyrSa4VinMe2PhAc



3allylPyrSa


Certain moieties useful as, e.g., aromatic amino acid residues



4F3MeF



BztA



3Thi



2Thi



2F3MeF



3COOHF



2OH3COOHF



4OH3COOHF



Pff



3cbmf



4COOHF



2COOHF



4F3Me2COOHF



5F3Me3COOHF



4F3Me3COOHF



3F2COOHF



5F3Me2COOHF



2FurA



2OMeF



2MeF



2BrF



2ClF



2CNF



2NO2F



2PyrA



3PyrA



4PyrA



3BrF



34MeF



34ClF



Phg



DipA



2cbmf



1NapA



2NapA (2Nal)



4FF



4ClF



4BrF



4CNF



4MeF



3FF



3ClF



3BrF



3OMeF



3MeF



3CNF



2FF



Aic



RbiPrF



SbiPrF



RbiPrDF



RbMeXylA



RbMeXylDA



SbMeXylA



SbMeXylDA



4cbmf



6F1NapA



Qui



5MeOW



345FF



34FF



WCHO



3F3MeF



4F3MeF



245FF



1MeH



tetz



3MeH



4Thz



5ClW



6ClW



1MeW



6FW



6ClaMeW



5ClW



d1NapA



d2NapA



CF3Tyr



34OMeF



24MeF



h4PyrA



6CNW



6MeW



6FW



3FTyr



35BrY



3ClY



3NO2Y



OTrp



c6Phe


3BOH2F



4BOH2F



7FBztA



7ClBztA



7MeBztA


Certain moieties useful as amino acid residues



Ala



Cys



Asp



Glu



Phe



Gly



His



Ile



Lys



Leu



Met


Asn



Pro



Gln



Arg





Certain moieties useful as, e.g., amino acid residues (e.g., D-amino acid residues, homologated amino acid residues, alkyl (e.g., methyl) amino acid residues, etc.)
















Certain moieties useful as, e.g., amino acid residues (e.g., alkyl amino acid residues, hydrophobic amino acid residues, etc.)



Npg



Aib



Cpg



Cbg



CyLeu



Cha



nLeu



Chg



Tle



NMebAla



OctG



DiethA



Cba



Abu



Nva



Cpa



2Cpg



hnLeu



CypA



Abu



alle



F3CA



HF2CA



Ppg



hCba



hCypA


hCha



Nip



dNip



4Abu



NHPent


Certain moieties useful as, e.g., amino acid residues (e.g., polar amino acid residues, basic amino acid residues, etc.)



aThr



Hse


Me2Gln



Met2O


MeAsn



S(OMe)





Certain moieties useful as, e.g., amino acid residues (e.g., acidic amino acid residues, non-aromatic amino acid residues, etc.)




Certain moieties (e.g., moieties utilized in [] in various agents)





Serol
Prool
Throl
isophthalate
Tf
35CF3PhPr
1NapPr
BiotinPEG8
succinate
Me2Mal
diphenate
Biphen33COOH
Bip
Acryl
22PhPr
F3CCro
MeSO2
NHiPr
NHnPr
NHCyPr
NHCyBu
NHMe
MorphAc
MePipAc
Ac
ClAc
IAc
MeBipipAc
4MePipBz
MeMorphBz
Me2NCBz
mPEG2
mPEG4



mPEG6
mPEG8
Bua
Hex
C2Mal
Oct
AdamantC
Me3AdamantC
AdamantPro
6AmHex
Leuol
Pheol
C3Mal
ES
3MPA
5Pnyl
isovaleryl
2PyBu
1Imidac
2F2PyAc
2IAPAc
124TriPr
6QuiAc
3PyAc
123TriAc
1PyrazoleAc
4PyPrpc
3PyPrpc
5PymAc
1PydoneAc
124TriAc
3IAPAc
Me2NAc
4MePipzPrpC
MeImid4SO2
8QuiSO2
PfBn
Tfb
mPyr
C3




mPEG16





mPEG24





mPEG37



CH2CO2H



SaiPrSuc



RaiPrSuc



SaMeSuc



Red



33Oxe


IsoE



13Ac



m5Meb



m5Pyr



m5OMeb


Certain moieties (e.g., moieties utilized in [] in various agents, amino acid residues, etc.)



NPyroR3



C3a



isobutyryl


Cpc



Cbc



CypCO


2PyCypCO





PEG4triPEG16



4THPCO


2NH2F


Bnc


BiPh
PEG4triPEG36
35
diaminopentane
diaminopropane
diaminobutane
malonate
Me2diaminohexane
Me2ethylenediamine
15PyraPy
2FPhc
3Phc3
4PymCO
5PymCO
8IAP
MeOPr
Ts
ethylenediamine
2PyzCO
2PhF
Ala_D3
CyhLeu
Dpg
HepG
HexG
NAsp
NGlu
2AmMePhe
3AmMePhe
4AmMePhe



24FF
46ClW
4CNW
5MeW
5Pnyl
6FlW
7ClW
7MeW
PyrR3
2IAPAc
6QuiAc
2PyBu
34FF
Az1
Az
46ClW
CF3CO
6QuiAc
124TriAc
5PymAc
2PyCypCO
2PyzCO
124TriPr
2PyAc
2PyPrpc
3PyPrpc
4PyPrpc
PhOPr
Me2MeOPr
Me2NPr
NdiMeButC
3IAPAc
15PyraPy
MorphAc
Nic
5PymCO




1MeK




dPEG2




Oct




PEG8




C18




GlnPDA




GlnBDA




GlnMePDA




GlnMe2BDA




GlnMeBDA




Gln5DA




Gln6DA




GlnT4CyMe




AcLys




GlnC4CyMe




Gln3ACPip




GlnPipAz




lithcholate





Gln4Pippip





GlnPip4AE



S3MePyrSc7



R3MePyrSc7


S3iPrPyrSc7


R3iPrPyrSc7


3FPyr2c


5ClW




6ClW


4FPyr3c

[0723] In some embodiments, within a bracket there are two moieties, e.g., [Ac-dPEG2], typically R_1 of the first is connected to R_1 of the latter. For example, in [Ac-dPEG2], R_1 of Ac is connected to R_1 of dPEG2. R_2 of dPEG2 can be connected to other moieties, e.g., in [Ac-dPEG2]-Lys, R_3 of Lys.

[0724] In some embodiments, the present disclosure provides an agent, e.g., a peptide agent (in various embodiments, a stapled peptide agent), comprising a moiety selected from the table above. In some embodiments, a residue is stapled, e.g., forming a staple with another moiety. In some embodiments, an agent comprises a staple formed between two moieties each independently selected from the table above. In some embodiments, a staple comprises a double bond. In some embodiments, a staple comprises an *E* double bond. In some embodiments, a staple comprises a *Z* double bond. In some embodiments, a double bond is converted into another moiety, e.g., to a saturated bond through hydrogenation, an epoxide through epoxidation, etc. In some embodiments, a moiety, e.g., an amino acid residue, comprises two groups that can be utilized for stapling. In some embodiments, an amino acid residue comprises two groups for stapling, e.g., B3, B4, B5, B6, Dap7Gly, Dap7Pent, DapAc7EDA, DapAc7PDA, Dap7Abu, etc. In some embodiments, a N-terminal group, e.g., 4pentenyl, 5hexenyl, etc., may be considered as part of the first amino acid residue for stapling. In some embodiments, amino acid residues with N-terminal groups (e.g., 4pentenyl, 5hexenyl, etc.) such as 4pentenyl-PL3, 5hexenyl-PL3, etc., comprise two groups, e.g., two double bonds, for stapling. In some embodiments, a group for stapling is a double bond. In some embodiments, each group for stapling is independently a double bond. In some embodiments, a group for stapling is a double bond and the other is not (e.g., amino group, or a group which is or comprises R_3). In some embodiments, an agent comprise two or more residues each independently comprising two or more groups (e.g., double bond) for stapling (e.g., 5hexenyl-PL3-Asp-AllylGly-B5-Asp-3COOHF-Ala-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-Gln-NH2 or salt thereof (ESP-1), 4pentenyl-PL3-Asp-AllylGly-B5-Asp-3COOHF-Ala-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-Gln-NH2 or salt thereof (ESP-2), etc., for stapling). In some embodiments, an agent comprises two or more amino acid residues each of which is independently bonded to two staples (e.g., 5hexenyl-PL3-Asp-AllylGly-B5-Asp-3COOHF-Ala-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-Gln-NH2 (ESP-1) or salt thereof, 4pentenyl-PL3-Asp-AllylGly-B5-Asp-3COOHF-Ala-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-Gln-NH2 or salt thereof (ESP2),

etc. wherein the double bonds are utilized to form staples; in some embodiments, staples are formed through olefin metathesis; in some embodiments, double bonds in staples are further converted, e.g., into saturated bonds (e.g., through hydrogenation)). In some embodiments, agents, e.g., ESP-1, ESP-2, etc., comprise two or more staples within a short sequence and provide high stapling density, for example, a (i, i+2) and a (i, i+3) staple bonded to the same amino acid residue. In some embodiments, staples in provided agents are more evenly distributed out so that for any amino acid residues bonded to two or more staples, one and only one is (i, i+2) or (i, i+3). Thus, in some embodiments, an agent is not ESP-1 or ESP-2 (wherein ESP-1 and ESP-2 are not stapled, stapled, or modified post-stapling (e.g., hydrogenation to convert double bonds in staples to single bonds)). In some embodiments, an agent comprise one and no more than one residue comprising two or more residues for stapling. In some embodiments, an agent comprising one and no more than one amino acid residue that is bonded to two staples. In some embodiments, agents comprise staples having different types of structures and/or formed by different types of transformations. For example, in some embodiments, an agent comprises a staple whose formation does not comprises an olefin metathesis transformation and/or modification of a carbon-carbon double bond (e.g., hydrogenation). In some embodiments, such agents may provide improved properties, activities, design flexibility, manufacturing efficiency, etc.

[0725] In some embodiments, a compound has a structure selected from the table above, wherein R_1 is −OH. In some embodiments, a compound has a structure selected from the table above, wherein R_1 is −H. In some embodiments, a compound is a compound has the structure selected from the table above, wherein R_1 is −H or amino protecting group (e.g., Fmoc, tBoc, etc.) and R_2 is −OH, a carboxyl protecting or activating group, or a salt thereof. In some embodiments, a compound is a compound has the structure selected from the table above, wherein R_1 is −H or amino protecting group and R_2 is −OH, or a salt thereof. In some embodiments, a compound is a compound has the structure selected from the table above, wherein R_1 is −H and R_2 is −OH, or a salt thereof. In some embodiments, a compound is a compound has the structure selected from the table above, wherein R_1 is −H, R_2 is −OH and R_3 is −H, or a salt thereof. In some embodiments, R_3 is −H or a protecting group. In some embodiments, R_3 is −H. In some embodiments, a compound has a structure selected from the table above, wherein R_1 is an amino protection group, e.g., Fmoc, tBoc, etc. In some embodiments, a compound has a structure selected from the table above, wherein R_1 is an amino protecting group, e.g., Fmoc, tBoc, etc., and R_2 is −OH, or $-COR_2$ is an optionally substituted, protected or activated carboxyl group. In some embodiments, R_2 is −OH. In some embodiments, an amino acid residue has a structure selected from the table above, wherein each of R_1 and R_2 independently represents a connection site (e.g., for structure  , the residue is of the structure ). In some embodiments, an agent, a peptide or a stapled peptide comprises such an amino acid residue.

[0726] In some embodiments, a peptide comprises one or more residues of amino acids selected from the Table above. In some embodiments, a peptide comprises one or more residues of TfeGA. In some embodiments, a peptide comprises one or more residues of 2COOHF. In some embodiments, a peptide comprises one or more residues of 3COOHF.

[0727] Among other things, the present disclosure provides peptides, including stapled peptides, comprising residues of amino acids described herein. In some embodiments, the present disclosure provides various methods comprising utilizing amino acids, optionally protected and/or activated, as described herein. In some embodiments, the present disclosure provides methods for preparing peptides, comprising utilizing amino acids, typically protected and/or activated, as described herein. For example, in some embodiments, various amino groups are Fmoc protected for peptide synthesis (particularly for forming backbone peptide bonds). In some embodiments, various side chain carboxylic acid groups are t-Bu protected (−C(O)−O−tBu).

[0728] In some embodiments, the present disclosure provides methods, comprising replacing one or more acidic amino acid residues, e.g., Asp, Glu, etc., in a first compound, each independently with a provided amino acid residue, e.g., TfeGA, 2COOHF, 3COOHF, etc., to provide a second compound. In some embodiments, each of the first and second compounds is independently or independently comprises a peptide. In some embodiments, a second compound provides improved properties and/or activities (e.g., lipophilicity, LogD, etc.) compared to a first compound. In some embodiments, a second compound provides, in addition to improved properties such as lipophilicity, one or more comparable or improved other properties and/or activities (e.g., solubility and/or target binding) compared to a first compound.

[0729] In some embodiments, an agent, e.g., a peptide, a stapled peptide, a stitched peptide, etc., is less than about 5000 Daltons in mass. In some embodiments, an agent is greater than or equal to about 900 Daltons and less than about 5000 Daltons in mass. In some embodiments, an agent is greater than or equal to about 1500 Daltons and less than about 5000 Daltons in mass. In some embodiments, an agent is greater than or equal to about 2000 Daltons and less than about 5000 Daltons in mass. In some embodiments, an agent is greater than or equal to about 2500 Daltons and less than about 5000 Daltons in mass. In some embodiments, an agent is greater than or equal to about 1000 Daltons and less than about 3000 Daltons in mass. In some embodiments, an agent is greater than or equal to about 1500 Daltons and less than about 3000 Daltons in mass. In some embodiments, an agent is greater than or equal to about 1500 Daltons and less than about 2500 Daltons in mass. In some embodiments, an agent is greater than or equal to about 1600 Daltons and less than about 2200 Daltons in mass. In some embodiments, the agent is no more than about 900 Daltons in mass. In some embodiments, an agent is no more than about 500 Daltons in mass. In some embodiments, an agent is no more than about 300 Daltons in mass. In some embodiments, an agent is no more than about 200 Daltons in mass.

Characterization

[0730] In some embodiments, agents, e.g., peptides, are characterized with respect to, for example, one

or more characteristics such as binding characteristics – e.g., with respect to a particular target of interest (e.g., beta-catenin or a portion thereof), stability characteristics, for example in solution or in dried form, cell permeability characteristics, solubility, lipophilicity, etc.

[0731] In some embodiments, a binding characteristic may be or comprise specificity, affinity, on-rate, off-rate, etc, optionally under (or over a range of) specified conditions such as, for example, concentration, temperature, pH, cell type, presence or level of a particular competitor, etc.

[0732] As will be appreciated by those skilled in the art, assessments of characteristics as described herein may involve comparison with an appropriate reference (e.g., a positive or negative control) which may, in some embodiments, be a contemporaneous reference or, in some embodiments, a historical reference.

[0733] In some embodiments, desirable characteristics may be, for example: binding to a desired target (e.g., a dissociation constant (K_D) of at least less than about 1 μM, and preferably a K_D of less than about 50 nM); cell penetration (e.g., as measured by fluorescence-based assays or mass spectrometry of cellular fractions, etc.); solubility (e.g., soluble at less than about 1000 uM agent, or soluble at less than about 500 uM agent, or soluble at less than about 100 uM agent, or less than about 50 uM, or less than about 35 uM); activity (e.g., modulating one or more functions of a target, which may be assessed in a cellular reporter assay (e.g., with an IC50 of less than a concentration, e.g., less than about 1 μM, less than about 500 nM, less than about 50 nM, less than about 10 nM, etc.), an animal model (e.g., various animal models for conditions, disorders or diseases, e.g., mouse melanoma models *Braf*^{V600E}*/Pten*$^{-/-}$ and *Braf*^{V600E}*/Pten*$^{-/-}$*/CAT-STA*) and/or a subject; stability, which may be assessed using a number of assays (e.g., in a rat pharmacokinetic study (e.g., administered via oral, iv, ip, etc.) with a terminal half-life of greater than a suitable time, e.g., 1 hour); low toxicity, which might be assessed by a number of assays (e.g., a standard ADME/toxicity assays); and/or low levels of cytotoxicity (e.g., low levels of lactate dehydrogenase (LDH) released from cells when treated at a suitable concentration, e.g., about 10 μM of a peptide). In some embodiments, an agent of the invention comprises an affinity of less than about 10 nM, for example, an IC50 of 7 nM).

[0734] In some embodiments, provided agents can bind to targets, e.g., beta-catenin, with an EC 50 of no more than about 2000 nM. In some embodiments, an EC50 is no more than about 1500 nM. In some embodiments, an EC50 is no more than about 1000 nM. In some embodiments, an EC50 is no more than about 500 nM. In some embodiments, an EC50 is no more than about 300 nM. In some embodiments, an EC50 is no more than about 200 nM. In some embodiments, an EC50 is no more than about 100 nM. In some embodiments, an EC50 is no more than about 75 nM. In some embodiments, an EC50 is no more than about 50 nM. In some embodiments, an EC50 is no more than about 25 nM. In some embodiments, an EC50 is no more than about 10 nM. In some embodiments, an EC50 is no more than about 5 nM. In some embodiments, an EC50 is measured by fluorescence polarization as described in the Examples.

[0735] In some embodiments, the present disclosure provides agents, e.g., stapled peptides, with suitable solubility for various purposes. In some embodiments, solubility of provided agents, e.g., in PBS, is about or at least about 5-100 uM (e.g., about or at least about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 uM).

In some embodiments, solubility is about or at least about 25 uM. In some embodiments, solubility is about or at least about 30 uM. In some embodiments, solubility is about or at least about 40 uM. In some embodiments, solubility is about or at least about 50 uM. In some embodiments, provided agents, e.g., stapled peptides, are protein bound in serum; in some embodiments, they are at least about 85%, 90%, or 95% protein bound in serum. In some embodiments, provided agents are over 95% protein bound in serum.

[0736] In some embodiments, provided agents can traverse a cell membrane of an animal cell. In some embodiments, provided agents can traverse a cell membrane of a human cell.

[0737] Among other things, provided agents can bind to motifs, residues, or polypeptides. In some embodiments, provided agents bind to beta-catenin. In some embodiments, a dissociation constant (K_D) is about 1 nM to about 1 uM. In some embodiments, a K_D is no more than about 1 uM. In some embodiments, a K_D is no more than about 500 nM. In some embodiments, a K_D is no more than about 250 nM. In some embodiments, a K_D is no more than about 100 nM. In some embodiments, a K_D is no more than about 50 nM. In some embodiments, a K_D is no more than about 25 nM. In some embodiments, a K_D is no more than about 10 nM. In some embodiments, a K_D is no more than about 5 nM. In some embodiments, a K_D is no more than about 1 nM. As appreciated by those skilled in the art, various technologies are available and can be utilized to measure K_D in accordance with the present disclosure. In some embodiments, K_D is measured by Surface Plasmon Resonance (SPR) as illustrated herein.

[0738] In some embodiments, provided agents binds to a polypeptide whose sequence is or comprising SEQ ID NO: 2, or a fragment thereof:

SVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIIL ASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCL WTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEAL VRT (SEQ ID NO: 2).

[0739] In some embodiments, provided agents have one or more or all of the following interactions with beta-catenin:

Direct interactions (), water mediated [], non-polar contacts {}

LQIL{AY}(G){NQ}ES(K)LIILA (residue 301-317 of Uniprot P35222 sequence) (SEQ ID NO: 3)

SRVL{(K)V}LS{V}CSSN (residue 341-353 of Uniprot P35222 sequence) (SEQ ID NO: 4)

RLV{QN}C{L}(W)TL{R}(N)LSDA (residue 376-391 of Uniprot P35222 sequence) (SEQ ID NO: 5)

LGSD[D]I(N){V}V{TC}AAGI (residue 409-423 of Uniprot P35222 sequence) (SEQ ID NO: 6)

[0740] In some embodiments, an agent, e.g., a peptide, binds to beta-catenin and interacts with one or more residues that are or correspond to at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight or at least nine, or at least ten, or at least eleven, or at least twelve, or at least thirteen, or at least fourteen, or at least fifteen, or at least sixteen, or at least seventeen, or at least eighteen, or at least nineteen, or at least twenty of the following amino acid residues in SEQ ID NO: 1 at the indicated positions: A305, Y306, G307, N308, Q309, K312, K345, V346, V349, Q379, N380, L382, W383,

R386, N387, D413, N415, V416, T418, and C419. In some embodiments, an agent, e.g., a peptide, binds to beta-catenin and interacts with one or more residues that are or correspond to at least two, or at least three, or at least four, or at least five, or at least six, or seven of the following amino acid residues in SEQ ID NO: 1 at the indicated positions: G307, K312, K345, W383, R386, N387, D413, and N415. In some embodiments, an agent, e.g., a peptide, binds to beta-catenin and interacts with one or more residues that are or correspond to at least two, or at least three, or at least four, or at least five, or at least six, or seven of the following amino acid residues in SEQ ID NO: 1 at the indicated positions: G307, K312, K345, W383, N387, D413, and N415.

[0741] In some embodiments, provided agents interact with beta-catenin at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8 or 9) of G307, K312, K345, Q379, L382, W383, N387, N415 and V416. In some embodiments, provided agents interact with beta-catenin at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of Y306, G307, K312, K345, Q379, L382, W383, N387, N415 and V416. In some embodiments, provided agents interact with beta-catenin at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of G307, K312, K345, Q379, L382, W383, R386, N387, N415 and V416. In some embodiments, provided agents interact with beta-catenin at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11) of Y306, G307, K312, K345, Q379, L382, W383, R386, N387, N415 and V416. In some embodiments, provided agents interact with beta-catenin at one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) of Y306, G307, K312, K345, V349, Q379, L382, W383, R386, N387, N415 and V416. In some embodiments, provided agents interact with beta-catenin at one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) of G307, K312, K345, W383, R386, N387, D413 and N415. In some embodiments, provided agents interact with beta-catenin at one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) of G307, K312, K345, W383, N387, D413 and N415. In some embodiments, provided agents interact with beta-catenin at one or both of K312 and R386. In some embodiments, provided agents interact with G307. In some embodiments, provided agents interact with K312. In some embodiments, provided agents interact with beta-catenin at one or more of K345, W383, D413 and N415. In some embodiments, provided agents interact with beta-catenin at one or more of K345 and W383. In some embodiments, provided agents interact with beta-catenin at one or more of D413 and N415. In some embodiments, provided agents interact with Y306. In some embodiments, provided agents interact with G307. In some embodiments, provided agents interact with K312. In some embodiments, provided agents interact with K345. In some embodiments, provided agents interact with V349. In some embodiments, provided agents interact with Q379. In some embodiments, provided agents interact with L382. In some embodiments, provided agents interact with W383. In some embodiments, provided agents interact with R386. In some embodiments, provided agents interact with N387. In some embodiments, provided agents interact with D413. In some embodiments, provided agents interact with N415. In some embodiments, provided agents interact with V416.

[0742] In some embodiments, provided agents interact with one or more of amino acid residues that are or correspond to K312, R386, K345 and W383 of SEQ ID NO: 1. In some embodiments, provided agents interact with one or more of amino acid residues that are or correspond to K312 and R386 of SEQ ID NO: 1. In some embodiments, interaction with an amino acid residue can be assessed through mutation of such an

amino acid residue (e.g., mutation of K, R, etc. to D, E, etc.).

[0743] As those skilled in the art reading the present disclosure will appreciate, in some embodiments, interactions with beta-catenin may be assessed by contacting an agent with either a full-length or a portion of beta-catenin. In some embodiments, a portion of beta-catenin comprises the interacting residues above. In some embodiments, a portion of beta-catenin is or comprises SEQ ID NO: 2. In some embodiments, a portion of beta-catenin is expressed with a tag (e.g., for purification, detection, etc.). In some embodiments, a tag is a fluorescent tag. In some embodiments, a tag is for detection. In some embodiments, a tag is for purification and detection. In some embodiments, a tag is a purification tag. In some embodiments, a tag is or comprises biotin. Many other types of tags are available in the art and can be utilized in accordance with the present disclosure.

[0744] Various technologies can be utilized for characterizing and/or assessing provided technologies (e.g., agents (e.g., various peptides), compositions, methods, etc.) in accordance with the present disclosure. As described herein, in some embodiments, a useful technology is or comprises fluorescence polarization. In some embodiments, a useful technology assesses LogP or LogD. In some embodiments, a useful technology is or comprises a CHI LogD assay. In some embodiments, a useful technology assesses solubility. In some embodiments, a useful technology is or comprises NanoBRET. In some embodiments, a useful technology is or comprises a reporter assay (e.g., DLD1 reporter assay). In some embodiments, a useful technology is or comprises alphascreen. Certain useful protocols are described in the Examples. Those skilled in the art appreciate that suitable adjustments may be made to such protocols, e.g., according to specific conditions, agents, purposes, etc.

Production

[0745] Various technologies are known in the art for producing provided agents. For example, various technologies for preparing small molecules, peptides (including stapled peptides) may be utilized in accordance with the present disclosure. Those skilled in the art, reading the present disclosure will well appreciate which such technologies are applicable in which aspects of the present disclosure in accordance with the present disclosure.

[0746] Stapling may be performed during and/or after peptide chain synthesis. In some embodiments, the present disclosure provides an unstapled peptide agent whose sequence is one described in Table E2 or Table E3. In some embodiments, amino acid residues are optionally protected for peptide synthesis (e.g., peptide synthesis using Fmoc-protected amino acids wherein certain side chains may be protected). In some embodiments, one or more stapling are achieved through olefin metathesis. In some embodiments, two or more stapling are formed through one olefin metathesis process. In some embodiments, the present disclosure provides a stapled peptide agent described in Table E2 or Table E3 or a salt thereof (e.g., a pharmaceutically acceptable salt thereof). In some embodiments, the present disclosure provides a stereoisomer of a stapled peptide agent described in Table E2 or Table E3 or a salt thereof (e.g., a

pharmaceutically acceptable salt thereof). In some embodiments, the present disclosure provides a *E/Z* stereoisomer of a stapled peptide agent described in Table E2 or Table E3 or a salt thereof (e.g., a pharmaceutically acceptable salt thereof). In some embodiments, from the N to C direction, an olefin double bond in the first staple that comprising such a bond is *Z*, and an olefin double in the second staple that comprising such a bond is *E* (*Z*-*E*); in some embodiments, it is (*Z*-*Z*); in some embodiments, it is (*E*-*Z*); in some embodiments, it is (*E*-*E*). In some embodiments, from the N to C direction, an olefin double bond in the first (i, i+2), (i, i+3) or (i, i+4) staple that comprising such a bond is *Z*, and an olefin double in the first (i, i+7) staple that comprising such a bond is *E* (*Z*-*E*); in some embodiments, it is (*Z*-*Z*); in some embodiments, it is (*E*-*Z*); in some embodiments, it is (*E*-*E*). In some embodiments, an agent comprises an olefin double bond in a third staple, and it is *E*; in some embodiments, it is *Z*. In some embodiments, an agent comprises an olefin double bond in a fourth staple, and it is *E*; in some embodiments, it is *Z*.

[0747] In some embodiments, one or more or all staples are formed after chain extension. In some embodiments, one or more or all staples are formed during chain extension. In some embodiments, one or more or all staples by metathesis are formed after chain extension. In some embodiments, one or more or all staples by metathesis are formed during chain extension.

[0748] In some embodiments, the present disclosure provides a method, comprising

a) preparing a first compound comprising two moieties each of which independently comprises an olefin double bond;

b) providing a second compound by stapling the two moieties by olefin metathesis of an olefin double bond of one moiety with an olefin double bond of the other to form a first-formed staple;

c) add one or more additional moieties to the second compound to provide a third compound which comprising two moieties each of which independently comprises an olefin double bond; and

d) providing a fourth compound by stapling the two moieties in the third compound by olefin metathesis of an olefin double bond of one moiety with an olefin double bond of the other to form a second-formed staple.

[0749] In some embodiments, a moiety is an amino acid residue. In some embodiments, each moiety is independently an amino acid residue. In some embodiments, each moiety is independently an amino acid residue comprising a terminal olefin as described herein. In some embodiments, there are two olefin double bonds in one moiety, e.g., of the first compound. For example, in some embodiments, such a moiety is B5. In some embodiments, two moieties of a first compound is independently X^4 and X^{11}. In some embodiments, a first-formed staple is a (i, i+7) staple. In some embodiments, a first compound comprises $-X^4X^5X^6X^7X^8X^9X^{10}X^{11}-$. In some embodiments, a first compound comprises $-X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}-$. In some embodiments, a first compound comprises a staple. In some embodiments, a staple is a (i, i+4) staple. In some embodiments, a staple is between X^{10} and X^{14}. In some embodiments, an olefin double bond in a third compound is present in the first compound (e.g., an unstapled olefin double bond of B5). In some embodiments, one and only one amino acid residue comprises an olefin

double bond is added to the second compound. In some embodiments, ae third compound is or comprises $-X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}-$. In some embodiments, a third compound is or comprises $-X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}-$. In some embodiments, a first- and second-formed staples are bonded to the same amino acid residue. In some embodiments, a first- and second-formed staples are bonded to the same atom. In some embodiments, a second-formed staple is a (i, i+2), (i, i+3) or (i, i+4) staple. In some embodiments, two moieties in the third compound is independently X^1 and X^4. In some embodiments, a first-formed staple is formed with *E* selectivity as described herein (e.g. about 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, or more). In some embodiments, a second-formed staple is formed with *Z* selectivity as described herein (e.g., about 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, or more). In some embodiments, synthesis may be performed on a solid support (e.g., solid phase peptide synthesis), and a compound or an agent may be on a solid support. In some embodiments, stapling during chain extension, or individually performed stapling for one or more staples, can provide advantages, e.g., increased selectivity, yield, purity, etc.

[0750] In some embodiments, two or more staples are formed in a metathesis reaction. In some embodiments, all staples formed by metathesis are formed in a metathesis reaction. In some embodiments, each of such staples are formed through olefin metathesis of terminal olefins. In some embodiments, multiple staples are formed after full lengths of peptides have been achieved. In some embodiments, one or more staples comprising double bonds are formed after full lengths of peptides have been achieved. In some embodiments, all staples comprising double bonds are formed after full lengths of peptides have been achieved. In some embodiments, one or more staples formed through metathesis are formed after full lengths of peptides have been achieved. In some embodiments, all staples formed through metathesis are formed after full lengths of peptides have been achieved.

[0751] In some embodiments, stepwise stapling, in which two or more staples are formed in two or more steps, were performed. In some embodiments, stepwise stapling provides improved levels of selectivity to form a desired product (e.g., I-66) over other compounds, e.g., stereoisomers (e.g., for I-66, I-67). In some embodiments, an improvement is about or at least about 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, or 10 fold. In some embodiments, an improvement is assessed by comparing percentage of a desired product among all related stereoisomers. In some embodiments, an improvement is assessed by ratios of a desired product versus a stereoisomer (e.g., I-66 versus I-67). In some embodiments, two staples comprising olefin double bonds are formed in two separate steps. In some embodiments, two staples formed by metathesis are formed in two separate steps. In some embodiments, two staples bonded to the same amino acid residue are formed in two separate steps. In some embodiments, two staples bonded to the same atom are formed in two separate steps. In some embodiments, two staples bonded to the same carbon atom are formed in two separate steps. In some embodiments, two staples formed from B5 are formed in two separate steps. In some embodiments, a provided technologies comprise a third step forming a third staple. In some embodiments, each staple is formed in a separate step. In some embodiments, the present disclosure provides a method for preparing a

stapled peptide, comprising:

1) reacting a first reactive group with a second reactive group to form a first staple, wherein the first and second reactive groups are in two different amino acid residues; and

2) reacting a third reactive group with a fourth reactive group to form a second staple, wherein the third and fourth reactive groups are in two different amino acid residues.

[0752] Alternatively or additionally, in some embodiments, a method comprises reacting a fifth reactive group with a sixth reactive group to form a third staple, wherein the fifth and sixth reactive groups are in two different amino acid residues. In some embodiments, a third staple is formed before a first and second staples.

[0753] In some embodiments, a first staple is formed through a metathesis reaction. In some embodiments, each of the first and second reactive groups independently is or comprises a double bond. In some embodiments, each of the first and second reactive groups is independently a terminal olefin. In some embodiments, a first staple is formed through olefin metathesis. In some embodiments, a first staple is an (i, i+7) staple. Various metathesis technologies may be utilized in accordance with the present disclosure to form a first staple. In some embodiments, a metathesis reaction is performed in the presence of a catalyst. In some embodiments, a catalyst is Hoveyda-Grubbs M720 catalyst (CAS 301224-40-8). In some embodiments, a first staple is between X^4 and X^{11}.

[0754] In some embodiments, a second staple is formed through a metathesis reaction. In some embodiments, each of the third and fourth reactive groups independently is or comprises a double bond. In some embodiments, each of the third and fourth reactive groups is independently a terminal olefin. In some embodiments, a second staple is formed through olefin metathesis. In some embodiments, a second staple is an (i, i+3) staple. Various metathesis technologies may be utilized in accordance with the present disclosure to form a second staple. In some embodiments, a metathesis reaction is performed in the presence of a catalyst. In some embodiments, a catalyst is Grubbs M102 catalyst (CAS 172222-30-9). In some embodiments, a second staple is between X^1 and X^4.

[0755] In some embodiments, one of the first and second reactive groups, and one of the third and fourth reactive groups, are in the same amino acid residues. In some embodiments, they are independently in a side chain and the two side chains are bonded to the same atom. In some embodiments, the two side chains are bonded to the same carbon atom, e.g., as in B5. In some embodiments, the first and second staples are bonded to the same amino acid residue. In some embodiments, they are bonded to same atom. In some embodiments, they are bonded to the same carbon, e.g., in B5.

[0756] In some embodiments, a third staple comprises an amide group, e.g., −C(O)N(R')− wherein R' is as described herein. In some embodiments, a third staple comprises −C(O)NH−. In some embodiments, a third staple is a (i, i+4) staple. In some embodiments, one of the fifth and the sixth reactive groups is or comprises an amino group or an activated form thereof, and the other is or comprises an acid group, e.g., a carboxyl group, or an activated form thereof. In some embodiments, a third staple is formed through an

amidation reaction. In some embodiments, a third staple is not formed by a metathesis reaction. In some embodiments, a third staple does not comprise an olefin double bond. Various amidation technologies are available and may be utilized herein. As described herein, other types of staples may be utilized and constructed as well. See, for example, preparation of I-66, I-335, etc. in the Examples. In some embodiments, a third staple is between X^{10} and X^{14}.

[0757] In some embodiments, as described herein, one or more stapling steps are independently performed before full lengths are achieved. For example, in some embodiments, a third staple is formed before the two amino acid residues comprising the first and second reactive groups are both installed. Alternatively or additionally, in some embodiments, a first staple is formed before the two amino acid residues comprising the third and fourth reactive groups are both installed. In some embodiments, a third staple is formed after an amino acid residue comprising one of the first and second reactive group is installed but before an amino acid residue comprising the other of the first and second reactive group is installed. In some embodiments, a first staple is formed after an amino acid residue comprising one of the third and fourth reactive group is installed but before an amino acid residue comprising the other of the third and fourth reactive group is installed. In some embodiments, two or more stapling steps are performed based on the positions of the related staples and the directions of peptide synthesis, and one or more staples closer to the starting termini are formed before one or more staples further away from the starting termini. In some embodiments, peptide synthesis is performed from C-terminus to N-terminus. In some embodiments, for a first staple and a second staple, the one that first has both related residues installed is formed first. For example, in a C-terminal to N-terminal peptide synthesis, a staple between X^4 and X^{11} is formed before a staple between X^1 and X^4.

[0758] Various metal complexes or catalysts are useful for metathesis. For example, in some embodiments, a metal complex is a Grubbs catalyst. In some embodiments, it is In some embodiments, a metal complex is a Hoveyda-Grubbs catalyst. In some embodiments, it is Grubbs I M102. Hoveyda-Grubbs M720 catalyst. In some embodiments, a catalyst provides product *E/Z* selectivity. As appreciated by those skilled in the art, catalysts can be utilized at various suitable levels, e.g., about 1%, 2%, 3%, 4%, 5%, 10%, 20%, 25%, 30%, 40%, 50% mol or more.

[0759] In some embodiments, the present disclosure provides technologies for controlling ratio of *E/Z* isomers of one or more or each olefin double bond formed during olefin metathesis. In some embodiments, one or more or each olefin double bond is formed with a isomer ratio of about 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, or more. In some embodiments, in a product composition one or more or each olefin double bond has an isomer ratio of about 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, or more. In some embodiments, it is independently about 1.5:1 or more. In some embodiments, it is independently about 2:1 or more. In some embodiments, it is independently about 3:1 or more. In some embodiments, it is independently about 4:1 or more. In some embodiments, it is independently about 5:1 or more. In some embodiments, it is independently about 6:1 or more. In some

embodiments, it is independently about 7:1 or more. In some embodiments, it is independently about 8:1 or more. In some embodiments, it is independently about 9:1 or more. In some embodiments, it is independently about 10:1 or more. In some embodiments, it is independently about 20:1 or more. In some embodiments, it is independently about 30:1 or more. In some embodiments, it is independently about 40:1 or more. In some embodiments, it is independently about 50:1 or more. In some embodiments, a ratio is *E*:*Z*. In some embodiments, a ratio is *Z*:*E*.

[0760] In some embodiments, stapling creates one or more chiral centers. For example, in some embodiments, when B5 forms two staples with two other amino acid residues, a chiral center may form. In some embodiments, a formed chiral center is *R* in an agent. In some embodiments, a formed chiral center is *S* in an agent. In some embodiments, a composition comprises both agents being *R* and *S* at a chiral center. In some embodiments, a chiral center is formed with stereoselectivity (e.g., in some embodiments, diastereoselectivity when other chiral elements are present in the same molecule). In some embodiments, the selectivity is about or at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%(when selectivity is 98%, 98% of all product molecules share the same stereochemistry at the chiral center.). In some embodiments, in a composition described herein, e.g., a pharmaceutical composition, about or at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% , 98% or 99% of all molecules having the same constitution and salts thereof share the same stereochemistry at a chiral center, e.g., a chiral center bonded to two staples (e.g., in B5). In some embodiments, it is about or at least about 70%. In some embodiments, it is about or at least about 75%. In some embodiments, it is about or at least about 80%. In some embodiments, it is about or at least about 85%. In some embodiments, it is about or at least about 90%. In some embodiments, it is about or at least about 95%. In some embodiments, it is about or at least about 98%. In some embodiments, it is about or at least about 99%.

[0761] In some embodiments, an olefin double bond in a staple may be further modified. In some embodiments, an olefin double bond in a staple is hydrogenated thus converting it into a single bond. In some embodiments, a modification is epoxidation. In some embodiments, a modification is halogenation. Those skilled in the art appreciate that various other modifications are suitable for olefin double and can be utilized in accordance with the present disclosure.

[0762] In some embodiments, crude product compositions are purified, e.g., through chromatography technologies such as liquid chromatography. In some embodiments, one or more product compositions are collected based on separated portions, e.g., HPLC peaks, with the correct observed mass. In some embodiments, each product composition independently corresponds to a different peak (e.g., in some embodiments, by UV detection at a suitable wavelength, e.g., 220 nm) with the correct observed mass. In some embodiments, a peak area of one or more or each product composition is independently about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%,80%, 90% or more of the total peak area of all peak(s) with the correct mass. In some embodiments, it is about 5% or more. In some embodiments, it is about 10% or more. In some embodiments, it is about 20% or more. In some embodiments, it is about 25% or more. In some

embodiments, it is about 30% or more. In some embodiments, it is about 40% or more. In some embodiments, it is about 50% or more. In some embodiments, a product composition comprises one isomer. In some embodiments, a product composition comprises two or more isomers (e.g., those that cannot be sufficiently separated). In some embodiments, each product composition independently has a purity and/or stereopurity as described herein, e.g., in some embodiments, for one or more (e.g., 1, 2, 3, 4, 5 or more) or each olefin double bond in a staple, the ratio of the two stereoisomers is independently about 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1 or more. In some embodiments, ratios may be assessed by NMR, HPLC, etc.

[0763] In some embodiments, as described herein, certain stapled peptides, and in particular cysteine stapled peptides, may be provided in and/or produced by a biological system and reacting with a provided reagent, e.g., one having the structure of R^x–L^{s2}–R^x, or a salt thereof, wherein R^x can react with −SH groups under suitable conditions. In some embodiments, each R^x is a suitable leaving group. In some embodiments, each R^x is independently −Br.

[0764] In some embodiments, peptides are prepared on solid phase on a synthesizer using, typically, Fmoc chemistry. In some embodiments, the present disclosure provides protected and/or activated amino acids for synthesis.

[0765] In some embodiments, staples are formed by olefin metathesis. In some embodiments, a product double bond of metathesis is reduced/hydrogenated. In some embodiments, CO_2 are extruded from a carbamate moiety of a staple. In some embodiments, provided stapled peptides are further modified, and/or conjugated to other entities. Conditions and/or reagents of these reactions are widely known in the art and can be performed in accordance with the present disclosure to provide stapled peptides.


[0766] Properties and/or activities of provided stapled peptides can be readily assessed in accordance with the present disclosure, for example, through use of one or more methods described in the examples.

[0767] In some embodiments, technologies for preparing and/or assessing provided stapled peptides include those described in US 9617309, US 2015-0225471, US 2016-0024153, US 2016-0215036, US2016-0244494, WO 2017/062518, *etc.*

[0768] In some embodiments, the present disclosure provides products manufactured and/or characterized by processes and/or technologies described herein.


[0769] In some embodiments, a provided compound, e.g., an amino acid or a protected form thereof, may be prepared utilizing the following technologies.

[0770] In some embodiments, a provide compound may be prepared using one or more or all steps described below:




Those skilled in the art will appreciate that other leaving groups can be utilized in place of −Cl for the first reaction, such as −Br, −I, −OTs, Oms, etc.


[0771] In some embodiments, a provide compound may be prepared using one or more or all steps described below:




[0772] In some embodiments, a provide compound may be prepared using one or more or all steps described below:



[0773] In some embodiments, a provide compound may be prepared using one or more or all steps described below:



[0774] In some embodiments, a provide compound may be prepared using one or more or all steps described below:



[0775] Provided compounds can be provided in high purity. In some embodiments, a provided compound is at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% pure. In some embodiments, provided compounds, e.g., amino acids optionally protected/activated, are essentially free of impurities, including stereoisomers.

[0776] In some embodiments, an agent may have one or more stereoisomers which may independently co-exist in a composition or preparation. In some embodiments, a provided agent has a stereopurity of about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, it is about or at least about 80%. In some embodiments, it is about or at least about 85%. In some embodiments, it is about or at least about 90%. In some embodiments, it is about or at least about 95%. In some embodiments, it is about or at least about 96%. In some embodiments, it is about or at least about 97%. In some embodiments, it is about or at least about 98%. In some embodiments, it is about or at least about 99%. In some embodiments, stereoisomers are essentially free from a preparation or composition (e.g., cannot be reliably observed in NMR or HPLC). In some embodiments, an agent comprises one or more staples independently comprising one or more olefin double bond. In some embodiments, stereopurity is with respect to *E*/Z stereoisomers. In some embodiments, for one or more (e.g., 1, 2, 3, 4, 5 or more) or each olefin double bond in a staple, the ratio of the two stereoisomers is independently about 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1 or more. In some embodiments, it is independently about 1.5:1 or more. In some embodiments, it is independently about 2:1 or more. In some embodiments, it is independently about 3:1 or more. In some embodiments, it is independently about 4:1 or more. In some embodiments, it is independently about 5:1 or more. In some embodiments, it is independently about 6:1 or more. In some embodiments, it is independently about 7:1 or more. In some embodiments, it is independently about 8:1 or more. In some embodiments, it is independently about 9:1 or more. In some embodiments, it is independently about 10:1 or more. In some embodiments, it is independently about 20:1 or more. In some embodiments, it is independently about 30:1 or more. In some embodiments, it is independently about 40:1 or more. In some embodiments, it is independently about 50:1 or more. In some embodiments, it is independently about 60:1 or more. In some embodiments, it is independently about 70:1 or more. In some embodiments, it is independently about 80:1 or more. In some embodiments, it is independently about 90:1 or more. In some embodiments, it is

independently about 100:1 or more. In some embodiments, a ratio is *E*:*Z*. In some embodiments, a ratio is *Z*:*E*. Those skilled in the art appreciate that *E* and *Z* isomers may be selectively enriched through modulating manufacturing processes, purification, staple positioning and/or lengths, etc.

Compositions

[0777] Among other things, the present disclosure provides compositions that comprise or otherwise relate to provided agents, e.g., small molecule agents, peptide agents (e.g., stapled peptides), as described herein.

[0778] In some embodiments, provided compositions are or comprise an assay system for characterizing (and optionally including) a stapled peptide as described herein.

[0779] In some embodiments, provided compositions are pharmaceutical compositions e.g., that comprise or deliver one or more provided agents.

[0780] In some embodiments, an agent is a peptide. In some embodiments, an agent is a stapled peptide. In some embodiments, an agent comprises a detectable moiety, e.g., fluorescent moiety, radioactive moiety, biotin, etc. In some embodiments, a detectable moiety is directly detectable. In some embodiments, a detectable antibody is detected indirectly, e.g., utilizing an antibody, an agent that can reacting with a detectable moiety to form a detectable product, etc.

[0781] In some embodiments, a pharmaceutical composition comprises a provided agent and a pharmaceutically acceptable excipient (e.g., carrier).

[0782] In some embodiments, a peptide composition may include or deliver a particular form (e.g., a particular optical isomer, diastereomer, salt form, covalent conjugate form [e.g., covalently attached to a carrier moiety], etc., or combination thereof) of an agent as described herein). In some embodiments, an agent included or delivered by a pharmaceutical composition is described herein is not covalently linked to a carrier moiety.

[0783] In some embodiments, multiple stereoisomers exist for an agent that contains chiral centers and/or double bonds. In some embodiments, level of a particular agent in a composition is enriched relative to one or more or all of its stereoisomers. For example, in some embodiments, a particularly configuration of a double bond (*E*/*Z*) is enrich. In some embodiments, for each double bond a configuration is independently enriched. In some embodiments, for a chiral element, e.g., a chiral center, one configuration is enriched. In some embodiments, for a chiral center bonded to two staples, one configuration is enriched. In some embodiments, for each chiral element a configuration is independently enriched. In some embodiments, for one or more or all stereochemical element (e.g., double bonds, chiral element, etc.), one configuration is independently enriched. In some embodiments, for each double bond in each staple, one configuration is independently enriched. In some embodiments, for each double bond in each staple, one configuration is independently enriched, and for a chiral center bonded to two staples, one configuration is enriched. In some embodiments, enrichment for each double bond is independently *E* or *Z*. In some embodiments, enrichment

for each chiral element is independently *R* or *S*. In some embodiments, enrichment for each stereochemical element, e.g., double bond, chiral center, etc., is about or at least about a certain level, e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (percentage of an agent). In some embodiments, about or at least about a certain level, e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of all molecules in a composition that share the constitution of an agent or a salt thereof are the agent or a salt thereof. In some embodiments, a level is about or at least about 60%. In some embodiments, it is about or at least about 65%. In some embodiments, it is about or at least about 70%. In some embodiments, it is about or at least about 75%. In some embodiments, it is about or at least about 80%. In some embodiments, it is about or at least about 85%. In some embodiments, it is about or at least about 90%. In some embodiments, it is about or at least about 95%. In some embodiments, it is about or at least about 96%. In some embodiments, it is about or at least about 97%. In some embodiments, it is about or at least about 98%. In some embodiments, it is about or at least about 99%.

[0784] In some embodiments, a provided therapeutic composition may comprise one or more additional therapeutic agents and/or one or more stabilizing agents and/or one or more agents that alters (e.g., extends or limits to a particular tissue, location or site) rate or extent of delivery over time.

[0785] In some embodiments, a composition is a pharmaceutical composition which comprises or delivers a provided agent (e.g., a stapled peptide) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. In some embodiments, a composition comprises one and only stereoisomer of an agent (e.g., a stapled peptide) and/or one or more salts thereof. In some embodiments, a composition comprises two or more stereoisomers of an agent (e.g., a stapled peptide) and/or one or more salts thereof. In some embodiments, the two or more stereoisomers of an agent (e.g., a stapled peptide) or salts thereof elute as a single peak (e.g., UV and/or MS detection) in a chromatography, e.g., HPLC.

Uses and Applications

[0786] Provided agents and compositions can be utilized for various purposes. For example, certain compounds may be utilized as amino acids, either directly or for preparation of other compounds such as peptides. Certain agents, e.g., peptides, may be utilized to prepare stapled peptides. Certain agents that are or comprise peptides, particularly stapled peptides, and compositions thereof, are biologically active and can be utilized for various purposes, e.g., as therapeutics toward various conditions, disorders or diseases, as tools for modulating biological functions, etc.

[0787] In some embodiments, the present disclosure provides agents and compositions thereof for modulating beta-catenin functions. In some instances, beta-catenin is reported to have multiple cellular functions including regulation and coordination of cell-cell adhesion and gene transcription. In some embodiments, agents described herein may inhibit beta-catenin activity and/or level and may, for example, inhibit neoplastic growth. In some embodiments, agents described herein may activate and/or increase level of beta-catenin and may, for example, be used to treat male pattern baldness or alopecia.

[0788] It is reported that beta-catenin can interact with members of the TCF/LEF family at a TCF site on beta-catenin. In some embodiments, provided technologies can decrease, suppress or block one or more of such interactions. In some embodiments, the present disclosure provides methods for modulating an interaction between beta-catenin and its binding partner (e.g., a TCF/LEF family member) comprising contacting beta-catenin with a provided agent.

[0789] In some embodiments, binding of provided agents to beta-catenin competes or inhibits binding of another agent. In some embodiments, binding of provided agents to beta-catenin competes or inhibits binding of another agent. In some embodiments, binding of provided agents to beta-catenin competes or inhibits binding of TCF or a fragment thereof.

[0790] In some embodiments, provided agents compete with TCF7, LEF1, TCF7L1, TCF7L2, Axin1, Axin2, APC, CDH1, or CDH2, or a fragment thereof, for beta-catenin binding.

[0791] In some embodiments, provided agents interfere with interactions of TCF7, LEF1, TCF7L1, TCF7L2, Axin1, Axin2, APC, CDH1, or CDH2, or a fragment thereof, with beta-catenin.

[0792] In some embodiments, provided technologies can reduce or block beta-catenin's interactions with all TCF family members, E-cadherin and APC, but did not significantly affect its interactions with ICAT, AXIN and BCL9. In some embodiments, provided technologies can interrupt beta-catenin/TCF interaction at both physical interaction level (e.g., as confirmed by NanoBRET, co-IP, etc.) and transcriptional level (e.g., as confirmed by reporter cell line, endogenous gene expression, etc.). In some embodiments, provided technologies show no effect on beta-catenin stability.

[0793] In some embodiments, the present disclosure provides methods for modulating interactions of beta-catenin with a partner, e.g., TCF7, LEF1, TCF7L1, TCF7L2, Axin1, Axin2, APC, CDH1, or CDH2, or a fragment thereof, comprising contacting beta-catenin with a provided agent or a composition that comprises or delivers a provided agent. In some embodiments, the present disclosure provides methods for modulating interactions of beta-catenin with a partner, e.g., TCF7, LEF1, TCF7L1, TCF7L2, Axin1, Axin2, APC, CDH1, or CDH2, or a fragment thereof, comprising administering or delivering to a system comprising beta-catenin and the partner a provided agent or a composition that comprises or delivers a provided agent. In some embodiments, a system is an *in vitro* system. In some embodiments, a system is an *in vivo* system. In some embodiments, a system is or comprises a cell, tissue or organ. In some embodiments, a system is a subject. In some embodiments, the present disclosure provides method for inhibiting cell growth, comprising administering or delivering to a population of cells an effective amount of a provided agent or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides method for killing cells associated with a condition, disorder or disease (e.g., cancer), comprising administering or delivering to a population of such cells an effective amount of a provided agent or a pharmaceutically acceptable salt thereof.

[0794] In some embodiments, the present disclosure provides methods for preventing a condition, disorder or disease associated with beta-catenin (e.g., a cancer, a neurodegenerative disease, etc.), comprising

administering or delivering to a subject susceptible thereto an effective amount of a provided agent or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides methods for treating a condition, disorder or disease associated with beta-catenin (e.g., aberrant beta-catenin activity and/or expression level), comprising administering or delivering to a subject suffering therefrom an effective amount of a provided agent or a pharmaceutically acceptable salt thereof. In some embodiments, a provided agent is administered as a pharmaceutical composition that comprises or delivers an effective amount of a provided agent or a pharmaceutically acceptable salt thereof. In some embodiments, a condition, disorder or disease is associated with beta-catenin interaction with a partner, e.g., TCF7, LEF1, TCF7L1, TCF7L2, Axin1, Axin2, APC, CDH1, and/or CDH2. In some embodiments, a condition, disorder or disease is associated with beta-catenin with TCF. In some embodiments, a condition, disorder or disease is cancer. In some embodiments, provided agents may be administered in combination with another therapy, e.g., immunotherapy. In some embodiments, a condition, disorder, or disease is selected from cancer, cardiac disease, dilated cardiomyopathy, fetal alcohol syndrome, depression, and diabetes. In some embodiments, a condition, disorder, or disease is a heart condition, disorder, or disease. In some embodiments, a condition, disorder, or disease is cancer. In some embodiments a cancer is selected from: colon cancer, colorectal cancer, rectal cancer, prostate cancer familial adenomatous polyposis (FAP), Wilms Tumor, melanoma, hepatocellular carcinoma, ovarian cancer, endometrial cancer, medulloblastoma pilomatricomas, primary hetpatocellular carcinoma, ovarial carcinoma, breast cancer, lung cancer, glioblastoma, pliomatrixoma, medulloblastoma, thyroid tumors, and ovarian neoplasms. In some embodiments, a condition, disorder or disease is a cancer, e.g., colorectal cancer, hepatocellular cancer, melanoma, gastric cancer, bladder cancer, and endometrial cancer. In some embodiments, a cancer is colorectal cancer. In some embodiments, a cancer is hepatocellular cancer. In some embodiments, a cancer is prostate cancer. In some embodiments, a cancer is melanoma.

[0795] In some embodiments, the present disclosure provides technologies for modulate level of expression and/or activity of a nucleic acid, e.g., a gene, a transcript, a polypeptide, and/or a product thereof in a system, comprising administering or delivering to the system a provided agent or a composition that comprises or delivers a provided agent. In some embodiments, level of expression of a nucleic acid, e.g., a gene, or a product thereof (e.g., a transcript, a polypeptide, etc.) is modulated. In some embodiments, level of activity of a nucleic acid, e.g., a gene, or a product thereof (e.g., a transcript, a polypeptide, etc.) is modulated. In some embodiments, level of a transcript and/or a product thereof (e.g., a polypeptide) is modulated. In some embodiments, level of activity of a transcript and/or a product thereof (e.g., a polypeptide) is modulated. In some embodiments, a transcript is a transcript of a nucleic acid, e.g., gene, described herein. In some embodiments, level of a polypeptide is modulated. In some embodiments, level of activity of a polypeptide is modulated. In some embodiments, a polypeptide is a encoded by a nucleic acid or a transcript described herein. In some embodiments, a level is increased. In some embodiments, a level is decreased. As described herein, in some embodiments, a system is an *in vitro* system. In some embodiments,

a system is an *in vivo* system. In some embodiments, a system is or comprises a cell, tissue or organ. In some embodiments, a system is or comprises one or more cancer cells. In some embodiments, a system is or comprises tumor. In some embodiments, a system is or comprises an organism. In some embodiments, a system is a subject. In some embodiments, a system is a human. In some embodiments, a system comprises beta-catenin. In some embodiments, a system expresses beta-catenin. In some embodiments, a system comprises beta-catenin and a partner. In some embodiments, a system expresses beta-catenin and a partner. In some embodiments, a level is regulated by beta-catenin. In some embodiments, a level is regulated by WNT activation. In some embodiments, a level is regulated by beta-catenin/WNT signaling. In some embodiments, a level is regulated by interaction of beta-catenin and a partner. In some embodiments, interaction of beta-catenin and a partner is modulated, e.g., reduced, prevented, etc., by an agent, e.g., a stapled peptide, as described herein. For example, in some embodiments, a partner is TCF. In some embodiments, level of expression and/or activity of a nucleic acid and/or a product thereof is modulated. In some embodiments, a nucleic acid is AXIN2. In some embodiments, level of an AXIN2 transcript, e.g., mRNA, is reduced. In some embodiments, level of an AXIN2 polypeptide is reduced. In some embodiments, a nucleic acid is SP5. In some embodiments, level of an SP5 transcript, e.g., mRNA, is reduced. In some embodiments, level of an SP5 polypeptide is reduced. In some embodiments, a nucleic acid is CXCL12. In some embodiments, level of a CXCL12 transcript, e.g., mRNA, is increased. In some embodiments, level of a CXCL12 polypeptide is increased. In some embodiments, a nucleic acid is a member of a negatively enriched gene set observed in, or can be identified using technologies in, e.g., Example 17. In some embodiments, a nucleic acid is a member of BCAT_GDS748_UP gene set. In some embodiments, a nucleic acid is a member of BCAT.100_UP.V1_UP gene set. In some embodiments, a nucleic acid is a member of HALLMARK_WNT_BETA_CATENIN_SIGNALING gene set. In some embodiments, a nucleic acid is a member of RASHI_RESPONSE_TO_IONIZING_RADIATION_1 gene set. In some embodiments, a nucleic acid is a member of REACTOME_RRNA_PROCESSING gene set. In some embodiments, a nucleic acid is a member of HALLMARK_MYC_TARGETS_V1 gene set. In some embodiments, a nucleic acid is a member of HALLMARK_MYC_TARGETS_V2 gene set. In some embodiments, a nucleic acid is a member of HALLMARK_OXIDATIVE_PHOSPHORYLATION gene set. In some embodiments, a nucleic acid is a member of HALLMARK_E2F_TARGETS gene set. In some embodiments, a nucleic acid is a member of HALLMARK_TNFA_SIGNALING_VIA_NFKB gene set. Description of various gene sets can be found publicly, e.g., https://www.gsea-msigdb.org/gsea/msigdb/. In some embodiments, one or more or some or a majority of but not all nucleic acids or genes in a gene set is impacted in the same way, but overall a gene set can be negatively or positively enriched. In some embodiments, a nucleic acid is selected from Table GS1. In some embodiments, a nucleic acid is selected from Table GS2. In some embodiments, a nucleic acid is selected from Table GS3. In some embodiments, a nucleic acid is selected from Table GS4. In some embodiments, a nucleic acid is selected from Table GS5. In some embodiments, a nucleic acid is selected from Table GS6. In some embodiments, a nucleic acid is

selected from Table GS7. In some embodiments, a nucleic acid is selected from Table GS8. In some embodiments, a nucleic acid is selected from Table GS9. In some embodiments, a nucleic acid is selected from Table GS10. In some embodiments, a nucleic acid is a gene selected Table GS1, Table GS2, Table GS3, Table GS4, Table GS5, Table GS6, Table GS7, Table GS8, Table GS9 or Table GS10. In some embodiments, a gene is CCND2. In some embodiments, a gene is WNT5B. In some embodiments, a gene is AXIN2. In some embodiments, a gene is NKD1. In some embodiments, a gene is WNT6. In some embodiments, a gene is DKK1. In some embodiments, a gene is DKK4. In some embodiments, expression of such a nucleic acid, e.g., a gene, is reduced. In some embodiments, level of a product of such a nucleic acid, e.g., a transcript (e.g., mRNA), a polypeptide, etc., is reduced. In some embodiments, level of activity of a product of such a nucleic acid, e.g., a transcript (e.g., mRNA), a polypeptide, etc., is reduced.

[0796] Table GS1. Certain examples of nucleic acids including various members of BCAT_GDS748_UP.

NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol
5243	ABCB1	26281	FGF20	4739	NEDD9
202	CRYBG1	2324	FLT4	4884	NPTX1
360	AQP3	8324	FZD7	5144	PDE4D
80150	ASRGL1	2571	GAD1	7262	PHLDA2
9531	BAG3	10912	GADD45G	5318	PKP2
25805	BAMBI	2643	GCH1	55041	PLEKHB2
79669	C3orf52	2650	GCNT1	10394	PRG3
84909	AOPEP	3087	HHEX	25797	QPCT
760	CA2	3680	ITGA9	861	RUNX1
842	CASP9	115207	KCTD12	23516	SLC39A14
1051	CEBPB	3823	KLRC3	6520	SLC3A2
23406	COTL1	51176	LEF1		SPRY4
23576	DDAH1	4005	LMO2	8406	SRPX
1670	DEFA5		LSM12	9540	TP53I3
1780	DYNC1I1	58530	LY6G6D	7334	UBE2N
2184	FAH	4488	MSX2	7481	WNT11
10447	FAM3C	4602	MYB		

[0797] Table GS2. Certain examples of nucleic acids including various members of BCAT.100_UP.V1_UP.

NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol
5243	ABCB1	2202	EFEMP1	3929	LBP
7984	ARHGEF5	8507	ENC1	4005	LMO2
638	BIK	2026	ENO2	85452	CFAP74
652	BMP4	5168	ENPP2	58530	LY6G6D
55640	FLVCR2	2119	ETV5	79156	PLEKHF1
928	CD9	26281	FGF20	5502	PPP1R1A
1045	CDX2	10367	MICU1	284119	CAVIN1
140578	CHODL	2523	FUT1	25797	QPCT

1428	CRYM	2571	GAD1	5947	RBP1
54440	SASH3	10912	GADD45G	861	RUNX1
79007	DBNDD1	2650	GCNT1	5274	SERPINI1
1670	DEFA5	3040	HBA2	23428	SLC7A8
22943	DKK1	3198	HOXA1	8470	SORBS2
5611	DNAJC3	8372	HYAL3	6926	TBX3
1846	DUSP4	3549	IHH	7481	WNT11
1848	DUSP6	3667	IRS1		
1917	EEF1A2	3680	ITGA9		

[0798] Table GS3. Certain examples of nucleic acids including various members of HALLMARK_WNT_BETA_CATENIN_SIGNALING.

NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol
6868	ADAM17	2770	GNAI1	85407	NKD1
8312	AXIN1	79885	HDAC11	4851	NOTCH1
8313	AXIN2	3066	HDAC2	4855	NOTCH4
894	CCND2	10014	HDAC5	8650	NUMB
1454	CSNK1E	23462	HEY1	5467	PPARD
1499	CTNNB1	23493	HEY2	5664	PSEN2
8454	CUL1	182	JAG1	5727	PTCH1
22943	DKK1	3714	JAG2	3516	RBPJ
27121	DKK4	2648	KAT2A	6502	SKP2
28514	DLL1	51176	LEF1	6932	TCF7
1856	DVL2	9794	MAML1	7157	TP53
10023	FRAT1	4609	MYC	7471	WNT1
8321	FZD1	9612	NCOR2	81029	WNT5B
8325	FZD8	23385	NCSTN	7475	WNT6

[0799] Table GS4. Certain examples of nucleic acids including various members of RASHI_RESPONSE_TO_IONIZING_RADIATION_1.

NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol
3725	JUN	7884	SLBP	1678	TIMM8A
1019	CDK4	55192	DNAJC17	55088	CCDC186
8433	UTF1	2353	FOS	1687	GSDME
1647	GADD45A	94234	FOXQ1	50486	G0S2
317772	H2AC21	7538	ZFP36	3290	HSD11B1
286826	LIN9	154	ADRB2	6446	SGK1
54361	WNT4	7535	ZAP70	7203	CCT3
7422	VEGFA	6513	SLC2A1	1958	EGR1
92906	HNRNPLL	8870	IER3	151295	SLC23A3
11060	WWP2	5362	PLXNA2	5049	PAFAH1B2
467	ATF3	6271	S100A1	9592	IER2
1843	DUSP1	54663	WDR74	51503	CWC15
10484	SEC23A	5269	SERPINB6	1306	COL15A1

[0800] Table GS5. Certain examples of nucleic acids including various members of

REACTOME_RRNA_PROCESSING.

NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol
81887	LAS1L	10436	EMG1	51504	TRMT112
60528	ELAC2	6192	RPS4Y1	54931	TRMT10C
115939	TSR3	25873	RPL36	6124	RPL4
6224	RPS20	23404	EXOSC2	6138	RPL15
51096	UTP18	1736	DKC1	6181	RPLP2
51106	TFB1M	25926	NOL11	6232	RPS27
51121	RPL26L1	6155	RPL27	55272	IMP3
23517	MTREX	57050	UTP3	54913	RPP25
51602	NOP58	51388	NIP7	54512	EXOSC4
55781	RIOK2	6210	RPS15A	55505	NOP10
6141	RPL18	134430	WDR36	6218	RPS17
10885	WDR3	55226	NAT10	6165	RPL35A
57418	WDR18	84946	LTV1	51118	UTP11
55623	THUMPD1	10200	MPHOSPH6	10607	TBL3
6160	RPL31	92856	IMP4	79050	NOC4L
114049	BUD23	54881	TEX10	51065	RPS27L
3028	HSD17B10	11224	RPL35	6228	RPS23
23016	EXOSC7	6194	RPS6	9045	RPL14
56915	EXOSC5	6176	RPLP1	27341	RRP7A
22894	DIS3	6229	RPS24	10438	C1D
6193	RPS5	55759	WDR12	6231	RPS26
27292	DIMT1	6123	RPL3L	6168	RPL37A
8602	NOP14	6187	RPS2	6136	RPL12
22803	XRN2	84916	UTP4	6191	RPS4X
6128	RPL6	28987	NOB1	6147	RPL23A
6175	RPLP0	27043	PELP1	4736	RPL10A
6222	RPS18	1453	CSNK1D	6170	RPL39
23481	PES1	6205	RPS11	9277	WDR46
4809	SNU13	23521	RPL13A	9277	WDR46
6122	RPL3	6135	RPL11	4550	MT-RNR2
9692	PRORP	6202	RPS8	4549	MT-RNR1
10528	NOP56	81875	ISG20L2	6235	RPS29
8780	RIOK3	6233	RPS27A	51202	DDX47
90459	ERI1	6161	RPL32	1454	CSNK1E
6217	RPS16	6189	RPS3A	7311	UBA52
2091	FBL	6167	RPL37	6222	RPS18
6223	RPS19	55651	NHP2	118460	EXOSC6
6142	RPL18A	6134	RPL10	6222	RPS18
54555	DDX49	6129	RPL7	9277	WDR46
55131	RBM28	6130	RPL7A	9277	WDR46
51010	EXOSC3	10556	RPP30	6171	RPL41
6158	RPL28	22984	PDCD11	6222	RPS18
6143	RPL19	6188	RPS3	6234	RPS28
117246	FTSJ3	2197	FAU	6222	RPS18
55813	UTP6	57647	DHX37	9277	WDR46
6164	RPL34	10557	RPP38	79897	RPP21
54433	GAR1	6156	RPL30	79897	RPP21
6207	RPS13	10813	UTP14A	6173	RPL36A

11103	KRR1	8568	RRP1	79897	RPP21
4839	NOP2	6132	RPL8	79897	RPP21
6206	RPS12	26168	SENP3	79897	RPP21
705	BYSL	6154	RPL26	5822	PWP2
6152	RPL24	6159	RPL29	79897	RPP21
9136	RRP9	79707	NOL9	79897	RPP21
4691	NCL	200916	RPL22L1	9724	UTP14C
6209	RPS15	6133	RPL9	23246	BOP1
84128	WDR75	11102	RPP14	84916	UTP4
56902	PNO1	23160	WDR43	6139	RPL17
6146	RPL22	116832	RPL39L	79159	NOL12
10969	EBNA1BP2	26354	GNL3	6203	RPS9
387338	NSUN4	84135	UTP15	6203	RPS9
27042	UTP25	6208	RPS14	6203	RPS9
6230	RPS25	25879	DCAF13	79922	MRM1
55127	HEATR1	65083	NOL6	6203	RPS9
51077	FCF1	140801	RPL10L	6203	RPS9
10171	RCL1	6166	RPL36AL	6203	RPS9
11340	EXOSC8	9188	DDX21	6203	RPS9
27340	UTP20	9790	BMS1	11056	DDX52
6144	RPL21	6157	RPL27A	11056	DDX52
130916	MTERF4	6137	RPL13	6203	RPS9
6125	RPL5	55720	TSR1	6218	RPS17
29960	MRM2	3921	RPSA	6203	RPS9
5393	EXOSC9	6203	RPS9	79922	MRM1
10199	MPHOSPH10	51013	EXOSC1	2091	FBL
88745	RRP36	5394	EXOSC10	6230	RPS25
6204	RPS10	6227	RPS21	6130	RPL7A
83732	RIOK1	55178	MRM3	140032	RPS4Y2
10799	RPP40	6201	RPS7	23246	BOP1
9349	RPL23	6169	RPL38	79050	NOC4L

[0801] Table GS6. Certain examples of nucleic acids including various members of HALLMARK_MYC_TARGETS_V1.

NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol
6059	ABCE1	3251	HPRT1	11137	PWP1
52	ACP1	3326	HSP90AB1	5887	RAD23B
7965	AIMP2	3329	HSPD1	5901	RAN
1176	AP3S1	3336	HSPE1	5902	RANBP1
328	APEX1	3376	IARS1	5984	RFC4
9184	BUB3	3475	IFRD1	10921	RNPS1
708	C1QBP	3608	ILF2	9045	RPL14
790	CAD	3615	IMPDH2	6141	RPL18
821	CANX	3735	KARS1	6146	RPL22
11335	CBX3	3838	KPNA2	6164	RPL34
890	CCNA2	3837	KPNB1	6128	RPL6
10576	CCT2	3939	LDHA	6175	RPLP0
7203	CCT3	57819	LSM2	6204	RPS10
10575	CCT4	51690	LSM7	6187	RPS2

22948	CCT5	4085	MAD2L1	6188	RPS3
10574	CCT7	4171	MCM2	6193	RPS5
991	CDC20	4173	MCM4	6194	RPS6
8318	CDC45	4174	MCM5	6240	RRM1
1017	CDK2	4175	MCM6	9136	RRP9
1019	CDK4	4176	MCM7	26156	RSL1D1
1207	CLNS1A	6150	MRPL23	10856	RUVBL2
7555	CNBP	65005	MRPL9	26135	SERBP1
10987	COPS5	28973	MRPS18B	6418	SET
9377	COX5A	4609	MYC	10291	SF3A1
1478	CSTF2	4673	NAP1L1	23450	SF3B3
1503	CTPS1	4686	NCBP1	5250	SLC25A3
8454	CUL1	22916	NCBP2	6599	SMARCC1
1537	CYC1	4706	NDUFAB1	6626	SNRPA
8886	DDX18	55651	NHP2	6627	SNRPA1
9188	DDX21	4830	NME1	6629	SNRPB2
7913	DEK	9221	NOLC1	6632	SNRPD1
1665	DHX15	51491	NOP16	6633	SNRPD2
1854	DUT	10528	NOP56	6634	SNRPD3
1933	EEF1B2	4869	NPM1	6637	SNRPG
1964	EIF1AX	4953	ODC1	6723	SRM
1965	EIF2S1	4999	ORC2	6732	SRPK1
8894	EIF2S2	5036	PA2G4	6426	SRSF1
8662	EIF3B	26986	PABPC1	6427	SRSF2
8664	EIF3D	8761	PABPC4	6428	SRSF3
8669	EIF3J	5093	PCBP1	6432	SRSF7
1973	EIF4A1	5111	PCNA	6741	SSB
1977	EIF4E	5230	PGK1	6742	SSBP1
1982	EIF4G2	5245	PHB	56910	STARD7
7458	EIF4H	11331	PHB2	10492	SYNCRIP
2058	EPRS1	5425	POLD2	23435	TARDBP
2079	ERH	54107	POLE3	6950	TCP1
2107	ETF1	5478	PPIA	7027	TFDP1
23016	EXOSC7	5496	PPM1G	9868	TOMM70
23196	FAM120A	10935	PRDX3	6434	TRA2B
2091	FBL	10549	PRDX4	10155	TRIM28
10146	G3BP1	26121	PRPF31	7284	TUFM
2739	GLO1	5634	PRPS2	10907	TXNL4A
10399	RACK1	5682	PSMA1	7298	TYMS
26354	GNL3	5683	PSMA2	7307	U2AF1
2806	GOT2	5685	PSMA4	10054	UBA2
2935	GSPT1	5687	PSMA6	7324	UBE2E1
3015	H2AZ1	5688	PSMA7	7332	UBE2L3
3066	HDAC2	5690	PSMB2	7398	USP1
51020	HDDC2	5691	PSMB3	7411	VBP1
3068	HDGF	5704	PSMC4	7416	VDAC1
3178	HNRNPA1	5706	PSMC6	7419	VDAC3
3181	HNRNPA2B1	5707	PSMD1	7514	XPO1
220988	HNRNPA3	10213	PSMD14	11260	XPOT
3183	HNRNPC	5709	PSMD3	2547	XRCC6
3184	HNRNPD	5713	PSMD7	7531	YWHAE

10236	HNRNPR	5714	PSMD8	10971	YWHAQ
3192	HNRNPU	10728	PTGES3		

[0802] Table GS7. Certain examples of nucleic acids including various members of HALLMARK_MYC_TARGETS_V2.

NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol
7965	AIMP2	10199	MPHOSPH10	10196	PRMT3
705	BYSL	51154	MRTO4	80324	PUS1
11335	CBX3	10514	MYBBP1A	10244	RABEPK
1019	CDK4	4609	MYC	10171	RCL1
79077	DCTPP1	29078	NDUFAF4	23223	RRP12
8886	DDX18	51388	NIP7	9136	RRP9
1844	DUSP2	79050	NOC4L	6573	SLC19A1
56915	EXOSC5	9221	NOLC1	3177	SLC29A2
2193	FARSA	51491	NOP16	6652	SORD
26354	GNL3	4839	NOP2	6723	SRM
83743	GRWD1	10528	NOP56	6832	SUPV3L1
3099	HK2	4869	NPM1	9238	TBRG4
3329	HSPD1	5036	PA2G4	6949	TCOF1
3336	HSPE1	23481	PES1	64216	TFB2M
92856	IMP4	5245	PHB	27346	TMEM97
79711	IPO4	5347	PLK1	7374	UNG
81887	LAS1L	10733	PLK4	27340	UTP20
9064	MAP3K6	56342	PPAN	23160	WDR43
4173	MCM4	23082	PPRC1	54663	WDR74
4174	MCM5				

[0803] Table GS8. Certain examples of nucleic acids including various members of HALLMARK_OXIDATIVE_PHOSPHORYLATION.

NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol
22	ABCB7	1743	DLST	4717	NDUFC1
30	ACAA1	1891	ECH1	4718	NDUFC2
10449	ACAA2	1892	ECHS1	4719	NDUFS1
34	ACADM	1632	ECI1	4720	NDUFS2
36	ACADSB	2108	ETFA	4722	NDUFS3
37	ACADVL	2109	ETFB	4724	NDUFS4
38	ACAT1	2110	ETFDH	4726	NDUFS6
50	ACO2	2230	FDX1	374291	NDUFS7
10939	AFG3L2	2271	FH	4728	NDUFS8
9131	AIFM1	2395	FXN	4723	NDUFV1
211	ALAS1	2746	GLUD1	4729	NDUFV2
4329	ALDH6A1	2806	GOT2	23530	NNT
481	ATP1B1	2821	GPI	4835	NQO2
498	ATP5F1A	2879	GPX4	4942	OAT
506	ATP5F1B	80273	GRPEL1	4967	OGDH
509	ATP5F1C	3030	HADHA	4976	OPA1

513	ATP5F1D	3032	HADHB	5018	OXA1L
514	ATP5F1E	3052	HCCS	5160	PDHA1
515	ATP5PB	3028	HSD17B10	5162	PDHB
516	ATP5MC1	3313	HSPA9	8050	PDHX
517	ATP5MC2	27429	HTRA2	5166	PDK4
518	ATP5MC3	3417	IDH1	54704	PDP1
10476	ATP5PD	3418	IDH2	11331	PHB2
521	ATP5ME	3419	IDH3A	5264	PHYH
522	ATP5PF	3420	IDH3B	23203	PMPCA
9551	ATP5MF	3421	IDH3G	5435	POLR2F
10632	ATP5MG	10989	IMMT	5447	POR
539	ATP5PO	81689	ISCA1	10935	PRDX3
537	ATP6AP1	23479	ISCU	54884	RETSAT
533	ATP6V0B	3939	LDHA	55288	RHOT1
527	ATP6V0C	3945	LDHB	89941	RHOT2
8992	ATP6V0E1	10128	LRPPRC	6389	SDHA
528	ATP6V1C1	4129	MAOB	6390	SDHB
51382	ATP6V1D	4190	MDH1	6391	SDHC
529	ATP6V1E1	4191	MDH2	6392	SDHD
9296	ATP6V1F	9927	MFN2	8402	SLC25A11
9550	ATP6V1G1	4259	MGST3	8604	SLC25A12
51606	ATP6V1H	65003	MRPL11	788	SLC25A20
581	BAX	29088	MRPL15	5250	SLC25A3
593	BCKDHA	64981	MRPL34	291	SLC25A4
56898	BDH2	51318	MRPL35	292	SLC25A5
51660	MPC1	64963	MRPS11	293	SLC25A6
840	CASP7	6183	MRPS12	8803	SUCLA2
1352	COX10	64960	MRPS15	8802	SUCLG1
1353	COX11	56945	MRPS22	6832	SUPV3L1
1355	COX15	10884	MRPS30	6834	SURF1
10063	COX17	9617	MTRF1	10312	TCIRG1
1327	COX4I1	4552	MTRR	26519	TIMM10
9377	COX5A	10651	MTX2	26517	TIMM13
1329	COX5B	4694	NDUFA1	10440	TIMM17A
1337	COX6A1	4695	NDUFA2	92609	TIMM50
1340	COX6B1	4696	NDUFA3	26521	TIMM8B
1345	COX6C	4697	NDUFA4	26520	TIMM9
1347	COX7A2	4698	NDUFA5	56993	TOMM22
9167	COX7A2L	4700	NDUFA6	9868	TOMM70
1349	COX7B	4701	NDUFA7	29796	UQCR10
1350	COX7C	4702	NDUFA8	10975	UQCR11
1351	COX8A	4704	NDUFA9	7381	UQCRB
1374	CPT1A	4706	NDUFAB1	7384	UQCRC1
1431	CS	4707	NDUFB1	7385	UQCRC2
1528	CYB5A	4708	NDUFB2	7386	UQCRFS1
1727	CYB5R3	4709	NDUFB3	7388	UQCRH
1537	CYC1	4710	NDUFB4	27089	UQCRQ
54205	CYCS	4711	NDUFB5	7416	VDAC1
1666	DECR1	4712	NDUFB6	7417	VDAC2
1737	DLAT	4713	NDUFB7	7419	VDAC3
1738	DLD	4714	NDUFB8		

[0804] Table GS9. Certain examples of nucleic acids including various members of HALLMARK_E2F_TARGETS.

NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol
204	AK2	3161	HMMR	10549	PRDX4
81611	ANP32E	51155	JPT1	5558	PRIM2
25842	ASF1A	3184	HNRNPD	5591	PRKDC
55723	ASF1B	3364	HUS1	5631	PRPS1
29028	ATAD2	3609	ILF3	11168	PSIP1
6790	AURKA	54556	ING3	29893	PSMC3IP
9212	AURKB	10527	IPO7	9232	PTTG1
580	BARD1	146909	KIF18B	29127	RACGAP1
332	BIRC5	3835	KIF22	5810	RAD1
672	BRCA1	11004	KIF2C	5885	RAD21
675	BRCA2	24137	KIF4A	10111	RAD50
84312	BRMS1L	3838	KPNA2	10635	RAD51AP1
701	BUB1B	3930	LBR	5889	RAD51C
23468	CBX5	3978	LIG1	5901	RAN
9133	CCNB2	4001	LMNB1	5902	RANBP1
898	CCNE1	51747	LUC7L3	5931	RBBP7
9738	CCP110	55646	LYAR	5981	RFC1
991	CDC20	4085	MAD2L1	5982	RFC2
993	CDC25A	4171	MCM2	5983	RFC3
994	CDC25B	4172	MCM3	10535	RNASEH2A
83461	CDCA3	4173	MCM4	6117	RPA1
55143	CDCA8	4174	MCM5	6118	RPA2
983	CDK1	4175	MCM6	6119	RPA3
1019	CDK4	4176	MCM7	9125	CNOT9
1026	CDKN1A	9833	MELK	6241	RRM2
1027	CDKN1B	4288	MKI67	6470	SHMT1
1029	CDKN2A	4292	MLH1	7884	SLBP
1031	CDKN2C	253714	MMS22L	8243	SMC1A
1033	CDKN3	4361	MRE11	9126	SMC3
1062	CENPE	4436	MSH2	10051	SMC4
79019	CENPM	10797	MTHFD2	79677	SMC6
1111	CHEK1	83463	MXD3	6628	SNRPB
11200	CHEK2	4605	MYBL2	10615	SPAG5
11113	CIT	4609	MYC	147841	SPC24
1163	CKS1B	84316	NAA38	57405	SPC25
1164	CKS2	4673	NAP1L1	6426	SRSF1
1434	CSE1L	4678	NASP	6427	SRSF2
10664	CTCF	4683	NBN	6749	SSRP1
1503	CTPS1	9918	NCAPD2	10274	STAG1
1633	DCK	4830	NME1	3925	STMN1
64858	DCLRE1B	9221	NOLC1	6839	SUV39H1
79077	DCTPP1	10528	NOP56	10492	SYNCRIP
10212	DDX39A	11051	NUDT21	10460	TACC3
7913	DEK	57122	NUP107	9238	TBRG4
55635	DEPDC1	9972	NUP153	6941	TCF19

81624	DIAPH3	23165	NUP205	7037	TFRC
9787	DLGAP5	4999	ORC2	8914	TIMELESS
1786	DNMT1	23594	ORC6	54962	TIPIN
29980	DONSON	5036	PA2G4	7083	TK1
79075	DSCC1	10606	PAICS	7112	TMPO
1854	DUT	9924	PAN2	7153	TOP2A
79733	E2F8	5111	PCNA	7157	TP53
8726	EED	23047	PDS5B	6434	TRA2B
1965	EIF2S1	84844	PHF5A	9319	TRIP13
9700	ESPL1	5347	PLK1	203068	TUBB
11340	EXOSC8	10733	PLK4	7283	TUBG1
2146	EZH2	5395	PMS2	27338	UBE2S
9837	GINS1	5411	PNN	29089	UBE2T
64785	GINS3	23649	POLA2	55148	UBR7
84296	GINS4	5424	POLD1	7374	UNG
2935	GSPT1	5425	POLD2	7398	USP1
3014	H2AX	10714	POLD3	197335	WDR90
3015	H2AZ1	5426	POLE	7465	WEE1
3070	HELLS	56655	POLE4	7514	XPO1
3159	HMGA1	10248	POP7	2547	XRCC6
3148	HMGB2	8493	PPM1D	9183	ZW10
3149	HMGB3	5511	PPP1R8		

[0805] Table GS10. Certain examples of nucleic acids including various members of HALLMARK_TNFA_SIGNALING_VIA_NFKB.

NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol	NCBI (Entrez) Gene Id	Nucleic Acid / Gene Symbol
19	ABCA1	1647	GADD45A	5187	PER1
374	AREG	4616	GADD45B	5209	PFKFB3
467	ATF3	2643	GCH1	22822	PHLDA1
490	ATP2B1	2669	GEM	7262	PHLDA2
2683	B4GALT1	9945	GFPT2	5328	PLAU
9334	B4GALT5	1880	GPR183	5329	PLAUR
597	BCL2A1	1839	HBEGF	5341	PLEK
602	BCL3	3280	HES1	10769	PLK2
604	BCL6	3383	ICAM1	56937	PMEPA1
8553	BHLHE40	23308	ICOSLG	10957	PNRC1
329	BIRC2	3398	ID2	8613	PLPP3
330	BIRC3	9592	IER2	23645	PPP1R15A
650	BMP2	8870	IER3	5734	PTGER4
694	BTG1	51278	IER5	5743	PTGS2
7832	BTG2	64135	IFIH1	5791	PTPRE
10950	BTG3	3433	IFIT2	5806	PTX3
6347	CCL2	3460	IFNGR2	1827	RCAN1
6364	CCL20	3593	IL12B	5966	REL
6351	CCL4	3601	IL15RA	5970	RELA
6352	CCL5	3606	IL18	5971	RELB
595	CCND1	3552	IL1A	388	RHOB
57018	CCNL1	3553	IL1B	8767	RIPK2
9034	CCRL2	51561	IL23A	127544	RNF19B

960	CD44	3569	IL6	6303	SAT1
969	CD69	3572	IL6ST	6385	SDC4
941	CD80	3575	IL7R	5055	SERPINB2
9308	CD83	3624	INHBA	5271	SERPINB8
1026	CDKN1A	3659	IRF1	5054	SERPINE1
1051	CEBPB	8660	IRS2	6446	SGK1
1052	CEBPD	182	JAG1	150094	SIK1
8837	CFLAR	3725	JUN	9120	SLC16A6
23529	CLCF1	3726	JUNB	6515	SLC2A3
1435	CSF1	23135	KDM6B	11182	SLC2A6
1437	CSF2	7071	KLF10	4088	SMAD3
2919	CXCL1	10365	KLF2	8303	SNN
3627	CXCL10	9314	KLF4	9021	SOCS3
6373	CXCL11	1316	KLF6	6648	SOD2
2920	CXCL2	687	KLF9	8877	SPHK1
2921	CXCL3	8942	KYNU	80176	SPSB1
6372	CXCL6	3914	LAMB3	8878	SQSTM1
57007	ACKR3	3949	LDLR	6776	STAT5A
3491	CCN1	3976	LIF	10010	TANK
23586	DDX58	9516	LITAF	6890	TAP1
23258	DENND5A	23764	MAFF	7050	TGIF1
11080	DNAJB4	5606	MAP2K3	25976	TIPARP
55332	DRAM1	1326	MAP3K8	7097	TLR2
1843	DUSP1	4082	MARCKS	3371	TNC
1844	DUSP2	4170	MCL1	7124	TNF
1846	DUSP4	9242	MSC	7127	TNFAIP2
1847	DUSP5	4084	MXD1	7128	TNFAIP3
1906	EDN1	4609	MYC	7130	TNFAIP6
1942	EFNA1	10135	NAMPT	25816	TNFAIP8
1958	EGR1	10725	NFAT5	3604	TNFRSF9
1959	EGR2	4780	NFE2L2	8744	TNFSF9
1960	EGR3	4783	NFIL3	10318	TNIP1
10938	EHD1	4790	NFKB1	79155	TNIP2
10209	EIF1	4791	NFKB2	7185	TRAF1
2114	ETS2	4792	NFKBIA	10221	TRIB1
2150	F2RL1	4794	NFKBIE	9322	TRIP10
2152	F3	4814	NINJ1	8848	TSC22D1
24147	FJX1	3164	NR4A1	7280	TUBB2A
2353	FOS	4929	NR4A2	7422	VEGFA
2354	FOSB	8013	NR4A3	79693	YRDC
8061	FOSL1	4973	OLR1	65986	ZBTB10
2355	FOSL2	24145	PANX1	80149	ZC3H12A
2526	FUT4	5142	PDE4B	7538	ZFP36
50486	G0S2	10611	PDLIM5		

[0806] In some embodiments, a nucleic acid is a member of a positively enriched gene set observed in, or can be identified using technologies in, e.g., Example 17.

[0807] In some embodiments, the present disclosure provides technologies for detecting, monitoring and/or confirming efficacy of an agent, e.g., a stapled peptide, or a method, e.g., a method of treating a

condition, disorder or disease, a method for modulating level of a transcript and/or a product and/or activity thereof, comprising assessing level of expression and/or activity of a nucleic acid, e.g., a gene, a transcript, a polypeptide, and/or a product thereof. In some embodiments, the present disclosure provides technologies for detecting, monitoring and/or confirming efficacy of an agent, e.g., a stapled peptide, comprising administering the agent to a subject, and assessing level of expression and/or activity of a nucleic acid, e.g., a gene, a transcript, a polypeptide, and/or a product thereof, in the subject. In some embodiments, the present disclosure provides technologies for detecting, monitoring and/or confirming efficacy of a method for treating a condition, disorder or disease in a subject, comprising assessing level of expression and/or activity of a nucleic acid, e.g., a gene, a transcript, a polypeptide, and/or a product thereof, in the subject. In some embodiments, a method is a method for treating a condition, disorder or disease associated with TCF-beta-catenin interaction in a subject. In some embodiments, a condition, disorder or disease is cancer as described herein. In some embodiments, the present disclosure provides technologies for selecting subjects for administration or delivery of an agent, e.g., stapled peptide agents described herein (e.g., for preventing or treating a condition, disorder or disease). In some embodiments, the present disclosure provides technologies for selecting subjects for continued administration or delivery of an agent, e.g., stapled peptide agents described herein (e.g., for preventing or treating a condition, disorder or disease) after one or more administrations or deliveries. In some embodiments, level of a transcript is assessed. In some embodiments, level of a polypeptide is assessed. In some embodiments, assessment is performed utilizing a sample or samples collected from a system or a subject. In some embodiments, a sample is collected during administration or delivery. In some embodiments, a sample is collected after administration or delivery. As described herein, in some embodiments, level of expression and/or activity of a nucleic acid and/or a product thereof is modulated. In some embodiments, a nucleic acid is AXIN2. In some embodiments, level of an AXIN2 transcript, e.g., mRNA, is reduced. In some embodiments, level of an AXIN2 polypeptide is reduced. In some embodiments, a nucleic acid is SP5. In some embodiments, level of an SP5 transcript, e.g., mRNA, is reduced. In some embodiments, level of an SP5 polypeptide is reduced. In some embodiments, a nucleic acid is CXCL12. In some embodiments, level of a CXCL12 transcript, e.g., mRNA, is increased. In some embodiments, level of a CXCL12 polypeptide is increased. In some embodiments, a nucleic acid is a member of a negatively enriched gene set observed in, or can be identified using technologies in, e.g., Example 17. In some embodiments, a nucleic acid is a member of BCAT_GDS748_UP gene set. In some embodiments, a nucleic acid is a member of BCAT.100_UP.V1_UP gene set. In some embodiments, a nucleic acid is a member of HALLMARK_WNT_BETA_CATENIN_SIGNALING gene set. In some embodiments, a nucleic acid is a member of RASHI_RESPONSE_TO_IONIZING_RADIATION_1 gene set. In some embodiments, a nucleic acid is a member of REACTOME_RRNA_PROCESSING gene set. In some embodiments, a nucleic acid is a member of HALLMARK_MYC_TARGETS_V1 gene set. In some embodiments, a nucleic acid is a member of HALLMARK_MYC_TARGETS_V2 gene set. In some embodiments, a nucleic acid is a member of HALLMARK_OXIDATIVE_PHOSPHORYLATION gene set.

In some embodiments, a nucleic acid is a member of HALLMARK_E2F_TARGETS gene set. In some embodiments, a nucleic acid is a member of HALLMARK_TNFA_SIGNALING_VIA_NFKB gene set. In some embodiments, a nucleic acid is selected from Table GS1. In some embodiments, a nucleic acid is selected from Table GS2. In some embodiments, a nucleic acid is selected from Table GS3. In some embodiments, a nucleic acid is selected from Table GS4. In some embodiments, a nucleic acid is selected from Table GS5. In some embodiments, a nucleic acid is selected from Table GS6. In some embodiments, a nucleic acid is selected from Table GS7. In some embodiments, a nucleic acid is selected from Table GS8. In some embodiments, a nucleic acid is selected from Table GS9. In some embodiments, a nucleic acid is selected from Table GS10. In some embodiments, a nucleic acid is a gene selected Table GS1, Table GS2, Table GS3, Table GS4, Table GS5, Table GS6, Table GS7, Table GS8, Table GS9 or Table GS10. In some embodiments, a gene is CCND2. In some embodiments, a gene is WNT5B. In some embodiments, a gene is AXIN2. In some embodiments, a gene is NKD1. In some embodiments, a gene is WNT6. In some embodiments, a gene is DKK1. In some embodiments, a gene is DKK4. In some embodiments, expression of such a nucleic acid, e.g., a gene, is reduced. In some embodiments, level of a product of such a nucleic acid, e.g., a transcript (e.g., mRNA), a polypeptide, etc., is reduced. In some embodiments, level of activity of a product of such a nucleic acid, e.g., a transcript (e.g., mRNA), a polypeptide, etc., is reduced. In some embodiments, a nucleic acid is a member of a positively enriched gene set observed in, or can be identified using technologies in, e.g., Example 17. In some embodiments, if one or more desired reductions of expression and/or levels of transcripts and/or products thereof, and/or one or more desired negatively and/or positively enriched gene sets, are observed, administration or delivery continues. In some embodiments, administration or delivery continues as prior one(s). In some embodiments, administration or delivery continue with an adjusted dose level and/or regimen. In some embodiments, if desired reductions of expression and/or levels of transcripts and/or products thereof, and/or one or more desired negatively and/or positively enriched gene sets, are not observed, administration or delivery may be adjusted, and in some embodiments, discontinued. In some embodiments, as described herein, desired reductions of expression and/or levels of transcripts and/or products thereof comprise reductions of expression and/or levels of transcripts and/or products thereof of one or more or a majority of or all of SP5, CCND2, WNT5B, AXIN2, NKD1, WNT6, DKK1 and DKK4, nucleic acids of BCAT_GDS748_UP, BCAT.100_UP.V1_UP, HALLMARK_WNT_BETA_CATENIN_SIGNALING, RASHI_RESPONSE_TO_IONIZING_RADIATION_1, REACTOME_RRNA_PROCESSING, HALLMARK_MYC_TARGETS_V1, HALLMARK_MYC_TARGETS_V2, HALLMARK_OXIDATIVE_PHOSPHORYLATION, HALLMARK_E2F_TARGETS, HALLMARK_TNFA_SIGNALING_VIA_NFKB, and Table GS1, Table GS2, Table GS3, Table GS4, Table GS5, Table GS6, Table GS7, Table GS8, Table GS9 and Table GS10. In some embodiments, as described herein, desired increase of expression and/or levels of transcripts and/or products thereof comprise increase of expression and/or levels of transcripts and/or products thereof of CXCL12. In some embodiments, desired

gene set enrichments comprise negative enrichment of one or more or all of BCAT_GDS748_UP, BCAT.100_UP.V1_UP, HALLMARK_WNT_BETA_CATENIN_SIGNALING, RASHI_RESPONSE_TO_IONIZING_RADIATION_1, REACTOME_RRNA_PROCESSING, HALLMARK_MYC_TARGETS_V1, HALLMARK_MYC_TARGETS_V2, HALLMARK_OXIDATIVE_PHOSPHORYLATION, HALLMARK_E2F_TARGETS, and HALLMARK_TNFA_SIGNALING_VIA_NFKB. In some embodiments, desired gene set enrichments comprise negative enrichment of one or more or all of the set in Table GS1, the set in Table GS2, the set in Table GS3, the set in Table GS4, the set in Table GS5, the set in Table GS6, the set in Table GS7, the set in Table GS8, the set in Table GS9, and the set in Table GS10. Those skilled in the art, e.g., those skilled in relevant clinical fields, reading the present disclosure will appreciate how to make decisions in accordance with the present disclosure.

[0808] In some embodiments, comparison is made to a reference. For example, reduction, increase, enrichment (negative or positive), changes, etc., are typically made to a suitable reference. In some embodiments, reduction, increase, enrichment (negative or positive), changes, etc., are to a reference assessment, in some embodiments, of a reference sample. In some embodiments, a reference assessment is or comprises assessment conducted prior to an administration or delivery of an agent. In some embodiments, a reference sample is collected prior to an administration or delivery of an agent. In some embodiments, a reference assessment is or comprises assessment conducted during an administration or delivery of an agent. In some embodiments, a reference sample is collected during an administration or delivery of an agent. In some embodiments, a reference assessment is or comprises assessment conducted after an administration or delivery of an agent. In some embodiments, a reference sample is collected after an administration or delivery of an agent. In some embodiments, a reference assessment is or comprises assessment conducted after an earlier administration or delivery of an agent. In some embodiments, a reference sample is collected after earlier an administration or delivery of an agent.

[0809] In some embodiments, a sample is an aliquot of material obtained or derived from a source of interest as described herein. In some embodiments, a source of interest is a biological or environmental source. In some embodiments, a source of interest may be or comprise a cell or an organism, such as a microbe, a plant, or an animal (e.g., a human). In some embodiments, a source of interest is or comprises biological tissue or fluid. In some embodiments, a biological tissue or fluid may be or comprise amniotic fluid, aqueous humor, ascites, bile, bone marrow, blood, breast milk, cerebrospinal fluid, cerumen, chyle, chime, ejaculate, endolymph, exudate, feces, gastric acid, gastric juice, lymph, mucus, pericardial fluid, perilymph, peritoneal fluid, pleural fluid, pus, rheum, saliva, sebum, semen, serum, smegma, sputum, synovial fluid, sweat, tears, urine, vaginal secreations, vitreous humour, vomit, and/or combinations or component(s) thereof. In some embodiments, a biological fluid may be or comprise an intracellular fluid, an extracellular fluid, an intravascular fluid (blood plasma), an interstitial fluid, a lymphatic fluid, and/or a transcellular fluid. In some embodiments, a biological fluid may be or comprise a plant exudate. In some

embodiments, a biological tissue or sample may be obtained, for example, by aspirate, biopsy (e.g., fine needle or tissue biopsy), swab (e.g., oral, nasal, skin, or vaginal swab), scraping, surgery, washing or lavage (e.g., brocheoalvealar, ductal, nasal, ocular, oral, uterine, vaginal, or other washing or lavage). In some embodiments, a biological sample is or comprises cells obtained from an individual. In some embodiments, a sample is a "primary sample" obtained directly from a source of interest by any appropriate means. In some embodiments, as will be clear from context, the term "sample" refers to a preparation that is obtained by processing (e.g., by removing one or more components of and/or by adding one or more agents to) a primary sample. For example, filtering using a semi-permeable membrane. Such a "processed sample" may comprise, for example nucleic acids or proteins extracted from a sample or obtained by subjecting a primary sample to one or more techniques such as amplification or reverse transcription of nucleic acid, isolation and/or purification of certain components, *etc.* In some embodiments, a sample comprise cancer cells. In some embodiments, a sample is obtained from a tumor. In some embodiments, a sample is obtained from a tumor in a patient.

[0810] In some embodiments, levels of two or more transcripts and/or products thereof may be assessed. In some embodiments, assessment is performed after one or more doses of agents, e.g., stapled peptides are administered or delivered to a subject. In some embodiments, if profiles, e.g., reduction, increase, etc., of one or more transcripts and/or products thereof matches those described herein, administration or delivery to a subject may continue. In some embodiments, if profiles, e.g., reduction, increase, etc., of one or more transcripts and/or products thereof matches those described herein, administration or delivery to a subject may be stopped and/or continued according to different dose levels and/or regimens.

[0811] Various technologies can be utilized in accordance with the present disclosure to formulate, distribute, administer or deliver provided technologies such as agents, peptides, compounds, compositions, etc. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, *etc.* In some particular embodiments, administration may be bronchial (*e.g.*, by bronchial instillation), buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, *etc*), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e. g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (*e.g.*, by intratracheal instillation), vaginal, vitreal, *etc.* In some embodiments, administration may involve dosing that is intermittent (*e.g.*, a plurality of doses separated in time) and/or periodic (*e.g.*, individual doses separated by a common period of time) dosing. In some embodiments, administration may involve continuous dosing (*e.g.*, perfusion) for at least a selected period of time. In some embodiments, provided technologies are administered intravenously.

[0812] Among other things, the present disclosure provides various structural moieties including designed amino acid residues that can be utilized to optimize various properties and activities, stability, delivery, pharmacodynamics, pharmacokinetics, etc. to provide various dosage forms, dosage regimen, therapeutic windows, etc. In some embodiments, provided agents and compositions thereof may be utilized

with improved dosage regimen and/or unit doses. In some embodiments, administration of provided agents are adjusted based on conditions, disorders or diseases and/or subpopulations. In some embodiments, administration and/or dosage regimen of provided technologies are adjusted according to certain biomarkers and genomic alterations.

[0813] Provided agents may deliver biological effects, e.g., therapeutic effects, via various mechanisms. In some embodiments, efficacy may be driven by AUC. In some embodiments, efficacy may be driven by Cmax.

[0814] In some embodiments, a provided agent is utilized in combination with another therapy. In some embodiments, a provided agent is utilized in combination with another therapeutic agent. In some embodiments, another therapy or therapeutic agent is administered prior to an administration or delivery of a provided agent. In some embodiments, another therapy or therapeutic agent is administered at about the same time as an administration or delivery of a provided agent. In some embodiments, a provided agent and another agent is in the same pharmaceutical composition. In some embodiments, another therapy or therapeutic agent is administered subsequently to an administration or delivery of a provided agent. In some embodiments, a subject is exposed to both a provided agent and another therapeutic agent. In some embodiments, both a provided agent and another agent can be detected in a subject. In some embodiments, a provided agent is administered before another agent is cleared out by a subject or vice versa. In some embodiments, a provided agent is administered within the half-life, or 2, 3, 4, 5 or 6 times of the half-life, of another agent or vice versa. In some embodiments, a subject is exposed to a therapeutic effect of a provided agent and a therapeutic effect of another therapeutic agent. In some embodiments, an agent may provide an effect after an agent is cleared out or metabolized by a subject. In some embodiments, a procedure, e.g., surgery, radiation, etc., may provide an effect after the procedure is completed.

[0815] In some embodiments, another therapy is a cancer therapy. In some embodiments, another therapy is or comprises surgery. In some embodiments, another therapy is or comprises radiation therapy. In some embodiments, another therapy is or comprises immunotherapy. In some embodiments, another therapeutic agent is or comprises a drug. In some embodiments, another therapeutic agent is or comprises a cancer drug. In some embodiments, another therapeutic agent is or comprises a chemotherapeutic agent. In some embodiments, another therapeutic agent is or comprises a hormone therapy agent. In some embodiments, another therapeutic agent is or comprises a kinase inhibitor. In some embodiments, another therapeutic agent is or comprises a checkpoint inhibitor (e.g., antibodies against PD-1, PD-L1, CTLA-4, etc.). In some embodiments, a provide agent can be administered with lower unit dose and/or total dose compared to being used alone. In some embodiments, another agent can be administered with lower unit dose and/or total dose compared to being used alone. In some embodiments, one or more side effects associated with administration of a provided agent and/or another therapy or therapeutic agent are reduced. In some embodiments, a combination therapy provides improved results, e.g., when compared to each agent utilized individually. In some embodiments, a combination therapy achieves one or more better results, e.g., when

compared to each agent utilized individually.

[0816] In some embodiments, another agent is a checkpoint inhibitor, an EGFR inhibitor, a VEGF inhibitor, a VEGFR inhibitor, a kinase inhibitor, or an anti-cancer drug.

[0817] In some embodiments, an additional agent is a checkpoint inhibitor. In some embodiments, an additional agent is an immune oncology agent. In some embodiments, an additional agent is an antibody against a checkpoint molecules. In some embodiments, an additional agent is an antibody of PD1, PDL-1, CTLA4, A2AR, B7-H3, B7-H4, BTLA, IDO, KIR, LAG3, TIM-s, C10orf54, *etc.* In some embodiments, an antibody is an anti-PD1 antibody. In some embodiments, an antibody is an anti-PD-L1 antibody. In some embodiments, an antibody is an anti-CTLA4.

[0818] In some embodiments, another agent is an EGFR inhibitor, *e.g.*, erlotinib, gefitinib, lapatinib, panitumumab, vandetanib, cetuximab, *etc.* In some embodiments, another agent is an VEGF and/or VEGFR inhibitor, *e.g.*, pazopanib, bevacizumab, sorafenib, sunitinib, axitinib, ponatinib, regorafenib, vandetanib, cabozantinib, ramucirumab, lenvatinib, ziv-aflibercept, *etc.* In some embodiments, another agent is a kinase inhibitor. In some embodiments, another therapeutic agent is a chemotherapeutic agent. In some embodiments, another therapeutic agent is an anti-cancer drug, *e.g.*, cyclophosphamide, methotrexate, 5-fluorouracil (5-FU), doxorubicin, mustine, vincristine, procarbazine, prednisolone, dacarbazine, bleomycin, etoposide, cisplatin, epirubicin, capecitabine, folinic acid, actinomycin, all-trans retinoic acid, azacitidine, azathioprine, bortezomib, carboplatin, chlorambucil, cytarabine, daunorubicin, docetaxel, doxifluridine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, irinotecan, mechlorethamine, mercaptopurine, mitoxantrone, paclitaxel, pemetrexed, teniposide, tioguanine, topotecan, valrubicin, vinblastine, vindesine, vinorelbine, oxaliplatin, *etc.*

[0819] Among other things, the present disclosure provides the following Embodiments:

1. An agent having the structure of formula I:

$$R^N–L^{P1}–L^{AA1}–L^{P2}–L^{AA2}–L^{P3}–L^{AA3}–L^{P4}–L^{AA4}–L^{P5}–L^{AA5}–L^{P6}–L^{AA6}–L^{P7}–R^C,$$

I

or a salt thereof, wherein:

R^N is a peptide, an amino protecting group or R'–L^{RN}–;

each of L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} is independently L, wherein L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} comprise:

a first R' group and a second R' group which are taken together to form –L^s– which is bonded to the atom to which a first R' group is attached and the atom to which a second R' group is attached; and

a third R' group and a fourth R' group which are taken together to form –L^s– which is bonded to the atom to which a third R' group is attached and the atom to which a fourth R' group is attached;

each L^s is independently –L^{s1}–L^{s2}–L^{s3}–, wherein each L^{s1}, L^{s2} and L^{s3} is independently L;

L^{AA1} is an amino acid residue that comprises a side chain comprising an acidic or polar group;

L^{AA2} is an amino acid residue that comprises a side chain comprising an acidic or polar group;

L^{AA3} is an amino acid residue;

L^{AA4} is an amino acid residue that comprises a side chain comprising an optionally substituted aromatic group;

L^{AA5} is an amino acid residue that comprises a side chain comprising an optionally substituted aromatic group;

L^{AA6} is an amino acid residue that comprises a side chain comprising an optionally substituted aromatic group;

R^C is a peptide, a carboxyl protecting group, $-L^{RC}-R'$, $-O-L^{RC}-R'$ or $-N(R')-L^{RC}-R'$;

each of L^{RN} and L^{RC} is independently L;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each $-Cy-$ is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;

each R' is independently $-L-R$, $-C(O)R$, $-CO_2R$, or $-SO_2R$;

each R is independently $-H$, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atom(s), 0-10 heteroatoms.

2. An agent having the structure of formula I:

$$R^N-L^{P1}-L^{AA1}-L^{P2}-L^{AA2}-L^{P3}-L^{AA3}-L^{P4}-L^{AA4}-L^{P5}-L^{AA5}-L^{P6}-L^{AA6}-L^{P7}-R^C,$$

I

or a salt thereof, wherein:

R^N is a peptide, an amino protecting group or $R'-L^{RN}-$;

each of L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} is independently L, wherein L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and

L^{P7} comprise:

a first R' group and a second R' group which are taken together to form $-L^{s}-$ which is bonded to the atom to which a first R' group is attached and the atom to which a second R' group is attached; and

a third R' group and a fourth R' group which are taken together to form $-L^{s}-$ which is bonded to the atom to which a third R' group is attached and the atom to which a fourth R' group is attached;

each L^{s} is independently $-L^{s1}-L^{s2}-L^{s3}-$, wherein each L^{s1}, L^{s2} and L^{s3} is independently L;

L^{AA1} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS1}-R^{AA1}$, wherein R^{AA1} is $-CO_2R$ or $-SO_2R$;

L^{AA2} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS2}-R^{AA2}$, wherein R^{AA2} is $-CO_2R$, or $-SO_2R$;

L^{AA3} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS3}-R^{AA3}$, wherein R^{AA3} is R';

L^{AA4} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS4}-R^{AA4}$, wherein R^{AA4} is an optionally substituted group selected from 6-14 membered aryl or 5-14 membered heteroaryl having 1-6 heteroatoms;

L^{AA5} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS5}-R^{AA5}$, wherein R^{AA5} is an optionally substituted group selected from 6-14 membered aryl or 5-14 membered heteroaryl having 1-6 heteroatoms;

L^{AA6} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS6}-R^{AA6}$, wherein R^{AA6} is an optionally substituted group selected from 6-14 membered aryl or 5-14 membered heteroaryl having 1-6 heteroatoms;

R^{C} is a peptide, a carboxyl protecting group, $-L^{RC}-R'$, $-O-L^{RC}-R'$ or $-N(R')-L^{RC}-R'$;

each of L^{RN} and L^{RC} is independently L;

each L^{AR} is independently an optionally substituted, bivalent C_1-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each of L^{AS1}, L^{AS2}, L^{AS3}, L^{AS4}, L^{AS5}, and L^{AS6} is independently L^{AS};

each R^{AS} is independently $-L^{AS}-R'$;

each L^{AS} is independently a covalent bond or an optionally substituted, bivalent C_1-C_{10} aliphatic or heteroaliphatic group having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each $-Cy-$ is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;

each R' is independently $-L-R$, $-C(O)R$, $-CO_2R$, or $-SO_2R$;

each R is independently $-H$, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atom(s), 0-10 heteroatoms.

3. The agent of any one of the preceding Embodiments, wherein a second R' group and a third R' group are attached to the same atom.

4. The agent of any one of the preceding Embodiments, wherein each of the first, second and fourth R' groups is independently attached to a different atom.

5. The agent of any one of the preceding Embodiments, wherein L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} further comprise a fifth R' group and a sixth R' groups which are taken together to form $-L^s-$ which is bonded to the atom to which a fifth R' group is attached and the atom to which a sixth R' group is attached.

6. The agent of any one of the preceding Embodiments, wherein each of the first, second, fourth, fifth and sixth R' groups is independently attached to a different atom.

7. The agent of any one of the preceding Embodiments, wherein L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} further comprise a seventh R' group and an eighth R' groups which are taken together to form $-L^s-$ which is bonded to the atom to which a seventh R' group is attached and the atom to which an eighth R' group is attached.

8. The agent of any one of the preceding Embodiments, wherein each of the first, second, fourth, fifth, sixth, seventh and eighth R' groups is independently attached to a different atom.

9. The agent of any one of the preceding Embodiments, wherein L^s formed by taking the first and the second R' groups together is a staple as described herein.

10. The agent of any one of the preceding Embodiments, wherein L^s formed by taking the first and the second R' groups together has a length of 5-20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms.

11. The agent of any one of the preceding Embodiments, wherein L^s formed by taking the third and the fourth R' groups together is a staple as described herein.

12. The agent of any one of the preceding Embodiments, wherein L^s formed by taking the third and the fourth R' groups together has a length of 5-20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms.

13. The agent of any one of the preceding Embodiments, wherein L^s formed by taking the third and the fourth R' groups together has a length of 10-20 (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms.

14. The agent of any one of the preceding Embodiments, wherein L^s formed by taking the fifth and the sixth R' groups together has a length of 5-20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms.

15. The agent of any one of the preceding Embodiments, wherein L^s formed by taking the seventh and the eighth R' groups together has a length of 5-20 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms.

16. The agent of any one of the preceding Embodiments, wherein L^{P1} is a covalent bond, or an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

17. The agent of any one of the preceding Embodiments, wherein the length of L^{P1} is 2-10 (2, 3, 4, 5, 6, 7, 8, 9, or 10) atoms.

18. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P1} are independently replaced with $-N(R')-$ or $-C(O)-$.

19. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P1} are independently replaced with $-N(R')-$ or $-C(O)N(R')-$.

20. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P1} are independently replaced with $-N(R')-$, $-C(R')_2$, or $-C(O)N(R')-$.

21. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{p1} are independently replaced with $-N(R')-$, and one or more methylene units of L^{p1} are independently replaced with $-C(O)N(R')-$.

22. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{P1} is replaced with $-C(R')_2-$, wherein one of the R' groups is a first R' group of the four R' groups, or a methylene unit of L^{P1} is replaced with $-N(R')-$, wherein the R' group is a first R' group of the four R' groups.

23. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{P1} is replaced

with $-C(R')_2-$, wherein one of the R' groups is a first R' group of the four R' groups.

24. The agent of any one of the preceding Embodiments, wherein L^{P1} is or comprises $-[X]_p-X^1-$, wherein each X and X^1 is independently an amino acid residue, wherein p is 0-10, and X^1 is bonded to L^{AA1}.

25. The agent of any one of the preceding Embodiments, wherein L^{P1} is or comprises $-X^1-$.

26. The agent of any one of the preceding Embodiments, wherein X^1 comprises the first R' group of the four R' groups.

27. The agent of any one of the preceding Embodiments, wherein L^{AA1} is an optionally substituted, bivalent C_2-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

28. The agent of any one of the preceding Embodiments, wherein L^{AA1} is $-N(R')-C(R')(R^{AS})-C(O)-$.

29. The agent of any one of the preceding Embodiments, wherein L^{AA1} is $-NH-C(R')(R^{AS})-C(O)-$.

30. The agent of any one of the preceding Embodiments, wherein L^{AS1} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

31. The agent of any one of the preceding Embodiments, wherein L^{AS1} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-S(O)-$, or $-S(O)_2-$.

32. The agent of any one of the preceding Embodiments, wherein L^{AS1} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-O-$, $-S-$, or $-N(R')-$.

33. The agent of any one of the preceding Embodiments, wherein L^{AS1} is an optionally substituted, bivalent C_1-C_{10} alkylene group.

34. The agent of any one of the preceding Embodiments, wherein L^{AS1} is optionally substituted $-CH_2-$.

35. The agent of any one of the preceding Embodiments, wherein L^{AS1} is $-CH_2-$.

36. The agent of any one of the preceding Embodiments, wherein R^{AA1} is $-CO_2R$.

37. The agent of any one of the preceding Embodiments, wherein R^{AA1} is $-CO_2H$.

38. The agent of any one of the preceding Embodiments, wherein L^{AA1} is an amino acid residue that comprises a side chain comprising an acidic group.

39. The agent of any one of the preceding Embodiments, wherein L^{AA1} is X^2.

40. The agent of any one of the preceding Embodiments, wherein L^{P2} is a covalent bond, or an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$,

−C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −$S(O)_2$−, −$S(O)_2$N(R')−, −C(O)S−, or −C(O)O−.

41. The agent of any one of the preceding Embodiments, wherein the length of L^{P2} is 2-10 (2, 3, 4, 5, 6, 7, 8, 9, or 10) atoms.

42. The agent of any one of the preceding Embodiments, wherein the length of L^{P2} is 6 atoms.

43. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P2} are independently replaced with −N(R')− or −C(O)−.

44. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P2} are independently replaced with −N(R')− or −C(O)N(R')−.

45. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P2} are independently replaced with −N(R')−, −$C(R')_2$, or −C(O)N(R')−.

46. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P2} are independently replaced with −N(R')−, and one or more methylene units of L^{P2} are independently replaced with −C(O)N(R')−.

47. The agent of any one of the preceding Embodiments, wherein L^{P2} is or comprises −[X]pX^4[X]p'−, wherein each X and X^4 is independently an amino acid residue, and each of p and p' is independently 0-10.

48. The agent of any one of the preceding Embodiments, wherein L^{P2} is or comprises −[X]pX^3X^4[X]p'−, wherein each X, X^3 and X^4 is independently an amino acid residue, and each of p and p' is independently 0-10.

49. The agent of any one of the preceding Embodiments, wherein L^{P2} is or comprises −X^3X^4−, wherein each X^3 and X^4 is independently an amino acid residue, and X^4 is bonded to L^{AA2}.

50. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{P2} is replaced with −$C(R')_2$−, wherein one of the R' groups is the second R' group and the other is the third R' group of the four R' groups.

51. The agent of any one of the preceding Embodiments, wherein X^4 comprises −$C(R')_2$−, wherein one of the R' groups is the second R' group and the other is the third R' group of the four R' groups.

52. The agent of any one of the preceding Embodiments, wherein the L^s formed by taking the first and the second R' groups together has the structure of a L^s group bonded to X^1 and X^4 as described herein.

53. The agent of any one of the preceding Embodiments, wherein the L^s formed by taking the third and the fourth R' groups together has the structure of a L^s group bonded to X^4 and X^{11} as described herein.

54. The agent of any one of Embodiments 1-49, wherein a methylene unit of L^{P2} is replaced with −$C(R')_2$−, wherein one of the R' groups is the second R' group.

55. The agent of any one of Embodiments 1-49, wherein X^3 comprises −$C(R')_2$−, wherein one of the R' groups is the second R' group.

56. The agent of any one of Embodiments 1-49 and 54-55, wherein a methylene unit of L^{P2} is replaced with −$C(R')_2$−, wherein one of the R' groups is the third R' group.

57. The agent of any one of Embodiments 1-49 and 54-55, wherein X^4 comprises $-C(R')_2-$, wherein one of the R' groups is the third R' group.

58. The agent of any one of Embodiments 1-49, wherein a methylene unit of L^{P2} is replaced with $-C(R')_2-$, wherein one of the R' groups is the fifth R' group.

59. The agent of any one of Embodiments 1-49, wherein X^3 comprises $-C(R')_2-$, wherein one of the R' groups is the fifth R' group.

60. The agent of any one of Embodiments 1-49, wherein a methylene unit of L^{P2} is replaced with $-C(R')_2-$, wherein one of the R' groups is the seventh R' group.

61. The agent of any one of Embodiments 1-49, wherein X^3 comprises $-C(R')_2-$, wherein one of the R' groups is the seventh R' group.

62. The agent of any one of Embodiments 1-49, wherein a methylene unit of L^{P2} is replaced with $-C(R')_2-$, wherein one of the R' groups is the first R' group.

63. The agent of any one of Embodiments 1-49, wherein X^4 comprises $-C(R')_2-$, wherein one of the R' groups is the first R' group.

64. The agent of any one of the preceding Embodiments, wherein L^{AA2} is an optionally substituted, bivalent C_2-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

65. The agent of any one of the preceding Embodiments, wherein L^{AA2} is $-N(R')-C(R')(R^{AS})-C(O)-$.

66. The agent of any one of the preceding Embodiments, wherein L^{AA2} is $-NH-C(R')(R^{AS})-C(O)-$.

67. The agent of any one of the preceding Embodiments, wherein L^{AS2} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

68. The agent of any one of the preceding Embodiments, wherein L^{AS2} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-S(O)-$, or $-S(O)_2-$.

69. The agent of any one of the preceding Embodiments, wherein L^{AS2} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-O-$, $-S-$, or $-N(R')-$.

70. The agent of any one of the preceding Embodiments, wherein L^{AS2} is an optionally substituted, bivalent C_1-C_{10} alkylene group.

71. The agent of any one of the preceding Embodiments, wherein L^{AS2} is optionally substituted $-CH_2-$.

72. The agent of any one of the preceding Embodiments, wherein L^{AS2} is $-CH_2-$.

73. The agent of any one of the preceding Embodiments, wherein R^{AA2} is $-CO_2R$.

74. The agent of any one of the preceding Embodiments, wherein R^{AA2} is $-CO_2H$.

75. The agent of any one of the preceding Embodiments, wherein L^{AA2} is an amino acid residue that comprises a side chain comprising an acidic group.

76. The agent of any one of the preceding Embodiments, wherein L^{AA2} is X^5.

77. The agent of any one of the preceding Embodiments, wherein the length of L^{P3} is 0-10 (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) atoms.

78. The agent of any one of the preceding Embodiments, wherein L^{P3} is a covalent bond, or an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

79. The agent of any one of the preceding Embodiments, wherein the length of L^{P3} is 2-10 (2, 3, 4, 5, 6, 7, 8, 9, or 10) atoms.

80. The agent of any one of the preceding Embodiments, wherein the length of L^{P3} is 6 atoms.

81. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P3} are independently replaced with $-N(R')-$ or $-C(O)-$.

82. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P3} are independently replaced with $-N(R')-$ or $-C(O)N(R')-$.

83. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P3} are independently replaced with $-N(R')-$, $-C(R')_2$, or $-C(O)N(R')-$.

84. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P3} are independently replaced with $-N(R')-$, and one or more methylene units of L^{P3} are independently replaced with $-C(O)N(R')-$.

85. The agent of any one of the preceding Embodiments, wherein L^{P3} is or comprises $-[X]pX^6X^7[X]p'-$, wherein each X, X^6 and X^7 is independently an amino acid residue, and each of p and p' is independently 0-10.

86. The agent of any one of the preceding Embodiments, wherein L^{P3} is or comprises $-X^6X^7-$, wherein each X^6 and X^7 is independently an amino acid residue, and X^7 is bonded to L^{AA3}.

87. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{P3} is replaced with $-C(R')_2-$, wherein one of the R' groups is the fifth, sixth, seventh or eighth R' group.

88. The agent of any one of the preceding Embodiments, wherein X^7 comprises $-C(R')_2-$, wherein one of the R' groups is the fifth, sixth, seventh or eighth R' group.

89. The agent of any one of Embodiments 87-88, wherein the R' group is the fifth R' group.

90. The agent of any one of Embodiments 87-88, wherein the R' group is the sixth R' group.

91. The agent of any one of Embodiments 87-88, wherein the R' group is the seventh R' group.

92. The agent of any one of Embodiments 87-88, wherein the R' group is the eighth R' group.

93. The agent of any one of the preceding Embodiments, wherein L^{P3} is a covalent bond.

94. The agent of any one of the preceding Embodiments, wherein L^{AA3} is an optionally substituted, bivalent C_2-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

95. The agent of any one of the preceding Embodiments, wherein L^{AA3} is $-N(R')-C(R')(R^{AS})-C(O)-$.

96. The agent of any one of the preceding Embodiments, wherein L^{AA3} is $-NH-C(R')(R^{AS})-C(O)-$.

97. The agent of any one of the preceding Embodiments, L^{AS3} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

98. The agent of any one of the preceding Embodiments, wherein R^{AS} is $-L^{AS3}-R^{AA3}$, wherein L^{AS3} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-S(O)-$, or $-S(O)_2-$.

99. The agent of any one of the preceding Embodiments, wherein L^{AS3} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-O-$, $-S-$, or $-N(R')-$.

100. The agent of any one of the preceding Embodiments, wherein L^{AS3} is an optionally substituted, bivalent C_1-C_{10} alkylene group.

101. The agent of any one of the preceding Embodiments, wherein L^{AS3} is optionally substituted $-CH_2-$.

102. The agent of any one of the preceding Embodiments, wherein L^{AS3} is $-CH_2-$.

103. The agent of any one of the preceding Embodiments, wherein R^{AA3} is $-CO_2R$.

104. The agent of any one of the preceding Embodiments, wherein R^{AA3} is $-CO_2H$.

105. The agent of any one of the preceding Embodiments, wherein L^{AA3} is an amino acid residue that comprises a side chain comprising an acidic group.

106. The agent of any one of the preceding Embodiments, wherein L^{AA3} is X^6.

107. The agent of any one of Embodiments 1-102, wherein L^{AA3} is an amino acid residue that comprises a hydrophobic side chain.

108. The agent of any one of Embodiments 1-102, wherein R^{AA3} is a hydrophobic group.

109. The agent of any one of Embodiments 1-102, wherein R^{AA3} is an optionally substituted C_{1-6} aliphatic group.

110. The agent of any one of Embodiments 1-102, wherein R^{AA3} is a C_{1-6} aliphatic group.

111. The agent of any one of Embodiments 1-102, wherein R^{AA3} is a C_{1-6} alkyl group.

112. The agent of any one of Embodiments 1-102, wherein L^{AA3} is X^8.

113. The agent of any one of the preceding Embodiments, wherein L^{P4} is a covalent bond, or an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

114. The agent of any one of the preceding Embodiments, wherein the length of L^{P4} is 0-10 (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) atoms.

115. The agent of any one of the preceding Embodiments, wherein the length of L^{P4} is 2-10 (2, 3, 4, 5, 6, 7, 8, 9, or 10) atoms.

116. The agent of any one of the preceding Embodiments, wherein the length of L^{P4} is 6 atoms.

117. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P4} are independently replaced with $-N(R')-$ or $-C(O)-$.

118. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P4} are independently replaced with $-N(R')-$ or $-C(O)N(R')-$.

119. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P4} are independently replaced with $-N(R')-$, $-C(R')_2$, or $-C(O)N(R')-$.

120. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P4} are independently replaced with $-N(R')-$, and one or more methylene units of L^{P4} are independently replaced with $-C(O)N(R')-$.

121. The agent of any one of the preceding Embodiments, wherein L^{P4} is or comprises $-[X]pX^7X^8[X]p'-$, wherein each X, X^7 and X^8 is independently an amino acid residue, and each of p and p' is independently 0-10.

122. The agent of any one of the preceding Embodiments, wherein L^{P4} is or comprises $-X^7X^8-$, wherein each X^7 and X^8 is independently an amino acid residue, and X^8 is bonded to L^{AA4}.

123. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{P4} is replaced with $-C(R')_2-$, wherein one of the R' groups is the fifth, sixth, seventh or eighth R' group.

124. The agent of any one of the preceding Embodiments, wherein X^7 comprises $-C(R')_2-$, wherein one of the R' groups is the fifth, sixth, seventh or eighth R' group.

125. The agent of any one of Embodiments 123-124, wherein the R' group is the fifth R' group.

126. The agent of any one of Embodiments 123-124, wherein the R' group is the sixth R' group.

127. The agent of any one of Embodiments 123-124, wherein the R' group is the seventh R' group.

128. The agent of any one of Embodiments 123-124, wherein the R' group is the eighth R' group

129. The agent of any one of Embodiments 1-112, wherein L^{P4} is a covalent bond.

130. The agent of any one of the preceding Embodiments, wherein L^{AA4} is an optionally substituted, bivalent C_2-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and

independently replaced with −C(R')$_2$−, −C(R')(R^{AS})−,−Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−.

131. The agent of any one of the preceding Embodiments, wherein L^{AA4} is −N(R')−C(R')(R^{AS})−C(O)−.

132. The agent of any one of the preceding Embodiments, wherein L^{AA4} is −NH−C(R')(R^{AS})−C(O)−.

133. The agent of any one of the preceding Embodiments, wherein L^{AS4} is an optionally substituted, bivalent C$_1$-C$_{10}$ aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−.

134. The agent of any one of the preceding Embodiments, wherein L^{AS4} is an optionally substituted, bivalent C$_1$-C$_{10}$ aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −N(R')−, −C(O)−, −S(O)−, or −S(O)$_2$−.

135. The agent of any one of the preceding Embodiments, L^{AS4} is an optionally substituted, bivalent C$_1$-C$_{10}$ aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with −O−, −S−, or −N(R')−.

136. The agent of any one of the preceding Embodiments, wherein L^{AS4} is an optionally substituted, bivalent C$_1$-C$_{10}$ alkylene group.

137. The agent of any one of the preceding Embodiments, wherein L^{AS4} is optionally substituted −CH$_2$−.

138. The agent of any one of the preceding Embodiments, wherein L^{AS4} is −CH$_2$−.


139. The agent of any one of the preceding Embodiments, wherein R^{AA4} is optionally substituted 6-14 membered aryl.

140. The agent of any one of the preceding Embodiments, wherein R^{AA4} is optionally substituted phenyl.

141. The agent of any one of the preceding Embodiments, wherein R^{AA4} is phenyl.

142. The agent of any one of Embodiments 1-138, wherein R^{AA4} is optionally substituted 5-14 membered heteroaryl having 1-6 heteroatoms.


143. The agent of any one of Embodiments 1-138, wherein R^{AA4} is optionally substituted 5-membered monocyclic heteroaryl having 1-4 heteroatoms.


144. The agent of any one of Embodiments 1-138, wherein R^{AA4} is optionally substituted 

.

145. The agent of any one of Embodiments 1-138, wherein R^{AA4} is optionally substituted 9-membered bicyclic heteroaryl having 1-4 heteroatoms.

146. The agent of any one of Embodiments 1-138, wherein R^{AA4} is optionally substituted 10-membered bicyclic heteroaryl having 1-4 heteroatoms.

147. The agent of any one of Embodiments 1-138, wherein R^{AA4} is optionally substituted  .

148. The agent of any one of Embodiments 1-138, wherein R^{AA4} is optionally substituted  .

149. The agent of any one of the preceding Embodiments, wherein L^{AA4} is an amino acid residue.

150. The agent of any one of the preceding Embodiments, wherein L^{AA4} is X^9.

151. The agent of any one of the preceding Embodiments, wherein L^{P5} is a covalent bond, or an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

152. The agent of any one of the preceding Embodiments, wherein the length of L^{P5} is 2-10 (2, 3, 4, 5, 6, 7, 8, 9, or 10) atoms.

153. The agent of any one of the preceding Embodiments, wherein the length of L^{P5} is 6 atoms.

154. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P5} are independently replaced with $-N(R')-$ or $-C(O)-$.

155. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P5} are independently replaced with $-N(R')-$ or $-C(O)N(R')-$.

156. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P5} are independently replaced with $-N(R')-$, $-C(R')_2$, or $-C(O)N(R')-$.

157. The agent of any one of the preceding Embodiments, wherein one or more methylene units of L^{P5} are independently replaced with $-N(R')-$, and one or more methylene units of L^{P5} are independently replaced with $-C(O)N(R')-$.

158. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{P5} is replaced with $-C(R')_2-$, wherein one of the R' groups is the second or fourth R' group.

159. The agent of any one of the preceding Embodiments, wherein L^{P5} is or comprises $-[X]pX^{10}X^{11}[X]p'-$, wherein each X, X^{10} and X^{11} is independently an amino acid residue, and each of p and p' is independently 0-10.

160. The agent of any one of the preceding Embodiments, wherein L^{P5} is or comprises $-X^{10}X^{11}-$, wherein each X^{10} and X^{11} is independently an amino acid residue, and X^{11} is bonded to L^{AA5}.

161. The agent of any one of the preceding Embodiments, wherein X^{11} comprises $-C(R')_2-$, wherein one of the R' groups is the second or fourth R' group.

162. The agent of Embodiment 158 or 161, wherein one of the R' groups is the second R' group.

163. The agent of Embodiment 158 or 161, wherein one of the R' groups is the fourth R' group.

164. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{P5} is replaced with $-C(R')_2-$, wherein one of the R' groups is the fifth, sixth, seventh or eighth R' group.

165. The agent of any one of the preceding Embodiments, wherein X^{10} comprises $-C(R')_2-$, wherein one of the R' groups is the fifth, sixth, seventh or eighth R' group.

166. The agent of any one of Embodiments 164-165, wherein the R' group is the fifth R' group.

167. The agent of any one of Embodiments 164-165, wherein the R' group is the sixth R' group.

168. The agent of any one of Embodiments 164-165, wherein the R' group is the seventh R' group.

169. The agent of any one of Embodiments 164-165, wherein the R' group is the eighth R' group.

170. The agent of any one of the preceding Embodiments, wherein L^{AA5} is an optionally substituted, bivalent C_2-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

171. The agent of any one of the preceding Embodiments, wherein L^{AA5} is $-N(R')-C(R')(R^{AS})-C(O)-$.

172. The agent of any one of the preceding Embodiments, wherein L^{AA5} is $-NH-C(R')(R^{AS})-C(O)-$.

173. The agent of any one of the preceding Embodiments, wherein L^{AS5} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

174. The agent of any one of the preceding Embodiments, wherein L^{AS5} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-S(O)-$, or $-S(O)_2-$.

175. The agent of any one of the preceding Embodiments, wherein L^{AS5} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-O-$, $-S-$, or $-N(R')-$.

176. The agent of any one of the preceding Embodiments, wherein L^{AS5} is an optionally substituted, bivalent C_1-C_{10} alkylene group.

177. The agent of any one of the preceding Embodiments, wherein L^{AS5} is optionally substituted $-CH_2-$.

178. The agent of any one of the preceding Embodiments, wherein L^{AS5} is $-CH_2-$.

179. The agent of any one of the preceding Embodiments, wherein R^{AA5} is optionally substituted 6-14 membered aryl.


180. The agent of any one of the preceding Embodiments, wherein R^{AA5} is optionally substituted phenyl.

181. The agent of any one of the preceding Embodiments, wherein R^{AA5} is phenyl.

182. The agent of any one of Embodiments 1-169, wherein R^{AA5} is optionally substituted 5-14 membered


heteroaryl having 1-6 heteroatoms.


183. The agent of any one of Embodiments 1-169, wherein R^{AA5} is optionally substituted 5-membered monocyclic heteroaryl having 1-4 heteroatoms.

184. The agent of any one of Embodiments 1-169, wherein R^{AA5} is optionally substituted  .

185. The agent of any one of Embodiments 1-169, wherein R^{AA5} is optionally substituted 9-membered bicyclic heteroaryl having 1-4 heteroatoms.

186. The agent of any one of Embodiments 1-169, wherein R^{AA5} is optionally substituted 10-membered bicyclic heteroaryl having 1-4 heteroatoms.

187. The agent of any one of Embodiments 1-169, wherein R^{AA5} is optionally substituted  .

188. The agent of any one of Embodiments 1-169, wherein R^{AA5} is optionally substituted  .

189. The agent of any one of the preceding Embodiments, wherein L^{AA5} is an amino acid residue.

190. The agent of any one of the preceding Embodiments, wherein L^{AA5} is X^{12}.

191. The agent of any one of the preceding Embodiments, wherein L^{P6} is a covalent bond, or an optionally substituted, bivalent C_2-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

192. The agent of any one of the preceding Embodiments, wherein the length of L^{P6} is 0-10 (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) atoms.

193. The agent of any one of the preceding Embodiments, wherein the length of L^{P6} is a covalent bond.

194. The agent of any one of the preceding Embodiments, wherein L^{AA6} is an optionally substituted, bivalent C_2-C_4 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

195. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{AA6} is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS}-R^{AA6}$, wherein L^{AS} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

196. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{AA6} is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS}-R^{AA6}$, wherein L^{AS} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-S(O)-$, or $-S(O)_2-$.

197. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{AA6} is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS}-R^{AA6}$, wherein L^{AS} is an optionally substituted, bivalent C_1-C_{10} aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-O-$, $-S-$, or $-N(R')-$.

198. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{AA6} is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS}-R^{AA6}$, wherein L^{AS} is an optionally substituted, bivalent C_1-C_{10} alkylene group.

199. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{AA6} is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-CH_2-R^{AA6}$.


200. The agent of any one of the preceding Embodiments, wherein R^{AA6} is optionally substituted 6-14 membered aryl.

201. The agent of any one of the preceding Embodiments, wherein R^{AA6} is optionally substituted phenyl.

202. The agent of any one of the preceding Embodiments, wherein R^{AA6} is phenyl.


203. The agent of any one of Embodiments 1-193, wherein R^{AA6} is optionally substituted 5-14 membered heteroaryl having 1-6 heteroatoms.


204. The agent of any one of Embodiments 1-193, wherein R^{AA6} is optionally substituted 5-membered monocyclic heteroaryl having 1-4 heteroatoms.

205. The agent of any one of Embodiments 1-193, wherein R^{AA6} is optionally substituted  .

206. The agent of any one of Embodiments 1-193, wherein R^{AA6} is optionally substituted 9-membered bicyclic heteroaryl having 1-4 heteroatoms.

207. The agent of any one of Embodiments 1-193, wherein R^{AA6} is optionally substituted 10-membered bicyclic heteroaryl having 1-4 heteroatoms.

208. The agent of any one of Embodiments 1-193, wherein R^{AA6} is optionally substituted  .

209. The agent of any one of Embodiments 1-193, wherein R^{AA6} is optionally substituted  .

210. The agent of any one of the preceding Embodiments, wherein L^{AA6} is an amino acid residue.

211. The agent of any one of the preceding Embodiments, wherein L^{AA6} is X^{13}.

212. The agent of any one of the preceding Embodiments, wherein L^{P7} is a covalent bond, or an optionally substituted, bivalent C_1-C_{10} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

213. The agent of any one of the preceding Embodiments, wherein the length of L^{P7} is 0-20 (e.g., 0-15, 0-10, 0-5, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms.

214. The agent of any one of the preceding Embodiments, wherein L^{P7} is or comprises $-X^{14}-[X]p'-$, wherein p' is 0-10, each of X and X^{14} is independently an amino acid residue, and X^{14} is bonded to L^{AA6}.

215. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{P7} is replaced with $-C(R')_2-$, wherein one of the R' groups is the sixth or eighth R' group.

216. The agent of any one of the preceding Embodiments, wherein X^{14} comprises $-C(R')_2-$, wherein one of the R' groups is the fifth, sixth, seventh or eighth R' group.

217. The agent of any one of Embodiments 215-216, wherein the R' group is the sixth R' group.

218. The agent of any one of Embodiments 215-216, wherein the R' group is the eighth R' group.

219. The agent of any one of the preceding Embodiments, wherein L^{RN} is a covalent bond, or an optionally substituted, bivalent C_1-C_{10} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

220. The agent of any one of the preceding Embodiments, wherein the length of L^{RN} is 0-20 (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms.

221. The agent of any one of the preceding Embodiments, wherein R^N is $R'-L^{RN}-$, wherein R' is $-C(O)R$, $-CO_2R$, or $-SO_2R$.

222. The agent of any one of the preceding Embodiments, wherein R^N is R', wherein R' is $-C(O)R$, $-CO_2R$, or $-SO_2R$.

223. The agent of any one of the preceding Embodiments, wherein L^{RC} is a covalent bond, or an optionally substituted, bivalent C_1-C_{10} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

224. The agent of any one of the preceding Embodiments, wherein the length of L^{RC} is 0-20 (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) atoms.

225. The agent of any one of the preceding Embodiments, wherein R^C is $-O-L^{RC}-R'$ or $-N(R')-L^{RC}-R'$.

226. The agent of any one of the preceding Embodiments, wherein R^C is $-OR'$ or $-N(R')_2$, wherein each R' is independently R.

227. An agent comprising one or more of:
a first acidic group (e.g., of a first acidic amino acid residue);
a second acidic group (e.g., of a second acidic amino acid residue);
a first aromatic group (e.g., of a first aromatic amino acid residue);
a second aromatic group (e.g., of a first aromatic amino acid residue); and
a third aromatic group (e.g., of a third aromatic amino acid residue).

228. An agent comprising:
a first acidic group (e.g., of a first acidic amino acid residue);
a second acidic group (e.g., of a second acidic amino acid residue);
a first aromatic group (e.g., of a first aromatic amino acid residue);
a second aromatic group (e.g., of a first aromatic amino acid residue); and
a third aromatic group (e.g., of a third aromatic amino acid residue).

229. An agent comprising:
a first acidic group (e.g., of a first acidic amino acid residue);
a second acidic group (e.g., of a second acidic amino acid residue);
a third acidic group (e.g., of a third acidic amino acid residue);
a first aromatic group (e.g., of a first aromatic amino acid residue);
a second aromatic group (e.g., of a first aromatic amino acid residue); and
a third aromatic group (e.g., of a third aromatic amino acid residue).

230. An agent comprising:
a first acidic group (e.g., of a first acidic amino acid residue);
a second acidic group (e.g., of a second acidic amino acid residue);
a hydrophobic group (e.g., of a hydrophobic amino acid residue)
a first aromatic group (e.g., of a first aromatic amino acid residue);
a second aromatic group (e.g., of a first aromatic amino acid residue); and
a third aromatic group (e.g., of a third aromatic amino acid residue).

231. An agent comprising:
a first acidic group (e.g., of a first acidic amino acid residue);
a second acidic group (e.g., of a second acidic amino acid residue);
a third acidic group (e.g., of a third acidic amino acid residue);
a hydrophobic group (e.g., of a hydrophobic amino acid residue)
a first aromatic group (e.g., of a first aromatic amino acid residue);
a second aromatic group (e.g., of a first aromatic amino acid residue); and
a third aromatic group (e.g., of a third aromatic amino acid residue).

232. The agent of any one of Embodiments 227-231, wherein a first acidic group is of a first acidic amino acid residue.

233. The agent of any one of Embodiments 227-231, wherein a first acidic group is of L^{AA1} of any one of the preceding Embodiments.

234. The agent of any one of Embodiments 227-231, wherein a first acidic group is of a first acidic amino acid residue which is X^2.

235. The agent of any one of Embodiments 227-234, wherein a second acidic group is of a second acidic amino acid residue.

236. The agent of any one of Embodiments 227-234, wherein a second acidic group is of L^{AA2} of any one of the preceding Embodiments.

237. The agent of any one of Embodiments 227-234, wherein a second acidic group is of a second acidic amino acid residue which is X^5.

238. The agent of any one of Embodiments 227-237, wherein a third acidic group is of a third acidic amino acid residue.

239. The agent of any one of Embodiments 227-237, wherein a third acidic group is of L^{AA3} of any one of the preceding Embodiments wherein L^{AA3} comprises an acidic group.

240. The agent of any one of Embodiments 227-237, wherein a third acidic group is of a third acidic amino acid residue which is X^6.

241. The agent of any one of Embodiments 227-240, wherein a hydrophobic group is of a hydrophobic acidic amino acid residue.

242. The agent of any one of Embodiments 227-240, wherein a hydrophobic group is of L^{AA3} of any one of the preceding Embodiments wherein L^{AA3} comprises a hydrophobic group.

243. The agent of any one of Embodiments 227-240, wherein a hydrophobic group is of a hydrophobic acidic amino acid residue which is X^8.

244. The agent of any one of Embodiments 227-243, wherein a first aromatic group is of a first aromatic amino aromatic residue.

245. The agent of any one of Embodiments 227-243, wherein a first aromatic group is of L^{AA4} of any one of the preceding Embodiments.

246. The agent of any one of Embodiments 227-243, wherein a first aromatic group is of a first aromatic amino aromatic residue which is X^9.

247. The agent of any one of Embodiments 227-246, wherein a second aromatic group is of a second aromatic amino aromatic residue.

248. The agent of any one of Embodiments 227-246, wherein a second aromatic group is of L^{AA5} of any one of the preceding Embodiments.

249. The agent of any one of Embodiments 227-246, wherein a second aromatic group is of a second aromatic amino aromatic residue which is X^{12}.

250. The agent of any one of Embodiments 227-249, wherein a third aromatic group is of a third aromatic amino aromatic residue.

251. The agent of any one of Embodiments 227-249, wherein a third aromatic group is of L^{AA3} of any one of the preceding Embodiments wherein L^{AA6} comprises an aromatic group.

252. The agent of any one of Embodiments 227-249, wherein a third aromatic group is of a third aromatic amino aromatic residue which is X^{13}.

253. The agent of any one of the preceding Embodiments, wherein the distance between a first acidic group and a second acidic group is about the distance between the acidic groups of two acidic amino acid residues of a peptide motif, wherein there are two amino acid residues between the two acidic amino acid residues.

254. The agent of any one of the preceding Embodiments, wherein a first acidic amino acid residue is at position N and a second is at position N+3.

255. The agent of any one of the preceding Embodiments, wherein the distance between a first acidic group and a third acidic group is about the distance between the acidic groups of two acidic amino acid residues of a peptide motif, wherein there are three amino acid residues between the two acidic amino acid residues.

256. The agent of any one of the preceding Embodiments, wherein a first acidic amino acid residue is at position N and a third is at position N+4.

257. The agent of any one of the preceding Embodiments, wherein the distance between a first acidic group and a hydrophobic group is about the distance between the acidic group of an acidic amino acid residue and the hydrophobic group of a hydrophobic amino acid residue of a peptide motif, wherein there are five amino acid residues between the first acidic amino acid residue and the hydrophobic amino acid residue.

258. The agent of any one of the preceding Embodiments, wherein a first acidic amino acid residue is at position N and a hydrophobic amino acid residue is at position N+6.

259. The agent of any one of the preceding Embodiments, wherein the distance between a first acidic group and a first aromatic group is about the distance between the acidic group of a first acidic amino acid residue and the aromatic group of an aromatic amino acid residue of a peptide motif, wherein there are six amino acid residues between the first acidic amino acid residue and the first aromatic amino acid residue.

260. The agent of any one of the preceding Embodiments, wherein a first acidic amino acid residue is at position N and a first aromatic amino acid residue is at position N+7.

261. The agent of any one of the preceding Embodiments, wherein the distance between the first aromatic group and the second aromatic group is about the distance between the aromatic groups of two aromatic amino acid residues of a peptide motif, wherein there are two amino acid residues between the two aromatic amino acid residues.

262. The agent of any one of the preceding Embodiments, wherein a first aromatic amino acid residue is at position M and a second is at position M+3.

263. The agent of any one of the preceding Embodiments, wherein the distance between the first aromatic group and the third aromatic group is about the distance between the aromatic groups of two aromatic amino

acid residues of a peptide motif, wherein there are three amino acid residues between the two aromatic amino acid residues.

264. The agent of any one of the preceding Embodiments,, wherein a first aromatic amino acid residue is at position N and a third is at position M+4).

265. The agent of any one of the preceding Embodiments, wherein N is 1-7.

266. The agent of any one of the preceding Embodiments, wherein N is 1, 2, 3, 4, or 5.

267. The agent of any one of the preceding Embodiments, wherein N is 1.

268. The agent of any one of the preceding Embodiments, wherein N is 2.

269. The agent of any one of the preceding Embodiments, wherein N is 3.

270. The agent of any one of the preceding Embodiments, wherein N is 4.

271. The agent of any one of the preceding Embodiments, wherein N is 5.

272. The agent of any one of the preceding Embodiments, wherein M is N+7.

273. The agent of any one of the preceding Embodiments, wherein M is 8-16.

274. The agent of any one of the preceding Embodiments, wherein M is 8.

275. The agent of any one of the preceding Embodiments, wherein M is 9.

276. The agent of any one of the preceding Embodiments, wherein M is 10.

277. The agent of any one of the preceding Embodiments, wherein M is 11.

278. The agent of any one of the preceding Embodiments, wherein M is 12.

279. The agent of any one of the preceding Embodiments, wherein M is 13.

280. The agent of any one of Embodiments 253-279, wherein the peptide motif is an alpha-helical motif wherein each amino acid residue is independently an alpha amino acid residue.

281. The agent of Embodiment 280, wherein the peptide motif is stapled.

282. The agent of Embodiment 281, wherein there are two staples in the peptide motif.

283. The agent of Embodiment 281, wherein there are three staples in the peptide motif.

284. The agent of Embodiment 281, wherein there are four staples in the peptide motif.

285. The agent of any one of Embodiments 253-279, wherein the peptide motif is or comprises an agent described in a Table herein (e.g., I-xxxx wherein xxxx is a number (e.g., I-1, I-10, I-100, I-1000, etc.)).

286. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a first acidic group interacts with Lys312 or an amino acid residue corresponding thereto.

287. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a first acidic group interacts with Gly307 or an amino acid residue corresponding thereto.

288. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a second acidic group interacts with Asn387 or an amino acid residue corresponding thereto.

289. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a second acidic group interacts with Trp383 or an amino acid residue corresponding thereto.

290. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a third acidic group interacts with Tyr306 or an amino acid residue corresponding thereto.

291. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a hydrophobic group interacts with Trp383 or an amino acid residue corresponding thereto.

292. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a first aromatic group interacts with Lys345 or an amino acid residue corresponding thereto.

293. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a first aromatic group interacts with Trp383 or an amino acid residue corresponding thereto.

294. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a second aromatic group interacts with Trp383 or an amino acid residue corresponding thereto.

295. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a second aromatic group interacts with Asn415 or an amino acid residue corresponding thereto.

296. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a third aromatic group interacts with Gln379 or an amino acid residue corresponding thereto.

297. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a third aromatic group interacts with Leu382 or an amino acid residue corresponding thereto.

298. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a third aromatic group interacts with Val416 or an amino acid residue corresponding thereto.

299. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a third aromatic group interacts with Asn415 or an amino acid residue corresponding thereto.

300. The agent of any one of the preceding Embodiments, wherein when the agent is contacted with a beta-catenin polypeptide, a third aromatic group interacts with Trp383 or an amino acid residue corresponding thereto.

301. The agent of any one of the preceding Embodiments, wherein the agent is or comprise a peptide.

302. The agent of any one of the preceding Embodiments, wherein the agent is a peptide.

303. The agent of any one of the preceding Embodiments, wherein the peptide is a stapled peptides comprising two or more staples.

304. The agent of any one of the preceding Embodiments, wherein the peptide is a stapled peptides comprising three or more staples.

305. The agent of any one of the preceding Embodiments, wherein the peptide is a stapled peptides comprising three and no more than three staples.

306. The agent of any one of the preceding Embodiments, wherein the peptide is a stapled peptides comprising four and no more than four staples.

307. The agent of any one of the preceding Embodiments, wherein a first acidic group, a second acidic group, a third acidic group, a hydrophobic group, a first aromatic group, a second aromatic group and a third aromatic group, if present, are presented from N to C direction of a peptide.

308. The agent of any one of the preceding Embodiments, wherein the agent is or comprises a helix structure.

309. An agent, comprising:

$$X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14},$$

wherein:

each of X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, and X^{14} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group; and

each of X^9, X^{12} and X^{13} comprises a side chain comprising an optionally substituted aromatic group.

310. An agent, wherein the agent is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group; and

each of X^9, X^{12} and X^{13} comprises a side chain comprising an optionally substituted aromatic group.

311. An agent, comprising:

$$X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14},$$

wherein:

each of X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, and X^{14} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group;

X^{13} comprises a side chain comprising an optionally substituted aromatic group; and

two or more of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

312. An agent, wherein the agent is or comprises:

$$X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}[X^{14}]_{p14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}[X^{18}]_{p18}[X^{19}]_{p19}[X^{20}]_{p20}[X^{21}]_{p21}[X^{22}]_{p22}[X^{23}]_{p23},$$

wherein each of p14, p15, p16, p17, p18, p19, p20, p21, p22, and p23 is independently 0 or 1, and each of X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, X^{17}, X^{18}, X^{19}, X^{20}, X^{21}, X^{22}, and X^{23} is independently an amino acid residue.

313. An agent, wherein the agent is or comprises:

$$[X]_pX^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}[X]_{p'},$$

wherein:

each of p15, p16 and p17 is independently 0 or 1;

each of p and p' is independently 0-10;

each of X, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue.

314. An agent, wherein the agent is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group;

X^{13} comprises a side chain comprising an optionally substituted aromatic group; and

two or more of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

315. The agent of any one of the preceding Embodiments, the agent comprises three or more staples within 10-20 amino acid residues.

316. The agent of any one of the preceding Embodiments, the agent comprises three or more staples within 10-15 amino acid residues.

317. The agent of any one of the preceding Embodiments, the agent comprises three or more staples within 15 amino acid residues.

318. The agent of any one of the preceding Embodiments, the agent comprises three or more staples within 14 amino acid residues.

319. The agent of any one of the preceding Embodiments, the agent comprises three or more staples within 11 amino acid residues.

320. The agent of any one of the preceding Embodiments, wherein there are three staples in the peptide.

321. The agent of any one of Embodiments 1-319, wherein there are four staples in the peptide.

322. The agent of any one of the preceding Embodiments, wherein three or more of X^0, X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

323. The agent of any one of the preceding Embodiments, wherein four or more of X^0, X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

324. The agent of any one of the preceding Embodiments, wherein five of X^0, X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

325. The agent of any one of the preceding Embodiments, wherein three or more of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

326. The agent of any one of the preceding Embodiments, wherein four or more of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

327. The agent of any one of the preceding Embodiments, wherein five of X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

328. The agent of any one of the preceding Embodiments, wherein X^0 and X^4 are each independently an amino acid residue suitable for stapling.

329. The agent of any one of Embodiments 1-327, wherein X^0 and X^4 are connected by a staple.

330. The agent of any one of the preceding Embodiments, wherein X^1 and X^4 are each independently an amino acid residue suitable for stapling.

331. The agent of any one of Embodiments 1-327, wherein X^1 and X^4 are connected by a staple.

332. The agent of any one of Embodiments 1-327, wherein X^1 and X^3 are each independently an amino acid residue suitable for stapling.

333. The agent of any one of Embodiments 1-327, wherein X^1 and X^3 are connected by a staple.

334. The agent of any one of the preceding Embodiments, wherein X^4 and X^{11} are each independently an amino acid residue suitable for stapling.

335. The agent of any one of Embodiments 1-333, wherein X^4 and X^{11} are connected by a staple.

336. The agent of Embodiment 309, wherein X^1, X^4 and X^{11} are each independently an amino acid residue

suitable for stapling.

337. The agent of Embodiment 309, wherein X^1 and X^4 are connected by a staple, and X^4 and X^{11} are connected by a staple.

338. The agent of any one of Embodiments 1-308, wherein the agent is an agent of any one of Embodiments 309-337.

339. The agent of any one of the preceding Embodiments, wherein X^{10} and X^{14} are each independently an amino acid residue suitable for stapling.

340. The agent of any one of Embodiments 1-337, wherein X^{10} and X^{14} are connected by a staple.

341. The agent of any one of the preceding Embodiments, wherein X^7 and X^{10} are each independently an amino acid residue suitable for stapling.

342. The agent of any one of Embodiments 1-340, wherein X^7 and X^{10} are connected by a staple.

343. The agent of any one of the preceding Embodiments, wherein X^7 and X^{14} are each independently an amino acid residue suitable for stapling.

344. The agent of any one of Embodiments 1-342, wherein X^7 and X^{14} are connected by a staple.

345. The agent of any one of Embodiments 1-331 and 334-340, wherein X^3 and X^7 are each independently an amino acid residue suitable for stapling.

346. The agent of any one of Embodiments 1-331 and 334-340, wherein X^3 and X^7 are connected by a staple.

347. The agent of any one of the preceding Embodiments, wherein the agent comprises a N-terminal group.

348. The agent of any one of the preceding Embodiments, wherein the N-terminal group is an acyl group.

349. The agent of Embodiment 347, wherein the N-terminal group comprises a moiety for stapling.

350. The agent of Embodiment 347, wherein the N-terminal group comprises a terminal olefin.

351. The agent of any one of the preceding Embodiments, wherein the agent comprises a N-terminal group which is Ac, NPyroR3, 5hexenyl, 4pentenyl, Bua, C3a, Cpc, Cbc, CypCO, Bnc, CF3CO, 2PyCypCO, 4THPCO, Isobutyryl, Ts, 15PyraPy, 2PyBu, 4PymCO, 4PyPrpc, 3IAPAc, 4MePipzPrpC, MePipAc, MeImid4SO2, BzAm2OAllyl, Hex, 2PyzCO, 3Phc3, MeOPr, lithocholate, 2FPhc, PhC, MeSO2, Isovaleryl, EtHNCO, TzPyr, 8IAP, 3PydCO, 2PymCO, 5PymCO, 1Imidac, 2F2PyAc, 2IAPAc, 124TriPr, 6QuiAc, 3PyAc, 123TriAc, 1PyrazoleAc, 3PyPrpc, 5PymAc, 1PydoneAc, 124TriAc, Me2NAc, 8QuiSO2, mPEG4, mPEG8, mPEG16, or mPEG24.

352. The agent of Embodiment 347, wherein the N-terminal group is Ac.

353. The agent of any one of the preceding Embodiments, wherein X^1 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a1} and R^{a3} are taken together with their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

354. The agent of any one of the preceding Embodiments, wherein X^1 is

$-N(R^{a1})-L^{a1}-C(-L^{a}-R^{SP1})(R^{a3})-L^{a2}-C(O)-$.

355. The agent of Embodiment 354, wherein R^{a1} is $-H$.

356. The agent of any one of Embodiments 354-355, wherein R^{a3} is $-H$.

357. The agent of any one of Embodiments 354-355, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

358. The agent of any one of the preceding Embodiments, wherein X^1 is $N(R^{a1})(-L^{a}-R^{SP1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

359. The agent of Embodiment 358, wherein R^{a2} is $-H$.

360. The agent of Embodiment 358, wherein R^{a2} is optionally substituted C_{1-6} aliphatic.

361. The agent of Embodiment 358, wherein R^{a2} is methyl.

362. The agent of Embodiments 354 and 358-361, wherein R^{a1} and R^{a3} are taken together with their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-3 heteroatoms in addition to the intervening atom(s).

363. The agent of Embodiment 362, wherein R^{a1} and R^{a3} are taken together with their intervening atom(s) to form an 5-membered saturated ring having no heteroatoms in addition to the nitrogen to which R^{a1} is attached.

364. The agent of any one of Embodiments 354-363, wherein L^{a1} is a covalent bond.

365. The agent of any one of Embodiments 354-364, wherein L^{a} is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

366. The agent of any one of Embodiments 354-364, wherein L^{a} is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

367. The agent of any one of Embodiments 354-364, wherein L^{a} is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

368. The agent of any one of Embodiments 354-367, wherein L^{a} is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

369. The agent of any one of Embodiments 354-368, wherein L^{a} is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

370. The agent of any one of Embodiments 354-369, wherein L^{a2} is a covalent bond.

371. The agent of any one of Embodiments 354-370, wherein R^{SP1} is optionally substituted $-CH=CH_2$.

372. The agent of any one of Embodiments 354-370, wherein R^{SP1} is $-CH=CH_2$.

373. The agent of any one of Embodiments 354-370, wherein R^{SP1} is $-COOH$.

374. The agent of any one of Embodiments 354-370, wherein R^{SP1} is or comprises an amino group.

375. The agent of any one of Embodiments 354-370, wherein R^{SP1} is $-NHR$, wherein R is hydrogen or optionally substituted C_{1-6} aliphatic.

376. The agent of any one of Embodiments 354-370, wherein R^{SP1} is −NHR, wherein R is C_{1-6} alkyl.

377. The agent of any one of Embodiments 354-370, wherein R^{SP1} is $-NH_2$, wherein R is C_{1-6} alkyl.

378. The agent of any one of Embodiments 354-370, wherein R^{SP1} is $-N_3$.

379. The agent of any one of Embodiments 354-370, wherein R^{SP1} is a terminal or activated alkyne.

380. The agent of any one of Embodiments 354-370, wherein R^{SP1} is −C≡CH.

381. The agent of any one of Embodiments 354-370, wherein R^{SP1} is −SH.

382. The agent of any one of Embodiments 1-352, wherein X^1 is PL3, S5, MePro, Asp, S6, Pro, Ala, Ser, ThioPro, Gly, NMebAla, TfeGA, or Asn.

383. The agent of any one of Embodiments 1-352, wherein X^1 is Ac-PL3, Ac-S5, NPyroR3-Asp, Ac-MePro, 5hexenyl-MePro, Ac-S6, 4pentenyl-MePro, Ac-Pro, Ac-Ala, Bua-PL3, C3a-PL3, Cpc-PL3, Cbc-PL3, CypCO-PL3, 4THPCO-PL3, Isobutyryl-PL3, Ac-Asp, Ac-Ser, Ts-PL3, 15PyraPy-PL3, 2PyBu-PL3, 4PymCO-PL3, 4pentenyl-ThioPro, 4PyPrpc-PL3, 3IAPAc-PL3, 4MePipzPrpC-PL3, MePipAc-PL3, MeImid4SO2-PL3, BzAm2OAllyl-MePro, Ac-Gly, Ac-Sar, Ac-NMebAla, Hex-PL3, 2PyzCO-PL3, 3Phc3-PL3, MeOPr-PL3, lithocholate-PL3, 2FPhc-PL3, PhC-PL3, MeSO2-PL3, Isovaleryl-PL3, EtHNCO-PL3, TzPyr-PL3, 8IAP-PL3, 3PydCO-PL3, 2PymCO-PL3, 5PymCO-PL3, 1Imidac-PL3, 2F2PyAc-PL3, 2IAPAc-PL3, 124TriPr-PL3, 6QuiAc-PL3, 3PyAc-PL3, 123TriAc-PL3, 1PyrazoleAc-PL3, 3PyPrpc-PL3, 5PymAc-PL3, 1PydoneAc-PL3, 124TriAc-PL3, Me2NAc-PL3, 8QuiSO2-PL3, mPEG4-PL3, mPEG8-PL3, mPEG16-PL3, mPEG24-PL3, NPyroR3-Asn, or NPyroR3-Ser.

384. The agent of any one of Embodiments 1-352, wherein X^1 is PL3, [4pentenyl]MePro, [5hexenyl]MePro, or [BzAm2OAllyl]MePro.

385. The agent of any one of Embodiments 1-352, wherein X^1 is PL3.

386. The agent of any one of Embodiments 1-352, wherein X^1 is [4pentenyl]MePro or [5hexenyl]MePro.

387. The agent of any one of the preceding Embodiments, wherein X^1 interacts with Val349 of beta-catenin or an amino acid residue corresponding thereto.

388. The agent of any one of the preceding Embodiments, wherein X^3 is a residue of an amino acid that comprises a carboxyl group.

389. The agent of any one of the preceding Embodiments, wherein X^3 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} comprises a carboxyl group.

390. The agent of any one of the preceding Embodiments, wherein R^{a2} or R^{a3} is $-L^a-CO_2R$.

391. The agent of any one of the preceding Embodiments, wherein X^3 is GlnR.

392. The agent of any one of Embodiments 1-387, wherein X^3 is a residue of an amino acid that comprises an olefin.

393. The agent of any one of Embodiments 1-387 and 392, wherein X^3 is a residue of an amino acid that comprises $-CH=CH_2$.

394. The agent of any one of Embodiments 1-387 and 392-393, wherein X^3 is a residue of an amino acid that comprises $-CH=CH_2$ and forms a staple with another amino acid residue through olefin metathesis.

395. The agent of any one of Embodiments 1-387, wherein X^3 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} comprises an olefin.

396. The agent of any one of Embodiments 1-387 and 395, wherein X^3 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} is $-L^a-CH=CH_2$.

397. The agent of any one of the preceding Embodiments, wherein X^3 is $-N(R^{a1})-L^{a1}-C(-L^a-R^{SP1})(R^{a3})-L^{a2}-C(O)-$.

398. The agent of Embodiment 397, wherein R^{a1} is $-H$.

399. The agent of any one of Embodiments 397-398, wherein R^{a3} is $-H$.

400. The agent of any one of Embodiments 397-398, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

401. The agent of any one of Embodiments 397-400, wherein L^{a1} is a covalent bond.

402. The agent of any one of Embodiments 397-401, wherein L^a is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

403. The agent of any one of Embodiments 397-401, wherein L^a is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

404. The agent of any one of Embodiments 397-401, wherein L^a is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$,$-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

405. The agent of any one of Embodiments 397-402, wherein L^a is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

406. The agent of any one of Embodiments 397-402, wherein L^a is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

407. The agent of any one of Embodiments 397-406, wherein L^{a2} is a covalent bond.

408. The agent of any one of Embodiments 397-407, wherein R^{SP1} is optionally substituted $-CH=CH_2$.

409. The agent of any one of Embodiments 397-407, wherein R^{SP1} is $-CH=CH_2$.

410. The agent of any one of Embodiments 397-407, wherein R^{SP1} is $-COOH$.

411. The agent of any one of Embodiments 397-407, wherein R^{SP1} is or comprises an amino group.

412. The agent of any one of Embodiments 397-407, wherein R^{SP1} is $-NHR$, wherein R is hydrogen or optionally substituted C_{1-6} aliphatic.

413. The agent of any one of Embodiments 397-407, wherein R^{SP1} is $-NHR$, wherein R is C_{1-6} alkyl.

414. The agent of any one of Embodiments 397-407, wherein R^{SP1} is $-NH_2$.

415. The agent of any one of Embodiments 397-407, wherein R^{SP1} is $-N_3$.

416. The agent of any one of Embodiments 397-407, wherein R^{SP1} is a terminal or activated alkyne.

417. The agent of any one of Embodiments 397-407, wherein R^{SP1} is $-C\equiv CH$.

418. The agent of any one of Embodiments 397-407, wherein R^{SP1} is $-SH$.

419. The agent of any one of Embodiments 1-387 and 392-396, wherein X^3 is AllylGly, [Bn][Allyl]Dap, [Phc][Allyl]Dap, [Piv][Allyl]Dap, or [CyCO][Allyl]Dap.

420. The agent of any one of the preceding Embodiments, wherein X^4 is a residue of an amino acid that comprises an olefin.

421. The agent of any one of the preceding Embodiments, wherein X^4 is a residue of an amino acid that comprises $-CH=CH_2$.

422. The agent of any one of the preceding Embodiments, wherein X^4 is a residue of an amino acid that comprises $-CH=CH_2$ and forms a staple with another amino acid residue through olefin metathesis.

423. The agent of any one of the preceding Embodiments, wherein X^4 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} comprises an olefin.

424. The agent of any one of the preceding Embodiments, wherein X^4 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} is $-L^a-CH=CH_2$.

425. The agent of any one of the preceding Embodiments, wherein X^4 is R5, R4, or R6.

426. The agent of any one of Embodiments 1-419, wherein X^4 is a residue of an amino acid that comprises two olefins.

427. The agent of any one of Embodiments 1-419 and 426, wherein X^4 is a residue of an amino acid that comprises two $-CH=CH_2$.

428. The agent of any one of Embodiments 1-419 and 426-427, wherein X^4 is a residue of an amino acid that comprises two $-CH=CH_2$ and each forms a staple with another amino acid residue through olefin metathesis.

429. The agent of any one of Embodiments 1-419, wherein X^4 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} and R^{a3} each independently comprises an olefin.

430. The agent of any one of Embodiments 1-419 and 429, wherein X^4 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} and R^{a3} are each independently $-L^a-CH=CH_2$.

431. The agent of any one of the preceding Embodiments, wherein X^4 is $-N(R^{a1})-L^{a1}-C(-L^a-R^{SP1})(R^{a3})-L^{a2}-C(O)-$.

432. The agent of Embodiment 431, wherein R^{a1} is $-H$.

433. The agent of any one of Embodiments 431-432, wherein R^{a3} is $-H$.

434. The agent of any one of Embodiments 431-432, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

435. The agent of any one of the preceding Embodiments, wherein X^4 is $-N(R^{a1})-L^{a1}-C(-L^a-R^{SP1})(-L^a-R^{SP2})-L^{a2}-C(O)-$.

436. The agent of any one of Embodiments 431-435, wherein L^{a1} is a covalent bond.

437. The agent of any one of Embodiments 431-436, wherein L^a is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

438. The agent of any one of Embodiments 431-436, wherein L^a is an optionally substituted bivalent C_{1-10}

aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

439. The agent of any one of Embodiments 431-436, wherein L^a is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

440. The agent of any one of Embodiments 431-437, wherein L^a bonded to R^{SP1} is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

441. The agent of any one of Embodiments 431-437, wherein L^a bonded to R^{SP1} is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

442. The agent of any one of Embodiments 431-441, wherein L^{a2} is a covalent bond.

443. The agent of any one of Embodiments 431-442, wherein R^{SP1} is optionally substituted $-CH=CH_2$.

444. The agent of any one of Embodiments 431-442, wherein R^{SP1} is $-CH=CH_2$.

445. The agent of any one of Embodiments 431-442, wherein R^{SP1} is −COOH.

446. The agent of any one of Embodiments 431-442, wherein R^{SP1} is or comprises an amino group.

447. The agent of any one of Embodiments 431-442, wherein R^{SP1} is −NHR, wherein R is hydrogen or optionally substituted C_{1-6} aliphatic.

448. The agent of any one of Embodiments 431-442, wherein R^{SP1} is −NHR, wherein R is C_{1-6} alkyl.

449. The agent of any one of Embodiments 431-442, wherein R^{SP1} is $-NH_2$.

450. The agent of any one of Embodiments 431-442, wherein R^{SP1} is $-N_3$.

451. The agent of any one of Embodiments 431-442, wherein R^{SP1} is a terminal or activated alkyne.

452. The agent of any one of Embodiments 431-442, wherein R^{SP1} is −C≡CH.

453. The agent of any one of Embodiments 431-442, wherein R^{SP1} is −SH.

454. The agent of any one of Embodiments 431-453, wherein R^{SP2} is optionally substituted $-CH=CH_2$.

455. The agent of any one of Embodiments 431-453, wherein R^{SP2} is $-CH=CH_2$.

456. The agent of any one of Embodiments 431-453, wherein R^{SP2} is −COOH.

457. The agent of any one of Embodiments 431-453, wherein R^{SP2} is or comprises an amino group.

458. The agent of any one of Embodiments 431-453, wherein R^{SP2} is −NHR, wherein R is hydrogen or optionally substituted C_{1-6} aliphatic.

459. The agent of any one of Embodiments 431-453, wherein R^{SP2} is −NHR, wherein R is C_{1-6} alkyl.

460. The agent of any one of Embodiments 431-453, wherein R^{SP2} is $-NH_2$.

461. The agent of any one of Embodiments 431-453, wherein R^{SP2} is $-N_3$.

462. The agent of any one of Embodiments 431-453, wherein R^{SP2} is a terminal or activated alkyne.

463. The agent of any one of Embodiments 431-453, wherein R^{SP2} is −C≡CH.

464. The agent of any one of Embodiments 431-453, wherein R^{SP2} is −SH.

465. The agent of any one of Embodiments 431-464, wherein L^a bonded to R^{SP1} is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and

independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

466. The agent of any one of Embodiments 431-464, wherein L^a bonded to R^{SP1} is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

467. The agent of any one of Embodiments 431-464, wherein L^a bonded to R^{SP1} is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

468. The agent of any one of Embodiments 431-464, wherein L^a bonded to R^{SP1} is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

469. The agent of any one of Embodiments 431-464, wherein L^a bonded to R^{SP1} is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

470. The agent of any one of Embodiments 435-469, wherein L^a bonded to R^{SP2} is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

471. The agent of any one of Embodiments 435-469, wherein L^a bonded to R^{SP2} is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

472. The agent of any one of Embodiments 435-469, wherein L^a bonded to R^{SP2} is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

473. The agent of any one of Embodiments 435-469, wherein L^a bonded to R^{SP2} is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

474. The agent of any one of Embodiments 435-469, wherein L^a bonded to R^{SP2} is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

475. The agent of any one of Embodiments 1-419 and 426-430, wherein X^4 is B5.

476. The agent of any one of Embodiments 1-419, wherein X^4 is B5, Npg, Asp, R5, Ile, Ala, Cha, Chg, Ser, Leu, R4, R6, Phe, or S5.

477. The agent of any one of the preceding Embodiments, wherein X^7 is a residue of an amino acid that comprises an optionally substituted carboxyl group, an optionally substituted amino group, or an azidyl group.

478. The agent of any one of the preceding Embodiments, wherein X^7 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} comprises a carboxyl group, an amino group, or an azidyl group.

479. The agent of any one of the preceding Embodiments, wherein X^7 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} is $-L^a-CO_2R$, $-L^a-N_3$, or $-L^a-L-R$.

480. The agent of any one of the preceding Embodiments, wherein X^7 is

$-N(R^{a1})-L^{a1}-C(-L^{a}-R^{SP1})(R^{a3})-L^{a2}-C(O)-$.

481. The agent of Embodiment 480, wherein R^{a1} is $-H$.

482. The agent of any one of Embodiments 480-481, wherein R^{a3} is $-H$

483. The agent of any one of Embodiments 480-481, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

484. The agent of any one of Embodiments 480-483, wherein L^{a1} is a covalent bond.

485. The agent of any one of Embodiments 480-484, wherein L^{a} is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

486. The agent of any one of Embodiments 480-485, wherein L^{a} is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

487. The agent of any one of Embodiments 480-486, wherein L^{a} is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

488. The agent of any one of Embodiments 480-487, wherein L^{a2} is a covalent bond.

489. The agent of any one of Embodiments 480-488, wherein R^{SP1} is optionally substituted $-CH=CH_2$.

490. The agent of any one of Embodiments 480-489, wherein R^{SP1} is $-CH=CH_2$.

491. The agent of any one of Embodiments 480-488, wherein R^{SP1} is $-COOH$.

492. The agent of any one of Embodiments 480-488, wherein R^{SP1} is or comprises an amino group.

493. The agent of any one of Embodiments 480-488, wherein R^{SP1} is $-NHR$, wherein R is hydrogen or optionally substituted C_{1-6} aliphatic.

494. The agent of any one of Embodiments 480-488, wherein R^{SP1} is $-NHR$, wherein R is C_{1-6} alkyl.

495. The agent of any one of Embodiments 480-488, wherein R^{SP1} is $-NH_2$.

496. The agent of any one of Embodiments 480-488, wherein R^{SP1} is $-N_3$.

497. The agent of any one of Embodiments 480-488, wherein R^{SP1} is a terminal or activated alkyne.

498. The agent of any one of Embodiments 480-488, wherein R^{SP1} is $-C\equiv CH$.

499. The agent of any one of Embodiments 480-488, wherein R^{SP1} is $-SH$.

500. The agent of any one of the preceding Embodiments, wherein X^7 is GlnR, Lys, [29N2spiroundecane]GlnR, [4aminopiperidine]GlnR, sAla, TriAzLys, [isophthalate]Lys, [succinate]Lys, [Me2Mal]Lys, [diphenate]Lys, or [Biphen33COOH]Lys.

501. The agent of any one of the preceding Embodiments, wherein X^7 is GlnR, [29N2spiroundecane]GlnR, or [4aminopiperidine]GlnR.

502. The agent of any one of Embodiments 1-500, wherein X^7 is Lys.

503. The agent of any one of Embodiments 1-500, wherein X^7 is TriAzLys.

504. The agent of any one of the preceding Embodiments, wherein X^{10} is a residue of an amino acid that comprises an optionally substituted carboxyl group, an optionally substituted amino group, an azidyl group, an optionally substituted alkynyl group, or an optionally substituted thiol group.

505. The agent of any one of the preceding Embodiments, wherein X^{10} is a residue of an amino acid

having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} comprises a carboxyl group, an amino group, an azidyl group, an alkynyl group, or a thiol group.

506. The agent of any one of the preceding Embodiments, wherein X^{10} is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} is $-L^a-CO_2R$, $-L^a-N_3$, or $-L^a-L-R$.

507. The agent of any one of the preceding Embodiments, wherein X^{10} is $-N(R^{a1})-L^{a1}-C(-L^a-R^{SP1})(R^{a3})-L^{a2}-C(O)-$.

508. The agent of Embodiment 507, wherein R^{a1} is $-H$.

509. The agent of any one of Embodiments 507-508, wherein R^{a3} is $-H$.

510. The agent of any one of Embodiments 507-508, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

511. The agent of any one of Embodiments 507-510, wherein L^{a1} is a covalent bond.

512. The agent of any one of Embodiments 507-511, wherein L^a is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

513. The agent of any one of Embodiments 507-512, wherein L^a is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

514. The agent of any one of Embodiments 507-513, wherein L^a is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

515. The agent of any one of Embodiments 507-514, wherein L^{a2} is a covalent bond.

516. The agent of any one of Embodiments 507-515, wherein R^{SP1} is optionally substituted $-CH=CH_2$.

517. The agent of any one of Embodiments 507-515, wherein R^{SP1} is $-CH=CH_2$.

518. The agent of any one of Embodiments 507-515, wherein R^{SP1} is $-COOH$.

519. The agent of any one of Embodiments 507-515, wherein R^{SP1} is or comprises an amino group.

520. The agent of any one of Embodiments 507-515, wherein R^{SP1} is $-NHR$, wherein R is hydrogen or optionally substituted C_{1-6} aliphatic.

521. The agent of any one of Embodiments 507-515, wherein R^{SP1} is $-NHR$, wherein R is C_{1-6} alkyl.

522. The agent of any one of Embodiments 507-515, wherein R^{SP1} is $-NH_2$.

523. The agent of any one of Embodiments 507-515, wherein R^{SP1} is $-N_3$.

524. The agent of any one of Embodiments 507-515, wherein R^{SP1} is a terminal or activated alkyne.

525. The agent of any one of Embodiments 507-515, wherein R^{SP1} is $-C\equiv CH$.

526. The agent of any one of Embodiments 507-515, wherein R^{SP1} is $-SH$.

527. The agent of any one of the preceding Embodiments, wherein X^{10} is Lys, GlnR, TriAzLys, sAla, dLys, AsnR, hGlnR, iPrLys, TriAzOrn, DGlnR, Orn, 4PipA, sCH2S, [8FBB]Cys, [4FB]Cys, [mXyl]Cys, [oXyl]Cys, [pXyl]Cys, dOrn, dDab, NMeOrn, [2_6-naph]Cys, or [3_3-biph]Cys.

528. The agent of any one of the preceding Embodiments, wherein X^{10} is Lys, GlnR, or TriAzLys.

529. The agent of any one of Embodiments 1-528, wherein X^{10} is Lys.

530. The agent of any one of Embodiments 1-528, wherein X^{10} is GlnR.

531. The agent of any one of Embodiments 1-528, wherein X^{10} is TriAzLys.

532. The agent of any one of the preceding Embodiments, wherein X^{11} is a residue of an amino acid that comprises an olefin.

533. The agent of any one of the preceding Embodiments, wherein X^{11} is a residue of an amino acid that comprises $-CH=CH_2$.

534. The agent of any one of the preceding Embodiments, wherein X^{11} is a residue of an amino acid that comprises $-CH=CH_2$ and forms a staple with another amino acid residue through olefin metathesis.

535. The agent of any one of the preceding Embodiments, wherein X^{11} is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} comprises an olefin.

536. The agent of any one of the preceding Embodiments, wherein X^{11} is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} is $-L^a-CH=CH_2$.

537. The agent of any one of the preceding Embodiments, wherein X^{11} is $-N(R^{a1})-L^{a1}-C(-L^a-R^{SP1})(R^{a3})-L^{a2}-C(O)-$.

538. The agent of Embodiment 537, wherein R^{a1} is $-H$.

539. The agent of any one of Embodiments 537-538, wherein L^{a1} is a covalent bond.

540. The agent of any one of Embodiments 537-539, wherein L^a is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

541. The agent of any one of Embodiments 537-539, wherein L^a is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

542. The agent of any one of Embodiments 537-539, wherein L^a is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

543. The agent of any one of Embodiments 537-540, wherein L^a is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

544. The agent of any one of Embodiments 537-540, wherein L^{a2} is a covalent bond.

545. The agent of any one of Embodiments 537-544, wherein R^{SP1} is optionally substituted $-CH=CH_2$.

546. The agent of any one of Embodiments 537-544, wherein R^{SP1} is $-CH=CH_2$.

547. The agent of any one of Embodiments 537-544, wherein R^{SP1} is $-COOH$.

548. The agent of any one of Embodiments 537-544, wherein R^{SP1} is or comprises an amino group.

549. The agent of any one of Embodiments 537-544, wherein R^{SP1} is $-NHR$, wherein R is hydrogen or optionally substituted C_{1-6} aliphatic.

550. The agent of any one of Embodiments 537-544, wherein R^{SP1} is $-NHR$, wherein R is C_{1-6} alkyl.

551. The agent of any one of Embodiments 537-544, wherein R^{SP1} is $-NH_2$.

552. The agent of any one of Embodiments 537-544, wherein R^{SP1} is $-N_3$.

553. The agent of any one of Embodiments 537-544, wherein R^{SP1} is a terminal or activated alkyne.

554. The agent of any one of Embodiments 537-544, wherein R^{SP1} is −C≡CH.

555. The agent of any one of Embodiments 537-544, wherein R^{SP1} is −SH.

556. The agent of any one of Embodiments 537-555, wherein one methylene unit of L is replaced with −N(R')−.

557. The agent of any one of Embodiments 537-555, wherein one methylene unit of L is replaced with −N(R')C(O)O−.

558. The agent of any one of Embodiments 556-557, wherein R' is −H.

559. The agent of any one of Embodiments 556-557, wherein R' is C_{1-6} aliphatic.

560. The agent of any one of Embodiments 556-557, wherein R' and R^{a3} are taken together with their intervening atom(s) to form an optionally substituted 3-14 membered ring having 0-5 heteroatoms in addition to the nitrogen atom to which R' is attached.

561. The agent of any one of Embodiments 556-557, wherein R' and R^{a3} are taken together with their intervening atom(s) to form an optionally substituted 3-8 membered ring having 0-5 heteroatoms in addition to the nitrogen atom to which R' is attached.

562. The agent of any one of Embodiments 556-557, wherein R' and R^{a3} are taken together with their intervening atom(s) to form an optionally substituted 3-7 membered ring having no heteroatoms in addition to the nitrogen atom to which R' is attached.

563. The agent of any one of Embodiments 560-562, wherein the ring is monocyclic.

564. The agent of any one of Embodiments 560-563, wherein the ring is saturated.

565. The agent of any one of Embodiments 560-564, wherein the ring is 5-membered.

566. The agent of any one of Embodiments 537-559, wherein R^{a3} is −H.

567. The agent of any one of Embodiments 537-559, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

568. The agent of any one of Embodiments 537-555 and 566-567, wherein L^a is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

569. The agent of Embodiment 568, wherein L^a is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

570. The agent of any one of the preceding Embodiments, wherein X^{11} is PyrS2, Lys, 3Thi, Ala, Phe, SPip3, PyrSadNip3Butene, SPip2, Az3, DapAc7EDA, Leu, 3allyloxyPyrSa, PyrSaV3Butene, Az2, PyrS1, PyrSc72SMe3ROMe, PyrSc72RMe3SOMe, PyrSc7O45RMe, PyrSc7O45SMe, PyrSc73Me2, PyrSc7, PyrSaA3Butene, PyrSadA3Butene, Dap7Gly, Dap7Pent, DapAc7PDA, Dap7Abu, 4VinylPyrSa, PyrSadV3Butene, PyrSaSar3Butene, PyrSaNip3Butene, PyrSaPro3Butene, PyrSa4VinMe2PhAc, or 3allylPyrSa.

571. The agent of any one of the preceding Embodiments, wherein X^{11} is PyrS2.

572. The agent of any one of the preceding Embodiments, wherein X^{14} is a residue of an amino acid that comprises a carboxyl group, an amino group, an azidyl group, an alkynyl group, or a thiol group.

573. The agent of any one of the preceding Embodiments, wherein X^{14} is a residue of an amino acid

having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} comprises a carboxyl group, an amino group, an azidyl group, an alkynyl group, or a thiol group.

574. The agent of any one of the preceding Embodiments, wherein X^{14} is $-N(R^{a1})-L^{a1}-C(-L^{a}-R^{SP1})(R^{a3})-L^{a2}-C(O)-$.

575. The agent of Embodiment 574, wherein R^{a1} is $-H$.

576. The agent of Embodiment 574-575, wherein R^{a3} is $-H$.

577. The agent of Embodiment 574-575, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

578. The agent of Embodiment 574-577, wherein L^{a1} is a covalent bond.

579. The agent of Embodiment 574-578, wherein L^{a} is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

580. The agent of Embodiment 574-578, wherein L^{a} is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

581. The agent of Embodiment 574-578, wherein L^{a} is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

582. The agent of Embodiment 574-579, wherein L^{a} is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

583. The agent of Embodiment 574-579, wherein L^{a} is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

584. The agent of Embodiment 574-583, wherein L^{a2} is a covalent bond.

585. The agent of Embodiment 574-584, wherein R^{SP1} is optionally substituted $-CH=CH_2$.

586. The agent of Embodiment 574-584, wherein R^{SP1} is $-CH=CH_2$.

587. The agent of Embodiment 574-584, wherein R^{SP1} is $-COOH$.

588. The agent of Embodiment 574-584, wherein R^{SP1} is or comprises an amino group.

589. The agent of Embodiment 574-584, wherein R^{SP1} is $-NHR$, wherein R is hydrogen or optionally substituted C_{1-6} aliphatic.

590. The agent of Embodiment 574-584, wherein R^{SP1} is $-NHR$, wherein R is C_{1-6} alkyl.

591. The agent of Embodiment 574-584, wherein R^{SP1} is $-NH_2$.

592. The agent of Embodiment 574-584, wherein R^{SP1} is $-N_3$.

593. The agent of Embodiment 574-584, wherein R^{SP1} is a terminal or activated alkyne.

594. The agent of Embodiment 574-584, wherein R^{SP1} is $-C\equiv CH$.

595. The agent of Embodiment 574-584, wherein R^{SP1} is $-SH$.

596. The agent of any one of the preceding Embodiments, wherein X^{14} is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} is $-L^{a}-CO_2R$,$-L^{a}-N_3$, or $-L^{a}-L-R$.

597. The agent of any one of the preceding Embodiments, wherein X^{14} is GlnR, Lys, sAla, Gln, Cys,

TriAzLys, AsnR, hGlnR, 4PipA, sAbu, Orn, GlnR, [4mampiperidine]GlnR, [39N2spiroundecane]GlnR, [29N2spiroundecane]GlnR, iPrLys, sCH2S, [diaminobutane]GlnR, [4aminopiperidine]GlnR, dGlnR.

598. The agent of any one of Embodiments 1-597, wherein X^{14} is GlnR, Lys, or sAla.

599. The agent of any one of Embodiments 1-598, wherein X^{14} is GlnR.

600. The agent of any one of Embodiments 1-598, wherein X^{14} is Lys.

601. The agent of any one of Embodiments 1-598, wherein X^{14} is sAla.

602. The agent of any one of the preceding Embodiments, wherein a pair of amino acid residues suitable for stapling each independently comprises an acid group.

603. The agent of any one of the preceding Embodiments, wherein a pair of amino acid residues suitable for stapling each independently comprises −COOH or an activated form thereof.

604. The agent of any one of Embodiments 602-603, wherein the pair is stapled by reacting with a linking reagent which is a diamine or a salt thereof.

605. The agent of any one of the preceding Embodiments, wherein a pair of amino acid residues suitable for stapling each independently comprises an amino group.

606. The agent of Embodiment 605, wherein the pair is stapled by reacting with a linking reagent which is a di-acid or a salt thereof.

607. The agent of Embodiment 605, wherein the pair is stapled by reacting with a linking reagent comprising two −COOH or a salt thereof.

608. The agent of any one of the preceding Embodiments, wherein a pair of amino acid residues suitable for stapling each independently comprises a reactive group, and the reactive group of one can react with the other through a cycloaddition reaction.

609. The agent of any one of the preceding Embodiments, wherein one of a pair of amino acid residues suitable for stapling comprises $-N_3$ and the other comprises an alkyne.

610. The agent of Embodiment 609, wherein the pair is stapled through a click reaction.

611. The agent of any one of the preceding Embodiments, wherein a pair of amino acid residues suitable for stapling each independently comprises a nucleophilic group.

612. The agent of any one of the preceding Embodiments, wherein a pair of amino acid residues suitable for stapling each independently comprises −SH.

613. The agent of any one of Embodiments 611-612, wherein the pair is stapled by reacting a linking reagent comprising two leaving groups.

614. The agent of any one of Embodiments 611-613, wherein the pair is stapled by reacting a linking reagent having the structure of R^x–L”–R^x, wherein each R^x is independently a leaving group.

615. The agent of any one of Embodiments 613-614, wherein each leaving group is −Br.

616. The agent of any one of the preceding Embodiments, wherein one of X^{10} and X^{14} is a residue of an amino acid that comprises a carboxyl group, and the other is a residue of an amino acid that comprises an amino group.

617. The agent of any one of the preceding Embodiments, wherein X^{10} and X^{14} are connected by a staple, wherein the staple comprises −C(O)N(R')−.

618. The agent of any one of the preceding Embodiments, wherein one of X^7 and X^{10} is a residue of an amino acid that comprises a carboxyl group, and the other is a residue of an amino acid that comprises an amino group.

619. The agent of any one of the preceding Embodiments, wherein X^7 and X^{10} are connected by a staple, wherein the staple comprises −C(O)N(R')−.

620. The agent of any one of the preceding Embodiments, wherein one of X^7 and X^{14} is a residue of an amino acid that comprises a carboxyl group, and the other is a residue of an amino acid that comprises an amino group.

621. The agent of any one of the preceding Embodiments, wherein X^7 and X^{14} are connected by a staple, wherein the staple comprises −C(O)N(R')−.

622. The agent of any one of the preceding Embodiments, wherein one of X^3 and X^7 is a residue of an amino acid that comprises a carboxyl group, and the other is a residue of an amino acid that comprises an amino group.

623. The agent of any one of the preceding Embodiments, wherein X^3 and X^7 are connected by a staple, wherein the staple comprises −C(O)N(R')−.

624. The agent of any one of the preceding Embodiments, wherein one of X^{10} and X^{14} is a residue of an amino acid that comprises an azidyl group, and the other is a residue of an amino acid that comprises an alkynyl group.

625. The agent of any one of the preceding Embodiments, wherein one of X^{10} and X^{14} are connected by a staple, wherein the staple comprises an optionally substituted triazolylene ring.

626. The agent of any one of the preceding Embodiments, wherein one of X^7 and X^{10} is a residue of an amino acid that comprises an azidyl group, and the other is a residue of an amino acid that comprises an alkynyl group.

627. The agent of any one of the preceding Embodiments, wherein one of X^7 and X^{10} are connected by a staple, wherein the staple comprises an optionally substituted triazolylene ring.

628. The agent of any one of the preceding Embodiments, wherein X^{10} and X^{14} are residues of amino acids that each independently comprises a thiol group.

629. The agent of any one of the preceding Embodiments, wherein X^{10} and X^{14} are connected by a staple, wherein the staple comprises –S–Cy–S−.

630. An agent, which is a stapled peptide comprising three staples, wherein the first and second staples are bonded to the same amino acid residue, and the third staple are bonded to two amino acid residues none of which is bonded to the first or second staple.

631. An agent, which is a stapled peptide comprising three staples, wherein the first and second staples are bonded to the same amino acid residue, and the third staple are bonded to two amino acid residues none of

which is bonded to the first or second staple.

632. The agent of any one of the preceding Embodiments, comprising a staple having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$.

633. The agent of any one of the preceding Embodiments, comprising three staples each independently having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$.

634. The agent of any one of the preceding Embodiments, wherein there are three staples in the agent each independently having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$.

635. The agent of any one of Embodiments 1-632, comprising four staples each independently having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$.

636. The agent of any one of Embodiments 1-632, wherein there are four staples in the agent each independently having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$.

637. The agent of any one of the preceding Embodiments, comprising a staple having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$, wherein the staple is bonded to X^1 and X^3.

638. The agent of any one of the preceding Embodiments, comprising a staple having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$, wherein the staple is bonded to X^1 and X^4.

639. The agent of any one of the preceding Embodiments, comprising a staple having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$, wherein the staple is bonded to X^4 and X^{11}.

640. The agent of any one of the preceding Embodiments, comprising a staple having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$, wherein the staple is bonded to X^3 and X^7.

641. The agent of any one of the preceding Embodiments, comprising a staple having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$, wherein the staple is bonded to X^7 and X^{10}.

642. The agent of any one of the preceding Embodiments, comprising a staple having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$, wherein the staple is bonded to X^7 and X^{14}.

643. The agent of any one of the preceding Embodiments, comprising a staple having the structure of L^s which is $-L^{s1}-L^{s2}-L^{s3}-$, wherein the staple is bonded to X^{10} and X^{14}.

644. The agent of any one of Embodiments 632-643, wherein L^{s1} is a covalent bond, or an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-S-Cy-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

645. The agent of Embodiment 644, wherein L^{s1} is an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-S-Cy-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

646. The agent of Embodiment 644, wherein L^{s1} is an optionally substituted bivalent linear or branched,

saturated or partially unsaturated C_{1-6} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with −O−, −Cy−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

647. The agent of Embodiment 644, wherein L^{s1} is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

648. The agent of any one of Embodiments 645-647, wherein L^{s1} comprises −N(R')−.

649. The agent of any one of Embodiments 645-647, wherein L^{s1} comprises −N(R')C(O)O−.

650. The agent of Embodiment 649, wherein −N(R')− is closer to L^{s2}.

651. The agent of Embodiment 649, wherein −O− is closer to L^{s2}.

652. The agent of any one of Embodiments 645-647, wherein L^{s1} is $-(CH_2)m-N(R')-(CH_2)n-$, wherein each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

653. The agent of any one of Embodiments 645-647, wherein L^{s1} is $-(CH_2)m-N(R')-C(O)-O-(CH_2)n-$, wherein each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

654. The agent of any one of Embodiments 652-653, wherein $-(CH_2)m-$ is bonded L^{s2}.

655. The agent of any one of Embodiments 652-653, wherein $-(CH_2)n-$ is bonded L^{s2}.

656. The agent of any one of Embodiments 652-655, wherein m is 1.

657. The agent of any one of Embodiments 652-655, wherein m is 2.

658. The agent of any one of Embodiments 652-657, wherein n is 3.

659. The agent of any one of Embodiments 648-658, wherein R' is −H.

660. The agent of any one of Embodiments 648-658, wherein R' is optionally substituted C_{1-6} aliphatic.

661. The agent of any one of Embodiments 648-658, wherein R' is methyl.

662. The agent of any one of Embodiments 648-658, wherein R' is taken together with R^{a3} of the amino acid residue to which L^{s1} is bonded to and their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

663. The agent of Embodiment 662, wherein R' is taken together with R^{a3} of the amino acid residue to which L^{s3} is bonded to and their intervening atom(s) to form a 3-10 membered monocyclic ring having 0-5 heteroatoms in addition to the intervening atom(s).

664. The agent of any one of Embodiments 662-663, wherein the formed ring is saturated.

665. The agent of any one of Embodiments 662-664, wherein the formed ring is 4-membered.

666. The agent of any one of Embodiments 662-664, wherein the formed ring is 5-membered.

667. The agent of any one of Embodiments 662-666, wherein the formed ring has no heteroatoms in addition to the intervening atom(s).

668. The agent of Embodiment 644, wherein L^{s1} is optionally substituted $-(CH_2)n-$, wherein n is 1, 2, 3, 4, 5, or 6.

669. The agent of Embodiment 644, wherein L^{s1} is $-(CH_2)n-$, wherein n is 1, 2, 3, 4, 5, or 6.

670. The agent of Embodiment 644, wherein L^{s1} is $-CH_2-$.

671. The agent of Embodiment 644, wherein L^{s1} is optionally substituted $-(CH_2)n-C(O)-$, wherein n is 1, 2, 3, 4, 5, or 6.

672. The agent of Embodiment 644, wherein L^{s1} is $-(CH_2)n-C(O)-$, wherein n is 1, 2, 3, 4, 5, or 6.

673. The agent of Embodiment 644, wherein L^{s1} is $-(CH_2)n-C(O)-$, wherein n is 2 or 3.

674. The agent of any one of Embodiments 632-673, wherein L^{s1} is bonded to an amino acid residue closer to the N-terminus than an amino acid residue to which $-L^{s3}-$ is bond.

675. The agent of any one of Embodiments 632-674, wherein L^{s1} is bond to a carbon atom of the peptide backbone.

676. The agent of any one of Embodiments 632-675, wherein L^{s1} is bond to an alpha carbon atom of an amino acid residue.

677. The agent of any one of Embodiments 632-674, wherein L^{s1} is bond to a nitrogen atom of the peptide backbone.

678. The agent of any one of Embodiments 632-674, wherein L^{s1} is bond to a nitrogen atom of the peptide backbone, wherein the nitrogen atom is of an amino group bonded to an alpha carbon atom of an amino acid residue.

679. The agent of any one of Embodiments 677-678, wherein the nitrogen atom is bond to $-C(O)-$ of L^{s1}.

680. The agent of any one of Embodiments 632-679, wherein L^{s2} is a covalent bond, or an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-S-Cy-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

681. The agent of any one of Embodiments 632-679, wherein L^{s2} is an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-S-Cy-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

682. The agent of Embodiment 681, wherein L^{s2} is optionally substituted $-CH=CH-$.

683. The agent of Embodiment 681, wherein L^{s2} is $-CH=CH-$.

684. The agent of Embodiment 681, wherein the double bond is *E*.

685. The agent of Embodiment 681, wherein the double bond is *Z*.

686. The agent of Embodiment 681, wherein L^{s2} is optionally substituted $-CH_2-CH_2-$.


687. The agent of Embodiment 681, wherein L^{s2} is $-CH_2-CH_2-$.


688. The agent of Embodiment 681, wherein L^{s2} is $-Cy-$.


689. The agent of Embodiment 688, wherein $-Cy-$ is optionally substituted saturated or partially unsaturated 5-6 membered ring having 0-4 heteroatoms.


690. The agent of Embodiment 688, wherein $-Cy-$ is optionally substituted phenyl ring.

691. The agent of Embodiment 688, wherein −Cy− is optionally substituted 5-6 membered aromatic ring having 1-4 heteroatoms.

692. The agent of Embodiment 688, wherein −Cy− is optionally substituted  .

693. The agent of Embodiment 688, wherein −Cy− is  .

694. The agent of Embodiment 688, wherein −Cy− is optionally substituted  .

695. The agent of Embodiment 688, wherein −Cy− is  .

696. The agent of any one of Embodiments 694-695, wherein the carbon atom is bonded to L^{s1}.

697. The agent of any one of Embodiments 694-695, wherein the carbon atom is bonded to L^{s3}.

698. The agent of Embodiment 681, wherein L^{s2} is −C(O)N(R')−.

699. The agent of Embodiment 698, wherein R' is −H.

700. The agent of Embodiment 698, wherein R' is optionally substituted C_{1-6} aliphatic.

701. The agent of any one of Embodiments 698-700, wherein the −N(R')− is bonded to L^{s1}.

702. The agent of any one of Embodiments 698-700, wherein the −N(R')− is bonded to L^{s3}.

703. The agent of Embodiment 681, wherein one or more methylene units are independently replaced with −C(O)N(R')− or −N(R')−, and one or more methylene units are independently replaced with $-C(R')_2-$, wherein one or more R' of one or more $-C(R')_2-$ are each independently taken together with R' of −C(O)N(R')− or −N(R')− and their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

704. The agent of Embodiment 703, wherein the formed ring is saturated.

705. The agent of any one of Embodiments 703-704, wherein the formed ring is 4-membered.

706. The agent of any one of Embodiments 703-705, wherein the formed ring is 5-membered.

707. The agent of any one of Embodiments 703-706, wherein the formed ring has no heteroatoms in addition to the intervening atom(s).

708. The agent of Embodiment 681, wherein L^{s2} is −S−L"−S−.

709. The agent of Embodiment 708, wherein L" is a covalent bond, or an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-C(R')_2-$, −Cy−, −O−, −S−, −S−S−, −S−Cy−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, $-S(O)_2-$, $-S(O)_2N(R')-$, −C(O)S−, or −C(O)O−.

710. The agent of Embodiment 708, wherein L" is an optionally substituted bivalent linear or branched,

saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-S-Cy-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

711. The agent of Embodiment 708, wherein L" is or comprise $-Cy-$.

712. The agent of Embodiment 708, wherein L" is or comprise $-(CH_2)m-Cy-(CH_2)n-$, wherein each m and n is optionally substituted 0 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and each $-CH_2-$ is optionally substituted.

713. The agent of Embodiment 712, wherein each m and n is independently 1.

714. The agent of any one of Embodiments 711-713, wherein is optionally substituted phenyl.

715. The agent of any one of Embodiments 711-713, wherein is optionally substituted 5-6 membered aromatic ring having 1-4 heteroatoms.

716. The agent of any one of Embodiments 632-715, wherein L^{s3} is a covalent bond, or an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-S-Cy-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

717. The agent of Embodiment 716, wherein L^{s3} is an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-S-Cy-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

718. The agent of Embodiment 716, wherein L^{s3} is an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-6} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-O-$, $-Cy-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

719. The agent of Embodiment 716, wherein L^{s3} is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

720. The agent of any one of Embodiments 717-719, wherein L^{s3} comprises $-N(R')-$.

721. The agent of any one of Embodiments 717-719, wherein L^{s3} comprises $-N(R')C(O)O-$.

722. The agent of Embodiment 721, wherein $-N(R')-$ is closer to L^{s2}.

723. The agent of Embodiment 721, wherein $-O-$ is closer to L^{s2}.

724. The agent of any one of Embodiments 717-719, wherein L^{s3} is $-(CH_2)m-N(R')-(CH_2)n-$, wherein each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

725. The agent of any one of Embodiments 717-719, wherein L^{s3} is $-(CH_2)m-N(R')-C(O)-O-(CH_2)n-$, wherein each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

726. The agent of any one of Embodiments 724-725, wherein $-(CH_2)n-$ is bonded L^{s2}.

727. The agent of any one of Embodiments 724-725, wherein $-(CH_2)m-$ is bonded L^{s2}.

728. The agent of any one of Embodiments 724-727, wherein m is 1.

729. The agent of any one of Embodiments 724-727, wherein m is 2.

730. The agent of any one of Embodiments 724-729, wherein n is 3.

731. The agent of any one of Embodiments 720-730, wherein R' is −H.

732. The agent of any one of Embodiments 720-730, wherein R' is optionally substituted C_{1-6} aliphatic.

733. The agent of any one of Embodiments 720-730, wherein R' is methyl.

734. The agent of any one of Embodiments 720-730, wherein R' is taken together with R^{a3} of the amino acid residue to which L^{s3} is bonded to and their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

735. The agent of any one of Embodiments 720-730, wherein R' is taken together with R^{a3} of the amino acid residue to which L^{s3} is bonded to and their intervening atom(s) to form a 3-10 membered monocyclic ring having 0-5 heteroatoms in addition to the intervening atom(s).

736. The agent of any one of Embodiments 734-735, wherein the formed ring is saturated.

737. The agent of any one of Embodiments 734-736, wherein the formed ring is 4-membered.

738. The agent of any one of Embodiments 734-737, wherein the formed ring is 5-membered.

739. The agent of any one of Embodiments 734-738, wherein the formed ring has no heteroatoms in addition to the intervening atom(s).

740. The agent of Embodiment 716, wherein L^{s3} is optionally substituted $-(CH_2)n-$, wherein n is 1, 2, 3, 4, 5, or 6.

741. The agent of Embodiment 716, wherein L^{s3} is $-(CH_2)n-$, wherein n is 1, 2, 3, 4, 5, or 6.

742. The agent of Embodiment 716, wherein L^{s3} is $-(CH_2)_3-$.

743. The agent of Embodiment 716, wherein L^{s3} is $-(CH_2)_2-$.

744. The agent of Embodiment 716, wherein L^{s3} is $-CH_2-$.

745. The agent of Embodiment 716, wherein L^{s3} is optionally substituted $-(CH_2)n-C(O)-$, wherein n is 1, 2, 3, 4, 5, or 6.

746. The agent of Embodiment 716, wherein L^{s3} is $-(CH_2)n-C(O)-$, wherein n is 1, 2, 3, 4, 5, or 6.

747. The agent of Embodiment 716, wherein L^{s3} is $-(CH_2)n-C(O)-$, wherein n is 2 or 3.

748. The agent of any one of Embodiments 632-747, wherein L^{s3} is bonded to an amino acid residue closer to the N-terminus than an amino acid residue to which $-L^{s3}-$ is bond.

749. The agent of any one of Embodiments 632-748, wherein L^{s3} is bond to a carbon atom of the peptide backbone.

750. The agent of any one of Embodiments 632-749, wherein L^{s3} is bond to an alpha carbon atom of an amino acid residue.

751. The agent of any one of Embodiments 632-748, wherein L^{s3} is bond to a nitrogen atom of the peptide backbone.

752. The agent of any one of Embodiments 632-748, wherein L^{s3} is bond to a nitrogen atom of the peptide backbone, wherein the nitrogen atom is of an amino group bonded to an alpha carbon atom of an amino acid residue.

753. The agent of any one of Embodiments 751-752, wherein the nitrogen atom is bond to −C(O)− of L^{s3}.

754. The agent of any one of Embodiments 632-753, wherein a staple is optionally substituted $-CH_2-CH=CH-(CH_2)_3-$.

755. The agent of any one of Embodiments 632-753, wherein a staple is $-CH_2-CH=CH-(CH_2)_3-$.

756. The agent of Embodiment 754-755, wherein −CH=CH− is *E*.

757. The agent of Embodiment 754-755, wherein −CH=CH− is *Z*.

758. The agent of any one of Embodiments 632-753, wherein a staple is optionally substituted $-CH_2-CH=CH-(CH_2)_3-C(O)-$.

759. The agent of any one of Embodiments 632-753, wherein a staple is $-CH_2-CH=CH-(CH_2)_3-C(O)-$.

760. The agent of any one of Embodiments 632-753, wherein a staple is optionally substituted $-CH_2-CH=CH-(CH_2)_2-C(O)-$.

761. The agent of any one of Embodiments 632-753, wherein a staple is $-CH_2-CH=CH-(CH_2)_2-C(O)-$.

762. The agent of Embodiment 758-761, wherein −CH=CH− is *E*.

763. The agent of Embodiment 758-761, wherein −CH=CH− is *Z*.

764. The agent of any one of Embodiments 632-753, wherein a staple is optionally substituted $-(CH_2)n-$, wherein n is 1-20.

765. The agent of any one of Embodiments 632-753, wherein a staple is $-(CH_2)n-$, wherein n is 1-20.

766. The agent of any one of Embodiments 632-753, wherein a staple is optionally substituted $-(CH_2)n-CO-$, wherein n is 1-20.

767. The agent of any one of Embodiments 632-753, wherein a staple is $-(CH_2)n-C(O)-$, wherein n is 1-20.

768. The agent of Embodiment 764-767, wherein n is 4-10.

769. The agent of Embodiment 764-767, wherein n is 5-8.

770. The agent of Embodiment 764-767, wherein n is 6.

771. The agent of any one of Embodiments 754-770, wherein optionally substituted $-(CH_2)_3-$ or −C(O)− is bonded to an amino acid residue closer to a N-terminus to the other amino acid residue bonded to the same staple.

772. The agent of any one of Embodiments 754-771, wherein optionally substituted $-(CH_2)_3-$ or −C(O)− is bonded to an alpha-carbon atom of an amino acid residue.

773. The agent of any one of Embodiments 754-771, wherein optionally substituted $-(CH_2)_3-$ or −C(O)− is bonded to a nitrogen atom of an amino acid residue.

774. The agent of any one of Embodiments 754-771, wherein optionally substituted $-(CH_2)_3-$ or −C(O)− is bonded to a nitrogen atom bonded to an alpha carbon atom of an amino acid residue.

775. The agent of any one of Embodiments 754-774, wherein optionally substituted $-(CH_2)_3-$ or $-C(O)-$ is bonded to X^1.

776. The agent of Embodiment 775, wherein the other amino acid residue bonded to the staple is X^3.

777. The agent of Embodiment 775, wherein the other amino acid residue bonded to the staple is X^4.

778. The agent of any one of Embodiments 632-777, wherein a staple is $-(CH_2)m-N(R')-(CH_2)n-CH=CH-(CH_2)n'-$, wherein each of m, n and n' is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and each $-CH_2-$ is independently optionally substituted.

779. The agent of any one of Embodiments 632-777, wherein a staple is $-(CH_2)m-N(R')-(CH_2)n-CH=CH-(CH_2)n'-$, wherein each of m, n and n' is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

780. The agent of any one of Embodiments 632-779, wherein a staple is $-(CH_2)m-N(R')-C(O)-O-(CH_2)n-CH=CH-(CH_2)n'-$, wherein each of m, n and n' is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and each $-CH_2-$ is independently optionally substituted.

781. The agent of any one of Embodiments 632-779, wherein a staple is $-(CH_2)m-N(R')-C(O)-O-(CH_2)n-CH=CH-(CH_2)n'-$, wherein each of m, n and n' is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

782. The agent of any one of Embodiments 778-781, wherein the $-CH=CH-$ is *E*.

783. The agent of any one of Embodiments 778-781, wherein the $-CH=CH-$ is *Z*.

784. The agent of any one of Embodiments 632-783, wherein a staple is $-(CH_2)m-N(R')-(CH_2)n-CH_2-CH_2-(CH_2)n'-$, wherein each of m, n and n' is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and each $-CH_2-$ is independently optionally substituted.

785. The agent of any one of Embodiments 632-784, wherein a staple is $-(CH_2)m-N(R')-(CH_2)n-CH_2-CH_2-(CH_2)n'-$, wherein each of m, n and n' is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

786. The agent of any one of Embodiments 632-785, wherein a staple is $-(CH_2)m-N(R')-C(O)-O-(CH_2)n-CH_2-CH_2-(CH_2)n'-$, wherein each of m, n and n' is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and each $-CH_2-$ is independently optionally substituted.

787. The agent of any one of Embodiments 632-786, wherein a staple is $-(CH_2)m-N(R')-C(O)-O-(CH_2)n-CH_2-CH_2-(CH_2)n'-$, wherein each of m, n and n' is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

788. The agent of any one of Embodiments 778-787, wherein $-(CH_2)m-$ is bonded an amino acid residue closer to a N-terminus to the other amino acid residue bonded to the same staple.

789. The agent of any one of Embodiments 778-787, wherein $-(CH_2)m-$ is bonded an amino acid residue closer to a C-terminus to the other amino acid residue bonded to the same staple.

790. The agent of any one of Embodiments 778-789, wherein m is 1.

791. The agent of any one of Embodiments 778-789, wherein m is 2.

792. The agent of any one of Embodiments 778-791, wherein n is 3.

793. The agent of any one of Embodiments 778-792, wherein n' is 3.

794. The agent of any one of Embodiments 778-793, wherein R' is −H.

795. The agent of any one of Embodiments 778-793, wherein R' is optionally substituted C_{1-6} aliphatic.

796. The agent of any one of Embodiments 778-793, wherein R' is methyl.

797. The agent of any one of Embodiments 778-793, wherein R' is taken together with R^{a3} of the amino acid residue to which L^{s3} is bonded to and their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

798. The agent of any one of Embodiments 778-793, wherein R' is taken together with R^{a3} of the amino acid residue to which L^{s3} is bonded to and their intervening atom(s) to form a 3-10 membered monocyclic ring having 0-5 heteroatoms in addition to the intervening atom(s).

799. The agent of any one of Embodiments 797-798, wherein the formed ring is saturated.

800. The agent of any one of Embodiments 797-799, wherein the formed ring is 4-membered.

801. The agent of any one of Embodiments 797-800, wherein the formed ring is 5-membered.

802. The agent of any one of Embodiments 797-801, wherein the formed ring has no heteroatoms in addition to the intervening atom(s).

803. The agent of any one of Embodiments 632-802, wherein a staple is optionally substituted −*CH_2−N(−CH_2−**CH_2−)−C(O)O−$(CH_2)_3$−CH=CH−$(CH_2)_3$−, wherein −*CH_2− and −**CH_2− are bonded to the same amino acid residue.

804. The agent of any one of Embodiments 632-802, wherein a staple is −*CH_2−N(−CH_2−**CH_2−)−C(O)O−$(CH_2)_3$−CH=CH−$(CH_2)_3$−, wherein −*CH_2− and −**CH_2− are bonded to the same amino acid residue.

805. The agent of Embodiment 803-804, wherein −CH=CH− is *E*.

806. The agent of Embodiment 803-804, wherein −CH=CH− is *Z*.

807. The agent of any one of Embodiments 632-802, wherein a staple is optionally substituted −*CH_2−N(−CH_2−**CH_2−)−C(O)O−$(CH_2)_3$−CH_2−CH_2−$(CH_2)_3$−, wherein −*CH_2− and −**CH_2− are bonded to the same amino acid residue.

808. The agent of any one of Embodiments 632-802, wherein a staple is −*CH_2−N(−CH_2−**CH_2−)−C(O)O−$(CH_2)_3$−CH_2−CH_2−$(CH_2)_3$−, wherein −*CH_2− and −**CH_2− are bonded to the same amino acid residue.

809. The agent of any one of Embodiments 803-808, wherein −*CH_2− and −**CH_2− are bonded to the same atom.

810. The agent of any one of Embodiments 778-809, wherein optionally substituted −$(CH_2)_m$− or −*CH_2− is bonded to an amino acid residue closer to a C-terminus to the other amino acid residue bonded to the same staple.

811. The agent of any one of Embodiments 778-810, wherein optionally substituted −$(CH_2)_m$− or −*CH_2−

is bonded to an alpha-carbon atom of an amino acid residue.

812. The agent of any one of Embodiments 778-811, wherein optionally substituted $-(CH_2)_m-$ or $-*CH_2-$ is bonded to X^{11}.

813. The agent of Embodiment 812, wherein the other amino acid residue bonded to the staple is X^4.

814. The agent of any one of Embodiments 632-813, wherein a staple is optionally substituted $-(CH_2)m-CH=CH-(CH_2)n-$.

815. The agent of any one of Embodiments 632-813, wherein a staple is $-(CH_2)m-CH=CH-(CH_2)n-$.

816. The agent of any one of Embodiments 632-813, wherein a staple is optionally substituted $-(CH_2)m-CH_2-CH_2-(CH_2)n-$.

817. The agent of any one of Embodiments 632-813, wherein a staple is $-(CH_2)m-CH_2-CH_2-(CH_2)n-$.

818. The agent of any one of Embodiments 814-817, wherein m is 1.

819. The agent of any one of Embodiments 814-817, wherein m is 2.

820. The agent of any one of Embodiments 814-817, wherein m is 3.

821. The agent of any one of Embodiments 814-817, wherein m is 4.

822. The agent of any one of Embodiments 814-817, wherein m is 5.

823. The agent of any one of Embodiments 814-817, wherein m is 6.

824. The agent of any one of Embodiments 814-817, wherein m is 7.

825. The agent of any one of Embodiments 814-817, wherein m is 8.

826. The agent of any one of Embodiments 814-825, wherein n is 1.

827. The agent of any one of Embodiments 814-825, wherein n is 2.

828. The agent of any one of Embodiments 814-825, wherein n is 3.

829. The agent of any one of Embodiments 814-825, wherein n is 4.

830. The agent of any one of Embodiments 814-825, wherein n is 5.

831. The agent of any one of Embodiments 814-825, wherein n is 6.

832. The agent of any one of Embodiments 814-825, wherein n is 7.

833. The agent of any one of Embodiments 814-825, wherein n is 8.

834. The agent of any one of Embodiments 814-833, wherein the staple is boned to X^4 and X^{11}.

835. The agent of any one of Embodiments 632-834, wherein a staple is $-(CH_2)m-N(R')-(CH_2)n-$, wherein each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and each $-CH_2-$ is independently optionally substituted.

836. The agent of any one of Embodiments 632-835, wherein a staple is $-(CH_2)m-N(R')-(CH_2)n-$, wherein each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

837. The agent of any one of Embodiments 632-836, wherein a staple is $-(CH_2)m-N(R')-C(O)-O-(CH_2)n-$, wherein each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and each $-CH_2-$ is independently optionally substituted.

838. The agent of any one of Embodiments 632-837, wherein a staple is


−(CH_2)m−N(R')−C(O)−O−(CH_2)n−, wherein each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.


839. The agent of any one of Embodiments 835-838, wherein R' is −H.


840. The agent of any one of Embodiments 835-838, wherein R' is optionally substituted C_{1-6} aliphatic.


841. The agent of any one of Embodiments 835-838, wherein R' is methyl.

842. The agent of any one of Embodiments 632-834, wherein a staple is −(CH_2)m−L^{s2}−(CH_2)n−, wherein each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

843. The agent of Embodiment 842, wherein L^{s2} is optionally substituted  .

844. The agent of Embodiment 842, wherein L^{s2} is  .

845. The agent of Embodiment 842, wherein L^{s2} is optionally substituted  .

846. The agent of Embodiment 842, wherein L^{s2} is  .

847. The agent of any one of Embodiments 842-845, wherein the carbon atom is bonded to −(CH_2)m−.

848. The agent of Embodiment 842, wherein L^{s2} is −C(O)−N(R')−$(CH_2)_n$−N(R')−C(O)−, where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and each −CH_2− is independently optionally substituted.

849. The agent of Embodiment 842, wherein L^{s2} is −C(O)−N(R')−$(CH_2)_n$−N(R')−C(O)−, where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

850. The agent of Embodiment 842, wherein L^{s2} is −N(R')−$(CH_2)_n$−N(R')−, where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and each −CH_2− is independently optionally substituted.

851. The agent of Embodiment 842, wherein L^{s2} is −N(R')−$(CH_2)_n$−N(R')−, where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

852. The agent of Embodiment 842, wherein L^{s2} is −C(O)−N(R')−$(CH_2)_{n1}$−C(R')$_2$−$(CH_2)_{n2}$−N(R')−C(O)−, where each of n1 and n2 is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and each −CH_2− is independently optionally substituted.

853. The agent of Embodiment 842, wherein L^{s2} is −C(O)−N(R')−$(CH_2)_{n1}$−C(R')$_2$−$(CH_2)_{n2}$−N(R')−C(O)−, where each of n1 and n2 is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

854. The agent of Embodiment 842, wherein L^{s2} is −N(R')−$(CH_2)_{n1}$−C(R')$_2$−$(CH_2)_{n2}$−N(R')−, where each of n1 and n2 is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and each −CH_2− is independently optionally substituted.

855. The agent of Embodiment 842, wherein L^{s2} is −N(R')−$(CH_2)_{n1}$−C(R')$_2$−$(CH_2)_{n2}$−N(R')−, where each of n1 and n2 is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

856. The agent of any one of Embodiments 848-855, wherein each R' is independently −H or optionally

substituted C_{1-6} aliphatic.

857. The agent of any one of Embodiments 848-855, wherein two R' are taken together with their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

858. The agent of Embodiment 857, wherein one R' of $-C(R')_2-$ and one R' of $-N(R')-$ or $-N(R')C(O)O-$ are taken together with their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

859. The agent of Embodiment 857, wherein one R' of $-C(R')_2-$ and one R' of $-N(R')-$ or $-N(R')C(O)O-$ are taken together with their intervening atom(s) to form a monocyclic 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

860. The agent of any one of Embodiments 857-859, wherein the formed ring is saturated.

861. The agent of any one of Embodiments 857-860, wherein the formed ring is 4-membered.

862. The agent of any one of Embodiments 857-860, wherein the formed ring is 5-membered.

863. The agent of any one of Embodiments 857-860, wherein the formed ring is 6-membered.

864. The agent of any one of Embodiments 857-863, wherein the formed ring has no heteroatoms in addition to the intervening atom(s).

865. The agent of any one of Embodiments 859-864, wherein the other R' of $-C(R')_2-$ and one R' of $-N(R')-$ or $-N(R')C(O)O-$ are taken together with their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

866. The agent of any one of Embodiments 859-865, wherein the other R' of $-C(R')_2-$ and one R' of $-N(R')-$ or $-N(R')C(O)O-$ are taken together with their intervening atom(s) to form a monocyclic 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

867. The agent of any one of Embodiments 865-866, wherein the formed ring is saturated.

868. The agent of any one of Embodiments 865-867, wherein the formed ring is 4-membered.

869. The agent of any one of Embodiments 865-867, wherein the formed ring is 5-membered.

870. The agent of any one of Embodiments 865-867, wherein the formed ring is 6-membered.

871. The agent of any one of Embodiments 865-870, wherein the formed ring has no heteroatoms in addition to the intervening atom(s).

872. The agent of any one of Embodiments 852-871, wherein n1 is 1.

873. The agent of any one of Embodiments 852-871, wherein n1 is 2.

874. The agent of any one of Embodiments 852-873, wherein n2 is 1.

875. The agent of any one of Embodiments 852-873, wherein n2 is 2.

876. The agent of any one of Embodiments 632-834, wherein a staple is $-S-CH_2-Cy-CH_2-S-$, wherein each $-CH_2-$ is independently optionally substituted.

877. The agent of Embodiment 876, wherein L^{s2} is $-S-CH_2-Cy-CH_2-S-$

878. The agent of any one of Embodiments 632-834, wherein a staple is $-S-CH_2-Cy-Cy-CH_2-S-$,

wherein each −CH_2− is independently optionally substituted.

879. The agent of Embodiment 878, wherein L^{s2} is −S−CH_2−Cy−Cy−CH_2−S−.

880. The agent of any one of Embodiments 876-879, wherein −Cy− is optionally substituted phenylene.

881. The agent of Embodiment 880, wherein −Cy− is 1,2-phenylene.

882. The agent of Embodiment 880, wherein −Cy− is 1,3-phenylene.

883. The agent of Embodiment 880, wherein −Cy− is 1,4-phenylene.

884. The agent of any one of Embodiments 632-834, wherein a staple is −S−Cy−Cy−S−.

885. The agent of any one of Embodiments 632-834, wherein a staple is −S−Cy−S−.

886. The agent of any one of Embodiments 884-885, wherein each −Cy− is optionally substituted phenylene.

887. The agent of any one of Embodiments 884-885, wherein each −Cy− is 1,4-tetrafluorophenylene.

888. The agent of any one of Embodiments 632-834, wherein a staple is −C(O)−Cy−C(O)−.

889. The agent of Embodiment 888, wherein −Cy− is optionally substituted monocyclic or bicyclic 5-12 membered ring, wherein each −C(O)− is independently bonded to a nitrogen atom.

890. The agent of any one of Embodiments 632-834, wherein a staple is −N(R')−C(O)−L"−C(O)−N(R')−.

891. The agent of Embodiment 890, wherein L" is −Cy−.

892. The agent of Embodiment 890, wherein L" is optionally substituted phenylene.

893. The agent of Embodiment 890, wherein L" is optionally substituted 1,3-phenylene.

894. The agent of Embodiment 890, wherein L" is optionally substituted bivalent C_{1-6} aliphatic.

895. The agent of Embodiment 890, wherein L" is optionally substituted −(CH_2)n−, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

896. The agent of Embodiment 890, wherein L" is −CH_2−CH_2−.

897. The agent of Embodiment 890, wherein L" is −$C(CH_3)_2$−.

898. The agent of Embodiment 890, wherein L" is −Cy−Cy−.

899. The agent of Embodiment 898, wherein each −Cy− is independently optionally substituted phenylene.

900. The agent of Embodiment 898, wherein each −Cy− is independently 1,2-phenylene.

901. The agent of Embodiment 898, wherein each −Cy− is independently 1,3-phenylene.


902. The agent of any one of Embodiments 890-901, wherein each R' of −N(R')− is independently −H or optionally substituted C_{1-6} aliphatic.


903. The agent of any one of Embodiments 890-901, wherein each R' of −N(R')− is independently −H.


904. The agent of any one of Embodiments 632-834, wherein a staple is −(CH_2)m−O−CH_2−L^{s2}−(CH_2)n−, wherein each −CH_2− is independently optionally substituted.


905. The agent of Embodiment 889, wherein a staple is −(CH_2)m−O−CH_2−L^{s2}−(CH_2)n−.

906. The agent of any one of Embodiments 889-905, wherein L^{s2} is −Cy−.

907. The agent of Embodiment 906, wherein −Cy− is optionally substituted  .

908. The agent of Embodiment 906, wherein −Cy− is  .

909. The agent of Embodiment 906, wherein −Cy− is optionally substituted  .

910. The agent of Embodiment 906, wherein −Cy− is  .

911. The agent of any one of Embodiments 909-910, wherein the carbon atom is bonded to $-(CH_2)n-$ which is bonded to an amino acid residue.

912. The agent of any one of Embodiments 909-910, wherein the carbon atom is bonded to $-CH_2-$ which is bonded to an −O−.

913. The agent of any one of Embodiments 835-912, wherein $-(CH_2)m-$ is bonded an amino acid residue closer to a N-terminus to the other amino acid residue bonded to the same staple.

914. The agent of any one of Embodiments 835-912, wherein $-(CH_2)m-$ is bonded an amino acid residue closer to a C-terminus to the other amino acid residue bonded to the same staple.

915. The agent of any one of Embodiments 835-914, wherein m is 1.

916. The agent of any one of Embodiments 835-914, wherein m is 2.

917. The agent of any one of Embodiments 835-914, wherein m is 3.

918. The agent of any one of Embodiments 835-914, wherein m is 4.

919. The agent of any one of Embodiments 835-918, wherein n is 1.

920. The agent of any one of Embodiments 835-918, wherein n is 2.


921. The agent of any one of Embodiments 835-918, wherein n is 3.


922. The agent of any one of Embodiments 835-918, wherein n is 4.


923. The agent of any one of Embodiments 632-922, wherein the agent comprises a staple that is optionally substituted $-(CH_2)_2C(O)NH(CH_2)_4-$.



924. The agent of any one of Embodiments 632-923, wherein the agent comprises a staple that is $-(CH_2)_2C(O)NH(CH_2)_4-$.


925. The agent of any one of Embodiments 632-924, wherein a staple is optionally substituted




926. The agent of any one of Embodiments 632-925, wherein a staple is  .

927. The agent of any one of Embodiments 632-925, wherein a staple is  .

928. The agent of any one of Embodiments 632-927, wherein a staple is optionally substituted  or  .

929. The agent of any one of Embodiments 632-928, wherein a staple is  .

930. The agent of any one of Embodiments 632-928, wherein a staple is  .

931. The agent of any one of Embodiments 923-930, wherein optionally substituted $-(CH_2)_4-$ is bonded to an amino acid residue closer to a N-terminus to the other amino acid residue bonded to the same staple.

932. The agent of any one of Embodiments 923-930, wherein optionally substituted $-(CH_2)_4-$ is bonded to an amino acid residue closer to a C-terminus to the other amino acid residue bonded to the same staple.

933. The agent of any one of Embodiments 632-932, wherein a staple is optionally substituted $-S-CH_2-$(1,3-phenylene)$-CH_2-S-$.

934. The agent of any one of Embodiments 632-933, wherein a staple is $-S-CH_2-$(1,3-phenylene)$-CH_2-S-$.

935. The staple of any one of Embodiments 835-934, wherein the staple is bonded to X^3 and X^7.

936. The staple of any one of Embodiments 835-934, wherein the staple is bonded to X^3 and X^{10}.

937. The staple of any one of Embodiments 835-934, wherein the staple is bonded to X^7 and X^{10}.

938. The staple of any one of Embodiments 835-934, wherein the staple is bonded to X^7 and X^{14}.

939. The staple of any one of Embodiments 835-934, wherein the staple is bonded to X^{10} and X^{14}.

940. The agent of any one of the preceding Embodiments, wherein a staple has a length of 5-10 chain atoms.

941. The agent of Embodiment 940, wherein the length is 5 chain atoms.

942. The agent of Embodiment 940, wherein the length is 6 chain atoms.

943. The agent of Embodiment 940, wherein the length is 7 chain atoms.

944. The agent of any one of Embodiments 940-943, wherein the staple is a (i, i+2) staple.

945. The agent of any one of Embodiments 940-943, wherein the staple is a (i, i+3) staple.

946. The agent of any one of the preceding Embodiments, wherein a staple has a length of 7-12 chain atoms.

947. The agent of Embodiment 946, wherein the length is 7 chain atoms.

948. The agent of Embodiment 946, wherein the length is 8 chain atoms.

949. The agent of Embodiment 946, wherein the length is 9 chain atoms.

950. The agent of any one of Embodiments 946-949, wherein the staple is a (i, i+3) staple.

951. The agent of any one of the preceding Embodiments, wherein a staple has a length of 10-25 chain atoms.

952. The agent of Embodiment 951, wherein the length is 12 chain atoms.

953. The agent of Embodiment 951, wherein the length is 13 chain atoms.

954. The agent of Embodiment 951, wherein the length is 14 chain atoms.

955. The agent of any one of Embodiments 951-954, wherein the staple is a (i, i+7) staple.

956. The agent of any one of Embodiments 630-955, wherein the three staples are within 10-20 consecutive amino acid residues.

957. The agent of any one of Embodiments 630-955, wherein the three staples are within 14 consecutive amino acid residues.

958. The agent of any one of Embodiments 630-955, wherein the three staples are within 11 consecutive amino acid residues.

959. The agent of any one of Embodiments 630-958, wherein the first staple connects two residues at positions i and i+2.

960. The agent of any one of Embodiments 630-958, wherein the first staple connects two residues at positions i and i+3.

961. The agent of any one of Embodiments 630-960, wherein the second staple connects two residues at positions i+3 and i+10.

962. The agent of any one of Embodiments 630-961, wherein the third staple connects two residues at positions i+9 and i+13.

963. The agent of any one of Embodiments 630-962, wherein the third staple connects two residues at positions i+6 and i+9.

964. The agent of any one of Embodiments 630-963, wherein the third staple connects two residues at positions i+6 and i+13.

965. The agent of any one of Embodiments 630-964, wherein the peptide comprises a fourth staple.

966. The agent of any one of Embodiments 630-965, wherein the fourth staple connects two residues at positions i+2 and i+6.

967. The agent of any one of Embodiments 630-966, wherein the first staple has the structure of $-L^{s1}-L^{s2}-L^{s3}-$.

968. The agent of any one of Embodiments 630-967, wherein the second staple has the structure of $-L^{s1}-L^{s2}-L^{s3}-$.

969. The agent of any one of Embodiments 630-968, wherein the third staple has the structure of

$-L^{s1}-L^{s2}-L^{s3}-$.

970. The agent of any one of Embodiments 630-969, wherein the fourth staple has the structure of $-L^{s1}-L^{s2}-L^{s3}-$.

971. The agent of any one of the preceding Embodiments, comprising a first staple comprising a *(E)*-double bond.

972. The agent of any one of the preceding Embodiments, comprising a first staple comprising a *(Z)*-double bond.

973. The agent of any one of the preceding Embodiments, comprising a second staple comprising a *(E)*-double bond.

974. The agent of any one of the preceding Embodiments, comprising a second staple comprising a *(Z)*-double bond.

975. The agent of any one of the preceding Embodiments, comprising a third staple comprising a *(E)*-double bond.

976. The agent of any one of the preceding Embodiments, comprising a third staple comprising a *(Z)*-double bond.

977. The agent of any one of the preceding Embodiments, wherein the staple between X^1 and X^4 has the structure of $-L^{s1}-L^{s2}-L^{s3}-$, wherein each of L^{s1}, L^{s2} and L^{s3} is independently a covalent bond, or an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-S-Cy-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

978. The agent of any one of the preceding Embodiments, wherein the staple between X^4 and X^{11} has the structure of $-L^{s1}-L^{s2}-L^{s3}-$, wherein each of L^{s1}, L^{s2} and L^{s3} is independently a covalent bond, or an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-S-Cy-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

979. The agent of any one of the preceding Embodiments, wherein the staple between X^{10} and X^{14} has the structure of $-L^{s1}-L^{s2}-L^{s3}-$, wherein each of L^{s1}, L^{s2} and L^{s3} is independently a covalent bond, or an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-S-Cy-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

980. The agent of any one of the preceding Embodiments, wherein the staple between X^7 and X^{10} has the structure of $-L^{s1}-L^{s2}-L^{s3}-$, wherein each of L^{s1}, L^{s2} and L^{s3} is independently a covalent bond, or an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein

one or more methylene units are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, –S–Cy–S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−.

981. The agent of any one of the preceding Embodiments, wherein the staple between X^7 and X^{14} has the structure of −L^{s1}−L^{s2}−L^{s3}−, wherein each of L^{s1}, L^{s2} and L^{s3} is independently a covalent bond, or an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, –S–Cy–S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−.

982. The agent of any one of the preceding Embodiments, wherein the staple between X^3 and X^7 has the structure of −L^{s1}−L^{s2}−L^{s3}−, wherein each of L^{s1}, L^{s2} and L^{s3} is independently a covalent bond, or an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with −C(R')$_2$−, −Cy−, −O−, −S−, −S−S−, –S–Cy–S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −S(O)$_2$−, −S(O)$_2$N(R')−, −C(O)S−, or −C(O)O−.

983. The agent of any one of the preceding Embodiments, wherein L^{s1} a covalent bond, or an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with −O−.

984. The agent of any one of the preceding Embodiments, wherein L^{s1} is an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain.

985. The agent of any one of the preceding Embodiments, wherein L^{s2} is −Cy−.

986. The agent of any one of the preceding Embodiments, wherein L^{s2} is an optionally substituted triazolylene ring.

987. The agent of any one of Embodiments 1-984, wherein L^{s2} is or comprises −C(O)−.

988. The agent of any one of Embodiments 1-984, wherein L^{s2} is or comprises −C(O)N(R')−.

989. The agent of any one of Embodiments 1-984 and 988, wherein L^{s2} is −C(O)NH−.

990. The agent of any one of Embodiments 1-984 and 988, wherein L^{s2} is −C(O)N(R')−, wherein R' is C_{1-6} aliphatic.

991. The agent of any one of Embodiments 1-984, wherein L^{s2} is –S–Cy–S−.

992. The agent of any one of Embodiments 1-984 and 991, wherein L^{s2} is –S–Cy–S−, wherein –Cy– is an optionally substituted monocyclic or bicyclic arylene ring.

993. The agent of any one of Embodiments 1-984 and 991-992, wherein L^{s2} is –S–Cy–S−, wherein –Cy– is an optionally substituted phenylene ring.

994. The agent of any one of Embodiments 1-984 and 991-992, wherein L^{s2} is –S–Cy–S−, wherein –Cy– is an optionally substituted biphenylene ring.

995. The agent of any one of the preceding Embodiments, wherein L^{s3} a covalent bond, or an optionally

substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain, wherein one or more methylene units are optionally and independently replaced with −O−.

996. The agent of any one of the preceding Embodiments, wherein L^{s3} is or comprises an optionally substituted bivalent linear or branched, saturated or partially unsaturated C_{1-10} hydrocarbon chain.

997. The agent of any one of the preceding Embodiments, wherein L^{s1} is bonded to an atom of the peptide backbone.

998. The agent of any one of the preceding Embodiments, wherein L^{s1} is bonded to an α-carbon of an amino acid residue.

999. The agent of any one of the preceding Embodiments, wherein L^{s1} is bonded to a ring atom of a ring, wherein the ring comprises one or more ring atoms that are atoms of the peptide backbone.

1000. The agent of any one of the preceding Embodiments, wherein L^{s1} is bonded to a ring atom of a ring, wherein the ring comprises an α-carbon of an amino acid residue.

1001. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{s1} is replaced with $-C(R')_2-$, wherein one R' of $-C(R')_2-$ and R' attached to the backbone are taken together with their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms.

1002. The agent of any one of the preceding Embodiments, wherein methylene unit of L^{s1} is replaced with −N(R')−, wherein one R' of the −N(R')− and R' attached to the backbone are taken together with their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms.

1003. The agent of any one of the preceding Embodiments, wherein R' attached to the backbone is R^{a2} of an amino acid.

1004. The agent of any one of the preceding Embodiments, wherein R' is attached to an atom of the same residue to which L^{s1} is bonded.

1005. The agent of any one of the preceding Embodiments, wherein L^{s3} is bonded to an atom of the peptide backbone.

1006. The agent of any one of the preceding Embodiments, wherein L^{s3} is bonded to an α-carbon of an amino acid residue.

1007. The agent of any one of the preceding Embodiments, wherein L^{s3} is bonded to a ring atom of a ring, wherein the ring comprises one or more ring atoms that are atoms of the peptide backbone.

1008. The agent of any one of the preceding Embodiments, wherein L^{s3} is bonded to a ring atom of a ring, wherein the ring comprises an α-carbon of an amino acid residue.

1009. The agent of any one of the preceding Embodiments, wherein a methylene unit of L^{s3} is replaced with $-C(R')_2-$, wherein one R' of $-C(R')_2-$ and R' attached to the backbone are taken together with their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms.

1010. The agent of any one of the preceding Embodiments, wherein methylene unit of L^{s3} is replaced with −N(R')−, wherein one R' of the −N(R')− and R' attached to the backbone are taken together with their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms. (e.g., R^{a2}

or the other group attached to alpha-carbon is R').

1011. The agent of any one of the preceding Embodiments, wherein R' attached to the backbone is R^{a2} of an amino acid.

1012. The agent of any one of the preceding Embodiments, wherein R' is attached to an atom of the same residue to which L^{s3} is bonded.

1013. The agent of any one of the preceding Embodiments, wherein R' is attached to the same atom as L^{s3}.

1014. The agent of any one of the preceding Embodiments, wherein p0 is 1.

1015. The agent of any one of the preceding Embodiments, wherein X^0 is a residue of an amino acid that comprises an olefin.

1016. The agent of any one of the preceding Embodiments, wherein X^0 is a residue of an amino acid that comprises $-CH=CH_2$.

1017. The agent of any one of the preceding Embodiments, wherein X^0 is a residue of an amino acid that comprises $-CH=CH_2$ and forms a staple with another amino acid residue through olefin metathesis.

1018. The agent of any one of the preceding Embodiments, wherein X^0 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} comprises an olefin

1019. The agent of any one of the preceding Embodiments, wherein X^0 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a2} or R^{a3} is $-L^a-CH=CH_2$.

1020. The agent of any one of the preceding Embodiments, wherein X^0 is S5 or S6.

1021. The agent of any one of the preceding Embodiments, wherein X^0 is stapled with X^4.

1022. The agent of any one of Embodiments 1-1014, wherein X^0 is selected from Gly, Sar, and NMebAla.

1023. The agent of any one of Embodiments 1-1013, wherein p0 is 0.

1024. The agent of any one of the preceding Embodiments, wherein X^2 is selected from Asp, Asn, Hse, Glu, Aad, Ser, aThr, Thr, MeAsn, SbMeAsp, RbMeAsp, aMeDAsp, and OAsp.

1025. The agent of any one of the preceding Embodiments, wherein X^2 is selected from Asp, Asn, Hse, Glu, Aad, Ser, and aThr.

1026. The agent of any one of the preceding Embodiments, wherein X^2 comprises a side chain comprising an acidic group.

1027. The agent of any one of the preceding Embodiments, wherein X^2 comprises a side chain comprising −COOH or a salt form thereof.

1028. The agent of any one of the preceding Embodiments, wherein X^2 is Asp.

1029. The agent of any one of Embodiments 1-1025, wherein X^2 comprises a side chain comprising a polar group.

1030. The agent of any one of Embodiments 1-1025 and 1029, wherein X^2 comprises a side chain comprising an amidyl group.

1031. The agent of any one of the preceding Embodiments, wherein X^2 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1032. The agent of Embodiment 1031, wherein R^{a1} is −H.

1033. The agent of any one of Embodiments 1031-1032, wherein R^{a3} is −H.

1034. The agent of any one of Embodiments 1031-1032, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1035. The agent of any one of Embodiments 1031-1034, wherein L^{a1} is a covalent bond

1036. The agent of any one of Embodiments 1031-1035, wherein L^{a2} is a covalent bond.

1037. The agent of any one of Embodiments 1031-1036, wherein R^{a2} is or comprises an acidic or polar group.

1038. The agent of any one of Embodiments 1031-1037, wherein R^{a2} is −L”−COOH.

1039. The agent of any one of Embodiments 1031-1037, wherein R^{a2} is −L”−Cy−COOH.

1040. The agent of Embodiment 1039, wherein −Cy− is optionally substituted phenylene.

1041. The agent of any one of Embodiments 1031-1037, wherein R^{a2} is −L”−C(O)N(R’)$_2$.

1042. The agent of any one of Embodiments 1038-1041, wherein L” is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R’)−, −C(O)−, −C(O)N(R’)−, or −N(R’)C(O)O−.

1043. The agent of any one of Embodiments 1038-1041, wherein L” is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R’)−, −C(O)−, −C(O)N(R’)−, or −N(R’)C(O)O−.

1044. The agent of any one of Embodiments 1038-1041, wherein L” is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R’)−, −C(O)−, −C(O)N(R’)−, or −N(R’)C(O)O−.

1045. The agent of any one of Embodiments 1038-1042, wherein L” is optionally substituted −(CH_2)n− wherein n is 1, 2, 3, 4, 5, or 6.

1046. The agent of any one of Embodiments 1038-1045, wherein L” is −(CH_2)n− wherein n is 1, 2, 3, 4, 5, or 6.

1047. The agent of any one of Embodiments 1-1025 and 1029-1030, wherein X^2 is Asn.

1048. The agent of any one of Embodiments 1-1025 and 1029, wherein X^2 comprises a side chain comprising −OH.

1049. The agent of any one of Embodiments 1-1025, 1029, and 1048, wherein X^2 is Hse.

1050. The agent of any one of Embodiments 1-1023, wherein X^2 is Asp, Ala, Asn, Glu, Npg, Ser, Hse, Val, S5, S6, AcLys, TfeGA, aThr, Aad, Pro, Thr, Phe, Leu, PL3, Gln, isoGlu, MeAsn, isoDAsp, RbGlu, SbGlu, AspSH, Ile, SbMeAsp, RbMeAsp, aMeDAsp, OAsp, 3COOHF, NAsp, 3Thi, NGlu, isoDGlu, BztA, Tle, Aib, MePro, Chg, Cha, or DipA.

1051. The agent of any one of the preceding Embodiments, wherein X^2 interacts with Gly307 of beta-catenin or an amino acid residue corresponding thereto.

1052. The agent of any one of the preceding Embodiments, wherein X^2 interacts with Lys312 of beta-catenin or an amino acid residue corresponding thereto.

1053. The agent of any one of the preceding Embodiments, wherein X^3 is selected from Npg, Leu, Cha, Val, nLeu, Ile, Phe, CypA, CyLeu, Chg, Pff, DiethA, Ala, Tyr, Trp, Ser, Aib, Phg, DipA, OctG, Cba, MorphNva, and F2PipNva.

1054. The agent of any one of the preceding Embodiments, wherein X^3 comprises one or two hydrophobic side chains.

1055. The agent of any one of the preceding Embodiments, wherein X^3 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1056. The agent of Embodiment 1055, wherein X^3 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$.

1057. The agent of Embodiment 1055, wherein X^3 is $-NH-C(R^{a2})(R^{a3})-C(O)-$.

1058. The agent of any one of Embodiments 1055-1057, wherein R^{a2} and R^{a3} are independently hydrogen or optionally substituted C_{1-10} aliphatic.

1059. The agent of any one of Embodiments 1055-1057, wherein one of R^{a2} and R^{a3} is hydrogen and the other is C_{1-10} aliphatic.

1060. The agent of any one of Embodiments 1055-1057, wherein R^{a2} and R^{a3} are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered ring having 1-3 heteroatoms.

1061. The agent of any one of Embodiments 1055-1057, wherein R^{a2} and R^{a3} are taken together with the carbon atom to which they are attached to form 3-8 membered cycloalkyl.

1062. The agent of any one of the preceding Embodiments, wherein the side chain of X^3 is C_{1-10} alkyl optionally substituted with one or more substituents independently selected from −Cy− and −OR, wherein −Cy− is an optionally substituted bivalent, 3-10 membered, monocyclic, bicyclic or polycyclic ring having 0-5 heteroatoms;

R is independently C_{1-4} alkyl; or

two C_{1-10} alkyl groups are taken together with their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

1063. The agent of any one of the preceding Embodiments, wherein the side chain of X^3 is C_{1-10} alkyl.

1064. The agent of any one of the preceding Embodiments, wherein X^3 is not stapled.

1065. The agent of any one of Embodiments 1-1052, wherein X^3 is Npg, Ile, Asp, Cha, DipA, Chg, Leu, B5, Cba, S5, Ala, Glu, AllylGly, nLeu, Ser, B6, Asn, B4, GlnR, Val, [Phc][Allyl]Dap, Hse, [Bn][Allyl]Dap, 1MeK, R5, Phe, CypA, CyLeu, Pff, DiethA, Tyr, Trp, Aib, Phg, OctG, MorphNva, F2PipNva, [Piv][Allyl]Dap, [CyCO][Allyl]Dap, Lys, or S3.

1066. The agent of any one of Embodiments 1-1052, wherein X^3 is Npg.

1067. The agent of any one of Embodiments 1-1052, wherein X^3 is Ile.

1068. The agent of any one of Embodiments 1-1052, wherein X^3 is Cha.

1069. The agent of any one of Embodiments 1-1052, wherein X^3 is DipA.

1070. The agent of any one of Embodiments 1-1052, wherein X^3 is Chg.

1071. The agent of any one of Embodiments 1-1052, wherein X^3 is Leu.

1072. The agent of any one of Embodiments 1-1052, wherein X^3 is B5.

1073. The agent of any one of Embodiments 1-1052, wherein X^3 is Asp.

1074. The agent of any one of Embodiments 1-1052, wherein X^3 is Cba.

1075. The agent of any one of Embodiments 1-1052, wherein X^3 is S5.

1076. The agent of any one of Embodiments 1-1052, wherein X^3 is Ala.

1077. The agent of any one of the preceding Embodiments, wherein X^3 interacts with Tyr306 of beta-catenin or an amino acid residue corresponding thereto.

1078. The agent of any one of the preceding Embodiments, wherein X^5 is selected from Asp, Glu, Asn, Hse, aThr, Aad, Ser, Thr, MeAsn, SbMeAsp, and RbMeAsp.

1079. The agent of any one of the preceding Embodiments, wherein X^5 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1080. The agent of Embodiment 1079, wherein R^{a1} is $-H$.

1081. The agent of any one of Embodiments 1079-1080, wherein R^{a3} is $-H$.

1082. The agent of any one of Embodiments 1079-1080, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1083. The agent of any one of Embodiments 1079-1082, wherein L^{a1} is a covalent bond.

1084. The agent of any one of Embodiments 1079-1083, wherein L^{a2} is a covalent bond.

1085. The agent of any one of Embodiments 1079-1084, wherein R^{a2} is or comprises an acidic or polar group.

1086. The agent of any one of Embodiments 1079-1085, wherein R^{a2} is $-L''-COOH$.

1087. The agent of any one of Embodiments 1079-1085, wherein R^{a2} is $-L''-Cy-COOH$.

1088. The agent of Embodiment 1087, wherein $-Cy-$ is optionally substituted phenylene.

1089. The agent of any one of Embodiments 1079-1085, wherein R^{a2} is $-L''-C(O)N(R')_2$.

1090. The agent of any one of Embodiments 1086-1089, wherein L" is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1091. The agent of any one of Embodiments 1086-1089, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1092. The agent of any one of Embodiments 1086-1089, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1093. The agent of any one of Embodiments 1086-1090, wherein L" is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1094. The agent of any one of Embodiments 1086-1090, wherein L" is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1095. The agent of any one of the preceding Embodiments, wherein X^5 comprises a side chain comprising an acidic group.

1096. The agent of any one of the preceding Embodiments, wherein X^5 comprises a side chain comprising −COOH or a salt form thereof.

1097. The agent of any one of the preceding Embodiments, wherein X^5 is Asp.

1098. The agent of any one of Embodiments 1-1078, wherein X^5 comprises a side chain comprising a polar group.

1099. The agent of any one of Embodiments 1-1078 and 1098, wherein X^5 comprises a side chain comprising −OH.

1100. The agent of any one of Embodiments 1-1078 and 1098, wherein X^5 comprises a side chain comprising an amidyl group.

1101. The agent of any one of Embodiments 1-1077, wherein X^5 is selected from 3COOHF, TfeGA, Asp, Gln, [CH2CMe2CO2H]TriAzDap, Thr, Glu, 2OH3COOHF, 4OH3COOHF, 4COOHF, 2COOHF, His, Tyr, 5F3Me2COOHF, 4F3Me2COOHF, 5F3Me3COOHF, 4F3Me3COOHF, 3F2COOHF, Val, Ser, Trp, Asn, Ala, Arg, dGlu, aThr, hTyr, 3cbmf, Leu, Phe, Lys, and Ile.

1102. The agent of any one of Embodiments 1-1077, wherein X^5 is Asp, B5, 3COOHF, Glu, Asn, Npg, Hse, aThr, Aad, Ser, Thr, MeAsn, AspSH, SbMeAsp or RbMeAsp.

1103. The agent of any one of Embodiments 1-1077, wherein X^5 is B5.

1104. The agent of any one of Embodiments 1-1077, wherein X^5 is 3COOHF.

1105. The agent of any one of Embodiments 1-1077, wherein X^5 is Glu.

1106. The agent of any one of the preceding Embodiments, wherein X^5 interacts with Trp383 of beta-catenin or an amino acid residue corresponding thereto.

1107. The agent of any one of the preceding Embodiments, wherein X^5 interacts with Arg386 of beta-catenin or an amino acid residue corresponding thereto.

1108. The agent of any one of the preceding Embodiments, wherein X^5 interacts with Asn387 of beta-catenin or an amino acid residue corresponding thereto.

1109. The agent of any one of the preceding Embodiments, wherein X^6 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1110. The agent of Embodiment 1109, wherein R^{a1} is −H.

1111. The agent of any one of Embodiments 1109-1110, wherein R^{a3} is −H

1112. The agent of any one of Embodiments 1109-1110, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1113. The agent of any one of Embodiments 1109-1112, wherein L^{a1} is a covalent bond.

1114. The agent of any one of Embodiments 1109-1113, wherein L^{a2} is a covalent bond.

1115. The agent of any one of Embodiments 1109-1114, wherein R^{a2} is or comprises an acidic or polar group.

1116. The agent of any one of Embodiments 1109-1115, wherein R^{a2} is −L”−COOH.

1117. The agent of any one of Embodiments 1109-1115, wherein R^{a2} is −L"−Cy−COOH.

1118. The agent of Embodiment 1117, wherein −Cy− is optionally substituted phenylene.

1119. The agent of any one of Embodiments 1109-1115, wherein R^{a2} is −L"−C(O)N(R')$_2$.

1120. The agent of any one of Embodiments 1116-1119, wherein L" is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1121. The agent of any one of Embodiments 1116-1119, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1122. The agent of any one of Embodiments 1116-1119, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1123. The agent of any one of Embodiments 1116-1120, wherein L" is optionally substituted −(CH_2)n− wherein n is 1, 2, 3, 4, 5, or 6.

1124. The agent of any one of Embodiments 1116-1123, wherein L" is −(CH_2)n− wherein n is 1, 2, 3, 4, 5, or 6.

1125. The agent of any one of Embodiments 1116-1122, wherein a methylene unit is replaced with −N(R')−.

1126. The agent of Embodiment 1125, wherein R' is −H.

1127. The agent of Embodiment 1125, wherein R' is optionally substituted C_{1-6} alkyl.

1128. The agent of any one of the preceding Embodiments, wherein X^6 comprises a side chain comprising an acidic or a polar group.

1129. The agent of any one of the preceding Embodiments, wherein X^6 comprises a side chain comprising an acidic group.

1130. The agent of any one of the preceding Embodiments, wherein X^6 comprises a side chain comprising −COOH or a salt form thereof.

1131. The agent of any one of the preceding Embodiments, wherein X^6 is 3COOHF.

1132. The agent of any one of Embodiments 1-1130, wherein X^6 is TfeGA.

1133. The agent of any one of Embodiments 1-1130, wherein X^6 is Asp.

1134. The agent of any one of Embodiments 1-1130, wherein X^6 is [CH2CMe2CO2H]TriAzDap.

1135. The agent of any one of Embodiments 1-1109, wherein X^6 comprises a side chain comprising a polar group.

1136. The agent of any one of Embodiments 1-1109 and 1135, wherein X^6 comprises a side chain comprising −OH.

1137. The agent of any one of Embodiments 1-1109 and 1135, wherein X^6 comprises a side chain comprising an amidyl group.

1138. The agent of any one of Embodiments 1-1109, 1135, and 1137, wherein X^6 is Gln.

1139. The agent of any one of the preceding Embodiments, wherein X^6 interacts with Tyr306 of beta-catenin or an amino acid residue corresponding thereto.

1140. The agent of any one of the preceding Embodiments, wherein X^6 interacts with Lys345 of beta-catenin or an amino acid residue corresponding thereto.

1141. The agent of any one of the preceding Embodiments, wherein X^7 is a hydrophobic amino acid residue.

1142. The agent of any one of the preceding Embodiments, wherein X^7 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1143. The agent of any one of the preceding Embodiments, wherein X^7 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$.

1144. The agent of any one of the preceding Embodiments, wherein X^7 is $-NH-C(R^{a2})(R^{a3})-C(O)-$.

1145. The agent of any one of Embodiments 1142-1144, wherein R^{a2} and R^{a3} are independently hydrogen or optionally substituted C_{1-10} aliphatic.

1146. The agent of any one of Embodiments 1142-1144, wherein one of R^{a2} and R^{a3} is hydrogen and the other is C_{1-10} aliphatic.

1147. The agent of any one of Embodiments 1142-1144, wherein R^{a2} and R^{a3} are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered ring having 1-3 heteroatoms.

1148. The agent of any one of Embodiments 1142-1144, wherein R^{a2} and R^{a3} are taken together with the carbon atom to which they are attached to form 3-8 membered cycloalkyl.

1149. The agent of any one of the preceding Embodiments, wherein X^7 is selected from Aib, Ala, MorphGln, Gln, Ser, iPrLys, nLeu, Cha, Hse, Npg, Val, CyLeu, Thr, Phe, Acp, Asn, DaMeS, aMeDF, Leu, Cpg, Cbg, Me2Gln, Met2O, AcLys, His, aMeL, DaMeL, aMeV, aMeS, and aMeF.

1150. The agent of any one of the preceding Embodiments, wherein X^7 is selected from Aib, Ala, MorphGln, Gln, Ser, iPrLys, nLeu, Cha, Hse, Npg, Val, and CyLeu.

1151. The agent of any one of the preceding Embodiments, wherein X^7 is selected from Aib, Ala, MorphGln, Gln, Ser, iPrLys, nLeu, Cha, and Hse.

1152. The agent of any one of the preceding Embodiments, wherein X^7 is Aib.

1153. The agent of any one of Embodiments 1-1140, wherein X^7 is Ala.

1154. The agent of any one of Embodiments 1-1140, wherein X^7 is CyLeu.

1155. The agent of any one of Embodiments 1-1140, wherein X^7 is Phe.

1156. The agent of any one of Embodiments 1-1140, wherein X^7 is nLeu.

1157. The agent of any one of Embodiments 1-1140, wherein X^7 is Val.

1158. The agent of any one of the preceding Embodiments, wherein X^8 is a hydrophobic amino acid residue.

1159. The agent of any one of the preceding Embodiments, wherein X^8 is

$-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1160. The agent of any one of the preceding Embodiments, wherein X^8 is $-N(R^{a1})-C(R^{a2})(R^{a3})-C(O)-$.

1161. The agent of any one of the preceding Embodiments, wherein X^8 is $-NH-C(R^{a2})(R^{a3})-C(O)-$.

1162. The agent of any one of Embodiments 1159-1161, wherein R^{a2} and R^{a3} are independently hydrogen or optionally substituted C_{1-10} aliphatic.

1163. The agent of any one of Embodiments 1159-1161, wherein one of R^{a2} and R^{a3} is hydrogen and the other is C_{1-10} aliphatic.

1164. The agent of any one of Embodiments 1159-1161, wherein R^{a2} and R^{a3} are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered ring having 1-3 heteroatoms.

1165. The agent of any one of Embodiments 1159-1161, wherein R^{a2} and R^{a3} are taken together with the carbon atom to which they are attached to form 3-8 membered cycloalkyl.

1166. The agent of any one of the preceding Embodiments, wherein X^8 is selected from Ala, Aib, Cpg, Val, Leu, Gln, Lys, Asp, Glu, Aad, nLeu, Cba, Ser, Thr, aThr, MorphGln, Phe, hPhe, hTyr, and AcLys.

1167. The agent of any one of Embodiments 1-1157, wherein X^8 is Ala, Aib, Phe, Asp, 3COOHF, aThr, Gly, Ser, nLeu, Thr, Cpg, Val, Leu, Gln, Lys, Glu, Aad, Cba, MorphGln, hPhe, hTyr, or AcLys.

1168. The agent of any one of the preceding Embodiments, wherein X^8 is Ala.

1169. The agent of any one of Embodiments 1-1157, wherein X^8 is Aib.

1170. The agent of any one of Embodiments 1-1157, wherein X^8 is Phe.

1171. The agent of any one of Embodiments 1-1157, wherein X^8 is Asp.

1172. The agent of any one of Embodiments 1-1157, wherein X^8 is 3COOHF.

1173. The agent of any one of the preceding Embodiments, wherein X^8 interacts with Trp383 of beta-catenin or an amino acid residue corresponding thereto.

1174. The agent of any one of the preceding Embodiments, wherein X^9 is selected from Phe, 3COOHF, 2NapA, nLeu, Tyr, 3Thi, 4FF, 4ClF, 4BrF, 3FF, 3ClF, 3BrF, 2FF, 3OMeF, 4CNF, 3CNF, 4MeF, 3MeF, Aic, RbiPrF, SbiPrF, RbiPrDF, RbMeXylA, RbMeXylDA, Cba, CypA, BztA, 1NapA, Trp, Leu, Ile, Ser, 2Thi, Chg, Hse, 4TriA, 3F3MeF, Thr, His, Val, Asn, Gln, 2Cpg, SbMeXylA, and SbMeXylDA.

1175. The agent of any one of the preceding Embodiments, wherein X^9 comprises a side chain which is or comprises an optionally substituted aromatic group.

1176. The agent of any one of the preceding Embodiments, wherein X^9 is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1177. The agent of Embodiment 1176, wherein R^{a1} is $-H$.

1178. The agent of any one of Embodiments 1176-1177, wherein R^{a3} is $-H$.

1179. The agent of any one of Embodiments 1176-1177, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1180. The agent of any one of Embodiments 1176-1179, wherein L^{a1} is a covalent bond.

1181. The agent of any one of Embodiments 1176-1180, wherein R^{a2} is $-L^a-R$, wherein R is or comprises

an aromatic group.

1182. The agent of Embodiment 1181, wherein R is optionally substituted 6-10 membered aryl.

1183. The agent of Embodiment 1181, wherein R is optionally substituted phenyl.

1184. The agent of Embodiment 1181, wherein R is phenyl.

1185. The agent of Embodiment 1181, wherein R is optionally substituted naphthyl.

1186. The agent of Embodiment 1181, wherein R is naphthyl.

1187. The agent of Embodiment 1181, wherein R is optionally substituted 5-membered heteroaryl having 1-4 heteroatoms.

1188. The agent of Embodiment 1181, wherein R is optionally substituted 6-membered heteroaryl having 1-4 heteroatoms.

1189. The agent of Embodiment 1181, wherein R is optionally substituted 9-membered bicyclic heteroaryl having 1-4 heteroatoms.

1190. The agent of Embodiment 1181, wherein R is optionally substituted 10-membered bicyclic heteroaryl having 1-4 heteroatoms.

1191. The agent of any one of Embodiments 1187-1190, wherein a heteroatom is nitrogen.

1192. The agent of any one of Embodiments 1187-1191, wherein a heteroatom is oxygen.

1193. The agent of any one of Embodiments 1187-1192, wherein a heteroatom is sulfur.

1194. The agent of any one of Embodiments 1187-1190, wherein the heteroaryl has only one heteroatom.

1195. The agent of Embodiment 1194, wherein the heteroatom is nitrogen.

1196. The agent of Embodiment 1194, wherein the heteroatom is oxygen.

1197. The agent of Embodiment 1194, wherein the heteroatom is sulfur.

1198. The agent of any one of Embodiments 1181-1197, wherein L^a is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1199. The agent of any one of Embodiments 1181-1197, wherein L^a is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1200. The agent of any one of Embodiments 1181-1197, wherein L^a is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1201. The agent of Embodiment 1198, wherein L^a is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1202. The agent of Embodiment 1198, wherein L^a is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1203. The agent of Embodiment 1198, wherein L^a is $-CH_2-$.

1204. The agent of any one of the preceding Embodiments, wherein X^9 comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group

is independently selected from halogen, −OR, −R, −C(O)OR, and −CN, wherein each R is independently −H, C_{1-4} alkyl, or haloalkyl.

1205. The agent of any one of the preceding Embodiments, wherein X^9 comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group is independently selected from halogen, −OR, −R, −C(O)OH, and −CN, wherein each R is independently C_{1-4} alkyl or haloalkyl.

1206. The agent of any one of the preceding Embodiments, wherein X^9 comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group is independently selected from halogen, −OR, −R, −C(O)OH, and −CN, wherein each R is independently C_{1-2} alkyl or haloalkyl.

1207. The agent of any one of the preceding Embodiments, wherein X^9 comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group is independently selected from halogen, −OR, −R, −C(O)OH, and −CN, wherein each R is independently methyl optionally substituted with one or more halogen.

1208. The agent of any one of the preceding Embodiments, wherein X^9 comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group is independently selected from halogen, −OR, −R, −C(O)OH, and −CN, wherein each R is independently methyl optionally substituted with one or more F.

1209. The agent of any one of the preceding Embodiments, wherein X^9 comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group is independently selected from −F, −Cl, −Br, $-OCH_3$, $-CH_3$, $-CF_3$, −C(O)OH, and –CN.

1210. The agent of any one of the preceding Embodiments, wherein X^9 comprises a side chain which is or comprises an unsubstituted aromatic group.

1211. The agent of any one of Embodiments 1-1173, wherein X^9 is AA9, Phe, Ala, Lys, 3COOHF, Aib, 2NapA, nLeu, 2Thi, Tyr, 3Thi, 4FF, 4ClF, 4BrF, 3FF, 3ClF, 3BrF, 2FF, 3OMeF, 4CNF, 3CNF, 4MeF, 3MeF, Aic, RbiPrF, SbiPrF, RbiPrDF, RbMeXylA, RbMeXylDA, Cba, CypA, BztA, 1NapA, Trp, Leu, Ile, Ser, Chg, Hse, 4TriA, 3F3MeF, Thr, His, Val, Asn, Gln, 2Cpg, SbMeXylA, or SbMeXylDA.

1212. The agent of any one of Embodiments 1-1173, wherein X^9 is Phe.

1213. The agent of any one of Embodiments 1-1173, wherein X^9 is Ala.

1214. The agent of any one of Embodiments 1-1173, wherein X^9 is Lys.

1215. The agent of any one of Embodiments 1-1173, wherein X^9 is 3COOHF.

1216. The agent of any one of Embodiments 1-1173, wherein X^9 is Aib.

1217. The agent of any one of the preceding Embodiments, wherein X^9 interacts with Lys345 of beta-catenin or an amino acid residue corresponding thereto.

1218. The agent of any one of the preceding Embodiments, wherein X^9 interacts with Trp383 of beta-catenin or an amino acid residue corresponding thereto.

1219. The agent of any one of the preceding Embodiments, wherein X^{10} is not stapled.

1220. The agent of any one of the preceding Embodiments, wherein X^{10} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1221. The agent of Embodiment 1220, wherein R^{a1} is $-H$.

1222. The agent of any one of Embodiments 1220-1221, wherein R^{a3} is $-H$.

1223. The agent of any one of Embodiments 1220-1221, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1224. The agent of any one of Embodiments 1220-1223, wherein L^{a1} is a covalent bond.

1225. The agent of any one of Embodiments 1220-1224, wherein L^{a2} is a covalent bond.

1226. The agent of any one of Embodiments 1220-1225, wherein R^{a2} is $-L"-R$.

1227. The agent of any one of Embodiments 1220-1225, wherein R^{a2} is $-L"-Cy-R$.

1228. The agent of any one of Embodiments 1226-1227, wherein R is hydrogen or optionally substituted C_{1-10} aliphatic.

1229. The agent of any one of Embodiments 1226-1227, wherein R is optionally substituted C_{1-10} aliphatic.

1230. The agent of any one of Embodiments 1226-1227, wherein R is C_{1-10} aliphatic.

1231. The agent of any one of Embodiments 1226-1227, wherein R is C_{1-10} alkyl.

1232. The agent of any one of Embodiments 1226-1227, wherein R is optionally substituted phenyl.

1233. The agent of any one of Embodiments 1220-1225, R^{a2} is $-L"-C(O)N(R')_2$.

1234. The agent of any one of Embodiments 1220-1225, R^{a2} is $-L"-OH$.

1235. The agent of any one of Embodiments 1220-1234, wherein L" is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1236. The agent of any one of Embodiments 1220-1234, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1237. The agent of any one of Embodiments 1220-1234, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1238. The agent of any one of Embodiments 1220-1234, wherein L" is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1239. The agent of any one of Embodiments 1220-1234, wherein L" is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1240. The agent of any one of Embodiments 1-1218, wherein X^{10} is Lys, Phe, TriAzLys, GlnR, Leu, PyrS2, Aib, Ala, sAla, AsnR, hGlnR, dOrn, PyrS1, dLys, dDab, [mPyr]Cys, PyrS3, iPrLys, [mXyl]Cys, TriAzOrn, 1MeK, [C3]Cys, [IsoE]Cys, DGlnR, Orn, [mPyr]hCys, [Red]Cys, [C3]hCys, 4PipA, sCH2S, [8FBB]Cys, [pXyl]Cys, [pXyl]hCys, [33Oxe]Cys, [Red]hCys, [IsoE]hCys, [13Ac]hCys, [m5Meb]Cys, [m5Meb]hCys, GlnS3APyr, AsnMeEDA, AsnR3APyr, [m5Pyr]Cys, [m5OMeb]Cys, [4FB]Cys, [oXyl]Cys, NMeOrn, [2_6-

naph]Cys, [3_3-biph]Cys, [mXyl]hCys, [3_3-biPh]hCys, [2_6-naph]hCys, [33Oxe]hCys, [13Ac]Cys, GlnR3APyr, AsnS3APyr, [IsoE]hCysOx, or [m5Pyr]hCys.

1241. The agent of any one of Embodiments 1-1218, wherein X^{10} is Lys.

1242. The agent of any one of Embodiments 1-1218, wherein X^{10} is Phe.

1243. The agent of any one of Embodiments 1-1218, wherein X^{10} is TriAzLys.

1244. The agent of any one of Embodiments 1-1218, wherein X^{10} is GlnR.

1245. The agent of any one of Embodiments 1-1218, wherein X^{10} is Leu.

1246. The agent of any one of Embodiments 1-1218, wherein X^{10} is PyrS2.

1247. The agent of any one of Embodiments 1-1218, wherein X^{10} is Aib.

1248. The agent of any one of Embodiments 1-1218, wherein X^{10} is Ala.

1249. The agent of any one of Embodiments 1-1218, wherein X^{10} is Leu.

1250. The agent of any one of the preceding Embodiments, wherein X^{12} is selected from 3Thi, 2F3MeF, Phe, nLeu, 2COOHF, CypA, 2ClF, Ala, Abu, Leu, hLeu, Npg, Cpa, Nva, Cba, ChA, 2FurA, 2OMeF, 2MeF, 2BrF, 2CNF, 2NO2F, 2PyrA, 3PyrA, 4PyrA, His, 1NapA, Val, Ile, Chg, DiethA, hnLeu, OctG, 2Thi, and 2cbmF.

1251. The agent of any one of the preceding Embodiments, wherein X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group.

1252. The agent of any one of the preceding Embodiments, wherein X^{12} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1253. The agent of Embodiment 1252, wherein R^{a1} is $-H$.

1254. The agent of any one of Embodiments 1252-1253, wherein R^{a3} is $-H$.

1255. The agent of any one of Embodiments 1252-1253, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1256. The agent of any one of Embodiments 1252-1255, wherein L^{a1} is a covalent bond.

1257. The agent of any one of Embodiments 1252-1256, wherein R^{a2} is $-L^{a}-R$, wherein R is or comprises an aromatic group.

1258. The agent of Embodiment 1257, wherein R is optionally substituted 6-10 membered aryl

1259. The agent of Embodiment 1257, wherein R is optionally substituted phenyl

1260. The agent of Embodiment 1257, wherein R is phenyl

1261. The agent of Embodiment 1257, wherein R is optionally substituted naphthyl

1262. The agent of Embodiment 1257, wherein R is naphthyl

1263. The agent of Embodiment 1257, wherein R is optionally substituted 5-membered heteroaryl having 1-4 heteroatoms

1264. The agent of Embodiment 1257, wherein R is optionally substituted 6-membered heteroaryl having 1-4 heteroatoms

1265. The agent of Embodiment 1257, wherein R is optionally substituted 9-membered bicyclic heteroaryl having 1-4 heteroatoms

1266. The agent of Embodiment 1257, wherein R is optionally substituted 10-membered bicyclic heteroaryl having 1-4 heteroatoms

1267. The agent of any one of Embodiments 1263-1266, wherein a heteroatom is nitrogen

1268. The agent of any one of Embodiments 1263-1267, wherein a heteroatom is oxygen

1269. The agent of any one of Embodiments 1263-1268, wherein a heteroatom is sulfur

1270. The agent of any one of Embodiments 1263-1266, wherein the heteroaryl has only one heteroatom

1271. The agent of Embodiment 1270, wherein the heteroatom is nitrogen.

1272. The agent of Embodiment 1270, wherein the heteroatom is oxygen.

1273. The agent of Embodiment 1270, wherein the heteroatom is sulfur.

1274. The agent of any one of Embodiments 1257-1273, wherein L^a is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1275. The agent of any one of Embodiments 1257-1273, wherein L^a is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1276. The agent of any one of Embodiments 1257-1273, wherein L^a is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1277. The agent of Embodiment 1274, wherein L^a is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1278. The agent of Embodiment 1274, wherein L^a is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1279. The agent of Embodiment 1274, wherein L^a is $-CH_2-$.

1280. The agent of any one of the preceding Embodiments, wherein X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group is independently selected from halogen, −OR, −R, −C(O)OR, $-C(O)N(R)_2$, −CN, and $-NO_2$, wherein each R is independently −H, C_{1-4} alkyl, or haloalkyl.

1281. The agent of any one of the preceding Embodiments, wherein X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group is independently selected from halogen, −OR, −R, −C(O)OH, $-C(O)NH_2$, −CN, and $-NO_2$, wherein each R is independently C_{1-4} alkyl or haloalkyl.

1282. The agent of any one of the preceding Embodiments, wherein X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group is independently selected from halogen, −OR, −R, −C(O)OH, $-C(O)NH_2$, −CN, and $-NO_2$, wherein each R is independently C_{1-2} alkyl or haloalkyl.

1283. The agent of any one of the preceding Embodiments, wherein X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group

is independently selected from halogen, −OR, −R, −C(O)OH, −C(O)NH_2, −CN, and –NO_2, wherein each R is independently methyl optionally substituted with one or more halogen.

1284. The agent of any one of the preceding Embodiments, wherein X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group is independently selected from halogen, −OR, −R, −C(O)OH, −C(O)NH_2, −CN, and –NO_2, wherein each R is independently methyl optionally substituted with one or more −F.

1285. The agent of any one of the preceding Embodiments, wherein X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group, wherein each optional substituent of the aromatic group is independently selected from −Br, −OCH_3, −CH_3, −CF_3, −C(O)OH, −C(O)NH_2, −CN, or –NO_2.

1286. The agent of any one of the preceding Embodiments, wherein X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group optionally substituted at 2'-position.

1287. The agent of any one of the preceding Embodiments, wherein X^{12} comprises a side chain which is or comprises an unsubstituted aromatic group.

1288. The agent of any one of Embodiments 1251-1287, wherein the aromatic group is a 5-membered heteroaryl group.

1289. The agent of any one of the preceding Embodiments, wherein X^{12} is 3Thi.

1290. The agent of any one of Embodiments 1251-1287, wherein the aromatic group is a phenyl group.

1291. The agent of any one of Embodiment 1290, wherein X^{12} is 2F3MeF.

1292. The agent of any one of Embodiment 1290, wherein X^{12} is Phe.

1293. The agent of any one of Embodiment 1290, wherein X^{12} is Phe wherein the phenyl is 2'-substituted.

1294. The agent of any one of Embodiment 1290, wherein X^{12} is 2F3MeF, 2COOHF, 2ClF, 2OMeF, 2MeF, 2BrF, 2CNF, 2NO2F, or 2cbmF.

1295. The agent of any one of Embodiments 1-1249, wherein X^{12} is 3Thi, Phe, 2F3MeF, PyrS2, 2ClF, hnLeu, BztA, 2Thi, 2MeF, 2FF, 34ClF, Lys, nLeu, 2COOHF, 2PhF, hCbA, hCypA, hCha, CypA, hPhe, DipA, HepG, Dap7Abu, hhLeu, hhSer, HexG, [2IAPAc]2NH2F, Ala, Abu, Leu, hLeu, Npg, Cpa, PyrS1, [Bnc]2NH2F, [Phc]2NH2F, [BiPh]2NH2F, [3PyAc]2NH2F, Nva, Cba, ChA, 2FurA, 2OMeF, 2BrF, 2CNF, 2NO2F, 2PyrA, 3PyrA, 4PyrA, His, 1NapA, Val, Ile, Chg, DiethA, OctG, 2cbmF, c6Phe, [MePipAc]2NH2F, or [2PyCypCO]2NH2F.

1296. The agent of any one of Embodiments 1-1249, wherein X^{12} is 3Thi.

1297. The agent of any one of Embodiments 1-1249, wherein X^{12} is Phe.

1298. The agent of any one of Embodiments 1-1249, wherein X^{12} is 2F3MeF.

1299. The agent of any one of Embodiments 1-1249, wherein X^{12} is PyrS2.

1300. The agent of any one of Embodiments 1-1249, wherein X^{12} is 2ClF.

1301. The agent of any one of Embodiments 1-1249, wherein X^{12} is hnLeu.

1302. The agent of any one of Embodiments 1-1249, wherein X^{12} is BztA.

1303. The agent of any one of Embodiments 1-1249, wherein X^{12} is 2Thi.

1304. The agent of any one of Embodiments 1-1249, wherein X^{12} is 2MeF.

1305. The agent of any one of Embodiments 1-1249, wherein X^{12} is 2FF.

1306. The agent of any one of Embodiments 1-1249, wherein X^{12} is 34ClF.

1307. The agent of any one of the preceding Embodiments, wherein X^{12} interacts with Trp383 of beta-catenin or an amino acid residue corresponding thereto.

1308. The agent of any one of the preceding Embodiments, wherein X^{12} interacts with Asn415 of beta-catenin or an amino acid residue corresponding thereto.

1309. The agent any one of the preceding Embodiments, wherein the side chain of X^{13} comprises an optionally substituted aromatic group.

1310. The agent of any one of the preceding Embodiments, wherein X^{13} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1311. The agent of Embodiment 1310, wherein R^{a1} is $-H$.

1312. The agent of any one of Embodiments 1310-1311, wherein R^{a3} is $-H$.

1313. The agent of any one of Embodiments 1310-1311, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1314. The agent of any one of Embodiments 1310-1313, wherein L^{a1} is a covalent bond

1315. The agent of any one of Embodiments 1310-1314, wherein R^{a2} is $-L^{a}-R$, wherein R is or comprises an aromatic group.

1316. The agent of Embodiment 1315, wherein R is optionally substituted 6-10 membered aryl.

1317. The agent of Embodiment 1315, wherein R is optionally substituted phenyl.

1318. The agent of Embodiment 1315, wherein R is phenyl.

1319. The agent of Embodiment 1315, wherein R is optionally substituted naphthyl.

1320. The agent of Embodiment 1315, wherein R is naphthyl.

1321. The agent of Embodiment 1315, wherein R is optionally substituted 5-membered heteroaryl having 1-4 heteroatoms.

1322. The agent of Embodiment 1315, wherein R is optionally substituted 6-membered heteroaryl having 1-4 heteroatoms.

1323. The agent of Embodiment 1315, wherein R is optionally substituted 9-membered bicyclic heteroaryl having 1-4 heteroatoms.

1324. The agent of Embodiment 1315, wherein R is optionally substituted 10-membered bicyclic heteroaryl having 1-4 heteroatoms.

1325. The agent of any one of Embodiments 1321-1324, wherein a heteroatom is nitrogen.

1326. The agent of any one of Embodiments 1321-1324, wherein a heteroatom is oxygen.

1327. The agent of any one of Embodiments 1321-1324, wherein a heteroatom is sulfur.

1328. The agent of any one of Embodiments 1321-1324, wherein the heteroaryl has only one heteroatom.

1329. The agent of Embodiment 1328, wherein the heteroatom is nitrogen.

1330. The agent of Embodiment 1328, wherein the heteroatom is oxygen.

1331. The agent of Embodiment 1328, wherein the heteroatom is sulfur.

1332. The agent of any one of Embodiments 1315-1331, wherein L^a is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1333. The agent of any one of Embodiments 1315-1331, wherein L^a is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1334. The agent of any one of Embodiments 1315-1331, wherein L^a is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1335. The agent of Embodiment 1332, wherein L^a is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1336. The agent of Embodiment 1332, wherein L^a is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1337. The agent of Embodiment 1332, wherein L^a is $-CH_2-$.

1338. The agent any one of the preceding Embodiments, wherein the side chain of X^{13} comprises an optionally substituted 8-10 membered bicyclic aromatic group.

1339. The agent any one of the preceding Embodiments, wherein the side chain of X^{13} comprises an optionally substituted 9-membered bicyclic heteroaryl group having 1-3 heteroatoms.

1340. The agent of any one of the preceding Embodiments, wherein X^{13} is BtzA.

1341. The agent of any one of Embodiments 1-1338, wherein X^{13} is 2NapA.

1342. The agent of any one of Embodiments 1309, wherein the aromatic group is a phenyl group.

1343. The agent of any one of Embodiment 1342, wherein X^{13} is 34ClF.

1344. The agent of any one of Embodiments 1-1308, wherein X^{13} is selected from BztA, 34ClF, 2NapA, 3BrF, and 34MeF.

1345. The agent of any one of Embodiments 1-1308, wherein X^{13} is 3Thi.

1346. The agent of any one of Embodiments 1-1308, wherein X^{13} is Phe.

1347. The agent of any one of Embodiments 1-1308, wherein X^{13} is GlnR.

1348. The agent of any one of Embodiments 1-1308, wherein X^{13} is 34MeF.

1349. The agent of any one of Embodiments 1-1308, wherein X^{13} is 2NapA.

1350. The agent of any one of Embodiments 1-1308, wherein X^{13} is Lys.

1351. The agent of any one of the preceding Embodiments, wherein X^{13} interacts with Gln379 of beta-catenin or an amino acid residue corresponding thereto.

1352. The agent of any one of the preceding Embodiments, wherein X^{13} interacts with Leu382 of beta-catenin or an amino acid residue corresponding thereto.

1353. The agent of any one of the preceding Embodiments, wherein X^{13} interacts with Val416 of beta-catenin or an amino acid residue corresponding thereto.

1354. The agent of any one of the preceding Embodiments, wherein X^{13} interacts with Asn415 of beta-catenin or an amino acid residue corresponding thereto.

1355. The agent of any one of the preceding Embodiments, wherein X^{13} interacts with Trp383 of beta-catenin or an amino acid residue corresponding thereto.

1356. The agent of any one of the preceding Embodiments, wherein X^{14} is not stapled.

1357. The agent of any one of the preceding Embodiments, wherein X^{14} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1358. The agent of Embodiment 1357, wherein R^{a1} is $-H$.

1359. The agent of any one of Embodiments 1357-1358, wherein R^{a3} is $-H$.

1360. The agent of any one of Embodiments 1357-1358, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1361. The agent of any one of Embodiments 1357-1360, wherein L^{a1} is a covalent bond.

1362. The agent of any one of Embodiments 1357-1361, wherein L^{a2} is a covalent bond.

1363. The agent of any one of Embodiments 1357-1362, wherein R^{a2} is $-L"-R$.

1364. The agent of any one of Embodiments 1357-1362, wherein R^{a2} is $-L"-Cy-R$.

1365. The agent of any one of Embodiments 1357-1362, wherein R^{a2} is $-L"-C(O)OR$.

1366. The agent of any one of Embodiments 1357-1362, wherein R^{a2} is $-L"-C(O)N(R')_2$.

1367. The agent of any one of Embodiments 1357-1362, wherein R^{a2} is $-L"-C(O)N(R)_2$.

1368. The agent of any one of Embodiments 1359-1367, wherein R is hydrogen or optionally substituted C_{1-10} aliphatic.

1369. The agent of any one of Embodiments 1359-1367, wherein R is hydrogen.

1370. The agent of any one of Embodiments 1359-1367, wherein R is optionally substituted C_{1-10} aliphatic.

1371. The agent of any one of Embodiments 1359-1367, wherein R is C_{1-10} aliphatic.

1372. The agent of any one of Embodiments 1359-1367, wherein R is C_{1-10} alkyl.

1373. The agent of any one of Embodiments 1357-1362, wherein R^{a2} is $-L"-OH$.

1374. The agent of any one of Embodiments 1357-1373, wherein L" is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1375. The agent of any one of Embodiments 1357-1373, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1376. The agent of any one of Embodiments 1357-1373, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1377. The agent of any one of Embodiments 1357-1373, wherein L" is optionally substituted $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1378. The agent of any one of Embodiments 1357-1373, wherein L" is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5,

or 6.

1379. The agent of any one of Embodiments 1-1355, wherein X^{14} is GlnR.

1380. The agent of any one of Embodiments 1-1355, wherein X^{14} is BztA.

1381. The agent of any one of Embodiments 1-1355, wherein X^{14} is sAla.

1382. The agent of any one of Embodiments 1-1355, wherein X^{14} is 34ClF.

1383. The agent of any one of Embodiments 1-1355, wherein X^{14} is Cys.

1384. The agent of any one of Embodiments 1-1355, wherein X^{14} is Ala.

1385. The agent of any one of Embodiments 1-1355, wherein X^{14} is Lys.

1386. The agent of any one of Embodiments 1-1355, wherein X^{14} is AsnR.

1387. The agent of any one of Embodiments 1-1355, wherein X^{14} is aMeC.

1388. The agent of any one of Embodiments 1-1355, wherein X^{14} is PyrS2.

1389. The agent of any one of Embodiments 1-1355, wherein X^{14} is hGlnR.

1390. The agent of any one of Embodiments 1-1355, wherein X^{14} is 3Thi.

1391. The agent of any one of Embodiments 1-1355, wherein X^{14} is Lys.

1392. The agent of any one of Embodiments 1-1355, wherein X^{14} is Gln.

1393. The agent of any one of the preceding Embodiments, wherein X^{14} comprises a C-terminal group.

1394. The agent of any one of the preceding Embodiments, wherein X^{15} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1395. The agent of Embodiment 1394, wherein R^{a1} is $-H$.

1396. The agent of any one of Embodiments 1394-1395, wherein R^{a3} is $-H$.

1397. The agent of any one of Embodiments 1394-1395, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1398. The agent of any one of Embodiments 1394-1397, wherein L^{a1} is a covalent bond.

1399. The agent of any one of Embodiments 1394-1398, wherein L^{a2} is a covalent bond.

1400. The agent of any one of Embodiments 1394-1399, wherein R^{a2} is $-L''-R$.

1401. The agent of any one of Embodiments 1394-1399, wherein R^{a2} is $-L''-Cy-R$.

1402. The agent of any one of Embodiments 1394-1399, wherein R^{a2} is $-L''-C(O)OR$.

1403. The agent of any one of Embodiments 1394-1399, wherein R^{a2} is $-L''-C(O)N(R')_2$.

1404. The agent of any one of Embodiments 1394-1399, wherein R^{a2} is $-L''-C(O)N(R)_2$.

1405. The agent of any one of Embodiments 1400-1404, wherein R is hydrogen or optionally substituted C_{1-10} aliphatic.

1406. The agent of any one of Embodiments 1400-1404, wherein R is hydrogen.

1407. The agent of any one of Embodiments 1400-1404, wherein R is optionally substituted C_{1-10} aliphatic.

1408. The agent of any one of Embodiments 1400-1404, wherein R is C_{1-10} aliphatic.

1409. The agent of any one of Embodiments 1400-1404, wherein R is C_{1-10} alkyl.

1410. The agent of any one of Embodiments 1394-1399, wherein R^{a2} is $-L''-OH$.

1411. The agent of any one of Embodiments 1394-1410, wherein L'' is a covalent bond or an optionally

substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1412. The agent of any one of Embodiments 1394-1410, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1413. The agent of any one of Embodiments 1394-1410, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1414. The agent of any one of Embodiments 1394-1410, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1415. The agent of any one of Embodiments 1394-1410, wherein L" is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1416. The agent of any one of the preceding Embodiments, wherein p15 is 1.

1417. The agent of any one of the preceding Embodiments, wherein X^{15} is selected from Ala, Leu, Val, Aib, MorphNva, Thr, dAla, dLeu, [BiotinPEG8]Lys, Glu, and AzLys.

1418. The agent of any one of the preceding Embodiments, wherein X^{15} comprises a hydrophobic side chain.

1419. The agent of any one of the preceding Embodiments, wherein the side chain of X^{15} is C_{1-10} alkyl.

1420. The agent of any one of the preceding Embodiments, wherein X^{15} is Ala.

1421. The agent of any one of the preceding Embodiments, wherein X^{15} is optionally substituted or labeled Lys.

1422. The agent of any one of Embodiments 1-1393, wherein X^{15} is Ala, GlnR, Leu, Val, Ser, Thr, 3Thi, BztA, Aib, MorphNva, dAla, dLeu, Pro, Phe, [BiotinPEG8]Lys, Throl, Glu, AzLys, Npg, Trp, Tyr, Lys, Prool, Alaol, Gly, dPro, Asn, Gln, Ala_D3, [mPEG4]Lys, [mPEG8]Lys, or [mPEG16]Lys.

1423. The agent of any one of Embodiments 1-1393, wherein X^{15} is Ala.

1424. The agent of any one of Embodiments 1-1393, wherein X^{15} is optionally substituted or labeled Lys.

1425. The agent of any one of Embodiments 1-1393, wherein X^{15} is GlnR.

1426. The agent of any one of Embodiments 1-1393, wherein X^{15} is Leu.

1427. The agent of any one of Embodiments 1-1393, wherein X^{15} is Val.

1428. The agent of any one of Embodiments 1-1393, wherein X^{15} is Ser.

1429. The agent of any one of Embodiments 1-1393, wherein X^{15} is Thr.

1430. The agent of any one of Embodiments 1-1393, wherein X^{15} is 3Thi.

1431. The agent of any one of Embodiments 1-1393, wherein X^{15} is BztA.

1432. The agent of any one of the preceding Embodiments, wherein X^{15} comprises a C-terminal group.

1433. The agent of any one of Embodiments 1-1393, wherein p15 is 0.

1434. The agent of any one of the preceding Embodiments, wherein p16 is 1.

1435. The agent of any one of the preceding Embodiments, wherein X^{16} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1436. The agent of Embodiment 1435, wherein R^{a1} is $-H$.

1437. The agent of any one of Embodiments 1435-1436, wherein R^{a3} is $-H$.

1438. The agent of any one of Embodiments 1435-1436, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1439. The agent of any one of Embodiments 1435-1438, wherein L^{a1} is a covalent bond.

1440. The agent of any one of Embodiments 1435-1439, wherein L^{a2} is a covalent bond.

1441. The agent of any one of Embodiments 1435-1440, wherein R^{a2} is $-L"-R$.

1442. The agent of any one of Embodiments 1435-1440, wherein R^{a2} is $-L"-Cy-R$.

1443. The agent of any one of Embodiments 1435-1440, wherein R^{a2} is $-L"-C(O)OR$.

1444. The agent of any one of Embodiments 1435-1440, wherein R^{a2} is $-L"-C(O)N(R')_2$.

1445. The agent of any one of Embodiments 1435-1440, wherein R^{a2} is $-L"-C(O)N(R)_2$.

1446. The agent of any one of Embodiments 1441-1445, wherein R is hydrogen or optionally substituted C_{1-10} aliphatic.

1447. The agent of any one of Embodiments 1441-1445, wherein R is hydrogen.

1448. The agent of any one of Embodiments 1441-1445, wherein R is optionally substituted C_{1-10} aliphatic.

1449. The agent of any one of Embodiments 1441-1445, wherein R is C_{1-10} aliphatic.

1450. The agent of any one of Embodiments 1441-1445, wherein R is C_{1-10} alkyl.

1451. The agent of any one of Embodiments 1435-1440, wherein R^{a2} is $-L"-OH$.

1452. The agent of any one of Embodiments 1435-1451, wherein L" is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1453. The agent of any one of Embodiments 1435-1451, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1454. The agent of any one of Embodiments 1435-1451, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1455. The agent of any one of Embodiments 1435-1451, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1456. The agent of any one of Embodiments 1435-1451, wherein L" is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1457. The agent of any one of Embodiments 1-1434, wherein X^{16} is selected from Ser, Ala, Glu, Aib, Asp, Thr, and aThr.

1458. The agent of any one of Embodiments 1-1434, wherein X^{16} is Ala, Ser, Glu, GlnR, BztA, Thr, Aib, Asp, Lys, aThr, Val, or Arg.

1459. The agent of any one of any one of the preceding Embodiments, wherein X^{16} comprises a C-terminal group.

1460. The agent of any one of Embodiments 1-1433, wherein p16 is 0.

1461. The agent of any one of the preceding Embodiments, wherein p17 is 1.

1462. The agent of any one of the preceding Embodiments, wherein X^{17} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1463. The agent of Embodiment 1462, wherein R^{a1} is $-H$.

1464. The agent of any one of Embodiments 1462-1463, wherein R^{a3} is $-H$.

1465. The agent of any one of Embodiments 1462-1463, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1466. The agent of any one of Embodiments 1462-1465, wherein L^{a1} is a covalent bond.

1467. The agent of any one of Embodiments 1462-1466, wherein L^{a2} is a covalent bond.

1468. The agent of any one of Embodiments 1462-1467, wherein R^{a2} is $-L"-R$.

1469. The agent of any one of Embodiments 1462-1467, wherein R^{a2} is $-L"-Cy-R$.

1470. The agent of any one of Embodiments 1462-1467, wherein R^{a2} is $-L"-C(O)OR$.

1471. The agent of any one of Embodiments 1462-1467, wherein R^{a2} is $-L"-C(O)N(R')_2$.

1472. The agent of any one of Embodiments 1462-1467, wherein R^{a2} is $-L"-C(O)N(R)_2$.

1473. The agent of any one of Embodiments 1468-1472, wherein R is hydrogen or optionally substituted C_{1-10} aliphatic.

1474. The agent of any one of Embodiments 1468-1472, wherein R is hydrogen.

1475. The agent of any one of Embodiments 1468-1472, wherein R is optionally substituted C_{1-10} aliphatic.

1476. The agent of any one of Embodiments 1468-1472, wherein R is C_{1-10} aliphatic.

1477. The agent of any one of Embodiments 1468-1472, wherein R is C_{1-10} alkyl.

1478. The agent of any one of Embodiments 1462-1467, wherein R^{a2} is $-L"-OH$.

1479. The agent of any one of Embodiments 1462-1478, wherein L" is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1480. The agent of any one of Embodiments 1462-1478, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-Cy-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1481. The agent of any one of Embodiments 1462-1478, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$, $-C(O)N(R')-$, or $-N(R')C(O)O-$.

1482. The agent of any one of Embodiments 1462-1478, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with $-O-$, $-S-$, $-N(R')-$, $-C(O)-$,

−C(O)N(R')−, or −N(R')C(O)O−.

1483. The agent of any one of Embodiments 1462-1478, wherein L" is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1484. The agent of any one of Embodiments 1-1460, wherein X^{17} is Ala, Leu, GlnR, GlnR, Pro, Thr, Val, Lys, Arg, [Ac]Lys, [mPEG4]Lys, [mPEG8]Lys, or [mPEG16]Lys.

1485. The agent of any one of Embodiments 1-1460, wherein X^{17} is selected from Ala and Leu.

1486. The agent of any one of the preceding Embodiments, wherein X^{17} comprises a C-terminal group.

1487. The agent of any one of Embodiments 1-1460, wherein p17 is 0.

1488. The agent of any one of the preceding Embodiments, wherein p18 is 1.

1489. The agent of any one of the preceding Embodiments, wherein X^{18} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1490. The agent of Embodiment 1489, wherein R^{a1} is −H.

1491. The agent of any one of Embodiments 1489-1490, wherein R^{a3} is −H.

1492. The agent of any one of Embodiments 1489-1490, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1493. The agent of any one of Embodiments 1489-1492, wherein L^{a1} is a covalent bond.

1494. The agent of any one of Embodiments 1489-1493, wherein L^{a2} is a covalent bond.

1495. The agent of any one of Embodiments 1489-1494, wherein R^{a2} is −L"−R.

1496. The agent of any one of Embodiments 1489-1494, wherein R^{a2} is −L"−Cy−R.

1497. The agent of any one of Embodiments 1489-1494, wherein R^{a2} is −L"−C(O)OR.

1498. The agent of any one of Embodiments 1489-1494, wherein R^{a2} is $-L"-C(O)N(R')_2$.

1499. The agent of any one of Embodiments 1489-1494, wherein R^{a2} is $-L"-C(O)N(R)_2$.

1500. The agent of any one of Embodiments 1495-1499, wherein R is hydrogen or optionally substituted C_{1-10} aliphatic.

1501. The agent of any one of Embodiments 1495-1499, wherein R is hydrogen.

1502. The agent of any one of Embodiments 1495-1499, wherein R is optionally substituted C_{1-10} aliphatic.

1503. The agent of any one of Embodiments 1495-1499, wherein R is C_{1-10} aliphatic.

1504. The agent of any one of Embodiments 1495-1499, wherein R is C_{1-10} alkyl.

1505. The agent of any one of Embodiments 1489-1494, wherein R^{a2} is −L"−OH.

1506. The agent of any one of Embodiments 1489-1505, wherein L" is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1507. The agent of any one of Embodiments 1489-1505, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1508. The agent of any one of Embodiments 1489-1505, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−,

−C(O)N(R')−, or −N(R')C(O)O−.

1509. The agent of any one of Embodiments 1489-1505, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1510. The agent of any one of Embodiments 1489-1505, wherein L" is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1511. The agent of any one of Embodiments 1-1487, wherein X^{18} is Ala, Pro, Leu, [Ac]Lys, [mPEG8]Lys, [mPEG4]Lys, [mPEG16]Lys, Thr, [mPEG37]Lys, [PEG4triPEG16]Lys, [PEG4triPEG36]Lys, or GlnR.

1512. The agent of any one of Embodiments 1-1487, wherein X^{18} is Ala.

1513. The agent of any one of the preceding Embodiments, wherein X^{18} comprises a C-terminal group.

1514. The agent of any one of Embodiments 1-1487, wherein p18 is 0.

1515. The agent of any one of the preceding Embodiments, wherein p19 is 1.

1516. The agent of any one of the preceding Embodiments, wherein X^{19} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1517. The agent of Embodiment 1516, wherein R^{a1} is −H.

1518. The agent of any one of Embodiments 1516-1517, wherein R^{a3} is −H.

1519. The agent of any one of Embodiments 1516-1517, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1520. The agent of any one of Embodiments 1516-1519, wherein L^{a1} is a covalent bond.

1521. The agent of any one of Embodiments 1516-1520, wherein L^{a2} is a covalent bond.

1522. The agent of any one of Embodiments 1516-1521, wherein R^{a2} is −L"−R.

1523. The agent of any one of Embodiments 1516-1521, wherein R^{a2} is −L"−Cy−R.

1524. The agent of any one of Embodiments 1516-1521, wherein R^{a2} is −L"−C(O)OR.

1525. The agent of any one of Embodiments 1516-1521, wherein R^{a2} is $-L"-C(O)N(R')_2$.

1526. The agent of any one of Embodiments 1516-1521, wherein R^{a2} is $-L"-C(O)N(R)_2$.

1527. The agent of any one of Embodiments 1522-1526, wherein R is hydrogen or optionally substituted C_{1-10} aliphatic.

1528. The agent of any one of Embodiments 1522-1526, wherein R is hydrogen.

1529. The agent of any one of Embodiments 1522-1526, wherein R is optionally substituted C_{1-10} aliphatic.

1530. The agent of any one of Embodiments 1522-1526, wherein R is C_{1-10} aliphatic.

1531. The agent of any one of Embodiments 1522-1526, wherein R is C_{1-10} alkyl.

1532. The agent of any one of Embodiments 1516-1521, wherein R^{a2} is −L"−OH.

1533. The agent of any one of Embodiments 1516-1532, wherein L" is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1534. The agent of any one of Embodiments 1516-1532, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−,

−S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1535. The agent of any one of Embodiments 1516-1532, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1536. The agent of any one of Embodiments 1516-1532, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1537. The agent of any one of Embodiments 1516-1532, wherein L" is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1538. The agent of any one of Embodiments 1-1514, wherein X^{19} is Ala, Leu, Thr, Val, or Pro.

1539. The agent of any one of Embodiments 1-1487, wherein X^{19} is Ala.

1540. The agent of any one of the preceding Embodiments, wherein X^{19} comprises a C-terminal group.

1541. The agent of any one of Embodiments 1-1487, wherein p19 is 0.

1542. The agent of any one of the preceding Embodiments, wherein p20 is 1.

1543. The agent of any one of the preceding Embodiments, wherein X^{20} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1544. The agent of Embodiment 1543, wherein R^{a1} is −H.

1545. The agent of any one of Embodiments 1543-1544, wherein R^{a3} is −H.

1546. The agent of any one of Embodiments 1543-1544, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1547. The agent of any one of Embodiments 1543-1546, wherein L^{a1} is a covalent bond.

1548. The agent of any one of Embodiments 1543-1547, wherein L^{a2} is a covalent bond.

1549. The agent of any one of Embodiments 1543-1548, wherein R^{a2} is −L"−R.

1550. The agent of any one of Embodiments 1543-1548, wherein R^{a2} is −L"−Cy−R.

1551. The agent of any one of Embodiments 1543-1548, wherein R^{a2} is −L"−C(O)OR.

1552. The agent of any one of Embodiments 1543-1548, wherein R^{a2} is $-L"-C(O)N(R')_2$.

1553. The agent of any one of Embodiments 1543-1548, wherein R^{a2} is $-L"-C(O)N(R)_2$.

1554. The agent of any one of Embodiments 1549-1553, wherein R is hydrogen or optionally substituted C_{1-10} aliphatic.

1555. The agent of any one of Embodiments 1549-1553, wherein R is hydrogen.

1556. The agent of any one of Embodiments 1549-1553, wherein R is optionally substituted C_{1-10} aliphatic.

1557. The agent of any one of Embodiments 1549-1553, wherein R is C_{1-10} aliphatic.

1558. The agent of any one of Embodiments 1549-1553, wherein R is C_{1-10} alkyl.

1559. The agent of any one of Embodiments 1543-1548, wherein R^{a2} is −L"−OH.

1560. The agent of any one of Embodiments 1543-1559, wherein L" is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1561. The agent of any one of Embodiments 1543-1559, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1562. The agent of any one of Embodiments 1543-1559, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1563. The agent of any one of Embodiments 1543-1559, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1564. The agent of any one of Embodiments 1543-1559, wherein L" is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1565. The agent of any one of Embodiments 1-1541, wherein X^{20} is Ala, Leu, Lys, nLeu, Val, or Arg.

1566. The agent of any one of Embodiments 1-1541, wherein X^{20} is Ala.

1567. The agent of any one of the preceding Embodiments, wherein X^{20} comprises a C-terminal group.

1568. The agent of any one of Embodiments 1-1541, wherein p20 is 0.

1569. The agent of any one of the preceding Embodiments, wherein p21 is 1.

1570. The agent of any one of the preceding Embodiments, wherein X^{21} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1571. The agent of Embodiment 1570, wherein R^{a1} is −H.

1572. The agent of any one of Embodiments 1570-1571, wherein R^{a3} is −H.

1573. The agent of any one of Embodiments 1570-1571, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1574. The agent of any one of Embodiments 1570-1573, wherein L^{a1} is a covalent bond.

1575. The agent of any one of Embodiments 1570-1574, wherein L^{a2} is a covalent bond.

1576. The agent of any one of Embodiments 1570-1575, wherein R^{a2} is −L"−R.

1577. The agent of any one of Embodiments 1570-1575, wherein R^{a2} is −L"−Cy−R.

1578. The agent of any one of Embodiments 1570-1575, wherein R^{a2} is −L"−C(O)OR.

1579. The agent of any one of Embodiments 1570-1575, wherein R^{a2} is $-L"-C(O)N(R')_2$.

1580. The agent of any one of Embodiments 1570-1575, wherein R^{a2} is $-L"-C(O)N(R)_2$.

1581. The agent of any one of Embodiments 1576-1580, wherein R is hydrogen or optionally substituted C_{1-10} aliphatic.

1582. The agent of any one of Embodiments 1576-1580, wherein R is hydrogen.

1583. The agent of any one of Embodiments 1576-1580, wherein R is optionally substituted C_{1-10} aliphatic.

1584. The agent of any one of Embodiments 1576-1580, wherein R is C_{1-10} aliphatic.

1585. The agent of any one of Embodiments 1576-1580, wherein R is C_{1-10} alkyl.

1586. The agent of any one of Embodiments 1570-1575, wherein R^{a2} is −L"−OH.

1587. The agent of any one of Embodiments 1570-1586, wherein L" is a covalent bond or an optionally

substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1588. The agent of any one of Embodiments 1570-1586, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1589. The agent of any one of Embodiments 1570-1586, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1590. The agent of any one of Embodiments 1570-1586, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1591. The agent of any one of Embodiments 1570-1586, wherein L" is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1592. The agent of any one of Embodiments 1-1568, wherein X^{21} is Ala, Leu, Lys, nLeu, Val, or Arg.

1593. The agent of any one of Embodiments 1-1568, wherein X^{21} is Ala.

1594. The agent of any one of the preceding Embodiments, wherein X^{21} comprises a C-terminal group.

1595. The agent of any one of Embodiments 1-1568, wherein p21 is 0.

1596. The agent of any one of the preceding Embodiments, wherein p22 is 1.

1597. The agent of any one of the preceding Embodiments, wherein X^{22} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1598. The agent of Embodiment 1597, wherein R^{a1} is −H.

1599. The agent of any one of Embodiments 1597-1598, wherein R^{a3} is −H.

1600. The agent of any one of Embodiments 1597-1598, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1601. The agent of any one of Embodiments 1597-1600, wherein L^{a1} is a covalent bond.

1602. The agent of any one of Embodiments 1597-1601, wherein L^{a2} is a covalent bond.

1603. The agent of any one of Embodiments 1597-1602, wherein R^{a2} is −L"−R.

1604. The agent of any one of Embodiments 1597-1602, wherein R^{a2} is −L"−Cy−R.

1605. The agent of any one of Embodiments 1597-1602, wherein R^{a2} is −L"−C(O)OR.

1606. The agent of any one of Embodiments 1597-1602, wherein R^{a2} is $-L"-C(O)N(R')_2$.

1607. The agent of any one of Embodiments 1597-1602, wherein R^{a2} is $-L"-C(O)N(R)_2$.

1608. The agent of any one of Embodiments 1603-1607, wherein R is hydrogen or optionally substituted C_{1-10} aliphatic.

1609. The agent of any one of Embodiments 1603-1607, wherein R is hydrogen.

1610. The agent of any one of Embodiments 1603-1607, wherein R is optionally substituted C_{1-10} aliphatic.

1611. The agent of any one of Embodiments 1603-1607, wherein R is C_{1-10} aliphatic.

1612. The agent of any one of Embodiments 1603-1607, wherein R is C_{1-10} alkyl.

1613. The agent of any one of Embodiments 1597-1602, wherein R^{a2} is −L”−OH.

1614. The agent of any one of Embodiments 1597-1613, wherein L” is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R’)−, −C(O)−, −C(O)N(R’)−, or −N(R’)C(O)O−.

1615. The agent of any one of Embodiments 1597-1613, wherein L” is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R’)−, −C(O)−, −C(O)N(R’)−, or −N(R’)C(O)O−.

1616. The agent of any one of Embodiments 1597-1613, wherein L” is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R’)−, −C(O)−, −C(O)N(R’)−, or −N(R’)C(O)O−.

1617. The agent of any one of Embodiments 1597-1613, wherein L” is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R’)−, −C(O)−, −C(O)N(R’)−, or −N(R’)C(O)O−.

1618. The agent of any one of Embodiments 1597-1613, wherein L” is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1619. The agent of any one of Embodiments 1-1595, wherein X^{22} is Lys.

1620. The agent of any one of the preceding Embodiments, wherein X^{22} comprises a C-terminal group.

1621. The agent of any one of Embodiments 1-1595, wherein p22 is 0.

1622. The agent of any one of the preceding Embodiments, wherein p23 is 1.

1623. The agent of any one of the preceding Embodiments, wherein X^{23} is $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1624. The agent of Embodiment 1623, wherein R^{a1} is −H.

1625. The agent of any one of Embodiments 1623-1624, wherein R^{a3} is −H.

1626. The agent of any one of Embodiments 1623-1624, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1627. The agent of any one of Embodiments 1623-1626, wherein L^{a1} is a covalent bond.

1628. The agent of any one of Embodiments 1623-1627, wherein L^{a2} is a covalent bond.

1629. The agent of any one of Embodiments 1623-1628, wherein R^{a2} is −L”−R.

1630. The agent of any one of Embodiments 1623-1628, wherein R^{a2} is −L”−Cy−R.

1631. The agent of any one of Embodiments 1623-1628, wherein R^{a2} is −L”−C(O)OR.

1632. The agent of any one of Embodiments 1623-1628, wherein R^{a2} is −L”−C(O)N(R’)$_2$.

1633. The agent of any one of Embodiments 1623-1628, wherein R^{a2} is −L”−C(O)N(R)$_2$.

1634. The agent of any one of Embodiments 1629-1633, wherein R is hydrogen or optionally substituted C_{1-10} aliphatic.

1635. The agent of any one of Embodiments 1629-1633, wherein R is hydrogen.

1636. The agent of any one of Embodiments 1629-1633, wherein R is optionally substituted C_{1-10} aliphatic.

1637. The agent of any one of Embodiments 1629-1633, wherein R is C_{1-10} aliphatic.

1638. The agent of any one of Embodiments 1629-1633, wherein R is C_{1-10} alkyl.

1639. The agent of any one of Embodiments 1623-1628, wherein R^{a2} is −L"−OH.

1640. The agent of any one of Embodiments 1623-1639, wherein L" is a covalent bond or an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1641. The agent of any one of Embodiments 1623-1639, wherein L" is an optionally substituted bivalent C_{1-10} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −Cy−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1642. The agent of any one of Embodiments 1623-1639, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1643. The agent of any one of Embodiments 1623-1639, wherein L" is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −C(O)N(R')−, or −N(R')C(O)O−.

1644. The agent of any one of Embodiments 1623-1639, wherein L" is $-(CH_2)n-$ wherein n is 1, 2, 3, 4, 5, or 6.

1645. The agent of any one of the preceding Embodiments, wherein X^{23} comprises a C-terminal group.

1646. The agent of any one of Embodiments 1-1621, wherein p23 is 0.

1647. The agent of any one of the preceding Embodiments, wherein the C-terminal group is R^C.

1648. The agent of any one of Embodiments 1-1646, wherein the C-terminal group is −OH.

1649. The agent of any one of Embodiments 1-1646, wherein the C-terminal group is $-N(R)_2$.

1650. The agent of any one of Embodiments 1-1646, wherein the C-terminal group is $-N(R)_2$, wherein each R is independently −H or optionally substituted C_{1-6} aliphatic.

1651. The agent of any one of Embodiments 1-1646, wherein the C-terminal group is $-NH_2$.

1652. The agent of any one of Embodiments 1-1646, wherein the C-terminal group is −NHMe.

1653. The agent of any one of Embodiments 1-1646, wherein the C-terminal group is −NHEt.

1654. The agent of any one of Embodiments 1-1646, wherein the C-terminal group is Serol.

1655. The agent of any one of Embodiments 1-1646, wherein the C-terminal group is dAlaol.

1656. The agent of any one of the preceding Embodiments, wherein the peptide comprises a hydrocarbon staple.

1657. The agent of any one of the preceding Embodiments, wherein the peptide comprises a non-hydrocarbon staple.

1658. The agent of any one of the preceding Embodiments, wherein the peptide comprises a staple whose chain comprises −N(R')− or −O−C(O)−N(R')−.

1659. The agent of any one of the preceding Embodiments, wherein the peptide has the structure of:

$$R^N-[X]_p-[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}-[X]_{p'}-R^C,$$

or a salt thereof, wherein:

each X is independently an amino acid residue;

each p and p' is independently 0-10;

R^N is independently a peptide, an amino protecting group or R'–L^{RN}–;

R^C is independently a peptide, a carboxyl protecting group, –L^{RC}–R', –O–L^{RC}–R' or –N(R')–L^{RC}–R';

each of L^{RN} and L^{RC} is independently L;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with –$C(R')_2$–, –Cy–, –O–, –S–, –S–S–, –N(R')–, –C(O)–, –C(S)–, –C(NR')–, –C(O)N(R')–, –N(R')C(O)N(R')–, –N(R')C(O)O–, –S(O)–, –$S(O)_2$–, –$S(O)_2$N(R')–, –C(O)S–, or –C(O)O–;

each –Cy– is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;

each R' is independently –R, –C(O)R, –CO_2R, or –SO_2R;

each R is independently –H, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atom(s), 0-10 heteroatoms.

1660. The agent of any one of the preceding Embodiments, wherein p is 0.

1661. The agent of any one of the preceding Embodiments, wherein p is 1-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).

1662. The agent of any one of Embodiments 1-1659, wherein p is 1.

1663. The agent of any one of Embodiments 1-1659, wherein p is 2.

1664. The agent of any one of Embodiments 1-1659, wherein p is 3.

1665. The agent of any one of Embodiments 1-1659, wherein p is 4.

1666. The agent of any one of Embodiments 1-1659, wherein p is 5.

1667. The agent of any one of the preceding Embodiments, wherein p' is 0.

1668. The agent of any one of Embodiments 1-1666, wherein p' is 1-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).

1669. The agent of any one of Embodiments 1-1666, wherein p' is 2.

1670. The agent of any one of Embodiments 1-1666, wherein p' is 3.

1671. The agent of any one of Embodiments 1-1666, wherein p' is 4.

1672. The agent of any one of Embodiments 1-1666, wherein p' is 5.

1673. The agent of any one of the preceding Embodiments, wherein R^N is −C(O)R.

1674. The agent of any one of the preceding Embodiments, wherein R^N is Ac.

1675. The agent of any one of Embodiments 1-1672, wherein R^N is Ac, NPyroR3, 5hexenyl, 4pentenyl, Bua, C3a, Cpc, Cbc, CypCO, Bnc, CF3CO, 2PyCypCO, 4THPCO, Isobutyryl, Ts, 15PyraPy, 2PyBu, 4PymCO, 4PyPrpc, 3IAPAc, 4MePipzPrpC, MePipAc, MeImid4SO2, BzAm2OAllyl, Hex, 2PyzCO, 3Phc3, MeOPr, lithocholate, 2FPhc, PhC, MeSO2, Isovaleryl, EtHNCO, TzPyr, 8IAP, 3PydCO, 2PymCO, 5PymCO, 1Imidac, 2F2PyAc, 2IAPAc, 124TriPr, 6QuiAc, 3PyAc, 123TriAc, 1PyrazoleAc, 3PyPrpc, 5PymAc, 1PydoneAc, 124TriAc, Me2NAc, 8QuiSO2, mPEG4, mPEG8, mPEG16 or mPEG24.

1676. The agent of any one of Embodiments 1-1672, wherein R^N is 4pentenyl.

1677. The agent of any one of Embodiments 1-1672, wherein R^N is 5hexenyl.


1678. The agent of any one of Embodiments 1-1672, wherein R^N is BzAm2OAllyl.


1679. The agent of any one of the preceding Embodiments, wherein R^C is $-N(R')_2$.


1680. The agent of any one of the preceding Embodiments, wherein R^C is $-N(R)_2$.


1681. The agent of any one of Embodiments 1-1680, wherein R^C is $-NH_2$.

1682. The agent of any one of Embodiments 1-1680, wherein R^C is −NHEt.


1683. The agent of any one of Embodiments 1-1680, wherein R^C is −Alaol, wherein the amino group of −Alaol is bonded to the last −C(O)− of the peptide backbone (R^C is ).

1684. The agent of any one of Embodiments 1-1680, wherein R^C is −dAlaol, wherein the amino group of −dAlaol is bonded to the last −C(O)− of the peptide backbone (R^C is ).

1685. The agent of any one of Embodiments 1-1680, wherein R^C is −Prool, wherein the amino group of −Prool is bonded to the last −C(O)− of the peptide backbone (R^C is ).

1686. The agent of any one of Embodiments 1-1680, wherein R^C is −Throl, wherein the amino group of −Throl is bonded to the last −C(O)− of the peptide backbone (R^C is ).

1687. The agent of any one of Embodiments 1-1680, wherein R^C is −Serol, wherein the amino group of

−Serol is bonded to the last −C(O)− of the peptide backbone (R^C is ).

1688. The agent of any one of Embodiments 1-1678, wherein R^C is −OH.

1689. The agent of any one of the preceding Embodiments, wherein each amino acid residue is independently $-N(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)-$.

1690. The agent of Embodiment 1689, wherein R^{a1} is −H.

1691. The agent of any one of Embodiments 1-1689, wherein R^{a1} are taken together with R^{a2} or R^{a3} and their intervening atom(s) to form an optionally substituted 3-10 (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) membered ring having in addition to the intervening atom(s) 0-5 heteroatoms.

1692. The agent of any one of Embodiments 1-1689, wherein R^{a1} are taken together with R^{a2} or R^{a3} and their intervening atom(s) to form an optionally substituted 5-7 membered ring having in addition to the intervening atom(s) no heteroatoms.

1693. The agent of any one of the preceding Embodiments, wherein L^{a1} is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −Cy−, −C(O)N(R')−, or −N(R')C(O)O−.

1694. The agent of any one of Embodiments 1-1692, wherein L^{a1} is a covalent bond.

1695. The agent of any one of the preceding Embodiments, wherein R^{a2} is $-L^a-R'$ wherein, L^a is a covalent bond or a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −Cy−, −C(O)N(R')−, or −N(R')C(O)O−.

1696. The agent of any one of the preceding Embodiments, wherein R^{a3} is $-L^a-R'$ wherein, L^a is a covalent bond or a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −Cy−, −C(O)N(R')−, or −N(R')C(O)O−.

1697. The agent of any one of Embodiments 1-1695, wherein R^{a3} is −H.

1698. The agent of any one of Embodiments 1-1695, wherein R^{a3} is optionally substituted C_{1-6} aliphatic.

1699. The agent of any one of the preceding Embodiments, wherein L^{a2} is a bivalent C_{1-6} aliphatic wherein one or more methylene units are optionally and independently replaced with −O−, −S−, −N(R')−, −C(O)−, −Cy−, −C(O)N(R')−, or −N(R')C(O)O−.

1700. The agent of any one of Embodiments 1-1698, wherein L^{a2} is a covalent bond.

1701. The agent of any one of the preceding Embodiments, wherein the agent is or comprises a stapled peptide which comprises a stapled residue at a position referred to as position P.

1702. The agent of Embodiment 1701, wherein the stapled residue at position P is stapled with a residue at position P+7.

1703. The agent of any one of Embodiments 1701-1702, wherein the stapled residue at position P is stapled with a residue at position P-4.

1704. The agent of any one of Embodiments 1701-1702, wherein the stapled residue at position P is stapled

with a residue at position P-3.

1705. The agent of any one of Embodiments 1701-1702, wherein the stapled residue at position P is stapled with a residue at position P-2.

1706. The agent of any one of Embodiments 1701-1705, wherein the stapled peptide comprises a staple stapling two residues at positons P+6 and P+10.

1707. The agent of any one of Embodiments 1701-1705, wherein the stapled peptide comprises a staple stapling two residues at positons P+3 and P+10.

1708. The agent of any one of Embodiments 1701-1707, wherein there are three staples in the stapled peptide.

1709. The agent of any one of Embodiments 1701-1707, wherein the stapled peptide comprises a staple stapling two residues at positons P-1 and P+3.

1710. The agent of any one of Embodiments 1701-1707 and 1709, wherein there are four staples in the stapled peptide.

1711. The agent of any one of Embodiments 1701-1710, wherein the stapled peptide comprises an acidic amino acid residue at position P-2.

1712. The agent of any one of Embodiments 1701-1711, wherein the stapled peptide comprises an acidic amino acid residue at position P+1.

1713. The agent of any one of Embodiments 1701-1712, wherein the stapled peptide comprises an acidic amino acid residue at position P+2.

1714. The agent of any one of Embodiments 1701-1713, wherein the stapled peptide comprises a hydrophobic amino acid residue at position P+4.

1715. The agent of any one of Embodiments 1701-1714, wherein the stapled peptide comprises an aromatic amino acid residue at position P+5.

1716. The agent of any one of Embodiments 1701-1715, wherein the stapled peptide comprises an aromatic amino acid residue at position P+8.

1717. The agent of any one of Embodiments 1701-1716, wherein the stapled peptide comprises an aromatic amino acid residue at position P+9.

1718. The agent of any one of Embodiments 1701-1717, wherein position P is position 3.

1719. The agent of any one of Embodiments 1701-1717, wherein position P is position 4.

1720. The agent of any one of Embodiments 1701-1717, wherein position P is position 5.

1721. The agent of any one of Embodiments 1701-1717, wherein position P is position 6.

1722. The agent of any one of Embodiments 1701-1717, wherein position P is position 7.

1723. The agent of any one of the preceding Embodiments, wherein the peptide forms a structure that comprises a helix.

1724. The agent of any one of the preceding Embodiments, wherein the peptide binds to beta-catenin.

1725. The agent of any one of the preceding Embodiments, wherein the peptide binds to beta-catenin with a

EC50 of no more than about 2000 nM, or no more than about 1500 nM, or no more than about 1000 nM, or no more than about 500 nM, or no more than about 300 nM, or no more than about 200 nM, or no more than about 100 nM, or no more than about 75 nM, or no more than about 50 nM, or no more than about 25 nM, or no more than about 10 nM as measured by fluorescence polarization.

1726. The agent of any one of the preceding Embodiments, wherein the peptide can compete with TCF7, LEF1, TCF7L1, TCF7L2, Axin1, Axin2, or APC, or a fragment thereof, for beta-catenin binding.

1727. The agent of any one of the preceding Embodiments, wherein the peptide binds to a polypeptide whose sequence is or comprising SEQ ID NO: 2, or a fragment thereof:
SVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIIL ASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCL WTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEAL VRT (SEQ ID NO: 2).

1728. The agent of any one of the preceding Embodiments, wherein the peptide binds to beta-catenin and interacts with one or more residues that are or correspond to at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight or at least nine, or at least ten, or at least eleven, or at least twelve, or at least thirteen, or at least fourteen, or at least fifteen, or at least sixteen, or at least seventeen, or at least eighteen, or at least nineteen, or at least twenty of the following amino acid residues in SEQ ID NO: 1 at the indicated positions: A305, Y306, G307, N308, Q309, K312, R342, K345, V346, V349, Q375, R376, Q379, N380, L382, W383, R386, N387, D413, N415, V416, T418, and C419.

1729. The agent of any one of the preceding Embodiments, wherein the peptide binds to beta-catenin and interacts with one or more residues that are or correspond to at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight or at least nine, or at least ten, or at least eleven, or at least twelve, or at least thirteen, or at least fourteen, or at least fifteen, or at least sixteen, or at least seventeen, or at least eighteen, or at least nineteen, or at least twenty of the following amino acid residues in SEQ ID NO: 1 at the indicated positions: A305, Y306, G307, N308, Q309, K312, R342, K345, V346, V349, Q375, Q379, N380, L382, W383, R386, N387, D413, N415, V416, T418, and C419.

1730. The agent of any one of the preceding Embodiments, wherein the peptide binds to beta-catenin and interacts with one or more residues that are or correspond to at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight or at least nine, or at least ten, or at least eleven, or at least twelve, or at least thirteen, or at least fourteen, or at least fifteen, or at least sixteen, or at least seventeen, or at least eighteen, or at least nineteen, or at least twenty of the following amino acid residues in SEQ ID NO: 1 at the indicated positions: A305, Y306, G307, N308, Q309, K312, K345, V346, V349, Q379, N380, L382, W383, R386, N387, D413, N415, V416, T418, and C419.

1731. The agent of any one of the preceding Embodiments, wherein the peptide binds to beta-catenin and interacts with one or more residues that are or correspond to at least two, or at least three, or at least four, or at least five, or at least six, or at least seven of the following amino acid residues in SEQ ID NO: 1 at the

indicated positions: G307, K312, K345, W383, N387, D413, and N415.

1732. The agent of any one of the preceding Embodiments, wherein the agent interacts with Y306 of beta-catenin or an amino acid residue corresponding thereto.

1733. The agent of any one of the preceding Embodiments, wherein the agent interacts with G307 of beta-catenin or an amino acid residue corresponding thereto.

1734. The agent of any one of the preceding Embodiments, wherein the agent interacts with K312 of beta-catenin or an amino acid residue corresponding thereto.

1735. The agent of any one of the preceding Embodiments, wherein the agent interacts with K345 of beta-catenin or an amino acid residue corresponding thereto.

1736. The agent of any one of the preceding Embodiments, wherein the agent interacts with Q379 of beta-catenin or an amino acid residue corresponding thereto.

1737. The agent of any one of the preceding Embodiments, wherein the agent interacts with L382 of beta-catenin or an amino acid residue corresponding thereto.

1738. The agent of any one of the preceding Embodiments, wherein the agent interacts with W383 of beta-catenin or an amino acid residue corresponding thereto.

1739. The agent of any one of the preceding Embodiments, wherein the agent interacts with N387 of beta-catenin or an amino acid residue corresponding thereto.

1740. The agent of any one of the preceding Embodiments, wherein the agent interacts with D413 of beta-catenin or an amino acid residue corresponding thereto.

1741. The agent of any one of the preceding Embodiments, wherein the agent interacts with N415 of beta-catenin or an amino acid residue corresponding thereto.

1742. The agent of any one of the preceding Embodiments, wherein the agent interacts with V416 of beta-catenin or an amino acid residue corresponding thereto.

1743. The agent of any one of the preceding Embodiments, wherein the agent binds to beta-catenin at a site that is not an axin binding site.


1744. The agent of any one of the preceding Embodiments, wherein the agent binds to beta-catenin at a site that is not a Bcl9 binding site.

1745. The agent of any one of the preceding Embodiments, wherein the agent binds to beta-catenin at a site that is not a TCF binding site.


1746. The agent of any one of the preceding Embodiments, wherein the agent is the peptide.

1747. An agent having a structure selected from Table E2 or a salt thereof.


1748. An agent having a structure selected from Table E3 or a salt thereof.



1749. An agent, having the structure of or a salt thereof.




1750. An agent, having the structure of or a salt thereof.





1751. An agent, having the structure of or a salt thereof.

1752. An agent, having the structure of




or a salt thereof.


1753. An agent, having the structure of  or a salt thereof.

1754. An agent, having the structure of  or a salt thereof.


1755. An agent, having the structure of




or a salt thereof.




1756. An agent, having the structure of or a salt thereof.




1757. An agent, having the structure of or a salt thereof.



1758. An agent, having the structure of or a salt thereof.




1759. An agent, having the structure of or a salt thereof.




1760. An agent, having the structure of or a salt thereof.


1761. An agent, having the structure of



or a salt thereof.



1762. An agent, having the structure of or a salt thereof.



1763. An agent, having the structure of or a salt thereof.

1764. The agent of any one of the preceding Embodiments, wherein a double bond of a staple bonded to the first stapled amino acid that is bonded to a staple with a double bond, counting from the N-terminus, is *E*.

1765. The agent of any one of the preceding Embodiments, wherein a double bond of a staple bonded to the first stapled amino acid that is bonded to a staple with a double bond, counting from the N-terminus, is *Z*.

1766. The agent of any one of the preceding Embodiments, wherein a double bond of a staple bonded to the first stapled amino acid that is bonded to a staple with a double bond, counting from the C-terminus, is *E*.

1767. The agent of any one of the preceding Embodiments, wherein a double bond of a staple bonded to the first stapled amino acid that is bonded to a staple with a double bond, counting from the C-terminus, is *Z*.

1768. The agent of any one of the preceding Embodiments, wherein a double bond of a (i, i+7) staple is *E*.

1769. The agent of any one of the preceding Embodiments, wherein a double bond of a (i, i+7) staple is *Z*.

1770. The agent of any one of the preceding Embodiments, wherein a double bond of a (i, i+2), (i, i+3) or (i, i+4) staple is *E*.

1771. The agent of any one of the preceding Embodiments, wherein a double bond of a (i, i+2), (i, i+3) or (i, i+4) staple is *Z*.

1772. The agent of any one of Embodiments 1747-1763, wherein a double bond of a staple bonded to the first amino acid from the N-terminus is *Z*.

1773. The agent of any one of Embodiments 1747-1771, wherein a double bond of a staple bonded to the 11th amino acid from the N-terminus is *E*.

1774. The agent of any one of Embodiments 1747-1771, wherein a double bond of a staple bonded to the

11th amino acid from the N-terminus is *Z*.

1775. The agent of any one of the preceding Embodiments, wherein a carbon atom bonded to two staples (e.g., in B5) is of *R* configuration.

1776. The agent of any one of any one of the preceding Embodiments, wherein a carbon atom bonded to two staples (e.g., in B5) is of *S* configuration.

1777. An agent, having the structure of SP-1-1 or a salt thereof.

1778. An agent, having the structure of SP-1-2 or a salt thereof.

1779. An agent, having the structure of SP-1-3 or a salt thereof.

1780. An agent, having the structure of SP-1-4 or a salt thereof.

1781. An agent, having the structure of SP-1-5 or a salt thereof.

1782. An agent, having the structure of SP-1-6 or a salt thereof.

1783. An agent, having the structure of SP-1-7 or a salt thereof.

1784. An agent, having the structure of SP-1-8 or a salt thereof.

1785. An agent, having the structure of SP-2-1 or a salt thereof.

1786. An agent, having the structure of SP-2-2 or a salt thereof.

1787. An agent, having the structure of SP-2-3 or a salt thereof.

1788. An agent, having the structure of SP-2-4 or a salt thereof.

1789. An agent, having the structure of SP-2-5 or a salt thereof.

1790. An agent, having the structure of SP-2-6 or a salt thereof.

1791. An agent, having the structure of SP-2-7 or a salt thereof.

1792. An agent, having the structure of SP-2-8 or a salt thereof.

1793. An agent, having the structure of SP-3-1 or a salt thereof.

1794. An agent, having the structure of SP-3-2 or a salt thereof.

1795. An agent, having the structure of SP-4-1 or a salt thereof.

1796. An agent, having the structure of SP-4-2 or a salt thereof.

1797. An agent, having the structure of SP-4-3 or a salt thereof.

1798. An agent, having the structure of SP-4-4 or a salt thereof.

1799. An agent, having the structure of SP-4-5 or a salt thereof.

1800. An agent, having the structure of SP-4-6 or a salt thereof.

1801. An agent, having the structure of SP-4-7 or a salt thereof.

1802. An agent, having the structure of SP-4-8 or a salt thereof.

1803. An agent, having the structure of SP-5-1 or a salt thereof.

1804. An agent, having the structure of SP-5-2 or a salt thereof.

1805. An agent, having the structure of SP-5-3 or a salt thereof.

1806. An agent, having the structure of SP-5-4 or a salt thereof.

1807. An agent, having the structure of SP-5-5 or a salt thereof.

1808. An agent, having the structure of SP-5-6 or a salt thereof.
1809. An agent, having the structure of SP-5-7 or a salt thereof.
1810. An agent, having the structure of SP-5-8 or a salt thereof.
1811. An agent, having the structure of SP-6 or a salt thereof.
1812. An agent, having the structure of SP-7-1 or a salt thereof.
1813. An agent, having the structure of SP-7-2 or a salt thereof.
1814. An agent, having the structure of SP-7-3 or a salt thereof.
1815. An agent, having the structure of SP-7-4 or a salt thereof.
1816. An agent, having the structure of SP-7-5 or a salt thereof.
1817. An agent, having the structure of SP-7-6 or a salt thereof.
1818. An agent, having the structure of SP-7-7 or a salt thereof.
1819. An agent, having the structure of SP-7-8 or a salt thereof.
1820. An agent, having the structure of SP-8-1 or a salt thereof.
1821. An agent, having the structure of SP-8-2 or a salt thereof.
1822. An agent, having the structure of SP-8-3 or a salt thereof.
1823. An agent, having the structure of SP-8-4 or a salt thereof.
1824. An agent, having the structure of SP-8-5 or a salt thereof.
1825. An agent, having the structure of SP-8-6 or a salt thereof.
1826. An agent, having the structure of SP-8-7 or a salt thereof.
1827. An agent, having the structure of SP-8-8 or a salt thereof.
1828. An agent, having the structure of SP-9-1 or a salt thereof.
1829. An agent, having the structure of SP-9-2 or a salt thereof.
1830. An agent, having the structure of SP-9-3 or a salt thereof.
1831. An agent, having the structure of SP-9-4 or a salt thereof.
1832. An agent, having the structure of SP-9-5 or a salt thereof.
1833. An agent, having the structure of SP-9-6 or a salt thereof.
1834. An agent, having the structure of SP-9-7 or a salt thereof.
1835. An agent, having the structure of SP-9-8 or a salt thereof.
1836. An agent, having the structure of SP-10-1 or a salt thereof.
1837. An agent, having the structure of SP-10-2 or a salt thereof.
1838. An agent, having the structure of SP-10-3 or a salt thereof.
1839. An agent, having the structure of SP-10-4 or a salt thereof.
1840. An agent, having the structure of SP-10-5 or a salt thereof.
1841. An agent, having the structure of SP-10-6 or a salt thereof.
1842. An agent, having the structure of SP-10-7 or a salt thereof.
1843. An agent, having the structure of SP-10-8 or a salt thereof.


1844. An agent, having the structure of SP-11-1 or a salt thereof.
1845. An agent, having the structure of SP-11-2 or a salt thereof.
1846. An agent, having the structure of SP-11-3 or a salt thereof.
1847. An agent, having the structure of SP-11-4 or a salt thereof.
1848. An agent, having the structure of SP-11-5 or a salt thereof.
1849. An agent, having the structure of SP-11-6 or a salt thereof.
1850. An agent, having the structure of SP-11-7 or a salt thereof.
1851. An agent, having the structure of SP-11-8 or a salt thereof.
1852. An agent, having the structure of SP-12-1 or a salt thereof.
1853. An agent, having the structure of SP-12-2 or a salt thereof.
1854. An agent, having the structure of SP-12-3 or a salt thereof.
1855. An agent, having the structure of SP-12-4 or a salt thereof.
1856. An agent, having the structure of SP-12-5 or a salt thereof.
1857. An agent, having the structure of SP-12-6 or a salt thereof.
1858. An agent, having the structure of SP-12-7 or a salt thereof.
1859. An agent, having the structure of SP-12-8 or a salt thereof.
1860. An agent, having the structure of SP-13-1 or a salt thereof.
1861. An agent, having the structure of SP-13-2 or a salt thereof.
1862. An agent, having the structure of SP-13-3 or a salt thereof.
1863. An agent, having the structure of SP-13-4 or a salt thereof.
1864. An agent, having the structure of SP-13-5 or a salt thereof.
1865. An agent, having the structure of SP-13-6 or a salt thereof.
1866. An agent, having the structure of SP-13-7 or a salt thereof.
1867. An agent, having the structure of SP-13-8 or a salt thereof.
1868. An agent, having the structure of SP-14-1 or a salt thereof.
1869. An agent, having the structure of SP-14-2 or a salt thereof.
1870. An agent, having the structure of SP-14-3 or a salt thereof.
1871. An agent, having the structure of SP-14-4 or a salt thereof.
1872. An agent, having the structure of SP-14-5 or a salt thereof.
1873. An agent, having the structure of SP-14-6 or a salt thereof.
1874. An agent, having the structure of SP-14-7 or a salt thereof.
1875. An agent, having the structure of SP-14-8 or a salt thereof.
1876. An agent, having the structure of SP-15-1 or a salt thereof.
1877. An agent, having the structure of SP-15-2 or a salt thereof.
1878. An agent, having the structure of SP-15-3 or a salt thereof.
1879. An agent, having the structure of SP-15-4 or a salt thereof.

1880. An agent, having the structure of SP-15-5 or a salt thereof.


1881. An agent, having the structure of SP-15-6 or a salt thereof.

1882. An agent, having the structure of SP-15-7 or a salt thereof.


1883. An agent, having the structure of SP-15-8 or a salt thereof.



1884. An agent having the structure of or a salt thereof.



1885. An agent having the structure of or a salt thereof.



1886. An agent having the structure of or a salt thereof.

1887. The agent of any one of Embodiments 1884-1886, wherein the agent has the same retention time under a HPLC condition as I-66 prepared as described in Example 9, wherein the HPLC condition can

separate I-66 and I-67 prepared as described in Example 9.

1888. The agent of any one of Embodiments 1884-1886, wherein the agent shows a retention time of about 15.3 min under the following HPLC condition: Agilent Poroshell 120 EC-C18; 4.6 x 100 mm; solvent A = 0.1% TFA in water; solvent B = 0.075% TFA in acetonitrile; gradient is 10% B to 95% B over 30 min; detection is UV absorbance at 220 nM.

1889. The agent of any one of Embodiments 1884-1888, wherein the agent elutes in a single peak with I-66 prepared as described in Example 9 under the following HPLC condition: Agilent Poroshell 120 EC-C18; 4.6 x 100 mm; solvent A = 0.1% TFA in water; solvent B = 0.075% TFA in acetonitrile; gradient is 10% B to 95% B over 30 min; detection is UV absorbance at 220 nM.

1890. The agent of any one of Embodiments 1884-1889, characterized in that the agent shows ^{1}H NMR peaks that overlap with the peaks between about 5.1-5.7 in Figure 6 under the same or comparable conditions.

1891. The agent of any one of Embodiments 1884-1889, characterized in that the agent shows the same ^{1}H NMR peaks between about 5.1-5.7 as Figure 6 under the same or comparable conditions.

1892. The agent of any one of Embodiments 1884-1889, characterized in that in its ^{1}H NMR spectrum, the peaks corresponding to ^{1}H bonded to carbon atoms overlap with peaks in Figure 6 under the same or comparable conditions.

1893. The agent of any one of Embodiments 1884-1889, characterized in that its ^{1}H NMR spectrum overlaps with peaks in Figure 6 under the same or comparable conditions.

1894. The agent of any one of Embodiments 1884-1886, wherein the agent has the same retention time under a HPLC condition as I-67 prepared as described in Example 9, wherein the HPLC condition can separate I-66 and I-67 prepared as described in Example 9.

1895. The agent of any one of Embodiments 1884-1886, wherein the agent shows a retention time of about 16.2 min under the following HPLC condition: Agilent Poroshell 120 EC-C18; 4.6 x 100 mm; solvent A = 0.1% TFA in water; solvent B = 0.075% TFA in acetonitrile; gradient is 10% B to 95% B over 30 min; detection is UV absorbance at 220 nM.

1896. The agent of any one of Embodiments 1884-1888, wherein the agent elutes in a single peak with I-67 prepared as described in Example 9 under the following HPLC condition: Agilent Poroshell 120 EC-C18; 4.6 x 100 mm; solvent A = 0.1% TFA in water; solvent B = 0.075% TFA in acetonitrile; gradient is 10% B to 95% B over 30 min; detection is UV absorbance at 220 nM.

1897. The agent of any one of Embodiments 1884-1888 and 1894-1896, characterized in that the agent shows ^{1}H NMR peaks that do not overlap with the peaks between about 5.1-5.7 in Figure 6 under the same or comparable conditions.

1898. The agent of any one of Embodiments 1884-1888 and 1894-1896, characterized in that the agent does not show the same ^{1}H NMR peaks between about 5.1-5.7 as Figure 6 under the same or comparable conditions.

1899. The agent of any one of Embodiments 1884-1888 and 1894-1896, characterized in that in its ^{1}H NMR spectrum, the peaks corresponding to ^{1}H bonded to carbon atoms do not all overlap with peaks in Figure 6 under the same or comparable conditions.

1900. The agent of any one of Embodiments 1884-1889, characterized in that its ^{1}H NMR spectrum does not overlap with peaks in Figure 6 under the same or comparable conditions.

1901. A compound having the structure of formula PA:

$$N(R^{PA})(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)R^{PC},$$

PA

or a salt thereof, wherein:

R^{PA} is −H or an amino protecting group;

each of R^{a1} and R^{a3} is independently $-L^a-R'$;

R^{a2} is $-L^{aa}-C(O)R^{PS}$;

each of L^a, L^{a1} and L^{a2} is independently L;

$-C(O)R^{PS}$ is optionally protected or activated −COOH;

$-C(O)R^{PC}$ is optionally protected or activated −COOH;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, −Cy−, −O−, −S−, −S−S−, $-N(R')-$, −C(O)−, −C(S)−, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, −S(O)−, $-S(O)_2-$, $-S(O)_2N(R')-$, −C(O)S−, or −C(O)O−;

each −Cy− is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;

each R' is independently −R, −C(O)R, $-CO_2R$, or $-SO_2R$; and

each R is independently −H, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atom(s), 0-10 heteroatoms.

1902. The compound of Embodiment 1901, wherein R^{a2} is $-L^{aa}-C(O)R^{PS}$, wherein L^{aa} is L and L^{aa} comprises $-N(R')-$ or −Cy−.

1903. The compound of any one of the preceding Embodiments, wherein L^{a1} is a covalent bond.

1904. The compound of any one of the preceding Embodiments, wherein L^{a2} is a covalent bond.

1905. The compound of any one of the preceding Embodiments, wherein L^{aa} is an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$, wherein at least one methylene unit is replaced with $-Cy-$.

1906. The compound of any one of the preceding Embodiments, wherein L^{aa} is $-L^{am1}-Cy-L^{am2}-$, wherein each of L^{am1} and L^{am2} is independently L^{am}, wherein each L^{am} is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{10} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$.

1907. The compound of any one of the preceding Embodiments, wherein $-L^{am2}-$ is bonded to $-C(O)R^{PS}$.


1908. The compound of any one of the preceding Embodiments, wherein L^{am2} is a covalent bond.

1909. The compound of any one of the preceding Embodiments, wherein $-Cy-$ is an optionally substituted 4-7 membered ring having 0-3 heteroatoms.


1910. The compound of any one of the preceding Embodiments, wherein $-Cy-$ is an optionally substituted 6-10 membered aryl ring or is an optionally substituted 5-10 membered heteroaryl ring having 1-5 heteroatoms.

1911. The compound of any one of the preceding Embodiments, wherein $-Cy-$ is an optionally substituted phenyl ring.


1912. The compound of any one of the preceding Embodiments, wherein $-Cy-$ is optionally substituted




.

1913. The compound of any one of the preceding Embodiments, wherein $-Cy-$ is  .


1914. The compound of any one of Embodiments 1901-1908, wherein $-Cy-$ is optionally substituted




.

1915. The compound of any one of Embodiments 1901-1908, wherein $-Cy-$ is  .


1916. The compound of any one of Embodiments 1901-1908, wherein $-Cy-$ is optionally substituted


 .

1917. The compound of any one of Embodiments 1901-1908, wherein −Cy− is  .

1918. The compound of any one of Embodiments 1901-1910, wherein −Cy− is an optionally substituted 5-10 membered heteroaryl ring having 1-5 heteroatoms.

1919. The compound of any one of Embodiments 1901-1910, wherein −Cy− is an optionally substituted 5-membered heteroaryl ring having 1-5 heteroatoms.

1920. The compound of any one of Embodiments 1901-1910, wherein −Cy− is optionally substituted  .

1921. The compound of any one of Embodiments 1901-1910, wherein −Cy− is  .

1922. The compound of any one of the preceding Embodiments, wherein L^{aa} comprises −N(R')−.

1923. The compound of Embodiment 1922, wherein L^{aa} is $-L^{am1}-(NR')-L^{am2}-$, wherein each of L^{am1} and L^{am2} is independently L^{am}, wherein each L^{am} is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{10} aliphatic group wherein one or more methylene units of the aliphatic group are optionally and independently replaced with $-C(R')_2-$, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, $-S(O)_2-$, $-S(O)_2N(R')-$, −C(O)S−, or −C(O)O−.

1924. The compound of any one of Embodiments 1922-1923, wherein R' of the −N(R')− is taken together with R^{a3} and their intervening atoms to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atoms.

1925. The compound of any one of Embodiments 1922-1924, wherein −N(R')− is bonded to two carbon atoms which two carbon atoms do not form any double bonds with heteroatoms.

1926. The compound of any one of Embodiments 1922-1925, wherein $-L^{am2}-$ is bonded to $-C(O)R^{PS}$.

1927. The compound of any one of Embodiments 1922-1926, wherein L^{am1} is optionally substituted C_{1-4} alkylene.

1928. The compound of any one of Embodiments 1922-1926, wherein L^{am1} is optionally substituted $-(CH_2)m-$, wherein m is 1, 2, 3, or 4.

1929. The compound of any one of Embodiments 1922-1926, wherein L^{am1} is optionally substituted $-CH_2-$.

1930. The compound of any one of Embodiments 1922-1926, wherein L^{am1} is $-CH_2-$.

1931. The compound of any one of Embodiments 1922-1930, wherein L^{am2} is optionally substituted linear

C_{1-2} alkylene.

1932. The compound of any one of Embodiments 1922-1930, wherein L^{am2} is $-[C(R')_2]n$, wherein n is 1 or 2.

1933. The compound of any one of Embodiments 1922-1930, wherein L^{am2} is $-[CHR']n$, wherein n is 1 or 2.

1934. The compound of any one of Embodiments 1932-1933, wherein each R' is independently −H or optionally substituted C_{1-6} alkyl.

1935. The compound of any one of Embodiments 1922-1930, wherein L^{am2} is optionally substituted $-CH_2-$.

1936. The compound of any one of Embodiments 1922-1935, wherein L^{am2} is $-CH_2-$.

1937. The compound of any one of Embodiments 1922-1936, wherein L^{aa} comprises $-N(R')-$, wherein R' of the $-N(R')-$ is $-R^{NR}$, wherein R^{NR} is R.

1938. The compound of any one of Embodiments 1922-1936, wherein L^{aa} comprises $-N(R')-$, wherein R' of the $-N(R')-$ is $-CH_2-R^{NR}$, wherein R^{NR} is R.

1939. The compound of any one of Embodiments 1922-1936, wherein L^{aa} comprises $-N(R')-$, wherein R' of the $-N(R')-$ is $-C(O)R^{NR}$, wherein R^{NR} is R.

1940. The compound of any one of Embodiments 1922-1936, wherein L^{aa} comprises $-N(R')-$, wherein R' of the $-N(R')-$ is $-SO_2R^{NR}$, wherein R^{NR} is R.

1941. The compound of any one of Embodiments 1937-1940, wherein R^{NR} is optionally substituted C_{1-6} aliphatic or heteroaliphatic having 1-4 heteroatoms.

1942. The compound of any one of Embodiments 1937-1941, wherein R^{NR} is C_{1-7} alkyl or heteroalkyl having 1-4 heteroatoms, wherein the alkyl or heteroalkyl is optionally substituted with one or more groups independently selected from halogen, a C_{5-6} aromatic ring having 0-4 heteroatoms, and an optionally substituted 3-10 membered cycloalkyl or heteroalkyl ring having 1-4 heteroatoms.

1943. The compound of any one of Embodiments 1937-1942, wherein R^{NR} is $-CF_3$.


1944. The compound of any one of Embodiments 1937-1941, wherein L^{am2} is or comprises $-C(R')_2-$ wherein the R' group and R' in $-N(R')-$ of L^{aa} are taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atom(s), 0-10 heteroatoms.

1945. The compound of any one of Embodiments 1901-1905, wherein L^{aa} is optionally substituted C_{1-4} alkylene.

1946. The compound of Embodiment 1945, wherein L^{aa} is optionally substituted $-CH_2-CH_2-$.

1947. The compound of Embodiment 1945, wherein L^{aa} is optionally substituted $-CH_2-$.

1948. The compound of Embodiment 1901, having the structure of:



or a salt thereof, wherein:

each of m and n is independently 1, 2, 3, or 4;

L^{RN} is L;

R^{RN} is R; and

R^{a5} is R'.

1949. The compound of Embodiment 1948, wherein m is 1.

1950. The compound of any one of Embodiments 1948-1949, wherein L^{RN} is $-CH_2-$, $-CO-$, or $-SO_2-$.

1951. The compound of any one of Embodiments 1948-1949, wherein L^{RN} is $-CH_2-$.

1952. The compound of any one of Embodiments 1948-1951, wherein R^{NR} is C_{1-7} alkyl or heteroalkyl having 1-4 heteroatoms, wherein the alkyl or heteroalkyl is optionally substituted with one or more groups independently selected from halogen, a C_{5-6} aromatic ring having 0-4 heteroatoms, and an optionally substituted 3-10 membered cycloalkyl or heteroalkyl ring having 1-4 heteroatoms.

1953. The compound of any one of Embodiments 1948-1952, wherein one or more R^{a5} are independently $-H$.

1954. The compound of any one of Embodiments 1948-1953, wherein one or more R^{a5} are independently optionally substituted C_{1-6} alkyl.

1955. The compound of any one of Embodiments 1948-1953, wherein $-L^{RN}-R^{RN}$ is R, and is taken together with a R^{a5} and their intervening atom(s) to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atom(s), 0-10 heteroatoms.

1956. The compound of Embodiment 1951, wherein R^{RN} is methyl.

1957. The compound of Embodiment 1951, wherein R^{RN} is $-CF_3$.

1958. The compound of any one of the preceding Embodiments, wherein R^{a1} is $-H$.

1959. The compound of any one of Embodiments 1901-1944, wherein R^{a1} is optionally substituted C_{1-6} alkyl.


1960. The compound of any one of the preceding Embodiments, wherein $-C(O)R^{PC}$ is a protected carboxylic acid group.

1961. The compound of any one of Embodiments 1901-1959, wherein $-C(O)R^{PC}$ is an activated carboxylic acid group.

1962. The compound of any one of Embodiments 1901-1959, wherein $-C(O)R^{PC}$ is $-C(O)OR'$.

1963. The compound of Embodiment 1962, wherein R' is −H.

1964. The compound of Embodiment 1962, wherein R' is pentafluorophenyl.

1965. The compound of Embodiment 1962, wherein R' is  .

1966. The compound of any one of the preceding Embodiments, wherein $-C(O)R^{PS}$ is $-C(O)OR'$.

1967. The compound of Embodiment 1966, wherein R' is −H.


1968. The compound of Embodiment 1966, wherein R' is optionally substituted C_{1-6} aliphatic.

1969. The compound of Embodiment 1966, wherein R' is t-butyl.

1970. The compound of Embodiment 1966, wherein R' is benzyl.


1971. The compound of Embodiment 1966, wherein R' is allyl.

1972. The compound of Embodiment 1901, wherein the compound has the structure of



or a salt thereof, wherein Ring A is an optionally substituted 3-7 membered saturated, partially unsaturated or aromatic ring.

1973. The compound of Embodiment 1901, wherein the compound has the structure of




or a salt thereof, wherein Ring A is an optionally substituted 3-7 membered saturated, partially unsaturated or aromatic ring.

1974. The compound of any one of Embodiment 1972 or 1973, wherein −C(O)OtBu is bonded to a chiral carbon atom having a *R* configuration.

1975. The compound of any one of Embodiment 1972 or 1973, wherein −C(O)OtBu is bonded to a chiral carbon atom having a *S* configuration.

1976. The compound of Embodiment 1901, wherein the compound has the structure of




or a salt thereof, wherein:

Ring A is an optionally substituted 3-10 membered ring;

n is 0, 1, or 2;

m is 0, 1, 2, or 3.

1977. The compound of Embodiment 1901, wherein the compound has the structure of



or a salt thereof, wherein:

Ring A is an optionally substituted 3-10 membered ring;

n is 0, 1, or 2;

m is 0, 1, 2, or 3.


1978. The compound of any one of Embodiments 1976-1977, wherein Ring A is an optionally substituted 4-10 membered ring.

1979. The compound of any one of Embodiments 1976-1978, wherein n is 1.

1980. The compound of any one of Embodiments 1976-1979, wherein Ring A is bonded to $-(CH_2)n-$ at a chiral carbon which is *R*.

1981. The compound of any one of Embodiments 1976-1979, wherein Ring A is bonded to $-(CH_2)n-$ at a chiral carbon which is *S*.

1982. The compound of Embodiment 1901, wherein the compound has the structure of




or a salt thereof, wherein:

Ring A is an optionally substituted 3-10 membered ring;

n is 0, 1, or 2;

m is 0, 1, 2, or 3.

1983. The compound of Embodiment 1901, wherein the compound has the structure of




or a salt thereof, wherein:

Ring A is an optionally substituted 3-10 membered ring;

n is 0, 1, or 2;

m is 0, 1, 2, or 3.



1984. The compound of Embodiment 1901, wherein the compound has the structure of or a salt thereof, wherein:

Ring A is an optionally substituted 3-10 membered ring;

n is 0, 1, or 2;

m is 0, 1, 2, or 3.

1985. The compound of any one of Embodiments 1976-1984, wherein n is 1.

1986. The compound of any one of Embodiments 1976-1985, wherein m is 0.

1987. The compound of any one of Embodiments 1976-1985, wherein m is 1, 2 or 3.

1988. The compound of any one of Embodiments 1976-1985, wherein m is 1.

1989. The compound of any one of Embodiments 1976-1988, wherein Ring A is or comprises an optionally substituted saturated monocyclic ring.

1990. The compound of any one of Embodiments 1976-1989, wherein Ring A is or comprises an optionally substituted partially unsaturated monocyclic ring.

1991. The compound of any one of Embodiments 1976-1990, wherein Ring A is or comprises an optionally substituted aromatic monocyclic ring.

1992. The compound of any one of Embodiments 1982-1988, wherein Ring A is optionally substituted phenyl.

1993. The compound of any one of Embodiments 1976-1988, wherein Ring A is optionally substituted 5-6

membered heteroaryl having 1-3 heteroatoms.

1994. The compound of any one of Embodiments 1976-1988, wherein Ring A is optionally substituted 5-6 membered heteroaryl having 1-3 heteroatoms, wherein at least one heteroatom is nitrogen.

1995. The compound of Embodiment 1994, wherein Ring A is an optionally substituted triazole ring.

1996. The compound of any one of Embodiments 1976-1988, wherein Ring A is an optionally substituted 8-10 membered bicyclic ring having 1-6 heteroatoms.

1997. The compound of any one of Embodiments 1976-1979, wherein Ring A is an optionally substituted 8-10 membered bicyclic aromatic ring having 1-6 heteroatoms, wherein each monocyclic unit is independently an optionally 5-6 membered aromatic ring having 0-3 heteroatoms.

1998. The compound of any one of Embodiments 1993-1997, wherein Ring A is bonded to $-(CH_2)n-$ at a carbon atom.

1999. The compound of any one of Embodiments 1993-1997, wherein Ring A is bonded to $-(CH_2)n-$ at a nitrogen atom.

2000. The compound of any one of the preceding Embodiments, wherein Ring A or −Cy− in L^{aa} is optionally substituted, and each substitute is independently selected from halogen, −R, $-CF_3$, $-N(R)_2$, −CN, and −OR, wherein each R is independently C_{1-6} aliphatic optionally substituted with one or more −F.


2001. The compound of any one of the preceding Embodiments, wherein Ring A or −Cy− in L^{aa} is optionally substituted, and each substitute is independently selected from halogen, C_{1-5} linear, branched or cyclic alkyl, −OR wherein R is C_{1-4} linear, branched or cyclic alkyl, fluorinated alkyl, $-N(R)_2$ wherein each R is independently C_{1-6} linear, branched or cyclic alkyl, or −CN.

2002. The compound of any one of the preceding Embodiments, wherein R^{a3} is −H or optionally substituted C_{1-6} aliphatic.

2003. The compound of any one of the preceding Embodiments, wherein R^{a3} is −H.

2004. The compound of any one of Embodiments 1901-2002, wherein R^{a3} is methyl.

2005. A compound having the structure of:



,


or a salt thereof, wherein:

R^{PA} is −H or an amino protecting group;

$-C(O)R^{PS}$ is optionally protected or activated −COOH; and

$-C(O)R^{PC}$ is optionally protected or activated −COOH.

2006. A compound having the structure of:



or a salt thereof, wherein:


R^{PA} is −H or an amino protecting group;

$-C(O)R^{PS}$ is optionally protected or activated −COOH; and

$-C(O)R^{PC}$ is optionally protected or activated −COOH.

2007. The compound of any one of the preceding Embodiments, wherein R^{PA} is an amino protecting group suitable for peptide synthesis.

2008. The compound of any one of the preceding Embodiments, wherein R^{PA} is −C(O)−O−R.

2009. The compound of Embodiment 2008, wherein R is optionally substituted  .

2010. The compound of any one of the preceding Embodiments, wherein R^{PA} is −Fmoc.

2011. The compound of any one of the preceding Embodiments, wherein R^{PA} is −Cbz.

2012. The compound of any one of the preceding Embodiments, wherein R^{PA} is −Boc.

2013. The compound of any one of the preceding Embodiments, wherein R^{PS} is a protecting group orthogonal to R^{PA}.

2014. The compound of any one of the preceding Embodiments, wherein R^{PS} is a protecting group orthogonal to R^{PC}.

2015. The compound of any one of the preceding Embodiments, wherein R^{PS} is compatible with peptide synthesis.

2016. The compound of any one of the preceding Embodiments, wherein $-C(O)R^{PS}$ is −C(O)OR'.

2017. The compound of Embodiment 1966, wherein R' is −H.

2018. The compound of Embodiment 1966, wherein R' is optionally substituted C_{1-6} aliphatic.

2019. The compound of Embodiment 1966, wherein R' is t-butyl.

2020. The compound of Embodiment 1966, wherein R' is benzyl.

2021. The compound of Embodiment 1966, wherein R' is allyl.

2022. The compound of any one of Embodiments 1901-2015, wherein $-C(O)R^{PS}$ is −C(O)S−L−R'.

2023. The compound of Embodiment 2022, wherein L is optionally substituted $-CH_2-$.

2024. The compound of Embodiment 2022, wherein L is $-CH_2-$.

2025. The compound of any one of Embodiments 2022-2024, wherein R' is optionally substituted phenyl.

2026. The compound of any one of Embodiments 2022-2024, wherein R' is 2, 4, 6-trimethoxyphenyl.

2027. The compound of Embodiment 2022, wherein R^{PS} is −SH.


2028. The compound of any one of the preceding Embodiments, wherein $-C(O)R^{PC}$ is a protected carboxylic acid group.

2029. The compound of any one of Embodiments 1901-2026, wherein $-C(O)R^{PC}$ is an activated carboxylic acid group.

2030. The compound of any one of Embodiments 1901-2026, wherein $-C(O)R^{PC}$ is −C(O)OR'.


2031. The compound of Embodiment 2030, wherein R' is −H.


2032. The compound of Embodiment 2030, wherein R' is pentafluorophenyl.


2033. The compound of Embodiment 2030, wherein R' is  .


2034. The compound of any one of the preceding Embodiments, wherein each heteroatom is independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.


2035. The compound of any one of the preceding Embodiments, wherein each heteroatom is independently selected from oxygen, nitrogen, and sulfur.


2036. A compound, wherein the compound is  or a salt thereof.


2037. A compound, wherein the compound is  or a salt thereof.


2038. A compound, wherein the compound is  or a salt thereof.


2039. A compound, wherein the compound is  or a salt thereof.


2040. A compound, wherein the compound is  or a salt thereof.


2041. A compound, wherein the compound is  or a salt thereof.


2042. A compound, wherein the compound is  or a salt thereof.


2043. A compound, wherein the compound is  or a salt thereof.


2044. A compound, wherein the compound is  or a salt thereof.


2045. A compound, wherein the compound is  or a salt thereof.


2046. A compound, wherein the compound is  or a salt thereof.


2047. A compound, wherein the compound is  or a salt thereof.


2048. A compound, wherein the compound is  or a salt thereof.


2049. A compound, wherein the compound is  or a salt thereof.


2050. A compound, wherein the compound is  or a salt thereof.

2051. A compound, wherein the compound is  or a salt thereof.

2052. A compound, wherein the compound is  or a salt thereof.

2053. A compound, wherein the compound is  or a salt thereof.


2054. A compound, wherein the compound is  or a salt thereof.


2055. A compound, wherein the compound is  or a salt thereof.


2056. The compound of any one of the preceding Embodiments, wherein the compound has a purity of at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.


2057. A compound, comprising a residue of any one of the preceding Embodiments.


2058. A compound, comprising a residue of Table A-IV.


2059. A compound, comprising a residue having the structure of  or a salt form thereof.


2060. A compound, comprising a residue having the structure of  or a salt form


2061. A compound, comprising a residue having the structure of  or a salt form thereof.


2062. A compound, comprising a residue having the structure of  or a salt form thereof.


2063. A compound, comprising a residue having the structure of  or a salt form thereof.

2064. A compound, comprising a residue having the structure of  or a salt form thereof.

2065. A compound, comprising a residue having the structure of  or a salt form thereof.

2066. A compound, comprising a residue having the structure of  or a salt form thereof.

2067. A compound, comprising a residue having the structure of  or a salt form thereof.

2068. A compound, comprising a residue having the structure of  or a salt form thereof.

2069. The compound of any one of Embodiments 2057-2068, wherein the compound is or comprise a peptide.

2070. The compound of any one of Embodiments 2057-2068, wherein the compound is an agent of any one of the preceding Embodiments.

2071. The compound of any one of Embodiments 2057-2068, wherein the compound is or comprise a stapled peptide.

2072. A method for preparing a compound of any one of Embodiments 2057-2071, comprising utilization of a compound of any one of the Embodiments 1901-2056.

2073. An agent, which agent comprises a residue of an amino acid of any one of the preceding Embodiments.

2074. The agent of any one of Embodiments 1-1900, wherein the agent comprises a residue of an amino acid of any one of the preceding Embodiments.

2075. The agent of any one of the preceding Embodiments, wherein each olefin double bond in a staple is independently and optionally converted into a single bond.

2076. The agent of any one of the preceding Embodiments, wherein each olefin double bond in a staple is converted into a single bond.

2077. The agent of any one of the preceding Embodiments, wherein each olefin double bond is converted into a single bond.

2078. The agent of any one of the preceding Embodiments, wherein each olefin double bond is independently and optionally converted into −CHR'−CHR'−, wherein each R is independently −H, −R, −OR, −OH, −$N(R)_2$, or −SR.

2079. The agent of any one of the preceding Embodiments, wherein each olefin double bond is converted into −CHR'−CHR'−, wherein each R is independently −H, −R, −OR, −OH, −$N(R)_2$, or −SR.

2080. The agent of any one of the preceding Embodiments, wherein each olefin double bond is independently and optionally converted into optionally substituted −CH_2−CH_2−.

2081. The agent of any one of the preceding Embodiments, wherein each olefin double bond is converted into −CH_2−CH_2−.

2082. The agent of any one of the preceding Embodiments, having a diastereopurity of about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more.

2083. The agent of any one of the preceding Embodiments, having a diastereopurity of about 90% or more.

2084. The agent of any one of the preceding Embodiments, having a diastereopurity of about 95% or more.

2085. The agent of any one of the preceding Embodiments, having a diastereopurity of about 98% or more.

2086. The agent of any one of the preceding Embodiments, having a purity of about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more.

2087. The agent of any one of the preceding Embodiments, having a purity of about 90% or more.

2088. The agent of any one of the preceding Embodiments, having a purity of about 95% or more.

2089. The agent of any one of the preceding Embodiments, having a purity of about 98% or more.

2090. A composition comprising an agent of any one of the preceding Embodiments or a salt thereof.

2091. A pharmaceutical composition, comprising or delivering an agent or amino acid of any one of the preceding Embodiments, and a pharmaceutically acceptable carrier.

2092. A composition selected from Table E2.

2093. A pharmaceutical composition, comprising or delivering one or more or all peptide agents in a composition selected from Table E2 and a pharmaceutically acceptable carrier.

2094. A composition selected from Table E3.

2095. A pharmaceutical composition, comprising or delivering one or more or all peptide agents in a composition selected from Table E3 and a pharmaceutically acceptable carrier.

2096. The composition of any one of the preceding Embodiments, comprising an agent comprising one or more staples each independently comprises one or more olefin double bond.

2097. The composition of any one of the preceding Embodiments, wherein the ratio of the two stereoisomers of an olefin double bond in a staple is about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 30:1, 40:1, 50:1 or more.

2098. The composition of Embodiment 2097, wherein the ratio is about 5:1 or more.

2099. The composition of Embodiment 2097, wherein the ratio is about 10:1 or more.

2100. The composition of Embodiment 2097, wherein the ratio is about 20:1 or more.

2101. The composition of Embodiment 2097, wherein the ratio is about 50:1 or more.

2102. The composition of any one of the preceding Embodiments, wherein each ratios of the two stereoisomers of each olefin double bond in each staple are independently about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 30:1, 40:1, 50:1 or more.

2103. The composition of Embodiment 2102, wherein each ratio is independently about 5:1 or more.

2104. The composition of Embodiment 2102, wherein each ratio is independently about 10:1 or more.

2105. The composition of Embodiment 2102, wherein each ratio is independently about 20:1 or more.

2106. The composition of Embodiment 2102, wherein each ratio is independently about 50:1 or more.

2107. The composition of any one of the preceding Embodiments, wherein a selectivity is favoring an *E* configuration.

2108. The composition of any one of the preceding Embodiments, wherein a selectivity is favoring a *Z* configuration.

2109. A method for preparing an agent or composition of any one of the preceding Embodiments,

comprising incorporating a residue of an amino acid of any one of the preceding Embodiments.

2110. The method of Embodiment 2109, comprising preparing a compound comprising one or more amino acid residues comprising terminal olefins, wherein one or more or all of such amino acid residues are not stapled.

2111. A method, comprising

a) preparing a first compound comprising two moieties each of which independently comprises an olefin double bond;

b) providing a second compound by stapling the two moieties by olefin metathesis of an olefin double bond of one moiety with an olefin double bond of the other to form a first-formed staple;

c) add one or more additional moieties to the second compound to provide a third compound which comprising two moieties each of which independently comprises an olefin double bond; and

d) providing a fourth compound by stapling the two moieties in the third compound by olefin metathesis of an olefin double bond of one moiety with an olefin double bond of the other to form a second-formed staple.

2112. The method of Embodiment 2111, wherein each moiety is independently an amino acid residue comprising a terminal olefin of any one of the preceding Embodiments.

2113. The method of any one of the preceding Embodiments, wherein there are two olefin double bonds in one moiety of the first compound.

2114. The method of any one of the preceding Embodiments, wherein a moiety in a first compound is an amino acid residue comprising two olefin double bond.

2115. The method of any one of the preceding Embodiments, wherein one moiety in a first compound is B5.

2116. The method of any one of Embodiments, wherein the two moieties of the first compound is independently X^4 and X^{11}.

2117. The method of any one of the preceding Embodiments, wherein a first-formed staple is a (i, i+7) staple.

2118. The method of any one of the preceding Embodiments, wherein the first compound comprises $-X^4X^5X^6X^7X^8X^9X^{10}X^{11}-$.

2119. The method of any one of the preceding Embodiments, wherein the first compound comprises $-X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}-$.

2120. The method of any one of the preceding Embodiments, wherein the first compound comprises a staple.

2121. The method of Embodiment 2120, wherein the staple is a (i, i+4) staple.

2122. The method of Embodiment 2120, wherein the staple is between X^{10} and X^{14}.

2123. The method any one of the preceding Embodiments, wherein an olefin double bond in the third compound is present in the first compound.

2124. The method of any one of the preceding Embodiments, wherein one and only one amino acid residue comprises an olefin double bond is added to the second compound.

2125. The method of any one of the preceding Embodiments, wherein the third compound is or comprises $-X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}-$.

2126. The method of any one of the preceding Embodiments, wherein the third compound is or comprises $-X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}-$.

2127. The method of any one of the preceding Embodiments, wherein the first- and second-formed staples are bonded to the same amino acid residue.

2128. The method of any one of the preceding Embodiments, wherein the first- and second-formed staples are bonded to the same atom.

2129. The method of any one of the preceding Embodiments, wherein the second-formed staple is a (i, i+2), (i, i+3) or (i, i+4) staple.

2130. The method of any one of the preceding Embodiments, wherein the two moieties in the third compound is independently X^1 and X^4.

2131. The method of any one of the preceding Embodiments, wherein the first-formed staple is formed with *E* selectivity.

2132. The method of any one of the preceding Embodiments, wherein the second-formed staple is formed with *Z* selectivity.

2133. The method of any one of Embodiments 2111-2132, wherein an agent of any one of the preceding Embodiments is prepared.

2134. The method of any one of the preceding Embodiments, comprising preparing a compound having an amino acid sequence of Table E2 or Table E3 but one or more or all amino acid residues comprising terminal olefins are not stapled.

2135. The method of any one of Embodiments 2109-2134, comprising stapling two or more amino acid residues each independently comprising one or more olefins to form one or more staples each independently comprising a carbon-carbon double bond.

2136. The method of Embodiment 2135, wherein the stapling is performed via olefin metathesis of terminal olefins.

2137. The method of any one of Embodiments 2109-2136, wherein a double bond in a staple is formed with about 1.1:1, 1.2:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1 or more stereoselectivity.

2138. The method of Embodiment 2137, wherein the selectivity is about 1.5:1 or more.

2139. The method of Embodiment 2137, wherein the selectivity is about 2:1 or more.

2140. The method of Embodiment 2137, wherein the selectivity is about 3:1 or more.

2141. The method of Embodiment 2137, wherein the selectivity is about 4:1 or more.

2142. The method of Embodiment 2137, wherein the selectivity is about 9:1 or more.

2143. The method of Embodiment 2137, wherein the selectivity is about 10:1 or more

2144. The method of Embodiment 2137-2143, wherein the staple is a first-formed staple.

2145. The method of any one of Embodiments 2109-2144, wherein each double bond in each staple is independently formed with about 1.1:1, 1.2:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1 or more stereoselectivity.

2146. The method of Embodiment 2145, wherein the selectivity is independently about 1.5:1 or more.

2147. The method of Embodiment 2145, wherein the selectivity is independently about 2:1 or more.

2148. The method of Embodiment 2145, wherein the selectivity is independently about 3:1 or more.

2149. The method of Embodiment 2145, wherein the selectivity is independently about 4:1 or more.

2150. The method of Embodiment 2145, wherein the selectivity is independently about 9:1 or more.

2151. The method of Embodiment 2145, wherein the selectivity is independently about 10:1 or more.

2152. The method of any one of Embodiments 2137-2151, wherein a selectivity is favoring an *E* isomer.

2153. The method of any one of Embodiments 2137-2151, wherein a selectivity is favoring a *Z* isomer.

2154. The method of any one of Embodiments 2109-2153, comprising purifying a composition to enrich one or more *E*/Z stereoisomers.

2155. The method of Embodiment 2154, wherein one configuration of an olefin double bond in a staple is enriched.

2156. The method of Embodiment 2155, wherein the ratio after enrichment is about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 30:1, 40:1, 50:1 or more.

2157. The method of Embodiment 2156, wherein the ratio is about 5:1 or more.

2158. The method of Embodiment 2156, wherein the ratio is about 10:1 or more.

2159. The method of Embodiment 2156, wherein the ratio is about 20:1 or more.

2160. The method of Embodiment 2156, wherein the ratio is about 50:1 or more.

2161. The method of Embodiment 2154, wherein configuration of each olefin double bond in each staple is independently enriched.

2162. The method of Embodiment 2161, wherein the ratio for each olefin double bond after enrichment is independently about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 30:1, 40:1, 50:1 or more.

2163. The method of Embodiment 2162, wherein each ratio is independently about 5:1 or more.

2164. The method of Embodiment 2162, wherein each ratio is independently about 10:1 or more.

2165. The method of Embodiment 2162, wherein each ratio is independently about 20:1 or more.

2166. The method of Embodiment 2162, wherein each ratio is independently about 50:1 or more.

2167. The method of any one of Embodiments 2154-2166, wherein a selectivity is favoring an *E* configuration.

2168. The method of any one of Embodiments 2154-2167, wherein a selectivity is favoring a *Z* configuration.

2169. The method of any one of the preceding Embodiments, wherein a chiral center is formed with about or at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% stereoselectivity.

2170. The method of any one of the preceding Embodiments, wherein a chiral center is formed with about or at least about 80% or more stereoselectivity.

2171. The method of any one of the preceding Embodiments, wherein a chiral center is formed with about or at least about 85% or more stereoselectivity.

2172. The method of any one of the preceding Embodiments, wherein a chiral center is formed with about or at least about 90% or more stereoselectivity.

2173. The method of any one of the preceding Embodiments, wherein a chiral center is formed with about or at least about 95% or more stereoselectivity.

2174. The method of any one of Embodiments 2169-2173, wherein the chiral center is bonded to two staples.

2175. The method of any one of Embodiments 2109-2174, comprising modifying a double bond in a staple.

2176. The method of any one of Embodiments 2109-2174, comprising hydrogenating a double bond in a staple.

2177. The method of any one of Embodiments 2109-2174, comprising hydrogenating each carbon-carbon double bond in each staple.

2178. The method of any one of the preceding Embodiments, comprising purifying a composition by chromatography and providing one or more compositions based on peak(s) observed during purification.

2179. The method of any one of the preceding Embodiments, comprising purifying a composition by liquid chromatography and providing one or more compositions based on peak(s) observed during purification.

2180. The method of any one of Embodiments 2178-2179, wherein the chromatography purification utilizes the same or similar conditions with respect to separation of peaks with the correct mass as those described for Table E2 or Table E3.

2181. The method of any one of Embodiments 2178-2180, wherein the chromatography purification utilizes the same or similar conditions with respect to elution order of peaks with the correct mass as those described for Table E2 or Table E3.

2182. The method of any one of the preceding Embodiments, comprising collecting the first peak with the correct mass as a product composition.

2183. The method of any one of the preceding Embodiments, comprising collecting the second peak with the correct mass as a product composition.

2184. The method of any one of the preceding Embodiments, comprising collecting the third peak with the correct mass as a product composition.

2185. The method of any one of the preceding Embodiments, comprising collecting the fourth peak with the correct mass as a product composition.

2186. The method of any one of the preceding Embodiments, comprising collecting each peak with the correct mass as a product composition.

2187. The method of any one of the preceding Embodiments, wherein the peak area of a product

composition is about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%,80%, 90% or more of the total peak area of all peak(s) with the correct mass.

2188. The method of Embodiment 2187, where the percentage is 10% or more.

2189. The method of Embodiment 2187, where the percentage is 20% or more.

2190. The method of Embodiment 2187, where the percentage is 50% or more.

2191. The method of Embodiment 2187, where the percentage is 60% or more.

2192. The method of any one of the preceding Embodiments, wherein the peak area of each product composition is about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%,80%, 90% or more of the total peak area of all peak(s) with the correct mass.

2193. The method of Embodiment 2192, wherein each percentage is independently 10% or more.

2194. The method of Embodiment 2192, wherein each percentage is independently 20% or more.

2195. The method of Embodiment 2192, wherein each percentage is independently 50% or more.

2196. The method of Embodiment 2192, wherein each percentage is independently 60% or more.

2197. The method of any one of Embodiments 2187-2196, wherein the peak is from MS detection.

2198. The method of any one of Embodiments 2187-2197, wherein the peak is from UV detection.

2199. The method of any one of Embodiments 2187-2197, wherein the peak is from UV detection at 220 nm.

2200. A composition produced from a method of any one of the preceding Embodiments.

2201. A pharmaceutical composition comprising or delivering a composition of Embodiment 2200 and a pharmaceutically acceptable carrier.

2202. A method for modulating beta-catenin interaction with a partner in a system, comprising contacting beta-catenin with an agent or composition of any one of the preceding Embodiments.

2203. A method for modulating beta-catenin interaction with a partner in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding Embodiments.

2204. The method of nay one of Embodiments 2202-2203, wherein the partner is TCF7, LEF1, TCF7L1, TCF7L2, Axin1, Axin2, or APC.

2205. A method for modulating a TCF-beta-catenin interaction in a system, comprising contacting beta-catenin with an agent or composition of any one of the preceding Embodiments.

2206. A method for modulating a TCF-beta-catenin interaction in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding Embodiments.

2207. A method for inhibiting beta-catenin dependent cell proliferation, comprising administering or delivering to the system an agent or composition of any one of the preceding Embodiments.

2208. A method for modulating WNT/beta-catenin pathway in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding Embodiments, wherein expression of a nucleic acid is modulated.

2209. A method, comprising administering or delivering to the system an agent or composition of any one

of the preceding Embodiments, wherein level of a transcript of a nucleic acid and/or a product thereof is modulated.

2210. A method, comprising administering or delivering to the system an agent or composition of any one of the preceding Embodiments, wherein expression of a nucleic acid is modulated.

2211. The method of any one of Embodiments 2208-2210, wherein a nucleic acid is or comprises a gene.

2212. The method of any one of Embodiments 2208-2211, wherein a nucleic acid is selected from gene set BCAT_GDS748_UP or Table GS1.

2213. The method of any one of Embodiments 2208-2212, wherein a nucleic acid is selected from gene set BCAT.100_UP.V1_UP or Table GS2.

2214. The method of any one of Embodiments 2208-2213, wherein a nucleic acid is selected from gene set HALLMARK_WNT_BETA_CATENIN_SIGNALING or Table GS3.

2215. The method of any one of Embodiments 2208-2214, wherein a nucleic acid is selected from gene set RASHI_RESPONSE_TO_IONIZING_RADIATION_1 or Table GS4.

2216. The method of any one of Embodiments 2208-2215, wherein a nucleic acid is selected from gene set REACTOME_RRNA_PROCESSING or Table GS5.

2217. The method of any one of Embodiments 2208-2216, wherein a nucleic acid is selected from gene set HALLMARK_MYC_TARGETS_V1 or Table GS6.

2218. The method of any one of Embodiments 2208-2217, wherein a nucleic acid is selected from gene set HALLMARK_MYC_TARGETS_V2 or Table GS7.

2219. The method of any one of Embodiments 2208-2218, wherein a nucleic acid is selected from gene set HALLMARK_OXIDATIVE_PHOSPHORYLATION or Table GS8.

2220. The method of any one of Embodiments 2208-2219, wherein a nucleic acid is selected from gene set HALLMARK_E2F_TARGETS or Table GS9.

2221. The method of any one of Embodiments 2208-2220, wherein a nucleic acid is selected from gene set HALLMARK_TNFA_SIGNALING_VIA_NFKB or Table GS10.

2222. The method of any one of Embodiments 2208-2221, wherein a nucleic acid is SP5.

2223. The method of any one of Embodiments 2208-2222, wherein a nucleic acid is CCND2.

2224. The method of any one of Embodiments 2208-2223, wherein a nucleic acid is WNT5B.

2225. The method of any one of Embodiments 2208-2224, wherein a nucleic acid is AXIN2.

2226. The method of any one of Embodiments 2208-2225, wherein a nucleic acid is NKD1.

2227. The method of any one of Embodiments 2208-2226, wherein a nucleic acid is WNT6.

2228. The method of any one of Embodiments 2208-2227, wherein a nucleic acid is DKK1.

2229. The method of any one of Embodiments 2208-2228, wherein a nucleic acid is DKK4.

2230. The method of any one of Embodiments 2208-2229, wherein expression of the nucleic acid is reduced.

2231. The method of any one of Embodiments 2208-2230, wherein BCAT_GDS748_UP is negatively

enriched.

2232. The method of any one of Embodiments 2208-2231, wherein BCAT.100_UP.V1_UP is negatively enriched.

2233. The method of any one of Embodiments 2208-2232, wherein HALLMARK_WNT_BETA_CATENIN_SIGNALING is negatively enriched.

2234. The method of any one of Embodiments 2208-2233, wherein RASHI_RESPONSE_TO_IONIZING_RADIATION_1 is negatively enriched.

2235. The method of any one of Embodiments 2208-2234, wherein REACTOME_RRNA_PROCESSING is negatively enriched.

2236. The method of any one of Embodiments 2208-2235, wherein HALLMARK_MYC_TARGETS_V1 is negatively enriched.

2237. The method of any one of Embodiments 2208-2236, wherein HALLMARK_MYC_TARGETS_V2 is negatively enriched.

2238. The method of any one of Embodiments 2208-2237, wherein HALLMARK_OXIDATIVE_PHOSPHORYLATION is negatively enriched.

2239. The method of any one of Embodiments 2208-2238, wherein HALLMARK_E2F_TARGETS is negatively enriched.

2240. The method of any one of Embodiments 2208-2239, wherein HALLMARK_TNFA_SIGNALING_VIA_NFKB is negatively enriched.

2241. The method of any one of Embodiments 2208-2240, wherein expression of the nucleic acid is reduced.

2242. The method of any one of Embodiments 2208-2241, wherein level of the transcript and/or a product thereof is reduced.

2243. The method of any one of Embodiments 2208-2242, wherein expression of a nucleic acid is increased.

2244. The method of any one of Embodiments 2208-2243, wherein level of a transcript of a nucleic acid or a product thereof is increased.

2245. The method of any one of Embodiments 2243-2244, wherein the nucleic acid is or comprises CXCL12 gene

2246. The method of any one of Embodiments 2208-2245, wherein one or more gene sets are independently positively enriched.

2247. The method of any one of Embodiments 2202-2246, wherein a system is an in vitro system.

2248. The method of any one of Embodiments 2202-2246, wherein a system is an in vivo system.

2249. The method of any one of Embodiments 2202-2246, wherein a system is or comprises a sample.

2250. The method of any one of Embodiments 2202-2249, wherein a system is or comprises a cell, tissue or organ.

2251. The method of any one of Embodiments 2202-2250, wherein a system is or comprises cancer cells.

2252. The method of any one of Embodiments 2202-2251, wherein a system is or comprises colorectal cancer cells.

2253. The method of any one of Embodiments 2202-2253, wherein a system is or comprises COLO320DM cells.

2254. The method of any one of Embodiments 2202-2253, wherein a system is or comprises a tumor.

2255. The method of any one of Embodiments 2202-2254, wherein a system is a subject.

2256. A method for treating or preventing a condition, disorder or disease associated with beta-catenin in a subject, comprising administering or delivering to the subject an effective amount of an agent or composition of any one of the preceding Embodiments.

2257. A method for treating cancer in a subject, comprising administering or delivering to the subject an effective amount of an agent or composition of any one of the preceding Embodiments.

2258. A method for treating or preventing a condition, disorder or disease associated with beta-catenin interaction with a partner in a subject, comprising administering or delivering to the subject an effective amount of an agent or composition of any one of the preceding Embodiments.

2259. The method of Embodiment 2258, wherein the partner is TCF7, LEF1, TCF7L1, TCF7L2, Axin1, Axin2, or APC.

2260. A method for treating or preventing a condition, disorder or disease associated with TCF-beta-catenin interaction in a subject, comprising administering or delivering to the subject an effective amount of an agent or composition of any one of the preceding Embodiments.

2261. The method of any one of the preceding Embodiments, wherein the condition, disorder or disease is melanoma.

2262. The method of any one of the preceding Embodiments, comprising administering or deliver to a subject a second therapeutic agent.

2263. The method of any one of the preceding Embodiments, comprising administering or deliver to a subject a second therapy.

2264. The method of Embodiment 2262 or 2263, wherein a second therapeutic agent or therapy is administered prior to an agent of any one of the preceding Embodiments.

2265. The method of Embodiment 2262 or 2263, wherein a second therapeutic agent or therapy is administered about or no more than about 1, 2, 3, 4, 5, 6, or 7 days, or 1, 2, 3, or weeks, or 1, 2, 3, 4, 5, or 6 months, prior to an agent of any one of the preceding Embodiments.

2266. The method of Embodiment 2262 or 2263, wherein a second therapeutic agent or therapy is administered concurrently with an agent of any one of the preceding Embodiments.

2267. The method of Embodiment 2262 or 2263, wherein a second therapeutic agent or therapy is administered subsequently to an agent of any one of the preceding Embodiments.

2268. The method of Embodiment 2262 or 2263, wherein a second therapeutic agent or therapy is

administered about or no more than about 1, 2, 3, 4, 5, 6, or 7 days, or 1, 2, 3, or weeks, or 1, 2, 3, 4, 5, or 6 months, subsequently to an agent of any one of the preceding Embodiments.

2269. The method of any one of the preceding Embodiments, wherein a subject is exposed to a second therapeutic agent or therapy and an agent of any one of the preceding Embodiments.

2270. The method of any one of the preceding Embodiments, wherein a subject is exposed to a therapeutic effect of a second therapeutic agent or therapy and a therapeutic effect of an agent of any one of the preceding Embodiments.

2271. The method of any one of the preceding Embodiments, wherein a second therapeutic agent is or comprises a chemotherapy agent.

2272. The method of any one of the preceding Embodiments, wherein a second therapeutic agent is or comprises a hormone therapy agent.

2273. The method of any one of the preceding Embodiments, wherein a second therapeutic agent is or comprises an immunotherapy agent.

2274. The method of any one of the preceding Embodiments, wherein a second therapeutic agent is or comprises a checkpoint inhibitor.

2275. The method of any one of the preceding Embodiments, wherein a second therapeutic agent is or comprises an antibody.

2276. The method of any one of the preceding Embodiments, wherein a second therapeutic agent is or comprises a CTLA-4, PD-1 or PD-L1 inhibitor.

2277. The method of any one of the preceding Embodiments, wherein a second therapeutic agent is or comprises a cell.

2278. The method of any one of the preceding Embodiments, wherein the second therapeutic agent reduces one or more side effects of an agent or composition of any one of the preceding Embodiments.

2279. The method of any one of the preceding Embodiments, wherein the agent or composition reduces one or more side effects of a second therapeutic agent.

2280. The method of any one of the preceding Embodiments, wherein a second therapy is or comprises surgery.

2281. The method of any one of the preceding Embodiments, wherein a second therapy is or comprises chemotherapy.

2282. The method of any one of the preceding Embodiments, wherein a second therapy is or comprises radiotherapy.

2283. The method of any one of the preceding Embodiments, wherein a second therapy is or comprises hormone therapy.

2284. The method of any one of the preceding Embodiments, wherein a second therapy is or comprises stem cell or bone marrow transplant.

2285. The method of any one of the preceding Embodiments, wherein a second therapy is or comprises

immunotherapy.

2286. The method of any one of the preceding Embodiments, wherein a second therapy is or comprises T-cell therapy.

2287. The method of any one of the preceding Embodiments, wherein a second therapy is or comprises CAR T-cell therapy.

2288. The method of any one of the preceding Embodiments, wherein a second therapy is or comprises administering to the subject a population of immune cells.

2289. The method of any one of the preceding Embodiments, wherein the agent or composition reduces one or more side effects of a second therapy.

2290. The method of any one of the preceding Embodiments, wherein unit dose of a second therapy or therapeutic agent is reduced compared to when it is administered alone.

2291. The method of any one of the preceding Embodiments, wherein total dose of a second therapy or therapeutic agent is reduced compared to when it is administered alone.

2292. The method of any one of the preceding Embodiments, wherein unit dose of an agent or composition of any one of the preceding Embodiments is reduced compared to when it is administered alone.

2293. The method of any one of the preceding Embodiments, wherein total dose of an agent or composition of any one of the preceding Embodiments is reduced compared to when it is administered alone.

2294. The method of any one of the preceding Embodiments, wherein the combination therapy provides higher efficacy than when an agent or composition is administered or delivered alone.

2295. The method of any one of the preceding Embodiments, wherein the combination therapy provides higher efficacy than when a second therapeutic agent or therapy is administered or delivered alone.

2296. The method of any one of the preceding Embodiments, comprising assessing expression of a nucleic acid.

2297. The method of any one of the preceding Embodiments, wherein expression of a nucleic acid is modulated.

2298. The method of any one of the preceding Embodiments, comprising assessing level of a transcript of a nucleic acid and/or a product thereof.

2299. The method of any one of the preceding Embodiments, wherein level of a transcript of a nucleic acid and/or a product thereof is modulated.

2300. The method of any one of the preceding Embodiments, comprising collecting a sample from a subject, and assessing expression of a nucleic acid in the sample.

2301. The method of any one of the preceding Embodiments, comprising collecting a sample from a subject, wherein expression of a nucleic acid in the sample is modulated.

2302. The method of any one of the preceding Embodiments, comprising collecting a sample from a system, and assessing expression of a nucleic acid in the sample.

2303. The method of any one of the preceding Embodiments, comprising collecting a sample from a

system, wherein expression of a nucleic acid in the sample is modulated.

2304. The method of any one of the preceding Embodiments, comprising collecting a sample from a subject, and assessing level of a transcript of a nucleic acid and/or a product thereof in the sample.

2305. The method of any one of the preceding Embodiments, comprising collecting a sample from a subject, and level of a transcript of a nucleic acid and/or a product thereof in the sample is modulated.

2306. The method of any one of the preceding Embodiments, comprising collecting a sample from a system, and assessing level of a transcript of a nucleic acid and/or a product thereof in the sample.

2307. The method of any one of the preceding Embodiments, comprising collecting a sample from a system, and level of a transcript of a nucleic acid and/or a product thereof in the sample is modulated.

2308. The method of any one of Embodiments 2296-2307, wherein a sample is or comprises a cell, tissue or organ.

2309. The method of any one of Embodiments 2296-2308, wherein a sample is or comprises cancer cells.

2310. The method of any one of Embodiments 2296-2309, wherein a sample is or comprises colorectal cancer cells.

2311. The method of any one of Embodiments 2296-2310, wherein a sample is or comprises COLO320DM cells.

2312. The method of any one of Embodiments 2296-2311, wherein a sample comprises cells from a tumor.

2313. The method of any one of Embodiments 2296-2312, wherein a sample comprises tissues from a tumor.

2314. The method of any one of Embodiments 2296-2313, wherein a sample is or comprises a tumor.

2315. The method of any one of Embodiments 2296-2311, wherein a sample is from a tumor.

2316. The method of any one of Embodiments 2296-2315, wherein a sample is from a biopsy.

2317. The method of any one of Embodiments 2296-2316, wherein a sample is collected after one or more administrations or deliveries.

2318. The method of any one of Embodiments 2296-2317, wherein an assessment is conducted after one or more administrations or deliveries.

2319. The method of any one of Embodiments 2296-2318, wherein a nucleic acid is or comprises a gene.

2320. The method of any one of Embodiments 2296-2319, wherein a nucleic acid is selected from gene set BCAT_GDS748_UP or Table GS1.

2321. The method of any one of Embodiments 2296-2320, wherein a nucleic acid is selected from gene set BCAT.100_UP.V1_UP or Table GS2.

2322. The method of any one of Embodiments 2296-2321, wherein a nucleic acid is selected from gene set HALLMARK_WNT_BETA_CATENIN_SIGNALING or Table GS3.

2323. The method of any one of Embodiments 2296-2322, wherein a nucleic acid is selected from gene set RASHI_RESPONSE_TO_IONIZING_RADIATION_1 or Table GS4.

2324. The method of any one of Embodiments 2296-2323, wherein a nucleic acid is selected from gene set

REACTOME_RRNA_PROCESSING or Table GS5.

2325. The method of any one of Embodiments 2296-2324, wherein a nucleic acid is selected from gene set HALLMARK_MYC_TARGETS_V1 or Table GS6.

2326. The method of any one of Embodiments 2296-2325, wherein a nucleic acid is selected from gene set HALLMARK_MYC_TARGETS_V2 or Table GS7.

2327. The method of any one of Embodiments 2296-2326, wherein a nucleic acid is selected from gene set HALLMARK_OXIDATIVE_PHOSPHORYLATION or Table GS8.

2328. The method of any one of Embodiments 2296-2327, wherein a nucleic acid is selected from gene set HALLMARK_E2F_TARGETS or Table GS9.

2329. The method of any one of Embodiments 2296-2328, wherein a nucleic acid is selected from gene set HALLMARK_TNFA_SIGNALING_VIA_NFKB or Table GS10.

2330. The method of any one of Embodiments 2296-2329, wherein a nucleic acid is CCND2.

2331. The method of any one of Embodiments 2296-2330, wherein a nucleic acid is WNT5B.

2332. The method of any one of Embodiments 2296-2331, wherein a nucleic acid is AXIN2.

2333. The method of any one of Embodiments 2296-2332, wherein a nucleic acid is NKD1.

2334. The method of any one of Embodiments 2296-2333, wherein a nucleic acid is WNT6.

2335. The method of any one of Embodiments 2296-2334, wherein a nucleic acid is DKK1.

2336. The method of any one of Embodiments 2296-2335, wherein a nucleic acid is DKK4.

2337. The method of any one of Embodiments 2296-2336, wherein expression of the nucleic acid is reduced.

2338. The method of any one of Embodiments 2296-2337, wherein BCAT_GDS748_UP is negatively enriched.

2339. The method of any one of Embodiments 2296-2338, wherein BCAT.100_UP.V1_UP is negatively enriched.

2340. The method of any one of Embodiments 2296-2339, wherein HALLMARK_WNT_BETA_CATENIN_SIGNALING is negatively enriched.

2341. The method of any one of Embodiments 2296-2340, wherein RASHI_RESPONSE_TO_IONIZING_RADIATION_1 is negatively enriched.

2342. The method of any one of Embodiments 2296-2341, wherein REACTOME_RRNA_PROCESSING is negatively enriched.

2343. The method of any one of Embodiments 2296-2342, wherein HALLMARK_MYC_TARGETS_V1 is negatively enriched.

2344. The method of any one of Embodiments 2296-2343, wherein HALLMARK_MYC_TARGETS_V2 is negatively enriched.

2345. The method of any one of Embodiments 2296-2344, wherein HALLMARK_OXIDATIVE_PHOSPHORYLATION is negatively enriched.

2346. The method of any one of Embodiments 2296-2345, wherein HALLMARK_E2F_TARGETS is negatively enriched.

2347. The method of any one of Embodiments 2296-2346, wherein HALLMARK_TNFA_SIGNALING_VIA_NFKB is negatively enriched.

2348. The method of any one of Embodiments 2296-2347, wherein expression of the nucleic acid is reduced.

2349. The method of any one of Embodiments 2296-2348, wherein level of the transcript and/or a product thereof is reduced.

2350. The method of any one of Embodiments 2296-2349, wherein expression of a nucleic acid is increased.

2351. The method of any one of Embodiments 2296-2350, wherein level of a transcript of a nucleic acid or a product thereof is increased.

2352. The method of any one of Embodiments 2350-2351, wherein the nucleic acid is or comprises CXCL12 gene

2353. The method of any one of Embodiments 2296-2352, wherein one or more gene sets are independently positively enriched.

2354. The method of any one of Embodiments 2296-2353, wherein administration or delivery continues for one or more times after the assessment.

2355. The method of any one of Embodiments 2296-2354, comprising evaluating an assessment and continue the administration or delivery.

2356. The method of any one of Embodiments 2296-2355, wherein administration or deliver is adjusted after an assessment.

2357. The method of any one of Embodiments 2296-2356, comprising evaluating an assessment and adjusting the administration or delivery.

2358. The method of any one of Embodiments 2296-2319, wherein administration or deliver is discontinued after an assessment.

2359. The method of any one of Embodiments 2296-2318 and 2358, comprising evaluating an assessment and discontinuing the administration or delivery.

2360. The method of any one of Embodiments 2356-2359, wherein expression of SP5 remains about the same or is increased.

2361. The method of any one of Embodiments 2356-2360, wherein expression of CCND2 remains about the same or is increased.

2362. The method of any one of Embodiments 2356-2361, wherein expression of WNT5B remains about the same or is increased.

2363. The method of any one of Embodiments 2356-2362, wherein expression of AXIN2 remains about the same or is increased.

2364. The method of any one of Embodiments 2356-2363, wherein expression of NKD1 remains about the same or is increased.

2365. The method of any one of Embodiments 2356-2364, wherein expression of WNT6 remains about the same or is increased.

2366. The method of any one of Embodiments 2356-2365, wherein expression of DKK1 remains about the same or is increased.

2367. The method of any one of Embodiments 2356-2366, wherein expression of DKK4 remains about the same or is increased.

2368. The method of any one of Embodiments 2356-2367, wherein expression of one or more of nucleic acids in BCAT_GDS748_UP or Table GS1 independently remains about the same or is increased.

2369. The method of any one of Embodiments 2356-2368, wherein expression of one or more of nucleic acids in BCAT.100_UP.V1_UP or Table GS2 independently remains about the same or is increased.

2370. The method of any one of Embodiments 2356-2369, wherein expression of one or more of nucleic acids in HALLMARK_WNT_BETA_CATENIN_SIGNALING or Table GS3 independently remains about the same or is increased.

2371. The method of any one of Embodiments 2356-2370, wherein expression of one or more of nucleic acids in RASHI_RESPONSE_TO_IONIZING_RADIATION_1 or Table GS4 independently remains about the same or is increased.

2372. The method of any one of Embodiments 2356-2371, wherein expression of one or more of nucleic acids in REACTOME_RRNA_PROCESSING or Table GS5 independently remains about the same or is increased.

2373. The method of any one of Embodiments 2356-2372, wherein expression of one or more of nucleic acids in HALLMARK_MYC_TARGETS_V1 or Table GS6 independently remains about the same or is increased.

2374. The method of any one of Embodiments 2356-2373, wherein expression of one or more of nucleic acids in HALLMARK_MYC_TARGETS_V2 or Table GS7 independently remains about the same or is increased.

2375. The method of any one of Embodiments 2356-2374, wherein expression of one or more of nucleic acids in HALLMARK_OXIDATIVE_PHOSPHORYLATION or Table GS8 independently remains about the same or is increased.

2376. The method of any one of Embodiments 2356-2375, wherein expression of one or more of nucleic acids in HALLMARK_E2F_TARGETS or Table GS9 independently remains about the same or is increased.

2377. The method of any one of Embodiments 2356-2376, wherein expression of one or more of nucleic acids in HALLMARK_TNFA_SIGNALING_VIA_NFKB or Table GS10 independently remains about the same or is increased.

2378. The method of any one of Embodiments 2356-2377, wherein expression of CXCL12 independently

remains about the same or is decreased.

2379. The method of any one of Embodiments 2356-2378, wherein BCAT_GDS748_UP is not enriched or is positively enriched.

2380. The method of any one of Embodiments 2356-2379, wherein BCAT.100_UP.V1_UP is not enriched or is positively enriched.

2381. The method of any one of Embodiments 2356-2380 , wherein HALLMARK_WNT_BETA_CATENIN_SIGNALING is not enriched or is positively enriched.

2382. The method of any one of Embodiments 2356-2381, wherein RASHI_RESPONSE_TO_IONIZING_RADIATION_1 is not enriched or is positively enriched.

2383. The method of any one of Embodiments 2356-2382, wherein REACTOME_RRNA_PROCESSING is not enriched or is positively enriched.

2384. The method of any one of Embodiments 2356-2383, wherein HALLMARK_MYC_TARGETS_V1 is not enriched or is positively enriched.

2385. The method of any one of Embodiments 2356-2384, wherein HALLMARK_MYC_TARGETS_V2 is not enriched or is positively enriched.

2386. The method of any one of Embodiments 2356-2385, wherein HALLMARK_OXIDATIVE_PHOSPHORYLATION is not enriched or is positively enriched.

2387. The method of any one of Embodiments 2356-2386, wherein HALLMARK_E2F_TARGETS is not enriched or is positively enriched.

2388. The method of any one of Embodiments 2356-2387, wherein HALLMARK_TNFA_SIGNALING_VIA_NFKB is not enriched or is positively enriched.

2389. The method of any one of the preceding Embodiments, wherein a comparison (e.g., reduced, increased, enriched, negatively enriched, positively enriched, etc.) is to a reference assessment prior to any administration or delivery.

2390. The method of any one of the preceding Embodiments, wherein a comparison (e.g., reduced, increased, enriched, negatively enriched, positively enriched, etc.) is to a reference assessment of a sample prior to any administration or delivery.

2391. The method of any one of the preceding Embodiments, wherein a comparison (e.g., reduced, increased, enriched, negatively enriched, positively enriched, etc.) is to a reference assessment at or during an administration or delivery.

2392. The method of any one of the preceding Embodiments, wherein a comparison (e.g., reduced, increased, enriched, negatively enriched, positively enriched, etc.) is to a reference assessment of a sample collected at or during an administration or delivery.

2393. The method of any one of the preceding Embodiments, wherein a comparison (e.g., reduced, increased, enriched, negatively enriched, positively enriched, etc.) is to a reference assessment after an earlier administration or delivery.

2394. The method of any one of the preceding Embodiments, wherein a comparison (e.g., reduced, increased, enriched, negatively enriched, positively enriched, etc.) is to a reference assessment of a sample collected after an earlier administration or delivery.

2395. The method of any one of the preceding Embodiments, wherein a comparison (e.g., reduced, increased, enriched, negatively enriched, positively enriched, etc.) is to a reference assessment after an administration or delivery of a reference agent.

2396. The method of any one of the preceding Embodiments, wherein a comparison (e.g., reduced, increased, enriched, negatively enriched, positively enriched, etc.) is to a reference assessment of a sample collected after an administration or delivery of a reference agent.

2397. The method of any one of Embodiments 2395-2396, wherein a reference agent is a therapeutic agent.

2398. The method of any one of Embodiments 2395-2396, wherein a reference agent is an inactive control agent.

2399. The method of any one of Embodiments 2395-2398, wherein the administration, delivery and/or assessment is conducted under comparably.

2400. An agent, compound, or composition, prepared and/or characterized by a method of any one of the preceding Embodiments.

2401. An agent, compound, or composition of any one of the preceding Embodiments, prepared and/or characterized by a method of any one of the preceding Embodiments.

EXEMPLIFICATION

[0820] Those skilled in the art appreciate that various technologies are available for manufacturing and assessing provided agents including various peptides such as stapled peptides in accordance with the present disclosure, for example, many technologies for preparing small molecules and peptides can be utilized to prepare provided agents, and various assays are available for assessing properties and/or activities of provided agents. Described below are certain such useful technologies. As demonstrated herein, in some embodiments, it is confirmed that provided technologies can exhibit nanomolar cell-based activity in protein-protein interaction (PPI), transcriptional regulation, proliferation assays, etc. In some embodiments, it is confirmed that provided technologies possess favorable pharmacokinetic properties. In some embodiments, *in vivo* dosing of provided technologies confirms on-target pharmacodynamic modulation of β-catenin activity and strong anti-tumor activity in multiple human xenograft models, which confirm that provided technologies are useful for treating various conditions, disorders or diseases as described herein.

[0821] Example 1. Peptide Synthesis.

[0822] Among other things, peptides can be prepared using various peptide synthesis technologies in accordance with the present disclosure. In many embodiments, peptides were prepared using Fmoc-based synthesis, often on suitable solid phase. For various stapled peptides, amino acid residues were stapled through suitable chemistry, e.g., olefin metathesis for amino acids that comprise olefin groups. Those skilled

in the art appreciates that other suitable technologies may also be utilized for stapling in accordance with the present disclosure, e.g., those described in WO/2019/051327, WO/2020/041270, etc., the peptide staples and technologies for preparing peptides are incorporated herein by reference.

[0823] For example, in some embodiments, peptides were synthesized on a Liberty Blue peptide synthesizer with 1 M DIC in DMF and 1 M Oxyma in DMF using standard Liberty Blue conditions on either Rink Protide amide resin (primary carboxamides), ethyl indole AM resin (ethyl amides), amino alcohol 2-chlorotrityl resin (amino alcohols), or Wang resin with the C-terminal amino acid pre-loaded (carboxylic acids). Single coupling was used for all amino acids, save for residues following a stapling amino acid, and B5, which were double coupled. Final Fmoc deprotection was performed on the N-terminal residue, and capping, e.g., acetate capping, was performed by treating the resin with a suitable capping agent, e.g., 5% acetic anhydride, 2.5% diisopropylethylamine and 92.5% NMP for acetate capping, at room temperature for 30 min. Non-acetate amide caps were appended with suitable amounts of reagents, e.g., five equivalents of a carboxylic acid, five equivalents of DIC, and five equivalents of Oxyma in a suitable solvent, e.g., DMF.

[0824] Lactam staples and triazole staples were closed prior to olefin metathesis. Lactam staples were generated by incorporating the amino-containing residue as an Alloc-protected amino acid, and the carboxylate-containing residue as an allyl-protected amino acid. Alloc/allyl deprotection was performed by treating the peptide with 10 mol% $Pd(Ph_3P)_4$, plus ten equivalents of either morpholine, phenylsilane, or dimethyl barbituric acid, in dichloroethane at room temperature for 1 h. Lactam formation was performed by treating the resin with 10 equivalents of Oxyma and 10 equivalents of DIC at 40 °C for 2 h, then draining and washing the resin with DMF.

[0825] Triazole staples were generated by incorporating both the azide-containing amino acid and alkyne-containing amino acid during the linear synthesis of the peptide. Triazole ring closure was performed by treating the acylated, linear peptide with copper (II) sulfate (2 equivalents) and sodium ascorbate (2 equivalents) in a mixture of tert-butanol/water (2/1). This mixture was heated in a microwave at 80 °C for 30 min, and then the resin filtered off, followed by washing with DMF and methanol.

[0826] Olefin metathesis was performed by treating peptides with suitable metathesis catalysts under suitable conditions, in some embodiments, optionally with multiple cycles, e.g., four cycles, of 30 mol% Grubbs' first generation catalyst (CAS 172222-30-9) in dichloroethane at 40 °C for 2 h, and washing the resin with dichloroethane after each treatment.

[0827] Peptide staple hydrogenation was performed by treating the resin with fresh 30 mol% Grubbs' first generation catalyst (CAS 172222-30-9) in 1,2-dichlorobenzene. Triethylsilane (50 equiv) was added, and the resin was placed in a heated shaker at 50 °C overnight, then washed with dichloroethane.

[0828] Peptide cleavage was performed by treating resin with 95% trifluoroacetic acid and 5% triisopropylsilane for 1 h, and precipitation of the crude peptide in diethyl ether. Purification was performed by preparative HPLC with MS detection and a Waters XSelect CSH C18 column using water with 0.1% formic acid and acetonitrile with 0.1% formic acid. Typically, if isomers were identified and separated by

HPLC purification they were isolated and tested separately by elution peaks (e.g., UV at 220 nm), otherwise peptides were isolated (often based on HPLC peaks) and tested as combinations (all peptides within a single HPLC peak were typically tested together in a single composition).

[0829] Amino acids suitable for synthesis are commercially available or can be prepared in accordance with the present disclosure. Certain amino acids and their preparations are described in the priority applications, WO 2022/020651 or WO 2022/020652, e.g., preparation of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-(tert-butoxycarbonyl)phenyl)propanoic acid, tert-butyl (S)-3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(benzyloxy)-3-oxopropyl)benzoate, TfeGA, etc., the amino acids and their preparations, including methods, reagents, intermediates, etc., of each of which are independently incorporated herein by reference.

[0830] Certain peptide preparations are presented below as examples.

[0831] Compounds with staples bridging substituted glutamine residues between AA7 and AA14 were synthesized in the following manner: Fmoc-BztA-Glu(OAllyl)-protide resin was synthesized on a Liberty Blue as described above. The allyl group was deprotected by treating with 10% $Pd(Ph_3P)_4$ and 10 equivalents phenylsilane in DCE for 1 h at room temperature. A mono-alloc protected diamine was coupled to the deprotected Glu residue by treating the resin with 4 equivalents of the protected diamine, 4 equivalents of DIC, and 4 equivalents of Oxyma in DMF at 40 °C for 2 h. The resin was then washed with DMF, and loaded back into the Liberty Blue, and the linear peptide sequence with Glu(OAllyl) at position 7 was completed. The resin was acetyl capped as described above. Alloc/allyl deprotection was performed by treating the peptide with 10 mol% Pd(Ph3P)4, plus ten equivalents of morpholine, and lactamization was performed by treating the resin with 10 equivalents of DIC and 10 equivalents of Oxyma in DMF at 40 °C. Ring closing metathesis, cleavage and purification were performed as described above.

[0832] I-45, I-46, I-47, I-48, I-49, I-50, I-51, I-52, I-53, I-54: Compounds with staples between lysine residues at positions 7 and 14 were generated in the following manner: The linear sequence was synthesized on a Liberty Blue as described above, incorporating Fmoc-Lys(ivDde)-OH at positions 7 and 14. After acetyl capping and olefin metathesis, the ivDde groups were removed by treating with two cycles of 5% hydrazine in DMF at 40 °C for 30 min, then washing with DMF. The resin was then treated with two equivalents of a diacid, 5 equivalents of DIC, and 5 equivalents of Oxyma in DMF at 40 °C for 2 h. The resin was then washed with DMF, and DCE, and cleaved and purified as described above.

[0833] I-303, I-517, I-518: Biotinylated peptides were generated by incorporating Fmoc-Lys(ivDde)-OH in the linear sequence. After acetyl capping and olefin metathesis, the ivDde group was removed by treating with two cycles of 5% hydrazine in DMF at 40 °C for 30 min, then washing with DMF. The resin was then treated with 3 equivalents Biotin-PEG8-acid (CAS 2143964-62-7), 3 equivalents of HATU, 10 equivalents of diisopropylethylamine in DMF at 40 °C for 2 h. The resin was then washed with DMF, and DCE, and cleaved and purified as described above.

[0834] I-606, I-607: Peptides with azidolysine in the final sequence were generated by incorporating

Fmoc-Lys(ivDde)-OH in the linear sequence. After olefin metathesis, the ivDde group was removed by treating with two cycles of 5% hydrazine in DMF at 40 °C for 30 min, then washing with DMF. The resin was then treated with three equivalents of 1H-imidazole-1-sulfonyl azide sulfate (CAS 1357503-23-1), 9 equivalents of diisopropylethylamine, and 0.5 equivalents of copper (II) sulfate pentahydrate in DMF at 40 °C for 3 h. The resin was then washed with DMF, water, DMF, and DCE, and cleaved and purified as described above.

[0835] Cysteine-containing staples were closed after olefin metathesis, peptide cleavage and purification. In a small vial the purified dicysteine peptide was dissolved in DMF, and 5 equiv. of the dibromo linker was added, followed by 100 mM ammonium bicarbonate pH 8 buffer, followed by DTT (10 mM). Upon completion of the stapling the crude reaction mixture was purified by preparative HPLC as described above.

[0836] I-469: Ac-PL3-OAsp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-protide resin was synthesized on Rink Amide resin and the lactam staple installed as above. A plastic syringe containing 200 mg of resin-bound peptide containing a free N-terminal amine was swollen in 0.5 mL DMF. To the swollen resin was added a solution of (2S)-4-(tert-butoxy)-2-hydroxy-4-oxobutanoic acid (85.5 mg, 0.45 mmol) in 0.5 mL DMF, 450 uL of 1 M DIC, and 450 uL of 1 M Oxyma. The syringe was shaken at room temperature for 90 minutes. The resin was then washed with DMF, DCM, MeOH, and again DCM, followed by drying under vacuum. The resin-bound peptide was swollen in 0.5 mL DCM. To the swollen resin was added 500 uL of 0.1 M DMAP in DCM, followed by a solution of PL3-Ac (88.75 mg 0.45 mmol) and DCC (92.8 mg 0.45 mmol) in DCM. The syringe was shaken at 40 °C for 3 hours. The resin was then washed with DMF, DCM, MeOH, and again DCM, followed by drying under vacuum. Ring-closing metathesis, peptide cleavage, and purification were then performed as described above.

[0837] I-427: Fmoc-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-protide resin was synthesized on Rink amide resin and the lactam staple installed as described above. On a polypropylene syringe equipped with a porous polypropylene disc at the bottom, 0.05 mmol (~ 0.18 g) of on-resin intermediate 1 was swollen on DCE for 15 min. Ring closing metathesis (RCM) between the side chains of R5 and PyrS2 was carried out under standard protocol (30 mol% Grubbs I catalyst, at 40 °C, 2x 2 h, in DCE). Afterwards the resin was washed with DCE 2x, DMF 2x, DCM, MeOH, and DCM. Next, the resin was swollen in DMF for 15 min, treated with 20% piperidine in DMF 2x 25 min and washed with DMF 5x and NMP 2x. To the swollen resin was added a pre-activated mixture of Fmoc-AllylGly-OH (5 eq), Oxyma (5 eq) and DIC (5 eq) in NMP (0.4M). The mixture was shaken for 2-3 h at room temperature. Chloranil test indicated complete coupling. The resin was then washed with DMF 5x, and the above cycle was repeated with Fmoc-Asp(OtBu)-OH, Fmoc-αMePro-OH, and 4-pentenoic acid. A second RCM, now between the side chain of AllylGly and the 4-pentenoic acid N-terminus cap, was carried out under standard protocol (30 mol% Grubbs I catalyst, 40 °C, 2x 2 h, in DCE). The resin was then washed with DMF 4x, DCM 3x, MeOH, DCM, and dried under high vacuum.

The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (1.5 mg).

[0838] I-429: The same experimental procedure described for I-427 was used in this synthesis. The only difference was the coupling of 5-hexenoic acid at the last step of the linear peptide synthesis. The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (1.3 mg)

[0839] I-428: Starting with Fmoc-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-protide resin, in a polypropylene syringe equipped with a porous polypropylene disc at the bottom, 0.05 mmol (~ 0.18 g) of on-resin intermediate 1 was swollen on DCE for 15 min. Ring closing metathesis (RCM) between the side chains of R5 and PyrS2 was carried out by the standard protocol (30 mol% Grubbs I catalyst, at 40 °C, 2x 2 h, in DCE). After the resin was washed with DCE 2x, DMF 2x, DCM, MeOH, and DCM, it was swollen in 1,2-dichlorobenzene (DCB) for 15 min. The solvent was drained and to the resin was added ~ 15 mg of Grubbs I catalyst as a solid. The syringe was closed with the moving plunger, followed by addition of triethylsilane (50 eq) and DCB (0.6 mL) to the mixture via needle. The syringe was shaken at 50 °C for 18 h to produce the corresponding i+7 reduced staple. The resin was then washed with DMF 4x, DCM 3x, MeOH, DCM and DMF. Next, the resin was swollen in DMF for 15 min, treated with 20% piperidine in DMF 2x 25 min, and washed with DMF 5x and NMP 2x. To the swollen resin was added a pre-activated mixture of Fmoc-AllylGly-OH (5 eq), Oxyma (5 eq) and DIC (5 eq) in NMP (0.4M). The mixture was shaken for 2-3 h at room temperature. Chloranil test indicated complete coupling. The resin was then washed with DMF 5x, and the above cycle was repeated with Fmoc-Asp(OtBu)-OH, Fmoc-αMePro-OH, and 4-pentenoic acid.A second RCM, now between the side chain of AllylGly and the 4-pentenoic acid N-terminus cap, was carried out by the standard protocol (30 mol% Grubbs I catalyst, 40 °C, 2x 2 h, in DCE). The resin was then washed with DMF 4x, DCM 3x, MeOH, DCM, and dried under high vacuum. The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (5.2 mg).

[0840] I-431: The same experimental procedure described for I-428 was used in this synthesis. The only difference was the coupling of 5-hexenoic acid at the last step of the linear peptide synthesis. The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (0.85 mg).

[0841] I-425: Starting with Fmoc-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-protide resin, in a polypropylene syringe equipped with a porous polypropylene disc at the bottom, 0.05 mmol (~0.18 g) of an on-resin advanced intermediate precursor in which a staple (e.g., a (i, i+7) staple

between R5 and Pyrs2) was not yet formed, was swollen in DMF for 15 min, treated with 20% piperidine in DMF 2x 25 min, and washed with DMF 5x and NMP 2x. To the swollen resin was added a pre-activated mixture of Fmoc-AllylGly-OH (5 eq), Oxyma (5 eq), and DIC (5 eq) in NMP (0.4M). The mixture was shaken for 2-3 h at room temperature. Chloranil test indicated complete coupling. The resin was then washed with DMF 6x, and the above cycle was repeated with Fmoc-Asp(OtBu)-OH, Fmoc-αMePro-OH, and 4-pentenoic acid. Simultaneous RCM between the side chain of AllylGly and the 4-pentenoic acid N-terminus cap, as well as the side chains of amino acids R5 and PyrS2, was carried out by the standard protocol (30 mol% Grubbs I catalyst, 40 °C, 4x 2 h, in DCE). Afterwards, the resin was washed liberally with DCE, DCM, DMF, MeOH and DCM, and dried under high vacuum for 3 to 4 h.The resin was swollen in 1,2-dichlorobenzene (DCB) for 15 min. The solvent was drained and to the resin was added ~ 15 mg of Grubbs I catalyst as a solid. The syringe was closed with the moving plunger, followed by addition of triethylsilane (50 eq) and DCB (0.6 mL) to the mixture via needle. The syringe was shaken at 50 °C for 18 h to produce the corresponding fully reduced analogue. The resin was then washed with DMF 4x, DCM 3x, MeOH, DCM, and dried under high vacuum. The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (2 mg).

[0842] I-426: The same experimental procedure described for I-425 was used in this synthesis. The only difference was the coupling of 5-hexenoic acid in the last step of the linear peptide synthesis. The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (1.5 mg).

[0843] I-471: Starting with Fmoc-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-protide resin, in a polypropylene syringe equipped with a porous polypropylene disc at the bottom, 0.05 mmol (~ 0.18 g) of an on-resin advanced intermediate precursor in which a staple (e.g., a (i, i+7) staple between R5 and Pyrs2) was not yet formed, was swollen in DMF for 15 min, treated with 20% piperidine in DMF 2x 25 min, and washed with DMF 5x and NMP 2x. To the swollen resin was added a pre-activated mixture of Fmoc-AllylGly-OH (5 eq), Oxyma (5 eq), and DIC (5 eq) in NMP (0.4M). The mixture was shaken for 2-3 h at room temperature. Chloranil test indicated complete coupling. The resin was then washed with DMF 6x. The above cycle was repeated with Fmoc-Asp(OtBu)-OH, Fmoc-αMePro-OH, and 2-(prop-2-en-1-yloxy)-benzoic acid. Simultaneous ring closing metathesis (RCM) between the side chains of AllylGly and the benzoyl-O-allyl N-terminus cap, as well as the side chains of amino acids R5 and PyrS2 was carried out by the standard protocol (30 mol% Grubbs I catalyst, 40 °C, 3x 3 h, in DCE). The resin was washed liberally with DCE, DCM, DMF, MeOH and DCM, and dried under high vacuum for 3 to 4 h.The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then

precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (0.83 mg).

[0844] I-519: Starting with Fmoc-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-protide resin, in a polypropylene syringe equipped with a porous polypropylene disc at the bottom, 0.05 mmol (~ 0.18 g) of an on-resin advanced intermediate precursor in which a staple (e.g., a (i, i+7) staple between R5 and Pyrs2 was not yet formed), was swollen in DCE for 15 min. Ring closing metathesis (RCM) between the side chains of R5 and PyrS2 was carried out by the standard protocol (30 mol% Grubbs I catalyst, 40 °C, 2x 2 h, in DCE). The resin was then washed with DCE 3x and DMF 3x. Afterwards, the resin was swollen in DMF for 15 min, treated with 20% piperidine in DMF 2x 25 min, and washed with DMF 5x and NMP 2x. To the swollen resin was added a pre-activated mixture of Fmoc-Dap(ivDde)-OH (5 eq), Oxyma (5 eq) and DIC (5 eq) in NMP (0.4M). The mixture was shaken for 2-3 h at room temperature. The resin was then washed with DMF 6x, and the above cycle was repeated with Fmoc-Asp(OtBu)-OH, Fmoc-αMePro-OH, and 5-hexenoic acid. The ivDde protecting group on the diamino propionic acid (Dap) side chain was removed by treating the DMF-swollen resin with a 5% solution of hydrazine in DMF, 2x 20 min at 40 °C. Afterwards, the resin was liberally washed with DMF and 2x NMP. To the swollen resin was added ortho-nitrobenzensulfonyl chloride (4 eq) and 2,4,6-collidine (4 eq) in NMP, and the reaction was shaken for 30 min at room temperature, to yield the desired N-activated intermediate. The resin was liberally washed with DMF. N-alkylation of the activated primary amine was carried out with allyl bromide (15 eq) and DBU (15 eq) in DMF, shaking the resin at room temperature for 2 days. The resin was liberally washed with DMF and 2x NMP. To push the N-alkylation reaction to completion, the resin was treated with allyl bromide (15 eq) and 2,6-lutidine (15 eq) in NMP at 110 °C for 30 min under microwave conditions. The resin was liberally washed with DMF and 2x NMP, and trial cleavage and analysis by LCMS showed complete reaction.The N-activating group (oNBS) was removed by treating the resin with mercaptoethanol (10 eq) and DBU (5 eq) in NMP (2 x 20 min at room temperature). The resulting secondary amine, at the side chain of Dap, was alkylated with benzyl bromide (10 eq) and 2,6-lutidine (15 eq), under microwave conditions at 110 °C 2x 25 min. A second RCM between the side chains of Dap(allyl) and the 5-hexenoic acid N-terminus cap, was carried out by the standard protocol (30 mol% Grubbs I catalyst, 40 °C, 2x 2 h, in DCE). The resin was washed liberally with DCE, DCM, DMF, MeOH and DCM, and dried under high vacuum for 3 to 4 h.The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (0.55 mg).

[0845] I-520: The same experimental procedure described for I-519 was used in this synthesis. The only difference was the acylation (instead of alkylation) of the produced secondary amine at the side chain of Dap using benzoic acid (5 eq), Oxyma (5 eq), and DIC (5eq) in NMP, at room temperature for 2-3 h. The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then

precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (0.62 mg).

[0846] I-564: The same experimental procedure described for I-519 was used in this synthesis, with two important changes. First was the acylation (instead of alkylation) of the produced secondary amine at the side chain of Dap using pivaloyl chloride (7 eq) and NMM (10 eq) at 77 °C for 15 min under microwave conditions. Second, the resin was swollen in 1,2-dichlorobenzene (DCB) for 15 min followed by, after solvent draining, addition of ~ 15 mg of Grubbs I catalyst as a solid. The syringe was closed with the moving plunger and triethylsilane (50 eq) and ~0.6 mL of DCB were added to the mixture via needle. The syringe was shaken at 50 °C for 18 h to produce the corresponding fully reduced analogue. The resin was then washed with DMF 4x, DCM 3x, MeOH, and DCM, and dried under high vacuum. The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (1.36 mg).

[0847] I-565:The same experimental procedure described for I-564 was used in this synthesis. The only difference was the acylation of the produced secondary amine at the side chain of Dap using cyclohexanecarboxylic acid (5 eq), Oxyma (5 eq), and DIC (5eq) in NMP at room temperature for 2-3 h. The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (1.19 mg).

[0848] I-562: A similar experimental procedure as described for I-519 was used in this synthesis, although with three important changes. First, 4-pentenoic acid was used as the N-terminus capping group. Second, N-alkylation of the secondary amine, at the side chain of Dap, was carried out with benzyl bromide (10 eq) and 2,6-lutidine (15 eq), under microwave conditions at 110 °C, 2x 25 min. Third, both alkene staples were simultaneously reduced. The resin was swollen in 1,2-dichlorobenzene (DCB) for 15 min, the solvent was drained, and to the resin was added ~ 15 mg of Grubbs I catalyst as a solid. The syringe was closed with the moving plunger and triethylsilane (50 eq) and DCB (0.6 mL) were added to the mixture via needle. The syringe was shaken at 50 °C for 18 h to produce the corresponding fully reduced analogue. The resin was then washed with DMF 4x, DCM 3x, MeOH, and DCM, and dried under high vacuum. The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to afford, after lyophilization of the pure fractions, the titled compound as a white powder (0.44 mg).

[0849] I-563: The same experimental procedure described for I-562 was used in this synthesis. The only difference was the acylation (instead of alkylation) of the produced secondary amine at the side chain of Dap using benzoic acid (5 eq), Oxyma (5 eq), and DIC (5eq) in NMP at room temperature for 2-3 h. The peptide was cleaved off the resin with 3 ml TFA/H2O/TIPS (95:2.5:2.5) for 2 h at room temperature, then precipitated by cold ethyl ether, and the obtained residue was applied to a reverse-phase HPLC column to

afford, after lyophilization of the pure fractions, the titled compound as a white powder (1.19 mg).

[0850] Mass spectrometry was performed as follows: 2 uL of a 200 uM solution of a peptide in DMSO was injected on a Waters Acquity UPLC-MS system with a 2.1 x 50 mm, 1.7 μM CSH C18 column at 40 °C, using a gradient of 95/5 water/acetonitrile to 5/95 water/acetonitrile over 7 minutes, flow rate = 0.6 mL/min. Product peaks were analyzed in both positive and negative ionization mode.

[0851] Example 2. Provided technologies can provide improved properties and/or activities.

[0852] In some embodiments, solubility was assessed. In some embodiments, a useful protocol is presented below as an example: 50 uM peptide was incubated in 99.5% PBS/0.5% DMSO at 37 °C for 15 min. After ultracentrifugation of the PBS solution, the supernatant was analyzed by HPLC and compared to an HPLC injection 50 uM peptide DMSO solution. Solubility was determined by: [(Area of PBS peak)/(Area of DMSO peak)]*50 uM. In some embodiments, provided agents, e.g., stapled peptides, have a solubility of about or at least about 1-50, 10-50, 10, 20, 30, 40, or 50 uM as measured using such a protocol.

[0853] In some embodiments, LogD of provided agents, e.g., stapled peptides, were assessed. In some embodiments, shake flask LogD was assessed using the following procedure as an example. In some embodiments, certain agents, e.g., stapled peptides, have a shake flask LogD of about 0-3, 0.1-2.5, 0.5-2, 1-2, 1.5-2, or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.

[0854] Instruments Required:

EP Motion

4titude Plate Sealer

Sample Scanner

Hamilton Decapper

Eppendorf Centrifuge

Eppendorf Shaker

Sonicator

Agilent Single Quad HPLC-MS

[0855] Materials Needed:

Eppendorf 384 well 100uL volume plate

Eppendorf 96 Well 1mL Plate

Eppendorf 96 Well 500uL Plate

EP Motion

EP Motion 50uL, 300uL, 1000uL tips.

[0856] Preparation for Plate Generation:

1. Take a tray of aliquots from compound management.
2. Use a maximum of 45 compounds and reserve the last 3 spots for aliquots of standard.
3. Scan the plate of aliquots on the SampleScan

4. Take the scanned values and generate an excel file
5. Generate a .csv file from the outputted excel
    a. This .csv should contain two columns
        i. First Column: Sample Location
        ii. Second Column: Sample Name
6. Spin compounds down in centrifuge for 15s, at 3000 rpm.
7. De-cap aliquots using the Hamilton decapper.
8. Take the tray of aliquots up to the EP Motion.

[0857] Plate Generation:

1. On the EP Motion select:
    a. Home>Chemistry>logDPart1v1_100mL_NoSTD
2. Place aliquots, tips, plate (96-well 1mL Eppendorf Plate,) and reservoirs according to instrument.

a. Reservoirs contain presaturated Octanol pH 7.4, and presaturated buffer pH 7.4.

3. Make sure the total number of samples reads 48.
4. Select run, and ensure "Detect Volumes" is selected, you can unselect "check tips" and "labware placement."
5. Run method.
6. Remove completed 96-well plate. Clean up the EP Motion.
7. Take completed plate to compound management and turn on the 4titude plate sealer.
    a. Wait until plate sealer displays a temperature of 170C.
    b. Place silver sheet over plate, utilize gold holder to keep silver sheet in place.
    c. Select operate, place plate in holder with holder in place. Press operate again.
    d. Use a roller to firmly seal the plate once it has been ejected.
8. Invert plate on side, place on Eppendorf shaker for 1 hour at 2000 rpm.
9. Remove Plate, sonicate for 10 minutes.
10. Centrifuge at 3000rpm for 10 minutes.

[0858] Plate Generation: Final

1. On the EP Motion select:
    a. Home>Chemistry>logDPart2v1_80mL
2. Place aliquots, tips, plates (96-well 1mL Eppendorf Plate, 96-well 500mL Eppendorf Plate, 384-well 100uL plate (Final),) and reservoirs according to instrument.
    a. Reservoirs contain (50/50) presaturated Octanol pH 7.4/ DMSO, DMSO, Acetonitrile, and presaturated buffer pH 7.4.
3. Make sure the total number of samples reads 48.
4. Select run, and ensure "Detect Volumes" is selected, you can unselect "check tips" and "labware placement."

5. Run method.
6. Remove completed 96-well plates and final 384-well plate. Clean up the EP Motion.
7. Seal both 96-well plates with a rubber plate seal, store in 4C freezer.
8. Take completed final plate to compound management and turn on the 4titude plate sealer.
    a. Wait until plate sealer displays a temperature of 170C.
    b. Place pierceable silver sheet over plate, utilize gold holder to keep silver sheet in place.
    c. Select operate, place plate in holder with holder in place. Press operate again.
    d. Use a roller to firmly seal the plate once it has been ejected.
9. Head over to Agilent HPLCMS.

[0859] Plate Programming:

1. Open Chemstation on the Agilent HPLCMS
2. Ensure buffers C (Water with 0.1% Formic Acid,) D (Acetonirile with 0.1% Formic Acid,) and wash (MeOH,) are full.
3. Hit the green on button to allow instrument sufficient time to equilibrate while the sequence is programmed.
4. Click the sequence button in the top drop-down menu:
    a. Select new sequence
    b. Save sequence as yyyymmdd_sol.
5. From the sequence menu:
    a. Select import samples
    b. Click browse and find the .csv file created earlier.
    c. Click next, then click finish.
6. Open the Sequence:
    a. The only columns that should be filled are the location:
    b. And the Sample Name:
7. Double click on the method box:
    a. Select 10_mincd 60-95
8. Enter 10 for the injection volume, 10uL will be injected
9. In the injection number enter 2, for 2 injections per well.
10. Now highlight the columns containing method, injection volume, and injection number and drag down to the bottom of the sequence. Hold Ctrl and right click, select fill down.
11. Insert a blank sample in the 1st and last slot.
    a. For sample location enter D1B-D1
    b. For sample name enter Blank
    c. Enter the same method 10_mincd 60-95.
    d. Enter 10 for injection volume

e. Enter 4 for number of injections

12. Right click on the widget for the Mass Spec and enter the mass range for the compounds selected to run.
13. Click start.

[0860] Data Processing:

1. Open the offline version of the Chemstation software, select the desired sequence by date.
2. Double-click on the line containing the compound of interest. This will bring up the chromatogram.
    a. Select the delimiting tool to remove any automatic integration.
    b. Select the Average Chromatogram tool for mass and drag it over the peaks of interest.
    c. Find the expected mass.
    d. Go back to the peak delimiting tool again and drag it over the peak containing the mass of interest to integrate the peak.
    e. Perform the same for the second preparation of the same compound.
3. Export the integrated compound results as a pdf.
4. Take the integrated area and enter it in the entry sheet in the excel.
5. Once all results are entered, the functions within the excel will automatically calculate the Average Logd and Standard deviation.
    a. To account for dilutions throughout the plate creation the final calculation for the Logd looks like this:
        i. Logd= log ((Octanol peak*40)/(Buffer peak*2))
        ii. Average Logd is the average of the calculated Logd values of peak 1 and 2, as is the standard deviation from the calculated Logd values of peak 1 and 2.
        iii. Special cases: Logd only seen in the Octanol phase is denoted as >0, Logd only seen in the buffer phase is denoted as <0.
        iv. If compound is not seen in either phase, it likely indicates a solubility problem. Generally noted as Div/0! and observation included in the notes section.

[0861] Certain results are presented herein as examples.

[0862] Example 3. Various provided peptides can bind to beta-catenin.

[0863] As those skilled in the art will appreciate, many technologies can be utilized in accordance with the present disclosure to assess binding to targets such as beta-catenin. Certain useful technologies and results are described below as examples.

[0864] In some embodiments, an assay is fluorescence polarization. A useful protocol is described below as an example.

[0865] Fluorescence polarization IC50: Using the Mosquito (SPT) peptide solutions were 3-fold serially diluted in 90% DMSO and 40 nL of titrated peptide was added into 20 uL buffer (50 mM HEPES, pH 7.5, 125 mM NaCl, 2% glycerol, 0.5mM EDTA, 0.05% v/v pluronic acid) for final concentrations of 10 uM to 5nM plated by Multidrop™ Combi (Thermo Scientific) into a black polystyrene 384-well plate (Corning).

Probe solution (10 nM full-length ß-Catenin (Uniprot ID P35222), mixed with 10nM 5FAM labeled TCF4 residues 10-53 (Uniprot ID Q9NQB0) peptide in buffer) was prepared and 20 uL per well was plated using a Multidrop™ Combi (Thermo Scientific). The plate was incubated protected from light for 60 minutes at 20 °C prior to read. Reads were performed on a CLARIOstar plate reader (BMG Labtech) in duplicate, and data were fitted to a 1:1 binding model with hill slope using an in-house script. All provided concentrations are final concentrations. Certain results were presented in Table E1 below as examples.

[0866] In some embodiments, binding to beta-catenin may be measured by surface plasmon resonance (SPR). A useful protocol is described below as an example. Various agents, e.g., those presented in E2 as examples, demonstrated binding to beta-catenin, in some embodiments, with low or sub-nM Kd; other values can and in various cases were also assessed, e.g., $t_{1/2}$.

[0867] Peptides at 10 mM concentration in DMSO are diluted into Biacore™ running buffer (50 mM Tris pH 8.0, 300 mM NaCl, 2% glycerol, 0.5 mM TCEP, 0.5 mM EDTA, 0.005% Tween-20, 0.09% DMSO) to afford an appropriate dilution range. These diluted peptide samples are then assayed on a Biacore™ S200 using the Biacore™ Biotin CAPture Kit (GE Healthcare) which had been functionalized with biotinylated ß-Catenin residues 134-665 (Uniprot ID P35222). Results were analyzed using the Biacore™ Insight Evaluation Software, fitting to a 1:1 binding model.

[0868] Example 4. Provided technologies can modulate interactions with beta-catenin in cells.

[0869] Various technologies may be utilized to assess properties and/or activities of provided compounds, e.g., stapled peptides, in cells. In some embodiments, a useful assay is Nano-BRET target engagement assay that assesses beta-catenin/TCF4 engagement. A useful protocol is described below as an example.

[0870] On Day 1, HEK293 cells were seeded. Cells at ~ 70% confluency were utilized. Trypsinize cells without washing with PBS (e.g. 5 ml trypsin/75 flask for 2-5 min @ Rm Temp). Quench trypsin with 10 mL MEM media. Transfer cells to a falcon tube. Spin down @ 250 g for 5 minutes at room temperature. Discard supernatant. Gently re-suspend the cells in 10 mL MEM media. Count the cells twice and calculate how many cells were needed. Plate Parental HEK293 Cell Line at 7 M cells/12 ml/75 cm2 flask using MEM media. Rock plate a couple of times to disperse cells evenly. Incubate at 37 °C, 5% CO_2 for 5 hours. Cells should be evenly spread and about 70% confluent after, e.g., 5h.

[0871] Transfection of Nano-BRET constructs (B-cat-Halo & TCF4-Luc): Allow Fugen-HD transfection reagent to reach room temperature. Mix by inverting tube, if precipitate is visible, warm up to 37 °C and them cool to room Temp. Check flasks under microscope for confluency of cells (70-80%). Add LiCl to flask containing cells (LiCl 30 mM working concentration - LiCl can be a GSK3 inhibitor and reduce beta-catenin degradation). Prepare the transfection mix in a tube containing Assay media based on the manufacturer instruction (see below table for an example):

[0872] Transfection mix preparation

#	Constructs	# of Flasks	Ratio	DNA (ug)	FuGene (6 ul/w)	Opti-MEM (ul)
1-a	Bcat-Halo	1	4	12.8	48	736
1-b	TCF4-Luc	1	1	3.2		

[0873] Add FuGene last and gently mix. Don't vortex. Incubate transfection mix at RT for 10-15 minutes. If more than one target pair is going to be tested, calculate the amounts of transfection mix using the above table for other construct pairs. Gently add 700 uL of transfection mix per flask and gently rock the plate a couple of times. Incubate cells at 37 °C, 5% CO2 for 18-24 hours.

[0874] On Day 2, transfected cells were harvested and re-plated in 384-well plates with media and compounds pre-dispensed in the wells. Dispense 20 uL of 30mM LiCl containing assay media in all wells of a 384-well plate. In some embodiments, a liquid handling system was utilized to prepare a compound plate with a top concentration of 10 mM and serially diluted in a 1:3 manner to a lowest concentration of 13 uM. Dispense 80 nL of these compound series into the 20 uL of media pre-dispensed in the plates. This created a 2x concentration in the wells that was further diluted once cells were added.

[0875] While compound dilutions and dispenses were being made, collect media from transfected cell flask in a Falcon tubes. This was to harvest the floaters as they may still be viable and transfected. Trypsinize cells without washing with PBS (5 ml trypsin/Flask). Quench trypsin with 5 mL of MEM media. Collect cells and add to falcon tube. Wash the flask with 5-10 mL of MEM media and add to falcon tube. Spin down @ 250 g for 5 minutes at room temperature. Discard supernatant. Gently re-suspend cells in 5 mL Assay media (optionally containing LiCl). Count the cells twice and calculate the average count. Dilute HaloTag® NanoBRET™ 618 Ligand 1:500 in cell dilution. Dispense 20 uL of cell suspension per each well for all except one column of 384-well plate (5,000 cells/40 uL/well) (use plate such as Corning Solid White Flat Bottom TC-treated plate). For final column add 20 uL of cells containing equivalent amounts of DMSO. LiCl at 30 mM concentration. This cell dispense to the 20 uL of compound containing media brings the compound concentrations to our desired final working dilutions. Incubate at 37 °C, 5% CO2 overnight.

[0876] On Day 3, fluorescence was read with Nano-BRET substrates. Remove plates from incubator to allow to reach to RT (30 min). Also equilibrate CTG reagent to room temperature. Dilute Nano-BRET substrate 1:100 in Assay media. Add 10 uL of diluted substrate to each well and shake for 30 seconds. Read on ClarioSTAR or GloMAX right away (within 10 min). Donor emission @ 460 nm. Acceptor emission @ 618 nm. Use the same plate to measure cell viability (Cell Titer-Glo-2.0 (CTG) Viability test). After reading BRET signal, add CTG reagent to each well at 1:2 ratio and shake on orbital shaker for 2 min. Incubate at Rm Temp for 10 - 30 min. Read luminescence on ClarioSTAR or GloMAX. Analysis was performed using non-linear regression in R, Log(inhibitor) vs. response with a two parameter Hill function, and a high control (cells with ligand) and low control (cells without ligand), to measure absolute IC50 (AbsIC50 = X[50]) of each compound.

[0877] Certain results were presented in Table E1 as examples.

[0878] Reporter IC50: Activities of provided technologies were also confirmed in TCF reporter assay as described below. Those skilled in the art will appreciate that other suitable reagents may be utilized and various parameters may be adjusted.

[0879] On Day 1, cultured cells (e.g., DLD1) in flasks that were no more than about 60-70% confluent were washed with PBS and typsinized in 3mL/T75 until cells were free floating. Cells were spun down for 5 minutes at 1100RPM. After spinning, the supernatant was gently aspirated and cells were resuspended in 10mL assay media (4%FBS RPMI or 20%FBS RPMI, depending on desired serum concentration). Cells were counted twice using a Countess cell counter, counts were averaged, and the cell concentration was adjusted. The desired seeding density was 2500 cells/well in 40uL assay media. Using a Multidrop Combi, the cells were plated in columns 1-22 in 384 well, white solid-bottom plate. Cell-free assay media was added to columns 23 and 24. Assay plates were incubated at 37 °C, 5% CO2 overnight on the top shelf (back) of an incubator.

[0880] On Day 2, compounds were added. Stock solution was 10 mM. A liquid handling system was used to prepare the compound dilution and dispense compound into assay plates. The compounds were serially diluted 1/2 or 1/3 (depending on desired assay conditions) in 90% DMSO to create a 7 point dose curve. From compound plate, 80nL of compound were dispensed directly into wells of the assay plates to create a dose curve starting at 20uM and ending at either 313nM (1/2 dilution) or 27nM (1/3 dilution). Untreated, control wells received 90% DMSO only. Assay plates were incubated at 37 °C, 5% CO2 overnight on the top shelf (back) of an incubator.

[0881] On Day 3, viability was read using Cell-Titer Fluor (CTF, Promega) and TCF activity was read using BrightGlo (Promega). CTF was mixed to 5x concentration using 35uL substrate to 14mL buffer. Warmed CTF was added directly to uncooled assay plates using Multidrop Combi, 10uL/well in columns 1-23. Assay plates were incubated at 37 °C, 5% CO2 on the top shelf (back) of an incubator for 2 hours and then removed. Removal of assay plates from incubator was staggered in 5 min intervals. Plates were cooled for 40min, protected from light, and read using GloMax CTF program (High Sensitivity).

[0882] After reading CTF, room temperature BrightGlo was added to room temperature assay plates using Multidrop Combi, 35uL/well in columns 1-23. The plates were incubated at room temperature for 2 minutes, protected from light. Then plates were read using a ClarioStar, end point luminescence readout.

[0883] Analysis was performed using non-linear regression in R, Log(inhibitor) vs. response with a two parameter Hill function, and a high control (DMSO treated cells) and low control (Cell-free wells), to measure absolute IC50 (AbsIC50 = X[50]) of each compound.

[0884] For various agents, e.g., certain stapled peptides in Table E2 or Table E3, low or sub-uM IC50 were observed. Certain results were presented in Table E1 as examples.

[0885] COLO320DM proliferation assay IC50: In some embodiments, inhibition of cell proliferation by provided technologies were assessed using cell lines related to or from certain conditions, disorders or diseases. In some embodiments, cell proliferation was assessed in COLO320DM cells. In some

embodiments, assessment was performed using the following procedure: On Day 1, cultured COLO320DM cells in a T75 flask were trypsinized in 3 mL of 0.25% trypsin/EDTA for 5 min and quenched with 10 mL RPMI-1640 + 4% HI FBS assay media. The cells were spun down at 1200 rpm for 5 min, the cell pellet collected and re-suspended at 5000 cells/mL in assay media. Using a Combi liquid handler, cells were dispensed (50 uL, 250 cells/well) into three 384 well plates. Plates were incubated at 37 °C, 5% CO2 for 18-22 h. On day 2, compounds were added. A liquid handling system was used to prepare the compound dilution and dispense compound into assay plates. The compounds were serially diluted 1/2 in 90% DMSO to create a 7 point dose curve. From compound plate, 100 nL of compound were dispensed directly into wells of the assay plates to create a dose curve starting at 20uM and ending at 313nM. Assay plates were incubated at 37 °C, 5% CO2 for 96 h. On day 6, assay plates were removed from the incubator and allowed to sit at room temperature for 30 min. Using a liquid handler, 20 uL of CellTiter Glo reagent was added to each well. The assay plates were shaken for 2 min and allowed to sit on the bench for 10-15 minutes. The assay plates were read using the CellTiter Glo protocol on a GloMax microplate reader, and the data analyzed using GraphPad Prism. Activities of various agents, including various stapled peptides in Table E2, were confirmed. Certain results are presented in Table E1 below.

[0886] Table E1. Certain data of various compositions as examples.

Structural information and compositions of stapled peptides are described in Table E2.

1. Compound ID

2. beta-Catenin FP IC50 (nM): A ≤ 50 nM; 50 nM < B ≤ 200 nM; 200 nM < C ≤ 750 nM; 750 nM < D ≤ 1000 nM; E > 1000 nM

3. NanoBRET Abs IC50 (uM): A ≤ 1.5 uM; 1.5 uM < B ≤ 3.0 uM; 3.0 uM < C ≤ 10.0 uM; D > 10.0 uM

4. DLD1 4% Abs IC50 (uM): "+" ≤ 1.0 uM; 1.0 uM < "++" ≤ 5.0 uM; "+++" > 5.0 uM

5. COLO320DM Proliferation Abs IC50 (uM): "+" ≤ 10.0 uM; 10.0 uM < "++" ≤ 20.0 uM; "+++" > 20.0 uM

6. Calculated Mass

7. Found m/z (positive mode)

8. Found m/z (negative mode)

9. C=C double bond (e.g., −CH=CH−) reduction to single bond (e.g., $-CH_2-CH_2-$). A: −CH=CH− in each staple reduced to $-CH_2-CH_2-$; B: −CH=CH− in C-terminal side staple reduced to $-CH_2-CH_2-$ (see, e.g., see preparation of I-428 and I-432 as examples)

1	2	3	4	5	6	7	8	9
I-1	A	D			1899.8	1901.4	1899.3	
I-2	A				1899.8	1901.3	1899.4	
I-3	A	C			1899.8	1901.3	1899.4	
I-4	A	D			1899.8	951.3	1899.5	
I-5	A	D			1899.8	1901.3	1899.4	
I-6	A	D			1899.8	951.2	1899.3	
I-7	A	D			1956.8	1958.4	1956.5	
I-8	A	D			1956.8	1958.4	1956.5	

I-9	A	C			1975.9	1977.4	1975.4	
I-10	A	D			1975.9	1977.3	1975.4	
I-11	A	B			1975.9	1977.4	1975.5	
I-12	A	C			1975.9	1977.3	1975.5	
I-13	A	C			1975.9	1977.3	1975.4	
I-14	A	C			1975.9	1977.4	1975.5	
I-15	A	B			1975.9	989.2	1975.4	
I-16	A	C			1975.9	989.3	1875.5	
I-17	A	D			1923.8	1925.5	1923.3	
I-18	A				1923.8	1925.3	1923.3	
I-19	A	C			1999.9	2001.4	1999.3	
I-20	A				1999.9	2001.3	1999.3	
I-21	A	B			2061.9	2063.3	2061.3	
I-22	A				2061.9	2063.4	2061.4	
I-23	A	C			1923.8	1925.2	1923.2	
I-24	A	C	++		1999.9	2001.3	1999.4	
I-25	A	C			2061.9	1032.2	2061.3	
I-26	D				1980.9	1982.3	1980.3	
I-27	C				2056.9	2058.3	2056.4	
I-28	D				2118.9	2120.2	2118.4	
I-29	A	D			1980.9	1982.3	1980.3	
I-30	A	D			2056.9	2058.5	2056.5	
I-31	A	D			2118.9	2120.3	2118.4	
I-32	A	A			1989.9	1992.0	1990.1	
I-33	A	C			1989.9	996.6	1990.1	
I-34	A	C			1975.9	1977.9	1976.0	
I-35	D				1975.9	1977.9	1976.1	
I-36	C				1975.9	1977.9	1975.9	
I-37	A	C			1975.9	1977.9	1976.2	
I-38	A	C			1975.9	989.6	1976.3	
I-39	A	D			1961.8	1964.0	1961.9	
I-40	E				1961.8	1963.9	1961.7	
I-41	C				1961.8	1963.9	1961.9	
I-42	A	B			2060.9	2063.1	2061.1	
I-43	A	B			2060.9	1032.2	2060.9	
I-44	D				2046.9	2049.0	2046.9	
I-45	A	D			2179.0	2181.3	2179.4	
I-46	A	C			2131.0	2133.4	2131.5	
I-47	A	D			2145.0	2147.3	2145.4	
I-48	A	D			2255.0	2257.6	2255.1	
I-49	B	C			2255.0	2257.4	2255.4	
I-50	B	D			2207.0	1105.4	2208.2	
I-51	A	C			2159.0	2161.7	2159.7	
I-52	A	D			2173.0	2175.5	2173.7	
I-53	B	D			2283.0	2285.6	2283.9	
I-54	B				2283.0	2285.7	2283.6	
I-55	A	B			2051.9	2053.9	2052.3	
I-56	A	C			2037.9	2039.9	2037.8	
I-57	A	B			2122.9	2125.0	2123.1	
I-58	B	D			2108.9	2111.1	2108.8	
I-59	B	D			2108.9	2111.1	2109.1	

I-60	A	C			2180.0	2182.1	2180.1	
I-61	A	D			2165.9	2168.2	2165.9	
I-62	A	C			2077.9	2080.1	2078.2	
I-63	A	C			2077.9	2080.0	2078.2	
I-64	A	B	++	++	2073.9	2076.1	2074.0	
I-65	A	B			2047.9	2050.0	2048.0	
I-66	A	A			2074.9	1038.8	1036.8	
I-67	A	A	+	+	2074.9	2076.6	2074.7	
I-68	A	B			2137.0	1069.7	1067.8	
I-69	A	A	+	+	2137.0	2138.7	2136.8	
I-70	A	A	+	+	2103.0	2104.6	2102.8	
I-71	A	B			2165.0	2166.7	2164.8	
I-72	A	B			2090.9	2092.5	2090.6	
I-73	A	B			2152.9	2154.6	2152.7	
I-74	A	D			2101.9	2103.5	2101.6	
I-75	A	D			2163.9	2165.5	2163.6	
I-76	A	C			2064.9	2066.6	2064.6	A
I-77	A	D			2127.0	2128.8	2126.8	A
I-78	A	D			2105.9	2107.6	2105.8	A
I-79	B				2168.0	2169.8	2167.9	A
I-80	A	C			2059.9	2061.6	2059.8	
I-81	B	C			2046.9	2048.5	2046.6	
I-82	A	C			2059.9	2061.5	2059.6	
I-83	C	D			2046.9	2048.5	2046.6	
I-84	A	C			2075.9	2077.6	2075.7	
I-85	B	D			2062.9	2064.5	2062.6	
I-86	B	D			2075.9	2077.7	2075.8	
I-87	C				2062.9	2064.6	2062.7	
I-88	A	D			2116.9	2118.8	2116.8	
I-89	B	D			2103.9	2105.7	2103.8	
I-90	B	D			2116.9	2118.6	2116.7	
I-91	C				2103.9	2105.7	2103.7	
I-92	A				2236.0	1119.3	1117.3	
I-93	C				2248.0	1125.6	1123.4	
I-94	C				2248.0	1125.6	1123.5	
I-95	B				2276.1	2277.5	2275.6	
I-96	C				2276.1	1140.5	1138.6	
I-97	A	B			2149.0	2150.5	2148.6	
I-98	A	C			2149.0	1075.8	1073.9	
I-99	A	D	+		2179.0	1090.8	2178.4	
I-100	A				2179.0	1090.8	1088.9	
I-101	A	B			2205.0	1103.8	2204.4	
I-102	A	C			2205.0	1103.8	2204.4	
I-103	A	C			2231.0	1116.8	2230.5	
I-104	A	B			2165.0	1083.8	2164.4	
I-105	A				2165.0	1083.8	1081.9	
I-106	A	B	+		2191.0	1096.8	2190.4	
I-107	A				2191.0	1097.0	1095.0	
I-108	A	D			2221.0	1111.8	2220.5	
I-109	B	D	++		2221.0	1111.8	2220.5	
I-110	B	C			2247.1	1124.8	2246.5	

I-111	B	C			2247.1	1224.8	2246.5	
I-112	A	C			2157.9	1080.3	1078.3	
I-113	A	D			2157.0	1079.1	2156.3	
I-114	B				2157.0	1079.8	2156.3	
I-115	E				2144.0	1073.3	2143.3	
I-116	E				2144.0	1073.3	2143.3	
I-117	C				2157.0	2158.2	2156.3	
I-118	E				2144.0	1073.3	2143.3	
I-119	E				2144.0	1073.3	2143.3	
I-120	A	B			2172.0	2173.2	2171.3	
I-121	A	B	++		2172.0	2173.2	2171.3	
I-122	A	D			2200.0	2201.2	2199.3	
I-123	B	D			2234.0	1118.3	2233.4	
I-124	A	D			2186.0	1094.3	1092.3	
I-125	A	D	++		2186.0	1094.3	1092.3	
I-126	A	C	++		2172.0	1087.2	2171.3	
I-127	A	C	++		2172.0	1087.2	2171.3	
I-128	B	C	++		2200.0	2201.2	2199.4	
I-129	A	C	++		2186.0	2187.2	2185.3	
I-130	B	D			2302.1	1152.3	-	
I-131	C	D			2302.1	2303.4	-	
I-132	B	D			2302.1	2303.5	-	
I-133	D	D			2306.1	2307.5	-	A
I-134	C	D			2306.1	2303.3	-	A
I-135	E	D			2306.1	2307.6	-	A
I-136	A	B			2252.0	1127.6	1125.6	
I-137	A	B			2294.1	1148.6	1146.6	
I-138	A	B	+	+	2266.0	1134.6	1132.6	
I-139	A	B	+		2264.0	1133.6	1131.6	
I-140	A	A	+		2278.0	1140.6	1138.6	
I-141	A	B	+		2292.0	1147.6	1145.5	
I-142	C	C	+++		2251.0	1127.0	1125.0	
I-143	C	D			2293.1	1148.1	1146.1	
I-144	A	C	++		2265.0	1134.1	1132.3	
I-145	E				2238.0	1120.5	1118.6	
I-146	E				2280.1	2282.1	2280.2	
I-147	D				2252.1	1127.6	1125.6	
I-148	C				1976.0	989.2	987.0	
I-149	C	D			2045.0	2046.7	2044.6	
I-150	E				2018.0	2019.4	2017.4	
I-151	B	D			1981.9	993.3.	991.2.	
I-152	D				2051.0	2011.4	2009.4	
I-153	E				1980.0	991.3.	989.2.	A
I-154	E				2049.1	2050.6	2048.4	A
I-155	E				1953.0	977.7	975.5	A
I-156	E				2022.1	2023.6	2021.5	A
I-157	E				1985.9	994.2.	1985.3	A
I-158	E				2055.0	2056.6	2054.5	A
I-159	A	B			2073.9	1038.3	1036.2	
I-160	A	C			2046.9	1024.8	1022.9	
I-161	C				2060.9	1031.8	1029.6	

I-162	C	D			2060.9	2062.0	2060.1	
I-163	A	C	+++		2060.9	1031.7	2060.1	
I-164	B	D			2088.0	1045.2	2087.2	
I-165	A	C			2073.9	1038.2	2073.2	
I-166	B	C			2046.9	1024.7	2046.1	
I-167	E				2060.9	1031.7	2060.2	
I-168	C	D			2060.9	1031.7	2060.2	
I-169	B	D			2060.9	1031.7	2060.2	
I-170	B	D			2088.0	1045.2	2087.2	
I-171	B	D			2078.0	1040.2	2077.2	A
I-172	D				2051.0	1026.7	2050.3	A
I-173	E				2065.0	1033.7	2064.2	A
I-174	E				2065.0	1033.7	2064.2	A
I-175	E				2065.0	1033.7	2064.2	A
I-176	E				2092.0	1047.2	2091.2	A
I-177	C	D			2078.0	1040.2	2077.2	A
I-178	E				2051.0	1026.7	2050.2	A
I-179	E				2065.0	1033.7	2064.2	A
I-180	E				2065.0	1033.7	2064.2	A
I-181	E				2065.0	1033.7	2064.2	A
I-182	E				2092.0	1047.2	1887.9	A
I-183	A	C	++		2074.9	1038.7	1036.8	
I-184	A				2137.0	1069.7	1067.7	
I-185	A				2074.9	1038.7	1036.8	
I-186	A				2137.0	1069.7	1067.6	
I-187	A	C	+++		2117.0	1059.7	1057.6	
I-188	A	C			2179.0	1090.7	1088.8	
I-189	A	C			2179.0	1090.7	1088.7	
I-190	A				2103.0	1052.7	1050.8	
I-191	B	C			2165.0	1083.7	1081.7	
I-192	A				2165.0	1083.7	1081.7	
I-193	A	C			2152.9	2175.8	2152.0	
I-194	A	A			2152.9	2175.8	2152.0	
I-195	A				2184.0	2184.9	2183.1	
I-196	B	C			2137.0	1069.6	2136.1	
I-197	A	B			2137.0	2159.8	2136.0	
I-198	A	C			2074.9	2097.8	2073.9	
I-199	A	C			2060.9	2083.8	2060.0	
I-200	B	D			2046.9	2069.8	2046.1	
I-201	B	C			2074.0	2096.8	2073.0	
I-202	A	D			2083.0	2084.1	2082.0	
I-203	E	D			2109.0	2131.9	2108.1	
I-204	A	C			2204.9	1103.6	1101.7	
I-205	A	C			2204.9	2227.8	2204.0	
I-206	A				2204.9	2227.8	2204.0	
I-207	A	B			2204.9	2227.8	2204.0	
I-208	A	C			2154.9	2177.8	2154.0	
I-209	E	D			2045.0	2067.8	2044.0	
I-210	B	C			2032.9	2055.8	2032.0	
I-211	C	D			2132.0	2154.9	2131.1	
I-212	A	C			2059.9	2082.8	2059.0	

I-213	B	C			2016.9	2039.8	2015.9	
I-214	B	D			2102.0	2103.2	2101.1	
I-215	A				2074.9	1038.7	1036.7	
I-216	B	C			2046.9	1024.7	1022.6	
I-217	E	D			2123.0	1062.7	1060.8	
I-218	B	C			2136.0	1069.2	1067.2	
I-219	C				2059.0	1030.7	1028.7	
I-220	C	D			2093.0	1047.7	1045.5	
I-221	C	D			2074.0	2075.2	2073.2	
I-222	E	D			2059.0	1030.7	1028.6	
I-223	A	B			2211.0	2212.2	2210.2	
I-224	A	D			2324.1	2325.3	2323.2	
I-225	A				2308.1	2309.3	2307.2	
I-226	A	B			2165.0	1083.7	1081.8	
I-227	A	B			2252.0	2253.1	2251.2	
I-228	A	C			2278.1	2279.3	2277.3	
I-229	A	D			2365.1	2366.4	2364.3	
I-230	A				2224.0	1113.2	1111.2	
I-231	A	D			2250.0	2251.1	2049.2	
I-232	A	D			2337.1	2338.1	2336.2	
I-233	A	D			2010.9	1006.6	2009.9	A
I-234	A	D			2024.9	1013.6	2023.9	A
I-235	A	D			2038.9	1020.6	2038.1	A
I-236	A	D			2010.9	1006.6	2009.9	A
I-237	A	D		+++	1996.9	999.6.	1995.8	A
I-238	A	D			2010.9	1006.6	2009.9	A
I-239	C	D			2045.9	2046.8	2044.8	A
I-240	B	D			2059.9	1031.1	2058.9	A
I-241	C	D			2073.9	1038.1	2073.2	A
I-242	C	D			2045.9	1024.1	2044.8	A
I-243	B	D			2031.9	1017.1	2030.8	A
I-244	B	D			2045.9	1024.1	2045.2	A
I-245	A	B		+	2060.9	1031.6	2059.9	
I-246	A	B			2060.9	1031.6	2060.2	
I-247	A	B			2060.9	1031.6	2060.2	
I-248	A	B			2046.9	1024.6	2045.9	
I-249	A	C			2094.9	1048.6	2093.9	
I-250	A	C			2100.9	1051.6	2100.2	
I-251	A	B			2086.9	1044.6	2085.9	
I-252	A	C			2058.9	1030.6	2057.9	
I-253	A	A		+	2086.9	1044.6	2086.2	
I-254	A	C			2184.8	1093.5	2183.9	
I-255	A	C			2074.9	1038.6	2073.9	
I-256	A	C			2086.9	1044.6	2086.2	
I-257	A	C			2149.0	1075.6	2147.9	
I-258	A	C			2086.9	1044.6	2085.9	
I-259	B	C			2149.0	1075.6	2147.9	
I-260	A				2100.9	1082.5	2161.9	
I-261	A				2163.0	1051.6	2100.2	
I-262	A	B	+	+	2114.9	1058.6	2114.2	
I-263	A	C			2114.9	1058.6	2113.9	

I-264	A				2100.9	1051.6	2099.9	
I-265	A	C			2100.9	1051.6	2099.9	
I-266	C	D			1992.9	1996.6	1994.8	
I-267	C				1992.9	1993.9	1992.0	
I-268	B	D			2006.9	1005.7	2008.3	
I-269	B	D			2006.9	1004.6	1002.6	
I-270	A	C			2021.0	1011.6	1009.7	
I-271	A	C			2035.0	1019.8	2036.6	
I-272	A	B			2035.0	1018.6	1016.8	
I-273	B	D			2035.0	1019.8	2036.8	
I-274	B	D			2035.0	1018.6	1016.6	
I-275	A	C			2049.0	1026.7	2050.4	
I-276	A	C			2049.0	1025.6	1023.7	
I-277	B	D			2049.0	1026.8	2050.4	
I-278	B	D			2049.0	1025.7	1023.8	
I-279	A	C			2069.0	1036.8	2070.8	
I-280	A	B			2069.0	2070.1	2068.2	
I-281	A	C			2033.0	1018.7	2034.4	
I-282	A	C			2033.0	1017.6	1015.7	
I-283	A	C			2047.0	1024.6	1022.7	
I-284	A	C			2061.0	1031.6	1029.4	
I-285	A	C			2075.0	1038.6	1036.7	
I-286	A				2151.0	2152.1	2150.2	
I-287	B	D			2151.0	1076.7	2150.0	
I-288	A	B			2151.0	2151.9	2150.0	
I-289	A	C			2151.0	1076.6	1074.6	
I-290	B				2151.0	1076.7	2150.3	
I-291	E	D	++		2165.0	1083.7	2164.0	
I-292	A	C			2058.9	2060.0	2058.0	
I-293	A	B			2099.0	2099.9	2098.1	
I-294	A	A		+	2083.0	2083.9	2082.1	
I-295	A	A			2146.9	1075.0	1073.1	
I-296	A	B			2102.9	1052.8	1050.9	
I-297	A	B			2094.0	2094.9	2093.1	
I-298	A	A			2113.9	2114.9	2113.0	
I-299	A	B		++	2070.0	2071.2	2069.1	
I-300	A	C		+++	2070.0	2071.2	2069.0	
I-301	A	D		+++	2070.0	2071.1	2069.1	
I-302	A	D			2059.0	2060.0	2058.0	
I-303	A	D			2843.3	1422.9	1420.8	
I-304	A	C		+	2018.9	1010.6	2017.9	
I-305	A	C			2110.9	1056.6	2110.0	
I-306	A	D			2133.9	1068.1	2133.0	
I-307	A	D			2034.9	1018.6	2033.9	
I-308	A				2032.9	2034.1	2032.1	
I-309	A				2080.9	2082.1	2080.1	
I-310	A	B			2170.9	1086.6	2170.1	
I-311	A	B			2117.0	1059.6	2116.0	
I-312	A	B			2072.9	1037.6	2072.0	
I-313	A	D		+++	2131.9	2133.1	2131.0	
I-314	A	C			2165.9	2167.2	2165.3	

I-315	A	C			2121.0	2122.1	2120.3	
I-316	B	D			2094.0	2095.2	2093.3	
I-317	E				2108.0	2109.1	2107.3	
I-318	A	C			2121.0	2122.1	2120.3	
I-319	A	D			2234.0	2235.3	2233.4	
I-320	B	D			2207.0	2208.3	2206.4	
I-321	E				2221.0	2222.2	2220.3	
I-322	A	C			2234.0	2235.3	2233.4	
I-323	A	B			2187.0	2188.2	2186.1	
I-324	A	D			2160.0	2161.1	2159.3	
I-325	C				2174.0	2175.1	2173.2	
I-326	A	C			2187.0	2188.2	2186.3	
I-327	A				2148.9	2150.6	2148.7	
I-328	A	B			2086.9	2088.6	2086.8	
I-329	A	A			2080.9	2082.6	2080.8	
I-330	A	C			2109.0	1055.6	1053.6	
I-331	A				2158.9	2160.8	2158.9	
I-332	A	C			2096.9	2098.7	2096.9	
I-333	A				2090.9	1047.0	1044.9	
I-334	A	B			2119.0	1060.6	1058.6	
I-335	A	A	+	+	2084.9	2085.9	2084.0	
I-336	A	B	++		2084.9	1043.6	2084.1	
I-337	A	B	+		2070.9	2071.9	2070.0	
I-338	A	C	+		2070.9	1036.6	2070.0	
I-339	C	D			2249.8	2250.7	2248.9	
I-340	C				2397.8	2398.7	2396.8	
I-341	C	D			2397.8	2398.8	2396.9	
I-342	A	B	+		2204.0	1103.1	1101.2	
I-343	A	B			2275.0	1138.6	1136.5	
I-344	A	D			2113.0	2113.9	2112.1	
I-345	A	C			2118.9	2119.9	2118.1	
I-346	B				2156.9	2157.9	2156.0	
I-347	B	D			2357.0	1179.6	1177.6	
I-348	A				2204.9	2206.0	2204.1	
I-349	A	D			2113.9	2114.8	2113.0	
I-350	A	D			2119.9	2120.9	2119.0	
I-351	B	D			2157.9	2158.8	2156.9	
I-352	B	D			2358.0	2358.9	2357.0	
I-353	A				2052.9	1027.6	1025.6	
I-354	B	D			2067.0	2067.9	2066.1	
I-355	A	C			2130.9	1066.6	1064.7	
I-356	A	D			2124.9	2125.9	2124.1	
I-357	A	C			2124.9	1063.7	1061.9	
I-358	A	B			2090.9	2091.9	2090.1	
I-359	A	C			2113.9	2114.9	2113.0	
I-360	D				2040.9	2041.9	2040.1	
I-361	E				2040.9	1021.6	1019.8	
I-362	A				2040.9	1021.6	1019.5	
I-363	B	D			2014.9	2015.9	2014.0	
I-364	A	A			2080.9	2082.0	2080.3	
I-365	A	B			2080.9	2081.9	2080.0	

I-366	E				2067.0	1034.6	1032.7	
I-367	B				2028.9	2029.9	2028.0	
I-368	C				2065.9	2067.0	2065.1	
I-369	A	C			2142.9	1072.6	1070.6	
I-370	E				2028.9	2029.9	2028.0	
I-371	C				2064.9	2066.1	2064.0	
I-372	E				2026.9	2027.9	2026.0	
I-373	E				2041.9	2042.9	2041.0	
I-374	C				2055.9	2056.9	2055.1	
I-375	A	C		+	2205.9	1104.2	1102.2	
I-376	C	D			2205.9	1104.2	1102.1	
I-377	B	C			2205.9	1104.1	1102.1	
I-378	A	B			2188.0	1095.1	1093.2	
I-379	A	B			2146.0	1074.1	1072.3	
I-380	A	D			2152.9	1077.6	1075.7	
I-381	A	B			2160.0	1081.1	1079.3	
I-382	A	B			2100.9	1051.6	1050.0	
I-383	A	A			2100.9	1051.6	1049.6	
I-384	A				2115.9	2117.2	2115.1	
I-385	A	D			2115.9	2117.1	2115.1	
I-386	A	A		+++	2136.9	1069.6	1067.6	
I-387	A	C			2126.9	2128.1	2126.1	
I-388	A	A			2088.9	1045.6	1043.6	
I-389	A	B			2076.9	1039.6	1037.7	
I-390	A	B			2076.9	1039.6	1037.7	
I-391	A	C			2117.9	1060.1	1058.2	
I-392	A	C			2117.9	1060.1	1058.2	
I-393	A	C			2103.9	1053.1	1051.2	
I-394	A				2103.9	2104.7	2102.9	
I-395	E				2024.9	2025.9	2024.1	
I-396	A	B			2103.0	1052.6	2102.2	
I-397	A	B			2088.9	2111.9	2088.1	
I-398	A	B			2104.9	2106.0	2104.1	
I-399	A	A			2190.0	1096.0	2189.0	
I-400	A	B			2176.0	1089.0	2175.0	
I-401	A	A			2192.0	2192.8	2191.0	
I-402	A	B			2174.0	2197.0	2173.2	
I-403	A				2174.0	1088.1	2173.0	
I-404	A	A			2160.0	2182.8	2159.0	
I-405	A	A			2160.0	2182.8	2159.0	
I-406	A	A			2176.0	1089.1	2075.1	
I-407	A	B			2188.0	2210.9	2187.0	
I-408	A	A			2188.0	2210.8	2187.0	
I-409	A	A			2174.0	2196.8	2173.0	
I-410	A				2174.0	2197.1	2173.3	
I-411	A	B			2190.0	2190.8	2188.8	
I-412	A	A			2190.0	2213.1	2189.3	
I-413	A	A			2112.9	1057.6	2112.0	
I-414	A	A			2127.0	2127.8	2126.0	
I-415	A	A			2114.9	2115.8	2113.9	
I-416	A	A			2171.9	2172.8	2171.0	

I-417	A	B			2200.0	1101.1	2199.0	
I-418	A	B			2079.0	2079.8	2077.9	
I-419	A				2093.0	2094.1	2092.1	
I-420	A	B			2093.0	2093.8	2091.9	
I-421	A	D			2070.9	2071.9	2070.0	
I-422	A	D			2064.9	2065.8	2063.9	
I-423	A	C			2084.9	2085.8	2083.9	
I-424	A	C			2079.0	2079.9	2078.0	
I-425	B	D			2008.9	1005.5	1003.6	A
I-426	A	D			2022.9	2024.0	2022.1	A
I-427	A	D			2004.8	1003.5	1001.6	
I-428	A	D			2006.9	2007.8	2006.0	B
I-429	A	D			2018.9	1010.5	1008.7	
I-430	B	D			2020.9	2022.3	2020.4	
I-431	A	D			2020.9	2022.1	2020.2	B
I-432	A	D			2117.0	2118.8	2116.9	
I-433	A	C			2117.0	1059.8	1057.9	
I-434	A	D			2103.0	1052.7	1050.9	
I-435	A	D			2090.9	1046.7	1044.8	
I-436	A	C			2090.9	2092.0	2090.2	
I-437	A	D			2090.9	1046.7	1044.9	
I-438	A	D			2151.0	1076.7	1074.9	
I-439	A	D			2088.9	1045.8	1043.9	
I-440	A	D			2086.9	1044.7	1042.8	
I-441	A	D			2074.9	1038.7	1036.9	
I-442	B	D			2074.9	1038.7	1036.7	
I-443	A	D			2072.9	1037.7	1035.8	
I-444	A	C			2090.9	1046.9	1044.9	
I-445	A	C			2104.9	1053.7	1051.8	
I-446	A	D			2104.9	2106.3	2104.5	
I-447	A	D			2103.0	1052.8	1050.8	
I-448	A	D			2103.0	1052.8	1051.0	
I-449	A	D			2117.0	1059.8	1057.9	
I-450	A	D			2117.0	1059.8	1057.9	
I-451	A	D			2131.9	1067.2	1065.4	
I-452	A	D			2131.9	1067.2	1065.3	
I-453	A	D			2202.0	1102.3	1100.4	
I-454	A	D			2132.0	2133.5	2131.5	
I-455	A	D			2132.0	2133.6	2131.5	
I-456	A	D			2151.0	1076.8	1074.8	
I-457	A	C			2151.0	1076.7	1074.8	
I-458	A	B			2074.9	1038.7	2074.3	
I-459	A				2074.9	2098.0	2074.2	
I-460	A				2162.0	2185.1	2161.3	
I-461	A	C			2162.0	1082.3	2161.5	
I-462	A	C			2117.0	2140.2	2116.3	
I-463	A				2204.0	2227.1	2203.4	
I-464	A	B			2275.0	2298.3	2274.7	
I-465	A	B			2317.1	2340.3	2316.5	
I-466	A				2317.1	2340.3	2316.5	
I-467	A	B			2317.1	1159.8	2316.6	

I-468	A	C			2317.1	1095.3	1093.4	
I-469	B	D			2155.9	1070.0	1068.1	
I-470	E	D			2103.0	1052.8	1050.8	
I-471	A	D			2082.9	2083.7	2081.8	
I-472	A	B			2114.9	1059.1	2115.3	
I-473	A	C			2046.9	2048.8	2047.1	
I-474	A	C			2046.9	1025.1	1023.3	
I-475	A	C			2072.9	1037.9	2073.1	
I-476	A	C			2072.9	1038.1	2073.2	
I-477	A	C			2096.9	2098.7	2096.9	
I-478	A	B			2086.9	2088.8	2086.8	
I-479	A	C			2046.9	1024.9	2047.6	
I-480	A	D			2046.9	1025.1	1023.1	
I-481	A				2130.9	1067.1	2131.1	
I-482	A				2130.9	1067.1	1065.1	
I-483	A	C			2063.0	2064.2	2062.2	
I-484	A	D			2063.0	2064.2	2062.2	
I-485	A	C			2069.0	2070.2	2068.1	
I-486	A				2069.0	2070.2	2068.1	
I-487	A	C			2097.0	1049.8	2096.6	
I-488	A				2097.0	1049.8	2096.7	
I-489	A				2029.0	2030.2	2028.2	
I-490	B				2029.0	1015.6	2028.2	
I-491	B				2055.0	1028.6	2054.2	
I-492	B				2055.0	1028.6	2054.2	
I-493	A	C			2303.0	1152.9	1151.1	
I-494	A	C			2317.0	1159.9	1157.9	
I-495	A	B			2317.0	1159.9	1158.1	
I-496	A	C			2275.0	1138.9	1137.1	
I-497	A	B			2275.0	1138.9	1137.1	
I-498	A	B			2289.1	1145.9	1144.1	
I-499	A	C			2289.1	1145.9	1143.9	
I-500	A	B			2289.1	1145.9	1144.1	
I-501	A	C			2289.1	1145.9	2287.9	
I-502	A	C			2345.1	1173.9	1172.1	
I-503	A	C			2345.1	1174.1	1171.9	
I-504	A	C			2359.1	1180.9	1179.1	
I-505	A	C			2359.1	1181.1	1178.9	
I-506	A	C			2289.0	1145.9	1144.1	
I-507	A	B			2303.0	1152.9	1151.1	
I-508	A	B			2275.0	1138.9	1137.1	
I-509	A	B			2275.0	1138.9	1137.1	
I-510	A	B			2275.0	1138.9	1136.9	
I-511	A	B			2275.0	1139.1	1137.1	
I-512	A	C			2331.1	1166.9	1165.1	
I-513	A	C			2331.1	1166.9	1164.9	
I-514	A	C			2132.9	2133.5	2131.7	
I-515	A	D			2146.9	1074.4	1072.5	
I-516	A	C			2161.0	1081.4	1079.4	
I-517	A	D			2781.3	1392.1	1390.2	
I-518	E				2809.3	1406.2	1404.2	

I-519	A	D			2137.9	2139.3	2137.4	
I-520	A	D			2151.9	2153.3	2151.4	
I-521	A				2118.9	2121.1	2119.0	
I-522	C				2104.9	2107.1	2105.1	
I-523	A				2132.9	2135.1	2133.1	
I-524	B				2118.9	2121.1	2118.9	
I-525	A				2146.9	2149.2	2146.9	
I-526	C				2133.0	2135.1	2133.2	
I-527	A				2117.0	2119.2	2117.1	
I-528	A				2117.0	2119.0	2117.0	
I-529	A				2151.0	2153.1	2150.8	
I-530	A				2165.0	2167.2	2165.1	
I-531	A				2129.0	2131.2	2129.1	
I-532	A				2129.0	2131.0	2129.1	
I-533	A				2181.0	2183.1	2180.6	
I-534	A				2174.0	2176.0	2174.0	
I-535	B				2021.0	2022.3	2020.5	
I-536	B				2035.0	2036.5	2034.6	
I-537	A				2061.0	1031.8	1029.8	
I-538	A				2049.0	2050.4	2048.5	
I-539	A				2049.0	2050.4	2048.6	
I-540	C				2091.0	2092.5	2090.6	
I-541	A				2074.9	2076.4	2074.6	
I-542	A				2112.0	2113.3	2111.5	
I-543	B				2088.9	1045.8	1043.9	
I-544	C				2088.9	1045.8	1043.8	
I-545	C	D			2103.0	2104.5	2102.5	
I-546	C				2103.0	1052.8	1050.9	
I-547	A	D			2088.9	2090.4	2088.2	
I-548	C	D			2103.0	2104.4	2102.5	
I-549	E	D			2117.0	2118.4	2116.6	
I-550	E	D			2117.0	2118.4	2116.6	
I-551	E	D			2131.0	2132.5	2130.6	
I-552	E				2040.9	2042.4	2040.5	
I-553	E	D			2055.0	2056.6	2054.7	
I-554	E	D			2026.9	2028.4	2026.6	
I-555	E	D			2040.9	2042.3	2040.5	
I-556	E	D			2069.0	2070.5	2068.6	
I-557	A				2074.9	2077.1	2075.0	
I-558	A				2060.9	2063.0	2060.9	
I-559	A				2046.9	2049.0	2047.2	
I-560	A				2074.9	2077.1	2074.8	
I-561	A				2088.9	2091.1	2089.1	
I-562	B	D			2127.9	2129.1	2127.2	A
I-563	A	D			2141.9	2143.0	2141.2	A
I-564	B	D			2136.0	1069.2	1067.3	A
I-565	A	D			2162.0	2163.1	2161.3	A
I-566	B				2193.9	1198.3	1196.3	
I-567	B				2219.9	1111.4	1109.3	
I-568	A				2092.9	2095.1	2093.1	
I-569	A				2092.9	2094.8	2092.6	

I-570	A				2108.9	2111.5	2110.0	
I-571	A				2108.9	2111.8	2109.9	
I-572	A				2152.8	2156.1	2153.8	
I-573	A				2152.8	2155.9	2153.7	
I-574	A				2092.9	2095.0	2092.8	
I-575	A				2092.9	2094.9	2092.6	
I-576	A				2108.9	2111.5	2110.0	
I-577	A				2108.9	1056.5	1054.8	
I-578	A				2152.8	2156.0	2153.8	
I-579	A				2152.8	2155.8	2154.4	
I-580	A				2092.9	2095.2	2093.3	
I-581	A				2092.9	2095.0	2093.2	
I-582	A				2104.9	1054.2	1052.4	
I-583	A				2104.9	2106.9	2104.8	
I-584	A				2099.9	2101.9	2100.1	
I-585	A				2099.9	2101.9	2099.8	
I-586	A				2099.9	2101.9	2099.8	
I-587	A				2099.9	2101.9	2100.0	
I-588	A				2088.9	2091.1	2088.8	
I-589	A				2088.9	2090.9	2089.0	
I-590	A				2088.9	2091.1	2089.6	
I-591	A				2088.9	2091.1	2088.8	
I-592	E				2086.9	2088.8	2087.1	
I-593	E				2086.9	2088.9	2087.0	
I-594	E				2117.0	2119.2	2117.2	
I-595	E				2117.0	2119.0	2117.1	
I-596	E				2117.0	2119.1	2116.8	
I-597	E				2117.0	2119.1	2117.0	
I-598	E				2117.0	2119.2	2117.3	
I-599	E				2117.0	2119.2	2116.9	
I-600	E				2117.0	2119.2	2117.1	
I-601	E				2117.0	2119.0	2117.0	
I-602	E				2117.0	2119.1	2116.9	
I-603	E				2117.0	2119.0	2117.0	
I-604	E				2117.0	2119.1	2116.9	
I-605	E				2117.0	2119.0	2117.2	
I-606	E				2186.0	2188.1	2186.2	
I-607	A				2158.0	2160.2	2158.1	

[0887] Table E2. Certain peptides and compositions thereof as examples.

Peptides are stapled unless indicated otherwise (among other things, the present disclosure also provides unstapled versions of such peptides, optionally protected with one or more protection group (e.g., protection of N-terminus, C-terminus, side chains, etc.), and intermediates thereof). As appreciated by those skilled in the art, stapling may provide more than one stereoisomers (e.g., *E/Z* of double bonds and/or diastereomers). In some embodiments, a double bond in a staple is *E*. In some embodiments, a double bond in a staple is *Z*. In some embodiments, isomers (or combinations thereof) are listed separately (typically based on reverse phase HPLC peaks (e.g., detected by UV (e.g., at 220 nm) and/or MS) in the order of elution: each earlier

eluted peak is assigned a smaller ID number than each later eluted peaks (if any); in some cases, a peak may contain two or more isomers; in some cases, isomers are not separated (or single isomer), e.g., when there is one peak on HPLC). Compositions utilized in various assays are typically of stapled peptides; the present disclosure also provides peptides prior to stapling and compositions thereof. A general HPLC method: Xselect CSH C18 column 1.7um 2.1x50mm 130 Å; Column temperature 40 °C; Flow 0.6 mL/min; 0.1% formic acid in both acetonitrile and water, 7.2 min gradient from 5 to 95% acetonitrile. In some embodiments, a different gradient and/or a C8 column were used.

1	Description
I-1	Ac-PL3-Asp-Leu-B5-Asp-Asp-Ala-Ala-Phe-dLys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-2	Ac-PL3-Asp-Leu-B5-Asp-Asp-Ala-Ala-Phe-dLys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-3	Ac-PL3-Asp-Leu-B5-Asp-Asp-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-4	Ac-PL3-Asp-Leu-B5-Asp-Asp-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-5	Ac-PL3-Asp-Leu-B5-Asp-Asp-Ala-Ala-Phe-DGlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-6	Ac-PL3-Asp-Leu-B5-Asp-Asp-Ala-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-7	Ac-PL3-Asp-Leu-B5-Asp-Asp-Lys*3-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Gln-NH2
I-8	Ac-PL3-Asp-Leu-B5-Asp-Asp-GlnR*3-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-Gln-NH2
I-9	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Ala-Ala-Phe-dLys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-10	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Ala-Ala-Phe-dLys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-11	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-12	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-13	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Ala-Ala-Phe-DGlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-14	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Ala-Ala-Phe-DGlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-15	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Ala-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-16	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Ala-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-17	Ac-PL3-Asp-Npg-B5-Asp-Asp-Ala-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-NH2
I-18	Ac-PL3-Asp-Npg-B5-Asp-Asp-Ala-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-NH2
I-19	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-NH2
I-20	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-NH2
I-21	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-TriAzLys*3-PyrS2-2F3MeF-BztA-sAla*3-NH2
I-22	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-TriAzLys*3-PyrS2-2F3MeF-BztA-sAla*3-NH2
I-23	Ac-PL3-Asp-Npg-B5-Asp-Asp-Ala-Ala-Phe-sAla*3-PyrS2-3Thi-BztA-TriAzLys*3-NH2
I-24	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-sAla*3-PyrS2-3Thi-BztA-TriAzLys*3-NH2
I-25	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-sAla*3-PyrS2-2F3MeF-BztA-TriAzLys*3-NH2
I-26	Ac-PL3-Asp-Npg-B5-Asp-Asp-sAla*3-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-Gln-NH2
I-27	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-sAla*3-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-Gln-NH2
I-28	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-sAla*3-Ala-Phe-TriAzLys*3-PyrS2-2F3MeF-BztA-Gln-NH2
I-29	Ac-PL3-Asp-Npg-B5-Asp-Asp-TriAzLys*3-Ala-Phe-sAla*3-PyrS2-3Thi-BztA-Gln-NH2
I-30	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-TriAzLys*3-Ala-Phe-sAla*3-PyrS2-3Thi-BztA-Gln-NH2
I-31	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-TriAzLys*3-Ala-Phe-sAla*3-PyrS2-2F3MeF-BztA-Gln-NH2
I-32	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-33	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-34	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-AsnR*3-NH2
I-35	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-AsnR*3-PyrS2-3Thi-BztA-Lys*3-NH2

I-36	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-AsnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-37	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Orn*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-38	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Orn*3-NH2
I-39	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Orn*3-PyrS2-3Thi-BztA-AsnR*3-NH2
I-40	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-AsnR*3-PyrS2-3Thi-BztA-Orn*3-NH2
I-41	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-AsnR*3-PyrS2-3Thi-BztA-Orn*3-NH2
I-42	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-43	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Lys*3-Ala-NH2
I-44	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-AsnR*3-PyrS2-3Thi-BztA-Lys*3-Ala-NH2
I-45	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[isophthalate]-Lys-Ala-Phe-Leu-PyrS2-3Thi-BztA-Lys-NH2
I-46	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[succinate]-Lys-Ala-Phe-Leu-PyrS2-3Thi-BztA-Lys-NH2
I-47	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Me2Mal]-Lys-Ala-Phe-Leu-PyrS2-3Thi-BztA-Lys-NH2
I-48	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[diphenate]-Lys-Ala-Phe-Leu-PyrS2-3Thi-BztA-Lys-NH2
I-49	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Biphen33COOH]-Lys-Ala-Phe-Leu-PyrS2-3Thi-BztA-Lys-NH2
I-50	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[isophthalate]-Lys-Ala-Phe-Leu-PyrS2-2ClF-BztA-Lys-NH2
I-51	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[succinate]-Lys-Ala-Phe-Leu-PyrS2-2ClF-BztA-Lys-NH2
I-52	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Me2Mal]Lys-Ala-Phe-Leu-PyrS2-2ClF-BztA-Lys-NH2
I-53	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[diphenate]Lys-Ala-Phe-Leu-PyrS2-2ClF-BztA-Lys-NH2
I-54	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Biphen33COOH]Lys-Ala-Phe-Leu-PyrS2-2ClF-BztA-Lys-NH2
I-55	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-NH2
I-56	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-AsnR*3-NH2
I-57	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-58	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-AsnR*3-Ala-NH2
I-59	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-AsnR*3-Ala-NH2
I-60	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Gln-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-61	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Gln-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-AsnR*3-Ala-NH2
I-62	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Throl
I-63	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Throl
I-64	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Prool
I-65	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Alaol
I-66	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-67	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-68	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-69	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-70	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-71	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-72	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Thr-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-73	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Thr-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-74	Ac-PL3-Asp-GlnR**3-B5-Asp-3COOHF-Lys**3-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-75	Ac-PL3-Asp-GlnR**3-B5-Asp-3COOHF-Lys**3-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-76	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-77	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-78	Ac-PL3-Asp-GlnR**3-B5-Asp-3COOHF-Lys**3-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-

	NH2
I-79	Ac-PL3-Asp-GlnR**3-B5-Asp-3COOHF-Lys**3-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-80	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-81	Ac-PL3-Hse-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-82	Ac-PL3-Asp-Npg-B5-Asn-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-83	Ac-PL3-Asp-Npg-B5-Hse-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-84	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Ser-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-85	Ac-PL3-Hse-Npg-B5-Asp-3COOHF-Ser-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-86	Ac-PL3-Asp-Npg-B5-Asn-3COOHF-Ser-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-87	Ac-PL3-Asp-Npg-B5-Hse-3COOHF-Ser-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-88	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Gln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-89	Ac-PL3-Hse-Npg-B5-Asp-3COOHF-Gln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-90	Ac-PL3-Asp-Npg-B5-Asn-3COOHF-Gln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-91	Ac-PL3-Asp-Npg-B5-Hse-3COOHF-Gln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-92	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-[diaminobutane]GlnR-Ala-NH2
I-93	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-[4aminopiperidine]GlnR-Ala-NH2
I-94	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[4aminopiperidine]GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-GlnR-Ala-NH2
I-95	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-[4mampiperidine]GlnR-Ala-NH2
I-96	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-[4mampiperidine]GlnR-Ala-NH2
I-97	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-98	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-99	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Npg-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-100	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Npg-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-101	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Cha-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-102	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Cha-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-103	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Cha-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-104	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-105	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-106	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-107	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-108	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Npg-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-109	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Npg-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-110	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Cha-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-111	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Cha-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-112	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-113	Ac-PL3-Asn-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2

I-114	Ac-PL3-Asn-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-115	Ac-PL3-Hse-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-116	Ac-PL3-Hse-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-117	Ac-PL3-Asp-Npg-B5-Asn-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-118	Ac-PL3-Asp-Npg-B5-Hse-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-119	Ac-PL3-Asp-Npg-B5-Hse-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-120	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-121	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-122	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Leu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-123	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Phe-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-124	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Val-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-125	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Val-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-126	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Aib-NH2
I-127	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Aib-NH2
I-128	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-129	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Val-NH2
I-130	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-[39N2spiroundecane]GlnR-Ala-NH2
I-131	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-[29N2spiroundecane]GlnR-Ala-NH2
I-132	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[29N2spiroundecane]GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-GlnR-Ala-NH2
I-133	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-[39N2spiroundecane]GlnR-Ala-NH2
I-134	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-[29N2spiroundecane]GlnR-Ala-NH2
I-135	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[29N2spiroundecane]GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-GlnR-Ala-NH2
I-136	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-137	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-138	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-139	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Cpg-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-140	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Cbg-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-141	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-142	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-143	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-144	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-145	Ac-PL3-Hse-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-146	Ac-PL3-Hse-Npg-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-147	Ac-PL3-Hse-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2

I-148	Ac-PL3-Asn-Cha-B5-Asp-Gln-Hse-Ala-Phe-GlnR*3-PyrS2-Phe-BztA-Lys*3-NH2
I-149	Ac-PL3-Asn-Cha-B5-Asp-Gln-iPrLys-Ala-Phe-GlnR*3-PyrS2-Phe-BztA-Lys*3-NH2
I-150	Ac-PL3-Asn-Cha-B5-Asp-Thr-iPrLys-Ala-Phe-GlnR*3-PyrS2-Phe-BztA-Lys*3-NH2
I-151	Ac-PL3-Asn-Cha-B5-Asp-Gln-Hse-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-152	Ac-PL3-Asn-Cha-B5-Asp-Gln-iPrLys-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-153	Ac-PL3-Asn-Cha-B5-Asp-Gln-Hse-Ala-Phe-GlnR*3-PyrS2-Phe-BztA-Lys*3-NH2
I-154	Ac-PL3-Asn-Cha-B5-Asp-Gln-iPrLys-Ala-Phe-GlnR*3-PyrS2-Phe-BztA-Lys*3-NH2
I-155	Ac-PL3-Asn-Cha-B5-Asp-Thr-Hse-Ala-Phe-GlnR*3-PyrS2-Phe-BztA-Lys*3-NH2
I-156	Ac-PL3-Asn-Cha-B5-Asp-Thr-iPrLys-Ala-Phe-GlnR*3-PyrS2-Phe-BztA-Lys*3-NH2
I-157	Ac-PL3-Asn-Cha-B5-Asp-Gln-Hse-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-158	Ac-PL3-Asn-Cha-B5-Asp-Gln-iPrLys-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2
I-159	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-160	Ac-PL3-Ser-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-161	Ac-PL3-Thr-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-162	Ac-PL3-Hse-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-163	Ac-PL3-aThr-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-164	Ac-PL3-MeAsn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-165	Ac-PL3-Asp-Npg-B5-Asn-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-166	Ac-PL3-Asp-Npg-B5-Ser-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-167	Ac-PL3-Asp-Npg-B5-Thr-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-168	Ac-PL3-Asp-Npg-B5-Hse-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-169	Ac-PL3-Asp-Npg-B5-aThr-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-170	Ac-PL3-Asp-Npg-B5-MeAsn-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-171	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-172	Ac-PL3-Ser-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-173	Ac-PL3-Thr-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-174	Ac-PL3-Hse-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-175	Ac-PL3-aThr-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-176	Ac-PL3-MeAsn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-177	Ac-PL3-Asp-Npg-B5-Asn-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-178	Ac-PL3-Asp-Npg-B5-Ser-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-179	Ac-PL3-Asp-Npg-B5-Thr-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-180	Ac-PL3-Asp-Npg-B5-Hse-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-181	Ac-PL3-Asp-Npg-B5-aThr-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-182	Ac-PL3-Asp-Npg-B5-MeAsn-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-183	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-hGlnR*3-Ala-NH2
I-184	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-hGlnR*3-Ala-NH2
I-185	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-hGlnR*3-PyrS2-3Thi-BztA-Lys*3-Ala-NH2
I-186	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-hGlnR*3-PyrS2-2F3MeF-BztA-Lys*3-Ala-NH2
I-187	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-iPrLys*3-PyrS2-3Thi-BztA-hGlnR*3-Ala-NH2
I-188	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-iPrLys*3-PyrS2-2F3MeF-BztA-hGlnR*3-Ala-NH2
I-189	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-hGlnR*3-PyrS2-2F3MeF-BztA-iPrLys*3-Ala-NH2
I-190	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-iPrLys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-191	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-iPrLys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-192	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-GlnR*3-PyrS2-2F3MeF-BztA-iPrLys*3-Ala-

	NH2
I-193	Ac-PL3-Asp-Npg-B5-Asp-2OH3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-194	Ac-PL3-Asp-Npg-B5-Asp-4OH3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-195	Ac-PL3-Asp-Npg-B5-Asp-[CH2CMe2CO2H]TriAzDap-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-196	Ac-PL3-Asp-Npg-B5-Asp-4COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-197	Ac-PL3-Asp-Npg-B5-Asp-2COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-198	Ac-PL3-Asp-Npg-B5-Asp-Glu-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-199	Ac-PL3-Asp-Npg-B5-Asp-Asp-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-200	Ac-PL3-Asp-Npg-B5-Asp-Thr-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-201	Ac-PL3-Asp-Npg-B5-Asp-Gln-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-202	Ac-PL3-Asp-Npg-B5-Asp-His-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-203	Ac-PL3-Asp-Npg-B5-Asp-Tyr-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-204	Ac-PL3-Asp-Npg-B5-Asp-5F3Me2COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-205	Ac-PL3-Asp-Npg-B5-Asp-4F3Me2COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-206	Ac-PL3-Asp-Npg-B5-Asp-5F3Me3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-207	Ac-PL3-Asp-Npg-B5-Asp-4F3Me3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-208	Ac-PL3-Asp-Npg-B5-Asp-3F2COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-209	Ac-PL3-Asp-Npg-B5-Asp-Val-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-210	Ac-PL3-Asp-Npg-B5-Asp-Ser-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-211	Ac-PL3-Asp-Npg-B5-Asp-Trp-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-212	Ac-PL3-Asp-Npg-B5-Asp-Asn-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-213	Ac-PL3-Asp-Npg-B5-Asp-Ala-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-214	Ac-PL3-Asp-Npg-B5-Asp-Arg-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-215	Ac-PL3-Asp-Npg-B5-Asp-dGlu-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-216	Ac-PL3-Asp-Npg-B5-Asp-aThr-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-217	Ac-PL3-Asp-Npg-B5-Asp-hTyr-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-218	Ac-PL3-Asp-Npg-B5-Asp-3cbmf-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-219	Ac-PL3-Asp-Npg-B5-Asp-Leu-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-220	Ac-PL3-Asp-Npg-B5-Asp-Phe-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-221	Ac-PL3-Asp-Npg-B5-Asp-Lys-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-222	Ac-PL3-Asp-Npg-B5-Asp-Ile-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-223	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-Serol
I-224	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-MorphNva-Serol
I-225	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-MorphNva-dAlaol
I-226	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NHEt
I-227	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-Ser-NHEt
I-228	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-MorphNva-NHEt
I-229	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-

	MorphNva-Ser-NHEt
I-230	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-Ser-NH2
I-231	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-MorphNva-NH2
I-232	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-MorphNva-Ser-NH2
I-233	Ac-MePro-Asp-Npg-R4-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-234	Ac-MePro-Asp-Npg-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-235	Ac-MePro-Asp-Npg-R6-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-236	Ac-MePro-Asp-Npg-R5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-237	Ac-MePro-Asp-Val-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-238	Ac-MePro-Asp-nLeu-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-239	Ac-MePro-Asp-Npg-R4-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-240	Ac-MePro-Asp-Npg-R5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-241	Ac-MePro-Asp-Npg-R6-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-242	Ac-MePro-Asp-Npg-R5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-243	Ac-MePro-Asp-Val-R5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-244	Ac-MePro-Asp-nLeu-R5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-245	Ac-PL3-Asp-nLeu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-246	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-247	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-248	Ac-PL3-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-249	Ac-PL3-Asp-Phe-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-250	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-251	Ac-PL3-Asp-CypA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-252	Ac-PL3-Asp-CyLeu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-253	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-254	Ac-PL3-Asp-Pff-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-255	Ac-PL3-Asp-DiethA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-256	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-4PipA*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-257	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-4PipA*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-258	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-4PipA*3-Ala-NH2
I-259	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-GlnR*3-PyrS2-2F3MeF-BztA-4PipA*3-Ala-NH2
I-260	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-hGlnR*3-PyrS2-3Thi-BztA-4PipA*3-Ala-NH2
I-261	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-hGlnR*3-PyrS2-2F3MeF-BztA-4PipA*3-Ala-NH2
I-262	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sCH2S*3-Ala-NH2
I-263	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-sCH2S*3-PyrS2-3Thi-BztA-TriAzLys*3-Ala-NH2
I-264	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sCH2S*3-Ala-NH2
I-265	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-sCH2S*3-PyrS2-3Thi-BztA-TriAzLys*3-Ala-NH2
I-266	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Ala-BztA-GlnR*3-Ala-NH2
I-267	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Ala-BztA-GlnR*3-Ala-NH2
I-268	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Abu-BztA-GlnR*3-Ala-NH2
I-269	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Abu-BztA-GlnR*3-Ala-NH2

I-270	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Nva-BztA-GlnR*3-Ala-NH2
I-271	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-nLeu-BztA-GlnR*3-Ala-NH2
I-272	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-nLeu-BztA-GlnR*3-Ala-NH2
I-273	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Leu-BztA-GlnR*3-Ala-NH2
I-274	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Leu-BztA-GlnR*3-Ala-NH2
I-275	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hLeu-BztA-GlnR*3-Ala-NH2
I-276	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hLeu-BztA-GlnR*3-Ala-NH2
I-277	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Npg-BztA-GlnR*3-Ala-NH2
I-278	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Npg-BztA-GlnR*3-Ala-NH2
I-279	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Ala-NH2
I-280	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Ala-NH2
I-281	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Cpa-BztA-GlnR*3-Ala-NH2
I-282	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Cpa-BztA-GlnR*3-Ala-NH2
I-283	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Cba-BztA-GlnR*3-Ala-NH2
I-284	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-CypA-BztA-GlnR*3-Ala-NH2
I-285	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-ChA-BztA-GlnR*3-Ala-NH2
I-286	Ac-PL3-Asp-Npg-B5-SbMeAsp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-287	Ac-PL3-Asp-Npg-B5-RbMeAsp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-288	Ac-PL3-SbMeAsp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-289	Ac-PL3-RbMeAsp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-290	Ac-PL3-aMeDAsp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-291	Ac-PL3-Glu-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-292	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FurA-BztA-GlnR*3-Ala-NH2
I-293	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2OMeF-BztA-GlnR*3-Ala-NH2
I-294	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2MeF-BztA-GlnR*3-Ala-NH2
I-295	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2BrF-BztA-GlnR*3-Ala-NH2
I-296	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-BztA-GlnR*3-Ala-NH2
I-297	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2CNF-BztA-GlnR*3-Ala-NH2
I-298	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2NO2F-BztA-GlnR*3-Ala-NH2
I-299	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2PyrA-BztA-GlnR*3-Ala-NH2
I-300	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3PyrA-BztA-GlnR*3-Ala-NH2
I-301	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-4PyrA-BztA-GlnR*3-Ala-NH2
I-302	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-His-BztA-GlnR*3-Ala-NH2
I-303	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-[BiotinPEG8]Lys-NH2
I-304	Ac-PL3-Asp-Ala-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-305	Ac-PL3-Asp-Tyr-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-306	Ac-PL3-Asp-Trp-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-307	Ac-PL3-Asp-Ser-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-308	Ac-PL3-Asp-Aib-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-309	Ac-PL3-Asp-Phg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-310	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-311	Ac-PL3-Asp-OctG-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-312	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-313	Ac-PL3-Asp-MorphNva-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2

I-314	Ac-PL3-Asp-F2PipNva-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-315	Ac-PL3-Asn-Npg-B5-Asp-[CH2CMe2CO2H]TriAzDap-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-316	Ac-PL3-Ser-Npg-B5-Asp-[CH2CMe2CO2H]TriAzDap-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-317	Ac-PL3-aThr-Npg-B5-Asp-[CH2CMe2CO2H]TriAzDap-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-318	Ac-PL3-Asp-Npg-B5-Asn-[CH2CMe2CO2H]TriAzDap-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-319	Ac-PL3-Asn-Npg-B5-Asp-[CH2CMe2CO2H]TriAzDap-MorphGln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-320	Ac-PL3-Ser-Npg-B5-Asp-[CH2CMe2CO2H]TriAzDap-MorphGln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-321	Ac-PL3-aThr-Npg-B5-Asp-[CH2CMe2CO2H]TriAzDap-MorphGln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-322	Ac-PL3-Asp-Npg-B5-Asn-[CH2CMe2CO2H]TriAzDap-MorphGln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-323	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-MorphGln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-324	Ac-PL3-Ser-Npg-B5-Asp-3COOHF-MorphGln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-325	Ac-PL3-aThr-Npg-B5-Asp-3COOHF-MorphGln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-326	Ac-PL3-Asp-Npg-B5-Asn-3COOHF-MorphGln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-327	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Ala-NH2
I-328	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-NH2
I-329	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-330	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-34MeF-GlnR*3-Ala-NH2
I-331	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-3BrF-GlnR*3-Ala-NH2
I-332	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-3BrF-GlnR*3-Ala-NH2
I-333	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-3BrF-GlnR*3-Ala-NH2
I-334	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-1NapA-BztA-GlnR*3-Ala-NH2
I-335	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-Ala-NH2
I-336	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-sAla*3-PyrS2-3Thi-BztA-TriAzLys*3-Ala-NH2
I-337	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-Ala-NH2
I-338	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-sAla*3-PyrS2-3Thi-BztA-TriAzLys*3-Ala-NH2
I-339	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[4FB]Cys-PyrS2-2F3MeF-BztA-Cys-Ala-NH2
I-340	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[8FBB]Cys-PyrS2-2F3MeF-BztA-Cys-Ala-NH2
I-341	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[8FBB]Cys-PyrS2-2F3MeF-BztA-Cys-Ala-NH2
I-342	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Glu-Ala-NH2
I-343	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Glu-

	Ala-NH2
I-344	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2COOHF-BztA-GlnR*3-Ala-NH2
I-345	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3COOHF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-346	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3COOHF-Lys*3-PyrS2-2COOHF-BztA-GlnR*3-Ala-NH2
I-347	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3COOHF-Lys*3-PyrS2-2COOHF-BztA-GlnR*3-Ala-Glu-Ala-NH2
I-348	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Glu-Ala-OH
I-349	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2COOHF-BztA-GlnR*3-Ala-OH
I-350	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3COOHF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-OH
I-351	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3COOHF-Lys*3-PyrS2-2COOHF-BztA-GlnR*3-Ala-OH
I-352	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3COOHF-Lys*3-PyrS2-2COOHF-BztA-GlnR*3-Ala-Glu-Ala-OH
I-353	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Cba-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-354	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-CypA-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-355	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-BztA-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-356	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-1NapA-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-357	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-2NapA-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-358	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Tyr-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-359	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Trp-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-360	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Leu-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-361	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Ile-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-362	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-nLeu-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-363	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Ser-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-364	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3Thi-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-365	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-2Thi-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-366	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Chg-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-367	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Hse-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-368	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-4TriA-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-369	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3F3MeF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-370	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Thr-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-371	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-His-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-372	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Val-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-373	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Asn-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-374	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Gln-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-375	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[mXyl]Cys-PyrS2-2F3MeF-BztA-Cys-Ala-NH2
I-376	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[oXyl]Cys-PyrS2-2F3MeF-BztA-Cys-Ala-NH2
I-377	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[pXyl]Cys-PyrS2-2F3MeF-BztA-Cys-Ala-NH2
I-378	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-MorphGln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-379	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Me2Gln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-380	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Met2O-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-381	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-AcLys-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2

I-382	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-383	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-384	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Acp-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-385	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Acp-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-386	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-387	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-His-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-388	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Val-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-389	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ser-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-390	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ser-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-391	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Gln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-392	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Gln-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-393	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Asn-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-394	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Asn-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-395	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-2Cpg-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-396	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-NH2
I-397	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Aib-NH2
I-398	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-NH2
I-399	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Ser-NH2
I-400	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Aib-Ser-NH2
I-401	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Ser-NH2
I-402	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Ala-NH2
I-403	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Ala-NH2
I-404	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Aib-Ala-NH2
I-405	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Aib-Ala-NH2
I-406	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Ala-NH2
I-407	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Aib-NH2
I-408	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Aib-NH2
I-409	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Aib-Aib-NH2
I-410	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Aib-Aib-NH2
I-411	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Aib-NH2
I-412	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Aib-NH2
I-413	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-Val-NH2
I-414	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-Leu-NH2
I-415	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-Thr-NH2
I-416	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-Ala-

	Ser-NH2
I-417	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-Val-Ser-NH2
I-418	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-Phe-BztA-sAla*3-Ala-NH2
I-419	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-Phe-BztA-sAbu*3-Ala-NH2
I-420	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-Phe-BztA-sAbu*3-Ala-NH2
I-421	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzOrn*3-PyrS2-3Thi-BztA-sAla*3-Ala-NH2
I-422	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzOrn*3-PyrS2-Phe-BztA-sAla*3-Ala-NH2
I-423	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzOrn*3-PyrS2-3Thi-BztA-sAbu*3-Ala-NH2
I-424	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzOrn*3-PyrS2-Phe-BztA-sAbu*3-Ala-NH2
I-425	4pentenyl-MePro-Asp-AllylGly-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-426	5hexenyl-MePro-Asp-AllylGly-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-427	4pentenyl-MePro-Asp-AllylGly-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-428	4pentenyl-MePro-Asp-AllylGly-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-429	5hexenyl-MePro-Asp-AllylGly-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-430	5hexenyl-MePro-Asp-AllylGly-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-431	5hexenyl-MePro-Asp-AllylGly-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-432	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-aMeL-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-433	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-DaMeL-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-434	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-aMeV-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-435	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-aMeS-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-436	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-DaMeS-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-437	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-DaMeS-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-438	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-aMeF-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-439	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Aib-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-440	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Cpg-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-441	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Aib-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-442	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Aib-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-443	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Cpg-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-444	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ser-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-445	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Thr-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-446	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-aThr-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-447	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Val-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-448	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Val-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-449	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Leu-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-450	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Leu-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-451	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Gln-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2

I-452	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Gln-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-453	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-MorphGln-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-454	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Lys-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-455	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Lys-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-456	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-aMeDF-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-457	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-aMeDF-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-458	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-dAla-NH2
I-459	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-dAla-NH2
I-460	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-dAla-Ser-NH2
I-461	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-dAla-Ser-NH2
I-462	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-dLeu-NH2
I-463	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-dLeu-Ser-NH2
I-464	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ser-Leu-NH2
I-465	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Ser-Leu-NH2
I-466	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Ser-Leu-NH2
I-467	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-dLeu-Ser-Leu-NH2
I-468	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-dLeu-Ser-Leu-NH2
I-469	Ac-PL3-OAsp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-470	Ac-PL3-Glu-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-471	BzAm2OAllyl-MePro-Asp-AllylGly-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-472	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-34ClF-GlnR*3-Ala-NH2
I-473	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-nLeu-34ClF-GlnR*3-Ala-NH2
I-474	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-nLeu-34ClF-GlnR*3-Ala-NH2
I-475	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-CypA-34ClF-GlnR*3-Ala-NH2
I-476	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-CypA-34ClF-GlnR*3-Ala-NH2
I-477	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Tyr-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-478	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3Thi-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-479	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-nLeu-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-480	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-nLeu-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-481	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-2NapA-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-482	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-2NapA-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-483	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-2NapA-GlnR*3-Ala-NH2
I-484	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-2NapA-GlnR*3-Ala-NH2
I-485	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-2NapA-GlnR*3-Ala-NH2
I-486	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-2NapA-GlnR*3-Ala-NH2
I-487	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-2NapA-GlnR*3-Ala-NH2
I-488	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-2NapA-GlnR*3-Ala-NH2
I-489	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-nLeu-2NapA-GlnR*3-Ala-NH2
I-490	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-nLeu-2NapA-GlnR*3-Ala-NH2
I-491	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-CypA-2NapA-GlnR*3-Ala-NH2

I-492	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-CypA-2NapA-GlnR*3-Ala-NH2
I-493	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Asp-Ala-NH2
I-494	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Glu-Ala-NH2
I-495	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Glu-Ala-NH2
I-496	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Ser-Ala-NH2
I-497	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Ser-Ala-NH2
I-498	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Thr-Ala-NH2
I-499	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Thr-Ala-NH2
I-500	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-aThr-Ala-NH2
I-501	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-aThr-Ala-NH2
I-502	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Asp-Leu-NH2
I-503	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Asp-Leu-NH2
I-504	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Glu-Leu-NH2
I-505	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Glu-Leu-NH2
I-506	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Asp-Ala-NH2
I-507	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Glu-Ala-NH2
I-508	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Thr-Ala-NH2
I-509	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Thr-Ala-NH2
I-510	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-aThr-Ala-NH2
I-511	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-aThr-Ala-NH2
I-512	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Asp-Leu-NH2
I-513	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Asp-Leu-NH2
I-514	Ac-Gly-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-515	Ac-Sar-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-516	Ac-NMebAla-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-517	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-[BiotinPEG8]Lys-NH2
I-518	Ac-PL3-Glu-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-[BiotinPEG8]Lys-NH2

I-519	5hexenyl-MePro-Asp-[Bn][Allyl]Dap-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-520	5hexenyl-MePro-Asp-[Phc][Allyl]Dap-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-521	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Asp-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-522	Ac-PL3-Asp-Npg-B5-aThr-3COOHF-Aib-Asp-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-523	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Glu-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-524	Ac-PL3-Asp-Npg-B5-aThr-3COOHF-Aib-Glu-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-525	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Aad-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-526	Ac-PL3-Asp-Npg-B5-aThr-3COOHF-Aib-Aad-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-527	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-nLeu-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-528	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-nLeu-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-529	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Phe-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-530	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-hPhe-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-531	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Cba-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-532	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Cba-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-533	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-hTyr-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-534	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-AcLys-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-535	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Val-BztA-GlnR*3-Ala-NH2
I-536	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Ile-BztA-GlnR*3-Ala-NH2
I-537	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Chg-BztA-GlnR*3-Ala-NH2
I-538	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-DiethA-BztA-GlnR*3-Ala-NH2
I-539	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-BztA-GlnR*3-Ala-NH2
I-540	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-OctG-BztA-GlnR*3-Ala-NH2
I-541	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2Thi-BztA-GlnR*3-Ala-NH2
I-542	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2cbmF-BztA-GlnR*3-Ala-NH2
I-543	Ac-PL3-Glu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-544	Ac-PL3-Glu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-545	Ac-PL3-Aad-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-546	Ac-PL3-Aad-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-547	Ac-PL3-Asp-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-548	Ac-PL3-Asp-Npg-B5-Aad-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-549	Ac-PL3-Aad-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-550	Ac-PL3-Glu-Npg-B5-Aad-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-551	Ac-PL3-Aad-Npg-B5-Aad-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-552	Ac-PL3-Glu-Npg-B5-Glu-Glu-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-553	Ac-PL3-Aad-Npg-B5-Glu-Glu-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-554	Ac-PL3-Glu-Npg-B5-Glu-Asp-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-555	Ac-PL3-Aad-Npg-B5-Glu-Asp-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-556	Ac-PL3-Aad-Npg-B5-Aad-Glu-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-557	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dLys*3-PyrS2-3Thi-BztA-dGlnR*3-Ala-NH2
I-558	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dOrn*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-559	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dDab*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-560	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Orn*3-PyrS2-3Thi-BztA-hGlnR*3-Ala-NH2
I-561	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-NMeOrn*3-PyrS2-3Thi-BztA-hGlnR*3-Ala-NH2
I-562	4pentenyl-MePro-Asp-[Bn][Allyl]Dap-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-563	4pentenyl-MePro-Asp-[Phc][Allyl]Dap-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-564	5hexenyl-MePro-Asp-[Piv][Allyl]Dap-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-

	GlnR*3-Ala-NH2
I-565	5hexenyl-MePro-Asp-[CyCO][Allyl]Dap-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-566	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[2_6-naph]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-567	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[3_3-biph]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-568	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-4FF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-569	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-4FF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-570	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-4ClF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-571	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-4ClF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-572	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-4BrF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-573	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-4BrF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-574	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3FF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-575	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3FF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-576	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3ClF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-577	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3ClF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-578	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3BrF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-579	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3BrF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-580	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-2FF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-581	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-2FF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-582	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3OMeF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-583	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3OMeF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-584	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-4CNF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-585	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-4CNF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-586	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3CNF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-587	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3CNF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-588	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-4MeF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-589	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-4MeF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-590	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3MeF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-591	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-3MeF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-592	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Aic-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-593	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Aic-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-594	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-RbiPrF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-595	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-RbiPrF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-596	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-SbiPrF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-597	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-SbiPrF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-598	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-RbiPrDF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-599	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-RbiPrDF-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-600	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-RbMeXylA-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-601	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-RbMeXylA-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-602	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-RbMeXylDA-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-603	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-RbMeXylDA-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2

I-604	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-SbMeXylA-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-605	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-SbMeXylDA-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-606	Ac-PL3-Glu-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-AzLys-NH2
I-607	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-AzLys-NH2

[0888] Certain results from various additional assessment for various additional agents and compositions are presented in Table E3 below. See Table E1 and Table E2 for description. Among other things, these data confirm that technologies of the present disclosure can provide various activities and/or benefits.

[0889] Table E3. Certain data of various compositions as examples.

1	2	3	4	5	6	7	8	9
I-608	A				1956.8426			
I-609	A				1956.8426			
I-700	A				1956.8426			
I-701	B				2136.9519			
I-702	B				2164.9832	2166.5	2164.6	
I-703	B				2150.9675	2152.6	2150.6	
I-704	A	C			2178.9988	2180.3	2178.4	
I-705	A	C			2221.0458	2222.4	2220.5	
I-706	A				2060.9052			
I-707	A				2086.9209			
I-708	A	B			2170.9209			
I-709	A	A		+	2084.9165			
I-710	A	B			2102.9522	2104.9	2102.9	
I-711	A	B			2088.9365	2090.8	2089.1	
I-712	A	A			2003.8838	2005.7	2003.8	
I-713	A				2003.8838	2005.7	2003.9	
I-714	A	A			2060.9052	2062.8	2061	
I-715	A	A			2116.9678	2118.8	2116.9	
I-716	A	B			2116.9678	2118.9	2116.9	
I-717	A	B			2130.9835	2132.9	2131.2	
I-718	A	C			2130.9835	2132.8	2131	
I-719	A	A	++	+	2100.9365	2102.8	2100.4	
I-720	A	C	++	+	2100.9365	2102.8	2100.7	
I-721	A	B	++	+	2090.9158	2092.8	2090.9	
I-722	A	B	+		2150.9522	2152.9	2151	
I-723	A	B			2117.9267	2119.7	2117.8	
I-724	A	B			2131.9424	2133.8	2132.2	
I-725	A	C			2189.9631	2191.9	2189.7	
I-726	B	C			2189.9631	2191.9	2190.2	
I-727	A	B			2166.9471	2168.9	2166.3	
I-728	A	B			2166.9471	2169	2166.7	
I-729	A	A			2122.9209	2124.7	2122.7	
I-730	A				2086.9209	2088.7	2086.7	
I-731	A				2128.9678	2130.8	2128.9	
I-732	A	A			2134.9209	2136.7	2134.4	
I-733	A	A			2098.9209	2100.8	2098.9	
I-734	A	B			2140.9678	2142.8	2140.6	

I-735	A	C			2148.9365	2150.8	2149.1	
I-736	A	A			2112.9365	2114.8	2113	
I-737	A	A			2154.9835	2156.8	2154.6	
I-738	A	C			2232.9365			
I-739	A	B			2232.9365	2234.8	2232.8	
I-740	A	A			2196.9365	2199	2197	
I-741	E	D		+++	2074.9209	2076.8	2075	
I-742	E	D		+++	2074.9209	2076.8	2075	
I-743	C	D			2101.8954	2103	2100.8	
I-744	A	D			2115.9111	2117.9	2115.7	
I-745	A	C			2115.9111	2117.9	2115.9	
I-746	A	C			2130.9835	2132.8	2130.9	
I-747	A	B		+	2102.9522	2104.8	2103	
I-748	A	C		+	2138.927	2140.8	2138.6	
I-749	A	C			2164.9678	2166.9	2164.9	
I-750	A	B			2118.9471	2120.8	2118.3	
I-751	C	D			2391.1975	2393.7	2391.6	
I-752	B	D			2154.9271	1079.2	2155.4	
I-753	A	C		+	2136.9365	2138.9	2137	
I-754	A	C			2110.8879	2112.9	2111.3	
I-755	A	C			2186.9192	1046.2	1044.3	
I-756	A	D			2186.9192	2188.9	2186.5	
I-757	A				2157.8749	2159.8	2157.7	
I-758	B				2157.8749	2159.9	2158.6	
I-759	B				2171.8905	2173.9	2171.4	
I-760	B				2171.8905	2173.9	2171.3	
I-761	A				2060.9458	2063.9	2062.4	
I-762	A	C			2060.9458	2063.8	2061.8	
I-763	A				2021.055	2023.1	2021.4	
I-764	A	C			2021.055	2023.1	2021.4	
I-765	B				2070.9342	2075	2072.9	
I-766	B				2070.9342	2073.9	2072.8	
I-767	A				2043.0394	2045.1	2043.5	
I-768	A				2043.0394	2045.2	2043.3	
I-769	A				2057.055	2059.2	2057.6	
I-770	A	C			2057.055	2059.2	2057.1	
I-771	A				2063.0114	2065.1	2063.4	
I-772	A	C		+	2063.0114	2065.1	2063.3	
I-773	B				2063.0114	2065.2	2063.4	
I-774	C	D			2063.0114	2065.1	2063.1	
I-775	A	C			2033.055	2035.1	2033.5	
I-776	A	C			2033.055	2035.2	2033.2	
I-777	B				2136.9519	2138.8	2136.9	
I-778	A				2150.9675	2152.8	2150.6	
I-779	B				2150.9675	2152.8	2151.1	
I-780	A				2074.9209	2076.8	2074.8	
I-781	A	D			2088.9365	2090.8	2088.8	
I-782	A	B			2216.9951	2219	2216.7	
I-783	A	C			2359.0693	2361.1	2359.7	
I-784	A				2501.1436	1252.3	1250.6	
I-785	A	B		+	2203.9999	2205.9	2204.2	

I-786	A	C		+	2017.8994	2019.7	2017.6	
I-787	A	B			2088.9365	2090.8	2089.2	
I-788	A	C		+++	1975.8525	1977.7	1975.8	
I-789	A	C		+	2188.9638	2191	2188.8	
I-790	A	C		+	2331.038	2333.1	2331.5	
I-791	A				2175.9686	2178	2175.7	
I-792	A	D			1975.8525	1977.7	1975.6	
I-793	A	D			2046.8896	2048.9	2046.8	
I-794	A				2046.8896	2077	2075.8	
I-795	A	D		+++	2188.9638	2191.1	2189.3	
I-796	A				2188.9638	2191	2189	
I-797	A				2175.9686	2178.2	2176	
I-798	A				2175.9686	2178.1	2176.2	
I-799	A	C			2102.9522	2105	2103.4	
I-800	A	C			2102.9522	2105	2103.1	
I-801	A	D			2116.9678	2119	2117.1	
I-802	A	C			2103.9474	2106	2104.2	
I-803	A	A			2080.9586	2082.9	2081	
I-804	A	A			2259.0421	2261.1	2259.4	
I-805	A	B		+	2259.0421	2261.1	2259	
I-806	A	B		+	2372.1261	2374.2	2371.9	
I-807	A	C			2330.0792	2332.1	2330.3	
I-808	B				2443.1632	2445.3	2442.9	
I-809	B				2443.1632	2445.3	2443.4	
I-810	B				2556.2473	1280	1278.2	
I-811	B				2556.2473	1280	1278	
I-812	A	B		+	2613.2688	1308.4	1306.7	
I-813	A	B		+	2684.3059	1344	1342.1	
I-814	A	C		+	2625.3052	1314.4	1312.7	
I-815	A	C		+	2696.3423	1350	1348.4	
I-816	A	A		+	2611.2644	1307.4	1305.9	
I-817	A	B		+	2682.3015	1342.9	1341.3	
I-818	A	D			2155.9424	2157.8	2155.4	A
I-819	B				2074.9209	2076.8	2074.9	
I-820	A	C			2150.9675	2153.2	2151.2	
I-821	A				2150.9675	2152.9	2151.1	
I-822	A	B			2237.9995	2240.2	2238.2	
I-823	A	C			2134.8862	2137.9	2135.9	
I-824	A				2162.9175	2166	2164.7	
I-825	A	C			2162.9175	2165.6	2163.9	
I-826	A	C			2249.9495	2252.8	2250.7	
I-827	A	C			2176.9331	2180.1	2178.8	
I-828	B				2176.9331	1090.6	1088.7	
I-829	B				2263.9652	2267.1	2265.4	
I-830	B				2263.9652	1134.1	1132.5	
I-831	A	C			2066.8988	2069.8	2068.2	
I-832	A	C			2066.8988	1035.5	1034.1	
I-833	A	C			2094.9301	2097.8	2096.2	
I-834	A	B			2094.9301	1049.5	1047.1	
I-835	A	C			2181.9621	2184.9	2183.1	
I-836	A	C			2181.9621	1093.2	1090.8	

I-837	A	C			2108.9458	2112	2109.4	
I-838	A	C			2108.9458	2111.8	2109.3	
I-839	A	B			2195.9778	2198.9	2197.2	
I-840	A	C			2195.9778	2198.9		
I-841	A	B			2162.9522	2165.3	2163.4	
I-842	A	B			2122.9209	2125.2	2123.2	
I-843	A	B			2134.9209	2137.2	2135	
I-844	A	B			2160.9365	2163.2	2160.9	
I-845	A	C			2244.9365	1124.3	1122.7	
I-846	A	C			2174.9522	2177.3	2175.9	
I-847	A	C			2146.9209	2149.2	2147.1	
I-848	A	C			2134.9209	2137.2	2135.3	
I-849	A				2100.9365	2102.9	2101.2	
I-850	A	B			2126.9522	2129.1	2127.1	
I-851	A				2210.9522	2213.2	2210.8	
I-852	A	B			2140.9678	2143.3	2141.1	
I-853	A				2140.9678	2142.9	2140.9	
I-854	A				2112.9365	2115.2	2112.9	
I-855	A				2100.9365	2102.9	2101.1	
I-856	A				2072.9052	2074.9	2073.2	
I-857	A				2098.9209	2101.2	2098.8	
I-858	A				2182.9209	1093.3	1091.3	
I-859	A	B			2112.9365	2115.1	2112.9	
I-860	A	C			2084.9052	2086.9	2084.9	
I-861	A	C			2072.9052	1038.2	1036.8	
I-862	A	B			2077.8647	2080.7	2078.9	
I-863	A				2077.8647	2080.8	2079.5	
I-864	A	C			2174.9175	1089.7	1087	
I-865	A	C			2164.8968	1084.6	1082.6	
I-866	B				2224.9331	2228.3	2226.2	
I-867	A	A		+	2015.8338	1010.2	1008	
I-868	A	C		+	2112.8865	2116.2	2113.3	
I-869	A	B		+	2102.8658	2105.9	2103.4	
I-870	A	C			2162.9022	2166.4	2164	
I-871	A	A		+	2009.8773	2013.5	2010.8	
I-872	A	C		+	2106.9301	2110	2108.5	
I-873	A	B			2096.9094	2099.9	2098.3	
I-874	A	C			2156.9458	2159.8	2158.3	
I-875	A				2038.8821	2041	2039.2	
I-876	A				2109.9192	2112.1	2110.2	
I-877	A				2238.9982	2241.2	2239.3	
I-878	A				2032.9256	2035	2033.1	
I-879	A				2103.9628	1053.8	1052	
I-880	A				2233.0417	2235.2	2233.5	
I-881	A				2050.832	2053.8	2052.9	
I-882	A				2121.8692	2124.8	2123.3	
I-883	A				2250.9481	2254	2252.6	
I-884	A				2044.8756	1024.6	1023	
I-885	A				2115.9127	2118.8	2117.4	
I-886	A				2244.9917	2247.9	2246.1	
I-887	A				2100.913	2103	2101.1	

I-888	B				2301.0291	1152.4	1150.4	
I-889	B				2301.0291	1152.4	1150.6	
I-890	A				2112.863	2115.8	2113.9	
I-891	A	C			2112.863	1058.7	1057	
I-892	A	D			2183.9001	1094.2	1091.8	
I-893	B				2312.9791	1158.8	1156.7	
I-894	A	C			2018.91	2021	2019.3	
I-895	A				2018.91	2021.1	2019.3	
I-896	A	C			2089.9471	2092.1	2090.2	
I-897	A				2089.9471	2092.1	2090.2	
I-898	A	C			2219.0261	2221.3	2219.3	
I-899	A				2219.0261	1111.5	1109.5	
I-900	A	D			2094.9413	2097.1	2095.2	
I-901	A	D			2165.9784	2168.2	2166.3	
I-902	B				2295.0574	1149.4	1147.6	
I-903	A	D		++	2178.9332	1091.4	1089.5	
I-904	A	C			2177.9379	2180.2	2178.1	
I-905	A				2177.9379	1090.8	1089	
I-906	A				2176.9427	1090.4	1087.9	
I-907	A				2138.927	2141.2	2139.4	
I-908	A	B		+	2179.9787	1091.9	1089.8	
I-909	A	C			2138.927	2141.2	2139.4	
I-910	A				2138.927	2141.2	2139.4	
I-911	A				2138.927	2141.2	2139	
I-912	A				2138.927	2141.4	2139.7	
I-913	A	B			2086.8709	2090.1	2089.3	
I-914	A	C			2086.8709	1045.8	1044.2	
I-915	A	C			2215.9499	2219	2217.6	
I-916	A	C			2215.9499	1110.3	1108.6	
I-917	A	C			2114.9022	2118	2116.6	
I-918	A	C			2114.9022	2118.2	2116.3	
I-919	A	C			2148.8865	2151.2	2150.3	
I-920	A	C			2148.8865	2152	2150.1	
I-921	B	C			2092.8273	2095.6	2093.9	
I-922	A	C			2092.8273	2095.6	2093.9	
I-923	A	B			2003.8838	2005.7	2003.5	
I-924	A	C			2003.8838	2006.2	2004.4	
I-925	A	B			2203.9999	2205.9	2204.1	
I-926	A	C			2102.9522	2105.3	2103.4	
I-927	A	B			2136.9365	2138.9	2136.9	
I-928	E				2106.9624	1055.3	1053.6	
I-929	C				2087.9525	2090.1	2088.1	
I-930	C				2087.9525	1045.8	2088.1	
I-931	E				2112.9188	1057.7	2112.5	
I-932	E				2036.9052	2039.1	2037.1	A
I-933	E				2036.8147	2039	2037.2	
I-934	E				2040.846	2042.7	2041	A
I-935	B	D			2088.9365	2091.3	2089.2	
I-936	B	D			2063.0114	2065.2	2063.2	
I-937	B	D			2063.0114	2065.3	2063.2	
I-938	B				2077.0271	2079.3	2077.8	

I-939	C				2077.0271	1040.4	2077.2	
I-940	A	C			2124.9365	2127.4	2125.3	
I-941	A				2124.9365	2127.3	2125.2	
I-942	A	D			2074.9614	2077.9	2075.2	
I-943	B				2088.9771	1046.8	1044.9	
I-944	A	D			2088.9771	1046.8	2090.1	
I-945	A	C			2136.8865	2140.4	2138.5	
I-946	A				2136.9519	2139.2	2137.2	
I-947	A	D			2060.9052	2063.3	2061.9	
I-948	A	D			2074.9209	2077.2	2076.4	
I-949	B				2144.9958	2147	2145.1	
I-950	B				2156.9458	2159.7	2157.6	
I-951	B				2156.9458	2159.8	2157.4	
I-952	C				2274.0748	2276.2	2274.3	
I-953	C				2274.0748	2276.2	2274	
I-954	C				2286.0247	2289	2288.2	
I-955	B	B			2178.0748	1091	2178.7	
I-956	A				2190.0247	1097.3	2191.4	
I-957	A	C			2074.9209	1039.3	1037.6	
I-958	E				2088.9365	1046.3	1044.4	
I-959	E				2088.9365	1046.3	1044.4	
I-960	E				2088.9365	1046.3	1044.5	
I-961	A	D			2088.9365	2091.1	2089.1	
I-962	E				2088.9365	2191.2	2089.2	
I-963	B				2078.9522	1041.3	1039.4	A
I-964	E				2092.9678	2095.1	2093.2	A
I-965	C				2092.9678	2095.2	2093.8	A
I-966	E				2092.9678	2095.3	2093.2	A
I-967	B				2092.9678	2095.2	2092.9	
I-968	E				2091.9838	2094.2	2091.7	
I-969	A	A			2046.8896			
I-970	A	B		+	2046.8896			
I-971	A	B			2074.9209			
I-972	A				2088.9365			
I-973	A				2088.9365			
I-974	A				2088.9365			
I-975	A				2116.9678			
I-976	A				2072.9052			
I-977	A				2072.9052			
I-978	A				2100.9365			
I-979	A				2114.9522			
I-980	A				2142.9835			
I-981	A				2142.9835			
I-982	A	B		+	2156.9052	2159.2	2157.5	
I-983	A	B			2156.9052	2159.3	2157.2	
I-984	A	B		+	2184.9365	1094.4	2185.9	
I-985	A	A			2198.9522	1101.4	1099.6	
I-986	A	A		+	2198.9522	2201.3	2198.9	
I-987	A	B		+	2058.8896	2061.1	2059.3	
I-988	A	B		+	2086.9209	2089.2	2087.6	
I-989	A	C		+	2100.9365	2103.2	2101.2	

I-990	A	C			2100.9365	2103.2	2101.4	
I-991	A			+++	2128.9678	2131.3	2129.2	
I-992	E				2032.8739	2035.2	2033.2	
I-993	D				2008.8739	2011.1	2009.5	
I-994	A				2058.8896	2061.3	2059	
I-995	A				2058.8896	2061.2	2059.3	
I-996	A	B			2072.9052	2075.2	2073.3	
I-997	A				2116.9315	2119.4	2116.8	
I-998	A	C			2116.9315	2119.4	2116.8	
I-999	A	C			2072.9052	2075.4	2073.7	
I-1000	A				2142.8896	2145.3	2142.6	
I-1001	A				2142.8896	2145.3	2142.4	
I-1002	A				2156.9052	2159.2	2157.3	
I-1003	A				2156.9052	2159.3	2157.4	
I-1004	A	C			2186.9158	2189.3	2187	
I-1005	A				2200.9315	2203.4	2201	
I-1006	A	D			2200.9315	2203.4	2200.9	
I-1007	A				2200.9315	2203.4	2201.2	
I-1008	A	C			2156.9052	2159.4	2156.9	
I-1009	A	C			2156.9052	2159.3	2157.4	
I-1010	A	B			2072.8552	2076.9	2075.3	
I-1011	A				2116.9315	2119.2	2116.6	
I-1012	A	B			2152.9315	2155.3	2153	
I-1013	A	C			2104.9315	2107.2	2105.5	
I-1014	A	C			2086.9209	2089.2	2087.6	
I-1015	A	C			2122.9209	2125.3	2123.2	
I-1016	A	D			2074.9209	2077.2	2075.1	
I-1017	A	D			2142.9835	2145.5	2143.2	
I-1018	A	C			2178.9835	2181.4	2178.9	
I-1019	B	D			2130.9835	2133.4	2131.9	
I-1020	A	C			2130.9471	2133.3	2131.7	
I-1021	B	D			2118.9471	2121.3	2119.3	
I-1022	B							A
I-1023	A	D			2060.9052	2061.9	2061.9	
I-1024	E				2043.8651	2047.4	2045.4	
I-1025	E				2208.0100	2210.6	2208.4	
I-1026	A	D			2157.9580	2160.5	2158.5	
I-1027	A	D		+++	2157.9580	2060.5	2158.0	
I-1028	A	D			2219.9737	2222.7	2220.6	
I-1029	A				2219.9737	2222.6	2220.8	
I-1030	A				2200.0050	2202.7	2201.0	
I-1031	B				2143.9424	1074.0	1072.0	
I-1032	B				2205.9580	1105.0	1102.9	
I-1033	B				2185.9893	1095.0	1092.9	
I-1034	A				2143.9424	2146.4	2144.9	
I-1035	A				2205.9580	1105.1	1103.3	
I-1036	A				2185.9893	2188.6	2185.9	
I-1037	A			+	2027.8338	2031.1	2029.4	
I-1038	A			+	2041.8494	2044.9	2043.6	
I-1039	A				2041.8494	2044.9	2043.6	
I-1040	A			+	2027.8338	2031.0	2029.4	

I-1041	A				2027.8338	2031.1	2029.3	
I-1042	A			+	2041.8494	2045.2	2042.2	
I-1043	A				2041.8494	2045.1	2043.3	
I-1044	A			+	2053.8494	2056.9	2054.4	
I-1045	A				2053.8494	2057.1	2054.9	
I-1046	A				2067.8651	2071.4	2069.4	
I-1047	A			+	2067.8651	2071.2	2068.5	
I-1048	A			+	2021.8773	2025.2	2023.2	
I-1049	A				2021.8773	2025.4	2024.6	
I-1050	A			+	2035.8930	2039.0	2037.3	
I-1051	A				2035.8930	2039.1	2036.8	
I-1052	A			+	2021.8773	2024.9	2022.7	
I-1053	A				2021.8773	2025.0	2023.7	
I-1054	A			+	2035.8930	2039.1	2037.6	
I-1055	A				2035.8930	2039.6	2037.4	
I-1056	A			+	2047.8930	2051.0	2049.1	
I-1057	A				2047.8930	2051.5	2049.1	
I-1058	A			ND	2061.9086	2065.1	2063.0	
I-1059	A				2061.9086	2065.0	2063.2	
I-1060	A				1947.8617	1951.0	1948.2	
I-1061	A				1961.8773	1964.9	1963.5	
I-1062	A				2140.9427	2143.5	2141.2	
I-1063	A				2187.9286	2190.2	2188.8	
I-1064	A			+++	2190.9583	2193.6	2190.9	
I-1065	A				2155.9536	2158.5	2156.9	
I-1066	A				2201.9631	2204.8	2202.1	
I-1067	A	D			2151.9474	2154.7	2152.7	
I-1068	A				2141.9379	1073.0	1070.8	
I-1069	A				2140.9427	2143.5	2141.6	
I-1070	A				2165.9631	2168.8	2167.7	
I-1071	A			+++	2165.9631	1082.2	1093.4	
I-1072	A				2165.9631	2168.7	2167.0	
I-1073	A				2152.9427	2155.6	2154.1	
I-1074	A				2157.9580	2160.3	2158.4	
I-1075	A			+++	2141.9379	2144.3	2142.2	
I-1076	A	D			2190.9583	2193.8	2191.4	
I-1077	A				2190.9583	2193.6	2191.6	
I-1078	A			+++	2117.9631	2120.7	2118.1	
I-1079	A			+++	2187.0209	2190.0	2187.8	
I-1080	A				2187.0209	1095.6	1093.4	
I-1081	A			+++	2173.0053	2175.6	2173.5	
I-1082	A				2173.0053	2175.8	2173.8	
I-1083	A				2176.9097	1090.6	1088.6	
I-1084	A				2176.9097	1090.6	1088.9	
I-1085	A				2223.9144	2226.5	2224.2	
I-1086	A				2025.8293	2029.1		
I-1087	A				2025.8293	2029.0	2027.8	
I-1088	A				2096.8665	2100.2		
I-1089	A				2011.8137	2015.0	2012.6	
I-1090	A				2073.8293	2077.1	2074.9	
I-1091	A				2144.8665	2148.2		

I-1092	A				2019.8729	2023.1	2020.6	
I-1093	A				2090.9100	2094.7	2092.3	
I-1094	A				2005.8573	2009.1		
I-1095	A				2076.8944	2080.1	2078.2	
I-1096	A				2067.8729	2071.2	2069.4	
I-1097	A				2138.9100	2142.1	2140.5	
I-1098	A				1975.9430	1978.2	1976.6	
I-1099	A				2032.9645	2035.3	2033.8	
I-1100	A				1961.9274	1964.2	1962.8	
I-1101	A				2094.9801	2097.3	2095.4	
I-1102	A			+	2023.9430	2026.3	2024.9	
I-1103	A			+	1969.9866	1972.3	1970.1	
I-1104	A				2027.0081	2029.3	2027.7	
I-1105	A				1955.9709	1958.2	1956.5	
I-1106	A			+	2089.0237	2091.4	2089.3	
I-1107	A			+	2017.9866	2020.3	2018.6	
I-1108	A			+	2111.8338	2115.3	2113.8	
I-1109	A				2182.8709	2186.3	2185.1	
I-1110	A				2198.8658	2202.1	2200.3	
I-1111	A			+	2097.8181	2101.6	2099.3	
I-1112	A				2168.8552	2172.1	2170.3	
I-1113	A				2184.8501	2188.3	2185.9	
I-1114	A				2173.8494	2178.2	2176.5	
I-1115	A				2244.8865	2247.5		
I-1116	A				2260.8814	1032.9	1030.7	
I-1117	A			+	2137.8494	1071.3	2139.3	
I-1118	A			+	2208.8865	1106.8	2210.1	
I-1119	A				2224.8814	2228.1	2226.4	
I-1120	A				2126.9634	2129.4	2127.3	
I-1121	A				2126.9634	2129.4	2127.4	
I-1122	B				2098.9321	2103.4	2101.6	
I-1123	B				2098.9321	2103.4	2101.8	
I-1124	A				2110.9685	2113.4		
I-1125	A				2082.9372	2085.3	2083.4	
I-1126	A				2111.9274	2114.3	2111.9	
I-1127	A				2111.9274	2114.3	2112.1	
I-1128	A	D			2163.9686	2166.4	2164.3	
I-1129	A	D			2163.9686	2166.4	2164.6	
I-1130	E	D			2176.0050	2155.9	2154.0	
I-1131	E	D			2176.0050	2114.0	2112.7	
I-1132	A	D			2190.0206	2192.6	2190.7	
I-1133	A	D	+++		2190.0206	2192.5	2190.6	
I-1134	A	D	+++		2177.9842	2180.5	2178.6	
I-1135	A	D			2177.9842	2180.5	2179.0	
I-1136	A	D			2224.0050	2226.5	2224.7	
I-1137	B	D			2224.0050	2226.6	2224.9	
I-1138	A	D			2245.0264	2247.5	2245.3	
I-1139	A	D			2245.0264	2247.6	2245.8	
I-1140	A	D			2235.0057	2237.5	2235.2	
I-1141	A	D			2235.0057	1119.6	1117.7	
I-1142	A	D			2219.0108	2221.5	2219.9	

I-1143	A	D			2219.0108	2221.5	2219.4	
I-1144	A	D		+++	2167.9999	2170.5	2168.6	A
I-1145	A	D	++	+	2180.0363	2180.6	2178.6	A
I-1146	A	D		+	2194.0519	2196.4	2194.1	A
I-1147	A	D		+++	2182.0155	2184.5	2182.4	A
I-1148	A	D			2228.0363	2230.4	2228.5	A
I-1149	B	D		+++	2249.0577	2251.4	2249.6	A
I-1150	A	D		+++	2239.0370	2241.5	2239.0	A
I-1151	A	D		+++	2223.0421	2225.3	2223.4	A
I-1152					2058.9624	2061.4	2059.2	
I-1153	E				2086.9937	2089.2	2087.3	
I-1154	E				2162.9344	2165.5	2163.2	
I-1155	A			+	2586.2076	1295.1	1293.5	
I-1156	A			+	2671.2716	1337.6	1336.2	
I-1157	A			+	2671.2716	1337.7	1335.9	
I-1158	A			+	2615.2593	1309.7	1307.7	
I-1159	A				2598.1963	1301.0	1299.2	
I-1160	A				2669.2335	1336.6	1334.5	
I-1161	B				2123.0114	2125.4	2123.0	
I-1162	A			+++	2002.8998	2005.3	2003.7	
I-1163	A			+++	2098.8998	2101.4		
I-1164	A			+++	2169.9369	2172.5	2170.7	
I-1165	A			+++	1988.8841	1991.3	1989.3	
I-1166	A			+++	1988.8841	1991.3	1989.6	
I-1167	A			+++	2059.9212	2062.3	2060.0	
I-1168	A			+++	2059.9212	2062.4	2060.4	
I-1169	A			+++	2075.9161	2078.3	2076.3	
I-1170	A			+++	2075.9161	2078.4	2076.5	
I-1171	A			+++	2008.8933	2012.0		
I-1172	A			+++	2008.8933	2012.0	2009.9	
I-1173	A			+++	2079.9304	2083.1	2081.2	
I-1174	A			+++	2079.9304	2083.1	2081.4	
I-1175	A			+++	2104.8933	1054.7		
I-1176	A				2104.8933	2108.1	2106.7	
I-1177	A			+++	2175.9304	1090.3	2176.1	
I-1178	A			+++	1994.8777	1998.0	1996.3	
I-1179	A				1994.8777	1998.0	1996.3	
I-1180	A			+++	2065.9148	2069.1	2066.7	
I-1181	A			+++	2350.0942	2352.7	2351.1	
I-1182	A			+++	2526.1990	1265.1	1263.5	
I-1183	A			+	2878.4087	1441.3	1439.5	
I-1184	A			+++	2251.0258	2253.6	2251.6	
I-1185	A			+++	2427.1306	2429.8	2427.8	
I-1186	A			+++	2779.3403	1391.8	1389.8	
I-1187	A			+++	3131.5500	1568.0	1566.2	
I-1188	B				2074.9380	1039.3	1037.7	
I-1189	B				2074.9380	1039.2	1037.2	
I-1190	B				2074.9380	2077.1	2075.7	
I-1191	C				2161.9893	2164.4		
I-1192	C				2161.9893	2164.4	2162.1	
I-1193	C				2146.9896	2149.6	2147.7	

I-1194	B				2146.9896	2149.1	2147.5	
I-1195	C				2119.9787	2122.4	2120.6	
I-1196	C				2119.9787	2122.3	2120.4	
I-1197	B				2133.9944	2136.4		
I-1198	E				2133.9944	2136.4	2134.6	
I-1199	B				2161.9893	2164.4	2162.2	
I-1200	C				2161.9893	2164.5	2162.3	
I-1201	C				2146.9896	2149.4	2147.3	
I-1202	C				2146.9896	2149.4	2147.3	
I-1203	C				2119.9787	2122.3	2120.4	
I-1204	E				2119.9787	2122.4	2120.3	
I-1205	E				2133.9944	2136.4	2134.6	
I-1206	E				2133.9944	2136.4	2134.0	
I-1207	E				2176.0050	2178.4	2176.3	
I-1208	E				2176.0050	2178.4	2176.6	
I-1209	E				2219.9948	2222.4	2220.6	
I-1210	D				2219.9948	2222.4	2220.3	
I-1211	A				2219.9948	2222.5	2221.1	
I-1212	A				2219.9948	2223.3	2221.3	
I-1213	B	D			2064.9729	2067.3	2065.6	A
I-1214	B	D			2107.0199	2109.3	2107.3	A
I-1215	A	D			2064.9729	2067.4	2064.8	A
I-1216	B	D			2078.9886	2181.4	2179.3	A
I-1217	C			+++	2166.0206	2168.5	2166.2	A
I-1218	B				2151.0209	2153.6	2151.5	A
I-1219	E				2124.0100	2126.6	2124.7	A
I-1220	C				2138.0257	2140.4	2137.9	A
I-1221	D			+++	2166.0206	2168.5	2166.9	A
I-1222	C				2151.0209	2153.4	2151.3	A
I-1223	E				2124.0100	2126.4	2124.4	A
I-1224	E				2138.0257	2140.4	2138.5	A
I-1225	E				2180.0363	2182.4	2180.2	A
I-1226	D				2224.0261	2226.5	2224.4	A
I-1227	B				2224.0261	2226.5		A
I-1228	E				2238.0417	2240.8	2238.9	A
I-1229	A				2157.9985	2161.2	2158.8	A
I-1230	A			+	2086.9614	2090.4	2088.6	A
I-1231	A			+	2163.9549	2167.1		A
I-1232	A			+	2092.9178	2096.0	2094.3	A
I-1233	A				2143.9829	2147.1	2145.4	A
I-1234	A				2072.9458	1038.8	1037.1	A
I-1235	A				2101.9359	1053.3	1051.3	A
I-1236	A				2030.8988	2033.9	2032.4	A
I-1237	A				2177.9672	2181.2	2180.2	A
I-1238	A				2106.9301	2110.4	2108.2	A
I-1239	A				2129.9672	2133.0	2131.5	A
I-1240	B				2058.9301	1031.7	2060.5	A
I-1241	A				2130.9413	1067.8	1066.0	
I-1242	A				1997.9274	2000.1	1998.1	
I-1243	A				1983.9117	1986.1	1984.5	
I-1244	A				2054.9488	2057.2	2055.1	

I-1245	A				2015.9179	2018.2	2016.2	
I-1246	A				2015.9179	2018.2	2016.8	
I-1247	A				2086.9551	2089.2	2087.1	
I-1248	A				2031.8884	2034.6	2032.3	
I-1249	A				2102.9255	2105.8	2104.4	
I-1250	A				2011.9430	2085.3	2083.3	
I-1251	A				2082.9801	2014.2	2012.6	
I-1252	A				2295.0098	2298.3	2296.0	
I-1253	A				2295.0098	2298.3	2295.8	
I-1254	A				2337.0568	1170.9	1169.2	
I-1255	A				2337.0568	2340.4	2338.6	
I-1256	A				2267.0149	1135.8	2268.1	
I-1257	A				2267.0149	1135.9	1134.3	
I-1258	A				2321.0255	2324.3	2322.0	
I-1259	A				2321.0255	2324.4	2321.8	
I-1260	A				2363.0724	2366.6	2364.3	
I-1261	A				2363.0724	1183.8	1182.1	
I-1262	A				2293.0305	1148.8	1147.0	
I-1263	A				2300.9662	2304.3	2302.7	
I-1264	A				2343.0132	1173.9		
I-1265	A				2272.9713	1138.8	1136.2	
I-1266	A				2326.9819	2330.3	2328.5	
I-1267	A				2369.0288	2372.5	2370.3	
I-1268	A			+	2298.9870	1152.0	2299.9	
I-1269	B				2233.9062	1119.0	2234.1	
I-1270	C				2207.8905	1106.0	1103.7	
I-1271	A				2144.8545			
I-1272	A				2143.8592			
I-1273	A			+	2158.8701	2161.4	2159.4	
I-1274	A			+	2081.8436	2084.2	2082.0	
I-1275	A				2095.8592	2098.3		
I-1276	A				2137.8698	2140.3		
I-1277	A				2123.8541	1063.9	1062.0	
I-1278	A			+	2093.8436	2096.3	2094.4	
I-1279	A		+++		2095.8592	2098.4	2096.9	
I-1280	A		++		2109.8749	2112.4	2110.3	
I-1281	A		++		2107.8592	2110.4		
I-1282	A				2095.8228	2098.3	2096.4	
I-1283	A				2109.8385	1056.8	2110.4	
I-1284	A		+++		2294.0792	2296.6	2294.2	A
I-1285	A				2338.0690	2340.7	2339.0	A
I-1286	B				2320.0948	2322.6	2320.3	A
I-1287	B				2310.0741	2312.8	2311.2	A
I-1288	A				2354.0639	2356.6	2354.9	A
I-1289	B				2336.0897	2338.6		A
I-1290	B	D		+	2336.1261	2338.6	2336.4	A
I-1291	A	D		+	2380.1160	2282.7	2281.1	A
I-1292	B			+	2362.1418	2364.6	2362.3	A
I-1293	B				2310.0741	2312.7	2310.7	A
I-1294	A				2354.0639	2356.5		A
I-1295	B				2336.0897	2338.6		A

I-1296	B				2114.9927	2118.0		A
I-1297	E				2251.1098	2253.6	2251.9	A
I-1298	E				2265.1254	2267.6	2265.4	A
I-1299	B		+++		2180.0726	1092.0	1090.4	A
I-1300	B		+++		2194.0883	2096.5	2094.7	A
I-1301	B				2090.8980	1046.4	1044.5	
I-1302	C				2090.8980	2091.3	2089.3	
I-1303	E				2106.8752	2106.1	2104.1	
I-1304	A				2063.0114	2065.3	2063.4	
I-1305	B				2082.9801	2085.3	2083.4	
I-1306	A				2036.9594	2039.2	2037.3	
I-1307	A				2074.9614	2078.1	2076.4	
I-1308	A				2094.9301	2098.1	2096.2	
I-1309	A				2048.9094	2052.1	2050.6	
I-1310	A				2048.9958	2051.3	2049.5	
I-1311	B				2068.9645	2071.3		
I-1312	B				2068.9645	2071.3	2069.3	
I-1313	A				2022.9437	2025.3	2023.1	
I-1314	A				2060.9458	2064.3		
I-1315	A				2080.9145	2084.0	2081.7	
I-1316	B				2034.8937	2037.9	2036.0	
I-1317	A				2060.9958	2063.3	2061.3	
I-1318	A				2075.0114	2077.4	2075.8	
I-1319	B				2089.0271	2091.3	2089.3	
I-1320	A				2072.9458	2076.1		
I-1321	A				2086.9614	2090.0	8087.8	
I-1322	A				2100.9771	2104.2		
I-1323	A				2046.9801	2049.3	2047.0	
I-1324	A				2060.9958	2063.2	2061.3	
I-1325	B				2075.0114	2077.3	2075.5	
I-1326	A				2058.9301	2062.0	2060.5	
I-1327	A				2072.9458	2076.1	2074.6	
I-1328	A				2086.9614	2090.1		
I-1329	A				2075.9737	2078.3	2076.3	A
I-1330	C				2089.9893	2092.3	2090.0	A
I-1331	E				2187.0032	2189.4	2187.6	A
I-1332	A				2101.9893	2104.4	2101.9	A
I-1333	C				2116.0050	2118.4	2116.2	A
I-1334	E				2213.0189	2215.3	2213.5	A
I-1335	A				2072.9458	1038.6	1036.8	A
I-1336	B				2072.9458	2076.3	2072.8	A
I-1337	A				1996.9145	1000.6	998.8	A
I-1338	C				2010.9301	1007.6	1005.7	A
I-1339	E				1995.9304	1998.8	1995.9	A
I-1340	C				2009.9461	2012.8	2010.8	A
I-1341	C				1968.9195	1971.7	1970.3	A
I-1342	B				2114.9927	1059.7		A
I-1343	B				2100.9771	2104.0	2102.0	A
I-1344	B				2114.9927	1059.8		A
I-1345	A			+	2289.1068	2291.6	2289.9	
I-1346	A			+	2303.1224	2305.6	2303.5	

I-1347	A			+++	2317.1381	2319.6	2318.1	
I-1348	A				2301.0568	2304.4	2302.3	
I-1349	A			+	2315.0724	2318.3		
I-1350	A			+	2329.0881	1166.9	1165.2	
I-1351	A				2296.9891	2300.4	2298.5	
I-1352	A				2282.9734	2286.4		
I-1353	A				2254.9785	2258.3	2256.6	
I-1354	A				2240.9629	2244.3	2242.8	
I-1355	A				2296.0414	2299.4		
I-1356	A				2282.0258	2285.5	2282.8	
I-1357	A				2339.0360	2342.4	2340.0	
I-1358	A				2325.0204	2328.5	2326.8	
I-1359	A				2297.0255	1150.7	1148.8	
I-1360	A				2283.0098	2286.3		
I-1361	A				2338.0884	2341.5		
I-1362	A				2324.0727	2327.5		
I-1363	B		+++		2102.9886	2105.4	2103.5	
I-1364	B		+++		2074.9573	2077.1		
I-1365	A		+++		2157.8749	2060.2	2158.1	
I-1366	C		+++		2171.8905	1087.9	1086.2	
I-1367	A			+	1995.8617	1999.0	1997.4	
I-1368	A				1995.8617	1999.1		
I-1369	A			+	2009.8773	2013.0		
I-1370	A			+	2009.8773	2012.9	2011.5	
I-1371	A			+++	2009.8773	2013.0	2011.4	
I-1372	A			+	2009.8773	2013.0	2011.1	
I-1373	A			+++	2023.8930	2027.0		
I-1374	A				2023.8930	1014.2	2025.2	
I-1375	A				2023.8930	2027.1	2025.5	
I-1376	A			+	2024.8519	2028.0	2026.2	
I-1377	A				2024.8519	2027.9	2026.0	
I-1378	A				2038.8675	2042.0	2040.5	
I-1379	A				2050.8675	2054.0	2052.7	
I-1380	A				2064.8832	2068.7	2066.8	
I-1381	A				2064.8832	2068.0	2066.6	
I-1382	A				2064.8832	2068.1	2066.2	
I-1383	A				2064.8832	2068.0		
I-1384	A				2064.8832	2068.0	2066.3	
I-1385	A				2064.8832	2068.0	2066.4	
I-1386	B				2157.8749	2160.4	2158.6	
I-1387	B				2158.8701	2161.4	2159.7	
I-1388	B				2095.8592	2098.2	2096.5	
I-1389	B				2107.8592	2110.4		
I-1390	B				2171.8905	2174.3	2172.6	
I-1391	B				2137.8698	2140.4	2138.2	
I-1392	A				2316.0635	2318.6		
I-1393	A				2308.0414	2311.3	2309.8	
I-1394	A				2387.1006	2389.7	2388.2	
I-1395	A				2379.0786	1192.0	1190.3	
I-1396	A				2011.9212	2014.2	2011.9	
I-1397	C				2067.9474	2070.5	2068.2	

I-1398	A				2207.9160	2210.4	2208.8	
I-1399	A				2137.9505	2140.4		
I-1400	A				2088.9365	2091.4	2089.3	
I-1401	A				2088.9365	2091.3	2089.3	
I-1402	B				2492.1684	1248.1	1246.2	
I-1403	A				2668.2733	1336.1	1334.8	
I-1404	A				3020.4830	1512.4	1510.7	
I-1405	B				2484.1463	2487.6	2485.6	
I-1406	A				2660.2512	1332.5	1330.8	
I-1407	A				3012.4609	1508.8	1506.9	
I-1408	A				2739.3104	1371.7	1370.2	
I-1409	A				3091.5201	1547.9	1545.8	
I-1410	A				4016.0706	2010.5	2008.5	
I-1411	A				2555.1834	1280.0	1278.1	
I-1412	A				2731.2883	1368.1	1366.7	
I-1413	A				3083.4980	1544.3	1542.8	
I-1414	A				2066.8988	2070.0	2068.5	
I-1415	A				2052.8832	2056.0	2053.3	
I-1416	A				2038.8675	2041.9	2039.4	
I-1417	A				2038.8675	2041.9		
I-1418	A				2038.8675	2042.0	2040.3	
I-1419	A				2050.8675	2054.0	2052.4	
I-1420	A				2036.8519	2039.9	2038.1	
I-1421	A				2050.8675	2054.0	2052.4	
I-1422	A				2036.8519	2054.0	2052.4	
I-1423	A				2050.8675	2054.0		
I-1424	A				2036.8519	2040.0	2038.5	
I-1425	B				2172.8858	2175.6	2174.8	
I-1426	B				2185.9062	1094.8	1093.7	
I-1427	B				2109.8749	2112.4	2110.4	
I-1428	C				2123.8905	1063.8	2124.4	
I-1429	A				2121.8749	2123.3		
I-1430	B				2123.8541	2126.7	2124.5	
I-1431	A				2069.9267	2072.3	2070.4	
I-1432	A				2055.9111	2058.3	2056.1	
I-1433	A				2083.9424	2086.3	2083.9	
I-1434	A				2111.9737	2114.3	2112.7	
I-1435	A				2083.9424	2086.3	2084.7	
I-1436	A				2111.9737	2114.4	2112.5	
I-1437	B				2102.9059	2105.3	2103.2	
I-1438	A				2132.9165	2135.4		
I-1439	A				2132.9165	2135.4	2133.2	
I-1440	A				2139.9587	2142.4	2140.6	
I-1441	A				2139.9587	2142.4	2140.0	
I-1442	A				2139.9587	2142.3	2140.8	
I-1443	B				2111.9274	1058.3	2112.4	
I-1444	B				2151.9587	1263.3		
I-1445	B				2151.9587	2154.2		
I-1446	B				2151.9587	2154.4	2152.3	
I-1447	B				2151.9587	1078.8		
I-1448	B				2137.9430	2140.2		

I-1449	B				2144.9529	2147.4	2145.3	
I-1450	B				2116.9216	2119.4	2117.3	
I-1451	A				2144.8545	2147.3	2145.1	
I-1452	A	C	++		2126.9927	2125.9		A
I-1453	A				2173.8698	2176.2	2174.4	
I-1454	A		++		2172.8858	2175.2	2173.2	
I-1455	A				2172.8858	2176.1	2174.1	
I-1456	B		+++		2201.9011	2005.1	2002.6	
I-1457	B		++		2123.8905	1064.3	2124.8	
I-1458	A		++		2121.8749	2124.4	2122.9	
I-1459	B				2109.8749	2111.0	2111.0	
I-1460	A				2137.8698	2139.1	2139.1	
I-1461	A				2158.8701	2160.1	2160.1	
I-1462	B				2107.8592	2109.0	2109.0	
I-1463	A	D	++		2140.9356	2143.8	2141.5	
I-1464	A		++		2124.9771	1064.6		
I-1465	A	D	++		2082.9301	2085.8	2084.2	
I-1466	A	D	++		2110.9614	1057.6		
I-1467	A		++		2154.9512	2156.5		
I-1468	A		+++		2096.9458	2099.8		
I-1469	A				2186.9014			
I-1470	B				2186.9014			
I-1471	B				2123.8905			
I-1472	A				2263.0006	2263.8	2262.1	
I-1473	A				2305.0476	2305.9	2304.4	
I-1474	A				2402.1003	1201.6	1099.7	
I-1475	A				2293.0112	2293.9	2292.4	
I-1476	A				2390.0639	2391.2	2389.7	
I-1477	A				2289.0163	2289.9	2288.4	
I-1478	A				2261.0213	2261.9	2260.2	
I-1479	A				2303.0683	2303.9	2302.5	
I-1480	A				2400.1210	2401.1	2399.6	
I-1481	A				2291.0319	2291.8	2290.4	
I-1482	A				2388.0847	2389.2	2387.7	
I-1483	A				2287.0370	2287.9	2285.7	
I-1484	E				2032.8739	2033.6	2031.4	
I-1485	E	D			2036.9052	2037.4	2035.7	A
I-1486	B				2060.9052	2062.7	2060.3	
I-1487	B				2060.9052	1031.9	1030.0	
I-1488	A			+	2074.9209	2077.0	2074.9	
I-1489	A				2074.9209	2076.9	2074.9	
I-1490	B				2088.9365	2091.1	2088.6	
I-1491	A				2088.9365	2091.0	2088.7	
I-1492	B				2004.8426	2006.7	2004.4	
I-1493	E				2018.8583	1011.0	1009.0	
I-1494	A				2032.8739	2034.9	2032.9	
I-1495	A				2032.8739	1017.8	1015.9	
I-1496	A		+++	+++	2064.9365	2067.2	2065.6	A
I-1497	A		+++	+++	2078.9522	2081.1	2079.6	A
I-1498	C		++	+	2092.9678	2095.1	2092.5	A
I-1499	A		+++		2008.8739	2010.8	2008.8	A

I-1500	A		+++		2022.8896	2024.9	2023.0	A
I-1501	A				2036.9052	1019.9	1017.9	A
I-1502	A				2069.8540	2072.9	2070.7	
I-1503	A				2055.8384	2058.9	2057.2	
I-1504	A				2095.8697	1049.9	1048.0	
I-1505	A			+	2055.8384	1030.4	1028.0	
I-1506	A			+	2041.8227	1022.8	1020.7	
I-1507	A				2081.8540	2085.0	2083.3	
I-1508	A			+	2009.8773	1006.6	1004.6	
I-1509	A				2009.8773	2012.0	2010.3	
I-1510	C				1995.8617	988.2	986.1	
I-1511	C				2035.8930	1008.6	1006.8	
I-1512	C				2009.8773	995.3	993.3	
I-1513	C				1995.8617	988.2	986.1	
I-1514	C				2035.8930	2038.6		
I-1515	C				2049.9086	1015.0	1013.3	
I-1516	C				2035.8930	1008.3	1006.4	
I-1517	C				2035.8930	1008.3	1006.4	
I-1518	A				2021.8773	1012.7	2022.9	
I-1519	A				2159.8541	2162.0	2160.6	
I-1520	A				2160.8494	2163.2	2160.9	
I-1521	A				2111.8541	2113.2	2111.1	
I-1522	A				2097.8385	2099.7	2097.3	
I-1523	A				2114.9927	1061.4	2119.7	A
I-1524	B				2141.0084	1075.5	1073.5	A
I-1525	A				5122.6777	1025.7		
I-1526	A				7764.2506	1554.1		
I-1527	A			+	2057.9040	2060.3	2057.8	
I-1528	A			+	2043.8884	2046.3	2044.2	
I-1529	A				2083.9197	1043.6	1041.4	
I-1530	A			+	2043.8884	2046.7	2044.2	
I-1531	A			+	2029.8727	2032.6	2030.3	
I-1532	B				2085.9086	2088.8	2085.5	
I-1533	C				2085.9086	2088.9	2086.8	
I-1534	A				2071.8930	2074.8	2072.9	
I-1535	B				2071.8930	2074.9	2073.2	
I-1536	B				2073.9587	2075.6	2073.3	
I-1537	A			+	2027.8679	2030.3	2029.1	
I-1538	A				2027.8679	2030.3	2029.5	
I-1539	A			+	2013.8523	2016.1	2013.9	
I-1540	A				2013.8523	2016.2	2013.7	
I-1541	A				2015.9179	2017.3	2015.3	
I-1542	A				2015.9179	2017.4	2015.3	
I-1543	A				2001.9023	2003.4	2001.1	
I-1544	A				2001.9023	2003.4	2001.2	
I-1545	C				2011.9430	1006.8	1004.4	
I-1546	A				1997.9274	1999.4	1997.2	
I-1547	A				1997.9274	1999.5	1996.8	
I-1548	A				2019.8651	2022.2	2020.9	A
I-1549	B			+++	1963.8025	1967.2	1965.2	A
I-1550	A			+++	2005.8494	2008.6	2006.3	A

I-1551	A			+++	1991.8338	1994.3	1992.1	A
I-1552	A			++	2005.8494	2008.7	2006.5	A
I-1553	A			+++	2039.8338	2042.6	2039.5	A
I-1554	A				2031.8651	2034.2	2032.6	A
I-1555	A				2045.8807	2048.0	2046.0	A
I-1556	A				2115.8651	2118.1	2116.6	A
I-1557	C				2018.8810	2021.2	2019.0	A
I-1558	D				1991.8701	1994.1	1991.5	A
I-1559	A				2001.8181	2007.2	2005.2	A
I-1560	A			+	2023.8930	2026.4	2024.5	
I-1561	A			+	2023.8930	1013.8	2024.4	
I-1562	A			+	2037.9086	2040.4	2038.5	
I-1563	A				2037.9086	2041.7	2039.4	
I-1564	A			+	2035.8930	2038.3	2036.9	
I-1565	A			+	2035.8930	1019.8	1017.4	
I-1566	A				2049.9086	1026.8		
I-1567	A				2049.9086	2053.1	2049.8	
I-1568	A			+	2063.9243	2066.6	2064.7	
I-1569	A			+	2063.9243	2066.6	2064.4	
I-1570	A				2079.9192	1041.8	1039.7	
I-1571	A				2079.9192	1041.8		
I-1572	A			+	2055.8651	2058.6	2056.0	
I-1573	A			+	2055.8651	2058.5	2056.4	
I-1574	A			+	2069.8807	2072.6	2070.5	
I-1575	A			+	2069.8807	2072.5	2070.0	
I-1576	A				2069.8807	1065.7	1063.7	
I-1577	A			+	2067.8651	2070.6	2068.7	
I-1578	A			+	2067.8651	2070.5	2068.6	
I-1579	A			+	2081.8807	1042.8	1040.6	
I-1580	A			+	2095.8964	2098.6	2096.0	
I-1581	A			+	2111.8913	2114.9	2112.8	
I-1582	A				2015.8338	1009.8	1007.9	
I-1583	A				2015.8338	1009.8	1007.8	
I-1584	A				2029.8494	2032.2	2030.4	
I-1585	A				2029.8494	2032.7	2030.3	
I-1586	A				2027.8338	2030.4	2027.9	
I-1587	A				2027.8338	2030.5	2028.1	
I-1588	A				2041.8494	2044.6	2042.3	
I-1589	A				2041.8494	1022.8	1020.7	
I-1590	A				2055.8651	2058.6	2056.4	
I-1591	A				2055.8651	1029.8	1027.9	
I-1592	A				2071.8600	1037.8	1035.3	
I-1593	A				2071.8600	2074.5	2072.1	
I-1594	A				1927.9396	1929.5	1927.3	
I-1595	A				1927.9396	1929.5	1927.4	
I-1596	B				1961.9007	1963.8	1961.6	
I-1597	B				1961.9007	1964.0	1961.8	
I-1598	A			+	1961.9007	1963.8	1962.0	
I-1599	A				1961.9007	1963.9	1962.0	
I-1600	A				1961.9007	982.4	980.6	
I-1601	A				1941.9553	1943.4	1941.3	

I-1602	B				2005.8502	2008.4	2005.8	
I-1603	C				2005.8502	1004.7	2006.7	
I-1604	A			+	2005.8502	2008.4	2006.0	
I-1605	A				2005.8502	1004.6	1002.8	
I-1606	A				2005.8502	1004.6	1002.6	
I-1607	A				2005.8502	1004.7	1002.8	
I-1608	A				1995.9270	1997.4	1995.3	
I-1609	A				1995.9270	1997.5	1995.2	
I-1610	A				1995.9270	1997.5	1995.2	
I-1611	A				1995.9270	1997.4	1995.3	
I-1612	A				2011.8066	1007.7	1005.7	
I-1613	A				2011.8066	1007.7	1005.9	
I-1614	A				2001.8834	2003.3	2001.3	
I-1615	A				2001.8834	2003.4	2001.1	
I-1616	A				2112.9771	2115.4	2113.6	A
I-1617	A				2138.9927	1071.2	1069.3	A
I-1618	B				2141.0084	1072.2	1070.1	A
I-1619	A				2170.9825	1087.2	1085.7	A
I-1620	A				2098.9614	2101.0	2099.3	A
I-1621	A				2124.9771	1064.1	1061.9	A
I-1622	A				2126.9927	2129.2	2127.4	A
I-1623	A				2156.9669	2160.0	2157.9	A
I-1624	A				2126.9927	1065.0	1063.0	A
I-1625	A				2112.9771	2115.5	2113.3	A
I-1626	A				2098.9614	1051.2	1049.3	A
I-1627	A				2084.9458	2087.4	2085.5	A
I-1628	A				2194.0097	2195.6	2193.5	
I-1629	A				2194.0097	2195.6	2193.4	
I-1630	A				2136.8654	2139.4	2137.3	
I-1631	B				2123.8701	1063.8	1062.0	
I-1632	A				2136.8654	1070.2		
I-1633	B				2123.8701	1063.8	1061.7	
I-1634	A				2139.8651	1071.7	1069.7	
I-1635	E				2127.8287	1814.1	1811.7	
I-1636	A				2138.8810	2141.5	2138.8	
I-1637	B				2125.8858	2128.7	2126.2	
I-1638	A			+	2138.8810	2041.9	2039.3	
I-1639	B			+	2125.8858	1064.8		
I-1640	E				2199.8804	1085.8	1084.0	
I-1641	A				2170.9881	2173.0	2171.0	
I-1642	A				2170.9881	2172.9	2171.4	
I-1643	A				2128.9412	2130.9	2128.7	
I-1644	A				2128.9412	1065.9	1064.0	
I-1645	A				2137.0271	2138.5	2136.5	
I-1646	A				2137.0271	2138.5	2136.4	
I-1647	A				2094.9801	2096.4	2094.4	
I-1648	A				2023.9430	2025.3	2023.4	
I-1649	A				2023.9430	2025.4	2023.3	
I-1650	A				2155.0177	2156.6	2154.4	
I-1651	A				2155.0177	2156.5	2154.1	
I-1652	A				2112.9707	2114.4	2112.6	

I-1653	A				2041.9336	2043.3	2041.4	
I-1654	B			+	2205.0145	2206.4	2204.3	
I-1655	B			+	2205.0145	2206.5	2204.2	
I-1656	A			+	2162.9675	2164.6	2162.3	
I-1657	A			+	2162.9675	2164.5	2162.1	
I-1658	A			+	2091.9304	2093.3	2091.3	
I-1659	A			+	2091.9304	2093.4	2091.2	
I-1660	A				2202.0172	2203.4	2201.3	
I-1661	C				2202.0172	1102.3	1100.3	
I-1662	B				2188.0016	2189.4	2187.3	
I-1663	D				2188.0016	1095.3	1093.4	
I-1664	A				2264.0329	2265.5	2263.3	
I-1665	B				2264.0329	2265.5	2263.7	
I-1666	A				2224.0703	2225.6	2223.5	
I-1667	B				2242.0234	2243.5	2241.4	
I-1668	A				2242.0234	1122.2	1120.4	
I-1669	A				2242.0234	2243.5	2241.6	
I-1670	A				2203.0125	2204.5	2202.4	
I-1671	C				2203.0125	2204.5	2202.4	
I-1672	A				2229.0281	2230.5	2228.5	
I-1673	A				2130.9512	1067.1	1065.0	A
I-1674	C				2129.9672	2132.4	2130.0	A
I-1675	C				2102.9563	1053.0	1051.2	A
I-1676	C				2144.9669	1074.2	1072.3	A
I-1677	C				2143.9829	1073.6	1071.7	A
I-1678	C				2116.9720	1060.1	1058.1	A
I-1679	B				2158.9825	1081.1	1079.3	A
I-1680	A				2126.9	2128.2	2125.8	
I-1681	A				2099.9	2101.3	2098.9	
I-1682	C				2113.9	2115.1	2113.0	
I-1683	C				2099.9	2101.2	2099.0	
I-1684	C				2113.9	2115.2	2113.3	
I-1685	C				2113.9	2115.1	2113.8	
I-1686	B				2113.9	2115.2	2113.1	
I-1687	C				2119.9	2121.2	2119.3	
I-1688	A				2211.0	1107.1	1105.3	A
I-1689	A			+	2197.0	2199.0	2197.3	A
I-1690	A			+	2225.0	2228.3	2226.0	A
I-1691	A				2211.0	2212.9	2210.3	A
I-1692	A			+	2183.0	2185.2	2183.6	A
I-1693	A			+	2168.9	2170.6	2169.0	A
I-1694	A				2195.0	1099.0	1097.2	A
I-1695	A			+	2223.0	2224.9	2222.8	A
I-1696	A				2209.0	2210.7	2208.7	
I-1697	A				1985.9	1987.7		A
I-1698	A				1971.9	1973.8	1971.6	A
I-1699	A				1985.9	1987.8	1985.5	A
I-1700	A				1971.9	1973.7	1971.5	A
I-1701	A			+	2620.1	1311.9	1309.9	
I-1702	A			+	3896.9	1950.3	1948.7	
I-1703	A	C		+	2762.2	1382.8	1381.0	

I-1704	A	D		+	4039.0	2021.3	2019.2	
I-1705	A	C		+	2833.2	1418.4	1416.2	
I-1706	A	D		+	4110.0	2056.9	2054.8	
I-1707	A			+	2751.3	1377.5	1375.3	
I-1708	A	D		+	4028.0	2016.0	2014.2	
I-1709	A		++		2004.9	2006.2	2004.0	
I-1710	A			+	2165.9	1084.4	1082.3	
I-1711	A				2179.9	2181.6	2179.9	
I-1712	A	C		+	2163.9	2165.4	2162.6	
I-1713	A	C		+	2177.9	2180.7	2178.1	
I-1714	A	C		+	2191.9	2193.6	2191.6	
I-1715	A				2213.9	2215.6	2212.8	
I-1716	A				2191.8	2193.5		
I-1717	A	B		+	2264.9	2266.5	2264.6	
I-1718	A				2204.9	2205.6	2203.5	
I-1719	A				2215.9	2216.9	2214.6	
I-1720	A				2240.9	2141.8	2140.2	
I-1721	A				2242.9	2244.6	2243.1	
I-1722	A				2201.9	2204.3		
I-1723	A	C		+	2164.9	2266.5	2263.7	
I-1724	A			+++	2178.9	2180.6	2179.2	
I-1725	A	C		+++	2162.9	2164.6		
I-1726	A			+++	2176.9	2179.5	2177.7	
I-1727	A			+++	2190.9	2193.8	2191.1	
I-1728	B				2212.9	2215.6	2213.5	
I-1729	A				2190.8	2193.4	2191.6	
I-1730	A			+++	2263.9	2265.5	2264.5	
I-1731	A				2203.9	2205.7		
I-1732	A			+++	2239.9	2241.5	2239.2	
I-1733	A			+++	2241.9	2243.7	2241.7	
I-1734	A				2200.9	2203.6	2201.6	
I-1735	C				2084.0	2086.1	2084.4	
I-1736	A			+	2084.0	2086.2	2084.7	
I-1737	A				2193.0	2195.1	2193.8	
I-1738	A				2207.0	2209.1	2207.8	
I-1739	A				2253.0	2255.1	2253.6	
I-1740	A			+	2203.0	2205.4	2203.5	
I-1741	A				2217.0	2217.8	2215.8	
I-1742	A			++	2217.0	2219.1	2217.7	
I-1743	A			++	2217.0	2219.2	2217.8	
I-1744	C				2170.0	2172.1	2170.4	
I-1745	B				2232.0	1117.7	1116.2	
I-1746	D				2198.0	1100.6	1198.9	
I-1747	A				2169.0	2171.2	2169.6	
I-1748	C				2169.0	2171.1	2169.1	
I-1749	A				2183.0	2182.8	2180.9	
I-1750	B				2197.1	1100.0	1098.5	
I-1751	A				2242.0	1122.9	1120.9	
I-1752	A	C		+	2229.0	1116.3	1114.4	
I-1753	A			+++	2211.0	2213.1	2212.0	
I-1754	A			+++	2189.0	2191.2		

I-1755	A			+++	2190.0	2192.2	2190.6	
I-1756	A				2190.0	1096.4	1094.6	
I-1757	A				1995.9			
I-1758	A				2009.9			
I-1759	B				2066.9			
I-1760	A				2009.9			
I-1761	A				2023.9			
I-1762	A				2080.9			
I-1763	B				2207.0	1104.9	1103.4	
I-1764	A				2207.0	2209.2	2207.7	
I-1765	A				2207.0	1105.1	1103.9	
I-1766	A	D		+++	2187.9			
I-1767	A				2296.9			
I-1768	A				2285.0			
I-1769	B	D		+	2313.0			
I-1770	B	D		+	2301.0			
I-1771	A				2286.9			
I-1772	A	D		+	2275.0			
I-1773	A	D		+	2298.9			
I-1774	A	C		+	2287.0			
I-1775	A				2287.0			
I-1776	A				2346.9			
I-1777	B	D		+	2335.0			
I-1778	A				2066.9			
I-1779	A				1981.8			
I-1780	A				1981.8	992.3	990.3	
I-1781	A				1995.9			
I-1782	A				2052.9			
I-1783	A				2211.0	2212.7	2210.0	
I-1784	A	C			2227.0	2229.1	2227.0	
I-1785	A				2211.0	2212.7	2210.6	
I-1786	A	C			2031.9	2033.8	2031.7	
I-1787	A		++	+	2569.1	1286.3	1284.3	
I-1788	A		++	+	2833.2	1418.3	1416.3	
I-1789	A		++	+	2653.2	1328.3	1326.3	
I-1790	A		++	+	2917.3	1460.4	1458.3	
I-1791	E		+	+	2793.3	1398.4		
I-1792	E		+	+	3057.5	1530.5		
I-1793	B				2080.9	2082.9	2080.6	
I-1794	C				2038.9	2040.8	2039.0	
I-1795	C				2066.9	2068.3	2065.7	
I-1796	A				2094.9	2097.0	2095.5	
I-1797	A	D			2052.9	2054.8		
I-1798	A	C			2080.9	1042.0		
I-1799	B				2094.9	2096.2	2094.5	
I-1800	C				2052.9	2055.9	2053.6	
I-1801	E				2080.9	2083.7	2082.1	
I-1802	B				2094.9	2096.8		
I-1803	C				2052.9	2055.0	2053.4	
I-1804	C				2080.9	2082.9	2080.9	
I-1805	A	C			2324.0	1163.5	1161.3	

I-1806	A	C			2289.0	1146.0	1144.1	
I-1807	A	D			2199.0	2200.8	2198.7	
I-1808	A	D			2245.0	1124.0	1121.6	
I-1809	A	B			2097.0	2098.0	2095.8	
I-1810	A	C			2097.0	2098.0	2095.9	
I-1811	B				2092.9	2095.1	2093.0	
I-1812	A	D			2125.0	2126.1	2124.0	
I-1813	A	C			2125.0	2126.1	2124.0	
I-1814	A	D			2125.0	2126.1	2123.8	
I-1815	A		++		2698.3	1350.2	1348.2	
I-1816	A		++		2698.3	1350.2	1348.2	
I-1817	A	C	++		2754.3	1378.2	1376.2	
I-1818	A				2726.3	1364.3	1362.4	
I-1819	A				2726.3	1364.3	1362.2	
I-1820	A	B	++		2726.3	1364.2	1362.2	
I-1821	A		++		2726.3	1364.2	1362.3	
I-1822	A		++		2698.3	1350.2	1348.3	
I-1823	B		++		2698.3	1350.6	1348.5	
I-1824	A				2108.9	2110.9	2109.2	
I-1825	A				2066.9	2068.8	2066.1	
I-1826	A				2094.9	2096.8	2095.1	
I-1827	A				2108.9	2110.9	2109.5	
I-1828	A				2066.9	2069.7	2066.8	
I-1829	A				2094.9	2096.9	2095.0	
I-1830	A				2108.9	2110.9	2107.7	
I-1831	A				2066.9	2068.8	2066.6	
I-1832	A				2094.9	2096.8	2094.9	
I-1833	A				2123.0	2124.9		
I-1834	A				2080.9	2082.8	2070.7	
I-1835	A				2108.9	2110.9	2109.3	
I-1836	A				2135.0	1069.0	2135.0	
I-1837	B				2120.9	2123.2	2121.5	
I-1838	A				2135.0	1069.0	1066.8	
I-1839	A				2092.9	1048.0	1046.1	
I-1840	B				2120.9	1062.0	1060.1	
I-1841	A				2079.9	2081.0	2079.0	
I-1842	A				2079.9	2081.4	2079.2	
I-1843	A				2177.0	2178.1	2175.5	
I-1844	A				2177.0	2178.3	2176.0	
I-1845	A				2177.0	2178.0	2175.9	
I-1846	A				2166.9	2168.2	2165.7	
I-1847	A				2179.0	2180.1	2177.9	
I-1848	A				2179.0	2180.2	2177.8	
I-1849	A				2179.0	2180.1	2178.1	
I-1850	A				2122.0	2123.1	2120.9	
I-1851	A				2122.0	2123.1	2120.9	
I-1852	A				2107.9	2109.0	2106.9	
I-1853	A				2109.9	2111.0	2108.9	
I-1854	A				2219.0	2220.1	2218.7	
I-1855	A			+	2205.0	2206.1	2203.6	
I-1856	A				2207.0	2208.1	2205.8	

I-1857	A	C		++	2005.9	2007.7	2006.2	
I-1858	A	C		+	2035.9	2037.6	2035.8	
I-1859	A	C		+	2035.9	2037.7	2036.4	
I-1860	A	C		+	2021.9	2023.8	2021.3	
I-1861	A			+	2021.9	2023.6	2021.7	
I-1862	A	C		+	2021.9	2023.7	2021.9	
I-1863	A			+	1991.8	1993.7	1991.9	
I-1864	A			+++	1991.8	1993.8	1992.3	
I-1865	A			+	2021.9	2023.8	2021.9	
I-1866	A			++	2021.9	2023.7	2022.3	
I-1867	A				2007.8	2009.6	2007.8	
I-1868	A				2007.8	2009.7		
I-1869	A			+	2007.8	2009.7	2007.9	
I-1870	A			+	2007.8	2009.7	2008.2	
I-1871	A				2206.9			A
I-1872	A				2221.0	2222.1	2220.1	A
I-1873	A	D			2262.0	2263.2	2261.4	A
I-1874	A				2205.0	2206.1	2204.1	A
I-1875	A				2283.0	2284.0	2282.1	A
I-1876	A				2163.0	2164.2	2162.6	A
I-1877	A			+	2082.9	2084.1	2082.3	A
I-1878	A			+	2096.9	2098.1	2096.2	A
I-1879	A	D		+++	2138.0	2139.2	2136.9	A
I-1880	A	D		+	2081.0	2082.2	2080.4	A
I-1881	A	D		+	2158.9	1080.7	1078.8	A
I-1882	A			+	2038.9	2040.0	2038.1	A
I-1883	A				2152.0	2157.8	2156.6	
I-1884	A				2152.0	2157.8	2156.0	
I-1885	A				2324.0			A
I-1886	A				2200.0	2202.3	2200.3	A
I-1887	A				2214.0	2216.0	2214.2	A
I-1888	A				2266.0	2068.0	2065.8	A
I-1889	A				2142.0	2144.1	2142.1	A
I-1890	A				2294.0			A
I-1891	A				2170.0	2171.9	2170.1	A
I-1892	A				2184.0	1093.5	1091.6	A
I-1893	A				2308.0	2310.0	2308.0	A
I-1894	A				2184.0	2186.0	2183.8	A
I-1895	A				2198.0	1100.5	1098.5	A
I-1896	A				2135.0	2136.9	2134.6	
I-1897	A				2092.9	2095.7	2093.8	
I-1898	A				2135.0	2138.2		
I-1899	A				2092.9	2094.8		
I-1900	B				2104.9	2106.8	2104.4	
I-1901	B				2147.0	2149.9		
I-1902	B				2104.9	2107.1	2105.4	
I-1903	A				2147.0	2148.9	2147.1	
I-1904	A				2104.9	2107.2		
I-1905	A				2147.0	2149.1	2147.3	
I-1906	A				2104.9	2107.8		
I-1907	A				2066.9	2069.0	2067.4	

I-1908	A				2105.9	2108.2		
I-1909	A				2122.9	2125.2	2123.1	
I-1910	A				2139.9	1071.9	1069.6	
I-1911	C				2139.9	1071.8	1070;1	
I-1912	A				2054.9	2056.3	2054.1	
I-1913	B				2094.0	2095.4	2093.3	
I-1914	A				2110.9	2112.4		
I-1915	D				2127.9	2129.5	2126.9	
I-1916	B				2127.9	2129.8	2127.9	
I-1917	A				2689.2			
I-1918	A				2953.3			
I-1919	B				2885.4			
I-1920	B				3149.5			
I-1921	A				2175.0	2177;2		
I-1922	A				2132.9	2136.1		
I-1923	A				2092.9	2095.1	2093.1	
I-1924	A				2135.0	2136.9	2135.3	
I-1925	A				2120.9	1062.1	1060.1	
I-1926	A				2092.9	1048.1	1046.4	
I-1927	A				2241.0			A
I-1928	A				2229.0			A
I-1929	A				2235.0			A
I-1930	A				2269.0			A
I-1931	A				2257.0			A
I-1932	A				2263.0			A
I-1933	A				2340.0			A
I-1934	A				2346.0			A
I-1935	A				2109.0			A
I-1936	A				2149.0			A
I-1937	A				2123.0			A
I-1938	A				2095.0			A
I-1939	A				2219.0			A
I-1940	A				2192.0			A
I-1941	A				2232.1			A

1	Description
I-608	Ac-PL3-Asp-Leu-B5-Asp-Asp-dLys*3-Ala-Phe-GlnR*3-PyrS2-3Thi-BztA-Gln-NH2
I-609	Ac-PL3-Asp-Leu-B5-Asp-Asp-DGlnR*3-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-Gln-NH2
I-700	Ac-PL3-Asp-Leu-B5-Asp-Asp-DGlnR*3-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-Gln-NH2
I-701	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[ethylenediamine]GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-GlnR-NH2
I-702	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Me2ethylenediamine]GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-GlnR-NH2
I-703	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[diaminopropane]GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-GlnR-NH2
I-704	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[diaminopentane]GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-GlnR-NH2
I-705	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Me2diaminohexane]GlnR-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-GlnR-NH2
I-706	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-707	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2

I-708	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-709	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-BztA-sAla*3-Ala-NH2
I-710	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-1MeK*3-PyrS2-3Thi-BztA-hGlnR*3-Ala-NH2
I-711	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-1MeK*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-712	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-713	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-714	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Gly-NH2
I-715	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-NH2
I-716	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-NH2
I-717	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Npg-NH2
I-718	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Npg-NH2
I-719	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Pro-NH2
I-720	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-dPro-NH2
I-721	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ser-NH2
I-722	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Phe-NH2
I-723	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Asn-NH2
I-724	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Gln-NH2
I-725	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Trp-NH2
I-726	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Trp-NH2
I-727	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Tyr-NH2
I-728	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Tyr-NH2
I-729	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-730	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-731	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Cha-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-732	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-733	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-734	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-Cha-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-735	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-736	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-737	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Cha-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-738	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-739	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-740	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-741	Ac-PL3-3COOHF-Npg-B5-Asp-Asp-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-742	Ac-PL3-Asp-Npg-B5-3COOHF-Asp-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-743	Ac-PL3-Asp-Lys**3-B5-Asp-3COOHF-GlnR**3-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-744	Ac-PL3-Asp-1MeK**3-B5-Asp-3COOHF-GlnR**3-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-745	Ac-PL3-Asp-1MeK**3-B5-Asp-3COOHF-GlnR**3-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-746	Hex-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-747	Bua-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-748	2PyzCO-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-749	3Phc3-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-750	MeOPr-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-751	lithocholate-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-752	2FPhc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-753	PhC-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-754	MeSO2-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2

I-755	Ts-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-756	Ts-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-757	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[pXyl]hCys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-758	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[pXyl]Cys-PyrS2-3Thi-BztA-hCys-Ala-NH2
I-759	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[mXyl]hCys-PyrS2-3Thi-BztA-hCys-Ala-NH2
I-760	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[pXyl]hCys-PyrS2-3Thi-BztA-hCys-Ala-NH2
I-761	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-34ClF-GlnR*3-Ala-NH2
I-762	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-34ClF-GlnR*3-Ala-NH2
I-763	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-34MeF-GlnR*3-Ala-NH2
I-764	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-34MeF-GlnR*3-Ala-NH2
I-765	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-3BrF-GlnR*3-Ala-NH2
I-766	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-3BrF-GlnR*3-Ala-NH2
I-767	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-2NapA-GlnR*3-Ala-NH2
I-768	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-2NapA-GlnR*3-Ala-NH2
I-769	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-RbMe2NapA-GlnR*3-Ala-NH2
I-770	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-RbMe2NapA-GlnR*3-Ala-NH2
I-771	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-RbMeBzta-GlnR*3-Ala-NH2
I-772	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-RbMeBzta-GlnR*3-Ala-NH2
I-773	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-SbMeBzta-GlnR*3-Ala-NH2
I-774	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-SbMeBzta-GlnR*3-Ala-NH2
I-775	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-5IndA-GlnR*3-Ala-NH2
I-776	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-5IndA-GlnR*3-Ala-NH2
I-777	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-SPip2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-778	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-SPip3-2F3MeF-BztA-GlnR*3-Ala-NH2
I-779	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-SPip3-2F3MeF-BztA-GlnR*3-Ala-NH2
I-780	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-SPip2-3Thi-BztA-GlnR*3-Ala-NH2
I-781	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-SPip3-3Thi-BztA-GlnR*3-Ala-NH2
I-782	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-NH2
I-783	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-Ala-Ala-NH2
I-784	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-Ala-Ala-Ala-Ala-NH2
I-785	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Ser-NH2
I-786	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-hGlnR*3-NH2
I-787	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-hGlnR*3-Ala-NH2
I-788	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dDab*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-789	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dDab*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-NH2
I-790	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dDab*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-Ala-Ala-NH2
I-791	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dDab*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Ser-NH2
I-792	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dOrn*3-PyrS2-3Thi-BztA-AsnR*3-NH2
I-793	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dOrn*3-PyrS2-3Thi-BztA-AsnR*3-Ala-NH2
I-794	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dOrn*3-PyrS2-3Thi-BztA-AsnR*3-Ala-NH2

I-795	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dOrn*3-PyrS2-3Thi-BztA-AsnR*3-Ala-Ala-Ala-NH2
I-796	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dOrn*3-PyrS2-3Thi-BztA-AsnR*3-Ala-Ala-Ala-NH2
I-797	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dOrn*3-PyrS2-3Thi-BztA-AsnR*3-Leu-Ser-NH2
I-798	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-dOrn*3-PyrS2-3Thi-BztA-AsnR*3-Leu-Ser-NH2
I-799	Isobutyryl-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-800	Isobutyryl-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-801	Isovaleryl-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-802	EtHNCO-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-803	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala_D3-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala_D3-NH2
I-804	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Leu-NH2
I-805	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Leu-NH2
I-806	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Leu-Leu-NH2
I-807	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-Leu-NH2
I-808	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-Leu-Leu-NH2
I-809	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-Leu-Leu-NH2
I-810	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-Leu-Leu-Leu-NH2
I-811	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-Leu-Leu-Leu-NH2
I-812	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Val-Pro-Thr-Leu-Lys-NH2
I-813	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Val-Pro-Thr-Leu-Lys-NH2
I-814	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Lys-Leu-Pro-Val-nLeu-NH2
I-815	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Lys-Leu-Pro-Val-nLeu-NH2
I-816	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Val-Pro-Ala-Leu-Arg-NH2
I-817	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Val-Pro-Ala-Leu-Arg-NH2
I-818	5hexenyl-MePro-Asp-[Phc][Allyl]Dap-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-819	Ac-PL3-NAsp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-820	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Val-NH2
I-821	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Val-NH2
I-822	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Val-Ser-

	NH2
I-823	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Ala-NH2
I-824	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Val-NH2
I-825	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Val-NH2
I-826	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Val-Ser-NH2
I-827	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Leu-NH2
I-828	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Leu-NH2
I-829	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Leu-Ser-NH2
I-830	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Leu-Ser-NH2
I-831	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-832	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-833	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-NH2
I-834	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-NH2
I-835	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Ser-NH2
I-836	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Ser-NH2
I-837	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Leu-NH2
I-838	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Leu-NH2
I-839	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Leu-Ser-NH2
I-840	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Leu-Ser-NH2
I-841	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-842	Ac-PL3-Asp-nLeu-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-843	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aic-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-844	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aic-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-845	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aic-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-846	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aic-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-847	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-Aic-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-848	Ac-PL3-Asp-nLeu-B5-Asp-3COOHF-Aic-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-849	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyhLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-850	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-CyhLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-851	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyhLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-852	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-CyhLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-853	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-CyhLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-854	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-CyhLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-855	Ac-PL3-Asp-nLeu-B5-Asp-3COOHF-CyhLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-856	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Cbg-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-857	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Cbg-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-858	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Cbg-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-859	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Cbg-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-860	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-Cbg-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-861	Ac-PL3-Asp-nLeu-B5-Asp-3COOHF-Cbg-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-862	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-NH2
I-863	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-NH2
I-864	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Pro-NH2
I-865	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Ser-NH2
I-866	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Phe-NH2
I-867	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-868	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Pro-NH2
I-869	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ser-NH2

I-870	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Phe-NH2
I-871	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-872	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Pro-NH2
I-873	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ser-NH2
I-874	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Phe-NH2
I-875	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-876	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-877	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Ser-NH2
I-878	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-879	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Ala-NH2
I-880	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Leu-Ser-NH2
I-881	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-882	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-NH2
I-883	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Leu-Ser-NH2
I-884	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-885	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-886	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Leu-Ser-NH2
I-887	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-NH2
I-888	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-889	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-Ser-NH2
I-890	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-NH2
I-891	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-NH2
I-892	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Ala-NH2
I-893	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Leu-Ser-NH2
I-894	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-895	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-896	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Ala-NH2
I-897	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Ala-NH2
I-898	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Leu-Ser-NH2
I-899	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Leu-Ser-NH2
I-900	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Phe-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-901	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Phe-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Ala-NH2
I-902	Ac-PL3-Asp-Npg-B5-Asp-TfeGA-Phe-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Leu-Ser-NH2
I-903	TzPyr-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-904	15PyraPy-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-905	15PyraPy-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-906	8IAP-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-907	3PydCO-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-908	2PyBu-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-909	2PymCO-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-910	5PymCO-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-911	4PymCO-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2

I-912	4PymCO-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-913	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2Thi-34ClF-GlnR*3-Ala-NH2
I-914	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2Thi-34ClF-GlnR*3-Ala-NH2
I-915	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2Thi-34ClF-GlnR*3-Leu-Ser-NH2
I-916	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2Thi-34ClF-GlnR*3-Leu-Ser-NH2
I-917	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS2-2Thi-34ClF-GlnR*3-Ala-NH2
I-918	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS2-2Thi-34ClF-GlnR*3-Ala-NH2
I-919	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-2Thi-34ClF-GlnR*3-Ala-NH2
I-920	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-2Thi-34ClF-GlnR*3-Ala-NH2
I-921	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-2Thi-Lys*3-PyrS2-2Thi-34ClF-GlnR*3-Ala-NH2
I-922	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-2Thi-Lys*3-PyrS2-2Thi-34ClF-GlnR*3-Ala-NH2
I-923	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2Thi-BztA-GlnR*3-NH2
I-924	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2Thi-BztA-GlnR*3-NH2
I-925	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2Thi-BztA-GlnR*3-Leu-Ser-NH2
I-926	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS2-2Thi-BztA-GlnR*3-Ala-NH2
I-927	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-2Thi-BztA-GlnR*3-Ala-NH2
I-928	Ac-PL3-Phe-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-929	Ac-PL3-Gln-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-930	Ac-PL3-Gln-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-931	Ac-PL3-3Thi-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-932	4pentenyl-MePro-Asp-B5-Ala-Asp-3COOHF-Ala-Ala-Phe-PyrS2-Lys*3-3Thi-BztA-Ala-GlnR*3-NH2
I-933	4pentenyl-ThioPro-Asp-B5-Ala-Asp-3COOHF-Ala-Ala-Phe-PyrS2-Lys*3-3Thi-BztA-Ala-GlnR*3-NH2
I-934	4pentenyl-ThioPro-Asp-B5-Ala-Asp-3COOHF-Ala-Ala-Phe-PyrS2-Lys*3-3Thi-BztA-Ala-GlnR*3-NH2
I-935	Ac-PL3-NGlu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-936	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-HexG-BztA-GlnR*3-Ala-NH2
I-937	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-HexG-BztA-GlnR*3-Ala-NH2
I-938	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-HepG-BztA-GlnR*3-Ala-NH2
I-939	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-HepG-BztA-GlnR*3-Ala-NH2
I-940	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-BztA-BztA-GlnR*3-Ala-NH2
I-941	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-BztA-BztA-GlnR*3-Ala-NH2
I-942	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-HexG-34ClF-GlnR*3-Ala-NH2
I-943	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-HepG-34ClF-GlnR*3-Ala-NH2
I-944	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-HepG-34ClF-GlnR*3-Ala-NH2
I-945	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-BztA-34ClF-GlnR*3-Ala-NH2
I-946	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-Az3-2F3MeF-BztA-GlnR*3-Ala-NH2
I-947	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-Az2-3Thi-BztA-GlnR*3-Ala-NH2
I-948	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-Az3-3Thi-BztA-GlnR*3-Ala-NH2
I-949	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2PhF-BztA-GlnR*3-Ala-NH2
I-950	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2PhF-34ClF-GlnR*3-Ala-NH2
I-951	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2PhF-34ClF-GlnR*3-Ala-NH2
I-952	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2PhF-BztA-GlnR*3-Leu-Ser-NH2
I-953	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2PhF-BztA-GlnR*3-Leu-Ser-NH2
I-954	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2PhF-34ClF-GlnR*3-Leu-Ser-NH2
I-955	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-BztA-GlnR*3-Leu-Ser-NH2
I-956	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hnLeu-34ClF-GlnR*3-Leu-Ser-

	NH2
I-957	Ac-PL3-isoDAsp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-958	Ac-PL3-isoGlu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-959	Ac-PL3-isoGlu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-960	Ac-PL3-isoDGlu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-961	Ac-PL3-RbGlu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-962	Ac-PL3-SbGlu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-963	Ac-PL3-isoDAsp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-964	Ac-PL3-isoGlu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-965	Ac-PL3-RbGlu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-966	Ac-PL3-SbGlu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-967	Ac-PL3-Glu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-968	Ac-PL3-Gln-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-969	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-970	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-971	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Val-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-972	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-973	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-974	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-975	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Dpg-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-976	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-977	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-978	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Val-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-979	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-980	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Dpg-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-981	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Dpg-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-982	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-983	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-984	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Val-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-985	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-986	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-987	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-988	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-Val-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-989	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-990	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-991	Ac-PL3-Asp-Cba-B5-Asp-3COOHF-Dpg-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-992	5hexenyl-MePro-Asp-B5-Ala-Asp-3COOHF-Ala-Ala-Phe-PyrS2-Lys*3-3Thi-BztA-Ala-GlnR*3-NH2
I-993	4pentenyl-MePro-Asp-B5-Ala-Asp-3COOHF-Ala-Ala-Phe-PyrS2-Lys*3-3Thi-BztA-Ala-GlnR*3-NH2
I-994	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Gly-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-995	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Gly-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-996	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-dAla-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-997	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aib-Thr-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-998	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aib-aThr-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-999	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aib-Gly-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1000	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Gly-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1001	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Gly-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1002	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-dAla-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1003	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-dAla-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1004	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aib-Ser-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2

I-1005	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aib-Thr-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1006	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aib-aThr-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1007	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aib-aThr-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1008	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aib-Gly-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1009	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aib-Gly-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1010	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-NH2
I-1011	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-CyLeu-Ser-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1012	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Phe-Ser-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1013	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Val-Ser-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1014	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-CyLeu-Gly-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1015	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Phe-Gly-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1016	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Val-Gly-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1017	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-CyLeu-nLeu-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1018	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Phe-nLeu-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1019	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Val-nLeu-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1020	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-CyLeu-aThr-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1021	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Val-aThr-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1022	5hexenyl-MePro-Asp-S3-R5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1023	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-Ala-NH2
I-1024	Ac-PL3-Glu-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1025	2PyBu-PL3-Glu-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1026	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Ac]Acp-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1027	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Ac]Acp-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1028	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Phc]Acp-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1029	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Phc]Acp-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1030	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[isovaleryl]Acp-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1031	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Ac]PyrSa-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1032	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Phc]PyrSa-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1033	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[isovaleryl]PyrSa-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1034	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Ac]PyrRa-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1035	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[Phc]PyrRa-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1036	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-[isovaleryl]PyrRa-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1037	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1038	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1039	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1040	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1041	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1042	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1043	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1044	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1045	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2

I-1046	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1047	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1048	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1049	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1050	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1051	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1052	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1053	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1054	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1055	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1056	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1057	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1058	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1059	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1060	Ac-PL3-Asp-Npg-B5-Asp-SbMeAsp-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1061	Ac-PL3-Asp-Npg-B5-Asp-bMe2Asp-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1062	1Imidac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1063	2F2PyAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1064	2IAPAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1065	124TriPr-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1066	6QuiAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1067	3PyAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1068	123TriAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1069	1PyrazoleAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1070	4PyPrpc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1071	4PyPrpc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1072	3PyPrpc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1073	5PymAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1074	1PydoneAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1075	124TriAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1076	3IAPAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1077	3IAPAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1078	Me2NAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1079	4MePipzPrpC-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1080	4MePipzPrpC-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1081	MePipAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1082	MePipAc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2

I-1083	MeImid4SO2-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1084	MeImid4SO2-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1085	8QuiSO2-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1086	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-34ClF-sAla*3-NH2
I-1087	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-34ClF-sAla*3-NH2
I-1088	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-34ClF-sAla*3-Ala-NH2
I-1089	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-34ClF-sAla*3-NH2
I-1090	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Phe-Ala-Phe-TriAzLys*3-PyrS2-3Thi-34ClF-sAla*3-NH2
I-1091	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Phe-Ala-Phe-TriAzLys*3-PyrS2-3Thi-34ClF-sAla*3-Ala-NH2
I-1092	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-Phe-34ClF-sAla*3-NH2
I-1093	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-Phe-34ClF-sAla*3-Ala-NH2
I-1094	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-Phe-34ClF-sAla*3-NH2
I-1095	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-Phe-34ClF-sAla*3-Ala-NH2
I-1096	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Phe-Ala-Phe-TriAzLys*3-PyrS2-Phe-34ClF-sAla*3-NH2
I-1097	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Phe-Ala-Phe-TriAzLys*3-PyrS2-Phe-34ClF-sAla*3-Ala-NH2
I-1098	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34MeF-GlnR*3-NH2
I-1099	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34MeF-GlnR*3-Ala-NH2
I-1100	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34MeF-GlnR*3-NH2
I-1101	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-34MeF-GlnR*3-Ala-NH2
I-1102	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-34MeF-GlnR*3-NH2
I-1103	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34MeF-GlnR*3-NH2
I-1104	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34MeF-GlnR*3-Ala-NH2
I-1105	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34MeF-GlnR*3-NH2
I-1106	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-Phe-34MeF-GlnR*3-Ala-NH2
I-1107	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-Phe-34MeF-GlnR*3-NH2
I-1108	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1109	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-NH2
I-1110	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ser-NH2
I-1111	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1112	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-NH2
I-1113	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ser-NH2
I-1114	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1115	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-NH2
I-1116	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Phe-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ser-NH2
I-1117	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1118	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-NH2
I-1119	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ser-NH2
I-1120	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrSc72SMe3ROMe-3Thi-BztA-sAla*3-Ala-NH2
I-1121	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrSc72RMe3SOMe-3Thi-BztA-sAla*3-Ala-NH2
I-1122	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[SMeIso2]PyrSc7O4-3Thi-BztA-sAla*3-Ala-NH2

I-1123	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[RMeIso2]PyrSc7O4-3Thi-BztA-sAla*3-Ala-NH2
I-1124	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrSc73Me2-3Thi-BztA-sAla*3-Ala-NH2
I-1125	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrSc7-3Thi-BztA-sAla*3-Ala-NH2
I-1126	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[CO][Ala]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1127	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[CO][dAla]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1128	Ac-S5-Ser-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1129	Ac-S5-Ser-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1130	Ac-S5-Val-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1131	Ac-S5-Val-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1132	Ac-S5-Leu-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1133	Ac-S5-Leu-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1134	Ac-S5-Thr-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1135	Ac-S5-Thr-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1136	Ac-S5-Phe-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1137	Ac-S5-Phe-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1138	Ac-Pro-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1139	Ac-Pro-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1140	Ac-Ser-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1141	Ac-Ser-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1142	Ac-Ala-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1143	Ac-Ala-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1144	Ac-S5-Ser-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1145	Ac-S5-Val-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1146	Ac-S5-Leu-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1147	Ac-S5-Thr-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1148	Ac-S5-Phe-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1149	Ac-Pro-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1150	Ac-Ser-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1151	Ac-Ala-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1152	Ac-PL3-Val-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1153	Ac-PL3-Npg-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1154	Ac-PL3-BztA-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1155	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Arg-Ala-Ala-Ala-Ala-NH2
I-1156	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Arg-Ala-

	Ala-Ala-Arg-Ala-NH2
I-1157	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Arg-Ala-Ala-Ala-Arg-NH2
I-1158	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Lys-Ala-Ala-Ala-Lys-NH2
I-1159	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-GlnR**3-Ala-Ala-Ala-Lys**3-NH2
I-1160	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-GlnR**3-Ala-Ala-Ala-Lys**3-NH2
I-1161	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-c6Phe-BztA-GlnR*3-Ala-NH2
I-1162	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1163	Ac-PL3-Asn-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1164	Ac-PL3-Asn-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1165	Ac-PL3-Asn-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1166	Ac-PL3-Asn-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1167	Ac-PL3-Asn-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1168	Ac-PL3-Asn-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1169	Ac-PL3-Asn-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ser-NH2
I-1170	Ac-PL3-Asn-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ser-NH2
I-1171	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1172	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1173	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-1174	Ac-PL3-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-1175	Ac-PL3-Asn-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1176	Ac-PL3-Asn-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1177	Ac-PL3-Asn-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-1178	Ac-PL3-Asn-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1179	Ac-PL3-Asn-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1180	Ac-PL3-Asn-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-1181	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-[mPEG4]Lys-NH2
I-1182	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-[mPEG8]Lys-NH2
I-1183	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-[mPEG16]Lys-NH2
I-1184	mPEG4-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1185	mPEG8-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1186	mPEG16-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1187	mPEG24-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1188	Ac-PL3-Asp-Npg-B5-Asp-3BOH2F-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1189	Ac-PL3-Asp-Npg-B5-Asp-4BOH2F-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1190	Ac-PL3-Asp-Npg-B5-Asp-4BOH2F-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1191	Ac-S5-Ala-Glu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1192	Ac-S5-Ala-Glu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1193	Ac-S5-Ala-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1194	Ac-S5-Ala-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2

I-1195	Ac-S5-Ala-Ser-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1196	Ac-S5-Ala-Ser-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1197	Ac-S5-Ala-Hse-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1198	Ac-S5-Ala-Hse-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1199	Ac-S5-Ala-Asp-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1200	Ac-S5-Ala-Asp-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1201	Ac-S5-Ala-Asp-Npg-B5-Asn-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1202	Ac-S5-Ala-Asp-Npg-B5-Asn-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1203	Ac-S5-Ala-Asp-Npg-B5-Ser-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1204	Ac-S5-Ala-Asp-Npg-B5-Ser-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1205	Ac-S5-Ala-Asp-Npg-B5-Hse-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1206	Ac-S5-Ala-Asp-Npg-B5-Hse-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1207	Ac-S5-Ala-Glu-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1208	Ac-S5-Ala-Glu-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1209	Ac-S5-Glu-Glu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1210	Ac-S5-Glu-Glu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1211	Ac-S5-Glu-Asp-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1212	Ac-S5-Glu-Asp-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1213	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Leu-[Red][Gly]Dap-3thi-BztA-Ala-GlnR-NH2
I-1214	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Leu-[Red][NHPent]Dap-3thi-BztA-Ala-GlnR-NH2
I-1215	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Leu-[SBut][CH2CH2NH]Dap-3thi-BztA-Ala-GlnR-NH2
I-1216	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Leu-[SBut][CH2CH2CH2NH]Dap-3thi-BztA-Ala-GlnR-NH2
I-1217	Ac-S5-Ala-Glu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1218	Ac-S5-Ala-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1219	Ac-S5-Ala-Ser-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1220	Ac-S5-Ala-Hse-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1221	Ac-S5-Ala-Asp-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1222	Ac-S5-Ala-Asp-Npg-B5-Asn-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1223	Ac-S5-Ala-Asp-Npg-B5-Ser-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1224	Ac-S5-Ala-Asp-Npg-B5-Hse-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1225	Ac-S5-Ala-Glu-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1226	Ac-S5-Glu-Glu-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1227	Ac-S5-Glu-Asp-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1228	Ac-S5-Glu-Glu-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1229	Ac-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-1230	Ac-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1231	Ac-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-NH2
I-1232	Ac-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1233	Ac-S5-Ala-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-1234	Ac-S5-Ala-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1235	Ac-S5-Ala-Asp-Ala-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-1236	Ac-S5-Ala-Asp-Ala-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1237	Ac-S5-Ala-Asp-Phe-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2

I-1238	Ac-S5-Ala-Asp-Phe-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1239	Ac-S5-Ala-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-1240	Ac-S5-Ala-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1241	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-[isovaleryl]Acp-Ala-Phe-TriAzLys*3-PyrS2-Phe-34ClF-sAla*3-NH2
I-1242	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-1243	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-1244	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Ala-NH2
I-1245	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-7FBztA-GlnR*3-NH2
I-1246	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-7FBztA-GlnR*3-NH2
I-1247	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-7FBztA-GlnR*3-Ala-NH2
I-1248	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-7ClBztA-GlnR*3-NH2
I-1249	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-7ClBztA-GlnR*3-Ala-NH2
I-1250	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-7MeBztA-GlnR*3-NH2
I-1251	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-7MeBztA-GlnR*3-Ala-NH2
I-1252	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Glu-Ala-NH2
I-1253	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Glu-Ala-NH2
I-1254	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Glu-Leu-NH2
I-1255	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Glu-Leu-NH2
I-1256	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Thr-Ala-NH2
I-1257	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Thr-Ala-NH2
I-1258	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Glu-Ala-NH2
I-1259	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Glu-Ala-NH2
I-1260	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Glu-Leu-NH2
I-1261	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Glu-Leu-NH2
I-1262	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Val-Thr-Ala-NH2
I-1263	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Val-Glu-Ala-NH2
I-1264	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Val-Glu-Leu-NH2
I-1265	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Val-Thr-Ala-NH2
I-1266	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Val-Glu-Ala-NH2
I-1267	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Val-Glu-Leu-NH2
I-1268	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Val-Thr-Ala-NH2
I-1269	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[3_3-biPh]hCys-PyrS2-3Thi-BztA-Cys-Ala-NH2

I-1270	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[2_6-naph]hCys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1271	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[mPyr]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1272	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[mXyl]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1273	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[mPyr]hCys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1274	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[C3]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1275	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[Red]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1276	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[33Oxe]hCys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1277	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[33Oxe]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1278	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[IsoE]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1279	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[C3]hCys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1280	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[Red]hCys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1281	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[IsoE]hCys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1282	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[13Ac]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1283	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[13Ac]hCys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1284	Ac-Ala-Ala-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1285	Ac-Asp-Ala-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1286	Ac-Pro-Ala-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1287	Ac-Ala-Ala-S5-Ser-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1288	Ac-Asp-Ala-S5-Ser-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1289	Ac-Pro-Ala-S5-Ser-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1290	Ac-Ala-Ala-S5-Leu-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1291	Ac-Asp-Ala-S5-Leu-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1292	Ac-Pro-Ala-S5-Leu-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1293	Ac-Ala-Ser-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1294	Ac-Asp-Ser-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1295	Ac-Pro-Ser-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala
I-1296	Ac-S5-Leu-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1297	Ac-S5-Ala-Asp-Npg-B5-Ala-Asp-3COOHF-Aib-Ala-Phe-[4Abu]DapAc7-Leu-3Thi-BztA-GlnR*3-Ala-NH2
I-1298	Ac-S6-Ala-Asp-Npg-B5-Ala-Asp-3COOHF-Aib-Ala-Phe-[4Abu]DapAc7-Leu-3Thi-BztA-GlnR*3-Ala-NH2
I-1299	Ac-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Leu-[4Abu]DapAc7-3thi-BztA-Ala-GlnR*3-NH2
I-1300	Ac-S6-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Leu-[4Abu]DapAc7-3thi-BztA-Ala-GlnR*3-NH2
I-1301	Ac-PL3-AspSH-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1302	Ac-PL3-Asp-Npg-B5-AspSH-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1303	Ac-PL3-AspSH-Npg-B5-AspSH-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1304	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hhLeu-BztA-GlnR*3-Ala-NH2

I-1305	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hPhe-BztA-GlnR*3-Ala-NH2
I-1306	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hhSer-BztA-GlnR*3-Ala-NH2
I-1307	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hhLeu-34ClF-GlnR*3-Ala-NH2
I-1308	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hPhe-34ClF-GlnR*3-Ala-NH2
I-1309	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hhSer-34ClF-GlnR*3-Ala-NH2
I-1310	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hhLeu-BztA-GlnR*3-Ala-NH2
I-1311	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hPhe-BztA-GlnR*3-Ala-NH2
I-1312	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hPhe-BztA-GlnR*3-Ala-NH2
I-1313	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hhSer-BztA-GlnR*3-Ala-NH2
I-1314	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hhLeu-34ClF-GlnR*3-Ala-NH2
I-1315	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hPhe-34ClF-GlnR*3-Ala-NH2
I-1316	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hhSer-34ClF-GlnR*3-Ala-NH2
I-1317	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCbA-BztA-GlnR*3-Ala-NH2
I-1318	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCypA-BztA-GlnR*3-Ala-NH2
I-1319	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCha-BztA-GlnR*3-Ala-NH2
I-1320	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCbA-34ClF-GlnR*3-Ala-NH2
I-1321	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCypA-34ClF-GlnR*3-Ala-NH2
I-1322	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCha-34ClF-GlnR*3-Ala-NH2
I-1323	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCbA-BztA-GlnR*3-Ala-NH2
I-1324	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCypA-BztA-GlnR*3-Ala-NH2
I-1325	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCha-BztA-GlnR*3-Ala-NH2
I-1326	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCbA-34ClF-GlnR*3-Ala-NH2
I-1327	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCypA-34ClF-GlnR*3-Ala-NH2
I-1328	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCha-34ClF-GlnR*3-Ala-NH2
I-1329	Ac-S5-Ala-Asp-Npg-B5-Asp-Asp-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1330	Ac-S5-Ala-Asp-Npg-B5-Glu-Asp-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1331	Ac-S5-Ala-Asp-Npg-B5-TfeGA-Asp-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1332	Ac-S5-Pro-Asp-Npg-B5-Asp-Asp-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1333	Ac-S5-Pro-Asp-Npg-B5-Glu-Asp-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1334	Ac-S5-Pro-Asp-Npg-B5-TfeGA-Asp-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1335	Ac-S5-Ala-Asp-Ile-B5-Asp-2COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1336	Ac-S5-Ala-Asp-Ile-B5-Asp-4COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1337	Ac-S5-Ala-Asp-Ile-B5-Asp-Asp-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1338	Ac-S5-Ala-Asp-Ile-B5-Asp-Glu-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1339	Ac-S5-Ala-Asp-Ile-B5-Asp-Asn-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1340	Ac-S5-Ala-Asp-Ile-B5-Asp-Gln-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1341	Ac-S5-Ala-Asp-Ile-B5-Asp-Ser-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1342	Ac-S5-Tle-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1343	Ac-S5-Val-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1344	Ac-S5-Ile-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1345	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCbA-BztA-GlnR*3-Val-Glu-Ala-NH2
I-1346	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCypA-BztA-GlnR*3-Val-Glu-Ala-NH2
I-1347	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCha-BztA-GlnR*3-Val-Glu-Ala-NH2

I-1348	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCbA-34ClF-GlnR*3-Val-Glu-Ala-NH2
I-1349	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCypA-34ClF-GlnR*3-Val-Glu-Ala-NH2
I-1350	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-hCha-34ClF-GlnR*3-Val-Glu-Ala-NH2
I-1351	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Thr-Glu-Ala-NH2
I-1352	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ser-Glu-Ala-NH2
I-1353	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Thr-Ser-Ala-NH2
I-1354	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ser-Ser-Ala-NH2
I-1355	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Thr-Lys-Ala-NH2
I-1356	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ser-Lys-Ala-NH2
I-1357	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Thr-Glu-Leu-NH2
I-1358	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ser-Glu-Leu-NH2
I-1359	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Thr-Ser-Leu-NH2
I-1360	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ser-Ser-Leu-NH2
I-1361	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Thr-Lys-Leu-NH2
I-1362	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ser-Lys-Leu-NH2
I-1363	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Leu-[4Abu]DapAc7-3thi-BztA-Ala-GlnR-NH2
I-1364	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Leu-[SBut][CH2CH2NH]Dap-3thi-BztA-Ala-GlnR-NH2
I-1365	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[m5Meb]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1366	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[m5Meb]hCys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1367	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-Lys*3-NH2
I-1368	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-Lys*3-NH2
I-1369	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-1MeK*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1370	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-1MeK*3-NH2
I-1371	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-hGlnR*3-NH2
I-1372	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-hGlnR*3-PyrS2-Phe-34ClF-Lys*3-NH2
I-1373	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-1MeK*3-PyrS2-Phe-34ClF-hGlnR*3-NH2
I-1374	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-hGlnR*3-PyrS2-Phe-34ClF-1MeK*3-NH2
I-1375	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-hGlnR*3-PyrS2-Phe-34ClF-1MeK*3-NH2
I-1376	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-AsnEDA*3-NH2
I-1377	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-AsnEDA*3-NH2
I-1378	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-GlnEDA*3-NH2
I-1379	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-AsnPpz*3-NH2
I-1380	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-GlnPpz*3-NH2

I-1381	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR3APyr*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1382	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-GlnR3APyr*3-NH2
I-1383	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnS3APyr*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1384	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnS3APyr*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1385	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-GlnS3APyr*3-NH2
I-1386	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[mXyl]Cys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1387	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[mPyr]Cys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1388	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[C3]Cys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1389	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[IsoE]Cys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1390	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[m5Meb]Cys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1391	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[33Oxe]Cys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1392	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-[Ac]Lys-NH2
I-1393	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-Ala-[Ac]Lys-NH2
I-1394	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-[Ac]Lys-NH2
I-1395	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-Ala-Ala-[Ac]Lys-NH2
I-1396	Ac-PL3-Asp-Npg-B5-Asp-[Ac]Dap-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1397	Ac-PL3-Asp-Npg-B5-Asp-[CH2CO2H]Acp-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1398	Ac-PL3-Asp-Npg-B5-Asp-[Pfbn]GA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1399	Ac-PL3-Asp-Npg-B5-Asp-[Tfb]GA-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1400	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NHMe
I-1401	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NHMe
I-1402	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-[mPEG4]Lys-NH2
I-1403	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-[mPEG8]Lys-NH2
I-1404	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-[mPEG16]Lys-NH2
I-1405	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-Ala-[mPEG4]Lys-NH2
I-1406	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-Ala-[mPEG8]Lys-NH2
I-1407	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-Ala-[mPEG16]Lys-NH2
I-1408	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-[mPEG8]Lys-NH2
I-1409	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-[mPEG16]Lys-NH2
I-1410	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-[mPEG37]Lys-NH2
I-1411	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-Ala-Ala-[mPEG4]Lys-NH2
I-1412	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-Ala-Ala-[mPEG8]Lys-NH2
I-1413	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-Ala-Ala-[mPEG16]Lys-NH2

I-1414	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-GlnMe2EDA*3-NH2
I-1415	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-AsnMe2EDA*3-NH2
I-1416	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-AsnMeEDA*3-NH2
I-1417	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-AsnMeEDA*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1418	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-AsnMeEDA*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1419	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-AsnR3APyr*3-NH2
I-1420	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-AsnR3APyr*3-PyrS2-Phe-34ClF-AsnR*3-NH2
I-1421	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-AsnR3APyr*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1422	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-AsnR*3-PyrS2-Phe-34ClF-AsnS3APyr*3-NH2
I-1423	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-AsnS3APyr*3-NH2
I-1424	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-AsnS3APyr*3-PyrS2-Phe-34ClF-AsnR*3-NH2
I-1425	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[mPyr]hCys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1426	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[m5Meb]hCys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1427	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[C3]hCys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1428	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[Red]hCys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1429	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[IsoE]hCys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1430	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[13Ac]hCys-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1431	Ac-PL3-Asp-Npg-B5-Asp-[Succinate]Dap-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1432	Ac-PL3-Asp-Npg-B5-Asp-[Malonate]Dap-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1433	Ac-PL3-Asp-Npg-B5-Asp-[Me2Mal]Dap-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1434	Ac-PL3-Asp-Npg-B5-Asp-[SaiPrSuc]Dap-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1435	Ac-PL3-Asp-Npg-B5-Asp-[SaMeSuc]Dap-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1436	Ac-PL3-Asp-Npg-B5-Asp-[RaiPrSuc]Dap-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1437	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[4VinylBzt]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1438	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[3OHBz]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1439	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[3OHBz]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1440	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[CO][Val]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1441	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[CO][Val]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1442	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[CO][dVal]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1443	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[CO][Sar]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1444	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[CO][Nip]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1445	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[CO][dNip]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1446	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[CO][dNip]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1447	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[CO][dNip]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1448	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[CO][Pro]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1449	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[2Me4VinPhAc2]PyrSa-3Thi-BztA-

	sAla*3-Ala-NH2
I-1450	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-[3SBz]PyrSa-3Thi-BztA-sAla*3-Ala-NH2
I-1451	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[m5Pyr]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1452	Ac-S6-Pro-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1453	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[m5OMeb]Cys-PyrS2-3Thi-BztA-Cys-Ala-NH2
I-1454	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[mPyr]Cys-PyrS2-3Thi-BztA-Pen-Ala-NH2
I-1455	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[m5Pyr]Cys-PyrS2-3Thi-BztA-Pen-Ala-NH2
I-1456	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[m5OMeb]Cys-PyrS2-3Thi-BztA-Pen-Ala-NH2
I-1457	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[Red]Cys-PyrS2-3Thi-BztA-Pen-Ala-NH2
I-1458	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[IsoE]Cys-PyrS2-3Thi-BztA-Pen-Ala-NH2
I-1459	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[C3]Cys-PyrS2-3Thi-BztA-Pen-Ala-NH2
I-1460	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[IsoE]hCysOx-PyrS2-3Thi-BztA-aMeC-Ala-NH2
I-1461	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[mPyr]Cys-PyrS2-3Thi-BztA-hCys-Ala-NH2
I-1462	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[IsoE]Cys-PyrS2-3Thi-BztA-hCys-Ala-NH2
I-1463	Ac-S5-Glu-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1464	Ac-S6-Val-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1465	Ac-S5-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1466	Ac-S5-Val-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1467	Ac-S6-Glu-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1468	Ac-S6-Ala-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1469	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[mPyr]hCys-PyrS2-3Thi-BztA-Pen-Ala-NH2
I-1470	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[m5Pyr]hCys-PyrS2-3Thi-BztA-Pen-Ala-NH2
I-1471	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[C3]hCys-PyrS2-3Thi-BztA-Pen-Ala-NH2
I-1472	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Ser-Ala-NH2
I-1473	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Ser-Leu-NH2
I-1474	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Ser-Leu-Pro-NH2
I-1475	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Ser-Thr-NH2
I-1476	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Ser-Thr-Pro-NH2
I-1477	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Ser-Pro-NH2
I-1478	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Ser-Ala-NH2
I-1479	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Ser-Leu-NH2
I-1480	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Ser-Leu-Pro-NH2
I-1481	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Ser-Thr-NH2
I-1482	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Ser-Thr-Pro-NH2
I-1483	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Ser-Pro-NH2

I-1484	Ac-PL3-Asp-R5-S5-Asp-3COOHF-Aib-Ala-Phe-PyrS2-Lys*3-3Thi-BztA-Ala-GlnR*3-NH2
I-1485	Ac-PL3-Asp-R5-S5-Asp-3COOHF-Aib-Ala-Phe-PyrS2-Lys*3-3Thi-BztA-Ala-GlnR*3-NH2
I-1486	NPyroR3-Asp-Npg-B4-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS3-3Thi-BztA-GlnR*3-Ala-NH2
I-1487	NPyroR3-Asp-Npg-B4-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS3-3Thi-BztA-GlnR*3-Ala-NH2
I-1488	NPyroR3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1489	NPyroR3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1490	NPyroR3-Asp-Npg-B6-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-Ala-NH2
I-1491	NPyroR3-Asp-Npg-B6-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-Ala-NH2
I-1492	NPyroR3-Asp-Ala-B4-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS3-3Thi-BztA-GlnR*3-Ala-NH2
I-1493	NPyroR3-Asp-Ala-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1494	NPyroR3-Asp-Ala-B6-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-Ala-NH2
I-1495	NPyroR3-Asp-Ala-B6-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-Ala-NH2
I-1496	NPyroR3-Asp-Npg-B4-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS3-3Thi-BztA-GlnR*3-Ala-NH2
I-1497	NPyroR3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1498	NPyroR3-Asp-Npg-B6-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-Ala-NH2
I-1499	NPyroR3-Asp-Ala-B4-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS3-3Thi-BztA-GlnR*3-Ala-NH2
I-1500	NPyroR3-Asp-Ala-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-NH2
I-1501	NPyroR3-Asp-Ala-B6-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-Ala-NH2
I-1502	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-34ClF-GlnR*3-NH2
I-1503	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2ClF-34ClF-GlnR*3-NH2
I-1504	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2ClF-34ClF-GlnR*3-NH2
I-1505	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-34ClF-GlnR*3-NH2
I-1506	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2ClF-34ClF-GlnR*3-NH2
I-1507	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2ClF-34ClF-GlnR*3-NH2
I-1508	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2MeF-34ClF-GlnR*3-NH2
I-1509	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2MeF-34ClF-GlnR*3-NH2
I-1510	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2MeF-34ClF-GlnR*3-NH2
I-1511	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2MeF-34ClF-GlnR*3-NH2
I-1512	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2MeF-34ClF-GlnR*3-NH2
I-1513	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2MeF-34ClF-GlnR*3-NH2
I-1514	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2MeF-34ClF-GlnR*3-NH2
I-1515	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2MeF-34ClF-GlnR*3-NH2
I-1516	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2MeF-34ClF-GlnR*3-NH2
I-1517	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2MeF-34ClF-GlnR*3-NH2
I-1518	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2MeF-34ClF-GlnR*3-NH2
I-1519	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[Mxyl]Cys-PyrS2-3Thi-BztA-Cys-Ser-NH2
I-1520	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[Mpyr]Cys-PyrS2-3Thi-BztA-Cys-Ser-NH2
I-1521	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[Red]Cys-PyrS2-3Thi-BztA-Cys-Ser-NH2
I-1522	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-[C3]Cys-PyrS2-3Thi-BztA-Cys-Ser-NH2
I-1523	Ac-S6-Aib-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1524	Ac-S6-MePro-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1525	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-[PEG4triPEG16]Lys-NH2
I-1526	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-[PEG4triPEG36]Lys-NH2
I-1527	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-BztA-GlnR*3-NH2

I-1528	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2ClF-BztA-GlnR*3-NH2
I-1529	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2ClF-BztA-GlnR*3-NH2
I-1530	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-BztA-GlnR*3-NH2
I-1531	Ac-PL3-Asp-Chg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-2ClF-BztA-GlnR*3-NH2
I-1532	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-DipA-34ClF-GlnR*3-NH2
I-1533	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-DipA-34ClF-GlnR*3-NH2
I-1534	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-DipA-34ClF-GlnR*3-NH2
I-1535	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-DipA-34ClF-GlnR*3-NH2
I-1536	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-DipA-BztA-GlnR*3-NH2
I-1537	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-34ClF-GlnR*3-NH2
I-1538	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-34ClF-GlnR*3-NH2
I-1539	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-34ClF-GlnR*3-NH2
I-1540	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-34ClF-GlnR*3-NH2
I-1541	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-BztA-GlnR*3-NH2
I-1542	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-BztA-GlnR*3-NH2
I-1543	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-BztA-GlnR*3-NH2
I-1544	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-BztA-GlnR*3-NH2
I-1545	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2MeF-BztA-GlnR*3-NH2
I-1546	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2MeF-BztA-GlnR*3-NH2
I-1547	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2MeF-BztA-GlnR*3-NH2
I-1548	NPyroR3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1549	NPyroR3-Asp-Ala-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1550	NPyroR3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1551	NPyroR3-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1552	NPyroR3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1553	NPyroR3-Asp-Phe-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1554	NPyroR3-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1555	NPyroR3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1556	NPyroR3-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1557	NPyroR3-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1558	NPyroR3-Ser-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1559	NPyroR3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1560	C3a-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1561	C3a-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1562	Bua-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1563	isobutyryl-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1564	Cpc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1565	Cpc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1566	Cbc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1567	Cbc-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1568	CypCO-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1569	CypCO-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1570	4THPCO-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1571	4THPCO-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1572	C3a-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2

I-1573	C3a-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1574	Bua-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1575	Bua-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1576	isobutyryl-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1577	Cpc-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1578	Cpc-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1579	Cbc-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1580	CypCO-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1581	4THPCO-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1582	C3a-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1583	C3a-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1584	Bua-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1585	Bua-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1586	Cpc-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1587	Cpc-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1588	Cbc-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1589	Cbc-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1590	CypCO-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1591	CypCO-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1592	4THPCO-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1593	4THPCO-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1594	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-Phe-GlnR*3-NH2
I-1595	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-Phe-GlnR*3-NH2
I-1596	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-2ClF-GlnR*3-NH2
I-1597	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-2ClF-GlnR*3-NH2
I-1598	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-3ClF-GlnR*3-NH2
I-1599	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-3ClF-GlnR*3-NH2
I-1600	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-4ClF-GlnR*3-NH2
I-1601	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-3MeF-GlnR*3-NH2
I-1602	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-2BrF-GlnR*3-NH2
I-1603	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-2BrF-GlnR*3-NH2
I-1604	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-3BrF-GlnR*3-NH2
I-1605	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-3BrF-GlnR*3-NH2
I-1606	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-4BrF-GlnR*3-NH2
I-1607	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-4BrF-GlnR*3-NH2
I-1608	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-3F3MeF-GlnR*3-NH2
I-1609	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-3F3MeF-GlnR*3-NH2
I-1610	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-4F3MeF-GlnR*3-NH2
I-1611	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-4F3MeF-GlnR*3-NH2
I-1612	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-2BrF-GlnR*3-NH2
I-1613	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-3BrF-GlnR*3-NH2
I-1614	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-3F3MeF-GlnR*3-NH2
I-1615	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-4F3MeF-GlnR*3-NH2
I-1616	Ac-S5-Ala-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1617	Ac-S5-Pro-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2

I-1618	Ac-S5-Val-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1619	Ac-S5-Glu-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1620	Ac-S5-Ala-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1621	Ac-S5-Pro-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1622	Ac-S5-Val-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1623	Ac-S5-Glu-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1624	Ac-S6-Ala-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1625	Ac-S6-Ala-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1626	Ac-S5-Ala-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1627	Ac-S5-Ala-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1628	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Lys-NH2
I-1629	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Lys-NH2
I-1630	Ac-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1631	Ac-PL3-aThr-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1632	Ac-PL3-Asp-DipA-B5-Asn-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1633	Ac-PL3-Asp-DipA-B5-aThr-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1634	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1635	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Thr-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1636	Ac-PL3-Asn-DipA-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1637	Ac-PL3-aThr-DipA-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1638	Ac-PL3-Asp-DipA-B5-Asn-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1639	Ac-PL3-Asp-DipA-B5-aThr-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1640	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-NH2
I-1641	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-BztA-GlnR*3-Leu-NH2
I-1642	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-BztA-GlnR*3-Leu-NH2
I-1643	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-BztA-GlnR*3-Ala-NH2
I-1644	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2ClF-BztA-GlnR*3-Ala-NH2
I-1645	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Leu-NH2
I-1646	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Leu-NH2
I-1647	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Ala-NH2
I-1648	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-1649	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-1650	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-BztA-GlnR*3-Leu-NH2
I-1651	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-BztA-GlnR*3-Leu-NH2
I-1652	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-BztA-GlnR*3-Ala-NH2
I-1653	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2FF-BztA-GlnR*3-NH2
I-1654	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-1655	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-1656	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-1657	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ala-NH2
I-1658	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-NH2
I-1659	Ac-PL3-Asp-Cha-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-NH2
I-1660	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[Bnc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1661	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[Bnc]2NH2F-BztA-GlnR*3-Ala-NH2

I-1662	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[Phc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1663	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[Phc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1664	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[BiPh]2NH2F-BztA-GlnR*3-Ala-NH2
I-1665	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[BiPh]2NH2F-BztA-GlnR*3-Ala-NH2
I-1666	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[MePipAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1667	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[2IAPAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1668	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[2IAPAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1669	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[2IAPAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1670	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[3PyAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1671	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[3PyAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1672	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[2PyCypCO]2NH2F-BztA-GlnR*3-Ala-NH2
I-1673	Ac-S5-Asp-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1674	Ac-S5-Asp-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1675	Ac-S5-Asp-Ser-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1676	Ac-S5-Asp-Asp-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1677	Ac-S5-Glu-Asn-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1678	Ac-S5-Glu-Ser-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1679	Ac-S5-Glu-Asp-Npg-B5-Glu-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1680	Ac-PL3-Asn-DipA-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1681	Ac-PL3-Ser-DipA-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1682	Ac-PL3-Thr-DipA-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1683	Ac-PL3-Asp-DipA-B5-Ser-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1684	Ac-PL3-Asp-DipA-B5-Thr-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1685	Ac-PL3-Asp-DipA-B5-aThr-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1686	Ac-PL3-Asp-DipA-B5-Hse-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1687	Ac-PL3-aThr-DipA-B5-Asp-3COOHF-nLeu-Ala-3Thi-Lys*3-PyrS2-3Thi-BztA-GlnR*3-NH2
I-1688	Ac-S5-Ala-Asp-DipA-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1689	Ac-S5-Ala-Asp-DipA-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1690	Ac-S6-Ala-Asp-DipA-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1691	Ac-S6-Ala-Asp-DipA-B5-Asp-3COOHF-nLeu-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1692	Ac-S5-Ala-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1693	Ac-S5-Ala-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1694	Ac-S5-Pro-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1695	Ac-S6-Pro-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1696	Ac-S6-Pro-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1697	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1698	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1699	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1700	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1701	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-[mPEG8]-

	Lys-NH2
I-1702	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-[mPEG37]-Lys-NH2
I-1703	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[mPEG8]-Lys-NH2
I-1704	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[mPEG37]-Lys-NH2
I-1705	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-Ala-[mPEG8]-Lys
I-1706	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-Ala-[mPEG37]-Lys
I-1707	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-Ala-[mPEG8]-Lys
I-1708	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-Ala-[mPEG37]-Lys
I-1709	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-OH
I-1710	Bua-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1711	Isovaleryl-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1712	Cpc-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1713	Cbc-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1714	CypCO-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1715	Bnc-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1716	CF3CO-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1717	6QuiAc-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1718	124TriAc-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1719	5PymAc-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1720	2PyCypCO-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1721	2PyBu-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1722	2PyzCO-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1723	Bua-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1724	Isovaleryl-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1725	Cpc-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1726	Cbc-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1727	CypCO-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1728	Bnc-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1729	CF3CO-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1730	6QuiAc-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1731	124TriAc-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1732	2PyCypCO-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1733	2PyBu-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1734	2PyzCO-PL3-Asn-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-NH2
I-1735	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2NH2F-BztA-GlnR*3-Ala-NH2
I-1736	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2NH2F-BztA-GlnR*3-Ala-NH2

I-1737	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[124TriAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1738	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[124TriPr]2NH2F-BztA-GlnR*3-Ala-NH2
I-1739	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[6QuiAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1740	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[2PyAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1741	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[2PyPrpc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1742	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[3PyPrpc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1743	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[4PyPrpc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1744	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[MeOPr]2NH2F-BztA-GlnR*3-Ala-NH2
I-1745	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[PhOPr]2NH2F-BztA-GlnR*3-Ala-NH2
I-1746	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[Me2MeOPr]2NH2F-BztA-GlnR*3-Ala-NH2
I-1747	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[Me2NAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1748	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[Me2NAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1749	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[Me2NPr]2NH2F-BztA-GlnR*3-Ala-NH2
I-1750	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[NdiMeButC]2NH2F-BztA-GlnR*3-Ala-NH2
I-1751	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[3IAPAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1752	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[15PyraPy]2NH2F-BztA-GlnR*3-Ala-NH2
I-1753	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[MorphAc]2NH2F-BztA-GlnR*3-Ala-NH2
I-1754	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[Nic]2NH2F-BztA-GlnR*3-Ala-NH2
I-1755	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[2PyzCO]2NH2F-BztA-GlnR*3-Ala-NH2
I-1756	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[5pymCO]2NH2F-BztA-GlnR*3-Ala-NH2
I-1757	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-dGlnR*3-NH2
I-1758	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-dGlnR*3-NHMe
I-1759	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-dGlnR*3-Ala-NH2
I-1760	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-1MeK*3-PyrS2-Phe-34ClF-dGlnR*3-NH2
I-1761	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-1MeK*3-PyrS2-Phe-34ClF-dGlnR*3-NHMe
I-1762	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-1MeK*3-PyrS2-Phe-34ClF-dGlnR*3-Ala-NH2
I-1763	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[3FPyr2c]2NH2F-BztA-GlnR*3-Ala-NH2
I-1764	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[4FPyr3c]2NH2F-BztA-GlnR*3-Ala-NH2
I-1765	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-[4FPyr3c]2NH2F-BztA-GlnR*3-Ala-NH2

I-1766	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-NH2
I-1767	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Pro-NH2
I-1768	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Pro-NH2
I-1769	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Leu-NH2
I-1770	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Leu-NH2
I-1771	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Ser-NH2
I-1772	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Ser-NH2
I-1773	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Val-NH2
I-1774	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Val-NH2
I-1775	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Val-NH2
I-1776	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-34ClF-GlnR*3-Phe-NH2
I-1777	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-CyLeu-Ala-Phe-Lys*3-PyrS2-2F3MeF-BztA-GlnR*3-Phe-NH2
I-1778	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-GlnR*3-PyrS2-Phe-34ClF-dLys*3-Ala-NH2
I-1779	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Orn*3-PyrS2-Phe-34ClF-dGlnR*3-NH2
I-1780	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Orn*3-PyrS2-Phe-34ClF-dGlnR*3-NH2
I-1781	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Orn*3-PyrS2-Phe-34ClF-dGlnR*3-NHMe
I-1782	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-Orn*3-PyrS2-Phe-34ClF-dGlnR*3-Ala-NH2
I-1783	Ac-S6-Val-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1784	Ac-S5-Glu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1785	Ac-S5-Leu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1786	Ac-PL3-Asp-Ile-B5-Asp-Me2Gln-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-1787	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[Ac-dPEG2]-Lys-NH2-NH2
I-1788	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[Ac-PEG8]-Lys-NH2-NH2
I-1789	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[Oct-dPEG2]-Lys-NH2-NH2
I-1790	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[Oct-PEG8]-Lys-NH2-NH2
I-1791	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[C18-dPEG2]-Lys-NH2-NH2
I-1792	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[C18-PEG8]-Lys-NH2-NH2
I-1793	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnPDA*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1794	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnPDA*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1795	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnPDA*3-Ala-Phe-Val-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1796	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnBDA*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1797	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnBDA*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1798	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnBDA*3-Ala-Phe-Val-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1799	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnMePDA*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1800	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnMePDA*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnR*3-NH2

I-1801	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnMePDA*3-Ala-Phe-Val-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1802	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnMePDA*3-NH2
I-1803	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnMePDA*3-NH2
I-1804	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Val-PyrS2-Phe-34ClF-GlnMePDA*3-NH2
I-1805	Ac-S5-TfeGA-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1806	Ac-S5-3COOHF-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1807	Ac-S5-Thr-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1808	Ac-S5-Phe-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1809	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-S3MePyrSc7-3Thi-BztA-sAla*3-Ala-NH2
I-1810	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-R3MePyrSc7-3Thi-BztA-sAla*3-Ala-NH2
I-1811	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnT4CyMe*3-NH2
I-1812	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-S3iPrPyrSc7-3Thi-BztA-sAla*3-Ala-NH2
I-1813	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-S3iPrPyrSc7-3Thi-BztA-sAla*3-Ala-NH2
I-1814	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-R3iPrPyrSc7-3Thi-BztA-sAla*3-Ala-NH2
I-1815	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Ala-[mPEG8]-Lys-NH2
I-1816	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Thr-Ala-[mPEG8]-Lys-NH2
I-1817	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Glu-[mPEG8]-Lys-NH2
I-1818	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Thr-[mPEG8]-Lys-NH2
I-1819	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Val-Thr-[mPEG8]-Lys-NH2
I-1820	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Ser-[mPEG8]-Lys-NH2
I-1821	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Leu-Ser-[mPEG8]-Lys-NH2
I-1822	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Aib-Ser-[mPEG8]-Lys-NH2
I-1823	Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Aib-Ser-[mPEG8]-Lys-NH2
I-1824	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnMeBDA*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1825	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnMeBDA*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1826	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnMeBDA*3-Ala-Phe-Val-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1827	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnMeBDA*3-NH2
I-1828	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnMeBDA*3-NH2
I-1829	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Val-PyrS2-Phe-34ClF-GlnMeBDA*3-NH2
I-1830	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-Gln5DA*3-NH2
I-1831	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-Gln5DA*3-NH2
I-1832	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Val-PyrS2-Phe-34ClF-Gln5DA*3-NH2
I-1833	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-Gln6DA*3-NH2
I-1834	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-Gln6DA*3-NH2
I-1835	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Val-PyrS2-Phe-34ClF-Gln6DA*3-NH2
I-1836	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnT4CyMe*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1837	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnT4CyMe*3-Ala-Phe-Val-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1838	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnT4CyMe*3-NH2

I-1839	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnT4CyMe*3-NH2
I-1840	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Val-PyrS2-Phe-34ClF-GlnT4CyMe*3-NH2
I-1841	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-1842	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-1843	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Pro-NH2
I-1844	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-dPro-NH2
I-1845	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-dPro-NH2
I-1846	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Ser-NH2
I-1847	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Val-NH2
I-1848	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-dVal-NH2
I-1849	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-dVal-NH2
I-1850	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-1851	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-1852	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Val-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-1853	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Thr-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-NH2
I-1854	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-dPro-NH2
I-1855	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Val-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-dPro-NH2
I-1856	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Thr-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-dPro-NH2
I-1857	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-sAla*3-PyrS2-Phe-34ClF-TriAzLys*3-NH2
I-1858	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzLys*3-PyrS2-Phe-34ClF-sCH2S*3-NH2
I-1859	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-sCH2S*3-PyrS2-Phe-34ClF-TriAzLys*3-NH2
I-1860	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzOrn*3-PyrS2-Phe-34ClF-sCH2S*3-NH2
I-1861	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-TriAzOrn*3-PyrS2-Phe-34ClF-sCH2S*3-NH2
I-1862	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Aib-Ala-Phe-sCH2S*3-PyrS2-Phe-34ClF-TriAzOrn*3-NH2
I-1863	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-TriAzLys*3-PyrS2-Phe-34ClF-sAla*3-NH2
I-1864	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-sAla*3-PyrS2-Phe-34ClF-TriAzLys*3-NH2
I-1865	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-TriAzLys*3-PyrS2-Phe-34ClF-sCH2S*3-NH2
I-1866	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-sCH2S*3-PyrS2-Phe-34ClF-TriAzLys*3-NH2
I-1867	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-TriAzOrn*3-PyrS2-Phe-34ClF-sCH2S*3-NH2
I-1868	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-TriAzOrn*3-PyrS2-Phe-34ClF-sCH2S*3-NH2
I-1869	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-sCH2S*3-PyrS2-Phe-34ClF-TriAzOrn*3-NH2
I-1870	Ac-PL3-Asp-Ile-B5-Asp-3COOHF-Ala-Ala-Phe-sCH2S*3-PyrS2-Phe-34ClF-TriAzOrn*3-NH2
I-1871	Ac-S5-Asp-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1872	Ac-S5-Glu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1873	Ac-S5-AcLys-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1874	Ac-S5-Leu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1875	Ac-S5-3COOHF-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1876	Ac-S5-Ala-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1877	Ac-S5-Asp-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1878	Ac-S5-Glu-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1879	Ac-S5-AcLys-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1880	Ac-S5-Leu-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1881	Ac-S5-3COOHF-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1882	Ac-S5-Ala-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1883	Ac-Pro-S5-Ala-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1884	Ac-Pro-S5-Ala-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1885	Ac-Pro-S5-Glu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1886	Ac-Pro-S5-Glu-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1887	Ac-Pro-S5-Glu-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1888	Ac-Pro-S5-Ala-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1889	Ac-Pro-S5-Ala-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2

I-1890	Ac-Pro-S5-Val-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1891	Ac-Pro-S5-Val-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1892	Ac-Pro-S5-Val-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1893	Ac-Pro-S5-Leu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1894	Ac-Pro-S5-Leu-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1895	Ac-Pro-S5-Leu-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1896	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnC4CyMe*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1897	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnC4CyMe*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1898	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnC4CyMe*3-NH2
I-1899	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnC4CyMe*3-NH2
I-1900	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Gln3ACPip*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1901	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-Gln3ACPip*3-NH2
I-1902	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-Gln3ACPip*3-NH2
I-1903	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnPipAz*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1904	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnPipAz*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1905	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnPipAz*3-NH2
I-1906	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnPipAz*3-NH2
I-1907	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-34ClF-GlnR*3-Ala-NH2
I-1908	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Trp-34ClF-GlnR*3-Ala-NH2
I-1909	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-BztA-34ClF-GlnR*3-Ala-NH2
I-1910	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-5ClW-34ClF-GlnR*3-Ala-NH2
I-1911	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-6ClW-34ClF-GlnR*3-Ala-NH2
I-1912	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Phe-BztA-GlnR*3-Ala-NH2
I-1913	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-Trp-BztA-GlnR*3-Ala-NH2
I-1914	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-BztA-BztA-GlnR*3-Ala-NH2
I-1915	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-5ClW-BztA-GlnR*3-Ala-NH2
I-1916	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-6ClW-BztA-GlnR*3-Ala-NH2
I-1917	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[AdamantC-dPEG2]-Lys-NH2
I-1918	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[AdamantC-PEG8]--Lys-NH2
I-1919	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[lithocholate-dPEG2]-Lys-NH2
I-1920	Ac-PL3-Asp-DipA-B5-Asp-3COOHF-Ala-Ala-Phe-Lys*3-PyrS2-3Thi-34ClF-GlnR*3-Ala-Ala-[lithocholate-PEG8]-Lys-NH2
I-1921	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Gln4Pippip*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1922	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-Gln4Pippip*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1923	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnPip4AE*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnR*3-NH2
I-1924	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Leu-PyrS2-Phe-34ClF-GlnPip4AE*3-NH2
I-1925	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Val-PyrS2-Phe-34ClF-GlnPip4AE*3-NH2
I-1926	Ac-PL3-Asp-Leu-B5-Asp-3COOHF-GlnR*3-Ala-Phe-Ala-PyrS2-Phe-34ClF-GlnPip4AE*3-NH2
I-1927	Ac-S6-Glu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1928	Ac-S6-Glu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-BztA-GlnR*3-NH2
I-1929	Ac-S6-Glu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1930	Ac-S6-Glu-Asp-DipA-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-NH2
I-1931	Ac-S6-Glu-Asp-DipA-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS1-Phe-BztA-GlnR*3-NH2
I-1932	Ac-S6-Glu-Asp-DipA-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1933	Ac-S6-Glu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-Phe-34ClF-GlnR*3-Val-NH2
I-1934	Ac-S6-Glu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-34ClF-GlnR*3-Val-NH2
I-1935	Ac-S5-Leu-Asp-Val-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1936	Ac-S5-Leu-Asp-Chg-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2


I-1937	Ac-S6-Leu-Asp-Val-B5-Asp-3COOHF-Leu-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1938	Ac-S6-Leu-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1939	Ac-S6-Leu-Asp-DipA-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1940	Ac-Pro-S6-Leu-Asp-Val-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2
I-1941	Ac-Pro-S6-Leu-Asp-Chg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS1-3Thi-BztA-GlnR*3-NH2

[0890] For agents described in the Tables, as described previously, in various embodiments N-terminal cap (N-Term) is connected via R_1 to the amino group (R_1) of the first amino acid (AA1). In some embodiments, a N-Term cap may be properly considered as part of AA1. From there, each carboxylate (R_2) of an amino acid is connected to the amino group (R_1) of the subsequent amino acid, until the carboxylate (R_2) of the final amino acid is connected to R_1 of a C-terminal group. For any amino acid that has a branch point (R_3) and a branching monomer is indicated in brackets, R_1 of the monomer in brackets is attached to R_3 of the amino acid. For the amino acid Dap, with two potential branch points (R_3 and R_4), if two branches are indicated, the R_1 of the first branch is connected to R_3, and R_1 of the second branch connected to R_4. For any pair of amino acids that terminate in a *3 designation, the R_3 groups of each of those amino acids are linked to each other. Likewise, for any pair of amino acids that terminate in a **3 designation, the R_3 groups of those amino acids are linked to each other. For any agent that contains a pair of branching amino acids with R_3 groups, and one contains a branching monomer that contains both R_1 and R_2 groups, then R_1 is attached to the branching amino acid adjacent to it in the sequence, and the R_2 group of the branching monomer is attached to R_3 of the amino acid with no branching monomer designated. For example, in various peptides that have one of Cys, hCys, Pen, or aMeC at position 10 and also one of Cys, hCys, Pen, or aMeC at position 14, and a branching group off of the amino acid residue 10, the R_1 of that branching group is tied to the R_3 of the amino acid residue at position 10, while the R_2 of that branching group is tied to the R_3 of the amino acid residue at position 14. For any amino acid which has a branching amino acid containing R_3 and nothing attached to it by the above, then R_3 = H. In various embodiments (e.g., agents described in Table E1, Table E2 and Table E3), PyrS2 is tied together with either R4, R5, R6, or one arm of B5, and if PL3 is present, it is typically tied to the other arm of B5. In various embodiments, if a N-terminal group contains an olefin, it is tied to either AA3, or a branching group off of AA3. If a peptide has been reduced as indicated, then olefins have been hydrogenated to $-CH_2-CH_2-$ after olefin metathesis; if it is indicated "C-term only", then only the C-terminal side staple, e.g., in many cases PyrS2/R5 olefin staple, has been hydrogenated to $-CH_2-CH_2-$. For peptides which have not been hydrogenated, two possible staple isomers can be generated for each olefin metathesis, leading to 2^n potential isomers (four if n=2). For peptides with the same description and different assigned numbers, these are two separable isomers or compositions comprising one or more isomers. In various embodiments, for a peptide comprising an amino acid residue starting with "Dap7" or "DapAc7", the olefin of that amino acid residue is tied together with one arm of B5 via olefin metathesis, while the R_3 group of that stapling amino acid residue is tied to the R_3 of another amino acid residue, e.g., GlnR*3 residue, elsewhere in the peptide. Special cases: For I-1484 and I-1485, PL3 is stapled to S5, while the R5 residue is


stapled to PyrS2.

[0891] In some embodiments, it was confirmed that various peptides, e.g., stapled peptides, comprising residues of amino acids described herein can provide higher affinity than reference peptides that comprise a reference amino acid, e.g., a natural amino acid such as Asp or Glu, but are otherwise identical.


[0892] Example 5. Preparation of an amino acid for peptide synthesis.


[0893] In some embodiments, the present disclosure provides various compounds. In some embodiments, such compounds are useful for incorporating related amino acids into peptides. In some embodiments, such a compound is compound 2-2  or a salt thereof, whose preparation and uses, including methods, reagents, intermediates, etc., are described in the priority applications, WO 2022/020651 or WO 2022/020652, and are incorporated herein by reference.

[0894] Example 6. Preparation of an amino acid for peptide synthesis.

[0895] In some embodiments, the present disclosure provides various compounds. In some embodiments, such compounds are useful for incorporating related amino acids into peptides. In some embodiments, such a compound is  or a salt thereof, whose preparation and uses, including methods, reagents, intermediates, etc., are described in the priority applications, WO 2022/020651 or WO 2022/020652, and are incorporated herein by reference.

[0896] Example 7. Preparation of an amino acid for peptide synthesis.


[0897] In some embodiments, the present disclosure provides various compounds. In some embodiments, such compounds are useful for incorporating related amino acids into peptides. In some embodiments, such a compound is  or a salt thereof, whose preparation and uses, including methods, reagents, intermediates, etc., are described in the priority applications, WO 2022/020651 or WO 2022/020652, and are incorporated herein by reference. In some embodiments, the present disclosure provides various compounds. In some embodiments, such a compound is




or a salt thereof, whose preparation and uses, including methods, reagents, intermediates, etc., are described in the priority applications, WO 2022/020651 or WO 2022/020652, and are incorporated herein by reference.

[0898] Example 8. Additional examples of manufacturing technologies.


[0899] Compounds with substitutions on a 2-aminophenylalanine residue (e.g., I-1660 to I-1672) were synthesized in the following manner: Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-2NO2F-BztA-GlnR*3-Ala-protide resin was synthesized on a Liberty Blue as above, and the lactam cyclization and olefin metathesis performed as above. The nitro group was reduced by treated with 30 equivalents of tin(II) chloride (2M solution in DMF) at 100 °C for 10 min. The resin was drained and washed with DMF. The resulting peptide was treated with the corresponding carboxylic acid (7 equivalents), HATU (7 equivalents) and diisopropylethylamine (14 equivalents) at 40 °C for 2 h. The coupling reaction was repeated in case of incomplete reaction. The resin was washed with DMF and dichloromethane, and the peptide cleaved and purified as above.




[0900] (R)-N-Fmoc-2-(2'-propylenyl)alanine (Fmoc-R3-OH, CAS 288617-76-5) (10.0 g, 30 mmol) was dissolved in dichloromethane (90 mL) and diisopropylethylamine (30.5 mL, 180 mmol) and 2-chlorotrityl resin (28.1 g, 30 mmol) was added. The resin was agitated for 2 h at room temperature, and methanol (30 mL) was added, and the resin agitated for another 30 min. The resin was washed with DMF (3 x 60 mL), and then treated with 20% piperidine in DMF (60 mL). The resin was agitated for 30 min at room temperature, then the resin washed with DMF (4 x 60 mL) and methanol (3 x 60 mL). The resin was then treated with a mixture of hexafluoroisopropanol (18 mL) and dichloromethane (72 mL) and the mixture stirred for 40 min. The resin was filtered off and the resulting solution concentrated to give R3-OH.




[0901] R3-OH (7.88 g, 55.5 mmol) was dissolved in methanol (100 mL) and thionyl chloride (13.2 g, 111 mmol) was added at 0 °C, and the reaction warmed to reflux and stirred for 14 h. All volatiles were removed under vacuum to give R3-OMe HCl salt (13.2 g) which was used directly in the next step.



[0902] To a solution of R3-OMe HCl salt (6.20 g, 28.6 mmol) in THF (100 mL) and triethylamine (10.0 mmol, 71.7 mmol) was added 4-bromobutyryl chloride (5.0 mL, 43.0 mmol) at room temperature. The reaction was stirred at room temperature for 4 h, then saturated ammonium chloride (100 mL) was added. The mixture was extracted with ethyl acetate (3 x 100 ml), and the combined organic layers washed with 1M HCl (200 mL), brine (150 mL), and dried with sodium sulfate and concentrated under vacuum. The residue was purified by silica gel chromatography (10% to 50% ethyl acetate in petroleum ether) to give 4-bromobutyrate R3-OMe (3.90 g, 13.3 mmol, 46.5% yield).




[0903] To a solution of 4-bromobutyrate R3-OMe (3.90 g, 13.3 mmol) in THF (70 mL) was added sodium hydride (961 mg, 24 mmol) and the reaction stirred at room temperature for 3 h. The mixture was diluted with ethyl acetate (20 mL) and quenched with saturated ammonium chloride (30 ml). The mixture was extracted with ethyl acetate (3 x 25 mL), and the combined organic layers dried with sodium sulfate and concentrated. The remaining crude residue was purified by silica gel chromatography (20% to 50% ethyl acetate in petroleum ether) to give a yellow oil. This oil was dissolved in methanol (50 mL) and water (50 ml), and lithium hydroxide hydrate (1.27 g, 30 mmol) was added. The reaction was stirred at room temperature for 1 h. The methanol was removed under vacuum, and the residue extracted with ethyl acetate (30 mL). The aqueous layer was acidified to pH = 3 with 1N HCl, and extracted with dichloromethane (5 x 30 mL). The combined dichloromethane layers were concentrated under vacuum to obtain NPyroR3-OH (2.54 g, 12.8 mmol, 96% yield).




1 2

[0904] To a solution of compound 1 (25.0 g, 113 mmol) in THF (500 mL) was added potassium hydroxide (38.0 g, 678 mmol) and propargyl bromide (101 g, 678 mmol) in portions. The reaction was stirred at room temperature for 14 h, and the mixture filtered and the filtrate concentrated under vacuum. Silica gel chromatography (1% to 10% ethyl acetate in petroleum ether) yielded compound 2 (23.2 g, 69.2 mmol, 61% yield).



2 3

[0905] A mixture of 2 (23.2 g, 69.2 mmol) was stirred in an HCl solution (4 M in ethyl acetate) for 30 min at room temperature. All volatiles were removed under vacuum to give compound 3 (18.4 g, 67.7 mmol, 98% yield) as a light yellow solid.



3 4

[0906] To a solution of PEG4-diacid (7.74 g, 26.3 mmol) in DMF (100 ml) was added HATU (10.0 g, 26.3 mmol) and diisopropylethylamine (8.33 mL, 47.8 mmol). The mixture was stirred at room temperature for 30 min, then compound 3 (6.5 g, 23.9 mmol) was added. The reaction was stirred at room temperature for 2.5 h, and the reaction diluted with water 9500 mL) and extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with brine (200 mL) and dried with sodium sulfate. The residue was purified by reverse phase HPLC to give compound 4 (3.5 g, 6.84 mmol, 29% yield). LCMS M/Z = 512 (M + H).


[0907] I-1525, I-1526: Compound with branched PEG at X^{18} were synthesized in the following manner: Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys*3-PyrS2-3Thi-BztA-GlnR*3-Ala-Ala-Ala-Lys(ivDde)-protide resin was synthesized by solid phase peptide synthesis as above, and the lactam

cyclization and olefin metathesis performed as above. The ivDde group was removed by treating the resin with 5% hydrazine in DMF at 40 °C for 30 min, and the resin drained and washed with DMF. The resin was treated with compound 4 (3 equivalents), HATU (3 equivalents), and diisopropylethylamine (10 equivalents) for 3 h at 40 °C. The peptide was cleaved as above and purified by reverse phase HPLC. This purified peptide (500 mg) was dissolved in 1:1 acetonitrile : water, and 4 equivalents of either mPEG16-azide (for I-1525) or mPEG36 (for I-1526) was dissolved in 1:1 acetonitrile : water and added to the peptide solution. The pH was adjusted to ~8 with ammonium bicarbonate, and copper sulfate (4 equivalents) and sodium ascorbate (5 equivalents) were added, with the pH again adjusted to ~8 with ammonium bicarbonate if necessary. The reaction was stirred at 40 °C for 2h, and the final peptide purified by preparative HPLC to give either I-1525 (65% yield) or I-1526 (55% yield).

[0908] Example 9. Provided technologies can provide high selectivity.

[0909] Among other things, the present disclosure provides various technologies for preparing stapled peptides, including those comprising multiple staples. As described herein, in some embodiments, two or more staples are formed in one step. For example, in some embodiments, two or more staples are formed in a metathesis reaction. In some embodiments, all staples formed by metathesis are formed in a metathesis reaction. In some embodiments, each of such staples are formed through olefin metathesis of terminal olefins. In some embodiments, multiple staples are formed after full lengths of peptides have been achieved. In some embodiments, one or more staples comprising double bonds are formed after full lengths of peptides have been achieved. In some embodiments, all staples comprising double bonds are formed after full lengths of peptides have been achieved. In some embodiments, one or more staples formed through metathesis are formed after full lengths of peptides have been achieved. In some embodiments, all staples formed through metathesis are formed after full lengths of peptides have been achieved.


[0910] For example, in some embodiments, to prepare I-66 and I-67, a full length peptide (in some embodiments, prepared on solid phase as shown below) was subject to olefin metathesis:



[0911] In some embodiments, about 3:1 ratio (I-66 : I-66) was observed.

[0912] In some embodiments, staples are formed in two or more staples. In some embodiments, two or more staples comprising olefin are formed in two or more staples. In some embodiments, two or more staples are formed in two or more metathesis steps. In some embodiments, two or more metathesis steps utilize different conditions, e.g., different catalysts. In some embodiments, each staple is formed in a separate step. In some embodiments, each staple comprising a double bond is formed in a separate step. In some embodiments, each staple comprising an olefin is formed in a separate step. In some embodiments, each staple formed by olefin metathesis is formed in a separate metathesis step. In some embodiments, stepwise stapling provides improved levels of selectivity to form a desired product (e.g., I-66) over other compounds, e.g., stereoisomers (e.g., for I-66, I-67). For example, in some embodiments, I-66 was prepared as described below, and over 10:1 I-66:I-67 ratio was observed. In some embodiments, the present disclosure provides a composition comprising I-66, wherein the ratio of I-66 to I-67 is about or at least about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. In some embodiments, the present disclosure provides a composition comprising I-66 and I-67, wherein the ratio of I-66 to I-67 is about or at least about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. In some embodiments, the ratio is about or at least about 5:1. In some embodiments, the ratio is about or at least about 10:1. In some embodiments, the ratio is about or at least about 20:1. In some embodiments, the ratio is about or at least about 30:1. In some embodiments, the ratio is about or at least about 50:1. In some embodiments, the ratio is about or at least about 80:1. In some embodiments, the ratio is about or at least

about 90:1. In some embodiments, the ratio is about or at least about 100:1. In some embodiments, I-66 is provided in a salt form, e.g., a pharmaceutically acceptable salt form. In some embodiments, I-66 is provided in multiple forms including multiple salt forms. In some embodiments, I-67 is provided in a salt form, e.g., a pharmaceutically acceptable salt form. In some embodiments, I-67 is provided in multiple forms including multiple salt forms.



[0913] In a preparation, I-66 was synthesized by manual SPPS on Rink amide MBHA resin (98 g, 0.51 mmol/g loading, 50 mmol total). Deprotection steps were performed by treating the resin with 20% piperidine in DMF (v/v, 1000 mL) for thirty minutes with agitation via nitrogen bubbling. The resin was drained and washed with DMF four times. An amino acid to be coupled was dissolved in DMF (800 mL), and the coupling agent indicated below and either diisopropylethylamine (DIEA), or HOAt, were added in the equivalents listed below. Coupling proceeded for 30 minutes at room temperature with nitrogen bubbling, and the amino acid solution drained and the resin washed with DMF four times.

Amino acid used	Coupling agent/base and amount used
Fmoc-Ala-OH (100 mmol)	HBTU (74 mmol), DIEA (75 mmol)
Fmoc-Glu(OAllyl)-OH (75 mmol)	DIC (75 mmol) and HOAt (75 mmol)
Fmoc-BztA-OH (65 mmol)	HBTU (61.5 mmol) and DIEA (65 mmol)
Fmoc-3Thi-OH (65 mmol)	HBTU (65 mmol) and DIEA (65 mmol)
Fmoc-PyrS2-OH (75 mmol)	HBTU (74 mmol), DIEA (75 mmol)
Fmoc-Lys(Alloc)-OH (100 mmol)	HATU (95 mmol) and DIEA (100 mmol)
Fmoc-Phe-OH (75 mmol)	HBTU (75 mmol), DIEA (75 mmol)
Fmoc-Ala-OH (90 mmol)	HBTU (85 mmol) and DIEA (90 mmol)

Fmoc-Aib-OH (100 mmol)	HBTU (95 mmol) and DIEA (100 mmol)

[0914] After Aib addition, prior to Fmoc deprotection, the resin was washed with DMF five times, and dichloromethane five times. A solution of phenylsilane (54 g, 500 mmol) and tetrakis(triphenylphosphine)palladium (0) (5.77 g, 5 mmol) in dichloromethane (500 mL) was added. The reaction proceeded at room temperature for 15 minutes with nitrogen bubbling, and the palladium solution drained. The palladium/phenylsilane treatment was repeated another two times, then the resin drained and washed with DMF five times. The lactam was closed by treating the resin with HOAt (400 mmol) and DIC (400 mmol) in DMF (1000 mL), at room temperature with nitrogen bubbling for 2 h. The resin was drained and washed with DMF four times. The cycles of Fmoc deprotection and amino acid addition continued as above. A repeat coupling step was performed for Fmoc-Npg-OH.

Amino acid used	Coupling agent/base and amount used
Fmoc-3COOHF(tBu)-OH (65 mmol)	HATU (61.5 mmol), DIEA (65 mmol)
Fmoc-Asp(tBu)-OH (80 mmol)	HBTU (75 mmol) and DIEA (80 mmol)
Fmoc-B5-OH (65 mmol)	HATU (61.5 mmol) and DIEA (65 mmol)
Fmoc-Npg-OH (75 mmol) (x2)	HATU (70 mmol) and DIEA (75 mmol) (x2)
Fmoc-Asp(tBu)-OH (75 mmol)	HBTU (70 mmol) and DIEA (75 mmol)

[0915] After coupling Asp2, the B5/PyrS2 staple was closed by treating the resin with Hoveyda-Grubbs M720 catalyst (15.7 g, 25 mmol) and 1,4-benzoquinone (13.5 g, 125 mmol) in dichloroethane. The reaction proceeded at room temperature for 2 h with nitrogen bubbling, the catalyst was drained, and the treatment with M720 catalyst and 1,4-benzoquinone was repeated one more time before continuing with linear peptide synthesis.


Amino acid/reagent used	Coupling agent/base and amount used
Fmoc-PL3-OH (75 mmol)	HBTU (75 mmol), DIC (75 mmol)
Ac2O (200 mmol)	DIEA (100 mmol)

[0916] After N-terminal acetate capping, the PL3/B5 staple was closed by treating the resin with Grubbs catalyst M102 (20.6 g, 25 mmol) in dichloroethane at room temperature for 2 h with nitrogen bubbling. The catalyst solution was drained, and the treatment with Grubbs catalyst M102 was repeated another two times. The peptide was cleaved by treating the resin with 95:5 TFA : water (800 mL, v/v) for 2 hours, and the peptide was precipitated by pouring the cleavage cocktail into cold methyl tert-butyl ether. The precipitated peptide was filtered, washed with cold MTBE twice, and dried under vacuum. The peptide was first purified by dissolving in DMF, and loading onto a Luna C8 10 um 100 Å column (flow rate: 20 mL/min) with a gradient of 45% to 75% acetonitrile in water (with 0.075% TFA) over 50 minutes. Product-containing fractions were dried, and the isolated peptide was subjected to a second purification, and was dissolved in 30% acetonitrile in water and loaded on a Kromasil C8 5 μm 100 Å column (20 mL/min), first flowing 0.4M ammonium acetate over the column for 25 min, then eluting with a gradient of 50% to 70% acetonitrile in


water with 0.5% acetic acid over 50 minutes. The product-containing fractions were lyophilized to provide I-66 (40:1 I-66:I-67, 4997 mg, 2.41 mmol, 4.8% yield) plus a second lot of I-66 (8:1 I-66:I-67, 2015 mg, 0.97 mmol, 1.9% yield). Ratio of I-66 and I-67 were assessed using HPLC: Agilent Poroshell 120 EC-C18; 4.6 x 100 mm; solvent A = 0.1% TFA in water; solvent B = 0.075% TFA in acetonitrile; gradient is 10% B to 95% B over 30 min; detection is UV absorbance at 220 nM; and ratio is calculated based on peak area. As an example, in one run, retention time of I-66 is 15.3 min and retention time of I-67 is 16.2 min. In some embodiments, such a protocol provides improved resolution compared to a reference protocol by which I-66 and I-67 may elute as one peak or may otherwise not sufficiently separated. For example, by the general method for Table E2 I-66 and I-67 can be eluted together as the second peak and the mixture may be designated as I-67). Alternatively or additionally, ratios can also be assessed using other technologies, e.g., NMR. In some embodiments, such a preparation of I-66 or preparations corresponding thereto were assessed in various biological assays and was confirmed to possess various properties and activities; see, e.g., Examples 11-18. ^{1}H NMR of such a preparation of I-66 is presented in Figure 6. As those skilled in the art reading the present disclosure will appreciate, Figure 6 may contain peaks of certain impurities and/or residue ^{1}H in a NMR solvent. In some embodiments, NOE was observed between the peaks at about 5.45-5.6 and at about 5.2-5.35. Fractions can be further purified to provide improved purity.

[0917] In some embodiments, I-66 and/or I-67 prepared herein may be utilized as standard/reference to assess and/or characterize other compounds and/or other preparations of I-66 and/or I-67 (e.g., different batches prepared by the same or different methods). In some embodiments, I-470 is similarly prepared. In some embodiments, I-470 differs from I-66 in that I-470 has Glu2 and Glu5 while I-66 has Asp2 and Asp5.


[0918] In some embodiments, the present disclosure provides a compound having the structure of



or a salt thereof. In some embodiments, the present disclosure provides a compound having the structure of



or a salt thereof. In some embodiments, the present disclosure provides a compound having the structure of




or a salt thereof. In some embodiments, the compound has the same retention time as I-66 prepared above under the same or comparable HPLC conditions. For example, in some embodiments, a HPLC condition is Agilent Poroshell 120 EC-C18; 4.6 x 100 mm; solvent A = 0.1% TFA in water; solvent B = 0.075% TFA in acetonitrile; gradient is 10% B to 95% B over 30 min; detection is UV absorbance at 220 nM; and a retention time of I-66 is about 15.3 min. In some embodiments, a HPLC condition separates I-66 and I-67. In some embodiments, when co-injected with a I-66 preparation described herein, the compound elute as a single peak as I-66. In some embodiments, the compound is characterized in that in its ^{1}H NMR spectrum, it shows peaks that overlap with those between about 5.1-5.7 in Figure 6. In some embodiments, the compound is characterized in that in its ^{1}H NMR spectrum, it has the same peak pattern as Figure 6 between about 5.1-5.7. In some embodiments, the compound has the same NMR spectra as I-66 under the same or comparable conditions. In some embodiments, the compound has the same ^{1}H NMR spectra as I-66 under the same or comparable conditions, e.g., DMSO-d6, 373 K. Those skilled in the art appreciate that peaks of certain ^{1}H, such as those bonded to nitrogen and oxygen, may shift in ^{1}H NMR for the same compound during different assessments. In some embodiments, the compound has such a structure that for its ^{1}H NMR, peaks of ^{1}H bonded to carbon are found in Figure 6 under the same or comparable conditions (DMSO-d6, 373 K). In some embodiments, the compound has such a structure that its ^{1}H NMR peaks are found in Figure 6 under the same or comparable conditions (DMSO-d6, 373 K). In some embodiments, the compound has such a structure that its ^{1}H NMR peaks for ^{1}H bonded to carbon atoms are found in Figure 6 under the same or comparable conditions (DMSO-d6, 373 K). In some embodiments, integration of peak(s) in Figure 6 that correspond(s) to each ^{1}H bonded to carbon in the compound is independently about 1 (e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 to about


1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2.0, about 0.2-1.8, about 0.5-1.5, about 0.7-1.5, 0.8-1.2, etc.) when integration of the triplet at about 5.45 to about 5.6 is set as 1. In some embodiments, integration of peak(s) in Figure 6 that correspond(s) to each ^{1}H in the compound is independently about 1 (e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 to about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2.0, about 0.2-1.8, about 0.5-1.5, about 0.7-1.5, 0.8-1.2, etc.) when integration of the triplet at about 5.45 to about 5.6 is set as 1. An integration of Figure 6 is presented in Figure 7 as an example. Those skilled in the art appreciate that ^{1}H NMR results, e.g., chemical shifts, integration of peaks, etc., may have typical error ranges. In some embodiments, peaks corresponding to two or more ^{1}H may overlap. In some embodiments, such peaks may be integrated together for assessment of numbers of ^{1}H. In some embodiments, NMR of a preparation of I-66 described above are the same or comparable with or without the addition of the compound at a detectable level (e.g., the same amount of I-66) under the same or comparable conditions. In some embodiments, ^{1}H NMR of a preparation of I-66 described above are the same or comparable with or without the addition of the compound at a detectable level (e.g., the same amount of I-66, or about 0.1-10, 0.2-5, 0.5-2, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3. 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10, etc. of I-66). In some embodiments, ^{1}H NMR are considered the same or comparable when peaks corresponding to ^{1}H bonded to carbon have comparable chemical shift, peak shapes and/or integration. In some embodiments, peaks from impurities and solvents are properly excluded when comparing NMR. In some embodiments, peaks from impurities, solvents, ^{1}H bonded to oxygen, nitrogen, etc. are properly excluded when comparing NMR. In some embodiments, the compound has the same retention time as I-67 prepared above under the same or comparable HPLC conditions. For example, in some embodiments, a HPLC condition is Agilent Poroshell 120 EC-C18; 4.6 x 100 mm; solvent A = 0.1% TFA in water; solvent B = 0.075% TFA in acetonitrile; gradient is 10% B to 95% B over 30 min; detection is UV absorbance at 220 nM; and a retention time of I-67 is about 16.2 min. In some embodiments, a HPLC condition separates I-66 and I-67. In some embodiments, when co-injected with a I-67 preparation described herein, the compound elute as a single peak as I-67. In some embodiments, the compound has the same ^{1}H NMR peaks between about 5.0-6.0 as I-67 under the same or comparable conditions. In some embodiments, the compound has the same NMR spectra as I-67 under the same or comparable conditions. In some embodiments, the compound has the same ^{1}H NMR spectra as I-67 under the same or comparable conditions, e.g., DMSO-d6, 373 K. In some embodiments, NMR of a preparation of I-67 described above are the same or comparable with or without the addition of the compound at a detectable level (e.g., the same amount of I-67) under the same or comparable conditions. In some embodiments, ^{1}H NMR of a preparation of I-67 described above are the same or comparable with or without the addition of the compound at a detectable level (e.g., the same amount of I-67). In some embodiments, in a composition comprising the compound, ratio of the compound to a stereoisomer of the compound is about or at least about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. In some embodiments, in a composition comprising the compound, ratio of the compound to each stereoisomer of the compound is independently about or at least about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1,

9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. In some embodiments, in a composition comprising the compound, ratio of all compounds that are the compound or a salt thereof to all compounds that is a stereoisomer of the compound or a salt of the stereoisomer is about or at least about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. In some embodiments, in a composition comprising the compound, for each stereoisomer of the compound, ratio of all compounds that are the compound or a salt thereof to all compounds that is a stereoisomer of the compound or a salt of the stereoisomer is about or at least about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. In some embodiments, the ratio is about or at least about 2:1. In some embodiments, the ratio is about or at least about 3:1. In some embodiments, the ratio is about or at least about 4:1. In some embodiments, the ratio is about or at least about 5:1. In some embodiments, the ratio is about or at least about 10:1. In some embodiments, the ratio is about or at least about 20:1. In some embodiments, the ratio is about or at least about 30:1. In some embodiments, the ratio is about or at least about 50:1. In some embodiments, the ratio is about or at least about 80:1. In some embodiments, the ratio is about or at least about 90:1. In some embodiments, the ratio is about or at least about 100:1.


[0919] In some embodiments, a preparation of I-66 comprises




or a salt thereof. In some embodiments, a



preparation of I-67 comprises or a salt thereof. In some embodiments, a preparation of I-66 or a preparation of I-67 comprises a first compound



or a salt thereof, and a second compound




or a salt thereof. In some embodiments, in a preparation of I-66, ratio of the first compound to the second compound is about or at least about 2:1, 3:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. In some embodiments, in a preparation of I-66, ratio of all compounds that are the first compound or a salt thereof to all compounds that are the second compound or a salt thereof is about or at least about 2:1, 3:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. In some embodiments, in a preparation of I-67, ratio of the second compound to the first compound is about or at least about 2:1, 3:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. In some embodiments, in a preparation of I-67, ratio of all compounds that are the second compound or a salt thereof to all compounds that are the first compound or a salt thereof is about or at least about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. In some embodiments, the ratio is about or at least about 2:1. In some embodiments, the ratio is about or at least about 3:1. In some embodiments, the ratio is about or at least about 4:1. In some embodiments, the ratio is about or at least about 5:1. In some embodiments, the ratio is about or at least about 10:1. In some embodiments, the ratio is about or at least about 20:1. In some embodiments, the ratio is about or at least about 30:1. In some embodiments, the ratio is about or at least about 50:1. In some embodiments, the ratio is about or at least about 80:1. In some embodiments, the ratio is about or at least about 90:1. In some embodiments, the ratio is about or at least about 100:1. As utilized in the present disclosure, depending on the context, in some embodiments, a ratio is a molar ratio; in some embodiments, a ratio is a weight ratio; in some embodiments, a ratio is a volume ratio; and in some embodiments, a ratio is according to an assessment. For example, in some embodiments, when ratio of compounds are assessed using HPLC/UV, a ratio is of peak area of UV


trace at a certain wavelength, e.g., 220 nm.

[0920] Example 10. Provided technologies can provide high selectivity.

[0921] As confirmed below, in some embodiments, the present disclosure provides technologies with high selectivity for forming staples comprising olefin double bonds.




[0922] Fmoc-azidolysine-PyrS2-3Thi-BztA-propargylglycine-Ala-protide resin was synthesized using standard solid phase peptide synthesis procedures. The triazole staple was closed by treating the resin with one equivalent of copper (I) iodide, one equivalent of sodium ascorbate, ten equivalents of diisopropylethylamine, and ten equivalents of 2,6-lutidine in dichloromethane at room temperature for 48 h. The resin was washed for 5 min with DCM 2X, MeOH 1X, H_2O 2X, 50% H_2O/MeOH 2X, and MeOH 2X. In some embodiments, it was observed there was a small layer of insoluble material floating on top of the reactor, which was eliminated by aspiration through a hose connected to a pump. Then, continued with washes with NMP 2X, DCM 1X, and MeOH 1X.



[0923] The cyclized product was elongated to Fmoc-Asp(OtBu)-Npg-B5-Asp(OtBu)-3COOHF(OtBu)-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-Bzta-sAla*3-Ala-protide resin using standard solid phase peptide

synthesis procedures. Afterwards, the resin was thoroughly washed with DCM 2X, NMP 1X, DCM 2X, MeOH 2X, DCM 1X, MeOH 1X, each for five minutes, then dried under a flow of nitrogen for 24 h to yield a gold color resin. The first staple was closed by treating the resin with 5 mol% Hoveyda-Grubbs M720 catalyst (CAS 301224-40-8) and 10 mol% benzoquinone in dichloromethane at reflux for 48 h. After 48 h, the catalyst solution was drained, the resin washed with dichloromethane 3X, dried, and then treated again with 5 mol% Hoveyda-Grubbs M720 catalyst (CAS 301224-40-8) and 10 mol% benzoquinone in dichloromethane at reflux for 48 h.

[0924] After analysis by LCMS, complete reaction was observed with no identifiable starting material. The desired product is detected in > 95%, no other isomer by-product is observed. Double bond configuration is assigned based on analysis of NMR data, reported selectivity, etc., and can also be assessed by other technologies, e.g., crystallography.



[0925] The above product was elongated to Ac-PL3-Asp(OtBu)-Npg-B5-Asp(OtBu)-3COOHF(OtBu)-Aib-Ala-Phe-TriAzLys*3-PyrS2-3Thi-Bzta-sAla*3-Ala-protide resin using standard solid phase peptide synthesis procedures. After acetyl capping of the N-terminus, the resin was thoroughly washed with DCM 2X, NMP 1X, DCM 2X, MeOH 2X, DCM 1X, MeOH 1X, each for five minutes, then dried under a flow of nitrogen for 24 h. The second staple was closed by treating the resin with 30 mol% Grubbs I M102 (CAS 172222-30-9) and 60 mol% benzoquinone in dichloromethane at reflux for 24 h. After 24 h, the catalyst solution was drained, the resin washed with dichloromethane 3X, dried, and then treated again with 30 mol% Grubbs I M102 (CAS 172222-30-9) and 60 mol% benzoquinone in dichloromethane at reflux for 24 h. The crude product was cleaved and deprotected, and was analyzed by LCMS and showed 82% (UV at, e.g., 210-

400 nm) of I-335. Two more peaks of olefin isomers were detected on as 13% and 5% of total area by HPLC, respectively. Double bond configuration is assigned based on analysis of NMR data, reported selectivity, etc., and can also be assessed by other technologies, e.g., crystallography.

[0926] Example 11. Provided technologies can provide various advantages.

[0927] Among other things, provided technologies can provide various advantages. In some embodiments, provided technologies can provide improved target binding profiles and/or activity profiles. As confirmed below, stapled peptides, particularly I-66, can provide strong binding to beta-catenin and modulation of gene expression. Useful protocols for various assessments are described in the Examples.

IC50	SPR Kd*	Competition Fluorescence Polarization	NanoBRET	TCF reporter	qPCR (AXIN2)**
Peptide A	20 nM	10 nM	3.0 μM	1.5 μM	1.4μM
I-66	700 pM	<5 nM	1.1 μM	0.7μM	0.3μM
I-470	>5000 nM	7500 nM	>20 μM	>20 μM	>20 μM

Peptide A: A stapled peptide Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-Gln-NH2. PL3 and B5, and B5 and PyrS2 are stapled.

*: $T_{1/2}$ = 12.6 min for I-66.

**: Reduction of AXIN2 transcripts after administration of agents to COLO320DM cells.

[0928] In some embodiments, it was confirmed, e.g., through biochemical competition assays, that provided technologies (e.g., I-66) can inhibit TCF/LEF transcription factor binding to β-catenin. In some embodiments, it was observed that provided technologies (e.g., I-66) compete with TCF1, TCF3, TCF4, LEF1, pAPC, mouse ECAD, human ECAD, etc. for beta-catenin interactions. In some embodiments, it was confirmed that provided technologies (e.g., I-66) can significantly reduce phospho-APC binding. In some embodiments, it was confirmed that provided technologies (e.g., I-66) can significantly reduce E-cadherin binding. In some embodiments, it was observed that there was little to no competitive effect for certain provided technologies, e.g., I-66, for ICAT, Axin or Bcl9. In some embodiments, interactions are dependent on phosphorylation, e.g., it has been reported that E-cadherin binding to beta-catenin is highly dependent on phosphorylation of up to eight Ser residues on E-cadherin.

[0929] In some embodiments, capabilities of provided technologies, e.g., binding to beta-catenin and/or disrupt its interactions (or lack thereof) with various partners were assessed and confirmed in cells, e.g., using a NanoBRET based assay in HEK293 cells.. In some embodiments, it was observed that provided technologies, e.g., I-66, can potently inhibit such interactions without affecting cell viability.

[0930] Among other things, direct inhibition of endogenous beta-catenin/TCF interaction was confirmed by co-immunoprecipitation (co-IP) assays as described herein.

[0931] Example 12. Provided technologies can modulate transcription.

[0932] Among other things, the present disclosure confirms that provided technologies can inhibit transcription of endogenous Wnt pathway target genes driven by the β-catenin/TCF interaction. Among

other things, it was confirmed that in DLD1 cells, peptide A and I-66 dose-dependently inhibited the expression of AXIN2 and SP5, two bona fide downstream genes of beta-catenin/TCF (peptide A: AXIN2 IC_{50}=9.3 uM, SP5 IC_{50}=9 uM; I-66: AXIN2 IC_{50}=1.6 uM, SP5 IC_{50}=1.3 uM). In some embodiments, no effect was observed on the expression of CTNNB1 for peptide A and I-66 in DLD1 cells under a tested condition. Reduction of expression level of a canonical beta-catenin target AXIN2, was also observed in COLO320DM cells (peptide A: IC_{50}=1.4 uM; I-66: IC_{50}=0.3 uM) while I-470 had no or very little or non-significant effect.

[0933] Among other things, provided technologies can modulate transcription and levels of various transcripts, in some embodiments, with certain types and/or levels of selectivity. For example, in various systems, e.g., HAP1 isogenic lines (+/− CTNNB1 knockout), provided technologies can modulate level of expression and/or activity of a nucleic acid, e.g., a gene, a transcript, a polypeptide, and/or a product thereof selectively in systems comprising or expressing beta-catenin. For example, in some embodiments, provided technologies inhibit beta-catenin driven transcription selectively in HAP1 WT cells. Certain data are presented in Figure 1 as examples. In cells expressing WT beta-catenin (WT), 24-hour CHIR treatment increased beta-catenin protein levels more than two-fold, and peptide A and I-66 treatment significantly reduced the expression of AXIN2 and SP5 as measured by qPCR (by about 3- and 8-fold, respectively, with I-66). Inhibition of RNF43 expression by peptide A and I-66 was also observed. In beta-catenin KO cells, neither CHIR nor peptide A and I-66 affected the expression of AXIN2, SP5, or RNF43. No reduction of transcription in WT cells was observed for I-470. In some embodiments, treatment with provided peptides, e.g., I-66 at 10 um for 72 or 144 hours, was observed to not significantly affect beta-catenin stability in cells with functioning beta-catenin destruction complex by western blot.

[0934] Example 13. Provided technologies can reduce beta-catenin levels in nuclei.

[0935] In some embodiments, provided technologies can reduce level of beta-catenin in nuclei. In some embodiments, provided technologies can block beta-catenin nuclear localization. In some embodiments, provided technologies can reduce level of beta-catenin nuclear translocation. For example, as confirmed in Figure 2, provided technologies can reduce levels of nuclear beta-catenin in various cells including COLO320DM cells (10 uM, 24 hr). Reduction of nuclear localization was also confirmed by immunofluorescence imaging. In some embodiments, it was observed that after 24-hr I-66 treatment, nuclear beta-catenin levels were reduced by over 70% compared to untreated cells. Similar results were obtained after 24- and 48-hr treatments.

[0936] Example 14. Provided technologies can inhibit proliferation and induce cell cycle arrest.

[0937] As described herein, among other things, provided technologies can inhibit proliferation of various cells including various cancer cells. In some embodiments, provided technologies modulate WNT specific transcription. In some embodiments, provided technologies induce cell cycle arrest. In some embodiments, provided technologies induce G1 cell cycle arrest. In some embodiments, provided technologies increased proportion of cells in G1 phase of cell cycle. As confirmed in Figure 3, provided

technologies can inhibit proliferation of COLO320DM, which is a colorectal cell line comprising various mutations such as APC, TP53, etc., modulate WNT specific transcription such as of AXIN2 and CXCL12, and induce G1 cell cycle arrest. In some embodiments, it was confirmed that provided technologies can reduce proportion of cells in S phase of cell cycle. In some embodiments, it was confirmed that provided technologies can significantly down-regulate Cyclin D2 and up-regulate p27. In some embodiments, changes of various genes, e.g., AXIN2, CXCL12, etc., were observed to be consistent with changes with shRNA-knockdown. Two separate doxycycline (dox)-inducible shRNAs were utilized to knockdown (KD) CTNNB1 in COLO320DM cells. Decreased expression of AXIN2 and increased expression of CXCL12 were observed. CTNNB1-KD also significantly reduced the proliferation of COLO320DM cells.

[0938] In some embodiments, an assessment was performed as follows. On day 0, cells were seeded in cell culture media (RPMI1640, 4% FBS) in a 96-well plate at desired density, typically at 1000 cells/well. On day 1, 10 mM agent stock solution (in DMSO) was first serially diluted into DMSO at 1:2 ratio, followed by diluting with cell culture media at two times of the final concentrations. Finally, agent-containing media were introduced to cell culture wells already having the same volume of cell culture media. Cells were incubated with agents for desired days before lysed for CellTiter-Glo® Luminescent Cell Viability Assay according to the manufacture instruction (Promega, G7570) . Luminescent signal was obtained from a microplate reader (GloMax, Promega). Cell viability data was expressed as % relative to DMSO control wells.

[0939] Example 15. Provided technologies can provide robust anti-tumor effects *in vivo*.

[0940] As described herein, provided technologies are useful for treating various conditions, disorders or diseases including cancer. Among other things, the present Example confirms that provided technologies can provide *in vivo* efficacy as demonstrated in various animal models. Certain useful models and/or protocols are described below as examples. Those skilled in the art reading the present disclosure appreciate that various models for various cancers may be utilized to assess provided technologies and confirm their effects in accordance with the present disclosure.

[0941] COLO320DM human colorectal cancer cells (ATCC, CCL-220), which comprise various mutations, e.g., APC and TP53, etc., were expanded in RPMI 1640 media (10% FBS) and inoculated subcutaneously, 10^7 cells per animal in 100 uL PBS/Matrigel (1:1) mixture, to male NU/J mice (JAX#2019) at 8 weeks of age. When the average tumor size reached 150 mm^3, mice were randomized into 3 cohorts (n=10) and treated with vehicle (1% Tween 80/99% 10 mM PBS pH 7.4), I-66 (30mg/kg), and I-66 (75mg/kg) via intraperitoneal injection, once every 4 days for 5 doses.

[0942] Tumor volume was measured by electronic caliper every 2-3 days until tumor volume reached 2000 mm^3 and estimated as (length × $width^2$)/2. Body weights were weighed every 2-3 days and represented as % body weight = (BWi − BW0)/BW0 × 100% (BWi : body weight at day i, BW0: body weight at day 0). Tumor growth inhibition was calculated as, TGI% = [1 − (TVi − TV0)/(TVvi − TVv0)] × 100% (TVi: average tumor volume of a dosing group on day i, TV0: average tumor volume of a dosing group on day 0,

TVvi: average tumor volume of a vehicle group on day i, TVv0: average tumor volume of a vehicle group on day0). Animals were euthanized by CO_2 asphyxiation on the designated terminal day for each study, and plasma, tumors, tissues, etc., were excised for further analysis. Certain data are presented in Figure 4 as examples.

[0943] As confirmed, technologies of the present disclosure can provide robust anti-tumor efficacy. For example, in some embodiments, in COLO320DM xenograft model, I-66 was dosed once every four days, and the treatment led to significant tumor growth inhibitions (TGI) of 66% and 89% at 30 and 75 mg/kg on day 14, respectively. At 75 mg/kg, an initial loss in body weight was observed after the first dose but recovered over time.

[0944] In some embodiments, transcriptional effects of pathway inhibition *in vivo* were assessed. For example, in some embodiments, several PD markers from COLO320DM tumors obtained at the end of the efficacy study (e.g., Day 18) were assessed. In agreement with *in vitro* and single-dose *in vivo* data, both AXIN2 and CXCL12 were dose-dependently regulated by provided technologies, e.g., I-66, in tumors (for AXIN2, down-regulation and for CXCL12, up-regulation), confirming durable target gene modulation. Reduction of mouse NOTUM level in plasma was also observed. In some embodiments, NOTUM may be utilized as a biomarker, e.g., for assessing a treatment, selecting patient population, determining whether to continue treatment, etc. In some embodiments, assessment of human plasma samples from normal and patients, e.g., colorectal cancer patients, confirms that NOTUM levels are correlated with stage of diseases and may be suitable for clinical applications, e.g., as a target engagement biomarker.

[0945] Example 16. Provided technologies can be delivered *in vivo*.

[0946] Among other things, various suitable *in vivo* pharmacokinetic and/or pharmacodynamic properties and/or activities have been confirmed. For example, as confirmed in Figure 5, (A), provided technologies can be effectively delivered to tumors. As shown, prolonged tumor exposure to I-66 was observed after a single dose, and tumor exposure was about 2~10 fold above *in vitro* IC50 for proliferation. It was also observed that I-66 tumor PK exceeded plasma PK at 96 hr time point. Further, I-66 provided significantly longer time periods during which tumor exposure was about or above *in vitro* IC50 for proliferation when compared to, e.g., Peptide A. A useful protocol for assessment is described below as an example.

[0947] Experiments were carried out under an Institutional Animal Care and Use Committee-approved protocol, and institutional guidelines for the proper and humane use of animals were followed.

[0948] For COLO320DM, male NU/J mice (6~8 weeks of age) were utilized, and mice were randomized when average tumor volume reached 300 mm^3. For IP dosing, agents were formulated in 10 mg/mL arginine and 6% PEG400 phosphate (pH 7.4) formulation.

[0949] Concentrations of agents in biological samples were measured by LC-MS/MS (Triple Quad 6500+). Using analytical grade chemicals and solvents, 25 ng/ml Tolbutamide in acetonitrile (ACN, LS120-4, Fisher Scientific) was used as internal standards. 8 uL of plasma or tissue lysate was used for LC method

with mobile phase A (1% formic acid (FA, LS118-4, Fisher Scientific) in H_2O) and mobile phase B (0.1% FA in ACN), 0.6ml/min flow rate in Waters ACQUITY UPLC BEH C18 2.1*50mm, 1.7μm column. The calibration curve was generated using 5-5000 ng/mL agent, e.g., I-66, in mouse plasma and tissue homogenates. MS was conducted by electrospray ionization and multi reaction monitor scans. PK parameters such as plasma maximum concentration (Cmax), and AUC were analyzed by noncompartmental model 200 of Phoenix WinNonlin 8.3, using the linear/log trapezoidal method.

[0950] Additional data confirm well-behaved pharmacokinetic (PK) profiles of provided technologies. See, for example, Figure 5, (B) and data below.

Certain PK parameters of I-66 in mouse by 2-compartmental analysis.

PK Parameters	IV	IP
Cmax(ng/mL)	498654	152000
$T_{1/2}$ (h)	28.71	41.7
T_{max} (h)	NA	6.67
Vd_{ss} (L/kg)	0.452	NA
Cl (mL/min/kg)	0.30	NA
T_{last} (h)	168.00	168.00
$AUC_{0\text{-}last}$ (ng·h/mL)	2741991	2971069
$AUC_{0\text{-}inf}$ (ng·h/mL)	2826191	3124730
Bioavailability (%)	NA	105.0

[0951] In some embodiments, broad tissue distribution was observed. For example, as shown in Figure 5, (C), I-66 was detected in all samples shown. In some embodiments, durable tissue residence was confirmed at least between 24- and 96-hr post-injection. In some embodiments, a single intraperitoneal (IP) dose of I-66 and I-470 at 100 mg/kg demonstrated comparable plasma AUC in mouse.

[0952] Robust and durable anti-tumor effects by provided technologies were confirmed in additional tumor models. In some embodiments, such effects were observed in a Patient-Derived Xenograft (PDX) cancer models. In some embodiments, a model is a mouse PDX colon cancer model. In some embodiments, this model has APC mutations (Tyr935Ter His1490LeufsTer20) and high AXIN2 expression. In some embodiments, for AXIN2 expression, LogCPM is about 2.5 or greater. Among other things, strong anti-tumor activities and durable tumor growth inhibition were confirmed. For example, TGI = 103% on day 45 was observed for animals dosed at 50 mg/kg. No significant body weight loss was observed. Certain data are presented in Figure 8, (A), as examples. In some embodiments, provided technologies were assessed in a mouse model carrying a patient-derived xenograft colorectal tumor. Again, robust anti-tumor effects were confirmed. Certain data are presented in Figure 8, (B), as examples. Vehicle vs. I-66, p=0.008. Mutation profile of model: APC mutant, KRAS WT. IP dosing Q4D, n=10/group. In some embodiments, animals were dosed and/or observed for longer time, e.g., beyond 24 days. No significant body weight loss was observed. For both PDX assessments, vehicle is 10mM sodium phosphate dibasic, 6% w/w PEG-400, 10 mg/mL L-Arginine.

[0953] Among other things, data in various Examples confirmed that provided technologies can provide robust PK properties, strong anti-tumor efficacy and on-target transcriptional modulation *in vivo*.

[0954] Example 17. Provided technologies modulate expressions *in vivo*.

[0955] As described herein, provided technologies can modulate expression of various nucleic acids and/or levels of products thereof, e.g., RNA transcripts, polypeptides, etc. For example, tumor RNA-sequencing analysis confirmed that I-66 can provide, among other things, strong on-target Wnt/beta-catenin pathway modulation in COLO320DM tumors. Certain negatively enriched gene sets are presented below as examples. In some embodiments, a negatively enriched gene is CCND2, WNT5B, AXIN2, NKD1, WNT6, DKK1, OR DKK4. It is noted that both negatively and positively enriched gene sets were observed. Among other things, the present disclosure provides technologies for assessing efficacy of a method, e.g., a treatment, comprising assessing expression of one or more negatively and/or positively enriched genes. In some embodiments, if expression profiles of one or more genes are negatively and/or positively enriched as identified herein, a method may be considered to have efficacy, and/or administration (e.g., of provided technologies such as stapled peptides, compositions, etc.) to a subject can continue.

[0956] Top Negatively Enriched Gene Sets include BCAT_GDS748_UP, BCAT.100_UP.V1_UP, HALLMARK_WNT_BETA_CATENIN_SIGNALING, RASHI_RESPONSE_TO_IONIZING_RADIATION_1, REACTOME_RRNA_PROCESSING, HALLMARK_MYC_TARGETS_V1, HALLMARK_MYC_TARGETS_V2, HALLMARK_OXIDATIVE_PHOSPHORYLATION, HALLMARK_E2F_TARGETS, HALLMARK_TNFA_SIGNALING_VIA_NFKB. I-66 vs. I-470. i.p. 30 mg/kg, 48 hr post single dose. NES -1.7 or smaller. FDR q-value 0.02 or smaller.

[0957] Comparable concentrations of I-66 and I-470 were found in tumors (e.g., in an assessment, 4266 and 5181 ng/gram, respectively) at 48-hr post-dose. As confirmed, GSEA revealed multiple Wnt/beta-catenin and MYC related gene sets ranked as the top hits among the negatively enriched gene sets. Consistent with cell-based data, this result confirms that provided technologies e.g., I-66, can provide strong on-target Wnt/beta-catenin pathway modulation in tumors as shown here in COLO320DM tumors.

[0958] In some embodiments, the present disclosure provides technologies for identifying regulated nucleic acids and/or products thereof including gene sets, and how they are regulated. In some embodiments, patterns of regulation of one or more nucleic acids and/or products thereof, or groups of nucleic acids and/or products thereof such as gene sets, are useful for selecting patient populations for treatment or continued or adjusted treatment (e.g., dose levels, regimens, etc.).

[0959] A useful protocol is described below as an example.

[0960] RNAseq Preparation. For RNA-seq of cell line grafted tumors, library preparation and sequencing were performed with a suitable kit, e.g., TruSeq stranded mRNA library kit on Novaseq S4 Platform, in some embodiments, with PolyA enrichment.

[0961] RNAseq Data Analysis. In some embodiments, sequence reads were trimmed to remove possible

adapter sequences and nucleotides with poor quality using Trimmomatic v.0.39. The trimmed reads were mapped to the Homo sapiens GRCh38 reference genome available on ENSEMBL using the STAR aligner v.2.7.7a. For grafted tumor samples, host reads were removed with XenofilteR. Unique gene hit counts were calculated by using featureCounts from the R Subread package v.2.4.2. Read filtering, normalization, and differentially expression analysis was performed with the edgeR package v.4.0.2 in R. Genes with an adjusted p-value < 0.01 and absolute log2 fold change > 1 were called as differentially expressed genes for each comparison. Genes that are differentially expressed in at least one comparison were used in heatmap and clustering analysis. Gene expression was normalized to fold changes over a reference, e.g., DMSO, controls at the same time. The R pheatmap package v.1.0.12 was used to make heatmap and for hierarchical clustering of genes, with correlation as similarity measure. For enrichment analysis, GSEA v4.1.0 was run with gene list ranked by fold change with the MSigDB database v7.3. In some embodiments, Venn diagram was produced with ggvenn v.0.1.9, where the p value of overlap was calculated with hypergeometric test in R v4.1.2. Those skilled in the art appreciate that other software, programs and/or algorithms may be utilized.

[0962] Time- and dose-dependent effects of provided technologies, e.g., I-66, on expression were also observed in COLO320DM cells through RNA seq. It was confirmed that treatment by provided technologies, e.g., I-66, led to both time- and dose-dependent effects on COLO320DM transcriptional profile. In some embodiments, at 1 uM, 0, 107 and 359 differentially expressed genes (DEGs) were detected at 6-, 24- and 48-hr post treatment, respectively. At 10 uM, 73, 876 and 1271 DEGs, respectively, were found at the three time points. RNAseq data from shRNA-expressing cells after 3-day dox treatment were also assessed. In some embodiments, it was observed that CTNNB1-KD by shRNA and provided technologies, e.g., I-66, led to a consistent transcriptome change in COLO320DM (R2=0.68, p<2.2E-16).

[0963] To assess impacts of provided technologies at pathway levels, Gene Set Enrichment Analysis (GSEA) was utilized to identify significantly enriched Hallmark gene sets (FDR< 0.05) in cells treated by provided technologies, e.g., I-66. Dox-induced CTNNB1-KD and shRNA-resistant CTNNB1 cDNA (shR-cDNA) rescue cell lines were included as comparators. GSEA identified a Hallmark Wnt/beta-catenin gene set that includes AXIN2, DKK4, NDK1 and other canonical Wnt target genes was significantly down-regulated at 10 uM at 6 hr (FDR=0.001), and at all 3 doses (1, 3, and 10 uM) at 24 hr and 48 hr (e.g., WNT_BETA_CATENIN_SIGNALING). MYC targeted gene sets and cell cycle related gene sets (E2F and G2M) were also significantly down regulated in treated cells by provided technologies, e.g., I-66, first observed at 24 hr and also found at 48 hr (e.g., MYC_TARGETS_V1, MYC_TARGETS_V2, E2F_TARGETS, G2M_CHECKPOINT, etc.). These gene set changes were confirmed by dox-induced CTNNB1-KD and were reversed by expressing shR-cDNA, indicating they were indeed downstream effects of beta-catenin. For those gene sets enriched by CTNNB1-KD (i.e. coagulation, myogenesis, interferon), treatments by provided technologies, e.g., I-66, largely showed consistent trends at 24 hr and 48 hr. In some embodiments, in certain assessments certain dose/time point combinations may not reach statically significance. In some embodiments, the present disclosure provides technologies for modulating expression

levels and/or functions of one or more nucleic acids, e.g., genes, in one or more such gene sets and/or pathways, and/or products encoded thereby. In some embodiments, the present disclosure provides technologies for modulating expression and/or functions of such gene sets and/or pathways. In some embodiments, levels are reduced. In some embodiments, levels of expression and/or functions may be utilized as bio-markers as described herein, e.g., for assessing a treatment, for monitoring treatment progress, for selection of patients for a treatment or continuation of a treatment, etc. In some embodiments, it was observed that glycolysis and cholesterol gene sets were negatively enriched by genetic perturbation but not by treatment of I-66. Among other things, on-target inhibition of beta-catenin signaling through disruption of its interaction with TCF/LEF transcription factors by provided technologies was confirmed in various embodiments.

[0964] Example 18. Additional characterization and assessment of provided technologies.

[0965] As described herein, various technologies may be utilized to characterize and assess provided technologies in accordance with the present disclosure. Certain technologies and results are described herein as examples. Those skilled in the art appreciate that these example technologies may be adjusted or modified.

[0966] Crystallography. In some embodiments, structures, interactions, etc. are characterized and assessed using X-Ray crystallography and structure determination. The following protocol is provided as example. In some embodiments, beta-catenin (Human Armadillo Repeat Domain 1-12 (aa146-aa665)) /I-66 complex was concentrated to 9.9 mg/mL and sitting drop trays were setup at 4 °C. In some embodiments, a complex was crystallized with 0.49M $(NH_4)_2SO_4$, 0.38M Li_2SO_4, 0.10 M Na_3Cit, pH=6.00 at 4 °C. Crystals were cryo protected followed by flash-freezing in liquid nitrogen. Diffraction datasets were collected at 100 K at beamlines PXII and X10SA of the SLS. Molecular replacement solutions were obtained using PHASER. In some embodiments, complete models were built through iterative cycles of manual model building in COOT and structure refinement using both REFMAC and PHENIX. In some embodiments, atomic coordinates and structure factors are deposited in the Protein Data Bank. Among other things, the structure confirmed that various amino acid residues in I-66 interact with various amino acid residues in beta-catenin, for example: PL3-1 with Val349, Asp2 with Lys312 and Gly307, Npg3 with Tyr306, Asp5 with Asn387 and Trp383, 3COOHF-6 with Lys345, Ala8 with Trp383, Phe9 with Lys345 and Trp383, 3Thi-12 with Trp-383 and Asn-415, and BztA-13 with Gln-379, Leu-382, Val-416, Asn-415, and Trp-383.

[0967] Competitive Fluorescence Polarization. In some embodiments, interactions are assessed using competitive fluorescence polarization. The following protocol is described as an example. In some embodiments, compounds at 10 mM in DMSO were serially diluted 1:3 in DMSO for a total of 11 concentrations using the Mosquito LV (SPT Labtech, Covina, CA), then diluted 1000-fold in buffer (50 mM HEPES, pH 7.5, 125 mM NaCl, 2% gycerol, 0.5mM EDTA, 0.05% v/v pluronic acid) in duplicate by the Mosquito LV into a black polystyrene 384-well plate (Corning, Corning, NY). Probe solution was prepared by mixing10 nM full-length beta-catenin (Uniprot ID P35222) with 10 nM fluorescently labeled (5FAM)

peptide representing TCF4 residues 10-53 (Uniprot ID Q9NQB0) peptide. The plate was incubated protected from light for 1 hour at room temperature prior to read. Reads were performed on a CLARIOstar plate reader (BMG Labtech, Cary, NC) with excitation at 485 nm, emission at 525 nm, and cutoff at 504 nm. Data were fitted to a 1:1 binding model with hill slope using an in-house script.

[0968] SPR. In some embodiments, SPR may be utilized for characterizing or assessing interactions, bindings, etc. The following protocol is described as an example. In some embodiments, SPR experiments were performed on a Biacore™ 8K (Cytiva, Marlborough, MA) instrument at 25 °C. Compounds were diluted into running buffer (50 mM Tris pH 8.0, 300 mM NaCl, 2% glycerol, 0.5 mM TCEP, 0.5 mM EDTA, 0.005% Tween-20, 1% DMSO). Compounds were diluted to 1 uM or 10 uM (e.g., peptide A, I-66, etc.) and serially diluted 1:3 for 9 concentrations and two blanks. Biotinylated beta-catenin residues 134-665 (Uniprot ID P35222) was immobilized to the active surface of the sensor chip for 25 seconds at 10 mL/min using the Biotin CAPture Kit, Series S (Cytiva) and compounds were injected over the reference and active surfaces for 180 seconds at 65 mL/min then allowed to dissociate for 400 seconds. Results were analyzed using the Biacore™ Insight Evaluation software, with double referencing and fitted to a 1:1 binding affinity model.

[0969] ABA Competition Assays. In some embodiments, an ABA competition assay is utilized to characterize or assess a provided technology. The following protocol is described as an example. In some embodiments, SPR experiments were performed on a Biacore™ S200 (Cytiva) instrument at 25 °C. beta-catenin binding regions of APC, E-cadherin, and AXIN1, ICAT were expressed and purified from E coli. In some embodiments, BCL9 utilized was a synthesized peptide comprising the amino acid sequence interacting with beta-catenin. In some embodiments, APC was treated with kinase to generate phosphorylated-APC (pAPC) as reported. In some embodiments, peptide sequences were obtained from Protein Data Bank (PDB) or Uniprot: TCF1 (Uniprot# P36402, aa 15-60), TCF3 (PDB: 1G3J), TCF4 (PDB:1JDH), LEF1(Uniprot# Q9UJU2 aa 14-62), pAPC (PDB: 1TH1), Mouse E-cadherin (PDB: 1I7X), Human E-cadherin (Uniprot#12830, aa 732-882), ICAT (PDB: 1LUJ), AXIN1 (PDB: 1QZ7), BCL9 (PDB: 2GL7). beta-catenin binding partners (proteins or peptides) were diluted into running buffer (50 mM Tris pH 8.0, 300 mM NaCl, 2% glycerol, 0.5 mM TCEP, 0.5 mM EDTA, 0.005% Tween-20, 0.09% DMSO). Biotinylated beta-catenin residues 134-665 (Uniprot #ID P35222) was immobilized to the active surface of the sensor chips for 25 seconds at 10 mL/min using the Biotin CAPture Kit, Series S (Cytiva) for an immobilization level ~200RU. Compounds (e.g., I-66, I-470 (as control), etc.) were diluted to 500 nM in running buffer and injected over the surface for 30 seconds at 90 mL/min seconds. In some embodiments, appropriate concentrations for each beta-catenin binding partners were chosen to ensure > 90% fractional occupancy for a compound (e.g., I-66) and they were injected 67 s at 90 uL/min over the surface plus or minus a compound (e.g., I-66) using SPR ABA injection protocol. In some embodiments, results were double-referenced and analyzed using the Biacore™ Insight Evaluation software to assess competition.

[0970] Cell lines and cell culture. As those skilled in the art appreciate, cell lines may be obtained from various sources including commercial vendors. For example, HAP1 isogenic pair (HZGHC001062c011) can

be obtained from Horizon Discovery (Waterbeach, United Kingdom), and many cell lines can be obtained from the American Type Culture Collection (ATCC). Various technologies may be utilized to culture cells in accordance with the present disclosure. Cells were routinely cultured in their preferred media according to vendor recommendations. In some embodiments, cells harboring inducible shRNA constructs were maintained in appropriate media with tetracycline-free fetal bovine serum (631101, Clontech Laboratories). Various reagents can be obtained from commercial sources. For example, CHIR99021 can be purchased from R&D System (#4423). In various embodiments, experiments were typically performed at 4% FBS condition. In some embodiments, experiments performed at other FBS concentrations were indicated.

[0971] NanoBRET. In some embodiments, NanoBRET is utilized to characterize or assess provided technologies. The following protocol is described as an example. In some embodiments, a bioluminescence resonance energy transfer (BRET)-based assay was established in HEK293 cells, using NanoBRET constructs to assess beta-catenin/TCF4 interaction (Promega, Madison, WI) according to the manufacturer protocol. TCF4 was fused to a luminescent donor NanoLuc™ and beta-catenin was fused to a HaloTag® NanoBRET™ 618 Ligand (HL) as an acceptor. Briefly, on day 1, cells were transfected with NanoBRET plasmids according to the manufacturer protocol and 30 mM (LiCl (, L7026, Sigma) was added to cell culture media to stabilize beta-catenin. On day 2, fresh media containing compounds and LiCl was added to the cells. On day 3, Nanoluciferase substrate (N157B, Promega) was added to the cells, and the fluorescence emission from HL measured using a GloMAX instrument (Promega) with emission at 460 nm (donor) and 618 nM (acceptor). Cell viability of these cells was monitored alongside the NanoBRET analyses using the luminescence-based assay, CellTiter-Glo (CTG) (G7570, Promega).

[0972] TCF Reporter and Negative Reporter Assays: In some embodiments, TCF report assays are utilized to characterize or assess provided technologies. TCF reporter assays including kits have been reported and can be utilized in accordance with the present disclosure. In some embodiments, in a TCF reporter assay, reporter cell line was generated by using TCF/LEF luciferase reporter lentivirus (79787, BPS Bioscience), and a negative control reporter line was generated using a control luciferase lentivirus (79578, BPS Bioscience). Parental DLD1 cells were transfected with the lentivirus and followed by 3-day puromycin selection. Single clone was selected for both reporter assays. Compounds were incubated with reporter cells for a suitable period of time, e.g., 24 hr. After that, luciferase activity was measured using the Bright-Glo Luciferase Assay System (E2620, Promega). Cell viability was monitored using the luminescence-based cell viability assay, CTG (G7570, Promega). Both peptide A and I-66 inhibited luciferase activity in a dose-dependent manner (IC_{50} 1.5μM and 0.7μM, respectively) without affecting cell viability. Neither showed any activity in a negative control reporter assay, where luciferase was under the control of a minimal TATA promoter.

[0973] Western Blotting. Various technologies may be utilized to detect or quantify polypeptides. In some embodiments, wester blotting is utilized. The following protocol is described as an example. Cells were harvested in 1X RIPA buffer (BP-115, Boston Bioproducts) containing phosphatase and protease

inhibitor cocktail (5872S, Cell Signaling Technologies). Tumors were homogenized in 4% SDS buffer using a polytron homogenizer(P000062-PEVO0-A, Bertin). Equal amount of proteins were resolved on precast 4-20% SDS-PAGE gels (5671093, Bio-Rad), and subsequently transferred onto nitrocellulose membrane for detection. In some embodiments, primary antibodies were probed overnight at 4 °C, membranes were washed with TBST, and incubated with appropriate secondary antibodies for 1 hour. Subsequently membranes were washed with TBST and visualized using Odyssey imaging system (LI-COR). In some embodiments, primary antibodies used were beta-catenin (8480, Cell Signaling Technology), anti-vinculin mouse antibody (V9131, Sigma-Aldrich), anti-Cyclin D2 (3741, Cell Signaling Technology), anti-p27 (3686, Cell Signaling Technology), anti-HDAC2 (5113, Cell Signaling Technology). Depending on polypeptide to be assessed, other antibodies may be utilized. In some embodiments, secondary antibodies used were Alexa Fluor 680 secondary antibody (A32734, Thermo Fisher Scientific) and anti-mouse Alexa Fluor 800 secondary antibody (A32730, Thermo Fisher Scientific). In some embodiments, protein bands were visualized and quantified using the Odyssey CLx Imaging System (Li-Cor) and ImageStudio software (Li-Cor).

[0974] RT-qPCR. In some embodiments, RT-qPCR is utilized for assessing transcripts or RNA. The following protocol is described as an example. In some embodiments, tumors were homogenized in RLT buffer followed by total RNA was isolated using RNAeasy kit (74104, Qiagen) according to manufacturer's protocol. Cells were washed with ice cold PBS and total RNA was extracted using RNeasy Kit (74104, Qiagen). cDNA conversion was performed immediately following RNA extraction using High-Capacity cDNA Reverse Transcription Kit (4374966, ThermoFisher). cDNA was stored in the -20 °C until use. qPCR was performed using TaqMan Universal PCR Master Mix (ThermoFisher) and TaqMan Probes (ThermoFisher) on a QuantStudio 7 Flex Real-Time PCR System (ThermoFisher) with technical duplicates. Relative gene expression levels were monitored using the Taqman Gene Expression probes for AXIN2 (Hs00610344_m1, ThermoFisher), SP5 (Hs01370227_mH, ThermoFisher), RNF43 (Hs00214886_m1, ThermoFisher), NOTUM (Hs00991061_m1, ThermoFisher), CXCL12 (Hs03676656_mH, ThermoFisher). Reactions used Advanced Fast Master Mix (4444557, ThermoFisher) and CT values were normalized to ACTB (4325788, ThermoFisher) as the endogenous control. Other suitable probes may be utilized in accordance with the present disclosure.

[0975] Co-Immunoprecipitation. In some embodiments, co-immunoprecipitation is utilized to assess interactions, complexing, etc. The following protocol is described as an example. In some embodiments, in cells, e.g., DLD1 cells, peptide A and I-66, but not I-470, dose-dependently blocked beta-catenin/TCF4 interaction as detected by Western blotting. In some embodiments, provided peptides traverse cell membrane and/or inhibit beta-catenin/TCF interaction. In some embodiments, provided peptides directly bind to intracellular beta-catenin. In some embodiments, it was observed that various peptides, e.g., I-66, did not affect beta-catenin/E-cadherin interaction, e.g., in DLD1 cells. In some embodiments, for co-IP experiments, DLD1 cells were treated with compounds for a period of time, e.g., 4 hours. Cell pellets were washed twice

with PBS and re-suspended in IP-MS Cell Lysis Buffer provided with the Pierce MS-Compatible Magnetic IP Kit (90409, ThermoFisher (containing Halt protease/phosphatase inhibitor (78440, ThermoFisher)) and sonicated for 2x 10 seconds (30% amplitude) followed by incubation on ice for 10 min to achieve cell lysis. Lysates were then centrifuged for 10 min at 14000 x g to pellet debris. Protein concentration was determined using a Pierce BCA Assay Kit (23225 , ThermoFisher), and final protein concentration was adjusted to about 1 mg/mL using lysis buffer. For each condition, 1 mL of lysate was added to a 96-deepwell plate and incubated with rabbit monoclonal beta-catenin antibody (8480, Cell Signaling Technology) 1:50 dilution or rabbit isotype control for 16hr at 4 ° C in a thermomixer at 300 rpm. Protein-antibody complexes were captured using magnetic protein A/G beads according to the Pierce MS-Compatible Magnetic IP Kit (90409, ThermoFisher) protocol using a Kingfisher Flex Magnetic Particle Processor (ThermoFisher). Briefly, 30 µL of protein A/G magnetic beads were added to each lysate and incubated for 1 hr at room temperature. The beads were then washed 3x in buffer B (5188-5217Agilent), and 2x in Buffer B (5185-5988, Agilent), followed by elution for 10 min in 100 µL of elution buffer. In some embodiments, eluates were dried in a vacuum concentrator (SPD120, ThermoFisher) and re-suspended in 50 µL of Preomics LYSE buffer and digested according to the protocol of PreOmics iST 96X kit (P.O.00027, PreOimics).

[0976] shRNA. In some embodiments, shRNA is utilized for gene knock-down. In some embodiments, shRNAs constructs were made in the pLKO-Tet-On lentiviral vector backbone. In some embodiments, specific sequences targeted were: shNT: 5'-CAACAAGATGAAGAGCACCAA-3'; sh637: 5'-CTATCAAGATGATGCAGAACT-3'; and sh1487: 5'-TCTAACCTCACTTGCAATAAT-3'. The cDNA construct directing overexpression of CTNNB1 was made in pLVX-EF1a-IRES-neo lentiviral vector, which was derived from a pLVXEF1a-IRES-puro vector (Clontech, 631988) by exchanging the selection cassettes. The cDNA construct was untagged. All constructs were confirmed by sequencing.

[0977] Lentiviral technologies. In some embodiments, lentivirus-based constructs (e.g., reporter, shRNAs, cDNA overexpression, etc.) were made using a standard protocol from, e.g., The RNAi Consortium (TRC) from the Broad Institute (http://portals.broadinstitute.org/gpp/public/resources/protocols). In some embodiments, shRNA viruses were titered on individual target cell lines and infected at MOI no greater than 0.7. In some embodiments, cDNA overexpression viruses were infected at higher MOI, where possible. To infect, cells were centrifuged for 1 hr at 2,250 rpm in the presence of the viruses and 8 ug/mL polybrene (H9268, Sigma). Media was preplaced after the spin, and drug selection was added 24 hr later (e.g., puromycin or neomycin, as appropriate). Selection was typically carried out until uninfected control cells were all dead.

[0978] 2D Colony Formation. In some embodiments, 2D colony formation is utilized for assessing cell growth or proliferation. In some embodiments, COLO320DM cells were plated into 6-well tissue culture plate at 6000 cells/well. Next day, cells received fresh media with or without 200 ng/mL doxycycline (dox, S5159, Selleck). Media, with or without dox, was changed every 3 days until cells without dox reached 50-70% confluency. Cells were fixed with Glyoxal (411, ANATECH) for 24h at 4 °C and then stained with

0.5% crystal violet (031-04852, WAKO) for 1 hour at RT. Extra stain was removed with multiple water washes before imaging by Odyssey CLx Imaging System (Li-Cor) and ImageStudio software (Li-Cor).

[0979] Proliferation Assay. In some embodiments, various proliferation assays are utilized to characterize or assess provided technologies. In some embodiments, on day 0, cells were seeded in cell culture media in a 96-well plate at desired density, typically at 1000 cells/well. On day 1, 10 mM compound stock solution was first serially diluted into DMSO, followed by diluting with cell culture media at two times of the final concentrations. Finally, compound-containing media were introduced to cell culture wells already having the same volume of cell culture media. Cells were incubated with compounds for desired days before lysed for CTG according to the manufacture instruction (G7570, Promega). Luminescent signal was obtained from a microplate reader (GloMax, Promega).

[0980] Cell Cycle Analysis. Various technologies may be utilized to assess effects on cell cycles by provided technologies in accordance with the present disclosure. For example, in some embodiments, COLO320DM cells were prepared for cell cycle analysis using the Click-iT EdU kit (Thermo Fisher C10337) to monitor cell proliferation and FxCycle Violet (Thermo Fisher R37166) for quantitation of DNA per manufacturer's instructions. In some embodiments, flow analysis was performed on a BD LSRFortessa Flow Cytometry. In some embodiments, compensation was conducted between the FITC and BV421 channels. In some embodiments, DNA undergoing active synthesis incorporated EdU dye and was visible in the FITC channel. In some embodiments, DNA content incorporated the FxCycle Dye and was visible in the BV421 channel. Cells were gated into three distinct populations: low FITC and low BV421 signal (G1 population), high FITC (S population), and low FITC and high BV421 (G2 population). Data analysis was conducted using FlowJo software (BD Life Sciences).

[0981] RNAseq Preparation. In some embodiments, RNAseq is utilized to assess expression of various nuclei acids including genes. The following describes a process as an example. In some embodiments, for RNA-seq of COLO320DM cell line treated with compounds, library preparation and sequencing reactions were conducted at GENEWIZ, LLC. (South Plainfield, NJ). RNA-seq libraries were prepared using the Illumina TruSeqstranded Total RNA protocol with subsequent PolyA enrichment. On average 25 million 2x150 base pair reads were produced per sample with Illumina HiSeq. For RNA-seq of shRNA treated samples, library preparation and sequencing were performed by Mingma Technologies (Shanghai, China) with TruSeq stranded mRNA library kit on Novaseq S4 Platform with PolyA enrichment. On average over 60 million 2x150 base pair reads were produced per sample. For RNA-seq of cell line grafted tumors, library preparation and sequencing were performed by Fulgent Gentetics (Houston, TX) with TruSeq stranded mRNA library kit on Novaseq S4 Platform with PolyA enrichment.

[0982] RNAseq Data Analysis. Various technologies may be utilized to analyze RNAseq data in accordance with the present disclosure. In some embodiments, sequence reads were trimmed to remove possible adapter sequences and nucleotides with poor quality using Trimmomatic v.0.39. The trimmed reads were mapped to the Homo sapiens GRCh38 reference genome available on ENSEMBL using the STAR

aligner v.2.7.7a. For grafted tumor samples, host reads were removed with XenofilteR. Unique gene hit counts were calculated by using featureCounts from the R Subread package v.2.4.2. Read filtering, normalization, and differentially expression analysis was performed with the edgeR package v.4.0.2 in R. In some embodiments, genes with an adjusted p-value < 0.01 and absolute log2 fold change > 1 were called as differentially expressed genes for each comparison. Genes that are differentially expressed in at least one comparison were used in heatmap and clustering analysis. In some embodiments, gene expression was normalized to fold changes over DMSO controls at the same time. In some embodiments, the R pheatmap package v.1.0.12 was used to make heatmap and for hierarchical clustering of genes, with correlation as similarity measure.

[0983] In some embodiments, for enrichment analysis, GSEA v4.1.0 was run with gene list ranked by fold change with the MSigDB database v7.3. Venn diagram was produced with ggvenn v.0.1.9, where the p value of overlap was calculated with hypergeometric test in R v4.1.2.

[0984] Nuclear Protein Extraction. In some embodiments, nuclear protein is extracted for assessment. The following protocol is described as an example. Cytoplasmatic and nuclear protein extraction was performed using NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (78833, Thermo Fisher Scientific) supplemented with Halt™ Protease and Phosphatase Inhibitor Cocktail (78442, Thermo Fisher Scientific) according to manufacturer protocol. Cytoplasmic and nuclear extracts were stored in the -80 °C until use.

[0985] Immunofluorescence Staining. In some embodiments, immunofluorescence staining is utilized to detect, quantify, characterize or assess a polypeptide. The following protocol is described as an example. In some embodiments, COLO320DM cells were seeded at initial density of 40,000 cells/chamber in Nunc™ Lab-Tek™ II Chamber Slide™ System (154534PK, Thermo Fisher Scientific) overnight in RPMI and 10% FBS. The following day, media was replaced with RPMI with 4% FBS containing 0.1% DMSO, 10 uM I-66 or I-470. After 24 hr compound treatment, cells were washed with PBS and fixed with 10% Neutral-Buffered Formalin (HT501128-4L, Sigma-Aldrich) for 15 minutes at room temperature. Cells were then simultaneously permeabilized and blocked with 0.1% Triton x-100 (X100-100ML, Sigma-Aldrich) and 10% donkey serum (D9663-10ML, Sigma-Aldrich) in PBS for 1hr at room temperature. Afterwards, cells were then incubated at 4 °C overnight using an anti-β-catenin rabbit primary antibody (8480, Cell Signaling Technology) diluted 1:100 (v/v) in 0.1% Triton x-100/10% Donkey Serum/PBS permeabilization/blocking buffer. Cells were then simultaneously incubated with an anti-rabbit Alexa Fluor 488 secondary antibody (A32790, Thermo Fisher Scientific) diluted 1:1000 (v/v) and phalloidin Alexa Fluor 647 (A30107, Thermo Fisher Scientific) diluted 1:200 (v/v) in 0.1% Triton x-100/10% Donkey Serum/PBS permeabilization/blocking buffer for 1hr at room temperature. Those skilled in the art appreciate that other primary and/or secondary antibodies can also be utilized. Afterwards, cells were then incubated with DAPI (D3571, Thermo Fisher Scientific) diluted 1:10000 in PBS for 15 minutes at room temperature. Cells were washed with PBS for 3x5 minutes after every step. Chamber walls were then removed and cells were mounted using ProLong™ Glass Antifade Mountant (P36980, Thermo Fisher Scientific) with a cover glass

overnight at room temperature. Cells were imaged using a Zeiss LSM 710 confocal laser scanning system. Confocal images were analyzed using FIJI/ImageJ.

[0986] Animal studies. In some embodiments, animal models are utilized to ass provided technologies. Experiments were typically carried out under an Institutional Animal Care and Use Committee-approved protocol, and institutional guidelines for the proper and humane use of animals were followed. The following protocol is described as an example. For example, for COLO320DM xenograft assessment, male NU/J mice (6~8 weeks of age) were used, and mice were randomized when the average tumor volume reached 300mm^3. For IP dosing, compounds were formulated in 10 mg/mL arginine and 6% PEG400 phosphate (pH 7.4) formulation. In some embodiments, PDX murine model was established in athymic nude-Foxn1 nu female mice, for example, in some embodiments, with CRC patient tumor with APC mutation (Tyr935Ter), amplified HER2, wild type KRAS and beta-catenin and high AXIN2 expression. Tumor volume was measured by electronic caliper every 2-3 days until tumor volume reached 2000 mm^3 and estimated as (length × width^2)/2. Body weights were weighed every 2-3 days. Tumor growth inhibition (TGI) was calculated as, TGI% = [1 − (TVi − TV0)/(TVvi − TVv0)] × 100% (TVi: average tumor volume of a dosing group on day i, TV0: average tumor volume of a dosing group on day 0, TVvi: average tumor volume of a vehicle group on day i, TVv0: average tumor volume of a vehicle group on day0). Animals were euthanized by CO_2 asphyxiation on the designated terminal day, and plasma, tumors, tissues, etc. were excised for further analysis.

[0987] Compound Quantification. In some embodiments, LC-MS is utilized for quantifying various compounds including stapled peptides. In some embodiments, concentrations of compounds, e.g., stapled peptides, in biological samples were measured by LC-MS/MS (Triple Quad 6500+). Using analytical grade chemicals and solvents, 25 ng/mL tolbutamide in acetonitrile (ACN, LS120-4, Fisher Scientific) was used as internal standards. 8 uL of plasma or tissue lysate was used for LC method with mobile phase A (1% formic acid (FA, LS118-4, Fisher Scientific) in H_2O) mobile phase B (0.1% FA in ACN), 0.6ml/min flowrate in Waters ACQUITY UPLC BEH C18 2.1*50 mm, 1.7 um column. The calibration curve was generated using 5-5000 ng/mL stapled peptides (e.g., I-66, I-470, etc.) in mouse plasma and tissue homogenates. In some embodiments, MS was conducted by electrospray ionization and multi reaction monitor scans. In some embodiments, PK parameters such as plasma maximum concentration (Cmax), and AUC were analyzed by noncompartmental model 200 of Phoenix WinNonlin 8.3, using the linear/log trapezoidal method.

[0988] Plasma NOTUM by Mass Spectrometry. The following protocol is described as an example for Plasma NOTUM by Mass Spectrometry. In some embodiments, plasma samples were collected from mice grafted with COLO320DM tumors for shotgun proteomic analysis. In some embodiments, plasma samples were first depleted of the most abundant proteins, e.g., the top 3, using Multiple Affinity Removal Column, Mouse-3 (4.6 x 50 mm, 5188-4217, Agilent), an immunoaffinity, HPLC-based methodology. In some embodiments, removal of highly abundant proteins allows for detection of medium to low abundant proteins by shotgun proteomics. An UltiMate™ 3000 Rapid Separation Quaternary System (ThermoFisher) was

configured as recommended in the operational guidelines. For each sample 45 uL was added to 180 uL of Agilent Buffer A (5185-5987) and centrifuged in 0.22 um spin filters (5185-5990, Agilent) for 1 minute at 16,000 x g. 180 uL of each sample was injected onto the Mouse-3 column. Elution of low/high abundant proteins from the Mouse-3 column was monitored at 280 nm by a UV detector. Low abundant proteins were collected by a fraction collector. The final volume for each low abundant fraction was about 1 mL. Each fraction was concentrated using a 5 kDa MWCO spin column concentrators (5185-8991, Agilent) for 60 minutes at 3,400 x g. Sample volumes were approximately 50-80 uL after this step was completed. Samples were digested with trypsin (25200114, ThermoFisher) using the PreOmics iST 96X digestion kit (P.O.00027) protocol.

[0989] For LC-MS/MS analysis of peptide mixtures, separations were carried out using an UltiMate 3000 RSLCnano System (ThermoFisher). Peptides were resolved based on hydrophobicity using an EASY-Spray PepMap RSLC C18, 2 um, 100 Å, 500 mm x 75 μm I.D. column thermostatically controlled at 50 °C and at 300 nL/min flow rate with a linear gradient from 2% to 30% acetonitrile containing 0.1% FA for a total duration of 90 minutes. After the gradient portion of the chromatogram the column was washed with 99% acetonitrile containing 0.1% FA for 14 minutes and equilibrated with 2% acetonitrile containing 0.1% FA for 26 minutes. In some embodiments, MS analyses were performed on Q Exactive HF-X (ThermoFisher) in the positive-ion mode using an EASY-Spray source (ES903, ThermoFisher). The instrument was operated with the spray voltage of 1.9 kV, an ion transfer capillary temperature of 250 °C and S lens RF level of 40%. One high resolution FTMS scan of 120,000 resolution including 1 micro scan with maximum injection time of 200 ms was followed by 18 dependent FTMS MS/MS scans of 15,000 resolution with maximum injection time of 28 ms. The dependent MS/MS scans were performed using an isolation width of 1.4 m/z for the parent ion of interest. The isolated multiple charged ions (2, 3, 4) were activated using the HCD normalized collision energy of 28 eV. To prevent an ion from triggering a subsequent data-dependent scan after it has already triggered a data-dependent scan dynamic exclusion of 30 s was enabled.

[0990] In some embodiments, protein identification and quantification was performed with Proteome Discoverer v 2.5.0.400 using the Sequest HT algorithm. For plasma proteomics experiments, database searches were performed using both *Homo sapiens* (sp_canonical TaxID=9606) (v2021-07-30) & *Mus musculus* databases (sp_canonical TaxID=10090) (v2021-09-30). Database searches were performed with the following settings: trypsin digestion, precursor mass tolerance of 20 ppm, fragment mass tolerance of 0.02 Da, static modification: carbamidomethyl, dynamic modification: oxidation/ N-terminal Met-loss. Protein abundances were normalized to total protein amount in each sample, and normalized protein abundance for NOTUM was extracted. Comparison of mean normalized NOTUM abundances between groups was performed by one-way ANOVA followed by Tukey's HSD. For co-immunoprecipitation experiments, database searches were performed with a *Homo sapiens* database and the same settings as for plasma proteomics above. Mean normalized abundances of beta-catenin binding partners were compared between conditions by one-way ANOVA followed by Tukey's HSD. In some embodiments, mass

spectrometry proteomics data are deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org), e.g., via a PRIDE partner repository.

[0991] Example 19. Compounds comprising thioether staples can provide various activities.

[0992] As described herein, various staples can be utilized in accordance with the present disclosure. In some embodiments, a staple comprises −S−. In some embodiments, a staple comprises two −S−. In some embodiments, two −S− are not bonded to each other. In some embodiments, a staple is a thioether staple. Various such staples are described herein, e.g., those having the structure of $-L^{s1}-S-L^{s2}-S-L^{s3}-$, wherein each of L^{s1}, L^{s2} and L^{s3} are independently as described herein. In some embodiments, L^{s1} and L^{s3} are independently from an amino acid residue, e.g., cysteine, homocysteine, alpha-methylcysteine, penicillamine, etc. In some embodiments, each is $-CH_2-$. In some embodiments, two thiol groups are linked by reacting with a compound having the structure of $LG-L^{s2}-LG$ or a salt thereof, wherein each of LG and L^{s2} is independently as described herein. Various such compounds are as described herein. In some embodiments, such a staple is a (i, i+4) staple. In some embodiments, such a staple is closer to a C-terminus. In some embodiments, such a staple is between X^{10} and X^{14}. Among other things, the present disclosure confirms that stapled peptides comprising such staples can provide various activities, e.g., binding to target (e.g., beta-catenin), inhibition of tumor growth, etc.). Certain stapled peptides and data are presented below as examples. C-1 is Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-Gln-NH2, wherein PL3 and B5, and B5 and PyrS2 are stapled. In some embodiments, C-1 is the second production peak/fraction on HPLC (see, e.g., Table E2) of a preparation of Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Ala-Ala-Phe-Leu-PyrS2-2F3MeF-BztA-Gln-NH2.

ID	beta-catenin TCF4 competition FP assay IC50 (nM)	beta-catenin TCF4 DLD1 cell reporter assay IC50 (uM)	ID	beta-catenin TCF4 competition FP assay IC50 (nM)	beta-catenin TCF4 DLD1 cell reporter assay IC50 (uM)
C-1	13	9.8	I-1365	42	n.d.
I-376	220	n.d. (not determined)	I-1453	35	n.d.
I-377	93	n.d.	I-1274	10	5.0
I-566	58	> 20	I-1275	22	5.2
I-567	120	> 20	I-1278	16	12
I-1272	15	5.5	I-1282	19	11
I-1271	5	2.9	I-1277	31	18
I-1451	14	n.d.			

[0993] It was confirmed that various stapled peptides can inhibit cell proliferation. For example, in an assay assessing COLO320 viability, IC50 for I-1271, I-1274, I-1278 and C-1 demonstrated an IC50 of 900 nM, 3.4 uM, 2.4 uM, and 4.1 uM, respectively.


[0994] As confirmed herein, certain amino acid residues (e.g., Cys/Cys) and/or staple structures (e.g., as in I-1271, I-1272, I-1274, I-1275, etc.) provide stronger binding and activities (e.g., inhibition of cell proliferation) compared to other stapled peptides.

[0995] While various embodiments have been described and illustrated herein, those of ordinary skill in


the art will readily envision a variety of other means and/or structures for performing the functions and/or obtaining the results and/or one or more of the advantages described in the present disclosure, and each of such variations and/or modifications is deemed to be included. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be example and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the teachings of the present disclosure is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described in the present disclosure. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, provided technologies, including those to be claimed, may be practiced otherwise than as specifically described and claimed. In addition, any combination of two or more features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the scope of the present disclosure.

CLAIMS


1. An agent having the structure of:




,




,




,




,




,




,




,




,




,




,





, or



,

or a salt thereof.

2. An agent, wherein the agent is or comprises:

$$[X]_pX^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17}[X]_{p'},$$

wherein:

each of p15, p16 and p17 is independently 0 or 1;

each of p and p' is independently 0-10; and

each of X, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue.

3. The agent of claim 4, wherein the agent is or comprises a peptide comprising:

$$[X^0]_{p0}X^1X^2X^3X^4X^5X^6X^7X^8X^9X^{10}X^{11}X^{12}X^{13}X^{14}[X^{15}]_{p15}[X^{16}]_{p16}[X^{17}]_{p17},$$

wherein:

each of p0, p15, p16 and p17 is independently 0 or 1;

each of X^0, X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{10}, X^{11}, X^{12}, X^{13}, X^{14}, X^{15}, X^{16}, and X^{17} is independently an amino acid residue, wherein:

X^2 comprises a side chain comprising an acidic or a polar group;

X^5 comprises a side chain comprising an acidic or a polar group; and

each of X^9, X^{12} and X^{13} comprises a side chain comprising an optionally substituted aromatic group.

4. The agent of any one of the preceding claims, the agent comprises three or more staples within 10-20 amino acid residues.

5. The agent of any one of the preceding claims, wherein five of X^0, X^1, X^3, X^4, X^7, X^{10}, X^{11} and X^{14} are each independently an amino acid residue suitable for stapling, or are each independently stapled.

6. The agent of any one of claims 1-5, wherein X^1 and X^4 are connected by a staple.

7. The agent of any one of claims 1-5, wherein X^0 and X^4 are connected by a staple.

8. The agent of any one of claims 1-7, wherein X^4 and X^{11} are connected by a staple.

9. The agent of any one of claims 1-8, wherein X^{10} and X^{14} are connected by a staple.

10. The agent of any one of claims 1-9, wherein X^7 and X^{10} are connected by a staple.

11. The agent of any one of claims 1-10, wherein X^7 and X^{14} are connected by a staple.

12. The agent of any one of the preceding claims, wherein the agent comprises a N-terminal group.

13. The agent of any one of the preceding claims, wherein X^1 is a residue of an amino acid having the structure of formula A-I, A-II or A-III, wherein R^{a1} and R^{a3} are taken together with their intervening atom(s) to form an optionally substituted 3-10 membered ring having 0-5 heteroatoms in addition to the intervening atom(s).

14. The agent of any one of the preceding claims, wherein X^1 is PL3.

15. The agent of any one of the preceding claims, wherein X^4 is a residue of an amino acid that comprises an olefin.

16. The agent of any one of the preceding claims, wherein X^4 is B5.

17. The agent of any one of the preceding claims, wherein X^{10} is a residue of an amino acid that comprises an optionally substituted carboxyl group, an optionally substituted amino group, an azidyl group, an optionally substituted alkynyl group, or an optionally substituted thiol group.

18. The agent of any one of the preceding claims, wherein X^{10} is Lys.

19. The agent of any one of the preceding claims, wherein X^{11} is a residue of an amino acid that comprises an olefin.

20. The agent of any one of the preceding claims, wherein X^{11} is PyrS2.

21. The agent of any one of the preceding claims, wherein X^{14} is a residue of an amino acid that comprises a carboxyl group, an amino group, an azidyl group, an alkynyl group, or a thiol group.

22. The agent of any one of the preceding claims, wherein X^{14} is GlnR.

23. The agent of any one of the preceding claims, wherein one of X^{10} and X^{14} is a residue of an amino acid that comprises a carboxyl group, and the other is a residue of an amino acid that comprises an amino group.

24. The agent of any one of the preceding claims, wherein X^{10} and X^{14} are connected by a staple, wherein the staple comprises −C(O)N(R')−.

25. The agent of any one of the preceding claims, wherein X^2 comprises a side chain comprising an acidic group.

26. The agent of any one of claims 1-24, wherein X^2 is Asp, Ala, Asn, Glu, Npg, Ser, Hse, Val, S5, S6, AcLys, TfeGA, aThr, Aad, Pro, Thr, Phe, Leu, PL3, Gln, isoGlu, MeAsn, isoDAsp, RbGlu, SbGlu, AspSH,

Ile, SbMeAsp, RbMeAsp, aMeDAsp, OAsp, 3COOHF, NAsp, 3Thi, NGlu, isoDGlu, BztA, Tle, Aib, MePro, Chg, Cha, or DipA.

27. The agent of any one of the preceding claims, wherein X^3 comprises one or two hydrophobic side chains.

28. The agent of any one of claims 1-26, wherein X^3 is Npg, Ile, Asp, Cha, DipA, Chg, Leu, B5, Cba, S5, Ala, Glu, AllylGly, nLeu, Ser, B6, Asn, B4, GlnR, Val, [Phc][Allyl]Dap, Hse, [Bn][Allyl]Dap, 1MeK, R5, Phe, CypA, CyLeu, Pff, DiethA, Tyr, Trp, Aib, Phg, OctG, MorphNva, F2PipNva, [Piv][Allyl]Dap, [CyCO][Allyl]Dap, Lys, or S3.

29. The agent of any one of the preceding claims, wherein X^5 comprises a side chain comprising an acidic group.

30. The agent of any one of claims 1-28, wherein X^5 is selected from Asp, 3COOHF, TfeGA, Gln, [CH2CMe2CO2H]TriAzDap, Thr, Glu, 2OH3COOHF, 4OH3COOHF, 4COOHF, 2COOHF, His, Tyr, 5F3Me2COOHF, 4F3Me2COOHF, 5F3Me3COOHF, 4F3Me3COOHF, 3F2COOHF, Val, Ser, Trp, Asn, Ala, Arg, dGlu, aThr, hTyr, 3cbmf, Leu, Phe, Lys, and Ile.

31. The agent of any one of the preceding claims, wherein X^6 comprises a side chain comprising an acidic group.

32. The agent of any one of the preceding claims, wherein X^6 is 3COOHF, TfeGA, or Asp.

33. The agent of any one of the preceding claims, wherein X^7 is a hydrophobic amino acid residue.

34. The agent of any one of claims 1-32, wherein X^7 is selected from Aib, Ala, MorphGln, Gln, Ser, iPrLys, nLeu, Cha, Hse, Npg, Val, CyLeu, Thr, Phe, Acp, Asn, DaMeS, aMeDF, Leu, Cpg, Cbg, Me2Gln, Met2O, AcLys, His, aMeL, DaMeL, aMeV, aMeS, and aMeF.

35. The agent of any one of the preceding claims, wherein X^8 is a hydrophobic amino acid residue.

36. T The agent of any one of claims 1-34, wherein X^8 is selected from Ala, Aib, Cpg, Val, Leu, Gln, Lys, Asp, Glu, Aad, nLeu, Cba, Ser, Thr, aThr, MorphGln, Phe, hPhe, hTyr, and AcLys.

37. The agent of any one of the preceding claims, wherein X^9 comprises a side chain which is or comprises an optionally substituted aromatic group.

38. The agent of any one of claims 1-36, wherein X^9 is AA9, Phe, Ala, Lys, 3COOHF, Aib, 2NapA, nLeu, 2Thi, Tyr, 3Thi, 4FF, 4ClF, 4BrF, 3FF, 3ClF, 3BrF, 2FF, 3OMeF, 4CNF, 3CNF, 4MeF, 3MeF, Aic, RbiPrF, SbiPrF, RbiPrDF, RbMeXylA, RbMeXylDA, Cba, CypA, BztA, 1NapA, Trp, Leu, Ile, Ser, Chg, Hse, 4TriA, 3F3MeF, Thr, His, Val, Asn, Gln, 2Cpg, SbMeXylA, or SbMeXylDA.

39. The agent of any one of the preceding claims, wherein X^{12} comprises a side chain which is or comprises an optionally substituted aromatic group.

40. The agent of any one of claims 1-38, wherein X^{12} is 3Thi, Phe, 2F3MeF, PyrS2, 2ClF, hnLeu, BztA, 2Thi, 2MeF, 2FF, 34ClF, Lys, nLeu, 2COOHF, 2PhF, hCbA, hCypA, hCha, CypA, hPhe, DipA, HepG, Dap7Abu, hhLeu, hhSer, HexG, [2IAPAc]2NH2F, Ala, Abu, Leu, hLeu, Npg, Cpa, PyrS1, [Bnc]2NH2F, [Phc]2NH2F, [BiPh]2NH2F, [3PyAc]2NH2F, Nva, Cba, ChA, 2FurA, 2OMeF, 2BrF, 2CNF, 2NO2F, 2PyrA,

3PyrA, 4PyrA, His, 1NapA, Val, Ile, Chg, DiethA, OctG, 2cbmF, c6Phe, [MePipAc]2NH2F, or [2PyCypCO]2NH2F.

41. The agent any one of the preceding claims, wherein the side chain of X^{13} comprises an optionally substituted aromatic group.

42. The agent of any one of claims 1-40, wherein X^{13} is selected from BztA, 34ClF, 2NapA, 3BrF, 34MeF, 3Thi, Phe, GlnR, 34MeF, 2NapA and Lys.

43. The agent of any one of the preceding claims, wherein p15 is 1.

44. The agent of any one of the preceding claims, wherein X^{15} comprises a hydrophobic side chain.

45. The agent of any one of the preceding claims, wherein the peptide forms a structure that comprises a helix.

46. The agent of any one of the preceding claims, wherein the peptide binds to beta-catenin.

47. The agent of any one of the preceding claims, wherein the peptide binds to a polypeptide whose sequence is or comprising SEQ ID NO: 2, or a fragment thereof:
SVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIIL ASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCL WTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEAL VRT (SEQ ID NO: 2).

48. The agent of any one of the preceding claims, wherein the peptide binds to beta-catenin and interacts with one or more residues that are or correspond to at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight or at least nine, or at least ten, or at least eleven, or at least twelve, or at least thirteen, or at least fourteen, or at least fifteen, or at least sixteen, or at least seventeen, or at least eighteen, or at least nineteen, or at least twenty of the following amino acid residues in SEQ ID NO: 1 at the indicated positions: A305, Y306, G307, N308, Q309, K312, R342, K345, V346, V349, Q375, R376, Q379, N380, L382, W383, R386, N387, D413, N415, V416, T418, and C419.

49. The agent of any one of the preceding claims, wherein a double bond of a (i, i+7) staple is *E*.

50. The agent of any one of the preceding claims, wherein a double bond of a (i, i+7) staple is *Z*.

51. The agent of any one of the preceding claims, wherein a double bond of a (i, i+2), (i, i+3) or (i, i+4) staple is *E*.


52. The agent of any one of the preceding claims, wherein a double bond of a (i, i+2), (i, i+3) or (i, i+4) staple is *Z*.


53. The agent of any one of the preceding claims, wherein a carbon atom bonded to two staples (e.g., in B5) is of *R* configuration.

54. The agent of any one of any one of the preceding claims, wherein a carbon atom bonded to two staples (e.g., in B5) is of *S* configuration.

55. An agent, having the structure of SP-1-1, SP-1-2, SP-1-3, SP-1-4, SP-1-5, SP-1-6, SP-1-7, SP-1-8, SP-2-1, SP-2-2, SP-2-3, SP-2-4, SP-2-5, SP-2-6, SP-2-7, SP-2-8, SP-3-1, SP-3-2, SP-4-1, SP-4-2, SP-4-3,

SP-4-4, SP-4-5, SP-4-6, SP-4-7, SP-4-8, SP-5-1, SP-5-2, SP-5-3, SP-5-4, SP-5-5, SP-5-6, SP-5-7, SP-5-8, SP-6, SP-7-1, SP-7-2, SP-7-3, SP-7-4, SP-7-5, SP-7-6, SP-7-7, SP-7-8, SP-8-1, SP-8-2, SP-8-3, SP-8-4, SP-8-5, SP-8-6, SP-8-7, SP-8-8, SP-9-1, SP-9-2, SP-9-3, SP-9-4, SP-9-5, SP-9-6, SP-9-7, SP-9-8, SP-10-1, SP-10-2, SP-10-3, SP-10-4, SP-10-5, SP-10-6, SP-10-7, SP-10-8, SP-11-1, SP-11-2, SP-11-3, SP-11-4, SP-11-5, SP-11-6, SP-11-7, SP-11-8, SP-12-1, SP-12-2, SP-12-3, SP-12-4, SP-12-5, SP-12-6, SP-12-7, SP-12-8, SP-13-1, SP-13-2, SP-13-3, SP-13-4, SP-13-5, SP-13-6, SP-13-7, SP-13-8, SP-14-1, SP-14-2, SP-14-3, SP-14-4, SP-14-5, SP-14-6, SP-14-7, SP-14-8, SP-15-1, SP-15-2, SP-15-3, SP-15-4, SP-15-5, SP-15-6, SP-15-7, SP-15-8, or a salt thereof.

56. An agent having the structure of  or a salt thereof.



57. An agent having the structure of or a salt thereof.

58. The agent of any one of claims 56-57, wherein the agent has the same retention time under a HPLC condition as I-66 prepared as described in Example 9, wherein the HPLC condition can separate I-66 and I-67 prepared as described in Example 9.

59. The agent of any one of claims 56-57, wherein the agent shows a retention time of about 15.3 min under the following HPLC condition: Agilent Poroshell 120 EC-C18; 4.6 x 100 mm; solvent A = 0.1% TFA in water; solvent B = 0.075% TFA in acetonitrile; gradient is 10% B to 95% B over 30 min; detection is UV absorbance at 220 nM.

60. The agent of any one of claims 56-59, wherein the agent elutes in a single peak with I-66 prepared as described in Example 9 under the following HPLC condition: Agilent Poroshell 120 EC-C18; 4.6 x 100 mm; solvent A = 0.1% TFA in water; solvent B = 0.075% TFA in acetonitrile; gradient is 10% B to 95% B over 30 min; detection is UV absorbance at 220 nM.

61. The agent of any one of claims 56-60, characterized in that the agent shows ^{1}H NMR peaks that overlap with the peaks between about 5.1-5.7 in Figure 6 under the same or comparable conditions.

62. The agent of any one of claims 56-60, characterized in that the agent shows the same ^{1}H NMR peaks between about 5.1-5.7 as Figure 6 under the same or comparable conditions.

63. The agent of any one of claims 56-60, characterized in that in its ^{1}H NMR spectrum, the peaks corresponding to ^{1}H bonded to carbon atoms overlap with peaks in Figure 6 under the same or comparable conditions.

64. The agent of any one of claims 56-60, characterized in that its ^{1}H NMR spectrum overlaps with peaks

in Figure 6 under the same or comparable conditions.

65. The agent of any one of claims 56-57, wherein the agent has the same retention time under a HPLC condition as I-67 prepared as described in Example 9, wherein the HPLC condition can separate I-66 and I-67 prepared as described in Example 9.

66. The agent of any one of claims 56-57, wherein the agent shows a retention time of about 16.2 min under the following HPLC condition: Agilent Poroshell 120 EC-C18; 4.6 x 100 mm; solvent A = 0.1% TFA in water; solvent B = 0.075% TFA in acetonitrile; gradient is 10% B to 95% B over 30 min; detection is UV absorbance at 220 nM.

67. The agent of any one of claims 56-59, wherein the agent elutes in a single peak with I-67 prepared as described in Example 9 under the following HPLC condition: Agilent Poroshell 120 EC-C18; 4.6 x 100 mm; solvent A = 0.1% TFA in water; solvent B = 0.075% TFA in acetonitrile; gradient is 10% B to 95% B over 30 min; detection is UV absorbance at 220 nM.

68. The agent of any one of claims 56-59 and 65-67, characterized in that the agent shows ^{1}H NMR peaks that do not overlap with the peaks between about 5.1-5.7 in Figure 6 under the same or comparable conditions.

69. The agent of any one of claims 56-59 and 65-67, characterized in that the agent does not show the same ^{1}H NMR peaks between about 5.1-5.7 as Figure 6 under the same or comparable conditions.

70. The agent of any one of claims 56-59 and 65-67, characterized in that in its ^{1}H NMR spectrum, the peaks corresponding to ^{1}H bonded to carbon atoms do not all overlap with peaks in Figure 6 under the same or comparable conditions.

71. The agent of any one of claims 56-60, characterized in that its ^{1}H NMR spectrum does not overlap with peaks in Figure 6 under the same or comparable conditions.

72. The agent of any one of any one of the preceding claims, wherein a carbon atom bonded to two staples (e.g., in B5) is of *S* configuration.

73. An agent having the structure of formula I:

$$R^N–L^{P1}–L^{AA1}–L^{P2}–L^{AA2}–L^{P3}–L^{AA3}–L^{P4}–L^{AA4}–L^{P5}–L^{AA5}–L^{P6}–L^{AA6}–L^{P7}–R^C,$$

I

or a salt thereof, wherein:

R^N is a peptide, an amino protecting group or R'–L^{RN}–;

each of L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} is independently L, wherein L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} comprise:

a first R' group and a second R' group which are taken together to form –L^S– which is bonded to the atom to which a first R' group is attached and the atom to which a second R' group is attached; and

a third R' group and a fourth R' group which are taken together to form –L^S– which is bonded to the atom to which a third R' group is attached and the atom to which a fourth R' group

is attached;

each L^s is independently $-L^{s1}-L^{s2}-L^{s3}-$, wherein each L^{s1}, L^{s2} and L^{s3} is independently L;

L^{AA1} is an amino acid residue that comprises a side chain comprising an acidic or polar group;

L^{AA2} is an amino acid residue that comprises a side chain comprising an acidic or polar group;

L^{AA3} is an amino acid residue;

L^{AA4} is an amino acid residue that comprises a side chain comprising an optionally substituted aromatic group;

L^{AA5} is an amino acid residue that comprises a side chain comprising an optionally substituted aromatic group;

L^{AA6} is an amino acid residue that comprises a side chain comprising an optionally substituted aromatic group;

R^C is a peptide, a carboxyl protecting group, $-L^{RC}-R'$, $-O-L^{RC}-R'$ or $-N(R')-L^{RC}-R'$;

each of L^{RN} and L^{RC} is independently L;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each $-Cy-$ is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;

each R' is independently $-L-R$, $-C(O)R$, $-CO_2R$, or $-SO_2R$;

each R is independently $-H$, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atom(s), 0-10 heteroatoms; or

an agent having the structure of formula I:

$$R^N-L^{P1}-L^{AA1}-L^{P2}-L^{AA2}-L^{P3}-L^{AA3}-L^{P4}-L^{AA4}-L^{P5}-L^{AA5}-L^{P6}-L^{AA6}-L^{P7}-R^C,$$

I

or a salt thereof, wherein:

R^N is a peptide, an amino protecting group or R'–L^{RN}–;

each of L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} is independently L, wherein L^{P1}, L^{P2}, L^{P3}, L^{P4}, L^{P5}, L^{P6}, and L^{P7} comprise:

a first R' group and a second R' group which are taken together to form $-L^s-$ which is bonded to the atom to which a first R' group is attached and the atom to which a second R' group is attached; and

a third R' group and a fourth R' group which are taken together to form $-L^s-$ which is bonded to the atom to which a third R' group is attached and the atom to which a fourth R' group is attached;

each L^s is independently $-L^{s1}-L^{s2}-L^{s3}-$, wherein each L^{s1}, L^{s2} and L^{s3} is independently L;

L^{AA1} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS1}-R^{AA1}$, wherein R^{AA1} is $-CO_2R$ or $-SO_2R$;

L^{AA2} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS2}-R^{AA2}$, wherein R^{AA2} is $-CO_2R$, or $-SO_2R$;

L^{AA3} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS3}-R^{AA3}$, wherein R^{AA3} is R';

L^{AA4} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS4}-R^{AA4}$, wherein R^{AA4} is an optionally substituted group selected from 6-14 membered aryl or 5-14 membered heteroaryl having 1-6 heteroatoms;

L^{AA5} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS5}-R^{AA5}$, wherein R^{AA5} is an optionally substituted group selected from 6-14 membered aryl or 5-14 membered heteroaryl having 1-6 heteroatoms;

L^{AA6} is L^{AR}, wherein a methylene unit is replaced with $-C(R')(R^{AS})-$, wherein R^{AS} is $-L^{AS6}-R^{AA6}$, wherein R^{AA6} is an optionally substituted group selected from 6-14 membered aryl or 5-14 membered heteroaryl having 1-6 heteroatoms;

R^C is a peptide, a carboxyl protecting group, $-L^{RC}-R'$, $-O-L^{RC}-R'$ or $-N(R')-L^{RC}-R'$;

each of L^{RN} and L^{RC} is independently L;

each L^{AR} is independently an optionally substituted, bivalent C_1-C_6 aliphatic group, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-C(R')(R^{AS})-$,$-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$, $-C(NR')-$, $-C(O)N(R')-$, $-N(R')C(O)N(R')-$, $-N(R')C(O)O-$, $-S(O)-$, $-S(O)_2-$, $-S(O)_2N(R')-$, $-C(O)S-$, or $-C(O)O-$;

each of L^{AS1}, L^{AS2}, L^{AS3}, L^{AS4}, L^{AS5}, and L^{AS6} is independently L^{AS};

each R^{AS} is independently $-L^{AS}-R'$;

each L^{AS} is independently a covalent bond or an optionally substituted, bivalent C_1-C_{10} aliphatic or heteroaliphatic group having 1-5 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, $-Cy-$, $-O-$, $-S-$, $-S-S-$, $-N(R')-$, $-C(O)-$, $-C(S)-$,

−C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −$S(O)_2$−, −$S(O)_2$N(R')−, −C(O)S−, or −C(O)O−;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units of the group are optionally and independently replaced with −$C(R')_2$−, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, −$S(O)_2$−, −$S(O)_2$N(R')−, −C(O)S−, or −C(O)O−;

each −Cy− is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;

each R' is independently −L−R, −C(O)R, −CO_2R, or −SO_2R;

each R is independently −H, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atom(s), 0-10 heteroatoms.

74. The agent of any one of the preceding claims, wherein each olefin double bond in a staple is independently and optionally converted into a single bond.

75. The agent of any one of the preceding claims, having a diastereopurity of about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more, or having a purity of about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more.

76. A pharmaceutical composition, comprising or delivering an agent or amino acid of any one of the preceding claims, and a pharmaceutically acceptable carrier.

77. A composition selected from Table E2 or Table E3, or a pharmaceutical composition, comprising or delivering one or more or all peptide agents in a composition selected from Table E2 or Table E3, and a pharmaceutically acceptable carrier.

78. The composition of any one of the preceding claims, comprising an agent comprising one or more staples each independently comprises one or more olefin double bond, wherein the ratio of the two stereoisomers of an olefin double bond in a staple is about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 30:1, 40:1, 50:1 or more.

79. A method, comprising

a) preparing a first compound comprising two moieties each of which independently comprises an olefin double bond;

b) providing a second compound by stapling the two moieties by olefin metathesis of an olefin double bond of one moiety with an olefin double bond of the other to form a first-formed staple;

c) add one or more additional moieties to the second compound to provide a third compound which comprising two moieties each of which independently comprises an olefin double bond; and

d) providing a fourth compound by stapling the two moieties in the third compound by olefin metathesis of an olefin double bond of one moiety with an olefin double bond of the other to form a second-formed staple.

80. A method for modulating beta-catenin interaction with a partner in a system, comprising contacting beta-catenin with an agent or composition of any one of the preceding claims; or

a method for modulating beta-catenin interaction with a partner in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims; or

a method for modulating a TCF-beta-catenin interaction in a system, comprising contacting beta-catenin with an agent or composition of any one of the preceding claims; or

a method for modulating a TCF-beta-catenin interaction in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims; or

a method for inhibiting beta-catenin dependent cell proliferation, comprising administering or delivering to the system an agent or composition of any one of the preceding claims; or

a method for modulating WNT/beta-catenin pathway in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims, wherein expression of a nucleic acid is modulated; or

a method, comprising administering or delivering to the system an agent or composition of any one of the preceding claims, wherein level of a transcript of a nucleic acid and/or a product thereof is modulated; or

a method, comprising administering or delivering to the system an agent or composition of any one of the preceding claims, wherein expression of a nucleic acid is modulated.

81. A method for treating or preventing a condition, disorder or disease associated with beta-catenin interaction with a partner in a subject, comprising administering or delivering to the subject an effective amount of an agent or composition of any one of the preceding claims, preferably wherein the partner is TCF7, LEF1, TCF7L1, TCF7L2, Axin1, Axin2, or APC.

82. A method for treating cancer in a subject, comprising administering or delivering to the subject an effective amount of an agent or composition of any one of the preceding claims.

83. The method of any one of the preceding claims, comprising administering or deliver to a subject a second therapeutic agent or therapy.

84. The method of any one of the preceding claims, wherein a second therapeutic agent is or comprises a

chemotherapy agent, a hormone therapy agent, an immunotherapy agent, a checkpoint inhibitor, an antibody, a CTLA-4, PD-1 or PD-L1 inhibitor, or a cell, or a second therapy is or comprises surgery, chemotherapy, radiotherapy, hormone therapy, stem cell or bone marrow transplant, immunotherapy, T-cell therapy, or CAR T-cell therapy.

85. The method of any one of the preceding claims, comprising assessing expression of a nucleic acid.

86. A compound having the structure of formula PA:

$$N(R^{PA})(R^{a1})-L^{a1}-C(R^{a2})(R^{a3})-L^{a2}-C(O)R^{PC},$$

PA

or a salt thereof, wherein:

R^{PA} is −H or an amino protecting group;

each of R^{a1} and R^{a3} is independently $-L^{a}-R'$;

R^{a2} is $-L^{aa}-C(O)R^{PS}$;

each of L^{a}, L^{a1} and L^{a2} is independently L;

$-C(O)R^{PS}$ is optionally protected or activated −COOH;

$-C(O)R^{PC}$ is optionally protected or activated −COOH;

each L is independently a covalent bond, or an optionally substituted, bivalent C_1-C_{25} aliphatic or heteroaliphatic group having 1-10 heteroatoms wherein one or more methylene units of the group are optionally and independently replaced with $-C(R')_2-$, −Cy−, −O−, −S−, −S−S−, −N(R')−, −C(O)−, −C(S)−, −C(NR')−, −C(O)N(R')−, −N(R')C(O)N(R')−, −N(R')C(O)O−, −S(O)−, $-S(O)_2-$, $-S(O)_2N(R')-$, −C(O)S−, or −C(O)O−;

each −Cy− is independently an optionally substituted bivalent, 3-30 membered, monocyclic, bicyclic or polycyclic ring having 0-10 heteroatoms;

each R' is independently −R, −C(O)R, $-CO_2R$, or $-SO_2R$; and


each R is independently −H, or an optionally substituted group selected from C_{1-30} aliphatic, C_{1-30} heteroaliphatic having 1-10 heteroatoms, C_{6-30} aryl, C_{6-30} arylaliphatic, C_{6-30} arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or

two R groups are optionally and independently taken together to form a covalent bond, or:

two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or

two or more R groups on two or more atoms are optionally and independently taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atom(s), 0-10 heteroatoms; or

a compound having the structure of:




or a salt thereof, wherein:

R^{PA} is −H or an amino protecting group;

$-C(O)R^{PS}$ is optionally protected or activated −COOH; and

$-C(O)R^{PC}$ is optionally protected or activated −COOH; or

a compound having the structure of:




or a salt thereof, wherein:

R^{PA} is −H or an amino protecting group;


$-C(O)R^{PS}$ is optionally protected or activated −COOH; and

$-C(O)R^{PC}$ is optionally protected or activated −COOH.

87. An agent, compound, method, or composition of any one of Embodiments 1-2401.



WT
KO
CHIR:
-
+
-
+
1.0
2.6
β-catenin
Vinculin

(A)


SP5
Relative Gene Expression
10
8
6
4
2
0
CHIR: - + + + + + + + - + + + + + + +
Agent (uM): 0 0 1 5 1 5 1 5 0 0 1 5 1 5 1 5
WT
KO

(B)

FIG. 1



(C)

FIG. 1 (CONTINUED)





DMSO
I-470
I-66
β-catenin
HDAC2
Total β-catenin in nuclear fraction
(24h)
β-catenin / HDAC2
1.5
1.0
0.5
0.0
DMSO
I-470
I-66

FIG. 2



CTG
(6-day treatment)
% Viability to DMSO
120
100
80
60
40
20
0
0.01
0.1
1
10
100
Concentration (μM)
Peptide A
I-66
I-470
IC50: 0.7μM
IC50: 4.0μM

(A)



Relative Gene Expression
1.5
1.0
0.5
0.0
0.01
0.1
1
10
100
Concentration (μM)
Peptide A
I-66
I-470
IC50:
0.3μM
IC50:
1.4μM

(B)

FIG. 3



(C)



(D)

FIG. 3 (CONTINUED)





Vehicle
I-66, 30 mg/kg, Q4D
I-66, 75 mg/kg, Q4D
Tumor Volume (mm3)
2500
2000
1500
1000
500
0
0
5
10
15
20
Days post 1st dose

FIG. 4



i.p. 50 mg/kg
Concentration (μM, Log10)
1000
100
10
1
0.1
Plasma PK
Tumor PK
0
24
48
72
96
120
Time (h)

(A)

FIG. 5



(B)



(C)

FIG. 5 (CONTINUED)



I-66, 1H NMR, d6-DMSO, 373 K
f1 (ppm)
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
-2000
-1000
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
13000
14000
15000
16000
17000
18000
19000
20000
21000
22000

FIG. 6





1H NMR, d6-DMSO, 373 K
1.94
0.94
0.96
3.95
2.50
1.48
3.49
4.54
1.07
1.25
6.46
2.19
0.90
0.99
2.02
1.00
3.16
1.10
1.24
7.79
2.81
2.55
1.71
3.34
6.56
2.47
4.24
3.37
1.02
1.06
2.32
9.74
3.50
3.18
3.49
5.56
3.08
4.05
4.02
6.26
7.10
1.33
9.56
1.01
.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
-2000 -1000 0 1000 2000 3000 4000 5000 6000 7000 8000 9000 10000 11000 12000 13000 14000 15000 16000 17000 18000 19000 20000 21000 22000

FIG. 7


Vehicle
I-66 (50 mg/kg)
Tumor Volume (mm3)
2000
1500
1000
500
0
0
10
20
30
40
50
Days of treatment

(A)


Vehicle Control
I-66 (60 mg/kg)
Tumor Volume (mm3)
1600
1400
1200
1000
800
600
400
200
0
0
10
20
30
Days of treatment

(B)

FIG. 8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US22/32738

A. CLASSIFICATION OF SUBJECT MATTER

IPC - INV. A61K 38/12; A61K 38/04; A61P 35/00; C07K 7/50; C07K 7/54; C07K 14/00 (2022.01)

ADD.

CPC - INV. A61K 38/12; A61K 38/04; A61P 35/00; C07K 7/50; C07K 7/54; C07K 14/00

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2020/0247858 A1 (FOG PHARMACEUTICALS, INC.) 6 August 2020; abstract; paragraph [0292]	1, 1/4, 56-57, 58/56-57, 59/56-57, 65/56-57, 66/56-57
A	US 2020/0276323 A1 (OHIO STATE INNOVATION FOUNDATION) 3 September 2020; figure 9	1, 1/4, 56-57, 58/56-57, 59/56-57, 65/56-57, 66/56-57
A	US 2017/0152286 A1 (THE UNIVERSITY OF HONG KONG) 1 June 2017; figure 3A	1, 1/4, 56-57, 58/56-57, 59/56-57, 65/56-57, 66/56-57
A	US 2017/0342108 A1 (SEOUL NATIONAL UNIVERSITY R AND DB FOUNDATION) 30 November 2017; figure 1	1, 1/4, 56-57, 58/56-57, 59/56-57, 65/56-57, 66/56-57
A	WO 2010/068684 A2 (DANA FARBER CANCER INSTITUTE, INC.) 17 June 2010; entire publication	1, 1/4, 56-57, 58/56-57, 59/56-57, 65/56-57, 66/56-57

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"D" document cited by the applicant in the international application
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
30 August 2022 (30.08.2022)	OCT 26 2022
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300	Authorized officer Shane Thomas Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US22/32738

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:

   a. ☐ forming part of the international application as filed:

      ☐ in the form of an Annex C/ST.25 text file.

      ☐ on paper or in the form of an image file.

   b. ☐ furnished together with the international application under PCT Rule 13*ter*.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.

   c. ☒ furnished subsequent to the international filing date for the purposes of international search only:

      ☐ in the form of an Annex C/ST.25 text file (Rule 13*ter*.1(a)).

      ☐ on paper or in the form of an image file (Rule 13*ter*.1(b) and Administrative Instructions, Section 713).

2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

An "Invitation to Furnish Nucleotide and/or Amino Acid Sequence Listing and to Pay, Where Applicable, Late Furnishing Fee" (Form PCT/ISA/225), was mailed on 27 June 2022 (27.06.2022). The sequence listing filed with the ISA/US on 27 July 2022 (27.07.2022), in response to the Form PCT/ISA/225, was defective. Therefore, the international search was carried out only to the extent possible without a sequence listing.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US22/32738

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 87
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claim 87 is an improper omnibus claim that fails to comply with the Rule 6.2(a) to such extent that no examination can be performed

3. ☒ Claims Nos.: 5-54, 60-64, 67-72, 74-76, 78 and 80-85
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
-***-Please See Supplemental Page-***-

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Group I, Claims 1, 4 (in part), 56-59 and 65-66.

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US22/32738

-***-Continued From Box No. III: Observations where unity of invention is lacking-***-

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, Claims 1, 4 (in part), 56-59 and 65-66 are directed toward an agent comprising two ortho condensed cycles with an additional spiro condensed cycle shown in claim 1.

Groups II+, Claims 2-3, 4 (in part) and 77 are directed toward an agent, wherein the agent is Ac-PL3-Asp-Leu-B5-Asp-Asp-Ala-Ala-Phe-dLvs*3-PvrS2-3Thi-BztA-GlnR*3-NH2 (agent).

Group III, Claims 73 and 87 are directed toward an agent having the structure of formula I.

Group IV, Claim 86 is directed toward a compound having the structure of formula PA.

The compounds of Claims 2-3, 4 (in part) and 77 are believed to encompass the first named invention of Groups II+ and thus these claims can be searched with payment of a fee for the search of Groups II+ to the extent that they encompass an agent, wherein the agent is Ac-PL3-Asp-Leu-B5-Asp-Asp-Ala-Ala-Phe-dLvs*3-PvrS2-3Thi-BztA-GlnR*3-NH2 (first exemplary agent). This first named invention of Group II+ has been selected to encompass the first species of the genus found in claims 2 and 77 based on the guidance set forth in section 10.54 of the PCT International Search and Preliminary Examination Guidelines.

Applicant is invited to elect additional agents, with specified substituents for each Rx, and where available as an option within at least one searchable claim, to be searched. Additional agent(s) will be searched upon the payment of additional fees. Applicants must specify the searchable claims that encompass any additionally elected agent(s). Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined. An exemplary election would be an agent, wherein the agent is Ac-PL3-Asp-Leu-B5-Asp-Asp-Ala-Ala-Phe-DGlnR*3-PyrS2-3Thi-BztA-Lys*3-NH2 (agent).

The inventions listed as Groups I, II+, III and IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical features of Group I include an agent comprising two ortho condensed cycles with an additional spiro condensed cycle shown in claim 1, which are not present in Groups II+, III and IV; the special technical features of Group II+ include the agent of formula [X]pX1X2X3X4X5X6X7X8X9X10X11X12X13X14[X15]p15[X16]p16[X17]p17[X]p', which are not present in Groups I, III and IV; the special technical features of Group III include the agent having the structure of formula I, which are not present in Groups I, II+ and IV; the special technical features of Group IV include a compound having the structure of formula PA, which are not present in Groups I, II+ and III.

Groups II+ share the technical features including an agent, wherein the agent comprises [X]pX1X2X3X4X5X6X7X8X9X10X11X12X13X14[X15]p15[X16]p16[X17]p17[X]p'. However, these shared technical features are previously disclosed by WO 2010/068684 A2 (DANA FARBER CANCER INSTITUTE, INC.) (hereinafter "DANA"). DANA discloses the agent an agent (the peptide LEVESXTQLXRFGDKLNFRQKL, SEQ ID NO: 7, comprising 22 amino acids, or the sequence LEVESXTQLXRFGDKLNF, SEQ ID NO: 65, comprising 18 amino acids; ; page 3, lines 10-15; claim 13; figure 20; figure 23-2), wherein the agent comprises [X]pX1X2X3X4X5X6X7X8X9X10X11X12X13X14[X15]p15[X16]p16[X17]p17[X]p' (the peptide LEVESXTQLXRFGDKLNFRQKL; page 3, lines 10-15; figure 20), wherein: each of p15, p16 and p17 is 1 (the KLN fragment is in the peptide; page 3, lines 10-15; figure 20); p is 0 (no amino acids are attached to the terminal LEV fragment of the peptide; page 3, lines 10-15; figure 20); and p' is 5 (the terminal FRQKL fragment is in the peptide; page 3, lines 10-15; figure 20); and each of X, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X 14, X15, X16, and X17 is an amino acid residue (the amino acid residues are in the peptide LEVESXTQLXRFGDKLNFRQKL; page 3, lines 10-15; figure 20).

Since none of the special technical features of the Groups II+ is found in more than one of the inventions, and since all of the shared technical features are previously disclosed by the DANA reference, unity of invention is lacking.

Groups I, II+, III and IV share the technical features including peptide. However, these shared technical features are previously disclosed by DANA, as above. DANA discloses the peptide (the peptide LEVESXTQLXRFGDKLNFRQKL, SEQ ID NO: 7, comprising 22 amino acids, or the sequence LEVESXTQLXRFGDKLNF, SEQ ID NO: 65, comprising 18 amino acids; page 3, lines 10-15; claim 13; figure 20; figure 23-2).

Since none of the special technical features of the Groups I, II+, III and IV is found in more than one of the inventions, and since all of the shared technical features are previously disclosed by the DANA reference, unity of invention is lacking.

Claim 3 is objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6, because Claim 3 is indefinite for the following reason(s): Claim 3 depends in claim 4, and Claim 4, in turn, depends on claim 3, i.e., where claim 3 depends on itself, which renders the claim indefinite. For the purposes of this LOU examination, an assumption was made that claim 3 depends on claim 2.